{"id": "Ga3fXaypa1uQ", "question_type": "multi_choice", "question": "A 52-year-old man with primary IgAN and UPCR of 1.8 g/g is being considered for VANRAFIA therapy to reduce proteinuria. He has a history of severe hepatic impairment. Which of the following is the most appropriate recommendation regarding VANRAFIA use in this patient?", "options": {"A": "Initiate VANRAFIA without dose adjustment and monitor liver enzymes regularly.", "B": "Begin VANRAFIA therapy and add a CYP3A inducer to reduce adverse effects.", "C": "Start VANRAFIA at half the recommended dose and monitor for hepatotoxicity.", "D": "Do not initiate VANRAFIA due to severe hepatic impairment."}}
{"id": "JqeCqjC0GN78", "question_type": "multi_choice", "question": "A 7-year-old boy with a diagnosis of immune thrombocytopenia, confirmed by thrombocytopenia and abnormal bleeding, has failed to respond to corticosteroids and IVIG. He has no significant hepatic or renal impairment. Which drug regimen is most suitable for his ongoing management?", "options": {"A": "Nplate (romiplostim) weekly subcutaneous injection", "B": "WAYRILZ (rilzabrutinib) 400 mg twice daily", "C": "DMT SUIK (corticosteroid) intravenous therapy", "D": "WAYRILZ (rilzabrutinib) with dose reduction"}}
{"id": "DBnUYA0Avadp", "question_type": "open_ended", "question": "Which of the following statements best describes the evaluation of carcinogenic or mutagenic potential for the drug Andembry?", "options": {"A": "Animal studies have confirmed carcinogenic potential for Andembry.", "B": "Animal studies have confirmed mutagenic potential for Andembry.", "C": "Animal studies have not been conducted to evaluate carcinogenic or mutagenic potential for Andembry.", "D": "Animal studies have shown Andembry to be both carcinogenic and mutagenic."}}
{"id": "C2xX89QEKptL", "question_type": "multi_choice", "question": "A 32-year-old male presents with severe reactive arthritis characterized by joint swelling, enthesitis, and recurrent aphthous stomatitis. He has a history of Crohn's disease and is currently taking methotrexate. Despite conventional therapy, his symptoms persist. He is not currently on any other biologic agents and has tested negative for latent tuberculosis. Which of the following is the most appropriate drug to initiate for his refractory inflammatory symptoms, considering his current medications and disease profile?", "options": {"A": "Renflexis administered intravenously every 8 weeks in combination with methotrexate", "B": "Doxycycline hyclate 100 mg orally twice daily", "C": "Renflexis administered concurrently with abatacept", "D": "Doxycycline hyclate in combination with penicillin"}}
{"id": "wGnzKp4VXRoh", "question_type": "open_ended", "question": "A 32-year-old pregnant woman with BH4-responsive phenylketonuria and a history of severe eczema and microcephaly in a previous child presents for management. She is not taking any contraindicated medications and has maintained her blood phenylalanine levels above 600 micromol/L in prior pregnancies. Which treatment plan is most appropriate to minimize fetal risk and control maternal Phe levels during pregnancy?", "options": {"A": "Sephience 60 mg/kg daily with a Phe-restricted diet", "B": "Sapropterin dihydrochloride 20 mg/kg daily with a Phe-restricted diet", "C": "JAVYGTOR 20 mg/kg daily with a Phe-restricted diet", "D": "Drug holiday from all PKU medications during pregnancy"}}
{"id": "H6mj9q4Fvnuh", "question_type": "multi_choice", "question": "A 35-year-old patient with myelodysplastic syndrome is scheduled for allogeneic hematopoietic stem cell transplantation. Which regimen including Grafapex is appropriate based on its approved indications?", "options": {"A": "Grafapex plus azacitidine for consolidation", "B": "Grafapex monotherapy as a preparative regimen", "C": "Grafapex plus cytarabine as maintenance therapy", "D": "Grafapex plus methotrexate for induction therapy"}}
{"id": "MkWX8MQ8kR5o", "question_type": "multi_choice", "question": "A 68-year-old woman with newly diagnosed locally advanced ROS1-positive non-small cell lung carcinoma is being considered for targeted therapy. She has a history of osteoporosis and is currently taking a proton pump inhibitor for chronic gastroesophageal reflux disease. Which of the following is the most appropriate approach regarding the use of taletrectinib for her treatment?", "options": {"A": "Initiate taletrectinib 600 mg orally once daily without modification.", "B": "Taletrectinib is contraindicated due to her osteoporosis.", "C": "Taletrectinib is contraindicated due to her age.", "D": "Initiate taletrectinib 600 mg orally once daily, but discontinue the proton pump inhibitor or adjust antacid timing."}}
{"id": "sI0ll6hggKLZ", "question_type": "open_ended_multi_choice", "question": "A 15-year-old with generalized myasthenia gravis, confirmed by positive anti-acetylcholine receptor antibodies and exhibiting fatigable weakness and ptosis, presents without a history of organophosphate exposure, pregnancy, or other health issues. Which medication regimen is considered safest and most effective for pediatric patients in this scenario?", "options": {"A": "Azathioprine, 50 mg daily, as an immunosuppressive adjunct", "B": "DuoDote, single dose for acute symptom management", "C": "IMAAVY, 15 mg/kg intravenous infusion every 2 weeks", "D": "Azathioprine, 100 mg daily, with a drug holiday every 2 months"}}
{"id": "pPBlWRUJ5ARL", "question_type": "open_ended_multi_choice", "question": "A 34-year-old pregnant patient has been diagnosed with NSTEMI and needs antiplatelet treatment for secondary prevention. She is concerned about the risks of medications in pregnancy. Which agent should be recommended for her condition?", "options": {"A": "Flyrcado", "B": "BRILINTA", "C": "Clopidogrel", "D": "BRILINTA with aspirin"}}
{"id": "VVwarS1iiJCZ", "question_type": "open_ended_multi_choice", "question": "A 32-year-old woman is newly diagnosed with metastatic epithelioid sarcoma. She has a history of mild hepatic impairment (serum bilirubin 2.0 mg/dL), and her cardiac function is normal. She is not pregnant and is not breastfeeding. She is currently taking a CYP3A4 inhibitor for another condition. Which of the following is the most appropriate initial drug treatment for her sarcoma, considering her comorbidities and current medications?", "options": {"A": "Doxorubicin Hydrochloride at standard dose every 3 weeks", "B": "Doxorubicin Hydrochloride with dose reduction every 3 weeks", "C": "KEYTRUDA QLEX as monotherapy every 3 weeks", "D": "Doxorubicin Hydrochloride in combination with trastuzumab every 3 weeks"}}
{"id": "EnjUzCeRsyBu", "question_type": "open_ended", "question": "A 5-year-old child with phenylketonuria presents with severe intellectual disability, hyperactivity, and elevated urinary phenylpyruvic acid levels. The patient is currently taking methotrexate for juvenile idiopathic arthritis. Genetic testing confirms sepiapterin-responsive PKU. Which drug regimen is most appropriate to reduce blood phenylalanine levels in this patient, considering drug interactions and safety?", "options": {"A": "Sapropterin dihydrochloride 20 mg/kg daily with a Phe-restricted diet", "B": "Sephience 60 mg/kg daily with a Phe-restricted diet", "C": "JAVYGTOR 20 mg/kg daily with a Phe-restricted diet", "D": "Sephience 60 mg/kg daily with a Phe-restricted diet and continued methotrexate"}}
{"id": "LsDl25y9pwVq", "question_type": "multi_choice", "question": "A patient receiving Grafapex presents with prolonged pancytopenia. Which scenario is most consistent with this finding?", "options": {"A": "The patient has experienced an overdose of Grafapex.", "B": "The patient is experiencing a typical therapeutic response.", "C": "The patient has developed an allergic reaction.", "D": "The patient has a viral infection."}}
{"id": "DSrSlka7YNco", "question_type": "multi_choice", "question": "A female patient of reproductive potential is prescribed Romvimza. What is the most appropriate counseling regarding contraception?", "options": {"A": "No contraception is necessary during Romvimza therapy.", "B": "Effective contraception should be used during treatment and for 1 month after the last dose.", "C": "Contraception is only required if the patient is pregnant.", "D": "Contraception should be used only for the first week of therapy."}}
{"id": "ICnPfd4kwOY0", "question_type": "open_ended_multi_choice", "question": "A 68-year-old man with a history of hypertension and chronic kidney disease (creatinine clearance 45 mL/min) presents with a sore throat and fever. He is diagnosed with bacterial pharyngitis. He reports a previous severe allergic reaction (anaphylaxis) to penicillin. Which of the following is the most appropriate management for his condition?", "options": {"A": "Cefixime, 400 mg orally once daily for 10 days", "B": "Ibuprofen, 400 mg orally every 6 hours as needed for pain and fever", "C": "Amphotericin B liposome, 3 mg/kg IV daily for 14 days", "D": "Cefixime, 200 mg orally once daily for 10 days with close monitoring"}}
{"id": "6JjIs5RR7ram", "question_type": "multi_choice", "question": "A 14-year-old patient presents with non-cystic fibrosis bronchiectasis, recurrent bronchopulmonary infections, and chronic sinusitis. The patient has a history of gingival sensitivity and is scheduled to receive a live attenuated vaccine in the coming weeks. Which drug regimen is most appropriate for managing this patient's bronchiectasis?", "options": {"A": "SYMDEKO, with dose adjustment for age and monitoring for cataracts", "B": "Brinsupri, with regular dental checkups and avoidance of live attenuated vaccines", "C": "ORKAMBI, with close monitoring of liver function and avoidance of CYP3A substrates", "D": "Brinsupri, administered concurrently with live attenuated vaccines"}}
{"id": "ZquI5x1o6OyM", "question_type": "multi_choice", "question": "A 55-year-old man with prurigo nodularis and a documented history of hypersensitivity to nemolizumab-ilto presents for therapy. He is otherwise healthy, not pregnant, and has no renal impairment. Which drug regimen is most suitable for his condition?", "options": {"A": "Nemluvio administered subcutaneously every four weeks", "B": "Apremilast 30 mg orally twice daily", "C": "Dupixent administered subcutaneously every two weeks", "D": "Apremilast 30 mg orally once daily"}}
{"id": "PVuy9invllKH", "question_type": "multi_choice", "question": "A 45-year-old man with chronic immune thrombocytopenia and autosomal dominant inheritance is being considered for second-line therapy after failing corticosteroids. He has severe renal impairment and is currently taking a strong CYP3A inhibitor for a fungal infection. Which drug is most appropriate for his condition?", "options": {"A": "WAYRILZ (rilzabrutinib) 400 mg twice daily", "B": "WAYRILZ (rilzabrutinib) with a drug scheduler to avoid CYP3A inhibitor overlap", "C": "DMT SUIK (corticosteroid) intravenous therapy", "D": "Nplate (romiplostim) weekly subcutaneous injection"}}
{"id": "wwir76jZAL7R", "question_type": "open_ended_multi_choice", "question": "A 32-year-old patient, currently in the second trimester of pregnancy, has been diagnosed with a Staphylococcus aureus bloodstream infection. With normal renal function and no drug allergies, what is the most appropriate choice of antibiotic therapy for this patient?", "options": {"A": "Doxycycline Hyclate, 100 mg twice daily for 14 days", "B": "Zevtera, dosed appropriately for renal function and infection severity", "C": "Rituximab and Hyaluronidase, administered as per oncology protocols", "D": "Doxycycline Hyclate, with a reduced dose to minimize fetal exposure"}}
{"id": "4DPpSpVeV8xb", "question_type": "multi_choice", "question": "A 62-year-old woman with metastatic pancreatic adenocarcinoma presents for first-line systemic therapy. Her laboratory results show a baseline absolute neutrophil count of 1,200 cells/mm³ and total bilirubin 1.2 x ULN. She has no history of hypersensitivity to taxanes, and her cardiac function is normal. Which drug regimen is most appropriate for her initial treatment?", "options": {"A": "Paclitaxel protein-bound particles for injectable suspension (albumin-bound) in combination with gemcitabine", "B": "Imbruvica (ibrutinib)", "C": "BIZENGRI (zenocutuzumab)", "D": "Paclitaxel protein-bound particles for injectable suspension (albumin-bound) monotherapy"}}
{"id": "FfLOYSXodOlg", "question_type": "open_ended_multi_choice", "question": "A 35-year-old woman with hemophilia A and a history of symptomatic gallbladder disease (cholecystectomy performed last year) presents for routine prophylaxis. She has normal hepatic function and is not pregnant. Which of the following is the most appropriate prophylactic therapy for her?", "options": {"A": "Qfitlia, administered according to antithrombin-based dosing regimen", "B": "Hemlibra, administered subcutaneously every two weeks", "C": "Qfitlia, administered at a fixed dose of 80 mg once monthly", "D": "Qfitlia, administered according to antithrombin-based dosing regimen with concurrent hormonal contraceptives"}}
{"id": "JEu16EdKt7WT", "question_type": "open_ended_multi_choice", "question": "A 3-year-old child presents with a severe hypersensitivity reaction requiring immediate management. The child has a history of mild asthma and is currently not taking any other medications. Considering the risks associated with drug administration in pediatric patients, which of the following is the most appropriate drug for acute management of this hypersensitivity reaction?", "options": {"A": "PHENERGAN (promethazine) injection", "B": "DOXEPIN HYDROCHLORIDE (PRUDOXIN) cream", "C": "DEXAMETHASONE SODIUM PHOSPHATE injection", "D": "Oral DOXEPIN HYDROCHLORIDE"}}
{"id": "OTFKnYK0lBto", "question_type": "open_ended_multi_choice", "question": "What is the mechanistic basis for the recommendation to not use Romvimza together with substrates of P-gp, BCRP, and OCT2?", "options": {"A": "Romvimza acts as an inhibitor of these transporters in vitro.", "B": "Romvimza induces hepatic enzymes.", "C": "Romvimza increases renal clearance of substrates.", "D": "Romvimza is a substrate for these transporters."}}
{"id": "mvYMua0ARtWP", "question_type": "open_ended_multi_choice", "question": "A 35-year-old woman with primary axillary hyperhidrosis is currently breastfeeding her 2-month-old infant. She is considering topical therapy for her symptoms. She is otherwise healthy and not taking any other medications. Which treatment option should be avoided due to the potential for drug transfer into breast milk?", "options": {"A": "Qbrexza", "B": "Sofdra", "C": "Oxybutynin", "D": "Both Qbrexza and Sofdra"}}
{"id": "9zYgouaGQjyW", "question_type": "open_ended_multi_choice", "question": "If a patient is prescribed Grafapex alongside another medication that relies heavily on CYP3A4 for metabolism, how should you proceed clinically?", "options": {"A": "Monitor for adverse reactions and consider reducing the substrate dosage if recommended.", "B": "Increase the substrate dosage to compensate for reduced metabolism.", "C": "Discontinue Grafapex immediately.", "D": "No action is necessary as there is no interaction."}}
{"id": "rXysiPRWu3my", "question_type": "multi_choice", "question": "A 58-year-old woman with malignant mesenchymoma is being considered for supportive therapy following induction chemotherapy. She has a history of supraventricular arrhythmias and is currently taking lithium for bipolar disorder. Which of the following drugs should be avoided due to the risk of exacerbating her underlying conditions or drug interactions?", "options": {"A": "Leukine administered for neutrophil recovery", "B": "Vincristine Sulfate administered intravenously", "C": "HYCAMTIN administered orally", "D": "Leukine administered with close cardiac monitoring"}}
{"id": "YqetMXfHy2Tu", "question_type": "open_ended_multi_choice", "question": "How does Journavx impact the effectiveness of hormonal contraceptives that utilize progestins aside from levonorgestrel and norethindrone?", "options": {"A": "No additional contraceptive method is required.", "B": "Journavx increases the efficacy of all hormonal contraceptives.", "C": "Patients should use an additional nonhormonal contraceptive method or an alternative hormonal contraceptive during and for 28 days after Journavx treatment.", "D": "Journavx is contraindicated with all hormonal contraceptives."}}
{"id": "AmgiZgwQWAg9", "question_type": "open_ended", "question": "A 10-year-old boy with X-linked intellectual disability with isolated growth hormone deficiency presents with short stature, anterior pituitary hypoplasia, and decreased response to growth hormone stimulation test. He also has mild global developmental delay and abnormal saccadic eye movements. His parents ask about the use of testosterone pellets to improve his growth. Which statement best describes the use of testosterone in this scenario?", "options": {"A": "Testosterone pellets are recommended for improving growth in children with growth hormone deficiency.", "B": "Testosterone pellets may accelerate bone maturation and compromise adult height in children with growth hormone deficiency.", "C": "Testosterone pellets are safe and effective for treating intellectual disability and developmental delay.", "D": "Testosterone pellets should be used in combination with growth hormone for optimal results."}}
{"id": "BUMJDq8TEYgn", "question_type": "multi_choice", "question": "A 28-year-old woman with cystic fibrosis and a history of cirrhosis and hepatosplenomegaly is planning to become pregnant. She has a confirmed F508del mutation and is currently taking oral contraceptives. Her liver function tests are mildly elevated (Child-Pugh Class A). Which of the following is the most suitable drug regimen for her cystic fibrosis management?", "options": {"A": "ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor) is contraindicated due to pregnancy risk", "B": "Insulin Aspart Protamine and Insulin Aspart Mix 70/30, administered before meals", "C": "ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor) at reduced dosage due to oral contraceptive use", "D": "ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor) at standard dosage, with regular liver function and ophthalmologic monitoring"}}
{"id": "GsRld3AMpjIH", "question_type": "open_ended_multi_choice", "question": "A 38-year-old woman, currently nursing her 2-month-old baby, presents with moderate to severe chronic hand eczema unresponsive to topical corticosteroids. She expresses concern about the safety of any medications for her infant. What is the best treatment strategy in this situation?", "options": {"A": "Initiate topical Anzupgo, advising her to avoid direct contact with the nipple and areola after application.", "B": "Initiate topical Anzupgo without any precautions regarding breastfeeding.", "C": "Initiate topical corticosteroids, despite her previous inadequate response.", "D": "Initiate topical Anzupgo in combination with another JAK inhibitor for enhanced efficacy."}}
{"id": "OLwY7kOdrYbz", "question_type": "open_ended_multi_choice", "question": "A 45-year-old woman presents with acquired thrombocytopenia and a history of hypertension. She requires corticosteroid therapy for her hematologic condition. She is currently taking a nonselective beta-adrenergic antagonist for blood pressure control. Which drug regimen is most appropriate for her thrombocytopenia management, considering her comorbidities and current medications?", "options": {"A": "Dyural 40 Kit (methylprednisolone acetate) administered intramuscularly, with careful monitoring for hypertension and bradycardia due to her beta-blocker use.", "B": "Betamethasone Dipropionate cream applied topically twice daily for two weeks.", "C": "Hormone Harmony oral homeopathic drops, three times daily.", "D": "Dyural 40 Kit (methylprednisolone acetate) administered intramuscularly, without monitoring for cardiovascular effects."}}
{"id": "CNAUcdsdIrB2", "question_type": "open_ended_multi_choice", "question": "If a patient is given Imaavy during pregnancy, or becomes pregnant while on Imaavy, what actions are recommended for healthcare professionals?", "options": {"A": "Discontinue Imaavy immediately", "B": "Report Imaavy exposure to Janssen", "C": "Increase the dose of Imaavy", "D": "No action is required"}}
{"id": "HJJOBCtJhcQk", "question_type": "multi_choice", "question": "A patient receiving Modeyso develops a rash, hives, and low blood pressure. What is the most appropriate immediate clinical action?", "options": {"A": "Continue Modeyso and monitor symptoms closely.", "B": "Temporarily interrupt Modeyso and observe for improvement.", "C": "Switch to another medication with similar efficacy.", "D": "Reduce the dose of Modeyso and prescribe antihistamines."}}
{"id": "X7XRiRfzmJUG", "question_type": "open_ended_multi_choice", "question": "A 58-year-old woman with a history of myocardial infarction and type 2 diabetes mellitus is prescribed antiplatelet therapy to reduce her risk of recurrent cardiovascular events. She has moderate hepatic impairment and is currently taking simvastatin 40 mg daily for dyslipidemia. Which antiplatelet agent is most appropriate for her ongoing management?", "options": {"A": "BRILINTA", "B": "Clopidogrel", "C": "Flyrcado", "D": "BRILINTA with simvastatin 80 mg"}}
{"id": "ZPQR5jfN9nTZ", "question_type": "open_ended_multi_choice", "question": "A teenage girl, age 14, with a recurrent low-grade glioma and documented BRAF fusion is on fluconazole for a fungal infection and is using hormonal contraceptives. As her oncologist considers targeted therapy, which option should not be selected due to risks of drug interaction and impact on contraceptive reliability?", "options": {"A": "VinCRIStine Sulfate administered intravenously, with careful monitoring for neurotoxicity.", "B": "OJEMDA administered orally once daily, despite concurrent fluconazole and hormonal contraceptive use.", "C": "Gliadel Wafer implantation as adjunct to surgery, regardless of glioma grade.", "D": "OJEMDA administered with a planned drug holiday every 3 months to minimize adverse effects."}}
{"id": "QkBg5f1l1LDg", "question_type": "open_ended_multi_choice", "question": "A 32-year-old woman with cystic fibrosis, who has at least one responsive CFTR mutation, presents with chronic pulmonary disease, hepatomegaly, and Child-Pugh Class C cirrhosis. She is planning to become pregnant and is currently taking hormonal contraceptives. What is the safest and most suitable drug regimen for her cystic fibrosis management?", "options": {"A": "ALYFTREK at standard dosage, with close liver function monitoring.", "B": "SYMDEKO at reduced dosage, with regular liver function monitoring.", "C": "ALYFTREK at reduced dosage, with interruption of hormonal contraceptives.", "D": "SYMDEKO at standard dosage, with interruption of hormonal contraceptives."}}
{"id": "jGisuBvMQ2cs", "question_type": "open_ended_multi_choice", "question": "A 55-year-old female patient, currently pregnant and diagnosed with metastatic esophageal squamous cell carcinoma, previously experienced feeding difficulties as an infant and has progressed on platinum-based chemotherapy. Considering her pregnancy and desire to avoid harm to the fetus, which medication is contraindicated for her treatment now?", "options": {"A": "Tislelizumab-jsgr as a single agent", "B": "Nivolumab and hyaluronidase as monotherapy", "C": "Lenvatinib monotherapy", "D": "All of the above"}}
{"id": "DHhUmeWhduKA", "question_type": "open_ended_multi_choice", "question": "For a patient diagnosed with hemophilia who also has a history of symptomatic gallbladder disease, what clinical approach should be taken when evaluating the use of Qfitlia therapy?", "options": {"A": "Consider alternative treatment for hemophilia", "B": "Increase Qfitlia dose", "C": "Monitor only for thrombotic events", "D": "Continue Qfitlia without modification"}}
{"id": "dv1yvN09MBEb", "question_type": "open_ended_multi_choice", "question": "A 68-year-old patient with extensive-stage small cell lung cancer (ES-SCLC) has experienced disease progression after platinum-based chemotherapy. The patient has a history of chronic kidney disease with a creatinine clearance of 45 mL/min and is currently taking a P-glycoprotein inhibitor for another condition. Which drug regimen is most appropriate for this patient, considering both efficacy and safety?", "options": {"A": "Topotecan capsules, standard dose, administered orally once daily for 5 consecutive days every 21 days", "B": "Imdelltra, step-up dosing schedule, administered intravenously as per protocol", "C": "Ipilimumab, administered as a single agent every 3 weeks", "D": "Topotecan capsules, standard dose, administered with a drug holiday after each cycle"}}
{"id": "8cIdztXrhX8f", "question_type": "open_ended_multi_choice", "question": "A 38-year-old pregnant woman is newly diagnosed with unresectable esophageal squamous cell carcinoma. Her tumor expresses PD-L1 (CPS = 3). She is experiencing feeding difficulties and nausea. Which of the following drugs is contraindicated for her due to her pregnancy status?", "options": {"A": "Tevimbra in combination with platinum-containing chemotherapy", "B": "Keytruda QLEX in combination with platinum- and fluoropyrimidine-based chemotherapy", "C": "Docetaxel anhydrous in combination with cisplatin and fluorouracil", "D": "All of the above"}}
{"id": "nbmIh0GZIiPN", "question_type": "multi_choice", "question": "When counseling patients on Romvimza, what is the most important advice regarding concomitant medications and supplements?", "options": {"A": "Patients should inform their healthcare providers of all concomitant products, including over-the-counter products and supplements.", "B": "Patients should avoid all over-the-counter products.", "C": "Patients may take any supplements without restriction.", "D": "Only prescription medications need to be reported."}}
{"id": "OezYfB9YmFus", "question_type": "multi_choice", "question": "Which of the following statements is correct regarding the use of Anzupgo in breastfeeding women?", "options": {"A": "Anzupgo is known to be safe during breastfeeding", "B": "Anzupgo passes into breast milk and is contraindicated", "C": "It is not known if Anzupgo passes into breast milk; avoid applying to nipple and surrounding area if breastfeeding", "D": "Anzupgo should be applied directly to the nipple for best results"}}
{"id": "XaNPn3sf46GA", "question_type": "multi_choice", "question": "A 55-year-old man with prurigo nodularis and a documented history of hypersensitivity to nemolizumab-ilto presents for therapy. He is otherwise healthy, not pregnant, and has no renal impairment. Which drug regimen is most suitable for his condition?", "options": {"A": "Nemluvio administered subcutaneously every four weeks", "B": "Apremilast 30 mg orally once daily", "C": "Apremilast 30 mg orally twice daily", "D": "Dupixent administered subcutaneously every two weeks"}}
{"id": "OLyLHZgTB77U", "question_type": "multi_choice", "question": "A patient receiving penpulimab-kcqx develops Grade 3 immune-mediated pneumonitis. What is the recommended initial management strategy?", "options": {"A": "Withhold or permanently discontinue penpulimab-kcqx and initiate systemic corticosteroids", "B": "Continue penpulimab-kcqx and monitor closely", "C": "Switch to another PD-1/PD-L1 inhibitor", "D": "Treat with antibiotics and continue penpulimab-kcqx"}}
{"id": "khSDNMZi1R4m", "question_type": "open_ended_multi_choice", "question": "A 58-year-old woman with a new diagnosis of multiple myeloma, evidenced by paraproteinemia and amyloidosis, has no prior exposure to chemotherapy or immunotherapy, is not pregnant, and has no history of thromboembolic events. She is currently taking antihistamines for seasonal allergies. What is the most suitable initial drug regimen for treating her multiple myeloma?", "options": {"A": "Thalidomide in combination with dexamethasone", "B": "Linvoseltamab-gcpt monotherapy", "C": "Talquetamab-tgvs monotherapy", "D": "Thalidomide monotherapy"}}
{"id": "jSM7x4IL3L2s", "question_type": "open_ended_multi_choice", "question": "A 32-year-old woman in her second trimester of pregnancy presents with a new episode of supraventricular tachycardia. She has no history of liver dysfunction, bronchospastic conditions, or other medical issues. As pharmacologic intervention for acute rate control is being considered, which medication is most suitable for her?", "options": {"A": "Pacerone", "B": "Propranolol", "C": "RAPIBLYK", "D": "Pacerone with a drug holiday"}}
{"id": "1G8kRlw0EHsx", "question_type": "open_ended", "question": "A 60-year-old woman with a history of glaucoma and recurrent herpes simplex eye infections is diagnosed with dry eye disease. She does not wear contact lenses and is not pregnant or breastfeeding. Which drug should be avoided due to her medical history, and which is the most appropriate for her treatment?", "options": {"A": "Lotemax SM (loteprednol etabonate ophthalmic gel) 0.38%, one drop in affected eye(s) twice daily", "B": "TRYPTYR (acoltremon ophthalmic solution), one drop in affected eye(s) twice daily", "C": "Xiidra (lifitegrast ophthalmic solution) 5%, one drop in affected eye(s) twice daily", "D": "Lotemax SM (loteprednol etabonate ophthalmic gel) 0.38%, one drop in affected eye(s) once daily"}}
{"id": "xXQlrNOdhMjk", "question_type": "multi_choice", "question": "A 45-year-old woman with primary IgA nephropathy and UPCR of 2.0 g/g is currently breastfeeding her 2-month-old infant. She is otherwise healthy and not pregnant. Which is the most appropriate recommendation regarding atrasentan (VANRAFIA) therapy for her?", "options": {"A": "Initiate atrasentan and continue breastfeeding.", "B": "Atrasentan is contraindicated only if she is pregnant.", "C": "Initiate atrasentan but advise her to stop breastfeeding during treatment.", "D": "Atrasentan is safe to use during lactation."}}
{"id": "OOmAc6nxC9Db", "question_type": "open_ended", "question": "A 3-month-old infant presents with seizures, spastic tetraplegia, feeding difficulties, and laboratory findings of increased urinary sulfite and S-sulfocysteine levels. Genetic testing confirms molybdenum cofactor deficiency type A. The infant has a history of nystagmus and macrocephaly. The parents are concerned about the risk of sunlight exposure due to the infant's fair skin. Which of the following is the most appropriate drug regimen to reduce mortality risk in this patient?", "options": {"A": "Nulibry, with strict avoidance of direct sunlight and use of protective clothing and sunscreen", "B": "Nulibry, with no precautions regarding sunlight exposure", "C": "No drug therapy is indicated for this condition", "D": "Nulibry, but only after the patient reaches 6 years of age"}}
{"id": "VngZlChvXu8r", "question_type": "open_ended_multi_choice", "question": "A 32-year-old pregnant woman in her second trimester is diagnosed with a Staphylococcus aureus bloodstream infection. She has no known drug allergies and normal renal function. Which of the following is the most appropriate antibiotic therapy for her condition?", "options": {"A": "Doxycycline Hyclate, 100 mg twice daily for 14 days", "B": "Zevtera, dosed appropriately for renal function and infection severity", "C": "Rituximab and Hyaluronidase, administered as per oncology protocols", "D": "Doxycycline Hyclate, with a reduced dose to minimize fetal exposure"}}
{"id": "yZJr4byFR7xG", "question_type": "multi_choice", "question": "A 45-year-old patient with infectious anterior uveitis and a history of steroid-induced intraocular pressure (IOP) elevation is being considered for corticosteroid therapy. The patient does not require the most potent steroid, and wishes to minimize the risk of IOP increase. Which drug is the most suitable for this patient, considering both efficacy and safety?", "options": {"A": "Prednisolone", "B": "Hydrocortisone", "C": "Loteprednol Etabonate", "D": "Prednisolone with a drug scheduler"}}
{"id": "VJYHKVJd4UKC", "question_type": "multi_choice", "question": "A 59-year-old woman with extensive-stage small cell lung cancer and autosomal dominant inheritance presents for therapy after progression on platinum-based chemotherapy. She is currently pregnant and seeks advice on the safest treatment option for her condition. Which drug should be strictly avoided due to its risk profile in pregnancy?", "options": {"A": "Topotecan capsules, administered orally as per standard schedule", "B": "Ipilimumab, administered every 3 weeks", "C": "Imdelltra, administered intravenously with step-up dosing", "D": "Supportive care only, with no cytotoxic or immunotherapy agents"}}
{"id": "nJ57Wf9FZ7AD", "question_type": "open_ended", "question": "How does moderate hepatic impairment (Child-Pugh Class B) affect the recommended dosage of Journavx compared to patients with normal hepatic function?", "options": {"A": "The recommended dosage is lower in patients with moderate hepatic impairment", "B": "The recommended dosage is higher in patients with moderate hepatic impairment", "C": "No dosage adjustment is required", "D": "Journavx is contraindicated in moderate hepatic impairment"}}
{"id": "GPraGZzmbFLC", "question_type": "multi_choice", "question": "A 15-year-old adolescent girl with hemophilia B (congenital factor IX deficiency) presents with menometrorrhagia and prolonged bleeding after dental extraction. She is currently pregnant and requires routine prophylaxis to prevent bleeding episodes. Which treatment option is most appropriate for her condition?", "options": {"A": "HYMPAVZI, administered weekly for prophylaxis", "B": "SEVENFACT, administered weekly for prophylaxis", "C": "REBINYN, administered weekly for prophylaxis", "D": "HYMPAVZI, administered only during bleeding episodes"}}
{"id": "xAROTpYW3cdD", "question_type": "open_ended_multi_choice", "question": "For overdose cases involving Journavx, which of the following statements is accurate regarding antidote availability?", "options": {"A": "A specific antidote is available and should be administered immediately.", "B": "No specific antidote is available for Journavx overdose.", "C": "Antidote availability depends on the dose ingested.", "D": "Antidote is only available in specialized centers."}}
{"id": "dgQwJehSogNI", "question_type": "open_ended", "question": "A 10-month-old infant, born at term and currently healthy, is about to enter their first RSV season. The parents are seeking preventive options. The infant is not hospitalized, has no underlying conditions, and there is no concern for pregnancy or lactation. Which drug regimen is most suitable for RSV prevention in this patient?", "options": {"A": "Ribavirin inhalation solution daily for 7 days", "B": "Enflonsia administered as a single dose prior to RSV season", "C": "Quinidine gluconate oral therapy for 2 weeks", "D": "No drug therapy, as none are indicated for prevention in this age group"}}
{"id": "K2cc8EkR0Iwt", "question_type": "open_ended_multi_choice", "question": "A patient is prescribed Journavx and is also taking a medication classified as a strong CYP3A inhibitor. What is the recommended clinical action?", "options": {"A": "Discontinue the strong CYP3A inhibitor", "B": "Reduce the dose of Journavx", "C": "Continue both medications with close monitoring", "D": "Increase the dose of Journavx"}}
{"id": "VzMxW9WTpUZc", "question_type": "open_ended_multi_choice", "question": "A 55-year-old male with metastatic non-squamous non-small cell lung cancer has been identified to have an activating mutation in the HER2 (ERBB2) tyrosine kinase domain. His medical history includes chronic heart failure with a left ventricular ejection fraction of 45%. He is neither pregnant nor taking any CYP3A inducers or BCRP substrates. What is the most appropriate initial treatment for his lung cancer?", "options": {"A": "Zongertinib, with close cardiac monitoring", "B": "Atezolizumab as first-line therapy", "C": "Imfinzi as a single agent", "D": "None of the above; alternative therapy should be considered due to cardiac contraindication"}}
{"id": "Ts5xrth7hh8z", "question_type": "open_ended", "question": "A 28-year-old pregnant woman in her second trimester presents with infectious diarrheal disease caused by susceptible Enterobacter species. She has no known drug allergies and is not taking any other medications. Which drug is most appropriate for her treatment?", "options": {"A": "Ofloxacin Otic Solution", "B": "Ampicillin with Sulbactam", "C": "Ciprofloxacin Ophthalmic Solution", "D": "No antibacterial therapy due to pregnancy"}}
{"id": "40muzcjOQYHA", "question_type": "multi_choice", "question": "Which of the following best describes the incidence of nausea or vomiting in patients treated with JOURNAVX compared to those treated with hydrocodone bitartrate/acetaminophen (HB/APAP) in Trial 1 for moderate to severe acute pain?", "options": {"A": "Lower in JOURNAVX-treated patients than in HB/APAP-treated patients", "B": "Higher in JOURNAVX-treated patients than in HB/APAP-treated patients", "C": "Equal incidence in both groups", "D": "Incidence only reported for JOURNAVX-treated patients"}}
{"id": "72CRzhOlrBS1", "question_type": "multi_choice", "question": "A 68-year-old woman with metastatic gastroesophageal junction adenocarcinoma is being considered for chemotherapy. She has a history of chronic liver disease with laboratory findings of bilirubin 2.1x ULN, AST 2.0x ULN, and alkaline phosphatase 3.0x ULN. She has no known drug allergies and is not taking anticoagulants. Which of the following drugs is contraindicated for her due to her hepatic impairment?", "options": {"A": "Capecitabine (with dose adjustment for hepatic impairment)", "B": "Zolbetuximab (Vyloy) in combination with fluoropyrimidine- and platinum-containing chemotherapy", "C": "Docetaxel in combination with cisplatin and fluorouracil", "D": "Zolbetuximab (Vyloy) monotherapy"}}
{"id": "I6iwZaO0xnUK", "question_type": "open_ended_multi_choice", "question": "A 60-year-old woman with BCG-unresponsive nonmuscle invasive bladder cancer (NMIBC) with CIS is currently pregnant and seeking treatment options. She is otherwise healthy and has no history of bladder perforation or mucosal compromise. Which therapy is contraindicated for her due to potential fetal harm?", "options": {"A": "Nogapendekin alfa inbakicept-pmln (ANKTIVA) with Bacillus Calmette-Guérin (BCG)", "B": "Valrubicin intravesical therapy", "C": "Observation with planned cystectomy after delivery", "D": "Valrubicin intravesical therapy with Bacillus Calmette-Guérin (BCG)"}}
{"id": "Dn0deNWhwV8n", "question_type": "multi_choice", "question": "If a patient on Vanrafia develops aminotransferase elevations accompanied by bilirubin >2x ULN or clinical symptoms of hepatotoxicity, what is the recommended action?", "options": {"A": "Reduce the dose of Vanrafia", "B": "Discontinue Vanrafia", "C": "Continue Vanrafia with close monitoring", "D": "Switch to another ERA"}}
{"id": "CY9RidXu6hFH", "question_type": "multi_choice", "question": "A 58-year-old woman with chronic kidney disease has been receiving dialysis for the past four months. She presents with symptomatic anemia (hemoglobin 9.2 g/dL). Her medical history includes well-controlled hypertension and mild hyperlipidemia, for which she takes simvastatin 10 mg daily. She is not pregnant and has no history of liver disease or malignancy. Which of the following is the most appropriate pharmacologic treatment for her anemia, considering her current medications and comorbidities?", "options": {"A": "Homeopathic combination (Adrenalinum, etc.) for appetite and water retention symptoms.", "B": "Fedratinib administered daily, with thiamine supplementation.", "C": "Vadadustat administered once daily, with careful monitoring of statin-related adverse effects and hemoglobin levels.", "D": "Vadadustat administered once daily, with no adjustment for statin therapy."}}
{"id": "E8KB2D9dKEKp", "question_type": "open_ended_multi_choice", "question": "A 14-year-old female weighing 90 pounds presents with an uncomplicated urinary tract infection (uUTI) caused by susceptible bacteria. Which of the following statements about the use of Blujepa in this patient is most accurate?", "options": {"A": "Blujepa is indicated for this patient and can be used as prescribed.", "B": "Blujepa is not indicated because the patient is under 18 years old.", "C": "Blujepa is not indicated because the patient weighs less than 100 pounds.", "D": "Blujepa is not indicated because the patient is under 12 years old."}}
{"id": "oQUDeDZ1Ij8y", "question_type": "multi_choice", "question": "A 45-year-old man with chronic immune thrombocytopenia and autosomal dominant inheritance is being considered for second-line therapy after failing corticosteroids. He has severe renal impairment and is currently taking a strong CYP3A inhibitor for a fungal infection. Which drug is most appropriate for his condition?", "options": {"A": "WAYRILZ (rilzabrutinib) 400 mg twice daily", "B": "DMT SUIK (corticosteroid) intravenous therapy", "C": "Nplate (romiplostim) weekly subcutaneous injection", "D": "WAYRILZ (rilzabrutinib) with a drug scheduler to avoid CYP3A inhibitor overlap"}}
{"id": "KiMn7e9TvoUo", "question_type": "open_ended_multi_choice", "question": "A 35-year-old female patient with hemophilia A, who underwent cholecystectomy last year for gallbladder disease and has normal hepatic function, presents for routine prophylaxis. She is not pregnant. What is the best choice for her prophylactic therapy?", "options": {"A": "Qfitlia, administered according to antithrombin-based dosing regimen", "B": "Hemlibra, administered subcutaneously every two weeks", "C": "Qfitlia, administered at a fixed dose of 80 mg once monthly", "D": "Qfitlia, administered according to antithrombin-based dosing regimen with concurrent hormonal contraceptives"}}
{"id": "XB2Edy6qDjtJ", "question_type": "open_ended_multi_choice", "question": "A 45-year-old woman with infertility disorder and a history of acute coronary syndrome is found to be a CYP2C19 poor metabolizer based on genetic testing. She is being considered for antiplatelet therapy. Which of the following is the most appropriate recommendation?", "options": {"A": "Clopidogrel bisulfate should be prescribed at standard doses, as genetic status does not affect its efficacy.", "B": "Clopidogrel bisulfate should be avoided due to diminished antiplatelet effect in CYP2C19 poor metabolizers; consider an alternative P2Y12 inhibitor.", "C": "Ergocalciferol should be used as an antiplatelet agent in CYP2C19 poor metabolizers.", "D": "Clopidogrel bisulfate should be prescribed at double the standard dose to overcome genetic resistance."}}
{"id": "LepV6qGxusZv", "question_type": "open_ended_multi_choice", "question": "A 35-year-old woman with a malignant non-epithelial tumor of the ovary is currently breastfeeding her 2-month-old infant. She is otherwise healthy and has normal renal and hepatic function. Which of the following is the most appropriate recommendation regarding chemotherapy for her condition?", "options": {"A": "Initiate etoposide therapy and continue breastfeeding", "B": "Initiate paclitaxel protein-bound particles for injectable suspension (albumin-bound) and continue breastfeeding", "C": "Advise discontinuation of breastfeeding before starting either etoposide or paclitaxel protein-bound particles for injectable suspension (albumin-bound)", "D": "Start etoposide therapy and resume breastfeeding immediately after the last dose"}}
{"id": "wdwx7MdjqWui", "question_type": "open_ended_multi_choice", "question": "A 38-year-old female patient with symptomatic TGCT and chronic hepatitis B (with elevated liver enzymes) is receiving a P-glycoprotein substrate for another illness. Surgery is not a viable option due to the risk of significant morbidity. Which systemic therapy regimen is most appropriate for managing her TGCT?", "options": {"A": "Turalio (pexidartinib hydrochloride) with standard dosing and no dietary restrictions", "B": "Romvimza (vimseltinib), ensuring it is administered at least 4 hours prior to her P-gp substrate", "C": "Romvimza (vimseltinib) with no adjustment for P-gp substrate timing", "D": "Turalio (pexidartinib hydrochloride) with a high-fat meal"}}
{"id": "vIVsB0Py7cXO", "question_type": "multi_choice", "question": "A 7-year-old boy is newly diagnosed with primary cutaneous T-cell lymphoma and presents with widespread pruritic lesions. He has a history of delayed growth and is currently receiving phenytoin for epilepsy. Which treatment approach is most suitable for his condition?", "options": {"A": "Vinblastine Sulfate intravenous chemotherapy administered every 7 days", "B": "Flurandrenolide topical lotion 0.05% applied sparingly to affected areas twice daily", "C": "Vinblastine Sulfate intravenous chemotherapy combined with phenytoin", "D": "Flurandrenolide topical lotion 0.05% applied liberally over all affected skin for several weeks"}}
{"id": "IvvjBzwE5jFc", "question_type": "open_ended_multi_choice", "question": "A 34-year-old woman, pregnant in her second trimester, develops symptomatic supraventricular tachycardia and needs acute rate management. She has no relevant medical history and takes no regular medications. Which agent is most suitable for her situation?", "options": {"A": "Pacerone (amiodarone)", "B": "RAPIBLYK (landiolol)", "C": "Propranolol", "D": "Digoxin"}}
{"id": "5nEvuf7GDdWm", "question_type": "multi_choice", "question": "A 10-day-old neonate, born at term and entering their first RSV season, is being evaluated for RSV prophylaxis. The infant has no history of hypersensitivity reactions and is otherwise healthy. The mother is of reproductive potential but is not currently pregnant or breastfeeding. Which drug is most appropriate for RSV prevention in this patient?", "options": {"A": "ENFLONSIA, administered as a single dose.", "B": "Virazole, administered as an inhalation solution.", "C": "Restasis MultiDose, administered twice daily.", "D": "Virazole, administered orally."}}
{"id": "ezCNIJFnBruZ", "question_type": "multi_choice", "question": "A 14-year-old female patient weighing 45 kg presents with symptoms of dysuria, urgency, and suprapubic pain. She is diagnosed with an uncomplicated urinary tract infection caused by Escherichia coli. Her medical history is notable for mild renal impairment (eGFR 50 mL/min), and she is currently taking digoxin for a cardiac condition. Which drug regimen is most appropriate for treating her infection, considering her age, renal function, and concomitant medication?", "options": {"A": "Flavoxate Hydrochloride tablets for symptomatic relief, administered three times daily.", "B": "Blujepa administered as per recommended dosing for uUTI, without monitoring of digoxin levels.", "C": "Imipenem and Cilastatin Sodium intravenous therapy, with dosage adjustment for renal impairment.", "D": "Blujepa administered as per recommended dosing for uUTI, with monitoring of digoxin levels."}}
{"id": "MXSVAdCo49tM", "question_type": "multi_choice", "question": "A 58-year-old woman with chronic kidney disease has been receiving dialysis for the past four months. She presents with symptomatic anemia (hemoglobin 9.2 g/dL). Her medical history includes well-controlled hypertension and mild hyperlipidemia, for which she takes simvastatin 10 mg daily. She is not pregnant and has no history of liver disease or malignancy. Which of the following is the most appropriate pharmacologic treatment for her anemia, considering her current medications and comorbidities?", "options": {"A": "Vadadustat administered once daily, with no adjustment for statin therapy.", "B": "Fedratinib administered daily, with thiamine supplementation.", "C": "Homeopathic combination (Adrenalinum, etc.) for appetite and water retention symptoms.", "D": "Vadadustat administered once daily, with careful monitoring of statin-related adverse effects and hemoglobin levels."}}
{"id": "9BsgqG9jQflF", "question_type": "open_ended_multi_choice", "question": "A 28-year-old woman with classic congenital adrenal hyperplasia, currently on glucocorticoid therapy, is planning a pregnancy and inquires about initiating crinecerfont (CRENESSITY) to manage her androgen levels. What is the best guidance regarding the use of crinecerfont in her situation?", "options": {"A": "Crinecerfont is contraindicated in all pregnant women.", "B": "Crinecerfont may be considered if the benefits outweigh the risks, but exposure should be reported and monitored.", "C": "Crinecerfont is safe and recommended for all women planning pregnancy.", "D": "Crinecerfont should be discontinued immediately upon conception."}}
{"id": "mSODQ6RoJdpv", "question_type": "multi_choice", "question": "A 68-year-old woman with newly diagnosed locally advanced ROS1-positive non-small cell lung carcinoma is being considered for targeted therapy. She has a history of osteoporosis and is currently taking a proton pump inhibitor for chronic gastroesophageal reflux disease. Which of the following is the most appropriate approach regarding the use of taletrectinib for her treatment?", "options": {"A": "Initiate taletrectinib 600 mg orally once daily, but discontinue the proton pump inhibitor or adjust antacid timing.", "B": "Initiate taletrectinib 600 mg orally once daily without modification.", "C": "Taletrectinib is contraindicated due to her age.", "D": "Taletrectinib is contraindicated due to her osteoporosis."}}
{"id": "86zsSH60fXDl", "question_type": "open_ended_multi_choice", "question": "Which of the following statements best describes the use of Journavx in combination with strong CYP3A inhibitors?", "options": {"A": "Journavx is contraindicated with strong CYP3A inhibitors.", "B": "Journavx dose should be doubled.", "C": "Journavx should be administered every 6 hours.", "D": "No dose adjustment is necessary."}}
{"id": "TX2XcongJ13V", "question_type": "multi_choice", "question": "A 32-year-old woman with moderate hepatic impairment (Child-Pugh class B) is being considered for treatment with Wayrilz. What is the recommended approach regarding the use of Wayrilz in this patient?", "options": {"A": "Administer Wayrilz at the standard dose.", "B": "Reduce the dose of Wayrilz.", "C": "Avoid administration of Wayrilz.", "D": "Increase the dose of Wayrilz."}}
{"id": "FWpk3ZqDyU7I", "question_type": "multi_choice", "question": "A 32-year-old woman with acute erythroleukemia and splenomegaly is currently 10 weeks pregnant. She is not taking any other medications and has no significant comorbidities. Which of the following drugs should be avoided due to the highest risk of embryo-fetal toxicity and teratogenicity, based on available evidence?", "options": {"A": "Revuforj administered twice daily at standard dosing", "B": "TaperDex 6-day oral regimen at the lowest effective dose", "C": "Aldesleukin administered intravenously in a hospital setting", "D": "Dexamethasone as adjunctive therapy for anemia"}}
{"id": "4sdasJ7mZJw8", "question_type": "multi_choice", "question": "A 32-year-old woman with a history of rheumatoid arthritis, currently 10 weeks pregnant, is diagnosed with hepatosplenic T-cell lymphoma. She is being considered for immunosuppressive therapy. Which of the following drugs should be avoided due to a high risk of fetal harm when administered during pregnancy?", "options": {"A": "Inflectra", "B": "Simponi Aria", "C": "Fludarabine phosphate", "D": "Methotrexate"}}
{"id": "dyRilwlgUg99", "question_type": "open_ended_multi_choice", "question": "A 30-year-old man with moderate chronic hand eczema has failed topical corticosteroid therapy. He is currently receiving treatment for active hepatitis C. Which of the following is the most suitable drug regimen for his hand eczema?", "options": {"A": "Delgocitinib topical therapy", "B": "Topical corticosteroids", "C": "Delgocitinib in combination with potent immunosuppressants", "D": "Delgocitinib after hepatitis C treatment is completed and infection resolved"}}
{"id": "6f0xZqJedSqW", "question_type": "open_ended_multi_choice", "question": "A 60-year-old man with a history of supraventricular tachycardia and moderate hepatic impairment (Child-Pugh B) is admitted for acute rate control. He is not pregnant and does not have bronchospastic disease. Which of the following drugs should be avoided due to his hepatic condition, and which is the most appropriate alternative?", "options": {"A": "RAPIBLYK should be avoided; Propranolol is the most appropriate alternative.", "B": "Pacerone should be avoided; RAPIBLYK is the most appropriate alternative.", "C": "Propranolol should be avoided; Pacerone is the most appropriate alternative.", "D": "RAPIBLYK should be avoided; Pacerone is the most appropriate alternative."}}
{"id": "EfxtSBFEo3NE", "question_type": "open_ended_multi_choice", "question": "Blujepa should not be administered to which group of patients?", "options": {"A": "Patients with a history of severe hypersensitivity to Blujepa", "B": "Patients with mild renal impairment", "C": "Patients with controlled hypertension", "D": "Patients with a history of seasonal allergies"}}
{"id": "aVDqT6jh1TrF", "question_type": "multi_choice", "question": "A 68-year-old man with relapsed multiple myeloma has previously received four lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. He has well-controlled hypertension and normal renal and hepatic function. He is not currently experiencing any infections. Which of the following is the most appropriate next-line therapy for his condition?", "options": {"A": "Thalomid in combination with dexamethasone", "B": "Mozobil in combination with filgrastim", "C": "LYNOZYFIC", "D": "Observation only, as no further therapy is indicated"}}
{"id": "OWZzQQ8msIru", "question_type": "multi_choice", "question": "What is the observed difference in safety or effectiveness of Emrelis between older (≥65 years) and younger patients with previously treated EGFR wild-type non-squamous NSCLC with c-Met protein overexpression?", "options": {"A": "Older patients have significantly higher adverse events", "B": "No overall differences in safety or effectiveness were observed", "C": "Younger patients have better effectiveness", "D": "Older patients require dose adjustment"}}
{"id": "nudhdNd55OIt", "question_type": "multi_choice", "question": "A 7-year-old boy with sepiapterin-responsive phenylketonuria presents with a history of recurrent nosebleeds and easy bruising. He is not taking any medications that affect folate synthesis or sepiapterin reductase. His parents are concerned about starting a new medication for PKU. Which of the following is the most appropriate drug to initiate for his hyperphenylalaninemia?", "options": {"A": "Trimethoprim", "B": "Javygtor", "C": "Sephience", "D": "Sapropterin dihydrochloride"}}
{"id": "5JYq9Z20zopW", "question_type": "open_ended_multi_choice", "question": "For a patient with unresectable metastatic biliary tract cancer who has already received prior treatment, is HER2-positive (IHC 3+) per FDA-approved test, has a documented reduced LVEF of 45%, and is taking multiple strong CYP3A inhibitors, what is the most suitable treatment choice?", "options": {"A": "Zanidatamab-hrii (ZIIHERA) every three weeks, standard dose", "B": "Futibatinib (LYTGOBI) once daily, standard dose", "C": "Pemigatinib (PEMAZYRE) once daily, standard dose", "D": "Zanidatamab-hrii (ZIIHERA) every three weeks, with cardiac monitoring and dose reduction"}}
{"id": "v5E8WTufucwi", "question_type": "open_ended_multi_choice", "question": "Which of the following statements is true regarding the presence of Penpulimab-kcqx in human milk and its effects on the breastfed child?", "options": {"A": "Penpulimab-kcqx is known to be present in human milk and is safe for the breastfed child.", "B": "There is no information regarding the presence of Penpulimab-kcqx in human milk or its effects on the breastfed child.", "C": "Penpulimab-kcqx is contraindicated only if the child is under 6 months old.", "D": "Penpulimab-kcqx increases milk production."}}
{"id": "gbhKTBen9gN7", "question_type": "open_ended_multi_choice", "question": "A 40-year-old man with a confirmed diagnosis of Niemann-Pick disease type C reports worsening gait, vertical supranuclear gaze palsy, and mild renal impairment (estimated creatinine clearance of 65 mL/min). He is not taking other medications. Which treatment should be selected for his neurological symptoms?", "options": {"A": "Miglustat (Yargesa) 100 mg twice daily, with dose adjustment for renal impairment", "B": "AQNEURSA (levacetylleucine), standard dosing without renal adjustment", "C": "Miglustat (Opfolda) in combination with Pombiliti, with dose reduction for renal impairment", "D": "AQNEURSA (levacetylleucine), with dose reduction for renal impairment"}}
{"id": "JaO7R4ZCYQZm", "question_type": "open_ended", "question": "A 15-year-old patient presents with generalized myasthenia gravis and tests positive for anti-muscle-specific tyrosine kinase antibodies. The patient has a history of frequent infections and is currently recovering from a mild viral illness. Which drug is most appropriate for initial treatment, considering both efficacy and safety for this patient profile?", "options": {"A": "Pyridostigmine Bromide", "B": "IMAAVY", "C": "DuoDote", "D": "Succinylcholine"}}
{"id": "7mdOGzuvGiWW", "question_type": "multi_choice", "question": "A 32-year-old man with a history of hypoparathyroidism and prior external beam radiation therapy involving the skeleton presents for ongoing management. His albumin-corrected serum calcium is stable at 8.0 mg/dL on calcium and active vitamin D. He is not taking digoxin. Which of the following is the most appropriate next step in pharmacologic management?", "options": {"A": "Initiate Yorvipath once daily", "B": "Start GENOTROPIN at a reduced dose", "C": "Continue calcium and active vitamin D supplementation only", "D": "Begin Tri-Vite Drops with Fluoride supplementation"}}
{"id": "UyEHo3iWw5KU", "question_type": "open_ended", "question": "A 32-year-old man with a history of hepatitis B carrier status is diagnosed with fulminating pulmonary tuberculosis. He is able to swallow and tolerate oral medications. Which adjunctive corticosteroid regimen should be selected to minimize the risk of hepatitis B reactivation while treating his tuberculosis?", "options": {"A": "DMT SUIK intravenous injection", "B": "Prednisone oral tablets with hepatitis B screening and specialist consultation", "C": "Dexamethasone sodium phosphate injection without hepatitis B consideration", "D": "GUNA-IL 2 oral solution"}}
{"id": "23W6PNy8BNcz", "question_type": "open_ended_multi_choice", "question": "A 52-year-old male with schizophrenia and benign prostatic hyperplasia (BPH) is being evaluated for maintenance antipsychotic therapy. He has no renal or hepatic impairment and his cognitive status is preserved. Which antipsychotic is most appropriate given his BPH and the concern for urinary retention?", "options": {"A": "Cobenfy (xanomeline and trospium chloride), standard adult dose", "B": "Abilify Maintena (aripiprazole), standard adult dose", "C": "Cobenfy (xanomeline and trospium chloride), reduced dose for geriatric patients", "D": "Abilify Maintena (aripiprazole), reduced dose for CYP2D6 poor metabolizers"}}
{"id": "fth7EFkBlWZW", "question_type": "multi_choice", "question": "In the AK105-304 trial, what was the major efficacy outcome measure used to evaluate penpulimab-kcqx in combination with platinum and gemcitabine?", "options": {"A": "BICR-assessed progression-free survival (PFS) according to RECIST v1.1", "B": "Objective response rate (ORR) by investigator assessment", "C": "Quality of life improvement", "D": "Reduction in adverse events"}}
{"id": "NRnSlHy8RqeK", "question_type": "open_ended_multi_choice", "question": "A 32-year-old pregnant woman at 10 weeks gestation presents with moderate dry eye disease and is concerned about medication safety for her fetus. She does not use contact lenses. Given her pregnancy and the safety profiles of available treatments, which medication is most suitable for managing her dry eye disease?", "options": {"A": "Loteprednol etabonate ophthalmic gel, administered twice daily", "B": "Lifitegrast ophthalmic solution, administered twice daily", "C": "Acoltremon ophthalmic solution, administered twice daily", "D": "Loteprednol etabonate ophthalmic gel, administered once daily"}}
{"id": "7RxWcIFJo4lr", "question_type": "multi_choice", "question": "A 14-year-old female patient weighing 45 kg presents with symptoms of dysuria, urgency, and suprapubic pain. She is diagnosed with an uncomplicated urinary tract infection caused by Escherichia coli. Her medical history is notable for mild renal impairment (eGFR 50 mL/min), and she is currently taking digoxin for a cardiac condition. Which drug regimen is most appropriate for treating her infection, considering her age, renal function, and concomitant medication?", "options": {"A": "Blujepa administered as per recommended dosing for uUTI, with monitoring of digoxin levels.", "B": "Flavoxate Hydrochloride tablets for symptomatic relief, administered three times daily.", "C": "Imipenem and Cilastatin Sodium intravenous therapy, with dosage adjustment for renal impairment.", "D": "Blujepa administered as per recommended dosing for uUTI, without monitoring of digoxin levels."}}
{"id": "K4rs4ir2K2OF", "question_type": "open_ended", "question": "A 13-year-old male with isolated growth hormone deficiency type IB presents with short stature, delayed skeletal maturation, and micropenis. His bone age is significantly delayed, and he has reduced circulating growth hormone concentration. The endocrinologist considers androgen therapy to stimulate puberty. Which treatment approach is most appropriate for this patient, considering the risk of compromised adult height and the need for bone age monitoring?", "options": {"A": "Initiate testosterone (Testopel) pellets with bone age monitoring every 6 months and conservative dosing.", "B": "Start high-dose testosterone (Testopel) pellets without bone age monitoring.", "C": "Begin testosterone (Testopel) pellets for athletic performance enhancement.", "D": "Avoid testosterone therapy due to delayed puberty and monitor only psychological support."}}
{"id": "XQFkOICthmAh", "question_type": "open_ended_multi_choice", "question": "How many months should females capable of becoming pregnant maintain effective contraception following their final dose of penpulimab-kcqx?", "options": {"A": "1 month", "B": "2 months", "C": "3 months", "D": "4 months"}}
{"id": "Q19rzxnnH99o", "question_type": "open_ended_multi_choice", "question": "A 68-year-old man with chronic obstructive pulmonary disease (COPD) and a history of liver dysfunction is seeking maintenance therapy. He is currently stable and has no psychiatric history. Taking into account his age and comorbid hepatic impairment, which medication would be the most suitable for ongoing COPD management?", "options": {"A": "Budesonide Inhalation", "B": "Fentanyl Citrate", "C": "Ensifentrine", "D": "Budesonide (oral)"}}
{"id": "6tpuf5ls0qvq", "question_type": "open_ended_multi_choice", "question": "An adult patient with hypersensitivity reaction disease and a history of major depressive disorder is currently taking fluoxetine (an SSRI). The patient develops moderate pruritus due to atopic dermatitis and requires short-term treatment. Which drug should be avoided due to the risk of significant drug interaction and possible toxicity?", "options": {"A": "PHENERGAN (promethazine) injection", "B": "DEXAMETHASONE SODIUM PHOSPHATE injection", "C": "DOXEPIN HYDROCHLORIDE (PRUDOXIN) cream", "D": "Cetirizine oral tablet"}}
{"id": "5HnsXRTtSNJZ", "question_type": "open_ended_multi_choice", "question": "A child aged 9 years is diagnosed with a metastatic solid tumor and is found to have an NTRK gene fusion confirmed by FDA-approved testing. With mild renal impairment (eGFR 55 mL/min) and no prior cardiac issues, which drug should be selected based on the patient's age, genetic profile, and kidney function?", "options": {"A": "Erlotinib, 85 mg/m²/day orally", "B": "Lazcluze (lazertinib + amivantamab), standard pediatric dosing", "C": "Rozlytrek, weight-based dosing once daily", "D": "Erlotinib in combination with gemcitabine"}}
{"id": "7Uy1vMsnZsU6", "question_type": "open_ended_multi_choice", "question": "During a routine prenatal visit, a 28-year-old pregnant patient with congenital hemophilia A (factor VIII deficiency) is considered for prophylactic management. She is in her second trimester and has never experienced inhibitors or allergic reactions to therapy. What is the recommended strategy for her prophylactic treatment?", "options": {"A": "Alhemo, as the benefits always outweigh the risks in pregnancy", "B": "Hemlibra, used only if the potential benefit outweighs the risk to the fetus", "C": "Alhemo, with no need for contraception or risk assessment", "D": "Hemlibra, as it is completely safe in pregnancy"}}
{"id": "VGAS5GUDUyZ7", "question_type": "multi_choice", "question": "During Vanrafia therapy, which of the following is a recommended action for patients who experience unprotected sex or contraceptive failure?", "options": {"A": "Wait until the next scheduled dose", "B": "Seek advice on emergency contraception", "C": "Discontinue Vanrafia immediately", "D": "Increase the dose of Vanrafia"}}
{"id": "EKn95LQCMVHN", "question_type": "multi_choice", "question": "A 56-year-old woman with metastatic, hormone receptor-positive, HER2-negative breast cancer has a confirmed PIK3CA mutation and has progressed after adjuvant endocrine therapy. She also has a history of well-controlled Type 2 diabetes managed with oral anti-hyperglycemic agents. Her oncologist is considering targeted therapy in combination with palbociclib and fulvestrant. Which drug regimen is most appropriate for her cancer management, considering her comorbidities and the need for close metabolic monitoring?", "options": {"A": "Ketorolac tromethamine for chronic pain management and cancer therapy", "B": "Morphine sulfate for pain control, as primary cancer therapy", "C": "Itovebi (inavolisib) in combination with palbociclib and fulvestrant, with intensified glucose monitoring and anti-hyperglycemic management", "D": "Itovebi (inavolisib) monotherapy without palbociclib or fulvestrant"}}
{"id": "tlWTEpnHPfi7", "question_type": "multi_choice", "question": "A 35-year-old woman with newly diagnosed non-keratinizing nasopharyngeal carcinoma is 10 weeks pregnant. She has no significant comorbidities and normal renal and hepatic function. Which of the following drugs is contraindicated for her cancer treatment due to risk of fetal harm?", "options": {"A": "Penpulimab-kcqx in combination with carboplatin and gemcitabine", "B": "Capecitabine 500 mg twice daily", "C": "Celecoxib 200 mg twice daily", "D": "Penpulimab-kcqx monotherapy"}}
{"id": "tsWzOgLDkON1", "question_type": "open_ended", "question": "A 68-year-old man with relapsed multiple myeloma presents after failing four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. He has a history of significant weight loss and oral mucositis. He is not pregnant and has normal hepatic and renal function. Which of the following is the most appropriate next-line drug therapy for his condition, considering his current symptoms and safety profile?", "options": {"A": "TALVEY administered with step-up dosing and ongoing monitoring for oral toxicity", "B": "LYNOZYFIC with step-up dosing and monitoring for neutropenia and hepatotoxicity", "C": "Mozobil in combination with filgrastim for direct anti-myeloma therapy", "D": "TALVEY with a drug holiday to minimize oral toxicity risk"}}
{"id": "CXimF7z4jje2", "question_type": "multi_choice", "question": "A 48-year-old woman with locally advanced breast cancer is experiencing severe postoperative pain following tumor resection. She has a history of peptic ulcer disease and mild renal impairment (eGFR 55 mL/min). She is not pregnant and weighs 65 kg. Which analgesic regimen is safest and most effective for her acute pain management over the next several days?", "options": {"A": "Morphine sulfate titrated to pain, with careful monitoring for respiratory depression", "B": "Ketorolac tromethamine for up to 5 days, with dose adjustment for renal impairment", "C": "Itovebi (inavolisib) in combination with palbociclib and fulvestrant for pain control", "D": "Ketorolac tromethamine for chronic pain management beyond 5 days"}}
{"id": "6tgLwtKfW19d", "question_type": "open_ended_multi_choice", "question": "A 35-year-old woman with hemophilia B (congenital factor IX deficiency) is seeking routine prophylaxis to reduce bleeding episodes. She is not pregnant and has no history of hypersensitivity to medications. Which of the following is the most suitable drug for her prophylactic treatment?", "options": {"A": "Hemlibra administered weekly", "B": "Alhemo administered as per recommended titration and monitoring", "C": "Hemlibra administered only during breakthrough bleeds", "D": "No prophylactic therapy is indicated for hemophilia B"}}
{"id": "po1DocB0O1ft", "question_type": "open_ended_multi_choice", "question": "A 72-year-old male with BCG-refractory carcinoma in situ (CIS) of the bladder is at high surgical risk and cannot undergo cystectomy right away. He had a transurethral resection of the bladder (TURB) 5 days ago and is now experiencing significant irritative bladder symptoms. Which of the following therapies should not be used in his current situation?", "options": {"A": "Valrubicin intravesical therapy", "B": "Nogapendekin alfa inbakicept-pmln (ANKTIVA) with Bacillus Calmette-Guérin (BCG)", "C": "Immediate cystectomy", "D": "Valrubicin intravesical therapy delayed for two weeks after TURB"}}
{"id": "ADOKSKGfiFWb", "question_type": "multi_choice", "question": "A 15-year-old adolescent presents to the emergency department with an acute attack of hereditary angioedema. The patient has no history of hepatic or renal impairment and is not currently taking any medications. Which drug is the most appropriate for treating this acute attack, considering age-specific approval and safety?", "options": {"A": "Icatibant acetate", "B": "Sajazir", "C": "Ekterly", "D": "Icatibant"}}
{"id": "gHNx3K9lwjfh", "question_type": "open_ended_multi_choice", "question": "A 38-year-old lactating woman with symptomatic TGCT, who is not a candidate for surgery, wishes to continue breastfeeding during her treatment. Her liver and kidney function are normal, she is not pregnant, and she has no allergy history. What is the most suitable drug and breastfeeding timing for her?", "options": {"A": "Turalio, with breastfeeding resumed 1 week after final dose", "B": "ROMVIMZA, with breastfeeding resumed 1 week after final dose", "C": "ROMVIMZA, with breastfeeding resumed 1 month after final dose", "D": "Turalio, with breastfeeding resumed 1 month after final dose"}}
{"id": "vDlBPwBXlVOe", "question_type": "open_ended_multi_choice", "question": "A 10-year-old boy with autosomal dominant inheritance of pemphigus vulgaris presents with feeding difficulties in infancy, oral mucosal blisters, and abnormal blistering of the skin. He has a history of recurrent infections and is scheduled for a drug holiday after 12 days of therapy. Which treatment regimen is most suitable for his age and clinical profile?", "options": {"A": "Proleukin administered intravenously every 8 hours for 5 days", "B": "TaperDex 12-day oral regimen, titrated to the lowest effective dose with careful monitoring of growth", "C": "DEXAMETHASONE SODIUM PHOSPHATE intravenous injection at high dose for 14 days", "D": "Proleukin administered subcutaneously every other day for 2 weeks"}}
{"id": "1sHrFXUc2rMD", "question_type": "multi_choice", "question": "A 10-year-old boy is diagnosed with acquired thrombocytopenia and requires pharmacologic intervention. He has no significant comorbidities and is not taking any other medications. Which of the following is the most suitable drug for his condition?", "options": {"A": "Dyural 40 Kit (methylprednisolone acetate) administered intramuscularly at standard adult dosage.", "B": "Betamethasone Dipropionate cream (augmented), 0.05%, applied twice daily for two weeks.", "C": "Dyural 40 Kit (methylprednisolone acetate) administered intramuscularly with pediatric dose adjustment and close monitoring.", "D": "Hormone Harmony oral drops, as directed."}}
{"id": "zF03uBQIc10L", "question_type": "open_ended_multi_choice", "question": "A 28-year-old woman with sepiapterin-responsive phenylketonuria is planning to become pregnant. She has a history of scleroderma and recently experienced heavy menstrual bleeding. Her current medications include sulfasalazine for her autoimmune condition. Which drug regimen should be avoided for the management of her PKU?", "options": {"A": "Sapropterin dihydrochloride administered daily with a phenylalanine-restricted diet", "B": "JAVYGTOR administered daily with a phenylalanine-restricted diet", "C": "Sephience administered daily with a phenylalanine-restricted diet", "D": "Sapropterin dihydrochloride administered every other day with a phenylalanine-restricted diet"}}
{"id": "0LgimwEOQvTD", "question_type": "multi_choice", "question": "A 62-year-old man is newly diagnosed with locally advanced unresectable gastroesophageal junction adenocarcinoma. His tumor is confirmed to be HER2-negative and CLDN18.2-positive by FDA-approved testing. He has normal hepatic and renal function, no history of hypersensitivity reactions, and is not taking any anticoagulants or CYP3A4 inhibitors. Which initial drug regimen is most appropriate for his first-line treatment?", "options": {"A": "Capecitabine monotherapy", "B": "Docetaxel in combination with cisplatin and fluorouracil", "C": "Docetaxel monotherapy", "D": "Zolbetuximab (Vyloy) in combination with fluoropyrimidine- and platinum-containing chemotherapy"}}
{"id": "IRkljbzeImYG", "question_type": "multi_choice", "question": "Has Tryptyr been shown to impair fertility in animal studies?", "options": {"A": "Yes, Tryptyr significantly impairs fertility in both male and female animals.", "B": "Studies to evaluate the potential effects of Tryptyr on fertility in animals have not been performed.", "C": "No, Tryptyr has been shown to have no effect on fertility in animal studies.", "D": "Tryptyr increases fertility in animal models."}}
{"id": "4XCXoIiJlOnu", "question_type": "multi_choice", "question": "A clinical trial protocol is being designed for a new medication. If the drug brand name is Ekterly, which exclusion criteria based on contraindications should be considered?", "options": {"A": "Exclude patients with a history of anaphylaxis to Ekterly.", "B": "Exclude patients with cardiac arrhythmias.", "C": "Exclude patients with active liver disease.", "D": "Exclude patients with severe renal impairment."}}
{"id": "muxLuGxiPRfG", "question_type": "open_ended_multi_choice", "question": "What contraindications should healthcare providers be aware of when examining the prescribing details for Romvimza?", "options": {"A": "Romvimza is contraindicated in patients with renal impairment.", "B": "Romvimza is contraindicated in patients with hepatic dysfunction.", "C": "Romvimza has no contraindications listed.", "D": "Romvimza is contraindicated in patients with cardiovascular disease."}}
{"id": "244McCgpkwsH", "question_type": "open_ended_multi_choice", "question": "A 72-year-old patient with BCG-refractory bladder carcinoma in situ, who cannot have immediate cystectomy due to elevated surgical risk, recently had TURB performed 5 days ago and is now suffering from pronounced irritative bladder symptoms. Which management approach should be avoided in this clinical scenario?", "options": {"A": "Valrubicin intravesical therapy", "B": "Nogapendekin alfa inbakicept-pmln (ANKTIVA) with Bacillus Calmette-Guérin (BCG)", "C": "Immediate cystectomy", "D": "Valrubicin intravesical therapy delayed for two weeks after TURB"}}
{"id": "lI3mwElEGeh2", "question_type": "multi_choice", "question": "A 45-year-old woman with primary IgA nephropathy and UPCR of 2.0 g/g is currently breastfeeding her 2-month-old infant. She is otherwise healthy and not pregnant. Which is the most appropriate recommendation regarding atrasentan (VANRAFIA) therapy for her?", "options": {"A": "Initiate atrasentan but advise her to stop breastfeeding during treatment.", "B": "Initiate atrasentan and continue breastfeeding.", "C": "Atrasentan is contraindicated only if she is pregnant.", "D": "Atrasentan is safe to use during lactation."}}
{"id": "4t6Jyv2rRB1z", "question_type": "open_ended_multi_choice", "question": "A 34-year-old woman with primary IgA nephropathy and a urine protein-to-creatinine ratio of 2.1 g/g is being evaluated for pharmacologic management of proteinuria. She is of childbearing age, not currently pregnant, but her contraceptive use is inconsistent. What is the most appropriate approach to starting atrasentan (VANRAFIA) therapy in this scenario?", "options": {"A": "Initiate atrasentan immediately, as she is not pregnant.", "B": "Delay atrasentan initiation until effective contraception is established and pregnancy is excluded.", "C": "Initiate atrasentan and advise her to start contraception after the first dose.", "D": "Atrasentan is safe to use regardless of contraception status."}}
{"id": "awVJEUemjWDo", "question_type": "multi_choice", "question": "A 6-year-old child presents with community-acquired bacterial pneumonia. The child has no history of severe allergies, is not taking any other medications, and has normal renal function. The physician is considering antibiotic therapy. Which drug is most appropriate for treating this infection in this patient, given the risks associated with tooth development and the approved indications for pediatric use?", "options": {"A": "Doxycycline hyclate", "B": "Ceftobiprole medocaril sodium", "C": "Acetaminophen", "D": "No antibiotic therapy is indicated"}}
{"id": "h8O2wfidPLR2", "question_type": "open_ended_multi_choice", "question": "A 42-year-old woman with recurrent low-grade serous ovarian carcinoma and a confirmed KRAS mutation has previously received systemic therapy. She is currently taking warfarin for atrial fibrillation and is not pregnant or breastfeeding. Which of the following is the most appropriate next step regarding systemic therapy for her ovarian cancer?", "options": {"A": "Initiate AVMAPKI FAKZYNJA CO-PACK (avutometinib and defactinib) without modification.", "B": "Initiate AVMAPKI FAKZYNJA CO-PACK but switch her anticoagulation from warfarin to an alternative agent.", "C": "Initiate AVMAPKI FAKZYNJA CO-PACK and closely monitor INR while continuing warfarin.", "D": "Defer systemic therapy until warfarin can be discontinued."}}
{"id": "mKaKsSKHNVUP", "question_type": "open_ended_multi_choice", "question": "A 70-year-old man with a history of acute coronary syndrome and recent stent placement is being considered for antiplatelet therapy. Genetic testing reveals he is a CYP2C19 poor metabolizer. He has no history of hepatic impairment or active bleeding. Which antiplatelet agent should be selected for optimal efficacy?", "options": {"A": "Clopidogrel", "B": "Flyrcado", "C": "BRILINTA", "D": "Clopidogrel with omeprazole"}}
{"id": "CXPEayFukYi2", "question_type": "open_ended_multi_choice", "question": "How should a patient schedule the administration of Tryptyr and another topical ophthalmic eye drop when both are prescribed together?", "options": {"A": "Administer both drops simultaneously", "B": "Administer Tryptyr first and the other drop immediately after", "C": "Administer the drugs at least five minutes apart", "D": "Wait one hour between drugs"}}
{"id": "zjtyaAUMFJR3", "question_type": "open_ended_multi_choice", "question": "Which statement correctly reflects the findings regarding the genotoxic potential of Lynozyfic?", "options": {"A": "Genotoxicity studies have demonstrated a significant risk.", "B": "Genotoxicity studies have demonstrated no risk.", "C": "No genotoxicity studies have been conducted with Lynozyfic.", "D": "Genotoxicity studies in animals have shown inconclusive results."}}
{"id": "RpFf30dCE3tW", "question_type": "open_ended_multi_choice", "question": "A 45-year-old man with primary IgA nephropathy (UPCR 2.1 g/g) is under consideration for VANRAFIA therapy and is currently taking a strong CYP3A inducer for another illness. What is the optimal approach to VANRAFIA treatment in this scenario?", "options": {"A": "Initiate VANRAFIA at the standard dose and continue the CYP3A inducer.", "B": "Avoid concomitant use of VANRAFIA and the CYP3A inducer due to reduced efficacy.", "C": "Start VANRAFIA and increase the dose to compensate for the CYP3A inducer.", "D": "Begin VANRAFIA therapy and add an OATP1B1/1B3 inhibitor to enhance drug exposure."}}
{"id": "jbnRMFuIVTQg", "question_type": "open_ended_multi_choice", "question": "A 32-year-old pregnant patient presents with an acute bacterial skin and skin structure infection (ABSSSI) due to methicillin-resistant Staphylococcus aureus. She has normal kidney function and no drug allergies. Which medication is the best choice for her, taking into account both pregnancy safety and approved therapeutic use?", "options": {"A": "Doxycycline hyclate", "B": "Acetaminophen", "C": "Ceftobiprole medocaril sodium", "D": "No antibiotic therapy is indicated during pregnancy"}}
{"id": "tcP7PkKfdas4", "question_type": "open_ended_multi_choice", "question": "A 35-year-old woman with newly diagnosed primary biliary cholangitis is currently 10 weeks pregnant. She reports mild jaundice and fatigue but has no signs of hepatic decompensation. Which of the following is the safest and most appropriate initial drug therapy for her condition?", "options": {"A": "IQIRVO (elafibranor) monotherapy", "B": "Tricor (fenofibrate) monotherapy", "C": "Urso 250 (ursodiol) monotherapy", "D": "IQIRVO (elafibranor) in combination with Tricor (fenofibrate)"}}
{"id": "JHKvrmOvLKiG", "question_type": "open_ended_multi_choice", "question": "A 45-year-old female patient with metastatic non-small cell lung cancer is found to have ROS1-positive disease by FDA-approved testing. She is planning to become pregnant in the next few months and is currently taking a medication known to prolong the QTc interval. Which treatment option is most appropriate for her, considering reproductive plans and drug interactions?", "options": {"A": "Rozlytrek, with strict contraception during treatment and for at least 5 weeks after the last dose, and avoidance of QTc-prolonging drugs", "B": "Erlotinib, standard dosing", "C": "Ensartinib, standard dosing", "D": "Rozlytrek, co-administered with QTc-prolonging drugs and no contraception"}}
{"id": "gG7vsb1aOrHg", "question_type": "open_ended_multi_choice", "question": "If a patient on the standard Journavx dosing schedule misses two or more doses, what is the recommended action?", "options": {"A": "Take 100 mg as soon as possible, then resume the next scheduled dose.", "B": "Skip all missed doses and wait until the next scheduled dose.", "C": "Take 50 mg as soon as possible, then double the next dose.", "D": "Take 200 mg immediately."}}
{"id": "WuPUntuib2MX", "question_type": "open_ended_multi_choice", "question": "For a 14-year-old diagnosed with Grade 2 astrocytoma after subtotal resection and found to have a susceptible IDH1 mutation, with no pregnancy, normal kidney and liver function, and no use of CYP1A2 or CYP3A4 inhibitors/inducers, what is the most appropriate ongoing drug regimen to balance efficacy and safety?", "options": {"A": "Vorasidenib 40 mg once daily, with regular liver function monitoring", "B": "Avastin administered every 2 weeks", "C": "Zortress in combination with cyclosporine and corticosteroids", "D": "Avastin in combination with carboplatin and paclitaxel"}}
{"id": "pgijjuNSgSQ3", "question_type": "open_ended_multi_choice", "question": "A 34-year-old woman with newly diagnosed multiple myeloma presents for initial therapy. She is of reproductive age and recently discovered she is 8 weeks pregnant. She has no significant comorbidities and is not currently taking any other medications. Which of the following is the most appropriate drug regimen for her multiple myeloma at this time?", "options": {"A": "Thalomid in combination with dexamethasone", "B": "LYNOZYFIC monotherapy", "C": "Mozobil in combination with filgrastim for stem cell mobilization", "D": "No drug therapy should be initiated due to pregnancy; alternative non-teratogenic approaches should be considered"}}
{"id": "xP9FsD4WIbh7", "question_type": "multi_choice", "question": "A 35-year-old woman with chronic hypoparathyroidism is currently pregnant and requires ongoing management of her condition. She is not on dialysis and has no history of skeletal malignancies, radiation therapy, or metabolic bone disease other than hypoparathyroidism. Which drug is the most appropriate for her treatment, considering fetal safety and established data for use in pregnancy?", "options": {"A": "Yorvipath", "B": "Calcitriol", "C": "Ergocalciferol", "D": "Palopegteriparatide"}}
{"id": "wHeZDOFwv4El", "question_type": "open_ended_multi_choice", "question": "Is Blujepa considered a suitable therapy for a 13-year-old girl weighing 45 kg who presents with an uncomplicated urinary tract infection?", "options": {"A": "Yes, Blujepa is indicated for this patient population.", "B": "No, Blujepa is not indicated for patients under 18 years of age.", "C": "No, Blujepa is only indicated for male pediatric patients.", "D": "No, Blujepa is not indicated for patients weighing less than 50 kg."}}
{"id": "YR5PkR1hm1UK", "question_type": "open_ended_multi_choice", "question": "In the context of pediatric use, what is known about the safety and effectiveness of Tryptyr in patients under 18 years of age?", "options": {"A": "Tryptyr is approved and well-studied in pediatric patients.", "B": "The safety and effectiveness of Tryptyr have not been established in pediatric patients.", "C": "Tryptyr is contraindicated in pediatric patients due to severe adverse effects.", "D": "Tryptyr is only used in pediatric patients for off-label indications."}}
{"id": "q66KMozXxm9W", "question_type": "multi_choice", "question": "A patient on Journavx is also taking a sensitive CYP3A substrate where small changes in concentration may lead to loss of efficacy. What is the recommended management strategy?", "options": {"A": "No action is needed.", "B": "Discontinue Journavx.", "C": "Refer to the prescribing information for the CYP3A substrate for dosing instructions and consider dosage modification.", "D": "Increase the dose of Journavx."}}
{"id": "MR2jo1JtimVe", "question_type": "open_ended_multi_choice", "question": "A 46-year-old woman with metastatic breast cancer, who is hormone receptor-positive and HER2-negative, is found to have a PIK3CA mutation. She has moderate renal impairment (eGFR 45 mL/min), is not pregnant, and is not breastfeeding. Considering her eligibility for targeted therapy and the necessity for dose adjustment due to renal function, which drug regimen should be selected?", "options": {"A": "Inavolisib in combination with palbociclib and fulvestrant, with reduced dosage", "B": "Carboplatin at standard dosage", "C": "Esketamine in conjunction with an oral antidepressant", "D": "Carboplatin in combination with aminoglycosides"}}
{"id": "WT1S4B1AXNhW", "question_type": "open_ended_multi_choice", "question": "A 52-year-old female with primary biliary cholangitis has developed compensated cirrhosis, new ascites, and gastroesophageal varices, all signs of portal hypertension. She has not responded adequately to ursodeoxycholic acid (UDCA) and is also taking warfarin for atrial fibrillation. What is the most suitable pharmacologic treatment for her PBC at this stage?", "options": {"A": "Ocaliva 10 mg once daily in combination with UDCA", "B": "Livdelzi 10 mg once daily in combination with UDCA", "C": "Tricor 145 mg once daily as adjunct to UDCA", "D": "No disease-specific drug therapy should be initiated; continue UDCA alone"}}
{"id": "AUcqVJRT0haI", "question_type": "multi_choice", "question": "A 55-year-old woman with chronic obstructive pulmonary disease (COPD) and a history of major depressive disorder is being considered for maintenance therapy. She has no hepatic or renal impairment. Which drug should be avoided due to her psychiatric history, and which is the most appropriate for her COPD maintenance?", "options": {"A": "Fentanyl Citrate", "B": "Budesonide (oral)", "C": "Budesonide Inhalation", "D": "Ensifentrine"}}
{"id": "CtCiJffbhuDu", "question_type": "open_ended_multi_choice", "question": "A patient with paroxysmal nocturnal hemoglobinuria (PNH), aged 38, is receiving pegcetacoplan and intends to conceive. She inquires about the risks and recommendations for continuing her current therapy during pregnancy and lactation. Which response most accurately addresses her concerns?", "options": {"A": "Continue pegcetacoplan throughout pregnancy and breastfeeding, as animal studies show no adverse effects.", "B": "Switch to crovalimab, as animal studies show no adverse developmental outcomes and breastfeeding is not recommended during and for 9 months after the last dose.", "C": "Continue pegcetacoplan, but discontinue breastfeeding for 40 days after the last dose due to potential risks.", "D": "Switch to danicopan, as animal studies show no adverse developmental effects and breastfeeding is not recommended during and for 3 days after the last dose."}}
{"id": "W54J8w8xRqWZ", "question_type": "open_ended_multi_choice", "question": "A 35-year-old woman with symptomatic New York Heart Association (NYHA) class II obstructive hypertrophic cardiomyopathy (HCM) is being considered for pharmacologic therapy. She is planning pregnancy within the next year and is currently using a combined hormonal contraceptive containing a progestin other than norethindrone. Which drug should be avoided due to its risk profile in women of reproductive potential?", "options": {"A": "Metoprolol Tartrate", "B": "Acoramidis Hydrochloride", "C": "Mavacamten", "D": "Diltiazem"}}
{"id": "O8fibJQeslZK", "question_type": "open_ended_multi_choice", "question": "What is the recommended clinical response when a patient on Anzupgo develops a fresh case of herpes zoster?", "options": {"A": "Continue Anzupgo without interruption", "B": "Increase the dose of Anzupgo", "C": "Interrupt Anzupgo treatment until the episode resolves", "D": "Administer a live herpes zoster vaccine immediately"}}
{"id": "Tc4hvHvT8tnJ", "question_type": "open_ended_multi_choice", "question": "Which of the following clinical measures should be taken if Blujepa must be administered to a patient with severe renal impairment (eGFR <30 mL/min)?", "options": {"A": "Monitor and correct serum electrolyte abnormalities and obtain ECG prior to and during treatment", "B": "Increase the dose of Blujepa", "C": "Administer Blujepa with a non-depolarizing neuromuscular blocker", "D": "Discontinue all other medications"}}
{"id": "PVxNLvnPzIbH", "question_type": "open_ended_multi_choice", "question": "A 68-year-old woman diagnosed with mild Alzheimer’s disease-related dementia is currently nursing her infant. She has no record of hypersensitivity reactions and is not using any antithrombotic drugs. What is the best way to manage her condition with medication?", "options": {"A": "Kisunla (donanemab-azbt), after weighing the benefits of treatment against potential unknown risks to the breastfed infant", "B": "Kisunla (donanemab-azbt), contraindicated due to breastfeeding", "C": "Kisunla (donanemab-azbt), recommended only if the patient is not breastfeeding", "D": "No drug therapy recommended for Alzheimer’s disease in breastfeeding women"}}
{"id": "8b80Vcf6zfVD", "question_type": "multi_choice", "question": "A 60-year-old man with moderate-to-severe atopic dermatitis, recurrent skin infections, and a recent diagnosis of hypertension is being considered for systemic therapy after failing topical agents. He is scheduled to receive a live vaccine in the next month. Which of the following is the most appropriate next step in his management?", "options": {"A": "Start dexamethasone sodium phosphate immediately and continue with planned vaccination", "B": "Initiate Ebglyss therapy and proceed with live vaccine administration", "C": "Start dexamethasone sodium phosphate and schedule a drug holiday during vaccination", "D": "Delay initiation of Adbry until after completion of live vaccine administration"}}
{"id": "yjerySO4mgC8", "question_type": "open_ended_multi_choice", "question": "A 59-year-old man with metastatic gastroesophageal junction adenocarcinoma is currently receiving warfarin for atrial fibrillation. He is being considered for systemic therapy. His renal and hepatic function are normal, and he has no history of hypersensitivity reactions. Which of the following drugs should be avoided due to a major drug interaction risk?", "options": {"A": "Docetaxel in combination with cisplatin and fluorouracil", "B": "Capecitabine", "C": "Zolbetuximab (Vyloy) in combination with fluoropyrimidine- and platinum-containing chemotherapy", "D": "Docetaxel monotherapy"}}
{"id": "5K6IK1sd33ak", "question_type": "open_ended_multi_choice", "question": "A 62-year-old woman previously treated for unresectable intrahepatic cholangiocarcinoma is identified as having a tumor with an FGFR2 gene fusion by FDA-approved testing. She has significant renal impairment (eGFR 20 mL/min/1.73 m²), is not pregnant, and does not take any strong CYP3A inhibitors or inducers. Considering her renal function, which targeted therapy is most appropriate?", "options": {"A": "LYTGOBI", "B": "ZIIHERA", "C": "PEMAZYRE", "D": "Gemcitabine"}}
{"id": "gAihA2iKKhYf", "question_type": "multi_choice", "question": "A 76-year-old man is diagnosed with wild-type transthyretin-mediated amyloid cardiomyopathy (ATTR-CM). He has a history of hyperlipidemia managed with rosuvastatin and is not taking any UGT inducers, CYP3A inducers, or CYP2C9 substrates. He is not planning to become pregnant and is not breastfeeding. Which of the following is the most appropriate drug to reduce his risk of cardiovascular death and hospitalization?", "options": {"A": "Dexrazoxane", "B": "Vyndaqel", "C": "Attruby", "D": "No pharmacologic therapy is indicated"}}
{"id": "jx2MyUG0aI1L", "question_type": "open_ended", "question": "Which statement best describes the contraindication profile of the drug Vizz?", "options": {"A": "Vizz is contraindicated in patients with liver dysfunction.", "B": "Vizz should not be used in patients with a history of hypersensitivity reactions.", "C": "Vizz has no listed contraindications in its labeling.", "D": "Vizz is contraindicated during pregnancy."}}
{"id": "vhBzmzLTfuOH", "question_type": "open_ended_multi_choice", "question": "A 35-year-old pregnant woman has metastatic ROS1-positive non-small cell lung cancer and is considering targeted therapy. She is otherwise healthy and not on any other medications. What is the best advice regarding the use of taletrectinib in her situation?", "options": {"A": "Start taletrectinib 600 mg orally once daily as it is safe in pregnancy.", "B": "Delay taletrectinib until after delivery due to risk of fetal harm.", "C": "Start taletrectinib with close fetal monitoring.", "D": "Taletrectinib is only contraindicated in pediatric patients, not pregnant women."}}
{"id": "8yQYFjM2SnOV", "question_type": "multi_choice", "question": "A 6-month-old infant with severe RSV infection is hospitalized and requires mechanical ventilation. The infant's mother is currently pregnant. Which of the following is the most appropriate management regarding antiviral therapy for this patient?", "options": {"A": "Administer Virazole via inhalation, ensuring staff are experienced with ventilator use and monitoring.", "B": "Administer ENFLONSIA as a preventive measure.", "C": "Administer Restasis MultiDose ophthalmic emulsion.", "D": "Avoid Virazole due to teratogenic risk and select an alternative antiviral agent."}}
{"id": "piYp2V5r3rp7", "question_type": "multi_choice", "question": "A 28-year-old woman with Niemann-Pick disease type C and progressive cognitive impairment is planning to become pregnant. She currently experiences frequent falls and dystonia. Which of the following is the most appropriate recommendation regarding drug therapy for her NPC-related neurological symptoms?", "options": {"A": "Start AQNEURSA (levacetylleucine) and advise contraception during treatment and for 7 days after discontinuation", "B": "Start Miglustat (Yargesa) and advise contraception during treatment and for 60 days after discontinuation", "C": "Start AQNEURSA (levacetylleucine) and advise contraception during treatment and for 60 days after discontinuation", "D": "Start Miglustat (Opfolda) in combination with Pombiliti and advise contraception during treatment and for 7 days after discontinuation"}}
{"id": "y0cuVo2raJcC", "question_type": "open_ended_multi_choice", "question": "A 45-year-old male diagnosed with primary IgAN and a UPCR of 2.1 g/g is a candidate for VANRAFIA therapy. He is concurrently using a strong CYP3A inducer for a separate health condition. What should be done about administering VANRAFIA?", "options": {"A": "Initiate VANRAFIA at the standard dose and continue the CYP3A inducer.", "B": "Avoid concomitant use of VANRAFIA and the CYP3A inducer due to reduced efficacy.", "C": "Start VANRAFIA and increase the dose to compensate for the CYP3A inducer.", "D": "Begin VANRAFIA therapy and add an OATP1B1/1B3 inhibitor to enhance drug exposure."}}
{"id": "VC1AtyIlU9iA", "question_type": "multi_choice", "question": "A 32-year-old woman with acute erythroleukemia and splenomegaly is currently 10 weeks pregnant. She is not taking any other medications and has no significant comorbidities. Which of the following drugs should be avoided due to the highest risk of embryo-fetal toxicity and teratogenicity, based on available evidence?", "options": {"A": "TaperDex 6-day oral regimen at the lowest effective dose", "B": "Dexamethasone as adjunctive therapy for anemia", "C": "Aldesleukin administered intravenously in a hospital setting", "D": "Revuforj administered twice daily at standard dosing"}}
{"id": "XcVWsMbB3HfY", "question_type": "multi_choice", "question": "For a patient with recurrent or metastatic nasopharyngeal carcinoma receiving Penpulimab-kcqx in combination with gemcitabine and cisplatin, what is the recommended order of drug administration during each cycle?", "options": {"A": "Gemcitabine first, cisplatin second, Penpulimab-kcqx last", "B": "Cisplatin first, Penpulimab-kcqx second, gemcitabine last", "C": "Penpulimab-kcqx first, gemcitabine second, cisplatin last", "D": "Gemcitabine first, Penpulimab-kcqx second, cisplatin last"}}
{"id": "SBMeHVILBZ1X", "question_type": "open_ended", "question": "For patients using hormonal contraceptives containing progestins other than levonorgestrel and norethindrone, what is the recommended contraceptive strategy during and after Journavx treatment?", "options": {"A": "Use an additional nonhormonal contraceptive or alternative contraceptives during treatment and for 28 days after discontinuation", "B": "No change in contraceptive strategy is needed", "C": "Discontinue contraceptives during Journavx treatment", "D": "Switch to estrogen-only contraceptives"}}
{"id": "vKUtWgV2liYy", "question_type": "multi_choice", "question": "A 10-year-old girl with progressive diffuse midline glioma harboring an H3 K27M mutation has completed prior therapy. She is currently taking a medication known to prolong the QTc interval for a cardiac arrhythmia. Her oncologist is considering starting a new treatment for her glioma. Which of the following is the most appropriate approach regarding the use of MODEYSO (dordaviprone) in this patient?", "options": {"A": "Initiate MODEYSO at the standard dose without any changes to her current medications.", "B": "Avoid using MODEYSO due to her age; it is not approved for pediatric patients.", "C": "Start MODEYSO, but separate its administration from the QTc-prolonging drug and increase ECG monitoring.", "D": "Discontinue the QTc-prolonging drug and start MODEYSO at a reduced dose."}}
{"id": "6wLCk2KT8Ym7", "question_type": "open_ended", "question": "In the event of ALT or AST elevations greater than 5× the upper limit of normal during Qfitlia therapy, what is the recommended clinical action?", "options": {"A": "Interrupt Qfitlia treatment", "B": "Increase Qfitlia dose", "C": "Continue Qfitlia without changes", "D": "Switch to fixed dose regimen"}}
{"id": "zZLnkof7gbWs", "question_type": "multi_choice", "question": "Which of the following is a recommended action if a patient receiving Hernexeos develops transaminase elevations during therapy?", "options": {"A": "Continue therapy without changes", "B": "Administer prophylactic antibiotics", "C": "Switch to a non-HER2 targeted therapy", "D": "Interrupt, reduce the dose, or permanently discontinue Hernexeos"}}
{"id": "GlFk61omlZuk", "question_type": "open_ended_multi_choice", "question": "For a patient with severe hepatic impairment (Child-Pugh Class C), what is the recommendation regarding the use of Ekterly for acute HAE attacks?", "options": {"A": "Use standard dosage", "B": "Reduce dosage to 300 mg", "C": "Reduce dosage to 150 mg", "D": "Avoid use of Ekterly"}}
{"id": "aqvyLV50NmOi", "question_type": "open_ended_multi_choice", "question": "For the drug Sephience, which statement best describes its contraindication status?", "options": {"A": "Sephience should not be used in patients with a history of anaphylaxis.", "B": "Sephience is contraindicated in patients with chronic kidney disease.", "C": "Sephience has no contraindications listed in its prescribing information.", "D": "Sephience is contraindicated in patients with severe hepatic impairment."}}
{"id": "Jj1TuFnhtzFJ", "question_type": "open_ended_multi_choice", "question": "A 60-year-old male with hypoparathyroidism, severe renal dysfunction (eGFR 20 mL/min/1.73 m²), and atrial fibrillation treated with digoxin, without any history of bone malignancy or radiation therapy, requires treatment for hypoparathyroidism. Taking into account his kidney disease and digoxin therapy, which drug should be selected as the safest and most effective option?", "options": {"A": "Ergocalciferol", "B": "Calcitriol", "C": "Yorvipath", "D": "Palopegteriparatide"}}
{"id": "cpKW4fxNTkmg", "question_type": "open_ended", "question": "A 45-year-old woman with a history of acromegaly, well-controlled on injectable octreotide, is seeking to switch to an oral maintenance therapy. She is also taking esomeprazole for GERD and combined oral contraceptives for birth control. Which treatment option is most appropriate for her maintenance therapy, considering her current medications?", "options": {"A": "MYCAPSSA (oral octreotide), with counseling on backup contraception and possible dose adjustment", "B": "Octreotide injection (continue current regimen)", "C": "Hormone Harmony (homeopathic oral remedy)", "D": "MYCAPSSA (oral octreotide), no adjustments or counseling needed"}}
{"id": "zATUR2jKhw7C", "question_type": "open_ended_multi_choice", "question": "A 6-year-old child presents with community-acquired bacterial pneumonia. The child has no history of drug allergies or renal impairment. The parents are concerned about the potential for long-term side effects, especially those affecting teeth and bone development. Which of the following is the most appropriate antibiotic therapy for this patient, considering both efficacy and safety?", "options": {"A": "Doxycycline Hyclate administered twice daily for 7 days", "B": "Rituximab and Hyaluronidase administered as a single agent", "C": "Zevtera administered according to pediatric dosing guidelines for 7 days", "D": "Doxycycline Hyclate with a planned drug holiday after 3 days"}}
{"id": "NFfxub25OFP9", "question_type": "open_ended_multi_choice", "question": "A 3-year-old child is brought in with numerous umbilicated papules on the trunk and limbs, and molluscum contagiosum has been diagnosed. The parents request a topical therapy. The child has no allergies or history of eczema or skin barrier issues. What is the most suitable topical treatment for this patient, taking into account both effectiveness and safety?", "options": {"A": "Adapalene applied once daily to affected areas", "B": "Zelsuvmi applied topically as directed for molluscum contagiosum", "C": "Adapalene applied twice daily to affected areas", "D": "No topical therapy recommended due to age"}}
{"id": "Bn6NPyCKyxbf", "question_type": "open_ended", "question": "A 7-year-old child presents with a rapidly growing vascular lesion on the skin, diagnosed as skin hemangioma. The child has no history of tuberous sclerosis, is not taking any CYP3A4 inhibitors, and is otherwise healthy. The parents inquire about topical or intravenous drug options for treatment. Which of the following is the most appropriate drug for this patient?", "options": {"A": "HYFTOR topical (sirolimus)", "B": "Vincristine Sulfate intravenous", "C": "HYFTOR oral (sirolimus)", "D": "Vincristine Sulfate intrathecal"}}
{"id": "fWQfdebRFVY3", "question_type": "multi_choice", "question": "A 7-year-old boy with X-linked intellectual disability with isolated growth hormone deficiency presents with short stature, global developmental delay, and decreased serum insulin-like growth factor 1. His bone age is delayed, and he has a decreased response to growth hormone stimulation test. His parents inquire about possible drug treatments to improve his growth and development. Which of the following is the most appropriate drug therapy for this patient?", "options": {"A": "Testosterone administered as pellets every 3-6 months", "B": "Growth hormone replacement therapy with daily subcutaneous injections", "C": "Testosterone administered as a single high-dose injection", "D": "Testosterone combined with thyroid hormone replacement"}}
{"id": "KkrBuruf3zlT", "question_type": "open_ended_multi_choice", "question": "A 70-year-old male patient with a recent coronary stent and past acute coronary syndrome is evaluated for antiplatelet therapy. Genetic analysis shows he is a poor metabolizer of CYP2C19. He does not have hepatic dysfunction or ongoing bleeding. Which antiplatelet drug would be most effective for him?", "options": {"A": "Clopidogrel", "B": "Flyrcado", "C": "BRILINTA", "D": "Clopidogrel with omeprazole"}}
{"id": "nbCkATZ5DcD6", "question_type": "multi_choice", "question": "A 35-year-old woman with pulmonary arterial hypertension is currently pregnant and presents for management of her PAH. She is concerned about the safety of her fetus and asks about drug therapy options. Which of the following is the most appropriate recommendation regarding drug therapy for her PAH?", "options": {"A": "Avoid Winrevair due to embryo-fetal toxicity and advise against its use during pregnancy", "B": "Start epinephrine infusion to manage her PAH", "C": "Initiate Winrevair, as it is the first-line therapy for PAH", "D": "Use vasopressin as a safe alternative for PAH in pregnancy"}}
{"id": "IckVPA6rwQhe", "question_type": "open_ended_multi_choice", "question": "If a patient with an eGFR below 30 mL/min needs Blujepa, which of the listed clinical measures should be implemented?", "options": {"A": "Monitor and correct serum electrolyte abnormalities and obtain ECG prior to and during treatment", "B": "Increase the dose of Blujepa", "C": "Administer Blujepa with a non-depolarizing neuromuscular blocker", "D": "Discontinue all other medications"}}
{"id": "Q33ANbAPMeHM", "question_type": "open_ended_multi_choice", "question": "What should a patient do if they want to switch their method of contraception while taking Vanrafia?", "options": {"A": "Change birth control without consulting a healthcare provider", "B": "Contact their healthcare provider to select another acceptable form", "C": "Stop all contraception immediately", "D": "Switch to natural family planning methods"}}
{"id": "s2z3e9X1GjSi", "question_type": "multi_choice", "question": "What is known about the reversibility of Gomekli-induced infertility in females based on animal studies?", "options": {"A": "Reversibility is well established", "B": "Reversibility is unknown", "C": "Gomekli does not impair fertility", "D": "Infertility is permanent"}}
{"id": "nG7w0s7f4jNs", "question_type": "open_ended_multi_choice", "question": "A 45-year-old woman with previously treated, unresectable intrahepatic cholangiocarcinoma harboring an FGFR2 rearrangement is currently pregnant. She is not taking any other medications. Which of the following is the most appropriate recommendation regarding targeted therapy for her cancer?", "options": {"A": "Initiate PEMAZYRE at standard dosing", "B": "Start LYTGOBI with close fetal monitoring", "C": "Defer targeted therapy due to risk of fetal harm", "D": "Begin ZIIHERA with dose reduction"}}
{"id": "vSBIuQkdIzPq", "question_type": "open_ended_multi_choice", "question": "How should healthcare providers respond if Imaavy is used in a pregnant patient or if pregnancy occurs during Imaavy treatment?", "options": {"A": "Discontinue Imaavy immediately", "B": "Report Imaavy exposure to Janssen", "C": "Increase the dose of Imaavy", "D": "No action is required"}}
{"id": "VG5wN3miW4Jy", "question_type": "open_ended_multi_choice", "question": "A 67-year-old patient with metastatic ROS1-positive NSCLC is prescribed IBTROZI (taletrectinib) 600 mg daily. He has osteoporosis and recently sustained a rib fracture from a minor fall. He is not currently taking medications that prolong QTc or alter CYP3A activity. What is the most crucial aspect to address for his ongoing IBTROZI treatment?", "options": {"A": "Continue IBTROZI at the same dose without additional monitoring", "B": "Discontinue IBTROZI permanently due to fracture risk", "C": "Continue IBTROZI with prompt evaluation and monitoring for further skeletal fractures", "D": "Reduce IBTROZI dose to minimize risk of future fractures"}}
{"id": "4IytjdCaYh81", "question_type": "open_ended", "question": "When administering Romvimza, which of the following recommendations should be followed if concomitant use with P-glycoprotein (P-gp) substrates cannot be avoided?", "options": {"A": "Take Romvimza at least 4 hours prior to P-gp substrates.", "B": "Take Romvimza and P-gp substrates simultaneously.", "C": "Increase the dose of Romvimza.", "D": "Discontinue Romvimza."}}
{"id": "Mhbv3Gs0IEDX", "question_type": "multi_choice", "question": "A 55-year-old woman with chronic obstructive pulmonary disease (COPD) and a history of major depressive disorder is being considered for maintenance therapy. She has no hepatic or renal impairment. Which drug should be avoided due to her psychiatric history, and which is the most appropriate for her COPD maintenance?", "options": {"A": "Fentanyl Citrate", "B": "Budesonide Inhalation", "C": "Ensifentrine", "D": "Budesonide (oral)"}}
{"id": "i10Gc8FI0l0h", "question_type": "open_ended_multi_choice", "question": "In the context of Romvimza's prescribing guidelines, which contraindications must clinicians consider before prescribing the medication?", "options": {"A": "Romvimza is contraindicated in patients with renal impairment.", "B": "Romvimza is contraindicated in patients with hepatic dysfunction.", "C": "Romvimza has no contraindications listed.", "D": "Romvimza is contraindicated in patients with cardiovascular disease."}}
{"id": "LgmAhztTZEZ9", "question_type": "multi_choice", "question": "A 32-year-old woman with neurofibromatosis type 1 and symptomatic plexiform neurofibromas is currently pregnant. She is seeking treatment options for her neurofibromas. Which of the following drugs should be avoided due to the risk of fetal harm?", "options": {"A": "Gomekli", "B": "Celecoxib", "C": "PNV-DHA", "D": "Both Celecoxib and Gomekli"}}
{"id": "f8hEBtzLcbM4", "question_type": "open_ended_multi_choice", "question": "A 15-year-old patient presents with Grade 2 oligodendroglioma confirmed to harbor a susceptible IDH1 mutation following subtotal resection. The patient is otherwise healthy, is not pregnant, and is not taking any medications known to induce or inhibit CYP1A2. Which of the following is the most appropriate pharmacological treatment for this patient, considering both efficacy and safety in this age group?", "options": {"A": "Avastin administered intravenously every 2 weeks", "B": "Zortress administered orally twice daily", "C": "Voranigo administered orally once daily", "D": "Avastin in combination with carboplatin and paclitaxel"}}
{"id": "PUShW584b69O", "question_type": "open_ended", "question": "Which of the following best describes the risk of immune-mediated adverse reactions with penpulimab-kcqx?", "options": {"A": "They only occur during active treatment and are always limited to a single organ system", "B": "They can be severe or fatal, may occur in any organ system, and can manifest after discontinuation of therapy", "C": "They are always mild and self-limited", "D": "They are limited to dermatologic manifestations"}}
{"id": "445HT9GX343B", "question_type": "open_ended_multi_choice", "question": "A 38-year-old woman with moderate to severe chronic hand eczema, refractory to topical corticosteroids, is breastfeeding her 2-month-old child and is concerned about the potential risks of treatment for her baby. Which therapeutic approach is most appropriate for her?", "options": {"A": "Initiate topical Anzupgo, advising her to avoid direct contact with the nipple and areola after application.", "B": "Initiate topical Anzupgo without any precautions regarding breastfeeding.", "C": "Initiate topical corticosteroids, despite her previous inadequate response.", "D": "Initiate topical Anzupgo in combination with another JAK inhibitor for enhanced efficacy."}}
{"id": "d4nE1ia8YimF", "question_type": "open_ended_multi_choice", "question": "What is the current status of safety and effectiveness data for Wayrilz in pediatric patients?", "options": {"A": "Safety and effectiveness have been established in pediatric patients.", "B": "Safety has been established, but effectiveness has not.", "C": "Effectiveness has been established, but safety has not.", "D": "Safety and effectiveness have not been established in pediatric patients."}}
{"id": "UKJPVYYU1Dzg", "question_type": "open_ended_multi_choice", "question": "A 10-year-old boy with Duchenne muscular dystrophy and a confirmed DMD gene mutation amenable to exon 51 skipping is being considered for therapy. He has a history of hypersensitivity reactions to intravenous medications. Which drug regimen is most suitable for his condition and medical history?", "options": {"A": "Eteplirsen administered once weekly", "B": "Deflazacort administered daily", "C": "Givinostat administered twice daily", "D": "Eteplirsen with a drug scheduler to minimize hypersensitivity risk"}}
{"id": "RdsikkZhZSe4", "question_type": "open_ended_multi_choice", "question": "Considering a 34-year-old woman with metastatic ROS1-positive NSCLC who is 8 weeks pregnant and not on any other medications, what is the most suitable advice about initiating IBTROZI (taletrectinib) treatment?", "options": {"A": "Initiate IBTROZI (taletrectinib) 600 mg orally once daily immediately", "B": "Initiate IBTROZI (taletrectinib) 600 mg orally once daily with close fetal monitoring", "C": "Defer IBTROZI (taletrectinib) therapy due to risk of embryo-fetal toxicity", "D": "Initiate IBTROZI (taletrectinib) at a reduced dose to minimize fetal risk"}}
{"id": "3907K0cE0Gdu", "question_type": "open_ended", "question": "A 65-year-old Black man with a benign peripheral nerve sheath tumor, hypertension, and left ventricular hypertrophy is being evaluated for stroke risk reduction. He is otherwise healthy and not on any interacting medications. Which of the following statements best reflects the use of Losartan Potassium in this patient?", "options": {"A": "Losartan Potassium is preferred for stroke risk reduction in this patient population", "B": "Losartan Potassium is not recommended for stroke risk reduction in Black patients with hypertension and left ventricular hypertrophy", "C": "Losartan Potassium should be avoided due to age-related safety concerns", "D": "Losartan Potassium is contraindicated in all patients with hypertension"}}
{"id": "Wyh4ZgdfMps8", "question_type": "open_ended_multi_choice", "question": "For a 14-year-old diagnosed with bronchiectasis not caused by cystic fibrosis, which branded medication is indicated for treatment?", "options": {"A": "Brinsupri", "B": "Albuterol", "C": "Azithromycin", "D": "Prednisone"}}
{"id": "W1nhc1AdECv8", "question_type": "multi_choice", "question": "A 28-year-old woman with newly diagnosed PNH is currently pregnant and requires complement inhibition therapy. She is eligible for all available therapies and has no history of complement inhibitor use. Which drug is the most appropriate choice, considering pregnancy safety data and recommendations?", "options": {"A": "Ultomiris", "B": "Sirolimus", "C": "Piasky", "D": "Cyclosporine"}}
{"id": "nGkFxFBIh4nu", "question_type": "multi_choice", "question": "A 45-year-old woman with Chagas cardiomyopathy presents with recurrent, life-threatening ventricular tachycardia that has not responded to other antiarrhythmic agents. She is not pregnant and has no history of hepatic or pulmonary disease. Her renal and hepatic function are within normal limits, and she is not taking any medications that prolong the QT interval. Which drug is most appropriate for her arrhythmia management, considering the need for close monitoring and toxicity risks?", "options": {"A": "Entresto administered twice daily for heart failure management", "B": "Diovan administered once daily for heart failure", "C": "Amiodarone hydrochloride initiated under specialist supervision with regular monitoring", "D": "Entresto with a drug holiday every two weeks to minimize toxicity"}}
{"id": "PRUQtzmKwRMe", "question_type": "open_ended_multi_choice", "question": "A 32-year-old woman with newly diagnosed generalized myasthenia gravis, positive for anti-MuSK antibodies, is currently 10 weeks pregnant. She has a history of Hashimoto thyroiditis and is concerned about the safety of medications during pregnancy. Which treatment option should be avoided due to its established teratogenic risk and contraindication in pregnancy?", "options": {"A": "IMAAVY, 15 mg/kg intravenous infusion every 2 weeks", "B": "Azathioprine, 75 mg daily oral administration", "C": "DuoDote, single dose for acute management", "D": "IMAAVY, 10 mg/kg intravenous infusion every 4 weeks"}}
{"id": "dkipUgbj2ni1", "question_type": "open_ended", "question": "A 30-year-old woman with hereditary angioedema is planning pregnancy and seeks prophylactic therapy to prevent attacks. She is concerned about fetal safety and wants a drug with reassuring animal pregnancy data. Which medication is best suited for her needs?", "options": {"A": "SAJAZIR", "B": "EKTERLY", "C": "TAKHZYRO", "D": "EKTERLY with dose adjustment"}}
{"id": "027NXEjXpCvU", "question_type": "open_ended_multi_choice", "question": "A 40-year-old man diagnosed with Niemann-Pick disease type C is experiencing worsening gait disturbance, vertical supranuclear gaze palsy, and has mild renal impairment (creatinine clearance estimated at 65 mL/min). He is not on any other medications. What is the most appropriate therapy to address his neurological symptoms?", "options": {"A": "Miglustat (Yargesa) 100 mg twice daily, with dose adjustment for renal impairment", "B": "AQNEURSA (levacetylleucine), standard dosing without renal adjustment", "C": "Miglustat (Opfolda) in combination with Pombiliti, with dose reduction for renal impairment", "D": "AQNEURSA (levacetylleucine), with dose reduction for renal impairment"}}
{"id": "baw9qQIZb38L", "question_type": "multi_choice", "question": "A 10-year-old boy with a history of epilepsy controlled on valproic acid presents with fever, flank pain, and a diagnosis of complicated urinary tract infection. He has normal renal function and no known drug allergies. Which of the following is the most appropriate treatment option?", "options": {"A": "Sulopenem etzadroxil and probenecid (Orlynvah) orally", "B": "Imipenem and cilastatin intravenously", "C": "Flavoxate hydrochloride orally", "D": "Imipenem and cilastatin intravenously, with valproic acid continued"}}
{"id": "W1qJoEJmKapo", "question_type": "open_ended", "question": "Which of the following statements best describes the management of breakthrough bleeds with Qfitlia after the first 7 days of treatment?", "options": {"A": "Use standard dose and frequency of CFC/BPA", "B": "Reduce the weight-based dose and double the dosing interval of CFC/BPA", "C": "Administer Qfitlia intravenously", "D": "Discontinue all prophylactic agents"}}
{"id": "e20eWl8J47g5", "question_type": "multi_choice", "question": "If a patient experiences Grade 3 cytokine release syndrome (CRS) during Lynozyfic therapy, what is the recommended action regarding the next dose?", "options": {"A": "Resume Lynozyfic at the same dose after CRS resolves", "B": "Switch to oral administration", "C": "Permanently discontinue Lynozyfic", "D": "Increase the infusion rate for the next dose"}}
{"id": "jOMGkXSoA7qO", "question_type": "multi_choice", "question": "A 62-year-old man is newly diagnosed with locally advanced unresectable gastroesophageal junction adenocarcinoma. His tumor is confirmed to be HER2-negative and CLDN18.2-positive by FDA-approved testing. He has normal hepatic and renal function, no history of hypersensitivity reactions, and is not taking any anticoagulants or CYP3A4 inhibitors. Which initial drug regimen is most appropriate for his first-line treatment?", "options": {"A": "Zolbetuximab (Vyloy) in combination with fluoropyrimidine- and platinum-containing chemotherapy", "B": "Docetaxel in combination with cisplatin and fluorouracil", "C": "Capecitabine monotherapy", "D": "Docetaxel monotherapy"}}
{"id": "5SX5cmYbnW8n", "question_type": "multi_choice", "question": "A clinician is considering prescribing Enflonsia to an infant who previously experienced anaphylaxis after administration of a medication containing similar excipients. What is the recommended course of action?", "options": {"A": "Do not prescribe Enflonsia", "B": "Prescribe Enflonsia with close monitoring", "C": "Reduce the dose of Enflonsia", "D": "Switch to a generic alternative"}}
{"id": "SAcQ63FIq9dL", "question_type": "open_ended_multi_choice", "question": "A 60-year-old man with presbyopia is currently taking a monoamine oxidase inhibitor (MAOI) for depression and beta-blockers for hypertension. He requests a medication to improve his near vision. Which treatment option is safest and most effective for him?", "options": {"A": "Mirvaso topical gel applied to the face daily", "B": "Oraverse intraoral injection following dental anesthesia", "C": "VIZZ topical ocular drops once daily", "D": "Mirvaso topical gel applied twice daily"}}
{"id": "HCRoNBndxmVi", "question_type": "open_ended_multi_choice", "question": "A 67-year-old patient with relapsed small cell lung cancer (SCLC) presents for second-line therapy. His baseline neutrophil count is 1,800/mm³ and platelet count is 120,000/mm³. He has mild renal impairment (creatinine clearance 55 mL/min) and is not currently taking any P-glycoprotein or BCRP inhibitors. He is not pregnant and does not have a history of interstitial lung disease. Which drug regimen is most appropriate for this patient, considering his age, renal function, and hematologic status?", "options": {"A": "KOSELUGO administered twice daily", "B": "TOPOTECAN (HYCAMTIN) capsules at standard dose for 5 consecutive days every 21-day cycle", "C": "TOPOTECAN (HYCAMTIN) capsules at reduced dose due to renal impairment", "D": "TOPOTECAN (HYCAMTIN) capsules at standard dose, but with concurrent P-glycoprotein inhibitor"}}
{"id": "bg93QV5rUf88", "question_type": "open_ended_multi_choice", "question": "When Journavx is administered, what is the appropriate guidance for patients using hormonal contraceptives with progestins other than levonorgestrel and norethindrone?", "options": {"A": "No additional contraceptive method is required.", "B": "Journavx increases the efficacy of all hormonal contraceptives.", "C": "Patients should use an additional nonhormonal contraceptive method or an alternative hormonal contraceptive during and for 28 days after Journavx treatment.", "D": "Journavx is contraindicated with all hormonal contraceptives."}}
{"id": "7oMbkRxIKYiK", "question_type": "multi_choice", "question": "Which of the following best describes the contraindication profile for the drug Qfitlia?", "options": {"A": "Qfitlia has no known contraindications.", "B": "Qfitlia is contraindicated in patients with hepatic impairment.", "C": "Qfitlia should not be used in patients with a history of hypersensitivity reactions.", "D": "Qfitlia is contraindicated in pregnancy."}}
{"id": "AKZwNy1OKx4K", "question_type": "open_ended_multi_choice", "question": "A 34-year-old female patient with a history of paroxysmal nocturnal hemoglobinuria (PNH) is being treated with ravulizumab but still has persistent extravascular hemolysis (EVH). She also takes rosuvastatin 10 mg daily for controlled hyperlipidemia, has normal liver function, and is not pregnant. What should be the next step in her pharmacologic management to target her EVH?", "options": {"A": "Add Voydeya to her current ravulizumab regimen, monitoring for statin-related adverse effects.", "B": "Switch to sirolimus monotherapy.", "C": "Increase the dose of rosuvastatin above 10 mg daily while continuing ravulizumab.", "D": "Discontinue ravulizumab and start Voydeya monotherapy."}}
{"id": "ZQG9OnWXty0q", "question_type": "open_ended_multi_choice", "question": "For a patient on Hernexeos who develops Grade 3 ALT and/or AST elevation without increased total bilirubin, what is the recommended management?", "options": {"A": "Continue Hernexeos at the same dose", "B": "Interrupt Hernexeos until recovery, then resume at reduced dose", "C": "Permanently discontinue Hernexeos", "D": "Increase Hernexeos dose"}}
{"id": "NzCh8uZak1fr", "question_type": "multi_choice", "question": "A 45-year-old man with schizophrenia and a history of benign prostatic hyperplasia (BPH) and incomplete bladder emptying is being considered for antipsychotic therapy. He has normal renal and hepatic function. Which antipsychotic is most suitable for this patient?", "options": {"A": "Cobenfy, administered orally twice daily", "B": "Abilify Maintena, administered as a biweekly intramuscular injection", "C": "Cobenfy, administered orally once daily with close monitoring", "D": "Abilify Maintena, administered as a monthly intramuscular injection"}}
{"id": "xPyrrWtidqt9", "question_type": "open_ended_multi_choice", "question": "If a patient misses a dose of Ibtrozi or vomits after taking it, what is the recommended action?", "options": {"A": "Resume Ibtrozi at its regularly scheduled time the next day", "B": "Take an extra dose immediately", "C": "Skip the next scheduled dose", "D": "Double the next dose"}}
{"id": "3Sr6mYttxXHg", "question_type": "open_ended", "question": "A patient is prescribed Journavx and is also taking a strong CYP3A inhibitor. Which of the following is the most appropriate clinical action?", "options": {"A": "Continue both drugs without adjustment.", "B": "Reduce the dose of Journavx.", "C": "Discontinue the CYP3A inhibitor.", "D": "Concomitant use is contraindicated and should be avoided."}}
{"id": "tF2CZ1MOJ519", "question_type": "multi_choice", "question": "For a patient with multiple comorbidities, which statement is correct regarding the use of Datroway based on its contraindication profile?", "options": {"A": "Datroway should be avoided in patients with hepatic failure due to contraindications.", "B": "Datroway is contraindicated in patients with a history of drug-induced QT prolongation.", "C": "There are no contraindications for Datroway, regardless of comorbidities.", "D": "Datroway is contraindicated in patients with active infection."}}
{"id": "LVcqi4bMkYDI", "question_type": "multi_choice", "question": "A 32-year-old woman with Niemann-Pick disease type C and neurological symptoms is planning to become pregnant. She is currently taking N-acetyl-DL-leucine for symptomatic relief. Her physician is considering starting disease-modifying therapy. Which of the following is the most appropriate recommendation regarding drug therapy for her current situation?", "options": {"A": "Continue N-acetyl-DL-leucine and initiate Aqneursa immediately", "B": "Initiate Opfolda (miglustat) in combination with Pombiliti regardless of pregnancy status", "C": "Start Yargesa (miglustat) without contraception precautions", "D": "Discontinue N-acetyl-DL-leucine and start Aqneursa after confirming non-pregnant status and counseling on contraception"}}
{"id": "7rAJqg2gR6fr", "question_type": "open_ended_multi_choice", "question": "What is the recommended management strategy for administering Blujepa to a patient who has severe hepatic impairment, as indicated by Child-Pugh Class C status?", "options": {"A": "Avoid administration of Blujepa due to increased drug exposure and risk of QTc prolongation.", "B": "Administer Blujepa at a reduced dose with close monitoring.", "C": "Administer Blujepa with a strong CYP3A4 inhibitor to reduce side effects.", "D": "Proceed with standard dosing of Blujepa without additional precautions."}}
{"id": "UU0Xs2MqTovb", "question_type": "open_ended_multi_choice", "question": "A 32-year-old female patient diagnosed with schizophrenia and mild renal impairment (eGFR 65 mL/min) is currently on a potent CYP2D6 inhibitor for a separate condition. She has no liver dysfunction or other comorbidities, and she favors oral medications due to concerns about drug interactions. Which antipsychotic treatment would be most appropriate in her case?", "options": {"A": "Cobenfy, administered orally at the standard adult dose", "B": "Abilify Maintena, administered as a monthly intramuscular injection with dose reduction", "C": "Cobenfy, administered orally with close monitoring for adverse reactions", "D": "Abilify Maintena, administered orally at the standard dose"}}
{"id": "zOXw2cB6FKQa", "question_type": "multi_choice", "question": "A 29-year-old woman with symptomatic TGCT is planning to become pregnant in the next few months. She is currently using hormonal contraceptives and has normal renal and hepatic function. Surgical resection is not feasible. Which of the following is the most appropriate pharmacologic approach for her?", "options": {"A": "Turalio (pexidartinib hydrochloride) with continued use of hormonal contraceptives", "B": "Romvimza (vimseltinib) without any contraception", "C": "Turalio (pexidartinib hydrochloride) with non-hormonal contraception", "D": "Romvimza (vimseltinib) with effective contraception and regular pregnancy testing"}}
{"id": "zbBy4pY24fN2", "question_type": "open_ended_multi_choice", "question": "A 65-year-old woman with metastatic HER2-mutant non-squamous non-small cell lung cancer is being considered for systemic treatment. She is currently on rifampin, a potent inducer of CYP3A, for latent tuberculosis. Her cardiac and hepatic functions are within normal limits, and she is not pregnant. What is the optimal strategy for selecting and managing her lung cancer therapy?", "options": {"A": "Initiate HERNEXEOS, but increase the dose due to the interaction with rifampin.", "B": "Start TECENTRIQ as a single agent, as it has no major CYP3A interactions.", "C": "Use etoposide in combination with other agents, as it is not affected by CYP3A inducers.", "D": "Avoid HERNEXEOS entirely and select an alternative therapy due to the drug interaction."}}
{"id": "Cur6KrIfzlk0", "question_type": "open_ended_multi_choice", "question": "A 15-year-old adolescent weighing 45 kg presents with moderate-to-severe atopic dermatitis that has not responded to topical prescription therapies. The patient also has a history of recurrent conjunctivitis and keratoconus. Which of the following is the most appropriate systemic therapy for this patient, considering both efficacy and safety for their age and comorbidities?", "options": {"A": "Dexamethasone sodium phosphate administered intramuscularly every 2 weeks", "B": "Adbry administered subcutaneously every other week", "C": "Ebglyss administered subcutaneously every 4 weeks", "D": "Dexamethasone sodium phosphate administered orally daily"}}
{"id": "DqC2ZNsKOeks", "question_type": "multi_choice", "question": "A 59-year-old woman with extensive-stage small cell lung cancer and autosomal dominant inheritance presents for therapy after progression on platinum-based chemotherapy. She is currently pregnant and seeks advice on the safest treatment option for her condition. Which drug should be strictly avoided due to its risk profile in pregnancy?", "options": {"A": "Topotecan capsules, administered orally as per standard schedule", "B": "Supportive care only, with no cytotoxic or immunotherapy agents", "C": "Ipilimumab, administered every 3 weeks", "D": "Imdelltra, administered intravenously with step-up dosing"}}
{"id": "UVxp1WEEAwgK", "question_type": "multi_choice", "question": "How should the dosage of Ekterly be modified for a patient with moderate hepatic impairment (Child-Pugh Class B) experiencing an acute HAE attack?", "options": {"A": "600 mg (two tablets) at earliest recognition, repeatable after 3 hours if needed", "B": "300 mg (one tablet) at earliest recognition, repeatable after 3 hours if needed", "C": "No dosage modification is necessary", "D": "Avoid use of Ekterly"}}
{"id": "IzOmn8KhEfHp", "question_type": "open_ended_multi_choice", "question": "A patient taking Vanrafia presents with newly developed jaundice and dark-colored urine. What should be the next course of action?", "options": {"A": "Continue Vanrafia and monitor symptoms", "B": "Increase the dose of Vanrafia", "C": "Temporarily or permanently discontinue Vanrafia and evaluate for liver dysfunction", "D": "Switch to another endothelin receptor antagonist"}}
{"id": "QE6TufW5a1G0", "question_type": "open_ended", "question": "A 45-year-old man with chronic diarrheal disease and newly diagnosed primary biliary cholangitis (PBC) has no evidence of cirrhosis or portal hypertension. He is currently taking cholestyramine for pruritus. What is the best approach to initiate Ocaliva therapy for this patient?", "options": {"A": "Start Ocaliva 10 mg once daily, taken at the same time as cholestyramine.", "B": "Start Ocaliva 5 mg once daily, ensuring it is taken at least 4 hours before or after cholestyramine.", "C": "Do not start Ocaliva due to risk of drug interaction with cholestyramine.", "D": "Start Ocaliva 5 mg once daily, but discontinue cholestyramine."}}
{"id": "UKOPXllQZCQf", "question_type": "open_ended_multi_choice", "question": "A 7-year-old patient has confirmed Niemann-Pick disease type C, showing progressive gait ataxia, cognitive impairment, and hepatosplenomegaly. Taking into account the child's age, normal renal function, and absence of other medications, which drug regimen should be selected to treat the neurological manifestations specific to this disease?", "options": {"A": "MIPLYFFA in combination with miglustat, administered according to pediatric dosing guidelines", "B": "OPFOLDA in combination with Pombiliti", "C": "Lithium carbonate", "D": "MIPLYFFA monotherapy"}}
{"id": "CXSLcsl9eu9x", "question_type": "open_ended_multi_choice", "question": "What dose adjustment is recommended for patients with mild hepatic impairment receiving Romvimza?", "options": {"A": "Increase the dose by 50%", "B": "Reduce the dose by half", "C": "No dose adjustment is recommended", "D": "Discontinue Romvimza"}}
{"id": "JNiVh9Fh5ZJx", "question_type": "open_ended_multi_choice", "question": "A 58-year-old woman with metastatic breast cancer has developed cardiomyopathy after receiving a cumulative doxorubicin dose of 320 mg/m². She is scheduled to continue doxorubicin therapy to maintain tumor control. She is not pregnant and is not breastfeeding. Which drug is most appropriate to reduce the incidence and severity of her cardiomyopathy?", "options": {"A": "Dexrazoxane", "B": "Attruby", "C": "Vyndaqel", "D": "Rosuvastatin"}}
{"id": "WBMTYyJJe8fH", "question_type": "open_ended_multi_choice", "question": "Considering a 68-year-old woman with BCG-unresponsive NMIBC involving both carcinoma in situ (CIS) and papillary tumors, who lacks a history of bladder perforation, severe irritative bladder symptoms, recent TURBT, pregnancy, or plans for breastfeeding, which intravesical drug regimen is most appropriate for her management?", "options": {"A": "Valrubicin intravesical therapy alone", "B": "Nogapendekin alfa inbakicept-pmln (ANKTIVA) in combination with Bacillus Calmette-Guérin (BCG)", "C": "Valrubicin in combination with Bacillus Calmette-Guérin (BCG)", "D": "Nogapendekin alfa inbakicept-pmln (ANKTIVA) monotherapy"}}
{"id": "os12lVZeO1ti", "question_type": "open_ended_multi_choice", "question": "Considering the pooled data from Trials 1 and 2, how did the frequency of patients with a reduction in estimated glomerular filtration rate (eGFR) of ≥25% but <50% differ between those treated with JOURNAVX and those given placebo?", "options": {"A": "Higher in JOURNAVX-treated patients", "B": "Lower in JOURNAVX-treated patients", "C": "Equal in both groups", "D": "Not reported for JOURNAVX"}}
{"id": "slMnmvBZodqU", "question_type": "open_ended_multi_choice", "question": "A 52-year-old woman with a malignant non-epithelial tumor of the ovary and a history of severe hepatic impairment (total bilirubin 6 x ULN, AST 12 x ULN) is being evaluated for chemotherapy. She is not pregnant and has no known drug allergies. Which of the following is the most appropriate chemotherapeutic approach for her?", "options": {"A": "Paclitaxel protein-bound particles for injectable suspension (albumin-bound) at standard dosing", "B": "Paclitaxel protein-bound particles for injectable suspension (albumin-bound) at a reduced dose", "C": "Etoposide administered by slow intravenous infusion with close monitoring", "D": "Paclitaxel protein-bound particles for injectable suspension (albumin-bound) in combination with gemcitabine"}}
{"id": "sqKfhjqPAxty", "question_type": "multi_choice", "question": "A 34-year-old woman with primary immunoglobulin A nephropathy (IgAN) and a urine protein-to-creatinine ratio (UPCR) of 2.0 g/g is at risk of rapid disease progression. She is planning to become pregnant and is currently not using any contraception. Which of the following is the most appropriate approach regarding drug therapy to reduce her proteinuria?", "options": {"A": "Initiate VANRAFIA (atrasentan) 0.75 mg once daily and monitor for pregnancy during treatment.", "B": "Start VANRAFIA (atrasentan) at a reduced dose and discontinue if pregnancy occurs.", "C": "Advise against VANRAFIA therapy and recommend alternative management due to pregnancy plans.", "D": "Begin VANRAFIA (atrasentan) and recommend breastfeeding during treatment."}}
{"id": "1P9SjcG1lleb", "question_type": "open_ended_multi_choice", "question": "A 58-year-old patient with non-alcoholic steatohepatitis (NASH) and stage F3 liver fibrosis is being considered for pharmacological intervention. She has a history of intermittent claudication and is currently taking warfarin for atrial fibrillation. Her liver function tests are within normal limits, and she does not have decompensated cirrhosis. Which medication should be selected for her NASH, taking into account her comorbidities and current therapy?", "options": {"A": "Resmetirom administered once daily in conjunction with diet and exercise", "B": "Pentoxifylline extended-release tablets twice daily", "C": "Dapagliflozin once daily", "D": "Pentoxifylline extended-release tablets once daily"}}
{"id": "AWWQM4SLpIAo", "question_type": "open_ended_multi_choice", "question": "What is the main issue that arises when a patient taking Wayrilz is also prescribed a potent CYP3A inducer?", "options": {"A": "Increased risk of hypertension", "B": "Reduced efficacy of Wayrilz", "C": "Increased risk of renal toxicity", "D": "Prolonged QT interval"}}
{"id": "QYtXV3LsbYnG", "question_type": "open_ended_multi_choice", "question": "A 45-year-old male patient with a prior diagnosis of basal cell carcinoma and moderate to severe chronic hand eczema is being evaluated for topical treatment. He is not currently on immunosuppressive medications and has no evidence of active infection. What is the most appropriate management approach in this scenario?", "options": {"A": "Start topical Anzupgo with regular skin examinations to monitor for non-melanoma skin cancer.", "B": "Start topical Anzupgo without any need for skin cancer monitoring.", "C": "Start topical Anzupgo in combination with potent immunosuppressants.", "D": "Start topical Anzupgo and schedule live vaccinations during treatment."}}
{"id": "5r6hvdlU9vUt", "question_type": "multi_choice", "question": "A 67-year-old man with persistent immune thrombocytopenia and autosomal dominant inheritance has failed previous corticosteroid therapy. He has a history of severe renal impairment and is currently taking a proton pump inhibitor for gastroesophageal reflux disease. Which drug should be avoided due to his comorbidities and medication regimen?", "options": {"A": "Prednisone", "B": "DMT SUIK (IV)", "C": "Rilzabrutinib", "D": "Dexamethasone sodium phosphate"}}
{"id": "iRFTWdmivkNA", "question_type": "open_ended_multi_choice", "question": "Select the option that outlines an appropriate directive for patients in relation to Andembry usage.", "options": {"A": "Inject Andembry intravenously without training.", "B": "Use Andembry for any condition with similar symptoms.", "C": "Do not give Andembry to other people, even if they have the same symptoms.", "D": "Mix Andembry with herbal supplements before injection."}}
{"id": "IHwtZmoRQIzr", "question_type": "open_ended_multi_choice", "question": "A 34-year-old woman who is pregnant is diagnosed with non–ST-segment elevation myocardial infarction (NSTEMI) and needs antiplatelet therapy for secondary prevention. She expresses concerns regarding medication safety during pregnancy. Which antiplatelet agent is most appropriate for her situation?", "options": {"A": "Flyrcado", "B": "BRILINTA", "C": "Clopidogrel", "D": "BRILINTA with aspirin"}}
{"id": "pwGLDSGWgwZg", "question_type": "open_ended_multi_choice", "question": "During the validation of a new aPTT assay in a clinical laboratory, which medication could interfere with the assay by affecting the contact activation pathway in patient samples?", "options": {"A": "Andembry", "B": "Warfarin", "C": "Aspirin", "D": "Clopidogrel"}}
{"id": "VAf1pkF9uKRk", "question_type": "open_ended_multi_choice", "question": "Which statement best describes the safety and effectiveness of Journavx in pediatric patients?", "options": {"A": "Safety and effectiveness have not been established", "B": "Journavx is approved for pediatric use", "C": "Journavx is contraindicated in pediatric patients", "D": "Journavx is recommended for children under 12"}}
{"id": "z6k37x7Nb1AC", "question_type": "open_ended_multi_choice", "question": "Which therapy for primary axillary hyperhidrosis should be avoided in a 35-year-old woman who is breastfeeding, has a history of urinary retention, and will be spending several weeks in a hot climate?", "options": {"A": "Qbrexza (glycopyrronium), topical wipes once daily", "B": "Sofdra (sofpironium bromide), topical gel once daily", "C": "Oxytrol for Women (oxybutynin), transdermal patch twice weekly", "D": "Both Qbrexza and Sofdra should be avoided"}}
{"id": "76HhB3Cqztbs", "question_type": "multi_choice", "question": "A 14-year-old female patient weighing 45 kg presents with symptoms of dysuria, urgency, and suprapubic pain. She is diagnosed with an uncomplicated urinary tract infection caused by Escherichia coli. Her medical history is notable for mild renal impairment (eGFR 50 mL/min), and she is currently taking digoxin for a cardiac condition. Which drug regimen is most appropriate for treating her infection, considering her age, renal function, and concomitant medication?", "options": {"A": "Flavoxate Hydrochloride tablets for symptomatic relief, administered three times daily.", "B": "Imipenem and Cilastatin Sodium intravenous therapy, with dosage adjustment for renal impairment.", "C": "Blujepa administered as per recommended dosing for uUTI, with monitoring of digoxin levels.", "D": "Blujepa administered as per recommended dosing for uUTI, without monitoring of digoxin levels."}}
{"id": "9ZYoeOXTIwXV", "question_type": "open_ended_multi_choice", "question": "How should the next dose of Modeyso be managed when a patient vomits soon after administration?", "options": {"A": "Retake the dose immediately", "B": "Skip the next scheduled dose", "C": "Do not take another dose; resume Modeyso on the next regularly scheduled weekly day", "D": "Double the dose at the next administration"}}
{"id": "qjL5wiFsAU7v", "question_type": "open_ended_multi_choice", "question": "A 17-year-old female with WHIM syndrome, recurrent bacterial infections, and decreased circulating antibody levels is currently taking digoxin for a cardiac condition and metformin for diabetes. She is not pregnant and has normal renal and hepatic function. What is the most appropriate approach for her drug therapy to increase mature neutrophil and lymphocyte counts?", "options": {"A": "XOLREMDI, daily oral administration with frequent monitoring of digoxin and glycemic control", "B": "Mavorixafor, daily oral administration without monitoring", "C": "XOLREMDI, daily oral administration with a drug holiday every month", "D": "No drug therapy recommended due to drug interactions"}}
{"id": "O9KyOiZXe5jV", "question_type": "open_ended_multi_choice", "question": "How should Hernexeos be managed when administered concurrently with BCRP substrates that are unlikely to cause significant adverse reactions due to minor concentration fluctuations?", "options": {"A": "Discontinue Hernexeos", "B": "Monitor for increased adverse reactions and adjust substrate dosage as clinically appropriate", "C": "Increase Hernexeos dose", "D": "No monitoring or adjustment needed"}}
{"id": "BMZ71B17H2Zj", "question_type": "multi_choice", "question": "A 42-year-old woman with recurrent low-grade serous ovarian carcinoma and confirmed KRAS mutation presents for treatment. She has previously received systemic therapy and is currently taking warfarin for atrial fibrillation. Which drug regimen is most appropriate for her cancer management?", "options": {"A": "AVMAPKI FAKZYNJA CO-PACK (avutometinib and defactinib)", "B": "AVMAPKI FAKZYNJA CO-PACK with warfarin co-administration", "C": "AVMAPKI FAKZYNJA CO-PACK with dose reduction due to warfarin", "D": "AVMAPKI FAKZYNJA CO-PACK after switching to a non-warfarin anticoagulant"}}
{"id": "lqy0EQ5KNVqY", "question_type": "multi_choice", "question": "Which of the following is a potential consequence of concomitant use of Journavx with strong or moderate CYP3A inducers?", "options": {"A": "Increased risk of Journavx toxicity.", "B": "Reduced efficacy of Journavx due to decreased exposure of suzetrigine and its active metabolite.", "C": "No effect on Journavx pharmacokinetics.", "D": "Increased efficacy of Journavx."}}
{"id": "KrXnEXIWYdEc", "question_type": "open_ended_multi_choice", "question": "A 35-year-old woman with a history of elevated systolic and diastolic blood pressure is diagnosed with hypertension. She is planning to become pregnant and is currently not using contraception. Her renal and hepatic function are normal. Which antihypertensive drug is most appropriate for her initial management?", "options": {"A": "TRYVIO", "B": "Candesartan cilexetil", "C": "Latanoprost", "D": "Lifestyle modification only"}}
{"id": "easQksITbJf8", "question_type": "multi_choice", "question": "A 28-year-old woman is admitted for labor and requests pain relief. She is otherwise healthy and is not taking any medications. She wishes to breastfeed her newborn after delivery. Which drug regimen is most appropriate for acute pain management during labor, considering safety for both mother and infant?", "options": {"A": "Suzetrigine administered every 6 hours", "B": "Childrens Pain Relief every 6 hours", "C": "Acetaminophen every 4 hours", "D": "Ropivacaine Hydrochloride via epidural infusion"}}
{"id": "J7u4bbmdaIY5", "question_type": "multi_choice", "question": "A 12-year-old patient weighing 32 kg presents with progressive neurological deterioration, gait ataxia, and hepatomegaly. Genetic testing confirms Niemann-Pick disease type C. The patient has a history of feeding difficulties and generalized hypotonia. She is currently taking N-acetyl-DL-leucine for another condition. Which drug regimen is most appropriate for treating her neurological manifestations of NPC?", "options": {"A": "Miglustat (Opfolda) in combination with Pombiliti", "B": "AQNEURSA (levacetylleucine) 4 g/day, continue N-acetyl-DL-leucine", "C": "Miglustat (Yargesa) 100 mg twice daily", "D": "AQNEURSA (levacetylleucine) 4 g/day, discontinue N-acetyl-DL-leucine prior to initiation"}}
{"id": "SceMuWtIkBrf", "question_type": "open_ended_multi_choice", "question": "A clinician is considering starting a patient on a strong CYP3A inducer while the patient is taking Wayrilz. What is the primary concern with this combination?", "options": {"A": "Increased risk of hypertension", "B": "Reduced efficacy of Wayrilz", "C": "Increased risk of renal toxicity", "D": "Prolonged QT interval"}}
{"id": "uQoGW0Pbq67d", "question_type": "multi_choice", "question": "A 58-year-old woman with chronic kidney disease has been receiving dialysis for the past four months. She presents with symptomatic anemia (hemoglobin 9.2 g/dL). Her medical history includes well-controlled hypertension and mild hyperlipidemia, for which she takes simvastatin 10 mg daily. She is not pregnant and has no history of liver disease or malignancy. Which of the following is the most appropriate pharmacologic treatment for her anemia, considering her current medications and comorbidities?", "options": {"A": "Fedratinib administered daily, with thiamine supplementation.", "B": "Vadadustat administered once daily, with careful monitoring of statin-related adverse effects and hemoglobin levels.", "C": "Homeopathic combination (Adrenalinum, etc.) for appetite and water retention symptoms.", "D": "Vadadustat administered once daily, with no adjustment for statin therapy."}}
{"id": "GuET4GTALjmO", "question_type": "multi_choice", "question": "A 35-year-old patient with myelodysplastic syndrome is scheduled for allogeneic hematopoietic stem cell transplantation. Which regimen including Grafapex is appropriate based on its approved indications?", "options": {"A": "Grafapex plus cytarabine as maintenance therapy", "B": "Grafapex monotherapy as a preparative regimen", "C": "Grafapex plus fludarabine as a preparative regimen", "D": "Grafapex plus methotrexate for induction therapy"}}
{"id": "QfOJWZOG5pkc", "question_type": "multi_choice", "question": "A male patient taking Modeyso has a female partner of reproductive potential. What is the recommended contraceptive advice for this patient?", "options": {"A": "Use effective contraception during treatment and for 1 month after the last dose.", "B": "No contraception is necessary.", "C": "Use contraception only during the first week of treatment.", "D": "Use contraception for 6 months after stopping Modeyso."}}
{"id": "b2Em5hoCniem", "question_type": "open_ended_multi_choice", "question": "A man aged 65, who has COPD and type 2 diabetes, presents with acute supraventricular tachycardia. He is receiving metformin and inhaled corticosteroids. Considering his comorbid conditions, which medication would be contraindicated?", "options": {"A": "RAPIBLYK (landiolol)", "B": "Pacerone (amiodarone)", "C": "Propranolol", "D": "Adenosine"}}
{"id": "DYAjhlTfEOhf", "question_type": "open_ended_multi_choice", "question": "A 24-year-old man of Southeast Asian ancestry with newly diagnosed primary motor cortex epilepsy is found to carry the HLA-B*1502 allele and the CYP2C9*3 variant. He has no other comorbidities. What is the most appropriate approach to antiepileptic drug selection for this patient?", "options": {"A": "Phenytoin Sodium is preferred, but requires a higher dose due to genetic variants.", "B": "Phenytoin Sodium should be avoided due to increased risk of severe skin reactions (SJS/TEN) and decreased drug clearance; alternative therapy is recommended.", "C": "Phenytoin Sodium can be used safely if administered orally rather than intravenously.", "D": "Phenytoin Sodium is contraindicated only if the patient has a history of hypersensitivity reactions."}}
{"id": "0wM0eAPqUaNR", "question_type": "multi_choice", "question": "If a patient has previously experienced an allergic reaction to any component of Vanrafia, what is the recommended course of action?", "options": {"A": "Vanrafia should not be prescribed", "B": "Vanrafia can be prescribed with antihistamines", "C": "Vanrafia dose should be reduced", "D": "Vanrafia can be administered under hospital supervision"}}
{"id": "V5egKJB2MJNW", "question_type": "open_ended_multi_choice", "question": "A 32-year-old woman with diffuse midline glioma (H3 K27M mutation, progressive after prior therapy) is currently pregnant. Her oncologist is considering treatment options. Which of the following statements best reflects the appropriateness of using dordaviprone (MODEYSO) in her case?", "options": {"A": "MODEYSO is safe to use during pregnancy if monitored closely.", "B": "MODEYSO should be avoided due to risk of fetal harm.", "C": "MODEYSO is only contraindicated in breastfeeding women, not pregnant women.", "D": "MODEYSO can be used if the patient is over 18 years old, regardless of pregnancy status."}}
{"id": "fFAh9E2C4uzY", "question_type": "multi_choice", "question": "A 42-year-old woman with newly diagnosed pulmonary arterial hypertension (PAH, WHO Group 1) presents for initial therapy. She is not pregnant, has no history of bleeding disorders, and is not taking any prostacyclin or antithrombotic agents. Her platelet count and hemoglobin are within normal limits. Which of the following is the most appropriate drug to initiate for her condition, considering efficacy and safety?", "options": {"A": "Epinephrine administered as a continuous infusion", "B": "Winrevair administered according to recommended dosing schedule", "C": "Vasopressin administered intravenously", "D": "Vasopressin combined with indomethacin"}}
{"id": "oeDG3OwauMnl", "question_type": "open_ended_multi_choice", "question": "A 65-year-old male with HIV wasting syndrome and a history of benign prostatic hyperplasia (BPH) and controlled hypertension is being evaluated for adjunctive pharmacologic therapy. He is not on anticoagulants and has no significant hepatic dysfunction. Which of the following drugs should be avoided due to the risk of worsening his underlying conditions?", "options": {"A": "Oxandrolone, due to risk of peliosis hepatis", "B": "XYOSTED, due to risk of worsening BPH and increasing blood pressure", "C": "Thalomid, due to risk of peripheral neuropathy", "D": "Oxandrolone, due to risk of hypoglycemia"}}
{"id": "eLezRVOL6Xlb", "question_type": "multi_choice", "question": "A 68-year-old male with a history of nonmuscle invasive bladder cancer presents with persistent carcinoma in situ (CIS) after failing two courses of Bacillus Calmette-Guérin (BCG) therapy. He has no significant comorbidities and is not currently taking any other medications. He is concerned about the risk of disease progression and wishes to avoid unnecessary systemic toxicity. Which of the following is the most appropriate next step in drug therapy for this patient, considering his disease subtype and treatment history?", "options": {"A": "Start Anktiva in combination with BCG administered intravesically.", "B": "Initiate Gemcitabine as a single agent administered intravenously weekly.", "C": "Begin Gemcitabine in combination with carboplatin.", "D": "Recommend systemic paclitaxel therapy."}}
{"id": "zrkP0kPBwvmC", "question_type": "open_ended_multi_choice", "question": "A 7-year-old child presents with progressive gait ataxia, cognitive impairment, and hepatosplenomegaly. Genetic testing confirms Niemann-Pick disease type C. The patient has normal renal function and is not taking any other medications. Which of the following is the most appropriate drug regimen for treating the neurological manifestations in this patient, considering age and disease specificity?", "options": {"A": "MIPLYFFA in combination with miglustat, administered according to pediatric dosing guidelines", "B": "OPFOLDA in combination with Pombiliti", "C": "Lithium carbonate", "D": "MIPLYFFA monotherapy"}}
{"id": "4IjfZN82qL5R", "question_type": "open_ended_multi_choice", "question": "Which combination regimen includes Penpulimab-kcqx for the first-line treatment of recurrent or metastatic non-keratinizing nasopharyngeal carcinoma?", "options": {"A": "Penpulimab-kcqx with cisplatin and gemcitabine", "B": "Penpulimab-kcqx with paclitaxel and carboplatin", "C": "Penpulimab-kcqx with gemcitabine alone", "D": "Penpulimab-kcqx with carboplatin and gemcitabine"}}
{"id": "MvYRa5PRZnZW", "question_type": "multi_choice", "question": "For a patient being considered for therapy with Andembry, which of the following is true regarding contraindications?", "options": {"A": "Andembry should be avoided in patients with renal insufficiency.", "B": "Andembry is contraindicated in patients with a history of anaphylaxis.", "C": "There are no contraindications for Andembry.", "D": "Andembry is contraindicated in pediatric populations."}}
{"id": "pgbEZTWpfrdq", "question_type": "multi_choice", "question": "A 58-year-old woman with non-alcoholic steatohepatitis (NASH) and moderate liver fibrosis (stage F2) is being considered for pharmacologic therapy. She has a history of well-controlled hypertension and is currently taking atorvastatin 40 mg daily for hyperlipidemia. Her liver function tests are within normal limits, and she does not have decompensated cirrhosis. Which drug regimen is most appropriate for her NASH management, considering her comorbidities and current medications?", "options": {"A": "Pentoxifylline extended-release tablets, 400 mg three times daily", "B": "Farxiga, 10 mg once daily", "C": "Rezdiffra, with atorvastatin dose limited to 40 mg daily", "D": "Rezdiffra, with atorvastatin dose increased to 80 mg daily"}}
{"id": "0I1jK5LCOtzY", "question_type": "multi_choice", "question": "Why might concomitant use of Grafapex and certain CYP2C19 substrates increase the risk of serious or life-threatening toxicities?", "options": {"A": "Grafapex induces CYP2C19, decreasing substrate exposure.", "B": "Grafapex inhibits CYP2C19, increasing substrate exposure.", "C": "Grafapex has no effect on CYP2C19 metabolism.", "D": "Grafapex increases renal clearance of CYP2C19 substrates."}}
{"id": "c9U6RD0GE725", "question_type": "open_ended", "question": "When considering the clinical use of Andembry, which of the following is true regarding its warnings and precautions section?", "options": {"A": "Andembry does not list any warnings or precautions.", "B": "Andembry lists warnings for teratogenicity.", "C": "Andembry includes precautions for elderly patients.", "D": "Andembry has warnings for drug-drug interactions."}}
{"id": "v6zAsaOtqyrK", "question_type": "open_ended_multi_choice", "question": "A 68-year-old woman diagnosed with hereditary transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) is currently receiving methotrexate for her rheumatoid arthritis and is not pregnant or breastfeeding. Identify the drug that should not be used due to the potential for heightened methotrexate toxicity, and specify the preferred therapy for her cardiomyopathy.", "options": {"A": "Dexrazoxane should be avoided; Attruby is preferred.", "B": "Vyndaqel should be avoided; Attruby is preferred.", "C": "Attruby should be avoided; Vyndaqel is preferred.", "D": "Dexrazoxane should be avoided; Vyndaqel is preferred."}}
{"id": "wns27Nr0xKO7", "question_type": "open_ended_multi_choice", "question": "A 35-year-old male with classic congenital adrenal hyperplasia is being treated with glucocortoid replacement therapy. He has recently begun taking a potent CYP3A4 inducer for an unrelated condition. What is the best way to modify his Crenessity dosing regimen?", "options": {"A": "Continue Crenessity at the standard dose without adjustment", "B": "Discontinue Crenessity due to CYP3A4 inducer interaction", "C": "Increase both morning and evening doses of Crenessity two-fold", "D": "Reduce the glucocorticoid dose to compensate for increased Crenessity metabolism"}}
{"id": "YY2cuBzhn5Yi", "question_type": "open_ended", "question": "A 3-year-old child presents with severe watery diarrhea. The pediatrician is considering pharmacologic intervention. The child has no history of organ transplantation, diabetes, or cardiac disease. Which of the following is the most appropriate recommendation regarding drug therapy for this patient?", "options": {"A": "Octreotide injection at standard pediatric dosing", "B": "MYCAPSSA (oral octreotide)", "C": "Hormone Harmony (homeopathic oral remedy)", "D": "Supportive care; avoid octreotide and MYCAPSSA due to lack of established safety and risk of serious adverse events in young children"}}
{"id": "6lRk3maYpiaV", "question_type": "open_ended", "question": "A 42-year-old woman with newly diagnosed locally advanced ROS1-positive non-small cell lung carcinoma is currently 10 weeks pregnant. She is seeking targeted therapy for her cancer. Which of the following is the most appropriate recommendation regarding the use of taletrectinib (IBTROZI) in her case?", "options": {"A": "Initiate taletrectinib at 600 mg orally once daily, as pregnancy does not affect its safety.", "B": "Defer taletrectinib therapy until after delivery due to risk of fetal harm.", "C": "Start taletrectinib at a reduced dose to minimize fetal exposure.", "D": "Proceed with taletrectinib but increase fetal monitoring during pregnancy."}}
{"id": "NLYk3FjqYzJq", "question_type": "open_ended_multi_choice", "question": "In the case of a 68-year-old man with acute erythroleukemia, congestive heart failure, anemia, thrombocytopenia, splenomegaly, and mild renal dysfunction, who cannot undergo stem cell transplantation, identify the drug that poses the greatest risk given his comorbidities and select the most appropriate option for palliative management.", "options": {"A": "Daunorubicin Hydrochloride administered intravenously at reduced dose", "B": "REVUMENIB administered orally with ECG monitoring", "C": "TaperDex 12-day administered at the lowest effective dose with careful monitoring for fluid retention and hypertension", "D": "Daunorubicin Hydrochloride combined with REVUMENIB for induction therapy"}}
{"id": "ryiOrfVuymkM", "question_type": "multi_choice", "question": "A patient on Journavx is also taking a sensitive CYP3A substrate where small changes in concentration may lead to loss of efficacy. What is the recommended management strategy?", "options": {"A": "No action is needed.", "B": "Discontinue Journavx.", "C": "Switch to a strong CYP3A inducer.", "D": "Increase the dose of Journavx."}}
{"id": "0tDKrHlpfKHF", "question_type": "open_ended_multi_choice", "question": "A 15-year-old female with WHIM syndrome presents with recurrent upper respiratory tract infections, neutropenia, and decreased circulating IgG concentration. She has a history of severe periodontitis and is currently taking metformin for type 2 diabetes. Her renal and hepatic function are normal, and she is not pregnant or breastfeeding. Which of the following is the most appropriate drug regimen for her WHIM syndrome?", "options": {"A": "XOLREMDI, with careful monitoring of glycemic control and metformin dose adjustment as needed.", "B": "XOLREMDI, without any adjustment or monitoring for metformin.", "C": "XOLREMDI, but discontinue metformin immediately.", "D": "XOLREMDI, only if the patient is switched to insulin for diabetes management."}}
{"id": "DwqRhReiEqmq", "question_type": "open_ended", "question": "For the brand drug Ekterly, which statement best describes its results in mutagenesis testing?", "options": {"A": "Ekterly was mutagenic in the Ames test.", "B": "Ekterly was clastogenic in human lymphocyte assays.", "C": "Ekterly was not mutagenic or clastogenic in multiple in vitro and in vivo assays.", "D": "Ekterly was mutagenic only in the rat micronucleus assay."}}
{"id": "g99HtveXzGcJ", "question_type": "multi_choice", "question": "A 15-year-old female with WHIM syndrome presents with recurrent upper respiratory tract infections, severe periodontitis, and decreased circulating IgG concentration. She is currently pregnant and seeks treatment to increase her mature neutrophil and lymphocyte counts. Which drug regimen is most appropriate for her condition?", "options": {"A": "XOLREMDI, daily oral administration", "B": "Mavorixafor, daily oral administration", "C": "XOLREMDI, weekly administration", "D": "No drug therapy recommended due to pregnancy"}}
{"id": "HlMghapcT48O", "question_type": "open_ended_multi_choice", "question": "A 45-year-old female with dry eye disease, who wears contact lenses on a daily basis, is seeking a medication for relief that does not require her to take out her lenses before use. Considering both her preference and the safety of the available drugs, which is the most appropriate choice?", "options": {"A": "Acoltremon ophthalmic solution, administered twice daily", "B": "Loteprednol etabonate ophthalmic gel, administered twice daily", "C": "Lifitegrast ophthalmic solution, administered twice daily", "D": "Loteprednol etabonate ophthalmic gel, administered once daily"}}
{"id": "vxUdWfEnFHbE", "question_type": "open_ended_multi_choice", "question": "For a 6-month-old infant with autosomal dominant adrenocortical carcinoma, prematurity, and impaired liver and renal function, which of the proposed treatments carries a particular risk owing to its excipient and should therefore not be used?", "options": {"A": "Etoposide injection containing polysorbate 80", "B": "Lumisight (pegulicianine) administered at 1 mg/kg for imaging", "C": "Etoposide administered orally at a low dose", "D": "Lumisight (pegulicianine) administered at a reduced dose"}}
{"id": "r9gYvMJPOdUz", "question_type": "open_ended_multi_choice", "question": "A 35-year-old male with moderate hepatic impairment (Child-Pugh Class B) and currently on a moderate CYP3A inhibitor presents following a traumatic injury with moderate to severe acute pain. What is the most suitable drug and dosing regimen for his pain control?", "options": {"A": "JOURNAVX at standard adult dosage", "B": "JOURNAVX at reduced dosage due to hepatic impairment and CYP3A inhibitor use", "C": "Ropivacaine Hydrochloride at standard adult dosage", "D": "Pain Relief Childrens (acetaminophen-based OTC) at pediatric dosing"}}
{"id": "elrSL58xftWF", "question_type": "open_ended", "question": "Which of the following statements is correct regarding the use of Ekterly with weak CYP3A4 inhibitors?", "options": {"A": "Avoid concomitant use", "B": "Reduce Ekterly dosage by half", "C": "No dosage modification is required", "D": "Increase Ekterly dosage"}}
{"id": "g1VW0ldlmiEf", "question_type": "multi_choice", "question": "A 34-year-old woman with newly diagnosed prurigo nodularis is 20 weeks pregnant. She is seeking treatment for her severe itching and is concerned about fetal safety. Which of the following is the most appropriate therapeutic approach for her condition?", "options": {"A": "NEMLUVIO administered every 4 weeks, with careful consideration of potential fetal exposure", "B": "Nalbuphine Hydrochloride injection for symptomatic relief, used routinely throughout pregnancy", "C": "NEMLUVIO combined with topical corticosteroids and live vaccines", "D": "Nalbuphine Hydrochloride injection during labor and delivery only"}}
{"id": "weRGjPzJcjdP", "question_type": "open_ended_multi_choice", "question": "In a 6-month carcinogenicity study using Tg.rasH2 mice, what was the observed effect of Sephience on tumor incidence at exposures approximately 12- and 16-fold higher than the human exposure at the MRHD?", "options": {"A": "Sephience increased tumor incidence in both male and female mice.", "B": "Sephience decreased tumor incidence in male mice only.", "C": "Sephience did not increase tumor incidence in either male or female mice.", "D": "Sephience caused tumor formation only in female mice."}}
{"id": "mMCNkT8TZGgB", "question_type": "open_ended_multi_choice", "question": "A child aged 7 years has cystic fibrosis due to homozygous F508del mutations and shows signs of bronchiectasis, failure to thrive, and increased sweat chloride levels. She is taking oral hormonal contraceptives for a separate medical issue. Which treatment regimen should be recommended?", "options": {"A": "Brinsupri, with monitoring for dermatologic adverse reactions", "B": "ORKAMBI, with counseling to use non-hormonal contraception", "C": "SYMDEKO, with standard dosing and no change to contraceptive regimen", "D": "ORKAMBI, with no contraceptive counseling required"}}
{"id": "0iGwmAmyNiwU", "question_type": "open_ended_multi_choice", "question": "A 7-year-old boy with a recent diagnosis of reactive arthritis presents with joint swelling, fever, and weight loss. He has a history of recurrent urinary tract infections and is currently being considered for antibiotic therapy. Which of the following is the most appropriate drug regimen for this patient, considering his age and the risks associated with each medication?", "options": {"A": "Doxycycline hyclate 100 mg orally twice daily for 10 days", "B": "Renflexis intravenous infusion every 8 weeks", "C": "Doxycycline hyclate only if the infection is life-threatening and no alternatives exist", "D": "Renflexis in combination with anakinra"}}
{"id": "uP7OSBUXiyfU", "question_type": "multi_choice", "question": "In patients with hemophilia B who have developed factor IX inhibitors, which brand name drug is indicated for routine prophylaxis to prevent or reduce bleeding episodes?", "options": {"A": "Qfitlia", "B": "Emicizumab", "C": "Desmopressin", "D": "Tranexamic acid"}}
{"id": "5F2sghFkO5lV", "question_type": "multi_choice", "question": "A 50-year-old woman with chronic hypoparathyroidism is currently being treated with digoxin for atrial fibrillation. Her serum calcium is well controlled on calcium and active vitamin D. She is being considered for additional therapy to better manage her hypoparathyroidism. Which of the following is the most important consideration if Yorvipath is initiated?", "options": {"A": "Yorvipath is contraindicated in patients with a history of atrial fibrillation", "B": "Yorvipath may increase the risk of digitalis toxicity due to elevated serum calcium", "C": "Yorvipath is not effective in patients taking active vitamin D", "D": "Yorvipath should be administered twice daily to minimize calcium fluctuations"}}
{"id": "nHjTTZZlKu2w", "question_type": "open_ended_multi_choice", "question": "A 42-year-old woman with transfusion-dependent anemia and low-risk myelodysplastic syndrome is found to have a deletion 5q abnormality. She intends to become pregnant and is not currently using contraception. Considering her reproductive plans, which medication should be absolutely contraindicated in her treatment?", "options": {"A": "Imetelstat sodium, 7.5 mg/kg intravenously every 4 weeks", "B": "Lenalidomide, 10 mg orally once daily", "C": "Inqovi, 35 mg orally once daily for 5 consecutive days every 28 days", "D": "Inqovi, 20 mg orally once daily for 5 consecutive days every 28 days"}}
{"id": "engalHQEEFXx", "question_type": "multi_choice", "question": "If a patient’s blood phenylalanine does not decrease after 2 weeks of Sephience at the maximum daily dose, what is the recommended clinical action?", "options": {"A": "Increase the dose beyond 60 mg/kg", "B": "Continue current dose and monitor monthly", "C": "Switch to a high-protein diet", "D": "Discontinue Sephience"}}
{"id": "2oQSoGUaVXyn", "question_type": "multi_choice", "question": "A 45-year-old woman with symptomatic tenosynovial giant cell tumor (TGCT) is not a candidate for surgery due to the risk of worsening functional limitation. She has a history of aspirin sensitivity and previously experienced bronchial asthma triggered by food dyes. Her liver and renal function tests are within normal limits, and she is not pregnant or breastfeeding. Which drug is the most appropriate for her treatment?", "options": {"A": "ROMVIMZA", "B": "Turalio", "C": "Turalio with dose reduction", "D": "ROMVIMZA with dose reduction"}}
{"id": "Wj7jfkavyxaq", "question_type": "multi_choice", "question": "If a patient’s blood phenylalanine does not decrease after 2 weeks of Sephience at the maximum daily dose, what is the recommended clinical action?", "options": {"A": "Increase the dose beyond 60 mg/kg", "B": "Continue current dose and monitor monthly", "C": "Add another PKU medication", "D": "Switch to a high-protein diet"}}
{"id": "BwIlPr7rcBmf", "question_type": "open_ended", "question": "A 35-year-old man with moderate chronic hand eczema is currently receiving potent immunosuppressant therapy for another autoimmune condition. He has no history of infection, cancer, or cardiovascular disease. Which of the following is the most appropriate approach regarding Anzupgo treatment?", "options": {"A": "Initiate Anzupgo topical therapy alongside his current immunosuppressant regimen.", "B": "Discontinue immunosuppressants and begin Anzupgo therapy.", "C": "Avoid Anzupgo due to contraindicated drug interactions with potent immunosuppressants.", "D": "Start Anzupgo and schedule live vaccinations during treatment."}}
{"id": "kwqlfYvchAUQ", "question_type": "open_ended_multi_choice", "question": "What is the most accurate description of the warnings and precautions associated with the drug Andembry?", "options": {"A": "There are no warnings and precautions listed for Andembry.", "B": "Andembry has multiple warnings and precautions related to hepatic impairment.", "C": "Andembry requires monitoring for cardiovascular side effects.", "D": "Andembry is contraindicated in pregnancy due to specific warnings."}}
{"id": "sk1TcufSIBkG", "question_type": "open_ended_multi_choice", "question": "Which recommendation is appropriate for women who are breastfeeding and have been prescribed Modeyso?", "options": {"A": "Do not breastfeed during treatment and for 1 week after the last dose.", "B": "Continue breastfeeding as usual.", "C": "Breastfeed only immediately before taking Modeyso.", "D": "Stop breastfeeding permanently."}}
{"id": "BRvTtyd7e67b", "question_type": "multi_choice", "question": "When administering Vizz, what instruction should be given to patients who wear contact lenses?", "options": {"A": "Remove contact lenses prior to instillation and wait 10 minutes before reinserting.", "B": "Keep contact lenses in during instillation.", "C": "Reinsert contact lenses immediately after instillation.", "D": "Wait 30 minutes before reinserting contact lenses."}}
{"id": "j750mfMMiFP9", "question_type": "open_ended_multi_choice", "question": "A 10-year-old child is newly diagnosed with nephrosis and presents with edema. The pediatrician is considering pharmacologic management. Which of the following drugs should NOT be selected due to lack of established safety and effectiveness in this age group?", "options": {"A": "PredniSONE Tablets, 5 mg daily", "B": "Bumex administered orally", "C": "Bumex administered intravenously", "D": "Depo-Provera injection every 3 months"}}
{"id": "n6N2IP3PHMkF", "question_type": "multi_choice", "question": "A 74-year-old man with intermediate-2 risk myelodysplastic syndrome (MDS) is being considered for drug therapy. He has moderate renal impairment (creatinine clearance 40 mL/min), is not eligible for stem cell transplantation, and is not taking any drugs metabolized by cytidine deaminase. Which of the following is the most suitable drug for his condition, considering his age, renal function, and MDS risk group?", "options": {"A": "Lenalidomide, with dose adjustment for renal impairment.", "B": "INQOVI (cedazuridine and decitabine), administered orally once daily in 28-day cycles.", "C": "TREOSULFAN (GRAFAPEX) in combination with fludarabine as a transplant preparative regimen.", "D": "Lenalidomide, standard dose without adjustment."}}
{"id": "MTU4fhsZQuwK", "question_type": "open_ended_multi_choice", "question": "A 15-year-old with hereditary angioedema comes to the emergency department for an acute attack. The medical record notes prior severe anaphylactic reactions to ecallantide. Which medication should be excluded from the treatment plan, and what is the preferred management for this episode?", "options": {"A": "Kalbitor", "B": "TAKHZYRO", "C": "ANDEMBRY", "D": "Supportive care only"}}
{"id": "l4jV79VblI4h", "question_type": "open_ended_multi_choice", "question": "For a 15-year-old presenting with generalized myasthenia gravis and a positive anti-MuSK antibody test, which brand name medication is indicated?", "options": {"A": "Imaavy", "B": "Pyridostigmine", "C": "Azathioprine", "D": "Eculizumab"}}
{"id": "JbiFHnyLmrPG", "question_type": "open_ended_multi_choice", "question": "A 34-year-old woman with chronic immune thrombocytopenia presents with abnormal bleeding and is found to be platelet antibody positive. She previously failed corticosteroid therapy and now seeks further treatment. She is planning to become pregnant and currently has mild hepatic impairment. Which drug is the most appropriate choice for her next line of therapy?", "options": {"A": "Rilzabrutinib", "B": "Prednisone", "C": "DMT SUIK (IV)", "D": "Dexamethasone sodium phosphate"}}
{"id": "qpMv0QnHai5m", "question_type": "open_ended_multi_choice", "question": "A 42-year-old breastfeeding woman with familial chylomicronemia syndrome, presenting with hepatic steatosis, cognitive deficits, and elevated chylomicron levels, seeks medication to lower her triglycerides. Which pharmacologic agent is most suitable for her?", "options": {"A": "MYCOPHENOLATE MOFETIL, as it has limited data but some infants breastfed during maternal use had no reported adverse events.", "B": "TRYNGOLZA, since animal data suggest low levels in milk and poor oral bioavailability, making it unlikely to harm the infant.", "C": "MYCOPHENOLATE MOFETIL, with additional barrier contraception to minimize infant exposure.", "D": "TRYNGOLZA, but only after cessation of breastfeeding due to unknown human data."}}
{"id": "R6pcTNrG4ctE", "question_type": "open_ended_multi_choice", "question": "A 67-year-old man with chronic hypertension, elevated cholesterol, and recurrent gout seeks advice regarding blood pressure control. His estimated glomerular filtration rate is 55 mL/min, and he does not have hepatic impairment. He is not using lithium. Considering his prior gout attacks and his worries about medications that might trigger further episodes, which antihypertensive agent should be selected for this patient?", "options": {"A": "Chlorthalidone (THALITONE), once daily", "B": "Aprocitentan (TRYVIO), once daily in combination with other antihypertensives", "C": "Bosentan (TRACLEER), twice daily", "D": "Chlorthalidone (THALITONE), twice daily"}}
{"id": "5o39cKHpYli2", "question_type": "open_ended_multi_choice", "question": "If a patient experiences a Grade 2 interstitial lung disease (ILD)/pneumonitis event while on Emrelis, what is the appropriate management?", "options": {"A": "Withhold Emrelis and resume upon radiographic resolution", "B": "Permanently discontinue Emrelis", "C": "Reduce the dose and continue", "D": "Continue Emrelis with corticosteroids"}}
{"id": "3XpPZTZ1GOQG", "question_type": "open_ended_multi_choice", "question": "How should a patient proceed if they have missed at least two doses while on the standard Journavx schedule?", "options": {"A": "Take 100 mg as soon as possible, then resume the next scheduled dose.", "B": "Skip all missed doses and wait until the next scheduled dose.", "C": "Take 50 mg as soon as possible, then double the next dose.", "D": "Take 200 mg immediately."}}
{"id": "6UMlCa94RvGa", "question_type": "multi_choice", "question": "A male patient taking Romvimza has a female partner of reproductive potential. What is the recommended guidance regarding contraception?", "options": {"A": "No contraception is needed for male patients.", "B": "Effective contraception should be used during treatment and for 1 month after the last dose.", "C": "Contraception is only required if the partner is pregnant.", "D": "Contraception is required for 6 months after stopping Romvimza."}}
{"id": "7QawAbZ5ke9o", "question_type": "open_ended_multi_choice", "question": "Why should age-appropriate vaccines be evaluated before initiating Imaavy therapy?", "options": {"A": "Imaavy causes transient reduction in IgG levels, making live vaccines not recommended during treatment", "B": "Imaavy increases the risk of vaccine-induced fever", "C": "Imaavy enhances the efficacy of live vaccines", "D": "Imaavy interacts with inactivated vaccines to cause hypersensitivity"}}
{"id": "F0z83zg7vb5g", "question_type": "multi_choice", "question": "A patient with metastatic non-keratinizing nasopharyngeal carcinoma has progressed after platinum-based chemotherapy and one additional prior therapy. Which treatment option involving Penpulimab-kcqx is appropriate?", "options": {"A": "Penpulimab-kcqx as a single agent", "B": "Penpulimab-kcqx in combination with cisplatin and gemcitabine", "C": "Penpulimab-kcqx with carboplatin and paclitaxel", "D": "Penpulimab-kcqx as maintenance therapy after chemotherapy"}}
{"id": "YLu9ROnP0aZ2", "question_type": "open_ended_multi_choice", "question": "A 58-year-old man with acute myeloid leukemia related to topoisomerase type 2 inhibitor exposure presents with severe hepatic impairment (Child Pugh Class C, serum bilirubin 6 mg/dL). He is not pregnant, not breastfeeding, and has no history of cardiac disease. Which of the following is the most appropriate course of action regarding chemotherapy selection?", "options": {"A": "Initiate Doxorubicin Hydrochloride at standard dosage", "B": "Initiate Idamycin PFS with dose reduction", "C": "Initiate Doxorubicin Hydrochloride with dose reduction", "D": "Avoid Doxorubicin Hydrochloride due to contraindication in severe hepatic impairment"}}
{"id": "FuTKI8VGrsPE", "question_type": "open_ended", "question": "What precaution should be taken regarding vaccinations when prescribing Brinsupri?", "options": {"A": "No precautions are necessary", "B": "Patients should avoid all vaccinations", "C": "Patients should inform their healthcare provider if they have recently received or are scheduled to receive any live attenuated vaccinations", "D": "Only inactivated vaccines are contraindicated"}}
{"id": "mR56syUnqSJe", "question_type": "open_ended_multi_choice", "question": "A man aged 60 who has presbyopia and is being treated with a monoamine oxidase inhibitor for depression as well as beta-blockers for hypertension wants to improve his ability to see up close. Which therapy would be both safe and effective for this patient?", "options": {"A": "Mirvaso topical gel applied to the face daily", "B": "Oraverse intraoral injection following dental anesthesia", "C": "VIZZ topical ocular drops once daily", "D": "Mirvaso topical gel applied twice daily"}}
{"id": "SiVb79SrzWLW", "question_type": "open_ended_multi_choice", "question": "Which of the following statements is accurate regarding the use of Ekterly 300 mg in the KONFIDENT trial?", "options": {"A": "Ekterly 300 mg was evaluated but is not a recommended dose for acute HAE attacks", "B": "Ekterly 300 mg was the preferred dose for all patients", "C": "Ekterly 300 mg was only used in patients under 18 years", "D": "Ekterly 300 mg was not evaluated in the trial"}}
{"id": "4yKvAIcaWZRF", "question_type": "open_ended_multi_choice", "question": "A woman aged 28 with classic congenital adrenal hyperplasia is receiving glucocorticoid replacement and wishes to become pregnant. She asks about starting crinecerfont (CRENESSITY) to control androgen excess. What is the most suitable advice concerning crinecerfont use for her?", "options": {"A": "Crinecerfont is contraindicated in all pregnant women.", "B": "Crinecerfont may be considered if the benefits outweigh the risks, but exposure should be reported and monitored.", "C": "Crinecerfont is safe and recommended for all women planning pregnancy.", "D": "Crinecerfont should be discontinued immediately upon conception."}}
{"id": "eRaQNa42uzjE", "question_type": "open_ended_multi_choice", "question": "A woman aged 34 with chronic immune thrombocytopenia and confirmed platelet antibodies presents with abnormal bleeding. Having failed corticosteroid therapy, she is planning pregnancy and has mild liver dysfunction. Which medication should be recommended as her next step in management?", "options": {"A": "Rilzabrutinib", "B": "Prednisone", "C": "DMT SUIK (IV)", "D": "Dexamethasone sodium phosphate"}}
{"id": "6F1pTVeBC5an", "question_type": "open_ended_multi_choice", "question": "A 68-year-old patient with ALK-positive locally advanced NSCLC has moderate hepatic impairment (total bilirubin >1.5 to ≤3 times ULN and any AST). The patient is not currently taking any CYP3A4 inhibitors or inducers. Which drug regimen is most suitable for this patient, considering hepatic function and drug safety?", "options": {"A": "Erlotinib, standard dosing", "B": "Ensartinib, with increased monitoring and possible dose adjustment", "C": "Rozlytrek, standard dosing", "D": "Ensartinib, avoid use due to hepatic impairment"}}
{"id": "ocx5s46UnCNT", "question_type": "open_ended_multi_choice", "question": "In the scenario of a 29-year-old pregnant patient with chronic hand eczema unresponsive to topical corticosteroids, what is the most appropriate guidance regarding Anzupgo treatment?", "options": {"A": "Consider Anzupgo only if the potential benefit justifies the potential risk to the fetus.", "B": "Initiate Anzupgo without any consideration of pregnancy status.", "C": "Anzupgo is contraindicated in all pregnant women regardless of severity.", "D": "Anzupgo is recommended as first-line therapy for all pregnant women with hand eczema."}}
{"id": "RD9QbzsykKSZ", "question_type": "open_ended_multi_choice", "question": "A 7-year-old boy with myelodysplastic syndrome is preparing for an allogeneic hematopoietic stem cell transplant. He has no seizure history and is not on any medications that are substrates of CYP2C19 or CYP3A4. Which drug regimen should be included in his conditioning protocol before transplantation?", "options": {"A": "Lenalidomide, oral daily dosing", "B": "Reblozyl, subcutaneous injection every 3 weeks", "C": "Treosulfan (GRAFAPEX) in combination with fludarabine, with supportive care for myelosuppression", "D": "Lenalidomide, with a planned drug scheduler to minimize cytopenias"}}
{"id": "fzImse0kupCw", "question_type": "multi_choice", "question": "A 60-year-old man with a history of inoperable adrenocortical carcinoma and mild hepatic impairment is being considered for Lysodren therapy. He is also taking warfarin for atrial fibrillation. What is the most appropriate next step regarding his cancer treatment?", "options": {"A": "Start Lysodren without any adjustments", "B": "Start Lysodren, but monitor warfarin INR closely and adjust warfarin dose as needed", "C": "Use Lumisight for systemic therapy", "D": "Avoid Lysodren due to interaction with warfarin"}}
{"id": "uRi909ZkLskl", "question_type": "multi_choice", "question": "A 55-year-old adult with hereditary angioedema is experiencing an acute attack. The patient is currently taking a strong CYP3A4 inhibitor for another condition. Which drug is the most suitable for treating the acute attack, considering drug-drug interactions?", "options": {"A": "Ekterly", "B": "Icatibant acetate", "C": "Sajazir", "D": "Icatibant"}}
{"id": "dZ0T1IXwpItw", "question_type": "open_ended_multi_choice", "question": "A 67-year-old man with relapsed multiple myeloma and a history of somatic mosaicism has failed four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. He is currently on warfarin for atrial fibrillation and has mild hepatic impairment. Which drug is most suitable for his next line of treatment, considering drug interactions and safety profile?", "options": {"A": "Thalidomide in combination with dexamethasone", "B": "Linvoseltamab-gcpt", "C": "Talquetamab-tgvs", "D": "Thalidomide monotherapy"}}
{"id": "fc4bDLL6o6F8", "question_type": "open_ended_multi_choice", "question": "In the process of validating a novel aPTT assay, which pharmaceutical agent might cause assay interference because of its influence on the contact system in patient samples?", "options": {"A": "Andembry", "B": "Warfarin", "C": "Aspirin", "D": "Clopidogrel"}}
{"id": "mlY0xMF0Yohu", "question_type": "open_ended_multi_choice", "question": "A 58-year-old male with chronic kidney disease (estimated creatinine clearance of 28 mL/min/1.73 m²) has been diagnosed with Niemann-Pick disease type C and is experiencing worsening neurological symptoms and gait problems. He is not receiving enzyme replacement therapy. Taking his renal impairment into account, which drug would be most appropriate for his treatment?", "options": {"A": "Yargesa (miglustat) at standard dosing", "B": "Aqneursa at the recommended adult dosage", "C": "Opfolda (miglustat) in combination with Pombiliti", "D": "Yargesa (miglustat) with dose reduction for renal impairment"}}
{"id": "jxmkWq8r0fYX", "question_type": "multi_choice", "question": "A 62-year-old woman with metastatic pancreatic adenocarcinoma presents for first-line systemic therapy. Her laboratory results show a baseline absolute neutrophil count of 1,200 cells/mm³ and total bilirubin 1.2 x ULN. She has no history of hypersensitivity to taxanes, and her cardiac function is normal. Which drug regimen is most appropriate for her initial treatment?", "options": {"A": "Paclitaxel protein-bound particles for injectable suspension (albumin-bound) in combination with gemcitabine", "B": "BIZENGRI (zenocutuzumab)", "C": "Imbruvica (ibrutinib)", "D": "Paclitaxel protein-bound particles for injectable suspension (albumin-bound) monotherapy"}}
{"id": "Z4i3acbBlvPQ", "question_type": "open_ended_multi_choice", "question": "What is the suggested approach when Hernexeos is given alongside BCRP substrates that do not have a high risk of serious adverse effects from small changes in their concentration?", "options": {"A": "Discontinue Hernexeos", "B": "Monitor for increased adverse reactions and adjust substrate dosage as clinically appropriate", "C": "Increase Hernexeos dose", "D": "No monitoring or adjustment needed"}}
{"id": "vatGZL8VzM4p", "question_type": "multi_choice", "question": "How did the requirement for rescue medication compare between the Wayrilz and placebo groups during the double-blind period of the LUNA-3 study?", "options": {"A": "Both groups had 33% requiring rescue medication", "B": "58% of Wayrilz patients and 33% of placebo patients required rescue medication", "C": "33% of Wayrilz patients and 58% of placebo patients required rescue medication", "D": "Both groups had 58% requiring rescue medication"}}
{"id": "XSI1ej2RURSn", "question_type": "open_ended_multi_choice", "question": "A 45-year-old man with a history of basal cell carcinoma and moderate to severe chronic hand eczema is being considered for topical therapy. He has no active infections and is not taking any immunosuppressants. Which of the following is the most suitable management plan?", "options": {"A": "Start topical Anzupgo with regular skin examinations to monitor for non-melanoma skin cancer.", "B": "Start topical Anzupgo without any need for skin cancer monitoring.", "C": "Start topical Anzupgo in combination with potent immunosuppressants.", "D": "Start topical Anzupgo and schedule live vaccinations during treatment."}}
{"id": "jjaCWhFSEMbV", "question_type": "open_ended_multi_choice", "question": "A patient currently on a moderate CYP3A4 inducer is prescribed Ekterly to treat an acute hereditary angioedema (HAE) attack. What should be done regarding the administration of Ekterly?", "options": {"A": "Administer standard Ekterly dosage", "B": "Reduce Ekterly dosage by half", "C": "Avoid concomitant use of Ekterly", "D": "Increase Ekterly dosage"}}
{"id": "biYDmSw0qMbf", "question_type": "open_ended", "question": "A 45-year-old patient with a confirmed diagnosis of pheochromocytoma presents with episodic hypertension, tachycardia, and excessive sweating. The patient is scheduled for tumor resection in two weeks. He has a history of mild congestive heart failure and is currently taking a low-dose beta-blocker. Which of the following is the most appropriate pharmacologic agent to initiate for preoperative blood pressure control in this patient?", "options": {"A": "Phentolamine Mesylate", "B": "Phenoxybenzamine Hydrochloride", "C": "Metyrosine", "D": "Lidocaine"}}
{"id": "F88bBuXMCprU", "question_type": "open_ended_multi_choice", "question": "In the event that a patient misses two or more scheduled doses of Journavx, what is the appropriate course of action?", "options": {"A": "Take 100 mg as soon as possible, then resume the next scheduled dose.", "B": "Skip all missed doses and wait until the next scheduled dose.", "C": "Take 50 mg as soon as possible, then double the next dose.", "D": "Take 200 mg immediately."}}
{"id": "4qlbyqSaURlp", "question_type": "open_ended_multi_choice", "question": "For the drug Ibtrozi, what does section 4 of the prescribing information indicate regarding contraindications?", "options": {"A": "Section 4 states that there are no contraindications for Ibtrozi.", "B": "Section 4 lists renal impairment as a contraindication.", "C": "Section 4 lists hepatic failure as a contraindication.", "D": "Section 4 lists pregnancy as a contraindication."}}
{"id": "qSCcAqUSiOOe", "question_type": "multi_choice", "question": "If a patient experiences Grade 3 cytokine release syndrome (CRS) during Lynozyfic therapy, what is the recommended action regarding the next dose?", "options": {"A": "Resume Lynozyfic at the same dose after CRS resolves", "B": "Increase the infusion rate for the next dose", "C": "Permanently discontinue Lynozyfic", "D": "Resume Lynozyfic at a reduced dose (2.5 mg if last dose was 5 mg; restart step-up dosing from 5 mg if last dose was 25 mg)"}}
{"id": "vfxynkwymzw6", "question_type": "open_ended_multi_choice", "question": "A 62-year-old woman with unresectable, metastatic non-squamous NSCLC has an activating HER2 (ERBB2) tyrosine kinase domain mutation confirmed by FDA-approved testing. She has already received platinum-based chemotherapy and now needs additional systemic treatment. Her cardiac function is normal, and she is not on any CYP3A inducers or BCRP substrates. She is neither pregnant nor planning to breastfeed. What is the most suitable next-line drug therapy for her, considering both indication and safety?", "options": {"A": "HERNEXEOS administered orally once daily, with regular monitoring of liver and cardiac function.", "B": "TECENTRIQ administered intravenously every 3 weeks as a single agent.", "C": "Etoposide administered intravenously in combination with other chemotherapeutic agents.", "D": "TECENTRIQ in combination with bevacizumab, paclitaxel, and carboplatin."}}
{"id": "IiIN7A56PYFz", "question_type": "open_ended_multi_choice", "question": "What advice should be given to male patients with female partners of reproductive potential who are being treated with Modeyso?", "options": {"A": "No contraception is necessary.", "B": "Use effective contraception during treatment and for 1 month after the last dose.", "C": "Discontinue Modeyso if pregnancy is suspected.", "D": "Monitor sperm count monthly."}}
{"id": "oWxGp2f4hr6N", "question_type": "open_ended_multi_choice", "question": "What guidance should clinicians provide to male patients taking Modeyso whose female partners are of childbearing age?", "options": {"A": "No contraception is necessary.", "B": "Use effective contraception during treatment and for 1 month after the last dose.", "C": "Discontinue Modeyso if pregnancy is suspected.", "D": "Monitor sperm count monthly."}}
{"id": "yFjm4kaVb4ac", "question_type": "open_ended_multi_choice", "question": "A 15-year-old adolescent girl weighing 45 kg presents with a new diagnosis of paroxysmal nocturnal hemoglobinuria (PNH). She has no hepatic impairment and has never been treated with complement inhibitors. Her parents want to know which available treatment would be safest and most effective to initiate. Which agent is most appropriate for initial therapy in her case?", "options": {"A": "Danicopan as monotherapy", "B": "Pegcetacoplan as monotherapy", "C": "Crovalimab as monotherapy", "D": "Danicopan as add-on to ravulizumab"}}
{"id": "2MnAMOZ91FTU", "question_type": "open_ended_multi_choice", "question": "In patients with mild to moderate renal impairment (creatinine clearance 30 to <90 mL/min), what monitoring is recommended when administering Datroway?", "options": {"A": "No monitoring required", "B": "Monitor for increased adverse reactions, including respiratory reactions", "C": "Increase dosage", "D": "Reduce dosage"}}
{"id": "z10wmQydLbtI", "question_type": "open_ended_multi_choice", "question": "A 12-year-old girl with phenylketonuria presents with elevated blood phenylalanine levels and a history of eczema and microcephaly. She is currently being treated for attention deficit hyperactivity disorder with methylphenidate and has recently started methotrexate for juvenile idiopathic arthritis. Her PKU is confirmed to be tetrahydrobiopterin (BH4)-responsive. Which drug regimen is most appropriate to reduce her blood phenylalanine levels, considering her current medications and disease profile?", "options": {"A": "Sephience administered daily with a phenylalanine-restricted diet", "B": "Sapropterin dihydrochloride administered daily with a phenylalanine-restricted diet", "C": "JAVYGTOR administered daily with a phenylalanine-restricted diet", "D": "Sephience administered every other day with a phenylalanine-restricted diet"}}
{"id": "WORhLGUZ2eph", "question_type": "multi_choice", "question": "If concomitant use of Modeyso with a QT-prolonging product cannot be avoided, what is the recommended approach?", "options": {"A": "Administer both drugs simultaneously", "B": "Separate administration of Modeyso and the QT-prolonging product", "C": "Increase the dose of Modeyso", "D": "Discontinue the QT-prolonging product"}}
{"id": "hydin7XmYb9h", "question_type": "open_ended_multi_choice", "question": "A child aged 10 years, diagnosed with cystic fibrosis and carrying at least one F508del mutation in the CFTR gene, presents with repeated respiratory infections, enlarged liver, and increased hepatic transaminases. The patient is Child-Pugh Class B for liver impairment and has a history of abnormal liver function. Which treatment regimen is most appropriate for this patient's cystic fibrosis?", "options": {"A": "ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor) once daily", "B": "Insulin Aspart Protamine and Insulin Aspart Mix 70/30, administered twice daily", "C": "ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor) with reduced dosage and close liver monitoring", "D": "No CFTR modulator therapy; supportive care only"}}
{"id": "2AeqMuYqu1Jc", "question_type": "open_ended_multi_choice", "question": "A researcher is designing a clinical trial for Sephience. Which patient population must be excluded based on the drug's contraindications?", "options": {"A": "Patients with a history of hypersensitivity to Sephience.", "B": "Patients with severe cardiac disease.", "C": "No patient population must be excluded due to contraindications.", "D": "Patients with active infection."}}
{"id": "4oCV4W8OxgMg", "question_type": "open_ended_multi_choice", "question": "A 58-year-old woman presents with newly diagnosed multiple myeloma, as shown by paraproteinemia and amyloidosis. She has no history of chemotherapy, immunotherapy, pregnancy, or thromboembolic events, but is currently taking antihistamines for allergies. Which initial treatment regimen is most appropriate for her multiple myeloma?", "options": {"A": "Thalidomide in combination with dexamethasone", "B": "Linvoseltamab-gcpt monotherapy", "C": "Talquetamab-tgvs monotherapy", "D": "Thalidomide monotherapy"}}
{"id": "4auUQhmRVghG", "question_type": "open_ended_multi_choice", "question": "A patient on Vanrafia develops new onset of yellowing of the skin and dark urine. What is the most appropriate next step?", "options": {"A": "Continue Vanrafia and monitor symptoms", "B": "Increase the dose of Vanrafia", "C": "Temporarily or permanently discontinue Vanrafia and evaluate for liver dysfunction", "D": "Switch to another endothelin receptor antagonist"}}
{"id": "qHztBaUl5dio", "question_type": "multi_choice", "question": "A patient is prescribed Sephience and is also taking sulfasalazine. What is the recommended clinical action based on their concomitant use?", "options": {"A": "Continue both drugs without monitoring", "B": "Increase the dose of Sephience", "C": "Avoid concomitant use or monitor blood phenylalanine (Phe) levels if unavoidable", "D": "Add a PDE-5 inhibitor"}}
{"id": "by1vLLNEKtFv", "question_type": "open_ended_multi_choice", "question": "A 28-year-old woman with severe alopecia areata is planning to become pregnant. She has no history of renal or hepatic impairment and is not currently taking any medications. Which drug is the safest and most appropriate for her to use for her condition?", "options": {"A": "LEQSELVI administered orally once daily", "B": "Hydroxychloroquine sulfate administered orally once daily", "C": "Triamcinolone acetonide nasal spray once daily", "D": "LEQSELVI administered orally every other day with a drug scheduler"}}
{"id": "gNAvJ6JaQjrn", "question_type": "open_ended_multi_choice", "question": "A 68-year-old male with familial chylomicronemia syndrome, hepatic steatosis, episodic abdominal pain, mild renal impairment (eGFR 55 mL/min), and mild hepatic impairment is being evaluated for medication to lower triglyceride levels. Which pharmacologic regimen would be most appropriate for him?", "options": {"A": "MYHIBBIN (mycophenolate mofetil) with dose adjustment for renal impairment", "B": "TRYNGOLZA (olezarsen sodium) at standard dosage and frequency", "C": "MYHIBBIN (mycophenolate mofetil) with dose adjustment for hepatic impairment", "D": "TRYNGOLZA (olezarsen sodium) with reduced frequency due to age"}}
{"id": "Qr1RUMzwKfNu", "question_type": "open_ended_multi_choice", "question": "When an adult patient on Modeyso therapy begins treatment with a potent CYP3A4 inhibitor, what is the advised modification to their Modeyso dosage?", "options": {"A": "Increase to 625 mg once weekly", "B": "Reduce to 375 mg once weekly", "C": "Reduce to 500 mg once weekly", "D": "Discontinue Modeyso"}}
{"id": "3vzYpkiQjlZG", "question_type": "multi_choice", "question": "A 32-year-old woman is diagnosed with a trophoblastic neoplasm. She is currently 8 weeks pregnant and is seeking treatment. She has no significant renal or hepatic impairment and is not taking any other medications. Which of the following is the most appropriate drug therapy for her condition?", "options": {"A": "Methotrexate", "B": "Paclitaxel protein-bound particles for injectable suspension (albumin-bound)", "C": "Trexall", "D": "No chemotherapy should be given due to pregnancy"}}
{"id": "K2k9Np8AwIoL", "question_type": "multi_choice", "question": "A 29-year-old woman with symptomatic TGCT is planning to become pregnant in the next few months. She is currently using hormonal contraceptives and has normal renal and hepatic function. Surgical resection is not feasible. Which of the following is the most appropriate pharmacologic approach for her?", "options": {"A": "Romvimza (vimseltinib) with effective contraception and regular pregnancy testing", "B": "Turalio (pexidartinib hydrochloride) with continued use of hormonal contraceptives", "C": "Turalio (pexidartinib hydrochloride) with non-hormonal contraception", "D": "Romvimza (vimseltinib) without any contraception"}}
{"id": "6o9ypBZ8FUDb", "question_type": "open_ended_multi_choice", "question": "A 45-year-old woman, pregnant and newly diagnosed with multiple myeloma and amyloidosis, is being evaluated for initial treatment. Which agent poses significant risks and must not be used in this patient?", "options": {"A": "Linvoseltamab-gcpt", "B": "Talquetamab-tgvs", "C": "Thalidomide", "D": "Dexamethasone monotherapy"}}
{"id": "vmCppyv4aXBJ", "question_type": "open_ended_multi_choice", "question": "A 48-year-old woman diagnosed with recurrent, metastatic non-keratinizing nasopharyngeal carcinoma, with a medical history significant for controlled hypertension and atrial fibrillation on warfarin, presents for treatment. She is neither pregnant nor breastfeeding, and her hepatic and renal functions are normal. What is the most appropriate initial drug regimen for her cancer?", "options": {"A": "Celecoxib 200 mg twice daily", "B": "Capecitabine 500 mg twice daily", "C": "Penpulimab-kcqx in combination with cisplatin and gemcitabine", "D": "Penpulimab-kcqx monotherapy"}}
{"id": "AmeiscOPB2vb", "question_type": "open_ended_multi_choice", "question": "For a patient classified as Child-Pugh Class C with severe hepatic impairment, what is the most suitable approach regarding the use of Blujepa?", "options": {"A": "Avoid administration of Blujepa due to increased drug exposure and risk of QTc prolongation.", "B": "Administer Blujepa at a reduced dose with close monitoring.", "C": "Administer Blujepa with a strong CYP3A4 inhibitor to reduce side effects.", "D": "Proceed with standard dosing of Blujepa without additional precautions."}}
{"id": "K3ZMmgg9NCUr", "question_type": "open_ended_multi_choice", "question": "A 75-year-old man with mild cognitive impairment due to Alzheimer’s disease is being evaluated for drug therapy. He has a history of serious hypersensitivity reaction to monoclonal antibodies. He is not pregnant, not breastfeeding, and does not require antithrombotic therapy. Which is the most appropriate drug treatment recommendation for this patient?", "options": {"A": "Kisunla (donanemab-azbt), with pre-treatment using antihistamines", "B": "Kisunla (donanemab-azbt), contraindicated due to history of serious hypersensitivity", "C": "Kisunla (donanemab-azbt), recommended with regular MRI monitoring", "D": "Kisunla (donanemab-azbt), recommended only if patient is not ApoE ε4 homozygote"}}
{"id": "l48O7yC01oSx", "question_type": "open_ended_multi_choice", "question": "A 13-year-old male with WHIM syndrome, presenting with myelokathexis, neutropenia, and recurrent bacterial infections, also has moderate hepatic impairment. He is not taking any other medications. Which of the following is the most suitable treatment option to increase his circulating mature neutrophils and lymphocytes?", "options": {"A": "XOLREMDI, daily oral administration", "B": "Mavorixafor, daily oral administration", "C": "No drug therapy recommended due to hepatic impairment", "D": "XOLREMDI, reduced dose due to hepatic impairment"}}
{"id": "Gm0oyTUbpJ02", "question_type": "open_ended_multi_choice", "question": "A 45-year-old male with schizophrenia, hyperactivity, and moderate renal impairment (eGFR 45 mL/min) is being evaluated for antipsychotic therapy. He has no history of hepatic impairment, BPH, or dementia-related psychosis. Which treatment option is most suitable for his condition?", "options": {"A": "Cobenfy (xanomeline and trospium chloride), standard adult dose", "B": "Abilify Maintena (aripiprazole), standard adult dose", "C": "Cobenfy (xanomeline and trospium chloride), reduced dose", "D": "Abilify Maintena (aripiprazole), reduced dose for CYP2D6 poor metabolizers"}}
{"id": "r8sgWk52rhXz", "question_type": "open_ended_multi_choice", "question": "A 15-year-old patient with generalized myasthenia gravis tests positive for anti-MuSK antibodies. Which brand name drug is indicated for this patient?", "options": {"A": "Imaavy", "B": "Pyridostigmine", "C": "Azathioprine", "D": "Eculizumab"}}
{"id": "jbNYYPNrjQBx", "question_type": "multi_choice", "question": "A 62-year-old man with non-alcoholic steatohepatitis (NASH) and advanced liver fibrosis (stage F3) presents for treatment. He has a history of decompensated cirrhosis (Child-Pugh Class B), chronic kidney disease (eGFR 50 mL/min/1.73 m²), and is currently taking clopidogrel for coronary artery disease. Which of the following drugs is most appropriate for his NASH management?", "options": {"A": "Pentoxifylline extended-release tablets, 400 mg three times daily", "B": "Rezdiffra, with dose reduction due to clopidogrel", "C": "Farxiga, 10 mg once daily", "D": "Rezdiffra, standard dose"}}
{"id": "4woJs3IIMil8", "question_type": "open_ended_multi_choice", "question": "A 29-year-old pregnant woman presents with a newly diagnosed choroid plexus carcinoma. She is in her second trimester and requires urgent management. Which of the following drugs is contraindicated for her due to the risk of teratogenicity and fetal harm?", "options": {"A": "Lumisight (pegulicianine) administered as a single intraoperative dose", "B": "Etoposide administered intravenously at 100 mg/m² daily for 5 days", "C": "Etoposide administered orally at a reduced dose", "D": "Lumisight (pegulicianine) administered at a reduced dose"}}
{"id": "8eV3mEPF9J2g", "question_type": "multi_choice", "question": "What is the recommendation regarding the use of live vaccines in patients receiving Anzupgo?", "options": {"A": "Live vaccines are recommended during Anzupgo therapy", "B": "Avoid live vaccines immediately prior to, during, and immediately after Anzupgo treatment", "C": "Live vaccines should be given only after discontinuing Anzupgo for 6 months", "D": "Live vaccines are contraindicated only in pediatric patients"}}
{"id": "oFVmC9z3lubG", "question_type": "open_ended_multi_choice", "question": "What is currently known about the results or progress of mutagenesis studies involving Enflonsia?", "options": {"A": "No mutagenesis studies have been performed with Enflonsia.", "B": "Mutagenesis studies have shown positive results.", "C": "Mutagenesis studies have shown negative results.", "D": "Mutagenesis studies are ongoing."}}
{"id": "YCH6yY5Tf6aa", "question_type": "open_ended_multi_choice", "question": "A 35-year-old mother, currently breastfeeding her infant, has primary axillary hyperhidrosis and is considering topical therapies. With no other medical concerns or medications, which option should be avoided because of the potential for the drug to enter breast milk?", "options": {"A": "Qbrexza", "B": "Sofdra", "C": "Oxybutynin", "D": "Both Qbrexza and Sofdra"}}
{"id": "DIUHUfztFJOw", "question_type": "multi_choice", "question": "A 68-year-old man with a history of chronic obstructive pulmonary disease (COPD) and latent tuberculosis (TB) is being evaluated for immunosuppressive therapy for severe scalp alopecia (alopecia totalis). He has never received ORENCIA or other biologic agents. Which of the following statements best describes the suitability of ORENCIA for this patient?", "options": {"A": "ORENCIA is appropriate and can be started without additional precautions.", "B": "ORENCIA is not indicated for alopecia totalis and should be used with caution due to COPD and latent TB.", "C": "ORENCIA is preferred over JAK inhibitors for alopecia totalis in patients with COPD.", "D": "ORENCIA can be combined with a TNF antagonist to improve efficacy in alopecia totalis."}}
{"id": "njohsuDo7MWA", "question_type": "open_ended_multi_choice", "question": "A 68-year-old with prurigo nodularis is being evaluated for treatment. Her history includes COPD and the use of benzodiazepines for anxiety. She reports severe itching but minimal pain. Considering her comorbidities and current prescriptions, which treatment regimen should be recommended?", "options": {"A": "NEMLUVIO administered subcutaneously every 4 weeks", "B": "Nalbuphine Hydrochloride injection for pain management, titrated slowly", "C": "Nalbuphine Hydrochloride injection combined with benzodiazepine, at standard dosing", "D": "NEMLUVIO combined with live vaccine administration during therapy"}}
{"id": "iRwhHDwe7YcU", "question_type": "open_ended", "question": "Which of the following statements is TRUE regarding FDA-approved testing for the H3 K27M mutation prior to Modeyso therapy?", "options": {"A": "An FDA-approved test for H3 K27M mutation is currently available", "B": "No FDA-approved test for H3 K27M mutation is currently available", "C": "Testing is not required before Modeyso therapy", "D": "Only blood-based tests are approved"}}
{"id": "4sHXQWQzF2TP", "question_type": "open_ended_multi_choice", "question": "If a patient taking Gomekli develops an asymptomatic absolute reduction in LVEF of at least 10% from baseline to below the lower limit of normal, how should their treatment be managed?", "options": {"A": "Continue Gomekli at current dose", "B": "Withhold Gomekli until ≤Grade 1, then resume at reduced dose", "C": "Permanently discontinue Gomekli", "D": "Increase Gomekli dose"}}
{"id": "cND0FUUk89e8", "question_type": "multi_choice", "question": "How did Vanrafia perform compared to placebo in terms of percent reduction in UPCR at Week 36 in the main cohort of the ALIGN study?", "options": {"A": "Vanrafia achieved a 38% reduction versus 3% for placebo", "B": "Vanrafia achieved a 3% reduction versus 38% for placebo", "C": "Vanrafia achieved a 15% reduction versus 10% for placebo", "D": "Vanrafia achieved a 26% reduction versus 45% for placebo"}}
{"id": "Uqh2xPj1wlvN", "question_type": "open_ended_multi_choice", "question": "Which of the following best describes the recommendation for pregnancy testing prior to initiating Wayrilz treatment in females of reproductive potential?", "options": {"A": "Pregnancy testing is not necessary.", "B": "Verify pregnancy status prior to initiating Wayrilz treatment.", "C": "Pregnancy testing should be done only after starting Wayrilz.", "D": "Pregnancy testing is required only if symptoms of pregnancy appear."}}
{"id": "Zk7RgKisbzwr", "question_type": "open_ended_multi_choice", "question": "A 72-year-old man with metastatic cutaneous squamous cell carcinoma is not a candidate for curative surgery or radiation. He has no history of autoimmune disease, is not taking immunosuppressive medications, and is not currently participating in a clinical trial. Which of the following is the most appropriate systemic therapy for his condition, considering both efficacy and approved indications?", "options": {"A": "ERBITUX administered weekly at 250 mg/m2", "B": "TECENTRIQ administered every 3 weeks", "C": "UNLOXCYT administered as per recommended dosing schedule", "D": "No systemic therapy is indicated for this patient"}}
{"id": "HS8T1RkItcsH", "question_type": "open_ended_multi_choice", "question": "A 32-year-old woman presents with patchy hair loss diagnosed as severe alopecia areata. She is currently breastfeeding and has a history of mild renal impairment. She is not taking any CYP2C9 inhibitors and has tested negative for CYP2C9 poor metabolizer status. Which of the following is the most appropriate drug treatment for her condition?", "options": {"A": "Minoxidil topical solution", "B": "Imiquimod cream", "C": "Leqselvi (deuruxolitinib phosphate)", "D": "No drug is appropriate from the options provided"}}
{"id": "vou03o5n0fdj", "question_type": "open_ended_multi_choice", "question": "A 7-year-old child with cystic fibrosis presents with childhood onset bronchiectasis, failure to thrive, and elevated sweat chloride. Genetic testing confirms homozygosity for the F508del mutation in the CFTR gene. The patient is currently taking oral hormonal contraceptives for another condition. Which drug regimen is most suitable for this patient?", "options": {"A": "Brinsupri, with monitoring for dermatologic adverse reactions", "B": "ORKAMBI, with counseling to use non-hormonal contraception", "C": "SYMDEKO, with standard dosing and no change to contraceptive regimen", "D": "ORKAMBI, with no contraceptive counseling required"}}
{"id": "pHDRvd6Jpa0Z", "question_type": "multi_choice", "question": "A 45-year-old woman with newly diagnosed presbyopia is considering pharmacological treatment. She has a history of severe allergic reactions to cholinergic agonists. She does not have cardiovascular disease, is not pregnant, and does not use contact lenses. Which drug should be avoided due to her allergy, and which is the most suitable alternative among the listed options?", "options": {"A": "Aceclidine should be avoided; Brimonidine tartrate is suitable", "B": "Aceclidine should be avoided; Phentolamine mesylate is suitable", "C": "Aceclidine should be avoided; no suitable alternative among listed drugs", "D": "Aceclidine is safe; Brimonidine tartrate is suitable"}}
{"id": "ZN304AsGWvb3", "question_type": "multi_choice", "question": "Which statement best describes the contraindication profile of Lynozyfic?", "options": {"A": "Lynozyfic has no listed contraindications.", "B": "Lynozyfic is contraindicated in patients with hypersensitivity to its active ingredient.", "C": "Lynozyfic has multiple contraindications, including renal and hepatic impairment.", "D": "Lynozyfic should not be used in elderly patients."}}
{"id": "GkGPut6H6try", "question_type": "open_ended_multi_choice", "question": "A 67-year-old male with metastatic ROS1-positive non-small cell lung cancer is receiving IBTROZI (taletrectinib) 600 mg orally once daily. He has osteoporosis and recently experienced a rib fracture after a minor fall. He is not on any medications that prolong QTc interval or interact with CYP3A. What is the key factor to consider in managing his ongoing IBTROZI treatment?", "options": {"A": "Continue IBTROZI at the same dose without additional monitoring", "B": "Discontinue IBTROZI permanently due to fracture risk", "C": "Continue IBTROZI with prompt evaluation and monitoring for further skeletal fractures", "D": "Reduce IBTROZI dose to minimize risk of future fractures"}}
{"id": "5Yc4hsQpC4em", "question_type": "multi_choice", "question": "For which of the following drugs does the official labeling state that there are no contraindications?", "options": {"A": "Anzupgo", "B": "Warfarin", "C": "Metformin", "D": "Amiodarone"}}
{"id": "X919cE3nk7Be", "question_type": "multi_choice", "question": "In the event of an overdose involving Ekterly, which resource is specifically recommended for obtaining management recommendations?", "options": {"A": "Refer to the drug manufacturer's website", "B": "Increase the dosage of Ekterly", "C": "Administer activated charcoal immediately", "D": "Monitor the patient without intervention"}}
{"id": "hoviFdTbwEp9", "question_type": "open_ended", "question": "Which precaution should be taken by breastfeeding women who use Anzupgo on their hands or wrists?", "options": {"A": "Avoid direct contact with the nipple and surrounding area immediately after application.", "B": "Increase the frequency of breastfeeding.", "C": "Apply Anzupgo directly to the nipple before breastfeeding.", "D": "Discontinue breastfeeding during treatment."}}
{"id": "xwF64mvR7CLX", "question_type": "open_ended_multi_choice", "question": "A 10-year-old boy with congenital hemophilia A presents for routine prophylaxis to prevent bleeding episodes. He has no history of hepatic impairment or gallbladder disease. Which drug is most appropriate for his condition, considering age and disease type?", "options": {"A": "Hemlibra administered subcutaneously once weekly", "B": "Qfitlia administered subcutaneously once monthly", "C": "Qfitlia administered subcutaneously once weekly", "D": "Fitusiran administered intravenously every two weeks"}}
{"id": "v0VTappo1JAX", "question_type": "open_ended_multi_choice", "question": "A 9-year-old boy with autosomal dominant atopic dermatitis presents with recurrent skin infections, pruritus, and dry skin. He weighs 32 kg and has a history of allergic rhinitis and asthma. His mother asks about starting a new medication for his moderate-to-severe symptoms, as topical therapies have been ineffective. Which of the following is the most appropriate drug choice for this patient?", "options": {"A": "Lebrikizumab-lbkz administered subcutaneously every 2 weeks", "B": "DMT SUIK administered intravenously as needed for severe exacerbations", "C": "Doxepin hydrochloride cream applied topically for up to 8 days", "D": "Lebrikizumab-lbkz administered subcutaneously every 4 weeks"}}
{"id": "OTTGZESVACcf", "question_type": "open_ended_multi_choice", "question": "A 70-year-old man with metastatic, unresectable esophageal squamous cell carcinoma (ESCC) and stage 3 chronic kidney disease (CKD) presents for initial treatment planning. He is experiencing nausea, vomiting, and mild proteinuria. His tumor demonstrates PD-L1 expression of at least 1%. Which agent would be the most appropriate choice for first-line therapy in this scenario?", "options": {"A": "Lenvatinib monotherapy", "B": "Tislelizumab-jsgr in combination with platinum-containing chemotherapy", "C": "Nivolumab and hyaluronidase in combination with fluoropyrimidine- and platinum-containing chemotherapy", "D": "Lenvatinib in combination with everolimus"}}
{"id": "qWYrXDRaEC4U", "question_type": "open_ended", "question": "For which of the following patient populations is Qfitlia contraindicated?", "options": {"A": "None; Qfitlia is not contraindicated in any patient population.", "B": "Patients with severe hepatic dysfunction.", "C": "Patients with known hypersensitivity to Qfitlia.", "D": "Patients under 18 years of age."}}
{"id": "rTBzY0NQ1Rgy", "question_type": "multi_choice", "question": "A clinical trial protocol is being developed for Emrelis. Which statement about its contraindications should be included in the protocol documentation?", "options": {"A": "Emrelis is contraindicated in patients with cardiovascular disease.", "B": "Emrelis should not be administered to pediatric patients.", "C": "Emrelis is contraindicated in patients taking CYP3A4 inhibitors.", "D": "Emrelis is contraindicated in patients with a history of drug allergy."}}
{"id": "TExQVXpKdpaG", "question_type": "open_ended_multi_choice", "question": "A 55-year-old man has been newly diagnosed with intermediate-2 risk myelodysplastic syndrome and has chronic kidney disease with a creatinine clearance of 40 mL/min. He is not on any medications metabolized by cytidine deaminase, and cytogenetic analysis shows no deletion of 5q. Taking into account his renal impairment, which drug regimen would be most appropriate for him?", "options": {"A": "Lenalidomide, 10 mg orally once daily (no dose adjustment)", "B": "Imetelstat sodium, 7.5 mg/kg intravenously every 4 weeks", "C": "Inqovi, 35 mg orally once daily for 5 consecutive days every 28 days", "D": "Lenalidomide, 25 mg orally once daily (no dose adjustment)"}}
{"id": "vK1XJVQDLzG8", "question_type": "multi_choice", "question": "A 15-year-old adolescent girl with hemophilia B (congenital factor IX deficiency) presents with menometrorrhagia and prolonged bleeding after dental extraction. She is currently pregnant and requires routine prophylaxis to prevent bleeding episodes. Which treatment option is most appropriate for her condition?", "options": {"A": "HYMPAVZI, administered weekly for prophylaxis", "B": "REBINYN, administered weekly for prophylaxis", "C": "SEVENFACT, administered weekly for prophylaxis", "D": "HYMPAVZI, administered only during bleeding episodes"}}
{"id": "NT2YY32698cF", "question_type": "open_ended", "question": "A 48-year-old woman presents with presbyopia and a history of iritis. She is seeking pharmacological treatment to improve her near vision. She has no known drug allergies and does not wear contact lenses. Which of the following is the most appropriate drug for her condition, considering her ocular history?", "options": {"A": "Aceclidine (VIZZ), one drop in each eye daily", "B": "VUITY, one drop in each eye daily", "C": "Pilocarpine Hydrochloride tablets, 5 mg orally three times daily", "D": "Aceclidine (VIZZ), two drops in each eye every 12 hours"}}
{"id": "dukDn0NZHo2P", "question_type": "multi_choice", "question": "In the event of an overdose with Enflonsia, what is the recommended management approach for infants?", "options": {"A": "Administer activated charcoal immediately.", "B": "Monitor for adverse reactions and provide symptomatic treatment as appropriate.", "C": "Initiate dialysis to remove the drug.", "D": "Give a specific antidote for Enflonsia."}}
{"id": "MMhMfotIL87e", "question_type": "multi_choice", "question": "A 42-year-old woman with a history of inoperable, functional adrenocortical carcinoma is being considered for systemic therapy. She is not pregnant, has normal hepatic and renal function, and is not taking any hormonal contraceptives or warfarin. Which drug is most appropriate for her treatment, considering her diagnosis and current medications?", "options": {"A": "Lumisight", "B": "Lysodren", "C": "Spironolactone", "D": "Blue dye for sentinel lymph node mapping"}}
{"id": "hXnLOamepth6", "question_type": "open_ended_multi_choice", "question": "A 38-year-old woman with paroxysmal nocturnal hemoglobinuria (PNH) is planning to become pregnant. She is currently receiving pegcetacoplan. She asks about the safety of continuing her current therapy during pregnancy and breastfeeding. Which of the following best addresses her situation?", "options": {"A": "Continue pegcetacoplan throughout pregnancy and breastfeeding, as animal studies show no adverse effects.", "B": "Switch to crovalimab, as animal studies show no adverse developmental outcomes and breastfeeding is not recommended during and for 9 months after the last dose.", "C": "Continue pegcetacoplan, but discontinue breastfeeding for 40 days after the last dose due to potential risks.", "D": "Switch to danicopan, as animal studies show no adverse developmental effects and breastfeeding is not recommended during and for 3 days after the last dose."}}
{"id": "eL2tiCZf8B51", "question_type": "multi_choice", "question": "A 7-year-old boy with severe hemophilia A and a history of factor VIII inhibitors requires routine prophylaxis to prevent bleeding episodes. He has normal hepatic and gallbladder function. Which of the following is the most appropriate prophylactic therapy for this patient?", "options": {"A": "Qfitlia, administered according to antithrombin-based dosing regimen", "B": "Qfitlia, administered according to antithrombin-based dosing regimen with a planned drug holiday every 3 months", "C": "Qfitlia, administered at a fixed dose of 80 mg once monthly", "D": "Hemlibra, administered subcutaneously once weekly"}}
{"id": "GIycYsupKCzL", "question_type": "open_ended_multi_choice", "question": "For a regulatory filing involving Qfitlia, what should be reported as contraindications?", "options": {"A": "There are no contraindications for Qfitlia.", "B": "Qfitlia is contraindicated in patients with renal failure.", "C": "Qfitlia is contraindicated in patients with a history of drug allergy.", "D": "Qfitlia is contraindicated in elderly patients."}}
{"id": "7cHnHburJDmz", "question_type": "open_ended_multi_choice", "question": "A 60-year-old male, whose epilepsy is controlled with valproic acid, is diagnosed with a severe urinary tract infection. He has no renal or hepatic impairment and reports no drug allergies. Which drug poses a risk of breakthrough seizures due to drug interaction and should be avoided?", "options": {"A": "Imipenem and Cilastatin Sodium intravenous therapy, following standard dosing.", "B": "Blujepa, administered according to recommended dosing for severe UTI.", "C": "Flavoxate Hydrochloride tablets for symptomatic relief.", "D": "Imipenem and Cilastatin Sodium with dose adjustment for renal function."}}
{"id": "12B97Lhmx91u", "question_type": "multi_choice", "question": "A 6-year-old child with neurofibromatosis type 1 (NF1) and symptomatic, inoperable plexiform neurofibromas is being considered for targeted therapy. The child has normal cardiac function, no history of ocular disease, and normal hepatic and renal function. She is not taking any CYP3A4 inhibitors, fluconazole, or vitamin-K antagonists. Which drug is most suitable for this patient, considering age, indication, and safety profile?", "options": {"A": "TOPOTECAN (HYCAMTIN) capsules at pediatric dose", "B": "KOSELUGO administered twice daily with regular cardiac and ophthalmic monitoring", "C": "TOPOTECAN (HYCAMTIN) capsules at standard adult dose", "D": "KOSELUGO administered once daily without monitoring"}}
{"id": "YG2FVVDHhuOt", "question_type": "open_ended_multi_choice", "question": "What is the recommended action if a patient on Wayrilz develops abnormal liver tests and Drug-Induced Liver Injury (DILI) is suspected?", "options": {"A": "Withhold Wayrilz and discontinue upon confirmation of DILI", "B": "Continue Wayrilz at the same dose", "C": "Increase the dose of Wayrilz", "D": "Switch to intravenous administration"}}
{"id": "J13Dzgs7zXwv", "question_type": "multi_choice", "question": "A 56-year-old woman with metastatic, hormone receptor-positive, HER2-negative breast cancer has a confirmed PIK3CA mutation and has progressed after adjuvant endocrine therapy. She also has a history of well-controlled Type 2 diabetes managed with oral anti-hyperglycemic agents. Her oncologist is considering targeted therapy in combination with palbociclib and fulvestrant. Which drug regimen is most appropriate for her cancer management, considering her comorbidities and the need for close metabolic monitoring?", "options": {"A": "Morphine sulfate for pain control, as primary cancer therapy", "B": "Itovebi (inavolisib) in combination with palbociclib and fulvestrant, with intensified glucose monitoring and anti-hyperglycemic management", "C": "Ketorolac tromethamine for chronic pain management and cancer therapy", "D": "Itovebi (inavolisib) monotherapy without palbociclib or fulvestrant"}}
{"id": "kAGYQq53T17W", "question_type": "open_ended_multi_choice", "question": "For patients taking moderate CYP3A inhibitors, how should the dosing of Journavx be modified after the fourth dose?", "options": {"A": "Reduce to 50 mg orally every 24 hours", "B": "Increase to 100 mg orally every 12 hours", "C": "Continue 50 mg orally every 12 hours", "D": "Discontinue Journavx"}}
{"id": "qyEl7DrR5lq2", "question_type": "open_ended_multi_choice", "question": "A 35-year-old woman with recurrent low-grade serous ovarian carcinoma harboring a KRAS mutation is about to begin AVMAPKI FAKZYNJA CO-PACK therapy. She is breastfeeding her 3-month-old baby and wants advice on whether she can safely continue nursing while undergoing this treatment. What is the best guidance to provide regarding her cancer therapy?", "options": {"A": "Start AVMAPKI FAKZYNJA CO-PACK and continue breastfeeding", "B": "Delay AVMAPKI FAKZYNJA CO-PACK until breastfeeding is discontinued", "C": "Start AVMAPKI FAKZYNJA CO-PACK and stop breastfeeding during treatment and for 2 weeks after the last dose", "D": "Start AVMAPKI FAKZYNJA CO-PACK with reduced dosage to minimize risk to the infant"}}
{"id": "JIhuiS6IHzIB", "question_type": "multi_choice", "question": "A 15-year-old female weighing 45 kg presents with symptoms of dysuria, urgency, and suprapubic pain. She is diagnosed with an uncomplicated urinary tract infection. Her medical history is notable for mild renal impairment (eGFR 55 mL/min), and she is currently taking digoxin for a cardiac condition. Which drug is the most appropriate for definitive treatment of her infection, considering her age, weight, renal function, and current medications?", "options": {"A": "Gepotidacin", "B": "Imipenem and Cilastatin", "C": "Flavoxate Hydrochloride", "D": "No drug is appropriate; recommend only symptomatic management"}}
{"id": "WnAFdE9eftS2", "question_type": "multi_choice", "question": "For a female patient of reproductive potential who is about to start Wayrilz therapy, which of the following is the most appropriate recommendation regarding contraception?", "options": {"A": "Use effective contraception during Wayrilz treatment and for 1 week after stopping treatment.", "B": "Use effective contraception only during Wayrilz treatment.", "C": "No contraception is required during Wayrilz treatment.", "D": "Use contraception for 1 month after stopping Wayrilz."}}
{"id": "sTvWaFJV66hM", "question_type": "multi_choice", "question": "A 15-year-old female with WHIM syndrome presents with recurrent upper respiratory tract infections, severe periodontitis, and decreased circulating IgG concentration. She is currently pregnant and seeks treatment to increase her mature neutrophil and lymphocyte counts. Which drug regimen is most appropriate for her condition?", "options": {"A": "XOLREMDI, daily oral administration", "B": "No drug therapy recommended due to pregnancy", "C": "Mavorixafor, daily oral administration", "D": "XOLREMDI, weekly administration"}}
{"id": "mL71cnkwnnoV", "question_type": "open_ended", "question": "A 68-year-old man with relapsed multiple myeloma has previously received two lines of therapy, including a proteasome inhibitor and an immunomodulatory agent. He is now being considered for further treatment. He has no history of cardiac disease, is not pregnant, and has normal renal function. Which of the following is the most appropriate next-line therapy for this patient, considering his disease status and prior treatments?", "options": {"A": "Darzalex Faspro monotherapy", "B": "Lynozyfic (linvoseltamab-gcpt)", "C": "Mozobil (plerixafor) with filgrastim", "D": "Darzalex Faspro in combination with pomalidomide and dexamethasone"}}
{"id": "yEh8JsDWxXBU", "question_type": "open_ended", "question": "If a patient with multiple comorbidities is being considered for treatment with Wayrilz, which of the following statements is accurate regarding contraindications?", "options": {"A": "Wayrilz should be avoided in patients with renal impairment.", "B": "Wayrilz has no listed contraindications regardless of comorbidities.", "C": "Wayrilz is contraindicated in patients with a history of drug allergies.", "D": "Wayrilz is contraindicated in elderly patients."}}
{"id": "V5vGXPpgIyOg", "question_type": "open_ended_multi_choice", "question": "A 7-year-old child with hereditary angioedema requires long-term prophylaxis to prevent future attacks. The patient has no history of hypersensitivity reactions and is not currently taking any anticoagulants. Which medication is the most appropriate for this patient, considering age and approved indications?", "options": {"A": "Kalbitor", "B": "ANDEMBRY", "C": "TAKHZYRO", "D": "No drug is appropriate for this patient"}}
{"id": "lZWlczdXHbsR", "question_type": "open_ended_multi_choice", "question": "A 32-year-old woman with acute myeloid leukemia (AML) is scheduled to receive Grafapex as part of her preparative regimen prior to allogeneic hematopoietic stem cell transplant. She is currently breastfeeding her 2-month-old infant. What is the most appropriate recommendation regarding breastfeeding during and after Grafapex therapy?", "options": {"A": "Continue breastfeeding throughout treatment and for 1 week after the last dose.", "B": "Discontinue breastfeeding only during active infusion of Grafapex.", "C": "Advise not to breastfeed during treatment and for 1 week after the last dose.", "D": "Breastfeeding is safe as long as the infant is monitored for adverse effects."}}
{"id": "T2AUVlARVESn", "question_type": "open_ended_multi_choice", "question": "A 29-year-old pregnant woman, currently in her second trimester, is found to have choroid plexus carcinoma and must begin urgent therapy. Which of the following drugs poses a risk of teratogenicity and fetal injury, making it unsuitable for use in her case?", "options": {"A": "Lumisight (pegulicianine) administered as a single intraoperative dose", "B": "Etoposide administered intravenously at 100 mg/m² daily for 5 days", "C": "Etoposide administered orally at a reduced dose", "D": "Lumisight (pegulicianine) administered at a reduced dose"}}
{"id": "xzNq78HLSEx1", "question_type": "multi_choice", "question": "A 15-year-old female weighing 45 kg presents with symptoms of dysuria, urgency, and suprapubic pain. She is diagnosed with an uncomplicated urinary tract infection. Her medical history is notable for mild renal impairment (eGFR 55 mL/min), and she is currently taking digoxin for a cardiac condition. Which drug is the most appropriate for definitive treatment of her infection, considering her age, weight, renal function, and current medications?", "options": {"A": "Flavoxate Hydrochloride", "B": "Gepotidacin", "C": "Imipenem and Cilastatin", "D": "No drug is appropriate; recommend only symptomatic management"}}
{"id": "X0zKWsNkuFJv", "question_type": "open_ended_multi_choice", "question": "In both the COMET-2 and COMET-3 studies, was there a statistically significant difference in tear production improvement between Tryptyr and vehicle?", "options": {"A": "No statistically significant difference was observed.", "B": "Statistically significant improvement favoring Tryptyr (p<0.01) was observed in both studies.", "C": "Statistically significant improvement favoring vehicle (p<0.01) was observed.", "D": "Statistical significance was only achieved in COMET-2."}}
{"id": "jxA2mOnuBCjT", "question_type": "open_ended", "question": "Which of the following is a contraindication for the use of Enflonsia in infants?", "options": {"A": "History of serious hypersensitivity reactions, including anaphylaxis, to any component of Enflonsia", "B": "History of mild gastrointestinal upset", "C": "History of seasonal allergies", "D": "History of eczema"}}
{"id": "bPcdcnVZZr5h", "question_type": "open_ended_multi_choice", "question": "A 42-year-old man presents with moderate to severe acute pain after a sports injury. He has normal hepatic and renal function but is currently taking a moderate CYP3A inhibitor for another condition. He uses a combined oral contraceptive containing ethinyl estradiol and norethindrone. Which drug and dosing strategy is most appropriate for his pain management?", "options": {"A": "Suzetrigine at standard adult dosage", "B": "Suzetrigine with reduced dosage", "C": "Ropivacaine Hydrochloride at standard dosage", "D": "Acetaminophen at maximum daily dosage"}}
{"id": "iSBVxT0JIcVy", "question_type": "open_ended_multi_choice", "question": "What is the advised approach for managing Modeyso therapy in adult and pediatric patients weighing 52.5 kg or more who are also taking strong CYP3A4 inhibitors?", "options": {"A": "Increase the dose of Modeyso", "B": "Reduce the dose of Modeyso", "C": "Discontinue Modeyso", "D": "Administer Modeyso with food"}}
{"id": "nJjIADaOIdOJ", "question_type": "multi_choice", "question": "A 35-year-old woman with newly diagnosed non-keratinizing nasopharyngeal carcinoma is 10 weeks pregnant. She has no significant comorbidities and normal renal and hepatic function. Which of the following drugs is contraindicated for her cancer treatment due to risk of fetal harm?", "options": {"A": "Celecoxib 200 mg twice daily", "B": "Capecitabine 500 mg twice daily", "C": "Penpulimab-kcqx monotherapy", "D": "Penpulimab-kcqx in combination with carboplatin and gemcitabine"}}
{"id": "ZyTKVOHsOctK", "question_type": "multi_choice", "question": "Which of the following statements best describes the results of mutagenicity testing for Hernexeos?", "options": {"A": "Hernexeos was not mutagenic in the in vitro bacterial reverse mutation (Ames) assay.", "B": "Hernexeos was mutagenic in the in vitro bacterial reverse mutation (Ames) assay.", "C": "Hernexeos induced DNA breaks in the comet assay in liver and duodenum.", "D": "Hernexeos was genotoxic in the in vivo rat bone marrow micronucleus test."}}
{"id": "mrBlZgQuupSZ", "question_type": "multi_choice", "question": "A 56-year-old woman with metastatic, hormone receptor-positive, HER2-negative breast cancer has a confirmed PIK3CA mutation and has progressed after adjuvant endocrine therapy. She also has a history of well-controlled Type 2 diabetes managed with oral anti-hyperglycemic agents. Her oncologist is considering targeted therapy in combination with palbociclib and fulvestrant. Which drug regimen is most appropriate for her cancer management, considering her comorbidities and the need for close metabolic monitoring?", "options": {"A": "Itovebi (inavolisib) in combination with palbociclib and fulvestrant, with intensified glucose monitoring and anti-hyperglycemic management", "B": "Morphine sulfate for pain control, as primary cancer therapy", "C": "Ketorolac tromethamine for chronic pain management and cancer therapy", "D": "Itovebi (inavolisib) monotherapy without palbociclib or fulvestrant"}}
{"id": "SIFTrgPIEA6A", "question_type": "open_ended_multi_choice", "question": "A 7-year-old male patient diagnosed with myelodysplastic syndrome is about to undergo allogeneic hematopoietic stem cell transplantation. He has never experienced seizures and is not currently taking any drugs metabolized by CYP2C19 or CYP3A4. What is the most suitable preparative drug regimen for him prior to transplant?", "options": {"A": "Lenalidomide, oral daily dosing", "B": "Reblozyl, subcutaneous injection every 3 weeks", "C": "Treosulfan (GRAFAPEX) in combination with fludarabine, with supportive care for myelosuppression", "D": "Lenalidomide, with a planned drug scheduler to minimize cytopenias"}}
{"id": "9gcXqz6Wbt90", "question_type": "open_ended", "question": "A 35-year-old woman with advanced primary cutaneous T-cell lymphoma presents for treatment. She is currently pregnant in her second trimester and is experiencing significant pruritus and skin inflammation. Which drug regimen is most appropriate for managing her symptoms and disease at this time?", "options": {"A": "Vinblastine Sulfate intravenous chemotherapy administered every 7 days", "B": "Flurandrenolide topical lotion 0.05% applied twice daily to affected areas", "C": "Vinblastine Sulfate combined with erythromycin administered intravenously every 7 days", "D": "Flurandrenolide topical lotion 0.05% applied extensively over large body surface area for prolonged periods"}}
{"id": "8s3UmoZaje5l", "question_type": "open_ended_multi_choice", "question": "A 52-year-old female patient with newly diagnosed locally advanced ROS1-positive non-small cell lung carcinoma is undergoing treatment with a strong CYP3A inhibitor for a fungal infection. She does not have a history of liver disease or arrhythmias, and she is not pregnant or breastfeeding. What is the best drug management option for her lung cancer right now?", "options": {"A": "IBTROZI (taletrectinib) 600 mg orally once daily", "B": "IBTROZI (taletrectinib) 600 mg orally once daily, with a drug holiday during antifungal therapy", "C": "IBTROZI (taletrectinib) 600 mg orally once daily, co-administered with the CYP3A inhibitor", "D": "Delay initiation of IBTROZI (taletrectinib) until the CYP3A inhibitor is discontinued"}}
{"id": "YhvPyu0SVNLe", "question_type": "multi_choice", "question": "Which of the following statements best describes the embryo-fetal toxicity risk associated with Romvimza?", "options": {"A": "Romvimza is safe for use during pregnancy.", "B": "Romvimza can cause fetal harm based on animal studies and its mechanism of action.", "C": "Romvimza has no effect on fetal development.", "D": "Romvimza only causes fetal harm at doses ten times the recommended human dose."}}
{"id": "Nkr3EtQF7QFB", "question_type": "open_ended_multi_choice", "question": "What impact does co-administration of Journavx have on the pharmacokinetic profiles of ethinyl estradiol and levonorgestrel in individuals using an oral contraceptive with these components?", "options": {"A": "Clinically significant increase in ethinyl estradiol and levonorgestrel levels.", "B": "Clinically significant decrease in ethinyl estradiol and levonorgestrel levels.", "C": "No clinically significant change in the pharmacokinetics of ethinyl estradiol and levonorgestrel.", "D": "Complete loss of contraceptive efficacy."}}
{"id": "scvhMHyerhIU", "question_type": "open_ended_multi_choice", "question": "What is the recommended dose adjustment for an adult patient taking Modeyso who must use a strong CYP3A4 inhibitor?", "options": {"A": "Increase to 625 mg once weekly", "B": "Reduce to 375 mg once weekly", "C": "Reduce to 500 mg once weekly", "D": "Discontinue Modeyso"}}
{"id": "DZ2wlAMlf4VX", "question_type": "open_ended_multi_choice", "question": "A patient receiving Anzupgo therapy experiences a new outbreak of herpes zoster. What is the appropriate management step?", "options": {"A": "Continue Anzupgo without interruption", "B": "Increase the dose of Anzupgo", "C": "Interrupt Anzupgo treatment until the episode resolves", "D": "Administer a live herpes zoster vaccine immediately"}}
{"id": "DAeoDNzgwOwF", "question_type": "open_ended_multi_choice", "question": "A 58-year-old patient with metastatic non-small cell lung cancer (NSCLC) is confirmed to have ROS1-positive disease using FDA-approved methods. The patient also has a history of congestive heart failure and is currently prescribed a drug that prolongs the QTc interval. Based on these clinical details, which treatment should be avoided due to potential adverse effects, and which option is most appropriate?", "options": {"A": "Rozlytrek monotherapy, 600 mg orally once daily", "B": "Erlotinib monotherapy, 150 mg orally once daily", "C": "Lazcluze (lazertinib + amivantamab) combination therapy, standard dosing", "D": "Rozlytrek with dose reduction due to QTc-prolonging medication"}}
{"id": "7zZ1r3aXLqMF", "question_type": "open_ended_multi_choice", "question": "A 7-year-old boy with cystic fibrosis, recurrent bronchopulmonary infections, and failure to thrive is found to have exocrine pancreatic insufficiency and abnormal liver function tests (ALT and AST >3× ULN, bilirubin >2× ULN). He is currently taking a strong CYP3A inducer for another condition. Which of the following is the best approach for his cystic fibrosis drug therapy?", "options": {"A": "Initiate ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor) at standard pediatric dosage", "B": "Initiate ALYFTREK with dose reduction due to CYP3A inducer", "C": "Avoid ALYFTREK and consider alternative supportive management", "D": "Switch CYP3A inducer to a CYP3A inhibitor and start ALYFTREK"}}
{"id": "Hs0Cn5Oc9dTp", "question_type": "multi_choice", "question": "A 32-year-old woman with WHIM syndrome, characterized by myelokathexis, recurrent bacterial infections, and bronchiectasis, is planning to become pregnant. She currently has normal renal and hepatic function and is not taking any medications that interact with CYP3A4 or P-gp. Which of the following is the most appropriate recommendation regarding XOLREMDI therapy?", "options": {"A": "XOLREMDI can be safely used during pregnancy with close fetal monitoring.", "B": "XOLREMDI should not be initiated due to the risk of fetal harm; effective contraception is required during and for 3 weeks after treatment.", "C": "XOLREMDI is recommended only if the patient is also taking a strong CYP3A4 inhibitor.", "D": "XOLREMDI is safe to use during breastfeeding."}}
{"id": "CxPijSobwcix", "question_type": "open_ended_multi_choice", "question": "Which of the following statements best describes the evaluation of carcinogenic potential for the drug Tryptyr?", "options": {"A": "Long-term animal studies have demonstrated a high carcinogenic risk for Tryptyr.", "B": "Long-term studies in animals have not been performed to evaluate the carcinogenic potential of Tryptyr.", "C": "Tryptyr has been shown to be non-carcinogenic in human clinical trials.", "D": "Tryptyr is classified as a probable human carcinogen based on in vitro data."}}
{"id": "YfHRytk6vHGI", "question_type": "open_ended_multi_choice", "question": "If a patient receiving Datroway develops symptomatic interstitial lung disease (ILD) of grade 2 or greater, what is the recommended management?", "options": {"A": "Continue Datroway at current dose", "B": "Reduce Datroway dose by one level", "C": "Withhold Datroway until resolution", "D": "Permanently discontinue Datroway and administer corticosteroids"}}
{"id": "k4OrpwNPNDiW", "question_type": "open_ended_multi_choice", "question": "What should be done if a patient experiences a Grade 3 infusion-related reaction while receiving Penpulimab-kcqx?", "options": {"A": "Interrupt or slow the rate of infusion", "B": "Withhold Penpulimab-kcqx and resume after resolution", "C": "Permanently discontinue Penpulimab-kcqx", "D": "Reduce the dose and continue infusion"}}
{"id": "vEfhwB7gZQAf", "question_type": "open_ended", "question": "A patient experiences dyspnea, flushing, and hypotension during an Emrelis infusion. What is the recommended management for subsequent infusions if treatment is continued?", "options": {"A": "No change in management", "B": "Increase the infusion rate", "C": "Administer premedications prior to subsequent infusions", "D": "Switch to oral Emrelis"}}
{"id": "L09qV1cmKg4k", "question_type": "multi_choice", "question": "Which of the following statements best describes the recommended dosing adjustment for Ekterly when administered concomitantly with moderate CYP3A4 inhibitors during an HAE attack?", "options": {"A": "Administer the standard dose of Ekterly and repeat every 3 hours as needed.", "B": "Reduce Ekterly to a single 300 mg dose; a second 300 mg dose may be taken at least 3 hours later if symptoms persist or recur.", "C": "Avoid use of Ekterly entirely with moderate CYP3A4 inhibitors.", "D": "Increase the dose of Ekterly to 600 mg initially."}}
{"id": "veCiUDwafQOZ", "question_type": "open_ended_multi_choice", "question": "A 32-year-old woman with a history of celiac disease presents with persistent abdominal pain, diarrhea, and reduced blood folate concentration. She is currently 10 weeks pregnant and is considering starting a new medication for her gastrointestinal symptoms. She is concerned about the safety of drug therapy during pregnancy and wishes to continue breastfeeding after delivery. Which drug is most appropriate for her condition and reproductive plans?", "options": {"A": "Vedolizumab administered intravenously every 8 weeks after induction", "B": "Ritlecitinib administered orally once daily", "C": "Vedolizumab administered in combination with a TNF blocker", "D": "Ritlecitinib administered with a strong CYP3A inducer"}}
{"id": "eT0O6TtWJCTu", "question_type": "open_ended_multi_choice", "question": "A 59-year-old female patient with a new diagnosis of multiple myeloma is undergoing evaluation for autologous stem cell transplant. She has no renal impairment, is not pregnant, and has no prior history of thromboembolism or neuropathy. She is not currently taking any central nervous system depressants or cardiac drugs. Which drug regimen should be used to mobilize hematopoietic stem cells prior to her transplant?", "options": {"A": "Thalomid in combination with dexamethasone", "B": "LYNOZYFIC", "C": "Mozobil in combination with filgrastim", "D": "Thalomid monotherapy"}}
{"id": "A88ELYTJ3XgH", "question_type": "open_ended_multi_choice", "question": "What is the recommended action if a patient on Modeyso develops a QTc interval absolute value greater than 500 ms?", "options": {"A": "Continue at the same dose", "B": "Interrupt Modeyso until QTc ≤480 ms or return to baseline, then resume at the next lower dose", "C": "Increase the dose", "D": "Switch to another medication"}}
{"id": "cR7UzdpMVlSd", "question_type": "multi_choice", "question": "A 74-year-old man with intermediate-2 risk myelodysplastic syndrome (MDS) is being considered for drug therapy. He has moderate renal impairment (creatinine clearance 40 mL/min), is not eligible for stem cell transplantation, and is not taking any drugs metabolized by cytidine deaminase. Which of the following is the most suitable drug for his condition, considering his age, renal function, and MDS risk group?", "options": {"A": "INQOVI (cedazuridine and decitabine), administered orally once daily in 28-day cycles.", "B": "TREOSULFAN (GRAFAPEX) in combination with fludarabine as a transplant preparative regimen.", "C": "Lenalidomide, with dose adjustment for renal impairment.", "D": "Lenalidomide, standard dose without adjustment."}}
{"id": "DQeWN45dutlE", "question_type": "multi_choice", "question": "A 7-year-old boy with sepiapterin-responsive phenylketonuria presents with a history of recurrent nosebleeds and easy bruising. He is not taking any medications that affect folate synthesis or sepiapterin reductase. His parents are concerned about starting a new medication for PKU. Which of the following is the most appropriate drug to initiate for his hyperphenylalaninemia?", "options": {"A": "Sapropterin dihydrochloride", "B": "Javygtor", "C": "Sephience", "D": "Trimethoprim"}}
{"id": "cOZ9KzBDOABB", "question_type": "multi_choice", "question": "A patient is prescribed Wayrilz and is also taking an antacid. How should the administration of Wayrilz be managed in relation to the antacid?", "options": {"A": "Take Wayrilz and the antacid together", "B": "Administer Wayrilz at least 2 hours before the antacid", "C": "Administer Wayrilz at least 2 hours after the antacid", "D": "Crush Wayrilz and mix with the antacid"}}
{"id": "DykC0CMz9T2D", "question_type": "open_ended_multi_choice", "question": "A 62-year-old woman with unresectable, metastatic non-squamous non-small cell lung cancer (NSCLC) is found to have a HER2 (ERBB2) tyrosine kinase domain activating mutation by FDA-approved testing. She previously received platinum-based chemotherapy and now requires further systemic therapy. Her cardiac function is normal, and she is not taking any CYP3A inducers or BCRP substrates. She is not pregnant and does not plan to breastfeed. Which of the following is the most appropriate next-line drug therapy for her condition, including consideration of indication and safety?", "options": {"A": "HERNEXEOS administered orally once daily, with regular monitoring of liver and cardiac function.", "B": "TECENTRIQ administered intravenously every 3 weeks as a single agent.", "C": "Etoposide administered intravenously in combination with other chemotherapeutic agents.", "D": "TECENTRIQ in combination with bevacizumab, paclitaxel, and carboplatin."}}
{"id": "fq4WMjwOKgSP", "question_type": "open_ended_multi_choice", "question": "A 45-year-old woman with myopathy with eye involvement presents with documented, sustained ventricular tachycardia. She is currently taking theophylline for asthma and drinks several cups of coffee daily. Which of the following is the most appropriate approach regarding the use of mexiletine hydrochloride for her arrhythmia management?", "options": {"A": "Initiate mexiletine hydrochloride at standard dosage without adjusting her current medications.", "B": "Start mexiletine hydrochloride but closely monitor and adjust theophylline and caffeine intake due to potential drug interactions.", "C": "Avoid mexiletine hydrochloride entirely due to her underlying myopathy.", "D": "Use mexiletine hydrochloride only if she is switched to a pediatric formulation."}}
{"id": "rvjpLRMyrCts", "question_type": "open_ended_multi_choice", "question": "For a patient taking Ekterly with a weak CYP3A4 inducer, what is the expected impact on sebetralstat exposure and dosing recommendations?", "options": {"A": "Significant decrease in exposure; dose increase required.", "B": "No significant change in exposure; no dose modification needed.", "C": "Significant increase in exposure; dose reduction required.", "D": "Complete loss of efficacy; discontinue Ekterly."}}
{"id": "jPdNyKseeHbz", "question_type": "open_ended", "question": "A 7-year-old child with hereditary angioedema requires long-term prophylaxis to prevent attacks. The child is otherwise healthy, not taking any other medications, and has no history of hypersensitivity reactions. Which drug regimen is most appropriate for this patient?", "options": {"A": "Firazyr administered subcutaneously as needed for prophylaxis", "B": "ANDEMBRY 200 mg subcutaneously every month for prophylaxis", "C": "TAKHZYRO administered subcutaneously for prophylaxis according to pediatric dosing schedule", "D": "ANDEMBRY 400 mg loading dose followed by 200 mg subcutaneously every month"}}
{"id": "ddWf0jiVa1AG", "question_type": "open_ended_multi_choice", "question": "A 55-year-old man with metastatic non-squamous non-small cell lung carcinoma has a confirmed HER2 (ERBB2) tyrosine kinase domain activating mutation. He has a history of chronic heart failure with a left ventricular ejection fraction (LVEF) of 45%. He is not pregnant and is not taking any CYP3A inducers or BCRP substrates. Which of the following is the most suitable initial therapy for his lung cancer?", "options": {"A": "Zongertinib, with close cardiac monitoring", "B": "Atezolizumab as first-line therapy", "C": "Imfinzi as a single agent", "D": "None of the above; alternative therapy should be considered due to cardiac contraindication"}}
{"id": "IGuav43gNsS8", "question_type": "open_ended_multi_choice", "question": "A 20-year-old man with hemophilia B who has developed inhibitors to factor IX is experiencing frequent spontaneous nosebleeds and delayed wound healing. He is about to undergo dental surgery and needs effective management for acute bleeding episodes during the perioperative period. Which medication is most appropriate for his care at this time?", "options": {"A": "REBINYN, administered perioperatively", "B": "HYMPAVZI, administered perioperatively", "C": "SEVENFACT, administered perioperatively", "D": "REBINYN, administered as routine prophylaxis only"}}
{"id": "9BJNfucZuS8L", "question_type": "open_ended_multi_choice", "question": "A 62-year-old patient with nephrosis presents with significant edema and a history of allergic reaction to furosemide. The patient also has mild renal impairment and is currently taking antihypertensive medication. Which drug is the most appropriate for managing this patient's edema, considering drug interactions and safety profile?", "options": {"A": "Bumex administered orally, starting at a low dose with careful monitoring", "B": "PredniSONE Tablets, 5 mg daily", "C": "Depo-Provera injection every 3 months", "D": "Bumex administered intravenously at a high dose without monitoring"}}
{"id": "JkwInSrpdlnJ", "question_type": "open_ended_multi_choice", "question": "Which step should be taken if a patient experiences acute gallbladder disease during treatment with Qfitlia?", "options": {"A": "Consider interruption or discontinuation of Qfitlia", "B": "Increase the Qfitlia dose", "C": "Add a statin", "D": "Continue Qfitlia without changes"}}
{"id": "6uXwPlCOsgl6", "question_type": "open_ended_multi_choice", "question": "For a patient prescribed Romvimza, what is the recommended management strategy if they must also take an Organic Cation Transporter 2 (OCT2) substrate?", "options": {"A": "Refer to the prescribing information of the OCT2 substrate for dose modifications.", "B": "Increase the dose of Romvimza.", "C": "Administer Romvimza and the OCT2 substrate at the same time.", "D": "Discontinue the OCT2 substrate."}}
{"id": "qQYmSbi6ZSgP", "question_type": "open_ended", "question": "A 68-year-old man with Japanese encephalitis develops severe functional motor deficit, increased intracranial pressure, and pulmonary edema. He has a history of hypertension and moderate renal impairment. The team is considering supportive pharmacologic therapy. Which regimen is most suitable for this patient?", "options": {"A": "Bupivacaine hydrochloride (from Dyural 40 Kit) at standard adult dose for regional anesthesia", "B": "Methylprednisolone acetate (from Dyural 40 Kit) at reduced dose for cerebral edema", "C": "Rituxan Hycela as a single agent", "D": "Enspryng administered subcutaneously every four weeks"}}
{"id": "g4OZt2dlccWy", "question_type": "open_ended", "question": "What is the recommendation regarding Vanrafia initiation in patients with severe hepatic impairment?", "options": {"A": "Initiate at a reduced dose", "B": "Initiate at the standard dose", "C": "Do not initiate Vanrafia", "D": "Initiate only with close monitoring"}}
{"id": "p5bzNAf6i5FK", "question_type": "open_ended_multi_choice", "question": "A 34-year-old woman diagnosed with chronic immune thrombocytopenia and positive for platelet antibodies presents with abnormal bleeding. After unsuccessful corticosteroid treatment, she wishes to conceive and has mild hepatic impairment. Which drug is most appropriate for her subsequent therapy?", "options": {"A": "Rilzabrutinib", "B": "Prednisone", "C": "DMT SUIK (IV)", "D": "Dexamethasone sodium phosphate"}}
{"id": "RSWhmxxaNmgG", "question_type": "multi_choice", "question": "A 42-year-old woman with a history of Grade 2 astrocytoma and recent surgical resection is found to have a susceptible IDH2 mutation. She is currently using a hormonal contraceptive and is considering starting targeted therapy. Which of the following is the most important consideration when initiating Voranigo for this patient?", "options": {"A": "Avoid Voranigo due to risk of nephrotoxicity", "B": "Reduce the dose of Voranigo due to her age", "C": "Switch to a nonhormonal contraceptive method before starting Voranigo", "D": "Delay Voranigo initiation until 6 months after surgery"}}
{"id": "uLGmYz78e8SD", "question_type": "open_ended_multi_choice", "question": "A 15-year-old with generalized myasthenia gravis has tested positive for anti-MuSK antibodies. What is the recommended brand name medication for this patient?", "options": {"A": "Imaavy", "B": "Pyridostigmine", "C": "Azathioprine", "D": "Eculizumab"}}
{"id": "7NHcpblwv9Rs", "question_type": "open_ended_multi_choice", "question": "When a patient is using Tryptyr in combination with a different topical ophthalmic eye drop, what is the recommended timing for administering the two medications?", "options": {"A": "Administer both drops simultaneously", "B": "Administer Tryptyr first and the other drop immediately after", "C": "Administer the drugs at least five minutes apart", "D": "Wait one hour between drugs"}}
{"id": "HrUAaaAKsUVp", "question_type": "multi_choice", "question": "A 62-year-old woman with unresectable, metastatic non-squamous non-small cell lung carcinoma is found to have a HER2 (ERBB2) tyrosine kinase domain activating mutation by FDA-approved testing. She has previously received platinum-based chemotherapy. Her cardiac function is normal, and she is not pregnant or breastfeeding. However, she is currently taking rifampin, a strong CYP3A inducer, for latent tuberculosis. Which drug regimen is most appropriate for her lung cancer treatment?", "options": {"A": "Zongertinib with dose adjustment to account for CYP3A induction", "B": "Atezolizumab as monotherapy", "C": "Imfinzi in combination with platinum-based chemotherapy", "D": "Zongertinib at standard dose without adjustment"}}
{"id": "QNIP1XXO4aRi", "question_type": "multi_choice", "question": "A 45-year-old man with chronic immune thrombocytopenia and autosomal dominant inheritance is being considered for second-line therapy after failing corticosteroids. He has severe renal impairment and is currently taking a strong CYP3A inhibitor for a fungal infection. Which drug is most appropriate for his condition?", "options": {"A": "WAYRILZ (rilzabrutinib) 400 mg twice daily", "B": "Nplate (romiplostim) weekly subcutaneous injection", "C": "DMT SUIK (corticosteroid) intravenous therapy", "D": "WAYRILZ (rilzabrutinib) with a drug scheduler to avoid CYP3A inhibitor overlap"}}
{"id": "ihpEJd6Jz0bf", "question_type": "open_ended_multi_choice", "question": "A 67-year-old patient with non-alcoholic steatohepatitis (NASH) and moderate fibrosis (F2) presents for consideration of drug therapy. He has mild renal impairment (eGFR 55 mL/min/1.73 m²) and is on a daily dose of atorvastatin 80 mg for hyperlipidemia. Which drug regimen should be chosen for his NASH, taking into account drug-drug interactions and required dosage modifications?", "options": {"A": "Resmetirom once daily with atorvastatin reduced to 40 mg daily", "B": "Pentoxifylline extended-release tablets twice daily with atorvastatin 80 mg daily", "C": "Resmetirom once daily with atorvastatin 80 mg daily", "D": "Dapagliflozin once daily with atorvastatin 80 mg daily"}}
{"id": "yOuJYnjgBXYd", "question_type": "open_ended_multi_choice", "question": "For a 29-year-old woman who is pregnant and has persistent moderate to severe hand eczema despite topical corticosteroids, what is the best recommendation about prescribing Anzupgo?", "options": {"A": "Consider Anzupgo only if the potential benefit justifies the potential risk to the fetus.", "B": "Initiate Anzupgo without any consideration of pregnancy status.", "C": "Anzupgo is contraindicated in all pregnant women regardless of severity.", "D": "Anzupgo is recommended as first-line therapy for all pregnant women with hand eczema."}}
{"id": "6eGopYq0DIcR", "question_type": "open_ended_multi_choice", "question": "A 70-year-old male patient with advanced, unresectable esophageal squamous cell carcinoma (ESCC) and moderate renal impairment (CKD stage 3) presents with complaints of nausea, vomiting, and mild proteinuria. The tumor is PD-L1 positive (≥1). What is the most appropriate first-line treatment option for him?", "options": {"A": "Lenvatinib monotherapy", "B": "Tislelizumab-jsgr in combination with platinum-containing chemotherapy", "C": "Nivolumab and hyaluronidase in combination with fluoropyrimidine- and platinum-containing chemotherapy", "D": "Lenvatinib in combination with everolimus"}}
{"id": "UWOT6L0dLbUg", "question_type": "open_ended_multi_choice", "question": "For a 38-year-old patient with metastatic HR-positive, HER2-negative breast cancer who is pregnant, has no renal or hepatic dysfunction, and has a history of endocrine and chemotherapy treatments, which of the following drugs poses a risk of embryo-fetal harm and should not be used?", "options": {"A": "Ketorolac Tromethamine", "B": "DATROWAY", "C": "MVASI", "D": "All of the above"}}
{"id": "ofGglqxpA6ew", "question_type": "open_ended_multi_choice", "question": "A male patient, aged 60, who manages his epilepsy with valproic acid, is admitted for a severe urinary tract infection. He has normal kidney and liver function and no drug allergies. Considering possible drug interactions that may trigger breakthrough seizures, which treatment should not be used?", "options": {"A": "Imipenem and Cilastatin Sodium intravenous therapy, following standard dosing.", "B": "Blujepa, administered according to recommended dosing for severe UTI.", "C": "Flavoxate Hydrochloride tablets for symptomatic relief.", "D": "Imipenem and Cilastatin Sodium with dose adjustment for renal function."}}
{"id": "NVuzjN16rOBA", "question_type": "multi_choice", "question": "A 42-year-old woman with end-stage renal disease on hemodialysis for six months presents with anemia. She has a history of uncontrolled hypertension and is currently being evaluated for possible active malignancy. Which of the following is the most appropriate course of action regarding vadadustat therapy for her anemia?", "options": {"A": "Start vadadustat at the lowest effective dose, monitoring for cardiovascular events.", "B": "Do not initiate vadadustat due to uncontrolled hypertension and possible active malignancy.", "C": "Begin fedratinib with thiamine supplementation.", "D": "Recommend the homeopathic combination for anemia management."}}
{"id": "PCBiRwREcqwl", "question_type": "open_ended_multi_choice", "question": "A patient is taking Ibtrozi and requires gastric acid suppression. Which of the following is the most appropriate management strategy?", "options": {"A": "Administer a proton pump inhibitor concurrently with Ibtrozi", "B": "Administer a locally acting antacid 2 hours before or after Ibtrozi", "C": "Administer an H2 receptor antagonist at the same time as Ibtrozi", "D": "Increase the dose of Ibtrozi when using acid-reducing agents"}}
{"id": "vn3dHRLpKCoR", "question_type": "multi_choice", "question": "How did Vanrafia perform compared to placebo in terms of percent reduction in UPCR at Week 36 in the main cohort of the ALIGN study?", "options": {"A": "Vanrafia achieved a 3% reduction versus 38% for placebo", "B": "Vanrafia achieved a 38% reduction versus 3% for placebo", "C": "Vanrafia achieved a 15% reduction versus 10% for placebo", "D": "Vanrafia achieved a 26% reduction versus 45% for placebo"}}
{"id": "5SJiAsz8FG3s", "question_type": "open_ended_multi_choice", "question": "A 7-year-old boy with congenital hemophilia A (factor VIII deficiency) is being considered for routine prophylaxis to prevent bleeding episodes. He has no history of factor VIII inhibitors, is otherwise healthy, and is not taking any other medications. Which of the following is the most appropriate drug for this patient?", "options": {"A": "Alhemo administered as routine prophylaxis", "B": "Hemlibra administered as routine prophylaxis", "C": "Alhemo administered only during breakthrough bleeds", "D": "No prophylactic treatment is indicated for this patient"}}
{"id": "LFtxbt1CjSsm", "question_type": "open_ended", "question": "A patient with pre-existing increased serum transaminases and active biliary tract disease is being considered for Romvimza therapy. What is the recommended approach?", "options": {"A": "Avoid Romvimza therapy", "B": "Initiate Romvimza at a reduced dose", "C": "Monitor liver function monthly and proceed", "D": "Administer Romvimza with concurrent corticosteroids"}}
{"id": "vQBH2qNcfw0U", "question_type": "multi_choice", "question": "A 65-year-old woman with acute myeloid leukemia and myelodysplastic syndrome related to topoisomerase type 2 inhibitor is scheduled for induction chemotherapy. She has a history of congestive heart failure and is currently taking trastuzumab for a prior breast cancer diagnosis, which was discontinued 2 months ago. Her hepatic and renal function are within normal limits. Which drug regimen should be avoided due to increased risk of cardiac toxicity in this patient?", "options": {"A": "Doxorubicin Hydrochloride administered every 3 weeks", "B": "Idamycin PFS in combination with other antileukemic drugs", "C": "GUNA-IL 2 administered 15 minutes before meals", "D": "Doxorubicin Hydrochloride administered after a drug holiday of 7 months post-trastuzumab"}}
{"id": "qTXdqdtle3Sl", "question_type": "open_ended_multi_choice", "question": "A 45-year-old female patient with metastatic non-keratinizing nasopharyngeal carcinoma has progressed following platinum-based chemotherapy and at least one other previous treatment. She is breastfeeding and wants to continue doing so. Which treatment approach is most appropriate for her present circumstances?", "options": {"A": "Penpulimab-kcqx as a single agent, administered every 3 weeks", "B": "Capecitabine 500 mg twice daily as monotherapy", "C": "Celecoxib 200 mg twice daily for symptom relief", "D": "Delay systemic therapy and continue breastfeeding for 4 months before starting Penpulimab-kcqx"}}
{"id": "5A6EidapK6aN", "question_type": "open_ended_multi_choice", "question": "A 62-year-old woman presents with unresectable, metastatic non-squamous NSCLC and has an FDA-confirmed activating mutation in the HER2 (ERBB2) tyrosine kinase domain. After prior platinum-based chemotherapy, she needs additional systemic therapy. Her cardiac function is normal, and she is not taking any medications that are CYP3A inducers or BCRP substrates. She is not pregnant and does not intend to breastfeed. What is the most appropriate next-line drug therapy for her, with consideration of both clinical indication and safety?", "options": {"A": "HERNEXEOS administered orally once daily, with regular monitoring of liver and cardiac function.", "B": "TECENTRIQ administered intravenously every 3 weeks as a single agent.", "C": "Etoposide administered intravenously in combination with other chemotherapeutic agents.", "D": "TECENTRIQ in combination with bevacizumab, paclitaxel, and carboplatin."}}
{"id": "wVaoD2bKMJ9Y", "question_type": "open_ended_multi_choice", "question": "A 68-year-old female patient presents with BCG-unresponsive nonmuscle invasive bladder cancer (NMIBC), including carcinoma in situ (CIS) and papillary lesions. She has no history of bladder perforation, severe irritative bladder symptoms, or recent transurethral resection, and is neither pregnant nor planning to breastfeed. What is the most suitable intravesical drug regimen for her?", "options": {"A": "Valrubicin intravesical therapy alone", "B": "Nogapendekin alfa inbakicept-pmln (ANKTIVA) in combination with Bacillus Calmette-Guérin (BCG)", "C": "Valrubicin in combination with Bacillus Calmette-Guérin (BCG)", "D": "Nogapendekin alfa inbakicept-pmln (ANKTIVA) monotherapy"}}
{"id": "0F0cQpPgjEvR", "question_type": "open_ended_multi_choice", "question": "What is the first step a clinician should take if a patient on Enflonsia exhibits symptoms of anaphylaxis?", "options": {"A": "Initiate appropriate medications and/or supportive therapy", "B": "Discontinue all medications", "C": "Administer additional Enflonsia", "D": "Perform a rapid antigen test for RSV"}}
{"id": "8gHMuyixxCWX", "question_type": "multi_choice", "question": "A 70-year-old man with advanced renal oncocytoma and a history of hypertension (currently controlled), mild hepatic impairment, and chronic use of a proton pump inhibitor (PPI) for gastroesophageal reflux disease is being considered for treatment. He is not taking any CYP3A4 inhibitors or inducers. Which drug regimen is most appropriate for his condition?", "options": {"A": "VOTRIENT, with concurrent PPI use and no adjustment", "B": "Pazopanib tablets, with avoidance of PPI and use of short-acting antacids separated by several hours from dosing", "C": "VOTRIENT, with dose reduction due to age", "D": "Pazopanib tablets, with no adjustment for PPI use"}}
{"id": "VZiRJZpA5ka5", "question_type": "open_ended_multi_choice", "question": "If a patient is being considered for treatment with Ibtrozi, which of the following statements best describes the contraindication profile?", "options": {"A": "There are no contraindications for Ibtrozi.", "B": "Ibtrozi is contraindicated in patients with cardiac arrhythmias.", "C": "Ibtrozi is contraindicated in pediatric patients.", "D": "Ibtrozi is contraindicated in patients with active infection."}}
{"id": "XIr7NgA3jnbX", "question_type": "open_ended_multi_choice", "question": "A 10-year-old child with cystic fibrosis presents with recurrent respiratory infections, hepatomegaly, and elevated hepatic transaminases. Genetic testing confirms the presence of at least one F508del mutation in the CFTR gene. The patient has a history of abnormal liver function tests and is currently classified as Child-Pugh Class B for hepatic impairment. Which drug regimen is most appropriate for managing this patient's cystic fibrosis?", "options": {"A": "ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor) once daily", "B": "Insulin Aspart Protamine and Insulin Aspart Mix 70/30, administered twice daily", "C": "ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor) with reduced dosage and close liver monitoring", "D": "No CFTR modulator therapy; supportive care only"}}
{"id": "etey4Kr1rr0x", "question_type": "open_ended", "question": "A 35-year-old woman with congenital dyserythropoietic anemia type 1B, presenting with anemia, pallor, and hepatomegaly, is currently pregnant. She is experiencing worsening anemia and her physician is considering pharmacologic intervention. Which of the following drugs should be avoided due to its teratogenic potential and risk to the fetus?", "options": {"A": "Filgrastim administered daily as needed for neutropenia", "B": "Fludarabine phosphate administered intravenously at 25 mg/m2/day for 5 days", "C": "Sitagliptin and metformin hydrochloride combination therapy", "D": "Supportive care with transfusions only"}}
{"id": "O46K7zTFrbzJ", "question_type": "open_ended_multi_choice", "question": "In a 60-year-old male patient with recurrent glioblastoma, congestive heart failure, and poorly managed hypertension, which anti-tumor drug is contraindicated due to an elevated risk of significant cardiovascular complications?", "options": {"A": "Zortress in combination with cyclosporine", "B": "Avastin administered every 2 weeks", "C": "Vorasidenib 40 mg once daily", "D": "Zortress combined with tacrolimus"}}
{"id": "tYtAnlDSKiiq", "question_type": "open_ended_multi_choice", "question": "After a dose delay of more than 49 days following a 200 mg Lynozyfic infusion, what is the recommended approach for restarting therapy?", "options": {"A": "Resume with 200 mg dose", "B": "Restart step-up dosing from 5 mg", "C": "Administer 25 mg dose", "D": "Discontinue Lynozyfic permanently"}}
{"id": "BfHaMzNG8Hwd", "question_type": "multi_choice", "question": "A 65-year-old man with chronic kidney disease and anemia is being evaluated for pharmacologic therapy. He has not yet started dialysis but is expected to begin within the next two months. His past medical history is significant for cirrhosis secondary to hepatitis C. Which of the following is the most appropriate recommendation regarding anemia management for this patient?", "options": {"A": "Initiate vadadustat immediately to treat anemia due to CKD.", "B": "Avoid vadadustat due to underlying cirrhosis; consider alternative anemia management.", "C": "Start fedratinib with thiamine supplementation.", "D": "Use the homeopathic combination for anemia symptoms."}}
{"id": "yBsTsghYKpTv", "question_type": "open_ended_multi_choice", "question": "A 62-year-old individual diagnosed with metastatic non-small cell lung cancer (NSCLC) is identified to have an EGFR exon 21 (L858R) mutation via FDA-approved testing. The patient's medical history includes peptic ulcer disease, and they are currently on omeprazole for gastric reflux management. Taking into account potential drug interactions and safety concerns, which first-line treatment regimen is most suitable for this patient?", "options": {"A": "Erlotinib, with avoidance of omeprazole and careful monitoring for gastrointestinal perforation", "B": "Ensartinib, administered once daily", "C": "Rozlytrek, administered once daily", "D": "Erlotinib, co-administered with omeprazole and no adjustment"}}
{"id": "hPaTqHFa1rpU", "question_type": "open_ended_multi_choice", "question": "Considering a 16-year-old patient with hemophilia A and established Child-Pugh Class B hepatic impairment, who does not have gallbladder disease and is not taking hormonal contraceptives, which routine prophylaxis regimen should be chosen?", "options": {"A": "Qfitlia administered subcutaneously once monthly", "B": "Hemlibra administered subcutaneously once weekly", "C": "Qfitlia administered subcutaneously using antithrombin-based dosing every four weeks", "D": "Fitusiran administered intravenously every two weeks"}}
{"id": "rzIbYD88JJjH", "question_type": "multi_choice", "question": "For a patient with recurrent or metastatic nasopharyngeal carcinoma receiving Penpulimab-kcqx in combination with gemcitabine and cisplatin, what is the recommended order of drug administration during each cycle?", "options": {"A": "Gemcitabine first, cisplatin second, Penpulimab-kcqx last", "B": "Cisplatin first, Penpulimab-kcqx second, gemcitabine last", "C": "Penpulimab-kcqx first, cisplatin second, gemcitabine last", "D": "Gemcitabine first, Penpulimab-kcqx second, cisplatin last"}}
{"id": "shmE3xGGZuaE", "question_type": "open_ended_multi_choice", "question": "A patient receiving Imaavy develops swelling of the face, lips, and tongue during infusion. What is the most appropriate immediate action?", "options": {"A": "Continue the infusion at a slower rate", "B": "Administer a live vaccine", "C": "Obtain emergency medical help for possible anaphylaxis", "D": "Give an additional dose of Imaavy"}}
{"id": "eXaLSVTXV6DB", "question_type": "open_ended_multi_choice", "question": "Has the safety and effectiveness of Datroway been determined for pediatric patients?", "options": {"A": "Safety and effectiveness have been established", "B": "Safety is established, but effectiveness is unknown", "C": "Effectiveness is established, but safety is unknown", "D": "Safety and effectiveness have not been established"}}
{"id": "p6ifYzqqVw7y", "question_type": "open_ended_multi_choice", "question": "Which modification could help patients tolerate Wayrilz better if they develop gastrointestinal side effects?", "options": {"A": "Take Wayrilz with food", "B": "Take Wayrilz on an empty stomach", "C": "Reduce the dose by half", "D": "Switch to intravenous administration"}}
{"id": "3FvoDDlEbbQ1", "question_type": "open_ended_multi_choice", "question": "A child aged 7 years is diagnosed with Niemann-Pick disease type C, presenting with progressive neurological symptoms and hepatosplenomegaly. Given that renal function is normal and no other drugs are being taken, which treatment approach is most appropriate for managing the neurological aspects of this condition, considering the patient's age and diagnosis?", "options": {"A": "MIPLYFFA in combination with miglustat, administered according to pediatric dosing guidelines", "B": "OPFOLDA in combination with Pombiliti", "C": "Lithium carbonate", "D": "MIPLYFFA monotherapy"}}
{"id": "lb9Myk19x3CS", "question_type": "multi_choice", "question": "Which of the following best describes the rationale for avoiding Blujepa in patients with severe hepatic impairment?", "options": {"A": "Increased exposure to gepotidacin and risk of QTc prolongation", "B": "Risk of hepatotoxicity due to drug accumulation", "C": "Lack of efficacy in this population", "D": "Blujepa is not metabolized by the liver"}}
{"id": "DPhtSL0x4Zn6", "question_type": "open_ended_multi_choice", "question": "A 32-year-old woman, currently in her first trimester of pregnancy (10 weeks), presents with newly diagnosed generalized myasthenia gravis and is positive for anti-MuSK antibodies. She has a background of Hashimoto thyroiditis and expresses concern about medication safety while pregnant. Which treatment option should not be used because of its recognized teratogenic risk and pregnancy contraindication?", "options": {"A": "IMAAVY, 15 mg/kg intravenous infusion every 2 weeks", "B": "Azathioprine, 75 mg daily oral administration", "C": "DuoDote, single dose for acute management", "D": "IMAAVY, 10 mg/kg intravenous infusion every 4 weeks"}}
{"id": "LLD4v3XW6TXg", "question_type": "multi_choice", "question": "A 42-year-old woman with end-stage renal disease on hemodialysis for six months presents with anemia. She has a history of uncontrolled hypertension and is currently being evaluated for possible active malignancy. Which of the following is the most appropriate course of action regarding vadadustat therapy for her anemia?", "options": {"A": "Start vadadustat at the lowest effective dose, monitoring for cardiovascular events.", "B": "Begin fedratinib with thiamine supplementation.", "C": "Do not initiate vadadustat due to uncontrolled hypertension and possible active malignancy.", "D": "Recommend the homeopathic combination for anemia management."}}
{"id": "xJWmHhomElv9", "question_type": "open_ended_multi_choice", "question": "A 62-year-old patient presents with metastatic non-small cell lung cancer and is found to have an EGFR exon 21 (L858R) substitution mutation confirmed by FDA-approved testing. The patient’s history includes peptic ulcer disease, and they are currently using omeprazole to manage gastric reflux. Which first-line drug regimen should be selected, given the need to consider drug-drug interactions and overall safety?", "options": {"A": "Erlotinib, with avoidance of omeprazole and careful monitoring for gastrointestinal perforation", "B": "Ensartinib, administered once daily", "C": "Rozlytrek, administered once daily", "D": "Erlotinib, co-administered with omeprazole and no adjustment"}}
{"id": "PDfarFZwHCF0", "question_type": "open_ended_multi_choice", "question": "A 32-year-old female with cystic fibrosis, confirmed to have at least one responsive CFTR mutation, presents with chronic lung disease, hepatomegaly, and cirrhosis (Child-Pugh Class C). She is planning pregnancy and is currently using hormonal contraceptives. Which of the following is the safest and most appropriate drug therapy for her cystic fibrosis management?", "options": {"A": "ALYFTREK at standard dosage, with close liver function monitoring.", "B": "SYMDEKO at reduced dosage, with regular liver function monitoring.", "C": "ALYFTREK at reduced dosage, with interruption of hormonal contraceptives.", "D": "SYMDEKO at standard dosage, with interruption of hormonal contraceptives."}}
{"id": "Di5am2f8QE5u", "question_type": "open_ended_multi_choice", "question": "Which dose adjustment is recommended for a patient weighing 85 kg who requires concomitant therapy with a strong CYP3A inducer while taking Hernexeos?", "options": {"A": "Increase to 240 mg once daily", "B": "Decrease to 60 mg once daily", "C": "Maintain at 120 mg once daily", "D": "Increase to 180 mg once daily"}}
{"id": "Tx72DucnV731", "question_type": "multi_choice", "question": "A 67-year-old man with persistent immune thrombocytopenia and autosomal dominant inheritance has failed previous corticosteroid therapy. He has a history of severe renal impairment and is currently taking a proton pump inhibitor for gastroesophageal reflux disease. Which drug should be avoided due to his comorbidities and medication regimen?", "options": {"A": "Rilzabrutinib", "B": "DMT SUIK (IV)", "C": "Prednisone", "D": "Dexamethasone sodium phosphate"}}
{"id": "jtxRNduDqJTc", "question_type": "open_ended_multi_choice", "question": "In a 14-year-old female patient with relapsed low-grade glioma and a confirmed BRAF fusion, who is currently taking fluconazole and hormonal contraceptives, which targeted therapy should be avoided because of possible interactions with her current medications and contraceptive concerns?", "options": {"A": "VinCRIStine Sulfate administered intravenously, with careful monitoring for neurotoxicity.", "B": "OJEMDA administered orally once daily, despite concurrent fluconazole and hormonal contraceptive use.", "C": "Gliadel Wafer implantation as adjunct to surgery, regardless of glioma grade.", "D": "OJEMDA administered with a planned drug holiday every 3 months to minimize adverse effects."}}
{"id": "ZWarZno4QwYJ", "question_type": "open_ended_multi_choice", "question": "A 16-year-old patient diagnosed with Niemann-Pick disease type C is experiencing worsening neurological symptoms and has hepatomegaly, along with moderate renal impairment (eGFR 35 mL/min/1.73 m²). Considering therapy aimed at neurological manifestations, what is the most suitable drug regimen and dosing strategy for this individual?", "options": {"A": "Standard-dose arimoclomol in combination with standard-dose miglustat", "B": "Standard-dose miglustat monotherapy", "C": "Dose-adjusted arimoclomol in combination with dose-adjusted miglustat", "D": "Standard-dose lithium carbonate"}}
{"id": "cxrdBvC8eST9", "question_type": "open_ended", "question": "A 3-year-old child with ALG12-CDG presents with recurrent edema and seizures. The patient also has a history of renal tubular acidosis and hepatomegaly. The clinician is considering adjunctive therapy for edema. Which of the following is the most appropriate recommendation regarding the use of acetazolamide in this patient?", "options": {"A": "Acetazolamide is appropriate for adjunctive treatment of edema in this pediatric patient.", "B": "Acetazolamide should be avoided due to risk of growth retardation and worsening acidosis.", "C": "Acetazolamide is recommended only if the patient is also receiving high-dose aspirin.", "D": "Acetazolamide is safe for use in pediatric patients with hepatic involvement."}}
{"id": "YWgb69vkVNE7", "question_type": "open_ended_multi_choice", "question": "In the case of a 6-year-old with classic congenital adrenal hyperplasia receiving glucocorticoid therapy, and with no renal dysfunction or hypersensitivity history, which drug regimen should be considered to further manage androgen levels?", "options": {"A": "Crenessity as adjunctive therapy to glucocorticoid replacement", "B": "Crenessity monotherapy without glucocorticoid replacement", "C": "Crenessity in a child under 4 years old", "D": "Crenessity in a patient with severe renal impairment"}}
{"id": "zEcih9m1x2e1", "question_type": "multi_choice", "question": "Which population should be advised not to breastfeed during and for 2 weeks after treatment with Hernexeos?", "options": {"A": "Geriatric patients", "B": "Men receiving Hernexeos", "C": "Pediatric patients", "D": "Women receiving Hernexeos"}}
{"id": "UUmWF1FAHfr2", "question_type": "multi_choice", "question": "A 16-year-old male with Niemann-Pick disease type C and progressive neurological decline is being considered for drug therapy. He has moderate renal impairment (eGFR 35 mL/min) and is currently taking metformin, an OCT2 substrate. Which of the following is the most appropriate approach to drug selection and management for this patient?", "options": {"A": "Start MIPLYFFA in combination with miglustat at reduced dosing and monitor for metformin toxicity", "B": "Start MIPLYFFA in combination with miglustat at standard dosing without adjustments", "C": "Start OPFOLDA in combination with Pombiliti", "D": "Start lithium carbonate therapy"}}
{"id": "1SZkL7rKHSnl", "question_type": "open_ended", "question": "Which of the following best describes the contraindication profile for the drug Wayrilz?", "options": {"A": "Wayrilz is contraindicated in patients with severe hepatic impairment.", "B": "Wayrilz should not be used in patients with known hypersensitivity to its active ingredient.", "C": "There are no known contraindications for Wayrilz.", "D": "Wayrilz is contraindicated in pediatric populations."}}
{"id": "59IYMFZmTmhI", "question_type": "multi_choice", "question": "Which of the following statements is correct regarding the freezing of Vizz?", "options": {"A": "Vizz should be frozen for long-term storage.", "B": "Vizz can be frozen for up to 8 days during shipment.", "C": "Vizz should not be frozen under any circumstances.", "D": "Vizz can be frozen after opening the vial."}}
{"id": "WdSjsLlmK1bI", "question_type": "multi_choice", "question": "A clinical trial protocol is being developed for Emrelis. Which statement about its contraindications should be included in the protocol documentation?", "options": {"A": "Emrelis is contraindicated in patients with cardiovascular disease.", "B": "Emrelis should not be administered to pediatric patients.", "C": "Emrelis is contraindicated in patients with a history of drug allergy.", "D": "There are no contraindications listed for Emrelis."}}
{"id": "Gyh0c0tUS0mH", "question_type": "open_ended_multi_choice", "question": "When considering the potential genotoxicity of Lynozyfic, which of the following is accurate?", "options": {"A": "Genotoxicity studies have demonstrated a significant risk.", "B": "Genotoxicity studies have demonstrated no risk.", "C": "No genotoxicity studies have been conducted with Lynozyfic.", "D": "Genotoxicity studies in animals have shown inconclusive results."}}
{"id": "p0QqGMtUiZe0", "question_type": "multi_choice", "question": "A 12-year-old patient weighing 32 kg presents with progressive neurological deterioration, gait ataxia, and hepatomegaly. Genetic testing confirms Niemann-Pick disease type C. The patient has a history of feeding difficulties and generalized hypotonia. She is currently taking N-acetyl-DL-leucine for another condition. Which drug regimen is most appropriate for treating her neurological manifestations of NPC?", "options": {"A": "AQNEURSA (levacetylleucine) 4 g/day, continue N-acetyl-DL-leucine", "B": "AQNEURSA (levacetylleucine) 4 g/day, discontinue N-acetyl-DL-leucine prior to initiation", "C": "Miglustat (Yargesa) 100 mg twice daily", "D": "Miglustat (Opfolda) in combination with Pombiliti"}}
{"id": "vPm6jB2bMXYD", "question_type": "open_ended", "question": "A 14-year-old patient presents with a history of recurrent bronchopulmonary infections, chronic sinusitis, and clubbing of fingers. The diagnosis of non-cystic fibrosis bronchiectasis is confirmed. The patient is scheduled to receive a new medication and is due for a live attenuated vaccine in two weeks. Which drug regimen is most appropriate for this patient, considering both disease indication and safety profile?", "options": {"A": "BRENSOCATIB once daily, with avoidance of live attenuated vaccines during treatment", "B": "SYMDEKO twice daily, with no restrictions regarding live vaccines", "C": "Insulin Aspart Protamine and Insulin Aspart Mix 70/30 twice daily, with no restrictions regarding live vaccines", "D": "BRENSOCATIB once daily, with concurrent administration of live attenuated vaccines"}}
{"id": "5Blz9NJsGMtZ", "question_type": "open_ended_multi_choice", "question": "When designing a clinical trial, a researcher needs to omit subjects who have contraindications to specific drugs. For which drug would there be no need to exclude patients due to contraindications?", "options": {"A": "Wayrilz", "B": "A drug with known contraindication in pregnancy", "C": "A drug contraindicated in patients with cardiac arrhythmia", "D": "A drug contraindicated in patients with hepatic insufficiency"}}
{"id": "jrdcZkhQOA3e", "question_type": "open_ended_multi_choice", "question": "A 32-year-old woman with Chagas cardiomyopathy and chronic heart failure is currently 10 weeks pregnant. Her ejection fraction is reduced, and she is seeking optimal pharmacologic management for her heart failure. Which of the following drugs should be avoided due to established fetal toxicity risks?", "options": {"A": "Diovan administered once daily", "B": "Amiodarone hydrochloride with weekly monitoring", "C": "Entresto administered twice daily", "D": "Low-dose Entresto with a planned drug scheduler"}}
{"id": "01qicqHruqug", "question_type": "multi_choice", "question": "A 60-year-old woman with recurrent low-grade serous ovarian carcinoma and a confirmed KRAS mutation is scheduled to begin AVMAPKI FAKZYNJA CO-PACK. She has a history of chronic gastroesophageal reflux disease and takes omeprazole (a proton pump inhibitor) daily. What is the best strategy to ensure effective cancer treatment?", "options": {"A": "Continue omeprazole and start AVMAPKI FAKZYNJA CO-PACK as planned", "B": "Discontinue omeprazole and avoid all gastric acid reducing agents during AVMAPKI FAKZYNJA CO-PACK therapy", "C": "Continue omeprazole but administer FAKZYNJA 2 hours before or after a locally acting antacid", "D": "Switch omeprazole to an H2 receptor antagonist and start AVMAPKI FAKZYNJA CO-PACK"}}
{"id": "7rO6UiU2inls", "question_type": "multi_choice", "question": "A female patient of reproductive potential is prescribed Romvimza. What is the most appropriate counseling regarding contraception?", "options": {"A": "No contraception is necessary during Romvimza therapy.", "B": "Contraception is only required if the patient is pregnant.", "C": "Effective contraception should be used during treatment and for 1 month after the last dose.", "D": "Contraception should be used only for the first week of therapy."}}
{"id": "mkoY6yZ8Kvjh", "question_type": "multi_choice", "question": "A 65-year-old man with a history of ulcerative colitis (currently in remission) and mild sensorineural hearing loss is diagnosed with endocrine exophthalmos. He is otherwise healthy and has well-controlled blood glucose. Considering his comorbidities, which statement best describes the use of TEPEZZA in his case?", "options": {"A": "TEPEZZA is appropriate, but hearing should be assessed before, during, and after treatment; monitor for IBD exacerbation.", "B": "TEPEZZA is contraindicated due to his age; alternative therapy is required.", "C": "TEPEZZA is contraindicated due to well-controlled blood glucose.", "D": "TEPEZZA is safe in patients with active IBD and hearing impairment without monitoring."}}
{"id": "EEw8xp7xBEdU", "question_type": "open_ended_multi_choice", "question": "A 32-year-old woman, currently in her second trimester of pregnancy, is experiencing new-onset supraventricular tachycardia. She has no underlying liver disease, bronchospastic disorders, or additional comorbidities. What is the most appropriate pharmacologic agent for acute rate control in this patient?", "options": {"A": "Pacerone", "B": "Propranolol", "C": "RAPIBLYK", "D": "Pacerone with a drug holiday"}}
{"id": "1T0HMgX28C7u", "question_type": "multi_choice", "question": "For a patient with recurrent or metastatic nasopharyngeal carcinoma receiving Penpulimab-kcqx in combination with gemcitabine and cisplatin, what is the recommended order of drug administration during each cycle?", "options": {"A": "Gemcitabine first, cisplatin second, Penpulimab-kcqx last", "B": "Cisplatin first, Penpulimab-kcqx second, gemcitabine last", "C": "Gemcitabine first, Penpulimab-kcqx second, cisplatin last", "D": "Penpulimab-kcqx first, gemcitabine second, cisplatin last"}}
{"id": "OEXsYDybWCUh", "question_type": "open_ended_multi_choice", "question": "What is the appropriate course of action for a patient receiving Hernexeos who experiences Grade 3 ALT and/or AST elevation in the absence of elevated total bilirubin?", "options": {"A": "Continue Hernexeos at the same dose", "B": "Interrupt Hernexeos until recovery, then resume at reduced dose", "C": "Permanently discontinue Hernexeos", "D": "Increase Hernexeos dose"}}
{"id": "Mjjd7umBlj4f", "question_type": "open_ended_multi_choice", "question": "If a patient on Qfitlia develops acute gallbladder disease, what is the advised management approach?", "options": {"A": "Consider interruption or discontinuation of Qfitlia", "B": "Increase the Qfitlia dose", "C": "Add a statin", "D": "Continue Qfitlia without changes"}}
{"id": "y8nfSNEFhe22", "question_type": "open_ended_multi_choice", "question": "A 72-year-old male presents with recurrent, metastatic non-keratinizing nasopharyngeal carcinoma, moderate renal dysfunction (creatinine clearance 35 mL/min), and a prior history of GI bleeding. Based on these comorbidities, which drug should not be used, and which is the best choice for his cancer therapy?", "options": {"A": "Capecitabine 500 mg twice daily, with dose reduction for renal impairment", "B": "Celecoxib 200 mg twice daily for pain management", "C": "Penpulimab-kcqx in combination with carboplatin and gemcitabine, administered every 3 weeks", "D": "Capecitabine 500 mg twice daily, standard dosing"}}
{"id": "kgYMxnEhmkMS", "question_type": "multi_choice", "question": "A 7-year-old boy with severe hemophilia A and a history of factor VIII inhibitors requires routine prophylaxis to prevent bleeding episodes. He has normal hepatic and gallbladder function. Which of the following is the most appropriate prophylactic therapy for this patient?", "options": {"A": "Hemlibra, administered subcutaneously once weekly", "B": "Qfitlia, administered according to antithrombin-based dosing regimen", "C": "Qfitlia, administered at a fixed dose of 80 mg once monthly", "D": "Qfitlia, administered according to antithrombin-based dosing regimen with a planned drug holiday every 3 months"}}
{"id": "xf0HtGsh9hdS", "question_type": "open_ended_multi_choice", "question": "A 52-year-old male with chronic graft-versus-host disease (cGVHD) presents with recurrent infections, elevated hepatic transaminase, and thickened skin. He has failed two prior lines of systemic therapy. He is not currently taking any immunosuppressive drugs, has normal hepatic function, and is not planning to conceive. Which drug is the most appropriate for his treatment, considering efficacy and safety for his condition?", "options": {"A": "PredniSONE, 5 mg orally once daily", "B": "Niktimvo, intravenous infusion every 2 weeks", "C": "PONVORY, 20 mg orally once daily", "D": "PredniSONE, 20 mg orally twice daily"}}
{"id": "psjDHtA5JPJt", "question_type": "open_ended_multi_choice", "question": "What is the advised approach for managing a patient who is prescribed Romvimza and concurrently requires therapy with an Organic Cation Transporter 2 (OCT2) substrate?", "options": {"A": "Refer to the prescribing information of the OCT2 substrate for dose modifications.", "B": "Increase the dose of Romvimza.", "C": "Administer Romvimza and the OCT2 substrate at the same time.", "D": "Discontinue the OCT2 substrate."}}
{"id": "XbkKkywZW50i", "question_type": "open_ended_multi_choice", "question": "Which statement best describes the safety profile of Enflonsia in infants at increased risk of severe RSV disease compared to palivizumab?", "options": {"A": "The safety profile of Enflonsia was similar to palivizumab and consistent with its profile in other infant populations.", "B": "Enflonsia showed significantly higher rates of severe adverse events than palivizumab.", "C": "Enflonsia was associated with more frequent gastrointestinal side effects than palivizumab.", "D": "Palivizumab had a better safety profile than Enflonsia in all measured outcomes."}}
{"id": "wSTwaeGC0A2w", "question_type": "open_ended_multi_choice", "question": "A patient on Ibtrozi presents with newly developed shortness of breath and coughing. What should be the first step in managing this situation?", "options": {"A": "Continue Ibtrozi and monitor symptoms", "B": "Immediately withhold Ibtrozi and evaluate for interstitial lung disease/pneumonitis", "C": "Reduce the dose of Ibtrozi without withholding", "D": "Start corticosteroids and continue Ibtrozi"}}
{"id": "s24ZkOd05Ink", "question_type": "multi_choice", "question": "If a patient experiences Grade 3 cytokine release syndrome (CRS) during Lynozyfic therapy, what is the recommended action regarding the next dose?", "options": {"A": "Resume Lynozyfic at the same dose after CRS resolves", "B": "Resume Lynozyfic at a reduced dose (2.5 mg if last dose was 5 mg; restart step-up dosing from 5 mg if last dose was 25 mg)", "C": "Permanently discontinue Lynozyfic", "D": "Increase the infusion rate for the next dose"}}
{"id": "7VSETxaSeqxQ", "question_type": "multi_choice", "question": "What is the recommended action if a patient experiences Grade 4 infusion-related reaction (IRR) during Lynozyfic administration?", "options": {"A": "Resume Lynozyfic at a reduced dose after symptoms resolve", "B": "Permanently discontinue Lynozyfic and treat symptoms", "C": "Continue Lynozyfic at the same dose", "D": "Switch to oral Lynozyfic"}}
{"id": "NJRRfA0bV7DO", "question_type": "open_ended_multi_choice", "question": "A woman aged 32, currently breastfeeding and with a history of mild renal impairment, is diagnosed with severe alopecia areata causing patchy hair loss. She has no CYP2C9 inhibitor use and is not a CYP2C9 poor metabolizer. Which drug treatment is most appropriate for her?", "options": {"A": "Minoxidil topical solution", "B": "Imiquimod cream", "C": "Leqselvi (deuruxolitinib phosphate)", "D": "No drug is appropriate from the options provided"}}
{"id": "O5pIJn12amQD", "question_type": "open_ended_multi_choice", "question": "When preparing a regulatory submission for Qfitlia, which contraindications must be included in the summary?", "options": {"A": "There are no contraindications for Qfitlia.", "B": "Qfitlia is contraindicated in patients with renal failure.", "C": "Qfitlia is contraindicated in patients with a history of drug allergy.", "D": "Qfitlia is contraindicated in elderly patients."}}
{"id": "FwLlh2o70TiX", "question_type": "open_ended_multi_choice", "question": "In evaluating Hernexeos, which contraindication details are important for a biomedical researcher to recognize?", "options": {"A": "There are no contraindications for Hernexeos.", "B": "Hernexeos is contraindicated in patients with a history of hypersensitivity reactions.", "C": "Hernexeos should not be administered to patients with cardiovascular disease.", "D": "Hernexeos is contraindicated in patients taking anticoagulants."}}
{"id": "1KZyu4AXWobD", "question_type": "open_ended_multi_choice", "question": "A woman, aged 35, presents with inoperable adrenocortical carcinoma and is pregnant. She does not have hepatic or renal dysfunction and is not taking additional drugs. What is the most suitable advice regarding systemic therapy for her malignancy?", "options": {"A": "Initiate Lysodren therapy immediately", "B": "Use Lumisight for systemic treatment", "C": "Avoid Lysodren due to risk of fetal harm", "D": "Start hormonal contraceptives before Lysodren"}}
{"id": "GOomDXlmlLm0", "question_type": "open_ended_multi_choice", "question": "For a 68-year-old man with moderate to severe chronic hand eczema, a previous basal cell carcinoma, and inadequate response to topical corticosteroids (without concurrent immunosuppressants), what is the best drug therapy strategy to pursue?", "options": {"A": "Delgocitinib topical therapy with periodic skin examinations", "B": "Delgocitinib without any skin cancer monitoring", "C": "Combination of Delgocitinib and another JAK inhibitor", "D": "Topical corticosteroids despite prior inadequate response"}}
{"id": "yKR4DSZNom9V", "question_type": "open_ended_multi_choice", "question": "Has Enflonsia undergone any studies to assess its mutagenic potential, and if so, what is the current status of these investigations?", "options": {"A": "No mutagenesis studies have been performed with Enflonsia.", "B": "Mutagenesis studies have shown positive results.", "C": "Mutagenesis studies have shown negative results.", "D": "Mutagenesis studies are ongoing."}}
{"id": "8vHTVIGLT5WE", "question_type": "open_ended_multi_choice", "question": "A 72-year-old man has recently been diagnosed with recurrent, metastatic non-keratinizing nasopharyngeal carcinoma. He also has moderate renal impairment (creatinine clearance of 35 mL/min) and a history of gastrointestinal bleeding. Considering his comorbid conditions, which medication should be avoided, and which would be most appropriate for treating his cancer?", "options": {"A": "Capecitabine 500 mg twice daily, with dose reduction for renal impairment", "B": "Celecoxib 200 mg twice daily for pain management", "C": "Penpulimab-kcqx in combination with carboplatin and gemcitabine, administered every 3 weeks", "D": "Capecitabine 500 mg twice daily, standard dosing"}}
{"id": "Ay6TadyOk0D6", "question_type": "multi_choice", "question": "A 32-year-old woman with neurofibromatosis type 1 and symptomatic plexiform neurofibromas is currently pregnant. She is seeking treatment options for her neurofibromas. Which of the following drugs should be avoided due to the risk of fetal harm?", "options": {"A": "Celecoxib", "B": "PNV-DHA", "C": "Gomekli", "D": "Both Celecoxib and Gomekli"}}
{"id": "rxk7kovJPeZe", "question_type": "multi_choice", "question": "A clinical trial protocol is being developed for Emrelis. Which statement about its contraindications should be included in the protocol documentation?", "options": {"A": "There are no contraindications listed for Emrelis.", "B": "Emrelis should not be administered to pediatric patients.", "C": "Emrelis is contraindicated in patients with cardiovascular disease.", "D": "Emrelis is contraindicated in patients with a history of drug allergy."}}
{"id": "PpHUOhWLhBhM", "question_type": "multi_choice", "question": "A 7-year-old boy is newly diagnosed with myelodysplastic syndrome (MDS) and is scheduled for allogeneic hematopoietic stem cell transplantation. He has no history of seizures, is not taking any CYP2C19 or CYP3A4 substrate medications, and is otherwise healthy. Which drug regimen is most appropriate as a preparative regimen for his transplant, considering age-specific safety and efficacy?", "options": {"A": "Lenalidomide, administered orally once daily.", "B": "INQOVI (cedazuridine and decitabine), administered orally in 28-day cycles.", "C": "Busulfan, administered intravenously for two days.", "D": "TREOSULFAN (GRAFAPEX) in combination with fludarabine, administered intravenously for three consecutive days."}}
{"id": "bvFO8reKBaX0", "question_type": "open_ended_multi_choice", "question": "For a 60-year-old man with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis and chronic hepatitis currently treated with ribavirin, which immunosuppressive agent should not be used because of the danger of severe pancytopenia and myelotoxicity related to drug interactions?", "options": {"A": "IMAAVY, 15 mg/kg intravenous infusion every 2 weeks", "B": "Azathioprine, 100 mg daily oral administration", "C": "DuoDote, single dose for acute management", "D": "IMAAVY, 10 mg/kg intravenous infusion every 4 weeks"}}
{"id": "gZxfvBUk7okw", "question_type": "multi_choice", "question": "A 48-year-old woman with locally advanced breast cancer is experiencing severe postoperative pain following tumor resection. She has a history of peptic ulcer disease and mild renal impairment (eGFR 55 mL/min). She is not pregnant and weighs 65 kg. Which analgesic regimen is safest and most effective for her acute pain management over the next several days?", "options": {"A": "Ketorolac tromethamine for up to 5 days, with dose adjustment for renal impairment", "B": "Ketorolac tromethamine for chronic pain management beyond 5 days", "C": "Itovebi (inavolisib) in combination with palbociclib and fulvestrant for pain control", "D": "Morphine sulfate titrated to pain, with careful monitoring for respiratory depression"}}
{"id": "zy7rUupyrvql", "question_type": "open_ended_multi_choice", "question": "For a 7-year-old male patient with congenital hemophilia A (factor VIII deficiency), no prior history of factor VIII inhibitors, and no other medical issues or medications, what is the most appropriate drug to use for routine prophylaxis against bleeding?", "options": {"A": "Alhemo administered as routine prophylaxis", "B": "Hemlibra administered as routine prophylaxis", "C": "Alhemo administered only during breakthrough bleeds", "D": "No prophylactic treatment is indicated for this patient"}}
{"id": "926tWkiLoDKe", "question_type": "multi_choice", "question": "A 42-year-old woman with recurrent low-grade serous ovarian carcinoma and confirmed KRAS mutation presents for treatment. She has previously received systemic therapy and is currently taking warfarin for atrial fibrillation. Which drug regimen is most appropriate for her cancer management?", "options": {"A": "AVMAPKI FAKZYNJA CO-PACK after switching to a non-warfarin anticoagulant", "B": "AVMAPKI FAKZYNJA CO-PACK with warfarin co-administration", "C": "AVMAPKI FAKZYNJA CO-PACK (avutometinib and defactinib)", "D": "AVMAPKI FAKZYNJA CO-PACK with dose reduction due to warfarin"}}
{"id": "aQhbPAp08QX7", "question_type": "open_ended_multi_choice", "question": "A woman aged 28, diagnosed with Niemann-Pick disease type C and experiencing dystonia and compulsive behaviors, is 10 weeks into her pregnancy. She seeks guidance on drug therapy for her neurological issues. What is the best recommendation concerning pharmacologic treatment for her condition at this stage?", "options": {"A": "Initiate arimoclomol in combination with miglustat", "B": "Start miglustat monotherapy", "C": "Avoid both arimoclomol and miglustat due to potential fetal harm", "D": "Begin lithium carbonate therapy"}}
{"id": "6zJ4xPeD2WIw", "question_type": "multi_choice", "question": "A 28-year-old woman is admitted for labor and requests pain relief. She is otherwise healthy and is not taking any medications. She wishes to breastfeed her newborn after delivery. Which drug regimen is most appropriate for acute pain management during labor, considering safety for both mother and infant?", "options": {"A": "Suzetrigine administered every 6 hours", "B": "Acetaminophen every 4 hours", "C": "Ropivacaine Hydrochloride via epidural infusion", "D": "Childrens Pain Relief every 6 hours"}}
{"id": "TPg0iBMUFWZg", "question_type": "open_ended_multi_choice", "question": "A 39-year-old woman with advanced breast cancer (HR-positive, HER2-negative, PIK3CA-mutated) is currently pregnant and seeking advice on targeted therapy options. She is otherwise healthy and has normal renal and hepatic function. Which of the following is the most appropriate recommendation regarding drug therapy for her breast cancer at this time?", "options": {"A": "Initiate inavolisib in combination with palbociclib and fulvestrant immediately", "B": "Start carboplatin-based chemotherapy", "C": "Delay initiation of inavolisib until after pregnancy due to embryo-fetal toxicity risk", "D": "Begin esketamine therapy for breast cancer"}}
{"id": "1hxgESM6oj9d", "question_type": "multi_choice", "question": "If a patient on Vanrafia develops aminotransferase elevations accompanied by bilirubin >2x ULN or clinical symptoms of hepatotoxicity, what is the recommended action?", "options": {"A": "Discontinue Vanrafia", "B": "Reduce the dose of Vanrafia", "C": "Continue Vanrafia with close monitoring", "D": "Switch to another ERA"}}
{"id": "xG6G95mZjTPm", "question_type": "open_ended_multi_choice", "question": "When assembling a list of drugs without any contraindications, is Vizz a suitable candidate for inclusion?", "options": {"A": "Yes, because Vizz has no contraindications listed", "B": "No, because Vizz is contraindicated in certain populations", "C": "No, because Vizz is contraindicated in patients with renal impairment", "D": "No, because Vizz is contraindicated in patients with allergies"}}
{"id": "wneTuRRgwDhx", "question_type": "open_ended_multi_choice", "question": "A 62-year-old male with unresectable esophageal squamous cell carcinoma presents with chest pain, cough, and lymphadenopathy. His tumor expresses PD-L1 (CPS = 2). He has a history of mild hepatic impairment (AST 1.7 × ULN, ALT 1.6 × ULN, alkaline phosphatase 2.7 × ULN). He is scheduled to begin first-line systemic therapy. Which of the following is the most appropriate initial drug regimen for this patient?", "options": {"A": "Tevimbra in combination with platinum-containing chemotherapy, administered every 3 weeks", "B": "Docetaxel anhydrous monotherapy, administered every 3 weeks", "C": "Keytruda QLEX in combination with platinum- and fluoropyrimidine-based chemotherapy, administered every 3 weeks", "D": "Docetaxel anhydrous in combination with cisplatin and fluorouracil, administered every 3 weeks"}}
{"id": "czFafOXV4ugJ", "question_type": "open_ended_multi_choice", "question": "A 72-year-old man with low-risk myelodysplastic syndromes and transfusion-dependent anemia (requiring 5 units of red blood cells over 8 weeks) has failed erythropoiesis-stimulating agent therapy. He is not taking any drugs metabolized by cytidine deaminase and has normal renal function. He is scheduled for outpatient therapy and prefers to avoid oral medications. Which treatment option is most suitable for his condition?", "options": {"A": "Decitabine intravenous infusion daily for 5 days every 4 weeks", "B": "INQOVI (oral decitabine + cedazuridine) once daily for 5 days every 28-day cycle", "C": "RYTELO intravenous infusion every 4 weeks with premedication for infusion reactions", "D": "Decitabine intravenous infusion with a drug scheduler alternating every other month"}}
{"id": "SIP4PCeC0rwS", "question_type": "open_ended_multi_choice", "question": "A 65-year-old pregnant woman has been diagnosed with locally advanced cutaneous squamous cell carcinoma and is being evaluated for systemic treatment. She is concerned about fetal safety and wants to avoid exposing the fetus to risk. What is the most appropriate advice regarding systemic drug therapy in her case?", "options": {"A": "Start ERBITUX, as it is safe in pregnancy", "B": "Begin TECENTRIQ, as immune checkpoint inhibitors are preferred in pregnancy", "C": "Initiate UNLOXCYT, as it is the only drug indicated for CSCC", "D": "Defer systemic therapy due to contraindication of all options in pregnancy"}}
{"id": "GRpBXCiUj0gL", "question_type": "open_ended_multi_choice", "question": "A 28-year-old woman with classic congenital adrenal hyperplasia is receiving glucocorticoid replacement and is planning to become pregnant. She asks about starting crinecerfont (CRENESSITY) to help control her androgen levels. What is the most appropriate recommendation regarding crinecerfont use in this scenario?", "options": {"A": "Crinecerfont is contraindicated in all pregnant women.", "B": "Crinecerfont may be considered if the benefits outweigh the risks, but exposure should be reported and monitored.", "C": "Crinecerfont is safe and recommended for all women planning pregnancy.", "D": "Crinecerfont should be discontinued immediately upon conception."}}
{"id": "Z2dwH9dDxDvw", "question_type": "open_ended_multi_choice", "question": "For a 7-year-old boy with myelodysplastic syndrome scheduled for allogeneic hematopoietic stem cell transplantation, who has no seizure history and is not receiving any CYP2C19 or CYP3A4 substrate medications, which regimen is most appropriate to use as part of his pre-transplant conditioning?", "options": {"A": "Lenalidomide, oral daily dosing", "B": "Reblozyl, subcutaneous injection every 3 weeks", "C": "Treosulfan (GRAFAPEX) in combination with fludarabine, with supportive care for myelosuppression", "D": "Lenalidomide, with a planned drug scheduler to minimize cytopenias"}}
{"id": "33fVXYgmgKQx", "question_type": "open_ended_multi_choice", "question": "Which of the following is a correct statement regarding the hospitalization requirements for patients receiving Lynozyfic?", "options": {"A": "Hospitalization is required for 24 hours after the first and second step-up doses", "B": "Hospitalization is required for every dose of Lynozyfic", "C": "No hospitalization is required for any dose", "D": "Hospitalization is required only after the first full treatment dose"}}
{"id": "vmeeTP5LJGKA", "question_type": "multi_choice", "question": "A 45-year-old woman is newly diagnosed with acute erythroleukemia and presents with anemia, thrombocytopenia, and splenomegaly. She has no history of cardiac disease, is not pregnant, and has normal hepatic and renal function. She is scheduled to begin induction therapy. Which drug regimen is most appropriate for remission induction in her case?", "options": {"A": "TaperDex 12-day administered orally for 12 days as supportive therapy", "B": "REVUMENIB administered orally twice daily for 28-day cycles", "C": "Daunorubicin Hydrochloride administered intravenously in combination with other approved anticancer drugs", "D": "TaperDex 12-day combined with REVUMENIB for induction therapy"}}
{"id": "W0k49v2PMM9m", "question_type": "open_ended_multi_choice", "question": "A boy aged 10 years, diagnosed with congenital hemophilia A and no history of hepatic or gallbladder problems, requires regular prophylaxis to avoid bleeding episodes. Considering his age and disease, which drug should be selected?", "options": {"A": "Hemlibra administered subcutaneously once weekly", "B": "Qfitlia administered subcutaneously once monthly", "C": "Qfitlia administered subcutaneously once weekly", "D": "Fitusiran administered intravenously every two weeks"}}
{"id": "nmheRbQB4Plo", "question_type": "multi_choice", "question": "Which statement is true regarding drug-drug interactions with Qfitlia?", "options": {"A": "Qfitlia is a strong inhibitor of CYP3A4", "B": "Qfitlia is likely to interact with drug transporters at clinical concentrations", "C": "CYP- or transporter-mediated interactions are unlikely at clinically relevant concentrations", "D": "Qfitlia induces CYP2D6"}}
{"id": "XPwvpNNav4St", "question_type": "open_ended_multi_choice", "question": "What have studies indicated about the safety of Tryptyr in older adults relative to younger individuals?", "options": {"A": "Clinically relevant differences in safety have been observed between elderly and younger patients.", "B": "Tryptyr is associated with increased adverse effects in elderly patients.", "C": "No clinically relevant differences in safety have been observed between elderly and younger patients.", "D": "Tryptyr is contraindicated in elderly patients."}}
{"id": "7tBZz6YmMFdN", "question_type": "multi_choice", "question": "A 15-year-old adolescent presents to the emergency department with an acute attack of hereditary angioedema. The patient has no history of hepatic or renal impairment and is not currently taking any medications. Which drug is the most appropriate for treating this acute attack, considering age-specific approval and safety?", "options": {"A": "Icatibant acetate", "B": "Sajazir", "C": "Icatibant", "D": "Ekterly"}}
{"id": "ADXjd73gn6Un", "question_type": "multi_choice", "question": "A 15-year-old adolescent girl with hemophilia B (congenital factor IX deficiency) presents with menometrorrhagia and prolonged bleeding after dental extraction. She is currently pregnant and requires routine prophylaxis to prevent bleeding episodes. Which treatment option is most appropriate for her condition?", "options": {"A": "REBINYN, administered weekly for prophylaxis", "B": "HYMPAVZI, administered weekly for prophylaxis", "C": "SEVENFACT, administered weekly for prophylaxis", "D": "HYMPAVZI, administered only during bleeding episodes"}}
{"id": "vbkiW73leZdr", "question_type": "multi_choice", "question": "A 60-year-old man with a history of inoperable adrenocortical carcinoma and mild hepatic impairment is being considered for Lysodren therapy. He is also taking warfarin for atrial fibrillation. What is the most appropriate next step regarding his cancer treatment?", "options": {"A": "Start Lysodren, but monitor warfarin INR closely and adjust warfarin dose as needed", "B": "Avoid Lysodren due to interaction with warfarin", "C": "Use Lumisight for systemic therapy", "D": "Start Lysodren without any adjustments"}}
{"id": "b3p4KFAqP1pg", "question_type": "open_ended_multi_choice", "question": "When reviewing the safety profile of Andembry, which statement accurately reflects its contraindication status?", "options": {"A": "Andembry is contraindicated in patients with autoimmune disorders.", "B": "Andembry has no contraindications listed in its prescribing information.", "C": "Andembry is contraindicated in elderly patients.", "D": "Andembry should not be used in patients with a history of thrombosis."}}
{"id": "8vXDl7augpGH", "question_type": "open_ended", "question": "Which statement best describes the safety and efficacy of Wayrilz in geriatric patients aged 65 years and older based on the LUNA-3 study?", "options": {"A": "Wayrilz is less effective in patients aged 65 years and older.", "B": "Wayrilz has increased adverse effects in patients aged 65 years and older.", "C": "No overall differences in safety and efficacy were observed between patients aged 65 years and older and younger adult patients.", "D": "Wayrilz should not be used in patients aged 65 years and older."}}
{"id": "oYmrLgg6z6T9", "question_type": "open_ended", "question": "A 59-year-old man with metastatic ROS1-positive non-small cell lung carcinoma is being considered for taletrectinib (IBTROZI) therapy. His current medications include amiodarone for arrhythmia and omeprazole for gastroesophageal reflux disease. What is the most appropriate next step regarding his cancer treatment?", "options": {"A": "Start taletrectinib at the recommended dose without adjusting his current medications.", "B": "Begin taletrectinib but continue omeprazole and amiodarone with close monitoring.", "C": "Avoid taletrectinib unless omeprazole and amiodarone can be discontinued or substituted.", "D": "Reduce the dose of taletrectinib to compensate for drug interactions."}}
{"id": "Os97Yw0lHjnG", "question_type": "open_ended", "question": "A 42-year-old woman with recurrent low-grade serous ovarian carcinoma and confirmed KRAS mutation has previously received systemic therapy. She is currently taking warfarin for atrial fibrillation and is not pregnant or breastfeeding. Which treatment regimen is most appropriate for her cancer management?", "options": {"A": "Initiate AVMAPKI FAKZYNJA CO-PACK while continuing warfarin therapy.", "B": "Initiate AVMAPKI FAKZYNJA CO-PACK and switch to a non-warfarin anticoagulant.", "C": "Initiate AVMAPKI FAKZYNJA CO-PACK and discontinue anticoagulation entirely.", "D": "Withhold AVMAPKI FAKZYNJA CO-PACK due to prior systemic therapy."}}
{"id": "pPA1Mo8kl29f", "question_type": "open_ended_multi_choice", "question": "In the event of an asymptomatic absolute decrease in left ventricular ejection fraction (LVEF) of 10% or greater from baseline and below the lower limit of normal, what is the recommended management for Gomekli?", "options": {"A": "Continue Gomekli at current dose", "B": "Withhold Gomekli until ≤Grade 1, then resume at reduced dose", "C": "Permanently discontinue Gomekli", "D": "Increase Gomekli dose"}}
{"id": "qpkEwD9nDGLw", "question_type": "multi_choice", "question": "A 52-year-old woman presents with progressive difficulty focusing on near objects and is diagnosed with presbyopia. She has a history of iritis and is seeking pharmacological treatment to improve her near vision. Which of the following drugs is most appropriate for her condition?", "options": {"A": "VIZZ administered as topical ocular drops once daily", "B": "Mirvaso topical gel applied once daily", "C": "Oraverse intraoral injection after dental procedures", "D": "VIZZ administered as topical ocular drops twice daily"}}
{"id": "vSPEnJnaE9GM", "question_type": "open_ended_multi_choice", "question": "What advice should be given to women who are breastfeeding and are prescribed Modeyso?", "options": {"A": "Do not breastfeed during treatment and for 1 week after the last dose.", "B": "Continue breastfeeding as usual.", "C": "Breastfeed only immediately before taking Modeyso.", "D": "Stop breastfeeding permanently."}}
{"id": "MjFWBx4ajpu8", "question_type": "open_ended_multi_choice", "question": "A 34-year-old woman presents with severe alopecia areata. She is currently breastfeeding her 2-month-old infant and has no history of renal or hepatic impairment. She is not taking any other medications. Which of the following is the most appropriate drug treatment for her condition?", "options": {"A": "LEQSELVI administered orally once daily", "B": "Hydroxychloroquine sulfate administered orally once daily", "C": "Triamcinolone acetonide nasal spray once daily", "D": "LEQSELVI administered orally every other day with a drug holiday every 2 weeks"}}
{"id": "HjvGfFonYPon", "question_type": "open_ended_multi_choice", "question": "Why should the preparative regimen with Grafapex not be started if the stem cell donor is unavailable?", "options": {"A": "Because profound myelosuppression with pancytopenia will occur in all patients", "B": "Because Grafapex requires donor stem cells for activation", "C": "Because the drug is ineffective without donor cells", "D": "Because of increased risk of renal toxicity"}}
{"id": "RRYcjEZoJPBD", "question_type": "open_ended_multi_choice", "question": "A 60-year-old man with pulmonary arterial hypertension is being considered for Winrevair therapy. His medical history is significant for recurrent gastrointestinal bleeding and he is currently on a prostacyclin infusion. His platelet count is 45,000/mm³. What is the most appropriate next step regarding Winrevair therapy?", "options": {"A": "Initiate Winrevair at standard dosing and monitor for bleeding", "B": "Withhold Winrevair due to increased risk of serious bleeding and thrombocytopenia", "C": "Switch to epinephrine infusion for PAH management", "D": "Start vasopressin as an alternative to Winrevair"}}
{"id": "zTLqaycXmHFk", "question_type": "open_ended_multi_choice", "question": "A 7-year-old boy with molluscum contagiosum and a history of atopic dermatitis (eczema) presents for treatment. His mother reports that his skin is currently inflamed and has areas of excoriation. Which topical therapy is most appropriate for his condition?", "options": {"A": "Adapalene applied to all lesions", "B": "Zelsuvmi applied to intact skin lesions only, avoiding areas of eczema or damaged skin", "C": "Adapalene applied only to areas of eczema", "D": "No topical therapy should be used due to his age"}}
{"id": "uTGflqn364YK", "question_type": "multi_choice", "question": "In the AK105-304 trial, what was the major efficacy outcome measure used to evaluate penpulimab-kcqx in combination with platinum and gemcitabine?", "options": {"A": "Quality of life improvement", "B": "Objective response rate (ORR) by investigator assessment", "C": "BICR-assessed progression-free survival (PFS) according to RECIST v1.1", "D": "Reduction in adverse events"}}
{"id": "oBEd7DT7sIvx", "question_type": "open_ended", "question": "A 10-year-old child with a benign peripheral nerve sheath tumor and hypertension is being considered for antihypertensive therapy. The child has a glomerular filtration rate (GFR) of 25 mL/min/1.73 m². Which of the following is the most appropriate next step regarding Losartan Potassium therapy?", "options": {"A": "Initiate Losartan Potassium at standard pediatric dosing", "B": "Start Losartan Potassium at a reduced dose due to renal impairment", "C": "Avoid Losartan Potassium due to low GFR and consider alternative antihypertensive therapy", "D": "Increase fluid intake and begin Losartan Potassium"}}
{"id": "nzF6SbBz6Z2q", "question_type": "open_ended", "question": "Which of the following statements best describes the evaluation of carcinogenic potential for the drug Lynozyfic?", "options": {"A": "Carcinogenicity studies have been completed and showed no risk.", "B": "Carcinogenicity studies are ongoing for Lynozyfic.", "C": "No carcinogenicity studies have been conducted with Lynozyfic.", "D": "Carcinogenicity studies in humans have shown increased risk."}}
{"id": "uq4UgT5wivnX", "question_type": "open_ended", "question": "Which of the following statements best describes the risk of antibacterial resistance associated with Blujepa?", "options": {"A": "Skipping doses or not completing therapy may increase resistance", "B": "Resistance is not a concern with Blujepa", "C": "Resistance only occurs with viral infections", "D": "Resistance is prevented by taking Blujepa with antacids"}}
{"id": "cgcOBwtdDPqx", "question_type": "open_ended_multi_choice", "question": "A 9-year-old with a metastatic solid tumor is identified as having a neurotrophic tyrosine receptor kinase (NTRK) gene fusion via FDA-approved testing. The patient exhibits mild renal impairment (eGFR 55 mL/min) and has no cardiac disease history. Considering these clinical factors, which therapy is best suited for this patient?", "options": {"A": "Erlotinib, 85 mg/m²/day orally", "B": "Lazcluze (lazertinib + amivantamab), standard pediatric dosing", "C": "Rozlytrek, weight-based dosing once daily", "D": "Erlotinib in combination with gemcitabine"}}
{"id": "IgVSYqO2Wafd", "question_type": "open_ended_multi_choice", "question": "A patient with previously treated, unresectable metastatic biliary tract cancer is confirmed to have HER2-positive (IHC 3+) status by FDA-approved testing. The patient has a history of reduced left ventricular ejection fraction (LVEF 45%) and is currently receiving multiple medications that are strong CYP3A inhibitors. Which treatment option is most suitable for this patient?", "options": {"A": "Zanidatamab-hrii (ZIIHERA) every three weeks, standard dose", "B": "Futibatinib (LYTGOBI) once daily, standard dose", "C": "Pemigatinib (PEMAZYRE) once daily, standard dose", "D": "Zanidatamab-hrii (ZIIHERA) every three weeks, with cardiac monitoring and dose reduction"}}
{"id": "JPpHo4NP5CvE", "question_type": "open_ended_multi_choice", "question": "A 68-year-old male patient with hypertension and chronic kidney disease (eGFR 20 mL/min) has persistently elevated mean arterial pressure despite standard antihypertensive treatment. As you consider an additional medication, which option would be least suitable for him?", "options": {"A": "TRYVIO", "B": "Candesartan cilexetil", "C": "Latanoprost", "D": "Thiazide diuretic"}}
{"id": "dlUjYmmSktTU", "question_type": "multi_choice", "question": "Which of the following is a recommended action if a patient receiving Hernexeos develops transaminase elevations during therapy?", "options": {"A": "Continue therapy without changes", "B": "Switch to a non-HER2 targeted therapy", "C": "Interrupt, reduce the dose, or permanently discontinue Hernexeos", "D": "Administer prophylactic antibiotics"}}
{"id": "IBZRctvRcMzB", "question_type": "open_ended_multi_choice", "question": "A 55-year-old male with symptomatic tenosynovial giant cell tumor (TGCT) and a creatinine clearance of 40 mL/min is being considered for systemic treatment. He has no liver disease, is not on any CYP3A substrates, and can adhere to dietary restrictions. What is the most appropriate therapeutic regimen for him?", "options": {"A": "Romvimza (vimseltinib) at standard dosing without renal adjustment", "B": "Turalio (pexidartinib hydrochloride) with dose reduction for renal impairment and administration with a low-fat meal", "C": "Turalio (pexidartinib hydrochloride) at standard dosing with a high-fat meal", "D": "Romvimza (vimseltinib) with dose reduction for renal impairment"}}
{"id": "Sz1vStHYeX1W", "question_type": "multi_choice", "question": "A male patient with isolated growth hormone deficiency type IB and a history of deep vein thrombosis (DVT) is being evaluated for androgen replacement therapy to address reduced circulating growth hormone and delayed skeletal maturation. Which statement best reflects the suitability of testosterone (Testopel) pellets for this patient?", "options": {"A": "Testosterone (Testopel) pellets are appropriate if DVT is well-managed.", "B": "Testosterone (Testopel) pellets should be discontinued if DVT symptoms recur.", "C": "Testosterone (Testopel) pellets are contraindicated due to increased risk of thromboembolic events.", "D": "Testosterone (Testopel) pellets are safe for patients with a history of DVT if administered at low doses."}}
{"id": "P1mIB5VDTIVd", "question_type": "multi_choice", "question": "A 77-year-old male with a diagnosis of wild-type transthyretin-mediated amyloidosis cardiomyopathy (ATTR-CM) presents for management. He has a history of hypertension controlled with amlodipine and is not taking any CYP2C9 substrate medications. He is otherwise healthy, with no hepatic impairment or respiratory disease. Which drug is most appropriate for reducing cardiovascular death and hospitalization in this patient, considering his age and disease subtype?", "options": {"A": "Acoramidis Hydrochloride", "B": "Mavacamten", "C": "Metoprolol Tartrate", "D": "Verapamil"}}
{"id": "yiRsBB95REeM", "question_type": "multi_choice", "question": "A 42-year-old woman with a history of inoperable, functional adrenocortical carcinoma is being considered for systemic therapy. She is not pregnant, has normal hepatic and renal function, and is not taking any hormonal contraceptives or warfarin. Which drug is most appropriate for her treatment, considering her diagnosis and current medications?", "options": {"A": "Lysodren", "B": "Lumisight", "C": "Spironolactone", "D": "Blue dye for sentinel lymph node mapping"}}
{"id": "FcDC6p2Zcpbc", "question_type": "open_ended_multi_choice", "question": "What should be done if a patient taking Ibtrozi experiences a QTc interval exceeding 500 milliseconds or an increase of more than 60 milliseconds from their baseline?", "options": {"A": "Continue Ibtrozi at the same dose", "B": "Reduce the dose of Ibtrozi", "C": "Withhold Ibtrozi", "D": "Switch to a CYP3A inducer"}}
{"id": "f2inCAwsV7pU", "question_type": "open_ended_multi_choice", "question": "A 54-year-old man with metastatic ROS1-positive non-small cell lung cancer is being evaluated for taletrectinib therapy. He has a history of atrial fibrillation and is currently on amiodarone, which can prolong the QTc interval. What is the most appropriate management regarding taletrectinib in this patient?", "options": {"A": "Proceed with taletrectinib 600 mg orally once daily and monitor ECG regularly.", "B": "Withhold taletrectinib due to risk of QTc interval prolongation from drug interaction.", "C": "Start taletrectinib at a reduced dose to minimize cardiac risk.", "D": "Taletrectinib is safe to use with amiodarone if electrolytes are monitored."}}
{"id": "r1oxnCvZoDpq", "question_type": "open_ended_multi_choice", "question": "When considering prescribing Lynozyfic to a patient who has multiple comorbid conditions, which contraindications should the clinician take into account?", "options": {"A": "Lynozyfic is contraindicated in patients with a history of anaphylaxis.", "B": "Lynozyfic should not be used in patients with severe renal impairment.", "C": "There are no contraindications listed for Lynozyfic.", "D": "Lynozyfic is contraindicated in pediatric populations."}}
{"id": "wYa9WadlVG2R", "question_type": "open_ended_multi_choice", "question": "A 15-year-old patient presents with generalized myasthenia gravis, confirmed by anti-acetylcholine receptor antibody positivity and symptoms of fatigable weakness and ptosis. The patient has no history of organophosphate poisoning, is not pregnant, and is otherwise healthy. Which drug regimen is most appropriate for treating this patient's condition, considering safety and efficacy in pediatric populations?", "options": {"A": "Azathioprine, 50 mg daily, as an immunosuppressive adjunct", "B": "DuoDote, single dose for acute symptom management", "C": "IMAAVY, 15 mg/kg intravenous infusion every 2 weeks", "D": "Azathioprine, 100 mg daily, with a drug holiday every 2 months"}}
{"id": "f6Nslxi42N0m", "question_type": "open_ended_multi_choice", "question": "A 45-year-old pregnant woman has been newly diagnosed with multiple myeloma and amyloidosis, with no prior treatment history. Her physician is reviewing therapeutic options and assessing their safety during pregnancy. Which medication is contraindicated in her case because of its associated risks?", "options": {"A": "Linvoseltamab-gcpt", "B": "Talquetamab-tgvs", "C": "Thalidomide", "D": "Dexamethasone monotherapy"}}
{"id": "uWgxIZNM1jlu", "question_type": "multi_choice", "question": "Following cholecystectomy due to gallbladder disease in patients treated with Qfitlia, what was the typical management regarding Qfitlia therapy?", "options": {"A": "Most patients resumed Qfitlia after surgery", "B": "Qfitlia was permanently discontinued in all cases", "C": "Qfitlia dose was doubled", "D": "Qfitlia was switched to fixed dose regimen"}}
{"id": "qQf8dI6UASQx", "question_type": "multi_choice", "question": "A 32-year-old woman with neurofibromatosis type 1 and symptomatic plexiform neurofibromas is currently pregnant. She is seeking treatment options for her neurofibromas. Which of the following drugs should be avoided due to the risk of fetal harm?", "options": {"A": "Celecoxib", "B": "Gomekli", "C": "PNV-DHA", "D": "Both Celecoxib and Gomekli"}}
{"id": "kZSAfEZqsJQ7", "question_type": "open_ended_multi_choice", "question": "A 68-year-old patient diagnosed with extensive-stage small cell lung cancer (ES-SCLC) has progressed despite prior platinum-based chemotherapy. The patient’s medical history includes chronic kidney disease (creatinine clearance 45 mL/min) and concurrent use of a P-glycoprotein inhibitor for another condition. Considering both the effectiveness and safety profile, which drug regimen is recommended for this patient?", "options": {"A": "Topotecan capsules, standard dose, administered orally once daily for 5 consecutive days every 21 days", "B": "Imdelltra, step-up dosing schedule, administered intravenously as per protocol", "C": "Ipilimumab, administered as a single agent every 3 weeks", "D": "Topotecan capsules, standard dose, administered with a drug holiday after each cycle"}}
{"id": "SYAc1fzHalS4", "question_type": "multi_choice", "question": "Which of the following best describes the recommended action when Ekterly is to be administered concomitantly with a strong CYP3A4 inhibitor?", "options": {"A": "Reduce Ekterly dose to 300 mg per administration", "B": "No dosage modification is required", "C": "Avoid concomitant use of Ekterly", "D": "Increase Ekterly dose to 900 mg per administration"}}
{"id": "jvAYjaCoHQFQ", "question_type": "multi_choice", "question": "A 15-year-old female weighing 45 kg presents with symptoms of dysuria, urgency, and suprapubic pain. She is diagnosed with an uncomplicated urinary tract infection. Her medical history is notable for mild renal impairment (eGFR 55 mL/min), and she is currently taking digoxin for a cardiac condition. Which drug is the most appropriate for definitive treatment of her infection, considering her age, weight, renal function, and current medications?", "options": {"A": "Flavoxate Hydrochloride", "B": "Imipenem and Cilastatin", "C": "No drug is appropriate; recommend only symptomatic management", "D": "Gepotidacin"}}
{"id": "na7oUzqQBy2t", "question_type": "multi_choice", "question": "A 76-year-old man is diagnosed with wild-type transthyretin-mediated amyloid cardiomyopathy (ATTR-CM). He has a history of hyperlipidemia managed with rosuvastatin and is not taking any UGT inducers, CYP3A inducers, or CYP2C9 substrates. He is not planning to become pregnant and is not breastfeeding. Which of the following is the most appropriate drug to reduce his risk of cardiovascular death and hospitalization?", "options": {"A": "Dexrazoxane", "B": "No pharmacologic therapy is indicated", "C": "Vyndaqel", "D": "Attruby"}}
{"id": "HV6kx0iGmi4W", "question_type": "open_ended_multi_choice", "question": "A patient has been started on Grafapex in addition to a drug that is highly sensitive to CYP3A4 metabolism. What is the best clinical management strategy in this scenario?", "options": {"A": "Monitor for adverse reactions and consider reducing the substrate dosage if recommended.", "B": "Increase the substrate dosage to compensate for reduced metabolism.", "C": "Discontinue Grafapex immediately.", "D": "No action is necessary as there is no interaction."}}
{"id": "Vp5cU7QBqXJE", "question_type": "open_ended_multi_choice", "question": "When a patient treated with Qfitlia 10 mg every two months has an AT activity level less than 15%, what is the advised next step?", "options": {"A": "Increase dose to 20 mg every 2 months", "B": "Continue current dosage", "C": "Discontinue Qfitlia", "D": "Switch to monthly dosing"}}
{"id": "4nQXUVikcRRv", "question_type": "multi_choice", "question": "A 7-year-old boy with severe hemophilia A and a history of factor VIII inhibitors requires routine prophylaxis to prevent bleeding episodes. He has normal hepatic and gallbladder function. Which of the following is the most appropriate prophylactic therapy for this patient?", "options": {"A": "Qfitlia, administered according to antithrombin-based dosing regimen", "B": "Hemlibra, administered subcutaneously once weekly", "C": "Qfitlia, administered at a fixed dose of 80 mg once monthly", "D": "Qfitlia, administered according to antithrombin-based dosing regimen with a planned drug holiday every 3 months"}}
{"id": "uEf2zIz8oSYV", "question_type": "open_ended_multi_choice", "question": "For a patient maintained on Qfitlia 10 mg every two months who exhibits AT activity under 15%, which management strategy is recommended?", "options": {"A": "Increase dose to 20 mg every 2 months", "B": "Continue current dosage", "C": "Discontinue Qfitlia", "D": "Switch to monthly dosing"}}
{"id": "AkmlWj5SzYG7", "question_type": "open_ended_multi_choice", "question": "A 35-year-old man diagnosed with classic congenital adrenal hyperplasia is receiving glucocorticoid replacement therapy. He has initiated treatment with a strong CYP3A4 inducer for a separate medical issue. What is the most suitable change to make to his Crenessity regimen?", "options": {"A": "Continue Crenessity at the standard dose without adjustment", "B": "Discontinue Crenessity due to CYP3A4 inducer interaction", "C": "Increase both morning and evening doses of Crenessity two-fold", "D": "Reduce the glucocorticoid dose to compensate for increased Crenessity metabolism"}}
{"id": "y2keFNyz3hc4", "question_type": "multi_choice", "question": "A patient receiving Emrelis develops new-onset blurred vision and keratitis. What is the recommended clinical action for Grade ≥2 ocular toxicity?", "options": {"A": "Continue Emrelis at the same dose", "B": "Reduce the dose of Emrelis without referral", "C": "Permanently discontinue Emrelis immediately", "D": "Withhold Emrelis and refer to an eye care professional"}}
{"id": "43np529v7wvA", "question_type": "open_ended_multi_choice", "question": "A 28-year-old pregnant woman with congenital hemophilia A (factor VIII deficiency) is being evaluated for routine prophylaxis. She is in her second trimester and has no history of inhibitors or hypersensitivity reactions. Which of the following is the most appropriate approach for her prophylactic therapy?", "options": {"A": "Alhemo, as the benefits always outweigh the risks in pregnancy", "B": "Hemlibra, used only if the potential benefit outweighs the risk to the fetus", "C": "Alhemo, with no need for contraception or risk assessment", "D": "Hemlibra, as it is completely safe in pregnancy"}}
{"id": "7aPxObliQYTW", "question_type": "open_ended_multi_choice", "question": "A 70-year-old male with unresectable, metastatic esophageal squamous cell carcinoma (ESCC) and a history of chronic kidney disease (CKD) stage 3 (moderate renal impairment) presents for treatment planning. He reports nausea and vomiting and has mild proteinuria. His tumor expresses PD-L1 (≥1). Which drug is most suitable for first-line therapy in this patient?", "options": {"A": "Lenvatinib monotherapy", "B": "Tislelizumab-jsgr in combination with platinum-containing chemotherapy", "C": "Nivolumab and hyaluronidase in combination with fluoropyrimidine- and platinum-containing chemotherapy", "D": "Lenvatinib in combination with everolimus"}}
{"id": "Z4KJQK7wC3RL", "question_type": "multi_choice", "question": "Which population should be advised not to breastfeed during and for 2 weeks after treatment with Hernexeos?", "options": {"A": "Women who have completed treatment more than 2 weeks ago", "B": "Men receiving Hernexeos", "C": "Pediatric patients", "D": "Geriatric patients"}}
{"id": "CyQ9v69LbSZh", "question_type": "multi_choice", "question": "Which of the following instructions should be given to patients regarding the timing of Modeyso administration?", "options": {"A": "Take Modeyso once daily at bedtime, regardless of food intake.", "B": "Take Modeyso twice daily with meals.", "C": "Take Modeyso orally once weekly on an empty stomach, at least 1 hour before or 3 hours after food, at the same time on the same day each week.", "D": "Take Modeyso every other day with a glass of milk."}}
{"id": "pFrhpdCy8uHv", "question_type": "open_ended_multi_choice", "question": "A 54-year-old man with metastatic ROS1-positive non-small cell lung carcinoma is being considered for taletrectinib treatment. He has atrial fibrillation and is currently prescribed amiodarone, which is known to increase QTc interval duration. What is the optimal strategy for administering taletrectinib in this clinical scenario?", "options": {"A": "Proceed with taletrectinib 600 mg orally once daily and monitor ECG regularly.", "B": "Withhold taletrectinib due to risk of QTc interval prolongation from drug interaction.", "C": "Start taletrectinib at a reduced dose to minimize cardiac risk.", "D": "Taletrectinib is safe to use with amiodarone if electrolytes are monitored."}}
{"id": "I9jVvIlKOyfY", "question_type": "open_ended_multi_choice", "question": "A 52-year-old woman presents with newly diagnosed locally advanced ROS1-positive non-small cell lung carcinoma and is currently being treated with a strong CYP3A inhibitor for a fungal infection. She has no liver disease, arrhythmias, or history of pregnancy or breastfeeding. Which drug regimen is most appropriate for her lung cancer at this point?", "options": {"A": "IBTROZI (taletrectinib) 600 mg orally once daily", "B": "IBTROZI (taletrectinib) 600 mg orally once daily, with a drug holiday during antifungal therapy", "C": "IBTROZI (taletrectinib) 600 mg orally once daily, co-administered with the CYP3A inhibitor", "D": "Delay initiation of IBTROZI (taletrectinib) until the CYP3A inhibitor is discontinued"}}
{"id": "CRclNJZ5hVjk", "question_type": "open_ended_multi_choice", "question": "A 15-year-old patient with autosomal dominant juvenile-onset reading seizures presents for treatment. The patient has a history of decreased appetite and is currently underweight. Cardiac evaluation via echocardiogram is normal, and there is no history of psychiatric illness or visual symptoms. The patient is not taking any serotonergic medications. Which of the following is the most appropriate drug treatment plan for this patient?", "options": {"A": "Fintepla, with regular monitoring of weight and growth during therapy", "B": "Fintepla, without any monitoring of weight or growth", "C": "Fintepla, only if the patient is also taking MAOIs", "D": "Fintepla, but discontinue immediately if appetite decreases"}}
{"id": "mLQaGbcY7RXo", "question_type": "open_ended", "question": "Which statement best describes the mutagenic potential of Sephience based on the weight of evidence from multiple assays?", "options": {"A": "Sephience is strongly genotoxic in all tested assays.", "B": "Sephience is not genotoxic, with negative results in the Ames, micronucleus, and comet assays.", "C": "Sephience is genotoxic only in in vivo assays.", "D": "Sephience is genotoxic only in the Ames assay."}}
{"id": "fqFqVhaUp3sC", "question_type": "open_ended_multi_choice", "question": "A 55-year-old man with metastatic pancreatic adenocarcinoma and a confirmed NRG1 gene fusion has progressed after prior gemcitabine-based chemotherapy. He has a history of symptomatic congestive heart failure (CHF) with a left ventricular ejection fraction of 40%. His neutrophil count and hepatic function are within normal limits. Which therapy is most suitable for his current condition?", "options": {"A": "BIZENGRI (zenocutuzumab)", "B": "Paclitaxel protein-bound particles for injectable suspension (albumin-bound) in combination with gemcitabine", "C": "Imbruvica (ibrutinib)", "D": "BIZENGRI (zenocutuzumab) with a drug holiday"}}
{"id": "hmwzpEXGxZPZ", "question_type": "multi_choice", "question": "A 34-year-old woman with newly diagnosed prurigo nodularis is 20 weeks pregnant. She is seeking treatment for her severe itching and is concerned about fetal safety. Which of the following is the most appropriate therapeutic approach for her condition?", "options": {"A": "NEMLUVIO combined with topical corticosteroids and live vaccines", "B": "Nalbuphine Hydrochloride injection for symptomatic relief, used routinely throughout pregnancy", "C": "NEMLUVIO administered every 4 weeks, with careful consideration of potential fetal exposure", "D": "Nalbuphine Hydrochloride injection during labor and delivery only"}}
{"id": "yf48g1Uh2v2x", "question_type": "open_ended_multi_choice", "question": "A 60-year-old male with a history of supraventricular tachycardia and moderate hepatic dysfunction (Child-Pugh class B) requires acute rate control. He is neither pregnant nor affected by bronchospastic illness. Based on his liver impairment, which medication should be avoided, and what is the best alternative?", "options": {"A": "RAPIBLYK should be avoided; Propranolol is the most appropriate alternative.", "B": "Pacerone should be avoided; RAPIBLYK is the most appropriate alternative.", "C": "Propranolol should be avoided; Pacerone is the most appropriate alternative.", "D": "RAPIBLYK should be avoided; Pacerone is the most appropriate alternative."}}
{"id": "2EZnERGpyTQ2", "question_type": "open_ended_multi_choice", "question": "A 62-year-old woman with a history of hepatic impairment (bilirubin > ULN, AST and ALT >1.5 × ULN with alkaline phosphatase >2.5 × ULN) is newly diagnosed with locally advanced cervical adenocarcinoma involving the lower third of the vagina. Her tumor expresses PD-L1 (CPS ≥1). She is not pregnant and has no history of hypersensitivity reactions. Which of the following is the safest and most effective initial treatment option for her?", "options": {"A": "Docetaxel as a single agent every 3 weeks", "B": "Keytruda QLEX in combination with chemoradiotherapy", "C": "Gemcitabine as a single agent weekly", "D": "Docetaxel in combination with doxorubicin and cyclophosphamide"}}
{"id": "0dtZOCEAFV4i", "question_type": "multi_choice", "question": "What is the recommended procedure regarding contact lens use when administering Vizz?", "options": {"A": "Do not use contact lenses at all during Vizz therapy.", "B": "Keep contact lenses in during instillation.", "C": "Remove contact lenses and wait 1 hour before reinserting.", "D": "Remove contact lenses before instillation and reinsert 10 minutes after."}}
{"id": "fNUke3bwHNHm", "question_type": "open_ended_multi_choice", "question": "Which precaution should be taken before prescribing Modeyso to females capable of reproduction?", "options": {"A": "No specific action is required.", "B": "Start Modeyso immediately regardless of pregnancy status.", "C": "Verify pregnancy status prior to initiation.", "D": "Advise permanent contraception."}}
{"id": "uTAkRyCVdnYT", "question_type": "open_ended_multi_choice", "question": "When using Enflonsia, which precaution should be taken regarding RSV diagnostic testing?", "options": {"A": "Confirm negative rapid antigen results with RT-PCR if clinical suspicion persists", "B": "Avoid all RSV diagnostic testing", "C": "Use only rapid antigen tests for RSV diagnosis", "D": "Discontinue Enflonsia before testing"}}
{"id": "ZrQoZcpw0iw9", "question_type": "multi_choice", "question": "Which of the following best describes the incidence of nausea or vomiting in patients treated with JOURNAVX compared to those treated with hydrocodone bitartrate/acetaminophen (HB/APAP) in Trial 1 for moderate to severe acute pain?", "options": {"A": "Equal incidence in both groups", "B": "Higher in JOURNAVX-treated patients than in HB/APAP-treated patients", "C": "Lower in JOURNAVX-treated patients than in HB/APAP-treated patients", "D": "Incidence only reported for JOURNAVX-treated patients"}}
{"id": "pCKU6PNA5jfu", "question_type": "multi_choice", "question": "A 32-year-old woman with chronic graft-versus-host disease (cGVHD) and symptoms of myalgia, nail dystrophy, and recurrent infections is currently pregnant. She has failed two prior lines of systemic therapy. Her weight is 58 kg. Which drug should be avoided due to her pregnancy status?", "options": {"A": "PredniSONE Tablets, USP, 5 mg", "B": "Budesonide Inhalation", "C": "AXATILIMAB-CSFR", "D": "Low-dose Budesonide Inhalation"}}
{"id": "1NfciHRYCPuO", "question_type": "open_ended_multi_choice", "question": "A 60-year-old man with primary biliary cholangitis and a history of cirrhosis presents with new-onset ascites and hepatic encephalopathy. He is currently taking ursodiol (Urso 250) and his physician is considering additional therapy due to persistently elevated alkaline phosphatase. Which of the following is the most appropriate recommendation regarding drug therapy?", "options": {"A": "Add IQIRVO (elafibranor) to current ursodiol therapy.", "B": "Switch to Tricor (fenofibrate) monotherapy.", "C": "Continue ursodiol (Urso 250) and avoid adding IQIRVO.", "D": "Discontinue ursodiol and initiate IQIRVO monotherapy."}}
{"id": "31GWW75t3GSb", "question_type": "open_ended_multi_choice", "question": "A clinical trial protocol is being designed for a new indication of Qfitlia. Which statement regarding exclusion criteria based on contraindications is accurate?", "options": {"A": "No exclusion criteria are required for contraindications, as Qfitlia has none.", "B": "Patients with renal impairment must be excluded due to contraindications.", "C": "Patients with a history of anaphylaxis must be excluded due to contraindications.", "D": "Pregnant women must be excluded due to contraindications."}}
{"id": "eixLURxFNc13", "question_type": "open_ended_multi_choice", "question": "A 58-year-old patient with metastatic non-small cell lung cancer (NSCLC) is found to have ROS1-positive disease by FDA-approved testing. The patient has a history of congestive heart failure (CHF) and is currently taking a medication known to prolong the QTc interval. Which treatment option should be avoided due to the patient's comorbidities and drug interactions, and which is most appropriate?", "options": {"A": "Rozlytrek monotherapy, 600 mg orally once daily", "B": "Erlotinib monotherapy, 150 mg orally once daily", "C": "Lazcluze (lazertinib + amivantamab) combination therapy, standard dosing", "D": "Rozlytrek with dose reduction due to QTc-prolonging medication"}}
{"id": "xp60QIwcJqAG", "question_type": "open_ended_multi_choice", "question": "What is the most appropriate description of the impact of Gomekli on fetal health when given to pregnant individuals?", "options": {"A": "Gomekli is safe for use during pregnancy", "B": "Gomekli may cause fetal harm or loss of pregnancy", "C": "Gomekli increases the risk of gestational diabetes", "D": "Gomekli prevents miscarriage"}}
{"id": "yGFRzSzXR0OS", "question_type": "open_ended_multi_choice", "question": "A 38-year-old woman with primary biliary cholangitis and elevated alkaline phosphatase is considering starting new therapy. She is of reproductive age, currently using a hormonal contraceptive pill, and is planning to become pregnant within the next year. Which treatment option is most suitable for her current situation?", "options": {"A": "Elafibranor in combination with UDCA, continuing hormonal contraceptive", "B": "Elafibranor with a switch to non-hormonal contraception", "C": "Colcrys daily for PBC management", "D": "Budesonide inhalation as monotherapy"}}
{"id": "dMSMg8RZqDPu", "question_type": "open_ended_multi_choice", "question": "For a 55-year-old man presenting with symptomatic TGCT and moderate renal dysfunction (CLcr 40 mL/min), who has no liver disease, takes no CYP3A substrate medications, and can follow dietary guidelines, which systemic therapy would be most suitable?", "options": {"A": "Romvimza (vimseltinib) at standard dosing without renal adjustment", "B": "Turalio (pexidartinib hydrochloride) with dose reduction for renal impairment and administration with a low-fat meal", "C": "Turalio (pexidartinib hydrochloride) at standard dosing with a high-fat meal", "D": "Romvimza (vimseltinib) with dose reduction for renal impairment"}}
{"id": "1Sza2hvzdqgB", "question_type": "open_ended", "question": "A patient is prescribed Romvimza and misses a dose by 36 hours. What is the recommended action regarding the missed dose?", "options": {"A": "Skip the missed dose and take the next dose on its regularly scheduled day.", "B": "Take the missed dose as soon as possible and resume the regular schedule.", "C": "Double the next scheduled dose.", "D": "Contact the physician before taking any further doses."}}
{"id": "wPc3woZ578OV", "question_type": "open_ended_multi_choice", "question": "For a pediatric patient whose weight falls in the 42.5 kg to under 52.5 kg range and who experiences a Grade 3 adverse event during Modeyso therapy, what is the recommended change to their dosing regimen?", "options": {"A": "Interrupt Modeyso until ≤Grade 1 or baseline, then resume at 375 mg once weekly", "B": "Permanently discontinue Modeyso", "C": "Increase dose to 500 mg once weekly", "D": "Continue at the same dose"}}
{"id": "LundF9J3rxng", "question_type": "open_ended_multi_choice", "question": "A 45-year-old man presents with moderate to severe chronic hand eczema and a past medical history of basal cell carcinoma. He is not immunosuppressed and does not have any ongoing infections. What would be the best topical therapy plan for him?", "options": {"A": "Start topical Anzupgo with regular skin examinations to monitor for non-melanoma skin cancer.", "B": "Start topical Anzupgo without any need for skin cancer monitoring.", "C": "Start topical Anzupgo in combination with potent immunosuppressants.", "D": "Start topical Anzupgo and schedule live vaccinations during treatment."}}
{"id": "9FQVhL1Dr83k", "question_type": "multi_choice", "question": "A female patient of reproductive potential is prescribed Romvimza. What is the most appropriate counseling regarding contraception?", "options": {"A": "No contraception is necessary during Romvimza therapy.", "B": "Contraception is required for 6 months after stopping Romvimza.", "C": "Contraception is only required if the patient is pregnant.", "D": "Contraception should be used only for the first week of therapy."}}
{"id": "T4FhXtSyD1OW", "question_type": "multi_choice", "question": "A 68-year-old man with relapsed multiple myeloma has previously received four lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. He has well-controlled hypertension and normal renal and hepatic function. He is not currently experiencing any infections. Which of the following is the most appropriate next-line therapy for his condition?", "options": {"A": "Thalomid in combination with dexamethasone", "B": "LYNOZYFIC", "C": "Mozobil in combination with filgrastim", "D": "Observation only, as no further therapy is indicated"}}
{"id": "vF6VuymleLIz", "question_type": "open_ended_multi_choice", "question": "A patient on Emrelis develops blurred vision and eye pain. What is the recommended clinical action?", "options": {"A": "Refer to an eye care professional for evaluation", "B": "Increase the dose of Emrelis", "C": "Continue therapy without intervention", "D": "Switch to oral administration"}}
{"id": "egwfmv7aDrPQ", "question_type": "open_ended_multi_choice", "question": "A clinician is reviewing the contraindications for Lynozyfic before prescribing it to a patient with multiple comorbidities. What should the clinician be aware of?", "options": {"A": "Lynozyfic is contraindicated in patients with a history of anaphylaxis.", "B": "Lynozyfic should not be used in patients with severe renal impairment.", "C": "There are no contraindications listed for Lynozyfic.", "D": "Lynozyfic is contraindicated in pediatric populations."}}
{"id": "WGR1g50xGiLb", "question_type": "multi_choice", "question": "In the KONFIDENT trial, what was the incidence of headache in the placebo group compared to the Ekterly 600 mg group?", "options": {"A": "1.2% in placebo vs 3.2% in Ekterly 600 mg", "B": "3.2% in placebo vs 1.2% in Ekterly 600 mg", "C": "2% in both groups", "D": "0% in placebo vs 2% in Ekterly 600 mg"}}
{"id": "n2iD4RtOma7X", "question_type": "multi_choice", "question": "A 35-year-old female patient with Grade 2 IDH1-mutant astrocytoma has recently undergone gross total resection. She is planning pregnancy and currently uses hormonal contraception. Her oncologist is considering post-surgical drug therapy. Which treatment option should be avoided due to its impact on contraception and potential risk to a future pregnancy?", "options": {"A": "Avastin administered every 2 weeks", "B": "No drug therapy; observation only", "C": "Zortress combined with tacrolimus and corticosteroids", "D": "Vorasidenib 40 mg once daily"}}
{"id": "F2dwWGQLF2sM", "question_type": "open_ended_multi_choice", "question": "What is the advised approach to Enflonsia administration for a child who is set to undergo heart surgery during their initial RSV season?", "options": {"A": "Delay Enflonsia until after the RSV season", "B": "Administer an additional Enflonsia injection soon after surgery", "C": "Discontinue Enflonsia permanently", "D": "Switch to oral Enflonsia therapy"}}
{"id": "0NSLSdNF5JMq", "question_type": "multi_choice", "question": "Which of the following is a recommended action if a patient receiving Hernexeos develops transaminase elevations during therapy?", "options": {"A": "Continue therapy without changes", "B": "Interrupt, reduce the dose, or permanently discontinue Hernexeos", "C": "Switch to a non-HER2 targeted therapy", "D": "Administer prophylactic antibiotics"}}
{"id": "diCPfwWrJ0py", "question_type": "open_ended_multi_choice", "question": "A 72-year-old man with CIS of the urinary bladder that has not responded to BCG is considered too high-risk for immediate cystectomy. Five days ago, he underwent TURB and now presents with severe bladder irritation. What is the treatment option that should be avoided for him at this time?", "options": {"A": "Valrubicin intravesical therapy", "B": "Nogapendekin alfa inbakicept-pmln (ANKTIVA) with Bacillus Calmette-Guérin (BCG)", "C": "Immediate cystectomy", "D": "Valrubicin intravesical therapy delayed for two weeks after TURB"}}
{"id": "gaxpum1h6Yyl", "question_type": "open_ended_multi_choice", "question": "A 6-year-old child with classic congenital adrenal hyperplasia is currently receiving glucocorticoid replacement therapy. The patient has normal renal function and no history of hypersensitivity reactions. The family is considering adjunctive therapy to better control androgen levels. Which drug regimen is most appropriate for this patient?", "options": {"A": "Crenessity as adjunctive therapy to glucocorticoid replacement", "B": "Crenessity monotherapy without glucocorticoid replacement", "C": "Crenessity in a child under 4 years old", "D": "Crenessity in a patient with severe renal impairment"}}
{"id": "5o7HQF6Ph1OI", "question_type": "multi_choice", "question": "A 68-year-old man with relapsed multiple myeloma has previously received four lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. He has well-controlled hypertension and normal renal and hepatic function. He is not currently experiencing any infections. Which of the following is the most appropriate next-line therapy for his condition?", "options": {"A": "LYNOZYFIC", "B": "Thalomid in combination with dexamethasone", "C": "Mozobil in combination with filgrastim", "D": "Observation only, as no further therapy is indicated"}}
{"id": "FjPAeQOGogGR", "question_type": "open_ended_multi_choice", "question": "A 7-year-old child diagnosed with relapsed low-grade glioma has tested positive for a BRAF V600 mutation. The patient does not have NF1 and is not taking CYP2C8 inhibitors or hormonal contraceptives. The family is concerned about possible adverse effects on growth and fertility from the treatment. Which drug regimen would be most appropriate, taking into account efficacy, safety, and approved use for this indication?", "options": {"A": "OJEMDA administered once daily, with routine monitoring of growth and liver function.", "B": "VinCRIStine Sulfate administered intravenously weekly, despite lack of LGG-specific indication.", "C": "Gliadel Wafer implantation during surgery, although pediatric safety and efficacy are not established.", "D": "OJEMDA combined with hormonal contraceptives to prevent breakthrough bleeding."}}
{"id": "VjdXoklfnf5t", "question_type": "open_ended_multi_choice", "question": "A clinical researcher is designing a trial and needs to exclude patients based on contraindications. For which of the following drugs would there be no exclusion criteria based on contraindications?", "options": {"A": "Wayrilz", "B": "A drug with known contraindication in pregnancy", "C": "A drug contraindicated in patients with cardiac arrhythmia", "D": "A drug contraindicated in patients with hepatic insufficiency"}}
{"id": "7N32RyQm7UAK", "question_type": "multi_choice", "question": "A 45-year-old man with schizophrenia and a history of benign prostatic hyperplasia (BPH) and incomplete bladder emptying is being considered for antipsychotic therapy. He has normal renal and hepatic function. Which antipsychotic is most suitable for this patient?", "options": {"A": "Cobenfy, administered orally twice daily", "B": "Cobenfy, administered orally once daily with close monitoring", "C": "Abilify Maintena, administered as a monthly intramuscular injection", "D": "Abilify Maintena, administered as a biweekly intramuscular injection"}}
{"id": "bXEGIF6dLz5L", "question_type": "multi_choice", "question": "A patient receiving penpulimab-kcqx develops Grade 3 immune-mediated pneumonitis. What is the recommended initial management strategy?", "options": {"A": "Continue penpulimab-kcqx and monitor closely", "B": "Reduce the dose of penpulimab-kcqx", "C": "Switch to another PD-1/PD-L1 inhibitor", "D": "Treat with antibiotics and continue penpulimab-kcqx"}}
{"id": "MhmMCbek7c15", "question_type": "open_ended_multi_choice", "question": "A 12-year-old boy diagnosed with Duchenne muscular dystrophy, whose genetic testing reveals a mutation suitable for exon 51 skipping, presents with mild renal impairment and a documented hypersensitivity to intravenous drugs. He does not have arrhythmias or liver problems. What is the most suitable therapy for his condition?", "options": {"A": "Viltepso administered intravenously once weekly", "B": "Exondys 51 administered intravenously once weekly", "C": "Duvyzat administered orally twice daily", "D": "Duvyzat administered with a drug holiday every 2 weeks"}}
{"id": "eRtPlLETPMO0", "question_type": "multi_choice", "question": "What is the recommended action if a patient experiences a grade 3 infusion-related reaction during Datroway administration?", "options": {"A": "Reduce infusion rate by 50% and continue", "B": "Interrupt infusion and restart at reduced rate", "C": "Permanently discontinue Datroway", "D": "Administer antihistamines and continue"}}
{"id": "0q6Lxqw4ysI0", "question_type": "multi_choice", "question": "A 55-year-old man with prurigo nodularis and a documented history of hypersensitivity to nemolizumab-ilto presents for therapy. He is otherwise healthy, not pregnant, and has no renal impairment. Which drug regimen is most suitable for his condition?", "options": {"A": "Nemluvio administered subcutaneously every four weeks", "B": "Dupixent administered subcutaneously every two weeks", "C": "Apremilast 30 mg orally twice daily", "D": "Apremilast 30 mg orally once daily"}}
{"id": "5Sa7l28DSCMF", "question_type": "multi_choice", "question": "A 10-year-old boy with a history of epilepsy controlled on valproic acid presents with fever, flank pain, and a diagnosis of complicated urinary tract infection. He has normal renal function and no known drug allergies. Which of the following is the most appropriate treatment option?", "options": {"A": "Imipenem and cilastatin intravenously", "B": "Imipenem and cilastatin intravenously, with valproic acid continued", "C": "Flavoxate hydrochloride orally", "D": "Sulopenem etzadroxil and probenecid (Orlynvah) orally"}}
{"id": "65fMpCLZBsHk", "question_type": "open_ended", "question": "Which of the following best describes the severity and clinical management of hypotension observed in patients treated with Vanrafia in the ALIGN study?", "options": {"A": "Severe and required treatment discontinuation", "B": "Mild or moderate, rarely symptomatic, did not necessitate discontinuation", "C": "Frequently symptomatic and required dose reduction", "D": "Not observed in Vanrafia-treated patients"}}
{"id": "PY75hUprs4sz", "question_type": "multi_choice", "question": "A 22-year-old patient with cystic fibrosis, cirrhosis, and hepatosplenomegaly is homozygous for the F508del mutation. The patient is currently taking cyclosporine following a recent organ transplant. Which drug regimen should be avoided due to potential drug interactions and organ-specific risks?", "options": {"A": "SYMDEKO, with dose adjustment for hepatic impairment", "B": "ORKAMBI, due to risk of liver failure and drug interaction with cyclosporine", "C": "Brinsupri, with monitoring for dental and skin adverse reactions", "D": "SYMDEKO, with standard dosing and no consideration for hepatic impairment"}}
{"id": "uEYzmDIRhX1v", "question_type": "multi_choice", "question": "A 58-year-old man with a history of glaucoma and previous herpes simplex eye infection is experiencing severe symptoms of dry eye disease. He is considering prescription therapy and currently wears contact lenses daily. Which medication should be avoided due to his medical history and which is the most suitable for his condition?", "options": {"A": "Lotemax SM", "B": "TRYPTYR", "C": "Xiidra", "D": "Cyclosporine ophthalmic emulsion"}}
{"id": "PfpuMsw8HK1H", "question_type": "multi_choice", "question": "A patient on Journavx is also taking a sensitive CYP3A substrate where small changes in concentration may lead to loss of efficacy. What is the recommended management strategy?", "options": {"A": "No action is needed.", "B": "Discontinue Journavx.", "C": "Increase the dose of Journavx.", "D": "Refer to the prescribing information for the CYP3A substrate for dosing instructions and consider dosage modification."}}
{"id": "wtyPBkWlwpsf", "question_type": "open_ended_multi_choice", "question": "A 58-year-old male presents with recurrent, metastatic non-keratinizing nasopharyngeal carcinoma. He has a history of coronary artery disease and is currently taking warfarin for atrial fibrillation. The oncology team is considering systemic therapy. Which drug regimen is most appropriate for this patient, considering his cancer diagnosis and comorbidities?", "options": {"A": "Penpulimab-kcqx in combination with cisplatin and gemcitabine, administered every 3 weeks", "B": "Capecitabine 500 mg twice daily as monotherapy", "C": "Celecoxib 200 mg twice daily for pain management", "D": "Capecitabine 500 mg twice daily in combination with warfarin"}}
{"id": "8ydV3suNMXYR", "question_type": "open_ended_multi_choice", "question": "For patients treated with Imaavy who must use FcRn-binding medications long-term, which of the following is NOT considered a recommended management strategy?", "options": {"A": "Discontinue Imaavy and use alternative therapies", "B": "Continue Imaavy and monitor for reduced effectiveness", "C": "Increase the dose of FcRn-binding medication", "D": "Switch to non-FcRn-binding alternatives"}}
{"id": "FtyhUo3g2nCm", "question_type": "open_ended_multi_choice", "question": "Given a 68-year-old female patient diagnosed with intermediate-2 risk MDS and chronic kidney disease (estimated creatinine clearance 35 mL/min), who is neither pregnant nor breastfeeding and is taking a cytidine deaminase-metabolized medication for a separate condition, which MDS therapy should be selected in light of her medical history and current drug regimen?", "options": {"A": "INQOVI (oral decitabine + cedazuridine) once daily for 5 days every 28-day cycle", "B": "Decitabine intravenous infusion daily for 5 days every 4 weeks", "C": "RYTELO intravenous infusion every 4 weeks with premedication for infusion reactions", "D": "INQOVI (oral decitabine + cedazuridine) with a drug holiday every other cycle"}}
{"id": "YQyGEcZzDv5A", "question_type": "open_ended_multi_choice", "question": "A pregnant 45-year-old woman presents with adult-onset multiple myeloma and amyloidosis. She has not yet received any treatment for her condition. As her physician considers starting therapy, which drug should be absolutely avoided due to its safety concerns in pregnancy?", "options": {"A": "Linvoseltamab-gcpt", "B": "Talquetamab-tgvs", "C": "Thalidomide", "D": "Dexamethasone monotherapy"}}
{"id": "M5zij9B0D3po", "question_type": "open_ended_multi_choice", "question": "A 7-year-old male with a history of cystic fibrosis, repeated bronchopulmonary infections, and failure to thrive is noted to have exocrine pancreatic insufficiency and markedly abnormal liver function tests (ALT and AST over three times ULN, bilirubin over twice ULN). He is being treated with a strong CYP3A inducer for a separate condition. What is the optimal approach to his cystic fibrosis medication regimen?", "options": {"A": "Initiate ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor) at standard pediatric dosage", "B": "Initiate ALYFTREK with dose reduction due to CYP3A inducer", "C": "Avoid ALYFTREK and consider alternative supportive management", "D": "Switch CYP3A inducer to a CYP3A inhibitor and start ALYFTREK"}}
{"id": "3BqOAD3EQ5Bi", "question_type": "open_ended_multi_choice", "question": "A 65-year-old male patient with chronic obstructive pulmonary disease (COPD) and type 2 diabetes is hospitalized for acute supraventricular tachycardia. His medications include metformin and inhaled corticosteroids. Based on his medical history, which drug should be avoided?", "options": {"A": "RAPIBLYK (landiolol)", "B": "Pacerone (amiodarone)", "C": "Propranolol", "D": "Adenosine"}}
{"id": "fxGAdqYEYk4C", "question_type": "open_ended_multi_choice", "question": "A patient with metastatic biliary tract cancer that is unresectable and has been previously treated is found to have HER2-positive (IHC 3+) status via FDA-approved testing. The patient also has a history of low left ventricular ejection fraction (45%) and is on several strong CYP3A inhibitors. Which treatment option is most appropriate in this scenario?", "options": {"A": "Zanidatamab-hrii (ZIIHERA) every three weeks, standard dose", "B": "Futibatinib (LYTGOBI) once daily, standard dose", "C": "Pemigatinib (PEMAZYRE) once daily, standard dose", "D": "Zanidatamab-hrii (ZIIHERA) every three weeks, with cardiac monitoring and dose reduction"}}
{"id": "zDNw6Xb90vsZ", "question_type": "open_ended_multi_choice", "question": "A newly diagnosed case of paroxysmal nocturnal hemoglobinuria (PNH) is seen in a 10-year-old child weighing 32 kg. The patient has no history of complement inhibitor use and is up to date on meningococcal vaccines. Which drug should be initiated first, considering the patient's age and weight limitations?", "options": {"A": "Ultomiris", "B": "Piasky", "C": "Sirolimus", "D": "Eculizumab"}}
{"id": "pdz9U9A9UaUy", "question_type": "multi_choice", "question": "Which statement best describes the safety profile of Andembry in pregnant or breastfeeding individuals?", "options": {"A": "Andembry is proven safe in pregnancy and breastfeeding.", "B": "Andembry is contraindicated in pregnancy.", "C": "It is not known if Andembry can harm an unborn baby or passes into breastmilk.", "D": "Andembry is recommended for all pregnant women with HAE."}}
{"id": "imI9K3JmAUeD", "question_type": "multi_choice", "question": "A 60-year-old man with congenital dyserythropoietic anemia type 1B, presenting with anemia of inadequate production, anisocytosis, and reticulocytosis, also has chronic kidney disease with a creatinine clearance of 25 mL/min/1.73 m2. The care team is evaluating potential pharmacologic therapies. Which drug is contraindicated for this patient due to his level of renal impairment?", "options": {"A": "Filgrastim administered subcutaneously at 5 mcg/kg/day", "B": "Fludarabine phosphate administered intravenously at standard dosing", "C": "Sitagliptin and metformin hydrochloride combination therapy", "D": "Supportive care with erythropoietin-stimulating agents"}}
{"id": "OEAWA8htBY0V", "question_type": "open_ended_multi_choice", "question": "According to the ASPEN study, what was observed regarding the annualized incidence of severe pulmonary exacerbations in patients treated with Brinsupri 25 mg versus those receiving placebo?", "options": {"A": "Higher in Brinsupri 25 mg", "B": "Lower in Brinsupri 25 mg", "C": "Equal in both groups", "D": "Not reported"}}
{"id": "yPXdmOOMSykw", "question_type": "multi_choice", "question": "A 7-year-old boy is newly diagnosed with myelodysplastic syndrome (MDS) and is scheduled for allogeneic hematopoietic stem cell transplantation. He has no history of seizures, is not taking any CYP2C19 or CYP3A4 substrate medications, and is otherwise healthy. Which drug regimen is most appropriate as a preparative regimen for his transplant, considering age-specific safety and efficacy?", "options": {"A": "TREOSULFAN (GRAFAPEX) in combination with fludarabine, administered intravenously for three consecutive days.", "B": "INQOVI (cedazuridine and decitabine), administered orally in 28-day cycles.", "C": "Lenalidomide, administered orally once daily.", "D": "Busulfan, administered intravenously for two days."}}
{"id": "BfsdY0u6GYFi", "question_type": "multi_choice", "question": "Has Tryptyr been shown to impair fertility in animal studies?", "options": {"A": "Yes, Tryptyr significantly impairs fertility in both male and female animals.", "B": "No, Tryptyr has been shown to have no effect on fertility in animal studies.", "C": "Studies to evaluate the potential effects of Tryptyr on fertility in animals have not been performed.", "D": "Tryptyr increases fertility in animal models."}}
{"id": "GlRtBwbou8ZB", "question_type": "open_ended_multi_choice", "question": "A 65-year-old man with a background of COPD and type 2 diabetes is admitted for acute supraventricular tachycardia and is currently taking metformin and inhaled corticosteroids. Given his comorbidities, which of the following drugs is not recommended?", "options": {"A": "RAPIBLYK (landiolol)", "B": "Pacerone (amiodarone)", "C": "Propranolol", "D": "Adenosine"}}
{"id": "GgIbvqLLQHr6", "question_type": "open_ended_multi_choice", "question": "A child aged 7 years is found to have relapsed acute erythroleukemia with a KMT2A translocation, along with symptoms of anemia, thrombocytopenia, and hepatomegaly. Considering the patient’s age, genetic profile, and absence of QTc-prolonging drugs or ECG abnormalities, which drug should be chosen for initial treatment based on its efficacy and safety in this context?", "options": {"A": "Revuforj administered twice daily, with BSA-based dosing for pediatric patients", "B": "Aldesleukin administered intravenously in a hospital setting", "C": "Dexamethasone administered as adjunctive palliative therapy", "D": "TaperDex 6-day oral regimen at standard adult dosing"}}
{"id": "SSTA3pdgoWT5", "question_type": "open_ended_multi_choice", "question": "A 45-year-old woman with paroxysmal nocturnal hemoglobinuria (PNH) presents with extravascular hemolysis despite ongoing treatment with ravulizumab. She has a history of mild hepatic impairment (Child-Pugh Class B) and is currently taking rosuvastatin for hyperlipidemia. Her rosuvastatin dose is 20 mg once daily. Which of the following is the most appropriate drug regimen to address her EVH, considering her comorbidities and current medications?", "options": {"A": "Add danicopan to her current ravulizumab regimen, maintaining her rosuvastatin dose at 20 mg once daily.", "B": "Switch to pegcetacoplan monotherapy and discontinue ravulizumab.", "C": "Add danicopan to her current ravulizumab regimen, but reduce rosuvastatin dose to no more than 10 mg once daily.", "D": "Switch to crovalimab monotherapy and discontinue ravulizumab."}}
{"id": "zKz5B9dSeDc8", "question_type": "open_ended_multi_choice", "question": "A woman aged 35 with hemophilia A and a history of cholecystectomy for gallbladder disease presents for routine prophylaxis. She has normal hepatic function and is not pregnant. Which prophylactic regimen is most appropriate in her case?", "options": {"A": "Qfitlia, administered according to antithrombin-based dosing regimen", "B": "Hemlibra, administered subcutaneously every two weeks", "C": "Qfitlia, administered at a fixed dose of 80 mg once monthly", "D": "Qfitlia, administered according to antithrombin-based dosing regimen with concurrent hormonal contraceptives"}}
{"id": "zGU0fkuV7yw5", "question_type": "open_ended_multi_choice", "question": "A woman aged 34, who is breastfeeding her 2-month-old baby and has no history of kidney or liver disease, presents with severe alopecia areata. She is not on any other medications. Which drug therapy is most appropriate for her?", "options": {"A": "LEQSELVI administered orally once daily", "B": "Hydroxychloroquine sulfate administered orally once daily", "C": "Triamcinolone acetonide nasal spray once daily", "D": "LEQSELVI administered orally every other day with a drug holiday every 2 weeks"}}
{"id": "gwJ7qK0bShLY", "question_type": "open_ended", "question": "A 7-year-old boy with persistent immune thrombocytopenia, autosomal dominant inheritance, and a history of abnormal bleeding has failed corticosteroid therapy. He has no hepatic or renal impairment and is not taking any other medications. Which drug regimen is most suitable for his condition, considering age-specific approvals and safety?", "options": {"A": "WAYRILZ (Rilzabrutinib) 400 mg twice daily", "B": "PROMACTA (Eltrombopag) 25 mg once daily", "C": "Prednisone 40 mg daily", "D": "WAYRILZ (Rilzabrutinib) 200 mg once daily"}}
{"id": "ZfgKSwCHr6T6", "question_type": "open_ended_multi_choice", "question": "For a 68-year-old woman with intermediate-2 risk myelodysplastic syndromes, chronic kidney disease (creatinine clearance 35 mL/min), and ongoing use of a medication metabolized by cytidine deaminase, who is not pregnant or breastfeeding, what is the most appropriate MDS treatment regimen considering her comorbidities and concurrent medications?", "options": {"A": "INQOVI (oral decitabine + cedazuridine) once daily for 5 days every 28-day cycle", "B": "Decitabine intravenous infusion daily for 5 days every 4 weeks", "C": "RYTELO intravenous infusion every 4 weeks with premedication for infusion reactions", "D": "INQOVI (oral decitabine + cedazuridine) with a drug holiday every other cycle"}}
{"id": "18hEOdIXSf8w", "question_type": "open_ended_multi_choice", "question": "Breastfeeding is not recommended during Gomekli treatment and for one week afterward for which population?", "options": {"A": "Women receiving Gomekli", "B": "Men receiving Gomekli", "C": "Pediatric patients under 2 years old", "D": "Patients with mild renal impairment"}}
{"id": "IokoVbKeezDg", "question_type": "open_ended_multi_choice", "question": "In the context of necessary prolonged use of FcRn-binding drugs in a patient receiving Imaavy, which strategy should be avoided?", "options": {"A": "Discontinue Imaavy and use alternative therapies", "B": "Continue Imaavy and monitor for reduced effectiveness", "C": "Increase the dose of FcRn-binding medication", "D": "Switch to non-FcRn-binding alternatives"}}
{"id": "SYrD9M6ZPJkX", "question_type": "multi_choice", "question": "A 48-year-old woman with locally advanced breast cancer is experiencing severe postoperative pain following tumor resection. She has a history of peptic ulcer disease and mild renal impairment (eGFR 55 mL/min). She is not pregnant and weighs 65 kg. Which analgesic regimen is safest and most effective for her acute pain management over the next several days?", "options": {"A": "Ketorolac tromethamine for up to 5 days, with dose adjustment for renal impairment", "B": "Itovebi (inavolisib) in combination with palbociclib and fulvestrant for pain control", "C": "Morphine sulfate titrated to pain, with careful monitoring for respiratory depression", "D": "Ketorolac tromethamine for chronic pain management beyond 5 days"}}
{"id": "05lvnSsgSd04", "question_type": "open_ended_multi_choice", "question": "What is the suggested Hernexeos dose modification for an 85 kg patient who requires concurrent administration of a strong CYP3A inducer?", "options": {"A": "Increase to 240 mg once daily", "B": "Decrease to 60 mg once daily", "C": "Maintain at 120 mg once daily", "D": "Increase to 180 mg once daily"}}
{"id": "JYfqDdOWUAUu", "question_type": "multi_choice", "question": "A 68-year-old male with a history of nonmuscle invasive bladder cancer presents with persistent carcinoma in situ (CIS) after failing two courses of Bacillus Calmette-Guérin (BCG) therapy. He has no significant comorbidities and is not currently taking any other medications. He is concerned about the risk of disease progression and wishes to avoid unnecessary systemic toxicity. Which of the following is the most appropriate next step in drug therapy for this patient, considering his disease subtype and treatment history?", "options": {"A": "Initiate Gemcitabine as a single agent administered intravenously weekly.", "B": "Start Anktiva in combination with BCG administered intravesically.", "C": "Begin Gemcitabine in combination with carboplatin.", "D": "Recommend systemic paclitaxel therapy."}}
{"id": "GWDUjcJbLsCo", "question_type": "multi_choice", "question": "Which of the following recommendations is most appropriate for a woman who is breastfeeding and requires treatment with Modeyso?", "options": {"A": "Continue breastfeeding during Modeyso therapy.", "B": "Discontinue breastfeeding only if adverse effects are observed in the infant.", "C": "Advise not to breastfeed during Modeyso treatment and for 1 week after the last dose.", "D": "Breastfeeding is safe if Modeyso is administered at a low dose."}}
{"id": "QP5N6nK1AukN", "question_type": "open_ended", "question": "A 62-year-old man with metastatic non-squamous lung adenocarcinoma and mild renal impairment (creatinine clearance 60 mL/min) is currently taking daily ibuprofen for arthritis. He is eligible for platinum-based chemotherapy. Which drug regimen should be used with caution or modification due to his current medications and renal status?", "options": {"A": "KEYTRUDA QLEX (Pembrolizumab and Berahyaluronidase Alfa) as monotherapy", "B": "Docetaxel as a single agent", "C": "Pemetrexed disodium in combination with platinum chemotherapy", "D": "Docetaxel in combination with cisplatin"}}
{"id": "TR7oTZBU6UN2", "question_type": "open_ended_multi_choice", "question": "A 15-year-old weighing 45 kg has moderate-to-severe atopic dermatitis unresponsive to prescription topical treatments. The patient also reports recurrent conjunctivitis and has a diagnosis of keratoconus. Taking into account the patient's age and comorbidities, which systemic therapy would be most suitable in terms of both safety and effectiveness?", "options": {"A": "Dexamethasone sodium phosphate administered intramuscularly every 2 weeks", "B": "Adbry administered subcutaneously every other week", "C": "Ebglyss administered subcutaneously every 4 weeks", "D": "Dexamethasone sodium phosphate administered orally daily"}}
{"id": "a4P30j32OMAR", "question_type": "multi_choice", "question": "For which patient populations is the use of Vizz contraindicated based on its official labeling?", "options": {"A": "Patients with severe hepatic impairment", "B": "Patients with known hypersensitivity to Vizz", "C": "None; there are no contraindications listed for Vizz", "D": "Patients with renal failure"}}
{"id": "aiyoAw5QxM8b", "question_type": "open_ended_multi_choice", "question": "A 35-year-old woman with primary axillary hyperhidrosis is planning to spend several weeks in a hot climate. She has a history of urinary retention and is currently breastfeeding. Which of the following treatments should be avoided due to her medical history and environmental exposure?", "options": {"A": "Qbrexza (glycopyrronium), topical wipes once daily", "B": "Sofdra (sofpironium bromide), topical gel once daily", "C": "Oxytrol for Women (oxybutynin), transdermal patch twice weekly", "D": "Both Qbrexza and Sofdra should be avoided"}}
{"id": "RchSswr1eG3H", "question_type": "open_ended_multi_choice", "question": "A 32-year-old woman presents with a sore throat, fever, and difficulty swallowing. She is diagnosed with bacterial pharyngitis caused by Streptococcus pyogenes. She has a history of mild asthma and is currently 24 weeks pregnant. She is not allergic to any medications and has normal renal function. Which of the following is the most appropriate drug for treating her infection, considering her pregnancy status and the need for effective therapy?", "options": {"A": "Ibuprofen, 400 mg orally every 6 hours as needed for pain and fever", "B": "Amphotericin B liposome, 3 mg/kg IV daily for 14 days", "C": "Cefixime, 400 mg orally once daily for 10 days", "D": "Ibuprofen, 800 mg orally every 8 hours for 7 days"}}
{"id": "YSQzXgsGnZBr", "question_type": "open_ended_multi_choice", "question": "When a patient on Vanrafia decides to alter their birth control method, what is the appropriate next step?", "options": {"A": "Change birth control without consulting a healthcare provider", "B": "Contact their healthcare provider to select another acceptable form", "C": "Stop all contraception immediately", "D": "Switch to natural family planning methods"}}
{"id": "cfD69UrmJUPV", "question_type": "multi_choice", "question": "A 7-year-old boy with Duchenne muscular dystrophy presents with progressive muscle weakness, calf muscle pseudohypertrophy, and elevated creatine kinase. Genetic testing confirms a DMD gene mutation amenable to exon 53 skipping. He has no history of renal impairment or arrhythmia. Which drug is the most appropriate for his treatment, considering his age and genetic profile?", "options": {"A": "Exondys 51 administered intravenously once weekly", "B": "Viltepso administered intravenously once weekly", "C": "Duvyzat administered orally twice daily", "D": "No drug therapy is appropriate due to age"}}
{"id": "jt4eOUpGpTrJ", "question_type": "open_ended_multi_choice", "question": "A 45-year-old man with schizophrenia, hyperactivity, and moderate renal impairment (eGFR 45 mL/min) is being considered for antipsychotic therapy. He does not have hepatic impairment, benign prostatic hyperplasia, or dementia-related psychosis. What is the most appropriate treatment option for him?", "options": {"A": "Cobenfy (xanomeline and trospium chloride), standard adult dose", "B": "Abilify Maintena (aripiprazole), standard adult dose", "C": "Cobenfy (xanomeline and trospium chloride), reduced dose", "D": "Abilify Maintena (aripiprazole), reduced dose for CYP2D6 poor metabolizers"}}
{"id": "d7ik8djbN1ya", "question_type": "multi_choice", "question": "Enflonsia should be avoided in infants with which of the following medical histories?", "options": {"A": "Serious hypersensitivity reactions to any component of Enflonsia", "B": "Mild skin rash after unrelated medication", "C": "Family history of asthma", "D": "History of otitis media"}}
{"id": "n41wN8wXiF9V", "question_type": "open_ended_multi_choice", "question": "For which patient population is Romvimza specifically contraindicated based on its official contraindication section?", "options": {"A": "Patients with severe renal impairment", "B": "Patients with known hypersensitivity to Romvimza", "C": "No patient population is specifically contraindicated", "D": "Pregnant or breastfeeding women"}}
{"id": "CgzBQY9l9XhB", "question_type": "open_ended_multi_choice", "question": "What statement most accurately characterizes whether Emrelis-induced fertility impairment in males can be reversed?", "options": {"A": "The effect is reversible", "B": "The effect is irreversible", "C": "The reversibility of the effect is unknown", "D": "Emrelis does not impair male fertility"}}
{"id": "p3DNYbeMXkGR", "question_type": "open_ended", "question": "Which of the following statements best describes the effect of strong or moderate CYP3A inducers on Ibtrozi therapy?", "options": {"A": "They increase taletrectinib exposure, raising adverse reaction risk.", "B": "They decrease taletrectinib exposure, potentially reducing effectiveness.", "C": "They have no effect on taletrectinib exposure.", "D": "They prolong the QTc interval."}}
{"id": "gcVeyR3trPBt", "question_type": "open_ended", "question": "Which conclusion can be drawn about the mutagenicity of Tryptyr based on standard genotoxicity tests?", "options": {"A": "Tryptyr was mutagenic in all standard genotoxicity tests.", "B": "Tryptyr was not mutagenic or clastogenic in the standard battery of genotoxicity tests.", "C": "Tryptyr was only mutagenic in bacterial assays.", "D": "Tryptyr was clastogenic but not mutagenic."}}
{"id": "QnT7M7sM6qu8", "question_type": "open_ended_multi_choice", "question": "A 34-year-old woman, 10 weeks into her pregnancy, presents with severe bone pain resulting from newly diagnosed metastatic breast cancer. She has no renal or liver dysfunction. Which analgesic would be most appropriate for her management?", "options": {"A": "Morphine sulfate, with counseling on fetal risks and neonatal opioid withdrawal syndrome", "B": "Ketorolac tromethamine for up to 5 days", "C": "Itovebi (inavolisib) in combination with palbociclib and fulvestrant", "D": "Ketorolac tromethamine for chronic pain management"}}
{"id": "iP6bgjbwPhvm", "question_type": "open_ended_multi_choice", "question": "A 45-year-old woman with severe renal impairment (creatinine clearance 25 mL/min) and a new diagnosis of hepatosplenic T-cell lymphoma is being evaluated for chemotherapy. She is not pregnant and has no history of autoimmune disease. Which drug is contraindicated in this patient due to her renal function?", "options": {"A": "Simponi Aria", "B": "Inflectra", "C": "Fludarabine phosphate", "D": "Azathioprine"}}
{"id": "R7y9va6HhSBZ", "question_type": "open_ended_multi_choice", "question": "A 48-year-old woman with recurrent, metastatic non-keratinizing nasopharyngeal carcinoma, well-controlled hypertension, and atrial fibrillation managed with warfarin presents for cancer treatment. She is neither pregnant nor breastfeeding, and her renal and hepatic function are normal. What is the most suitable first-line drug regimen for her condition?", "options": {"A": "Celecoxib 200 mg twice daily", "B": "Capecitabine 500 mg twice daily", "C": "Penpulimab-kcqx in combination with cisplatin and gemcitabine", "D": "Penpulimab-kcqx monotherapy"}}
{"id": "IIvKecFTNN4q", "question_type": "open_ended_multi_choice", "question": "What evidence exists regarding fertility impairment in the context of a regulatory submission for Enflonsia?", "options": {"A": "No reproductive toxicity studies have been conducted with Enflonsia.", "B": "Reproductive toxicity studies indicate no impairment of fertility.", "C": "Reproductive toxicity studies indicate potential impairment of fertility.", "D": "Reproductive toxicity studies are currently under review."}}
{"id": "tXOTOvaXkEaW", "question_type": "multi_choice", "question": "A 55-year-old adult with hereditary angioedema is experiencing an acute attack. The patient is currently taking a strong CYP3A4 inhibitor for another condition. Which drug is the most suitable for treating the acute attack, considering drug-drug interactions?", "options": {"A": "Ekterly", "B": "Icatibant", "C": "Icatibant acetate", "D": "Sajazir"}}
{"id": "EUrrG7J79L2U", "question_type": "open_ended_multi_choice", "question": "A woman, age 34, is newly diagnosed with hypertension and has a high mean arterial pressure. She plans to try for pregnancy soon and is currently using oral hormonal contraception. Her renal and hepatic function tests are within normal limits, and she has no other comorbidities. Which antihypertensive agent should be recommended for her at this time?", "options": {"A": "Aprocitentan (TRYVIO), once daily", "B": "Bosentan (TRACLEER), twice daily", "C": "Chlorthalidone (THALITONE), once daily", "D": "Aprocitentan (TRYVIO), twice daily"}}
{"id": "wvaA4GH5gFYL", "question_type": "open_ended_multi_choice", "question": "For a 52-year-old individual with cardiovascular risk factors considering topical Anzupgo for hand eczema, which statement most accurately describes the associated risk profile of Anzupgo?", "options": {"A": "Anzupgo is associated with increased risk of death in patients with cardiovascular risk factors, similar to oral JAK inhibitors for rheumatoid arthritis.", "B": "Anzupgo is contraindicated in all patients over 50 years old.", "C": "It is unknown whether Anzupgo carries the same risk of increased mortality as oral JAK inhibitors used for rheumatoid arthritis.", "D": "Anzupgo is recommended over TNF blockers in patients with cardiovascular risk factors."}}
{"id": "5yMWB2edgxbh", "question_type": "open_ended_multi_choice", "question": "A 35-year-old woman, currently pregnant and diagnosed with metastatic ROS1-positive non-small cell lung carcinoma, is evaluating targeted therapy options. She has no other health issues and is not taking any medications. What should be recommended about initiating taletrectinib therapy for her?", "options": {"A": "Start taletrectinib 600 mg orally once daily as it is safe in pregnancy.", "B": "Delay taletrectinib until after delivery due to risk of fetal harm.", "C": "Start taletrectinib with close fetal monitoring.", "D": "Taletrectinib is only contraindicated in pediatric patients, not pregnant women."}}
{"id": "k7RrSfLta8w8", "question_type": "open_ended_multi_choice", "question": "A 6-year-old child with malignant mesenchymoma is undergoing autologous bone marrow transplantation and is experiencing delayed neutrophil recovery. The patient has no history of cardiac arrhythmias or fluid retention, and is not taking any medications that induce myeloproliferation. Which of the following is the most appropriate drug to accelerate myeloid reconstitution in this patient, considering safety and efficacy in pediatric populations?", "options": {"A": "Leukine administered at the recommended pediatric dose post-transplant", "B": "HYCAMTIN administered orally for 5 consecutive days every 21 days", "C": "Vincristine Sulfate administered intravenously as a single agent", "D": "Leukine reconstituted with Bacteriostatic Water for Injection (contains benzyl alcohol)"}}
{"id": "4z9fUGA4K4NU", "question_type": "open_ended_multi_choice", "question": "A 68-year-old man with symptomatic obstructive hypertrophic cardiomyopathy (NYHA class III) is currently being treated with verapamil and metoprolol tartrate for arrhythmia management. When considering additional drug therapy, which medication should be avoided because of the increased risk of negative inotropic effects and possible progression to heart failure?", "options": {"A": "Acoramidis Hydrochloride", "B": "Mavacamten", "C": "Metoprolol Tartrate", "D": "Diltiazem"}}
{"id": "A6ksKkiUGZH2", "question_type": "open_ended_multi_choice", "question": "A contraindication to prescribing Blujepa would be indicated by which of the following patient histories?", "options": {"A": "Severe hypersensitivity to Blujepa", "B": "Mild gastrointestinal upset after Blujepa", "C": "Family history of hypertension", "D": "Previous use of Blujepa without adverse effects"}}
{"id": "iFfqw7E41iJm", "question_type": "open_ended_multi_choice", "question": "If a patient on Qfitlia 10 mg every 2 months has AT activity less than 15%, what is the recommended course of action?", "options": {"A": "Increase dose to 20 mg every 2 months", "B": "Continue current dosage", "C": "Discontinue Qfitlia", "D": "Switch to monthly dosing"}}
{"id": "rZlnpyPBEEfE", "question_type": "multi_choice", "question": "Which of the following best describes the contraindication profile for the drug Qfitlia?", "options": {"A": "Qfitlia is contraindicated in pediatric populations.", "B": "Qfitlia is contraindicated in patients with hepatic impairment.", "C": "Qfitlia should not be used in patients with a history of hypersensitivity reactions.", "D": "Qfitlia is contraindicated in pregnancy."}}
{"id": "BXvLDYnDmVWO", "question_type": "open_ended_multi_choice", "question": "A 45-year-old woman with presbyopia is breastfeeding her infant and is concerned about the safety of medications. She has no history of ocular inflammation or retinal disease. Which of the following is the most appropriate pharmacological treatment for her presbyopia?", "options": {"A": "Oraverse administered as an intraoral injection", "B": "VIZZ topical ocular drops, considering low systemic absorption", "C": "Mirvaso topical gel applied to the face", "D": "VIZZ topical ocular drops, contraindicated due to lactation"}}
{"id": "BBeneDckr0qB", "question_type": "open_ended_multi_choice", "question": "A 7-year-old boy diagnosed with congenital hemophilia A (factor VIII deficiency), who has never developed inhibitors to factor VIII and is otherwise healthy, is being evaluated for regular prophylactic therapy to reduce bleeding risk. What is the most suitable medication for him?", "options": {"A": "Alhemo administered as routine prophylaxis", "B": "Hemlibra administered as routine prophylaxis", "C": "Alhemo administered only during breakthrough bleeds", "D": "No prophylactic treatment is indicated for this patient"}}
{"id": "vw4cIDkMXuQZ", "question_type": "multi_choice", "question": "Which of the following best describes the evidence for the safety and effectiveness of Penpulimab-kcqx in pediatric patients?", "options": {"A": "Safety and effectiveness have been established in pediatric patients.", "B": "Safety has been established, but effectiveness has not.", "C": "Effectiveness has been established, but safety has not.", "D": "Neither safety nor effectiveness has been established in pediatric patients."}}
{"id": "hm7C2s2UZBYD", "question_type": "open_ended_multi_choice", "question": "A 42-year-old woman diagnosed with metastatic NSCLC and an EGFR exon 19 mutation is pregnant and preparing to start first-line treatment. She does not have any history of thromboembolism, cardiac conditions, or liver/kidney problems. Which treatment option should not be used in her case due to her pregnancy?", "options": {"A": "CYRAMZA in combination with erlotinib", "B": "Rozlytrek", "C": "LAZCLUZE (lazertinib plus amivantamab)", "D": "All of the above"}}
{"id": "RXjFcYtzHy1o", "question_type": "open_ended_multi_choice", "question": "A 45-year-old man with prurigo nodularis is scheduled to receive a live vaccine for travel. He has no history of hypersensitivity reactions and is otherwise healthy. Which treatment plan should be recommended for his prurigo nodularis?", "options": {"A": "Initiate NEMLUVIO therapy immediately and administer the live vaccine during treatment", "B": "Delay NEMLUVIO therapy until after completion of all age-appropriate live vaccinations", "C": "Start Nalbuphine Hydrochloride injection for prurigo nodularis management", "D": "Begin NEMLUVIO therapy and combine with Nalbuphine Hydrochloride for enhanced efficacy"}}
{"id": "mjdS5QqvxBIR", "question_type": "multi_choice", "question": "A 28-year-old woman with Niemann-Pick disease type C and progressive cognitive impairment is planning to become pregnant. She currently experiences frequent falls and dystonia. Which of the following is the most appropriate recommendation regarding drug therapy for her NPC-related neurological symptoms?", "options": {"A": "Start Miglustat (Yargesa) and advise contraception during treatment and for 60 days after discontinuation", "B": "Start AQNEURSA (levacetylleucine) and advise contraception during treatment and for 7 days after discontinuation", "C": "Start AQNEURSA (levacetylleucine) and advise contraception during treatment and for 60 days after discontinuation", "D": "Start Miglustat (Opfolda) in combination with Pombiliti and advise contraception during treatment and for 7 days after discontinuation"}}
{"id": "eVvRbVsOt8lC", "question_type": "open_ended_multi_choice", "question": "Regarding Penpulimab-kcqx, what information exists about its detection in human milk and any potential effects on breastfed children?", "options": {"A": "Penpulimab-kcqx is known to be present in human milk and is safe for the breastfed child.", "B": "There is no information regarding the presence of Penpulimab-kcqx in human milk or its effects on the breastfed child.", "C": "Penpulimab-kcqx is contraindicated only if the child is under 6 months old.", "D": "Penpulimab-kcqx increases milk production."}}
{"id": "Ls0q13XuYk9w", "question_type": "open_ended_multi_choice", "question": "A 54-year-old woman presents with unresectable, metastatic, hormone receptor-positive, HER2-negative breast cancer. She has previously undergone both endocrine therapy and chemotherapy. Her medical history includes mild renal impairment (creatinine clearance of 60 mL/min), but she has no history of interstitial lung disease or pneumonitis and is neither pregnant nor breastfeeding. Based on her renal function and prior treatments, which medication is most suitable for her cancer management?", "options": {"A": "MVASI", "B": "Ketorolac Tromethamine", "C": "DATROWAY", "D": "None of the above"}}
{"id": "pe0MjUPzdpkU", "question_type": "open_ended_multi_choice", "question": "A 58-year-old man with recurrent, metastatic non-keratinizing nasopharyngeal carcinoma and a history of coronary artery disease is currently on warfarin for atrial fibrillation. The oncology team is evaluating systemic treatment options. Taking into account his cancer type and existing medical conditions, which drug regimen should be selected?", "options": {"A": "Penpulimab-kcqx in combination with cisplatin and gemcitabine, administered every 3 weeks", "B": "Capecitabine 500 mg twice daily as monotherapy", "C": "Celecoxib 200 mg twice daily for pain management", "D": "Capecitabine 500 mg twice daily in combination with warfarin"}}
{"id": "eKjSUNxuW6z1", "question_type": "multi_choice", "question": "A 32-year-old woman with WHIM syndrome, characterized by myelokathexis, recurrent bacterial infections, and bronchiectasis, is planning to become pregnant. She currently has normal renal and hepatic function and is not taking any medications that interact with CYP3A4 or P-gp. Which of the following is the most appropriate recommendation regarding XOLREMDI therapy?", "options": {"A": "XOLREMDI should not be initiated due to the risk of fetal harm; effective contraception is required during and for 3 weeks after treatment.", "B": "XOLREMDI can be safely used during pregnancy with close fetal monitoring.", "C": "XOLREMDI is recommended only if the patient is also taking a strong CYP3A4 inhibitor.", "D": "XOLREMDI is safe to use during breastfeeding."}}
{"id": "w5t8axzUauiI", "question_type": "open_ended_multi_choice", "question": "How is the potential for reversing male fertility impairment caused by Emrelis best described?", "options": {"A": "The effect is reversible", "B": "The effect is irreversible", "C": "The reversibility of the effect is unknown", "D": "Emrelis does not impair male fertility"}}
{"id": "1Hyn8U0QXwlN", "question_type": "multi_choice", "question": "When counseling patients on Romvimza, what is the most important advice regarding concomitant medications and supplements?", "options": {"A": "Patients should avoid all over-the-counter products.", "B": "Patients may take any supplements without restriction.", "C": "Patients should inform their healthcare providers of all concomitant products, including over-the-counter products and supplements.", "D": "Only prescription medications need to be reported."}}
{"id": "BYTfIEhgBIGA", "question_type": "open_ended_multi_choice", "question": "A 15-year-old adolescent with PNH and a body weight of 45 kg is switching therapy after previously receiving eculizumab. The patient is scheduled for a drug holiday of 6 weeks before starting a new complement inhibitor. Which drug should be avoided due to the risk of Type III hypersensitivity reactions related to switching from another C5 inhibitor?", "options": {"A": "Sirolimus", "B": "Ultomiris", "C": "Piasky", "D": "Tacrolimus"}}
{"id": "ds6xczVyGM3S", "question_type": "open_ended_multi_choice", "question": "A 60-year-old man with generalized myasthenia gravis who is positive for anti-acetylcholine receptor antibodies and has chronic hepatitis is currently on ribavirin treatment. As immunosuppressive therapy is being considered, which medication should be avoided because of the heightened risk of severe pancytopenia and myelotoxicity resulting from drug interactions?", "options": {"A": "IMAAVY, 15 mg/kg intravenous infusion every 2 weeks", "B": "Azathioprine, 100 mg daily oral administration", "C": "DuoDote, single dose for acute management", "D": "IMAAVY, 10 mg/kg intravenous infusion every 4 weeks"}}
{"id": "3gMRjYiWqk54", "question_type": "multi_choice", "question": "A 62-year-old man with metastatic non-small cell lung carcinoma (NSCLC) presents for second-line therapy. His tumor is non-squamous, shows high c-Met protein overexpression (≥50% of tumor cells with strong staining), and he has a history of mild hepatic impairment (total bilirubin ≤ULN and AST >ULN). He is not taking any CYP3A inhibitors. Which drug regimen is most appropriate for this patient, considering his tumor profile and hepatic function?", "options": {"A": "Telisotuzumab vedotin (EMRELIS)", "B": "Ipilimumab in combination with nivolumab", "C": "Entrectinib (Rozlytrek)", "D": "Ipilimumab monotherapy"}}
{"id": "NiikMPZ9qgTM", "question_type": "open_ended", "question": "What is the current status of pregnancy safety data for Blujepa in humans?", "options": {"A": "Extensive human data show no risk in pregnancy.", "B": "There are no available data on the use of Blujepa in pregnant women to evaluate for drug-associated risk.", "C": "Blujepa is contraindicated in pregnancy due to proven teratogenicity.", "D": "Blujepa is recommended as first-line therapy in pregnancy."}}
{"id": "hJKLoQ4e1Ymd", "question_type": "open_ended_multi_choice", "question": "A pregnant 32-year-old woman in her second trimester develops supraventricular tachycardia. She does not have hepatic impairment, bronchospastic disease, or other significant comorbidities. Which drug should be chosen for acute rate control in this scenario?", "options": {"A": "Pacerone", "B": "Propranolol", "C": "RAPIBLYK", "D": "Pacerone with a drug holiday"}}
{"id": "kC3oekWp6UtR", "question_type": "multi_choice", "question": "A 60-year-old male with recurrent glioblastoma multiforme is being evaluated for systemic therapy. He has a history of hypertension that is well-controlled with medication and no evidence of recent surgery or wound healing complications. Genetic testing does not reveal an IDH1 or IDH2 mutation. Which of the following is the most appropriate treatment option for this patient?", "options": {"A": "Voranigo administered orally once daily", "B": "Zortress administered in combination with tacrolimus and corticosteroids", "C": "Voranigo in combination with a CYP1A2 inhibitor", "D": "Avastin administered intravenously every 2 weeks"}}
{"id": "5de9iklRYZ00", "question_type": "multi_choice", "question": "A 35-year-old woman with pulmonary arterial hypertension is currently pregnant and presents for management of her PAH. She is concerned about the safety of her fetus and asks about drug therapy options. Which of the following is the most appropriate recommendation regarding drug therapy for her PAH?", "options": {"A": "Initiate Winrevair, as it is the first-line therapy for PAH", "B": "Start epinephrine infusion to manage her PAH", "C": "Use vasopressin as a safe alternative for PAH in pregnancy", "D": "Avoid Winrevair due to embryo-fetal toxicity and advise against its use during pregnancy"}}
{"id": "0nUuefaS2rxq", "question_type": "open_ended_multi_choice", "question": "For lactating women using ANZUPGO, what clinical advice should be given to minimize potential infant exposure?", "options": {"A": "Discontinue breastfeeding while using ANZUPGO.", "B": "Avoid direct contact of the nipple and surrounding area immediately after applying ANZUPGO to hands and/or wrists.", "C": "Increase the frequency of breastfeeding.", "D": "Apply ANZUPGO only to the chest area."}}
{"id": "AxJetLKhsV5f", "question_type": "multi_choice", "question": "Which statement best describes the safety profile of Andembry in pregnant or breastfeeding individuals?", "options": {"A": "Andembry is proven safe in pregnancy and breastfeeding.", "B": "It is not known if Andembry can harm an unborn baby or passes into breastmilk.", "C": "Andembry is contraindicated in pregnancy.", "D": "Andembry is recommended for all pregnant women with HAE."}}
{"id": "5Nsiz9fu5MvL", "question_type": "open_ended", "question": "A 32-year-old woman with a genetic skin disease characterized by severe psoriasis is being considered for systemic therapy. She is of reproductive age, currently using a microdosed progestin 'minipill' for contraception, and reports occasional alcohol consumption. Which of the following is the most appropriate drug management strategy for her condition?", "options": {"A": "Initiate acitretin therapy with her current contraceptive method and no change in alcohol intake.", "B": "Start acitretin therapy only after switching to two effective forms of contraception (excluding the 'minipill') and abstaining from alcohol during and for 2 months after treatment.", "C": "Begin acitretin therapy while continuing alcohol consumption, but switch to a combined oral contraceptive.", "D": "Prescribe acitretin with no contraception requirements, as long as alcohol is avoided."}}
{"id": "4CvnKm3s1CR3", "question_type": "open_ended_multi_choice", "question": "A 9-year-old boy diagnosed with autosomal dominant atopic dermatitis presents with ongoing skin infections, itching, and dryness. He weighs 32 kg and has a background of allergic rhinitis and asthma. With topical agents proving ineffective, his mother asks about the best medication to manage his moderate-to-severe symptoms. Which drug should be recommended for this patient?", "options": {"A": "Lebrikizumab-lbkz administered subcutaneously every 2 weeks", "B": "DMT SUIK administered intravenously as needed for severe exacerbations", "C": "Doxepin hydrochloride cream applied topically for up to 8 days", "D": "Lebrikizumab-lbkz administered subcutaneously every 4 weeks"}}
{"id": "NupxBFtKlWDc", "question_type": "multi_choice", "question": "A 14-year-old patient presents with non-cystic fibrosis bronchiectasis, recurrent bronchopulmonary infections, and chronic sinusitis. The patient has a history of gingival sensitivity and is scheduled to receive a live attenuated vaccine in the coming weeks. Which drug regimen is most appropriate for managing this patient's bronchiectasis?", "options": {"A": "ORKAMBI, with close monitoring of liver function and avoidance of CYP3A substrates", "B": "SYMDEKO, with dose adjustment for age and monitoring for cataracts", "C": "Brinsupri, with regular dental checkups and avoidance of live attenuated vaccines", "D": "Brinsupri, administered concurrently with live attenuated vaccines"}}
{"id": "yxLXXUk3lmPx", "question_type": "open_ended_multi_choice", "question": "A 62-year-old woman with carcinoma of the stomach, salivary gland type, is being considered for off-label therapy. She is scheduled for elective abdominal surgery in two weeks and has a history of controlled diabetes. Which drug should be avoided due to the risk of impaired wound healing and surgical complications if administered before or soon after surgery?", "options": {"A": "Onivyde", "B": "Avastin", "C": "Irinotecan Hydrochloride", "D": "All are equally appropriate"}}
{"id": "4C3wYi0uzXnm", "question_type": "open_ended_multi_choice", "question": "A middle-aged man, aged 45, presents with prurigo nodularis and is scheduled for a live vaccine due to upcoming travel. His medical history is unremarkable except for prurigo nodularis. What is the recommended approach to treating his skin condition?", "options": {"A": "Initiate NEMLUVIO therapy immediately and administer the live vaccine during treatment", "B": "Delay NEMLUVIO therapy until after completion of all age-appropriate live vaccinations", "C": "Start Nalbuphine Hydrochloride injection for prurigo nodularis management", "D": "Begin NEMLUVIO therapy and combine with Nalbuphine Hydrochloride for enhanced efficacy"}}
{"id": "0sIPGSnIL6OX", "question_type": "multi_choice", "question": "How frequently was single-agent penpulimab-kcqx administered in the AK105-202 study for patients with unresectable or metastatic non-keratinizing nasopharyngeal carcinoma?", "options": {"A": "400 mg intravenously every 4 weeks", "B": "200 mg orally every day", "C": "200 mg intravenously every 2 weeks", "D": "100 mg intravenously every week"}}
{"id": "UJjGDOMY62ez", "question_type": "open_ended_multi_choice", "question": "A woman aged 45, currently breastfeeding her infant, has presbyopia and is worried about the safety of medications. There is no history of retinal disease or ocular inflammation. Which pharmacological option is most appropriate for treating her presbyopia?", "options": {"A": "Oraverse administered as an intraoral injection", "B": "VIZZ topical ocular drops, considering low systemic absorption", "C": "Mirvaso topical gel applied to the face", "D": "VIZZ topical ocular drops, contraindicated due to lactation"}}
{"id": "pkBxcrJGZj5B", "question_type": "open_ended_multi_choice", "question": "A 28-year-old man with severe alopecia areata is being considered for drug therapy. He has tested positive as a CYP2C9 poor metabolizer and is currently taking a moderate CYP2C9 inhibitor for another condition. He is not pregnant or breastfeeding and has normal renal and hepatic function. Which drug should be selected for his treatment?", "options": {"A": "Leqselvi (deuruxolitinib phosphate), once daily", "B": "Minoxidil topical solution, twice daily", "C": "Imiquimod cream, three times per week", "D": "None of the above drugs are appropriate"}}
{"id": "eXiyWB1DmUwK", "question_type": "open_ended_multi_choice", "question": "A 10-year-old child weighing 32 kg is newly diagnosed with paroxysmal nocturnal hemoglobinuria (PNH). The patient has no history of complement inhibitor therapy and is up to date with meningococcal vaccination. Which drug is the most appropriate for initial treatment in this patient, considering age and weight restrictions?", "options": {"A": "Ultomiris", "B": "Piasky", "C": "Sirolimus", "D": "Eculizumab"}}
{"id": "Se9ZpOH8kv46", "question_type": "open_ended_multi_choice", "question": "Which of the following is an instruction for patients regarding the use of Andembry?", "options": {"A": "Inject Andembry intravenously without training.", "B": "Use Andembry for any condition with similar symptoms.", "C": "Do not give Andembry to other people, even if they have the same symptoms.", "D": "Mix Andembry with herbal supplements before injection."}}
{"id": "zQZEWdjUuFUk", "question_type": "multi_choice", "question": "A 55-year-old adult with hereditary angioedema is experiencing an acute attack. The patient is currently taking a strong CYP3A4 inhibitor for another condition. Which drug is the most suitable for treating the acute attack, considering drug-drug interactions?", "options": {"A": "Ekterly", "B": "Sajazir", "C": "Icatibant acetate", "D": "Icatibant"}}
{"id": "EaZWemcPWJ05", "question_type": "open_ended", "question": "A 28-year-old woman with chronic immune thrombocytopenia and abnormal bleeding is planning pregnancy. She is currently not pregnant but is of reproductive potential. She previously failed corticosteroids and is considering a drug holiday for 2 weeks due to travel. Which drug should be avoided due to embryo-fetal toxicity risk and contraceptive requirements, even during a short drug holiday?", "options": {"A": "PROMACTA (Eltrombopag) 50 mg once daily", "B": "Prednisone 60 mg daily", "C": "WAYRILZ (Rilzabrutinib) 400 mg twice daily", "D": "PROMACTA (Eltrombopag) 25 mg once daily"}}
{"id": "2qeglxs2YH5o", "question_type": "open_ended_multi_choice", "question": "A patient is prescribed Grafapex along with a medication that is a sensitive CYP3A4 substrate. What is the recommended clinical approach?", "options": {"A": "Monitor for adverse reactions and consider reducing the substrate dosage if recommended.", "B": "Increase the substrate dosage to compensate for reduced metabolism.", "C": "Discontinue Grafapex immediately.", "D": "No action is necessary as there is no interaction."}}
{"id": "FCxY8jwGxSNW", "question_type": "open_ended_multi_choice", "question": "For a pediatric patient scheduled for cardiac surgery in their first RSV season, what should clinicians do regarding Enflonsia treatment?", "options": {"A": "Delay Enflonsia until after the RSV season", "B": "Administer an additional Enflonsia injection soon after surgery", "C": "Discontinue Enflonsia permanently", "D": "Switch to oral Enflonsia therapy"}}
{"id": "iL6SuTpST1Kg", "question_type": "open_ended_multi_choice", "question": "A 45-year-old woman with chronic graft-versus-host disease (cGVHD) presents with recurrent infections, elevated hepatic transaminase, and thickened skin. She has failed two prior lines of systemic therapy. She is not pregnant and does not plan to breastfeed. Her weight is 65 kg. Which drug is the most appropriate for her next line of treatment, considering her disease history and current clinical status?", "options": {"A": "PredniSONE Tablets, USP, 5 mg", "B": "Budesonide Inhalation", "C": "AXATILIMAB-CSFR", "D": "Budesonide Inhalation combined with PredniSONE"}}
{"id": "SUVJhlTI38eE", "question_type": "open_ended_multi_choice", "question": "What should be done if a patient receiving Qfitlia 10 mg every two months presents with antithrombin (AT) activity below 15%?", "options": {"A": "Increase dose to 20 mg every 2 months", "B": "Continue current dosage", "C": "Discontinue Qfitlia", "D": "Switch to monthly dosing"}}
{"id": "wAScIHkcK9T8", "question_type": "open_ended_multi_choice", "question": "A 28-year-old male with a diagnosis of severe alopecia areata is being considered for medication. He has tested as a CYP2C9 poor metabolizer and is concurrently using a moderate CYP2C9 inhibitor for another health issue. He has normal kidney and liver function and is not pregnant or breastfeeding. Which drug should be chosen for his therapy?", "options": {"A": "Leqselvi (deuruxolitinib phosphate), once daily", "B": "Minoxidil topical solution, twice daily", "C": "Imiquimod cream, three times per week", "D": "None of the above drugs are appropriate"}}
{"id": "q9UhXQJXppdL", "question_type": "multi_choice", "question": "A 62-year-old man with metastatic non-small cell lung carcinoma (NSCLC) presents for second-line therapy. His tumor is non-squamous, shows high c-Met protein overexpression (≥50% of tumor cells with strong staining), and he has a history of mild hepatic impairment (total bilirubin ≤ULN and AST >ULN). He is not taking any CYP3A inhibitors. Which drug regimen is most appropriate for this patient, considering his tumor profile and hepatic function?", "options": {"A": "Ipilimumab in combination with nivolumab", "B": "Telisotuzumab vedotin (EMRELIS)", "C": "Entrectinib (Rozlytrek)", "D": "Ipilimumab monotherapy"}}
{"id": "QuLcg4awbWGQ", "question_type": "multi_choice", "question": "A 5-year-old boy with BH4-responsive phenylketonuria presents with fair hair, generalized hypopigmentation, and a history of seizures. He is currently receiving levodopa for a movement disorder. His parents are concerned about the risk of hypophenylalaninemia and neurological side effects. Which drug regimen requires the most careful monitoring for neurological status and blood phenylalanine levels in this patient?", "options": {"A": "Sapropterin dihydrochloride at 20 mg/kg per day with a phenylalanine-restricted diet", "B": "Sephience at 60 mg/kg per day with a phenylalanine-restricted diet", "C": "JAVYGTOR at 20 mg/kg per day with a phenylalanine-restricted diet", "D": "Sephience at 20 mg/kg per day with a phenylalanine-restricted diet"}}
{"id": "0KoR4ER4gd9I", "question_type": "multi_choice", "question": "A 60-year-old woman with recurrent low-grade serous ovarian carcinoma and a confirmed KRAS mutation is scheduled to begin AVMAPKI FAKZYNJA CO-PACK. She has a history of chronic gastroesophageal reflux disease and takes omeprazole (a proton pump inhibitor) daily. What is the best strategy to ensure effective cancer treatment?", "options": {"A": "Continue omeprazole and start AVMAPKI FAKZYNJA CO-PACK as planned", "B": "Switch omeprazole to an H2 receptor antagonist and start AVMAPKI FAKZYNJA CO-PACK", "C": "Continue omeprazole but administer FAKZYNJA 2 hours before or after a locally acting antacid", "D": "Discontinue omeprazole and avoid all gastric acid reducing agents during AVMAPKI FAKZYNJA CO-PACK therapy"}}
{"id": "KFWViA7VdZdl", "question_type": "open_ended_multi_choice", "question": "A 68-year-old male patient with moderate to severe chronic hand eczema and a prior diagnosis of basal cell carcinoma has not responded adequately to topical corticosteroids and is not currently on any immunosuppressive medications. Which drug therapy approach is most suitable for him?", "options": {"A": "Delgocitinib topical therapy with periodic skin examinations", "B": "Delgocitinib without any skin cancer monitoring", "C": "Combination of Delgocitinib and another JAK inhibitor", "D": "Topical corticosteroids despite prior inadequate response"}}
{"id": "oExVIBVQd5sF", "question_type": "open_ended", "question": "What should patients be advised regarding the potential impact of Romvimza on fertility?", "options": {"A": "Romvimza has no known effect on fertility.", "B": "Romvimza may impair fertility.", "C": "Romvimza improves fertility in both males and females.", "D": "Romvimza only affects fertility in males."}}
{"id": "8o6FHrra2R3p", "question_type": "open_ended_multi_choice", "question": "A 68-year-old woman with metastatic undifferentiated pancreatic carcinoma and a history of chronic kidney disease requiring dialysis is being considered for systemic chemotherapy. She is not pregnant and is not taking any strong CYP3A4 inducers or inhibitors. Which of the following regimens is most appropriate for her?", "options": {"A": "Irinotecan Hydrochloride 100 mg/5 mL as a single agent", "B": "Onivyde in combination with fluorouracil and leucovorin", "C": "Irinotecan Hydrochloride 100 mg/5 mL in combination with fluorouracil and leucovorin", "D": "Onivyde as a single agent"}}
{"id": "q3a7eRnYONX1", "question_type": "open_ended_multi_choice", "question": "If a patient wishes to change their form of birth control while on Vanrafia, what is the recommended course of action?", "options": {"A": "Change birth control without consulting a healthcare provider", "B": "Contact their healthcare provider to select another acceptable form", "C": "Stop all contraception immediately", "D": "Switch to natural family planning methods"}}
{"id": "7oSleid5muNU", "question_type": "open_ended_multi_choice", "question": "A 58-year-old woman with locally advanced, hormone receptor-positive, HER2-negative breast cancer is found to have a PIK3CA mutation by FDA-approved testing. She has a history of well-controlled type 2 diabetes managed with oral anti-hyperglycemic agents. Her renal function is normal, and she is not pregnant or breastfeeding. She is being considered for targeted therapy in combination with palbociclib and fulvestrant. Which drug regimen is most appropriate for her condition, considering her comorbidities and the safety profile of available agents?", "options": {"A": "Carboplatin in combination with cyclophosphamide", "B": "Inavolisib in combination with palbociclib and fulvestrant", "C": "Esketamine as monotherapy", "D": "Carboplatin as a single agent"}}
{"id": "GZRx4Fzby9Cb", "question_type": "multi_choice", "question": "Which of the following immune-mediated endocrinopathies has the highest reported incidence in patients treated with penpulimab-kcqx as a single agent?", "options": {"A": "Hyperthyroidism", "B": "Hypothyroidism", "C": "Thyroiditis", "D": "Adrenal insufficiency"}}
{"id": "DDVe33DB7xMo", "question_type": "open_ended_multi_choice", "question": "A patient with hemophilia and a history of symptomatic gallbladder disease is being considered for Qfitlia therapy. What is the recommended clinical consideration in this scenario?", "options": {"A": "Consider alternative treatment for hemophilia", "B": "Increase Qfitlia dose", "C": "Monitor only for thrombotic events", "D": "Continue Qfitlia without modification"}}
{"id": "SfCRjrrVwHsa", "question_type": "open_ended_multi_choice", "question": "A 34-year-old pregnant woman presents with non–ST-segment elevation myocardial infarction (NSTEMI). She requires antiplatelet therapy for secondary prevention. She is concerned about the safety of medications during pregnancy. Which agent is most suitable for her condition?", "options": {"A": "Flyrcado", "B": "BRILINTA", "C": "Clopidogrel", "D": "BRILINTA with aspirin"}}
{"id": "Q32nFtd6miAx", "question_type": "open_ended_multi_choice", "question": "If a pediatric patient weighing 42.5 kg to less than 52.5 kg experiences a Grade 3 adverse reaction while on Modeyso, what is the recommended dosage modification?", "options": {"A": "Interrupt Modeyso until ≤Grade 1 or baseline, then resume at 375 mg once weekly", "B": "Permanently discontinue Modeyso", "C": "Increase dose to 500 mg once weekly", "D": "Continue at the same dose"}}
{"id": "tD8UkNGWs09N", "question_type": "multi_choice", "question": "Why might concomitant use of Grafapex and certain CYP2C19 substrates increase the risk of serious or life-threatening toxicities?", "options": {"A": "Grafapex increases renal clearance of CYP2C19 substrates.", "B": "Grafapex induces CYP2C19, decreasing substrate exposure.", "C": "Grafapex has no effect on CYP2C19 metabolism.", "D": "Grafapex inhibits CYP2C19, increasing substrate exposure."}}
{"id": "hWcmhsHKNEkk", "question_type": "multi_choice", "question": "A 34-year-old woman with familial chylomicronemia syndrome presents with recurrent pancreatitis, hepatosplenomegaly, and eruptive xanthomas. She is currently 10 weeks pregnant and is seeking a medication to reduce her triglyceride levels. She is concerned about the safety of drug therapy during pregnancy. Which of the following is the most appropriate pharmacological option for her condition?", "options": {"A": "MYCOPHENOLATE MOFETIL, with strict contraception counseling and regular pregnancy testing.", "B": "TRYNGOLZA administered as an adjunct to diet, with careful monitoring for hypersensitivity reactions.", "C": "MYCOPHENOLATE MOFETIL, combined with a drug holiday during the first trimester.", "D": "TRYNGOLZA, but only after delivery due to lack of safety data in pregnancy."}}
{"id": "ZSduEDnBoJQr", "question_type": "open_ended_multi_choice", "question": "In preparing a clinical study, a researcher must exclude individuals with contraindications to the study drugs. For which of the following drugs is it unnecessary to set exclusion criteria based on contraindications?", "options": {"A": "Wayrilz", "B": "A drug with known contraindication in pregnancy", "C": "A drug contraindicated in patients with cardiac arrhythmia", "D": "A drug contraindicated in patients with hepatic insufficiency"}}
{"id": "oY7FAfEveR4f", "question_type": "open_ended_multi_choice", "question": "What is a recommended action if a patient develops acute gallbladder disease while on Qfitlia?", "options": {"A": "Consider interruption or discontinuation of Qfitlia", "B": "Increase the Qfitlia dose", "C": "Add a statin", "D": "Continue Qfitlia without changes"}}
{"id": "YkHn1tFBFrFV", "question_type": "multi_choice", "question": "In patients treated with penpulimab-kcqx, which of the following adverse events is specifically associated with an increased risk if the patient has received prior thoracic radiation?", "options": {"A": "Immune-mediated hepatitis", "B": "Immune-mediated pneumonitis", "C": "Immune-mediated nephritis", "D": "Immune-mediated colitis"}}
{"id": "RZ7mDHPLwDB0", "question_type": "open_ended_multi_choice", "question": "A 59-year-old woman recently diagnosed with multiple myeloma is being considered for autologous stem cell transplantation. Her renal function is normal, she is not pregnant, and she has no history of thromboembolism or neuropathy. She is also not using CNS depressants or cardiac medications. What is the most suitable drug regimen to mobilize hematopoietic stem cells before transplantation?", "options": {"A": "Thalomid in combination with dexamethasone", "B": "LYNOZYFIC", "C": "Mozobil in combination with filgrastim", "D": "Thalomid monotherapy"}}
{"id": "SOcosyX3j7jK", "question_type": "open_ended_multi_choice", "question": "A 55-year-old female patient with WHO Group 1 pulmonary arterial hypertension is on prostacyclin infusion and antithrombotic therapy. Her platelet count is 45,000/mm³. She is being evaluated for a new medication to enhance exercise capacity and prevent clinical deterioration. Which medication should not be used in this scenario?", "options": {"A": "Ambrisentan once daily", "B": "Macitentan once daily", "C": "Sotatercept-csrk every three weeks", "D": "Ambrisentan in combination with tadalafil"}}
{"id": "97OedQ1e16IV", "question_type": "multi_choice", "question": "A 60-year-old woman with recurrent low-grade serous ovarian carcinoma and a confirmed KRAS mutation is scheduled to begin AVMAPKI FAKZYNJA CO-PACK. She has a history of chronic gastroesophageal reflux disease and takes omeprazole (a proton pump inhibitor) daily. What is the best strategy to ensure effective cancer treatment?", "options": {"A": "Discontinue omeprazole and avoid all gastric acid reducing agents during AVMAPKI FAKZYNJA CO-PACK therapy", "B": "Continue omeprazole and start AVMAPKI FAKZYNJA CO-PACK as planned", "C": "Continue omeprazole but administer FAKZYNJA 2 hours before or after a locally acting antacid", "D": "Switch omeprazole to an H2 receptor antagonist and start AVMAPKI FAKZYNJA CO-PACK"}}
{"id": "odBI5XnSzq3f", "question_type": "multi_choice", "question": "A 77-year-old male with a diagnosis of wild-type transthyretin-mediated amyloidosis cardiomyopathy (ATTR-CM) presents for management. He has a history of hypertension controlled with amlodipine and is not taking any CYP2C9 substrate medications. He is otherwise healthy, with no hepatic impairment or respiratory disease. Which drug is most appropriate for reducing cardiovascular death and hospitalization in this patient, considering his age and disease subtype?", "options": {"A": "Verapamil", "B": "Mavacamten", "C": "Metoprolol Tartrate", "D": "Acoramidis Hydrochloride"}}
{"id": "85L4BMLwMvyK", "question_type": "multi_choice", "question": "A 35-year-old pregnant woman is diagnosed with low-grade glioma. She is seeking treatment options that minimize risk to her fetus. Genetic testing reveals no BRAF fusion or V600 mutation. Which of the following therapies is contraindicated for her due to pregnancy risk and lack of efficacy for her tumor profile?", "options": {"A": "OJEMDA, as a kinase inhibitor targeting BRAF mutations, administered orally.", "B": "VinCRIStine Sulfate, administered intravenously, with risk of fetal harm.", "C": "Supportive care only, deferring cytotoxic or targeted therapy until after pregnancy.", "D": "Gliadel Wafer, implanted during surgery, with known embryo-fetal toxicity."}}
{"id": "1E1ygN0Nd3fQ", "question_type": "open_ended_multi_choice", "question": "When initiating therapy with a strong CYP3A inducer in a patient already on Wayrilz, what is the principal clinical concern?", "options": {"A": "Increased risk of hypertension", "B": "Reduced efficacy of Wayrilz", "C": "Increased risk of renal toxicity", "D": "Prolonged QT interval"}}
{"id": "iltLLc7G6YEM", "question_type": "open_ended_multi_choice", "question": "A patient is taking a moderate CYP3A4 inducer and is prescribed Ekterly for an acute HAE attack. What is the appropriate course of action?", "options": {"A": "Administer standard Ekterly dosage", "B": "Reduce Ekterly dosage by half", "C": "Avoid concomitant use of Ekterly", "D": "Increase Ekterly dosage"}}
{"id": "bUniA0IrRU45", "question_type": "multi_choice", "question": "A 45-year-old man with schizophrenia and a history of benign prostatic hyperplasia (BPH) and incomplete bladder emptying is being considered for antipsychotic therapy. He has normal renal and hepatic function. Which antipsychotic is most suitable for this patient?", "options": {"A": "Abilify Maintena, administered as a monthly intramuscular injection", "B": "Cobenfy, administered orally twice daily", "C": "Cobenfy, administered orally once daily with close monitoring", "D": "Abilify Maintena, administered as a biweekly intramuscular injection"}}
{"id": "PfCeFXA4cZBw", "question_type": "open_ended", "question": "A 54-year-old patient presents with difficulty reading small print and reports gradual worsening of near vision over the past year. The patient has no history of retinal disease, iritis, or hypersensitivity to medications. He asks about available drug treatments for presbyopia. Which of the following is the most appropriate pharmacological option for this patient, considering both efficacy and safety?", "options": {"A": "Oraverse administered as an intraoral injection after dental procedures", "B": "Mirvaso topical gel applied once daily to the face", "C": "VIZZ (aceclidine) ophthalmic drops administered as directed for presbyopia", "D": "Oraverse administered daily for vision improvement"}}
{"id": "kDZJ4Rhex55r", "question_type": "open_ended_multi_choice", "question": "In the context of drug-drug interactions, what is the mechanistic basis for Grafapex increasing the exposure of certain CYP3A4 substrates?", "options": {"A": "Inhibition of CYP3A4 by treosulfan", "B": "Induction of CYP3A4 by treosulfan", "C": "Inhibition of P-glycoprotein by treosulfan", "D": "Increased hepatic blood flow caused by Grafapex"}}
{"id": "0n1rwBrRppF5", "question_type": "open_ended_multi_choice", "question": "A pregnant woman, aged 32, is diagnosed with an ABSSSI caused by MRSA. She has no allergies to medications and her renal function is normal. Which treatment option is most appropriate, considering both its safety profile in pregnancy and its approved indications?", "options": {"A": "Doxycycline hyclate", "B": "Acetaminophen", "C": "Ceftobiprole medocaril sodium", "D": "No antibiotic therapy is indicated during pregnancy"}}
{"id": "1yrOm0stD4Nc", "question_type": "open_ended", "question": "A 7-month-old infant with ciliary dyskinesia-bronchiectasis is being considered for pharmacologic therapy for airway management. The infant does not have cystic fibrosis or any known CFTR mutations. Which of the following is the most suitable drug option for this patient, considering age, efficacy, and safety?", "options": {"A": "Albuterol Sulfate HFA inhalation aerosol, 90 mcg per actuation, administered with a valved holding chamber and mask three times daily", "B": "Kalydeco oral granules, 5.8 mg twice daily", "C": "Albuterol Sulfate HFA inhalation aerosol, 180 mcg per actuation, administered with a valved holding chamber and mask three times daily", "D": "Kalydeco oral granules, 25 mg twice daily"}}
{"id": "p2lLqAZIuglt", "question_type": "multi_choice", "question": "A 56-year-old woman with metastatic, hormone receptor-positive, HER2-negative breast cancer has a confirmed PIK3CA mutation and has progressed after adjuvant endocrine therapy. She also has a history of well-controlled Type 2 diabetes managed with oral anti-hyperglycemic agents. Her oncologist is considering targeted therapy in combination with palbociclib and fulvestrant. Which drug regimen is most appropriate for her cancer management, considering her comorbidities and the need for close metabolic monitoring?", "options": {"A": "Itovebi (inavolisib) monotherapy without palbociclib or fulvestrant", "B": "Morphine sulfate for pain control, as primary cancer therapy", "C": "Ketorolac tromethamine for chronic pain management and cancer therapy", "D": "Itovebi (inavolisib) in combination with palbociclib and fulvestrant, with intensified glucose monitoring and anti-hyperglycemic management"}}
{"id": "MvOC6Rzfaw43", "question_type": "open_ended_multi_choice", "question": "What is the best description of the data regarding Tryptyr's potential to cause cancer?", "options": {"A": "Long-term animal studies have demonstrated a high carcinogenic risk for Tryptyr.", "B": "Long-term studies in animals have not been performed to evaluate the carcinogenic potential of Tryptyr.", "C": "Tryptyr has been shown to be non-carcinogenic in human clinical trials.", "D": "Tryptyr is classified as a probable human carcinogen based on in vitro data."}}
{"id": "UKFe5TC34xEj", "question_type": "open_ended_multi_choice", "question": "A 34-year-old woman, currently 10 weeks pregnant, has chronic graft-versus-host disease (cGVHD) with symptoms including morphea, muscle weakness, and repeated infections. After failing two systemic therapies, her weight is 65 kg and her liver function tests are normal. Which medication regimen is most appropriate and safest for her at this time?", "options": {"A": "Niktimvo, intravenous infusion every 2 weeks", "B": "PredniSONE, 5 mg orally once daily", "C": "PONVORY, 20 mg orally once daily", "D": "Niktimvo, intravenous infusion every 4 weeks"}}
{"id": "nOgByrBlAAas", "question_type": "open_ended_multi_choice", "question": "What is the most accurate summary of the clinical knowledge related to Enflonsia overdose?", "options": {"A": "Extensive clinical data are available regarding overdose management.", "B": "There is limited experience of overdose with Enflonsia.", "C": "Overdose cases always require surgical intervention.", "D": "Overdose is well-characterized in adult populations."}}
{"id": "yTKSwe29G4KN", "question_type": "open_ended_multi_choice", "question": "If a patient on Ibtrozi develops a QTc interval greater than 500 msec or a change from baseline greater than 60 msec, what is the recommended action?", "options": {"A": "Continue Ibtrozi at the same dose", "B": "Reduce the dose of Ibtrozi", "C": "Withhold Ibtrozi", "D": "Switch to a CYP3A inducer"}}
{"id": "Wk67CsjvEXki", "question_type": "open_ended_multi_choice", "question": "A 10-year-old boy presents with progressive lower limb muscle weakness, limb ataxia, and impaired vibration sensation at the ankles. MRI reveals gadolinium enhancement and a Loes score of 3. He is diagnosed with early, active cerebral adrenoleukodystrophy (CALD). He has no available HLA-matched donor for stem cell transplant. His medical history is negative for HIV, hepatic, or renal impairment. Which therapy is most appropriate to slow the progression of his neurologic dysfunction, considering his age and disease stage?", "options": {"A": "Skysona administered as a single autologous hematopoietic stem cell-based gene therapy infusion", "B": "Actos 30 mg orally once daily", "C": "PNV-DHA multivitamin/mineral supplementation daily", "D": "Supportive care only, as no disease-modifying therapy is available"}}
{"id": "pKRGslpdEx2E", "question_type": "open_ended_multi_choice", "question": "A 38-year-old woman with symptomatic TGCT, not amenable to surgery, is currently breastfeeding and wishes to continue after treatment. She has normal liver and renal function, no history of allergies, and is not pregnant. Which drug and breastfeeding schedule is most appropriate for her?", "options": {"A": "Turalio, with breastfeeding resumed 1 week after final dose", "B": "ROMVIMZA, with breastfeeding resumed 1 week after final dose", "C": "ROMVIMZA, with breastfeeding resumed 1 month after final dose", "D": "Turalio, with breastfeeding resumed 1 month after final dose"}}
{"id": "ihymczVAZwxx", "question_type": "multi_choice", "question": "A patient is prescribed Wayrilz and is also taking an antacid. How should the administration of Wayrilz be managed in relation to the antacid?", "options": {"A": "Administer Wayrilz at least 2 hours after the antacid", "B": "Take Wayrilz and the antacid together", "C": "Administer Wayrilz at least 2 hours before the antacid", "D": "Crush Wayrilz and mix with the antacid"}}
{"id": "8CqUA2gvQqBt", "question_type": "multi_choice", "question": "What risk is increased when Lynozyfic is administered with CYP substrates?", "options": {"A": "Risk of enhanced metabolism of CYP substrates", "B": "Risk of decreased efficacy of Lynozyfic", "C": "Risk of adverse reactions related to CYP substrates", "D": "Risk of reduced cytokine release"}}
{"id": "QoeodTQRBR1y", "question_type": "multi_choice", "question": "A clinical trial protocol is being designed for a new medication. If the drug brand name is Ekterly, which exclusion criteria based on contraindications should be considered?", "options": {"A": "No exclusion criteria based on contraindications are necessary.", "B": "Exclude patients with cardiac arrhythmias.", "C": "Exclude patients with a history of anaphylaxis to Ekterly.", "D": "Exclude patients with severe renal impairment."}}
{"id": "cvl9UKY8c6I2", "question_type": "open_ended", "question": "A 48-year-old woman with recurrent low-grade serous ovarian carcinoma and confirmed KRAS mutation presents for treatment after failing prior systemic therapy. She is currently taking warfarin for atrial fibrillation and requires ongoing anticoagulation. Which of the following is the most appropriate drug regimen for her cancer management?", "options": {"A": "AVMAPKI FAKZYNJA CO-PACK (avutometinib and defactinib)", "B": "AVMAPKI FAKZYNJA CO-PACK with close INR monitoring and continued warfarin", "C": "AVMAPKI FAKZYNJA CO-PACK after switching to a non-warfarin anticoagulant", "D": "No systemic therapy due to drug interactions"}}
{"id": "31dGIIz7Xufl", "question_type": "open_ended", "question": "When reviewing the safety profile of Tryptyr, which of the following best reflects its contraindication status?", "options": {"A": "Tryptyr is contraindicated in pediatric patients.", "B": "Tryptyr is contraindicated in patients with a history of anaphylaxis.", "C": "Tryptyr has no contraindications listed in its prescribing information.", "D": "Tryptyr is contraindicated in patients with severe liver disease."}}
{"id": "rQnnzaaXM4H1", "question_type": "multi_choice", "question": "A 14-year-old patient presents with non-cystic fibrosis bronchiectasis, recurrent bronchopulmonary infections, and chronic sinusitis. The patient has a history of gingival sensitivity and is scheduled to receive a live attenuated vaccine in the coming weeks. Which drug regimen is most appropriate for managing this patient's bronchiectasis?", "options": {"A": "Brinsupri, administered concurrently with live attenuated vaccines", "B": "SYMDEKO, with dose adjustment for age and monitoring for cataracts", "C": "ORKAMBI, with close monitoring of liver function and avoidance of CYP3A substrates", "D": "Brinsupri, with regular dental checkups and avoidance of live attenuated vaccines"}}
{"id": "GOL3H2XtBLsf", "question_type": "open_ended_multi_choice", "question": "A 34-year-old woman presents with abnormal bleeding due to chronic immune thrombocytopenia and is confirmed to be platelet antibody positive. Her medical history includes moderate hepatic impairment and use of a proton pump inhibitor for GERD. What is the best drug therapy option for managing her ITP?", "options": {"A": "WAYRILZ (rilzabrutinib) 400 mg twice daily", "B": "Nplate (romiplostim) weekly subcutaneous injection", "C": "DMT SUIK (corticosteroid) intravenous therapy", "D": "WAYRILZ (rilzabrutinib) with a drug holiday during PPI use"}}
{"id": "Mg0ODsqnTtSm", "question_type": "open_ended_multi_choice", "question": "For which of the following conditions is Blujepa contraindicated?", "options": {"A": "History of severe hypersensitivity to Blujepa", "B": "History of mild rash after Blujepa", "C": "History of severe hypersensitivity to penicillin", "D": "History of mild hypersensitivity to Blujepa"}}
{"id": "JUfmcgOkGJTi", "question_type": "multi_choice", "question": "Which of the following statements best describes the carcinogenicity assessment for Imaavy (nipocalimab-aahu)?", "options": {"A": "Carcinogenicity studies have been conducted and showed no risk.", "B": "Carcinogenicity studies have not been conducted for Imaavy.", "C": "Carcinogenicity studies showed a high risk of cancer.", "D": "Carcinogenicity studies were inconclusive."}}
{"id": "LUisXuKOSbbu", "question_type": "open_ended_multi_choice", "question": "A 45-year-old male with progressive diffuse midline glioma harboring an H3 K27M mutation, previously treated, is being considered for MODEYSO therapy. He is also receiving a potent CYP3A4 inhibitor for another medical issue. What is the best approach to manage his glioma treatment in this context?", "options": {"A": "Start MODEYSO at the standard dose without adjusting for drug interactions.", "B": "Avoid using MODEYSO entirely due to his age.", "C": "Reduce the dose of MODEYSO if concomitant use with the CYP3A4 inhibitor cannot be avoided.", "D": "Discontinue the CYP3A4 inhibitor and start MODEYSO at a higher dose."}}
{"id": "w14i2yZ7Nkh7", "question_type": "multi_choice", "question": "A 10-year-old child weighing 25 kg is newly diagnosed with Niemann-Pick disease type C and presents with progressive gait ataxia, cognitive impairment, and hepatomegaly. The patient is not currently taking any other medications and has normal renal function. The family is concerned about long-term safety and wants a treatment specifically approved for pediatric use in NPC. Which drug is the most appropriate choice for this patient, considering the safety and efficacy profile?", "options": {"A": "N-acetyl-DL-leucine monotherapy", "B": "Yargesa (miglustat) administered at standard adult dosing", "C": "Opfolda (miglustat) in combination with Pombiliti", "D": "Aqneursa administered at the recommended dosage for pediatric patients ≥15 kg"}}
{"id": "Ls53fMf7K8bV", "question_type": "open_ended_multi_choice", "question": "For individuals capable of becoming pregnant who are prescribed Vanrafia, what is the advised approach to contraception?", "options": {"A": "No contraception is needed", "B": "Use contraception only during treatment", "C": "Use effective contraception prior to, during, and for two weeks after discontinuation of Vanrafia", "D": "Use contraception for one month after discontinuation"}}
{"id": "MaYmcc26I1fi", "question_type": "open_ended_multi_choice", "question": "A 16-year-old boy with primary axillary hyperhidrosis is being considered for topical anticholinergic therapy. He is currently taking paroxetine, a strong CYP2D6 inhibitor, for depression. Which of the following is the most appropriate treatment option for his hyperhidrosis?", "options": {"A": "Oxybutynin", "B": "Qbrexza", "C": "Sofdra", "D": "None of the above are appropriate"}}
{"id": "Gc6etjY49tLm", "question_type": "open_ended_multi_choice", "question": "A 3-year-old presents with multiple umbilicated papules on the trunk and extremities, confirmed as molluscum contagiosum. The parents are interested in topical management. There is no history of eczema, skin damage, or allergies. Which topical option is most appropriate for this child, considering safety and efficacy?", "options": {"A": "Adapalene applied once daily to affected areas", "B": "Zelsuvmi applied topically as directed for molluscum contagiosum", "C": "Adapalene applied twice daily to affected areas", "D": "No topical therapy recommended due to age"}}
{"id": "BWqAW7trG2gh", "question_type": "open_ended_multi_choice", "question": "Have animal studies been conducted to assess whether Tryptyr affects fertility in males or females?", "options": {"A": "Yes, and Tryptyr was found to impair fertility in both sexes.", "B": "Yes, and Tryptyr was found to have no effect on fertility.", "C": "No, studies to evaluate the potential effects of Tryptyr on fertility in animals have not been performed.", "D": "Yes, but only in female animals."}}
{"id": "bwh2oYIiEkjB", "question_type": "open_ended_multi_choice", "question": "A 35-year-old man presents with moderate to severe acute pain after a traumatic injury. He has moderate hepatic impairment (Child-Pugh Class B) and is currently taking a moderate CYP3A inhibitor. Which drug and dosing strategy is most appropriate for his pain management?", "options": {"A": "JOURNAVX at standard adult dosage", "B": "JOURNAVX at reduced dosage due to hepatic impairment and CYP3A inhibitor use", "C": "Ropivacaine Hydrochloride at standard adult dosage", "D": "Pain Relief Childrens (acetaminophen-based OTC) at pediatric dosing"}}
{"id": "HDtwvHavcXHt", "question_type": "open_ended_multi_choice", "question": "What safety measure should individuals follow if they notice short-term dim or dark vision while taking the brand medication Vizz?", "options": {"A": "Avoid night driving and hazardous activities in poor illumination.", "B": "Increase screen time to improve vision adaptation.", "C": "Take Vizz only in the morning.", "D": "Wear sunglasses indoors."}}
{"id": "dFXAQ1G6cuUW", "question_type": "multi_choice", "question": "A 62-year-old man with non-alcoholic steatohepatitis (NASH) and advanced liver fibrosis (stage F3) presents for treatment. He has a history of decompensated cirrhosis (Child-Pugh Class B), chronic kidney disease (eGFR 50 mL/min/1.73 m²), and is currently taking clopidogrel for coronary artery disease. Which of the following drugs is most appropriate for his NASH management?", "options": {"A": "Rezdiffra, with dose reduction due to clopidogrel", "B": "Farxiga, 10 mg once daily", "C": "Pentoxifylline extended-release tablets, 400 mg three times daily", "D": "Rezdiffra, standard dose"}}
{"id": "fjtcdQDOd5Py", "question_type": "open_ended_multi_choice", "question": "For a 17-year-old female with WHIM syndrome, recurrent bacterial infections, and diminished circulating antibodies, currently prescribed digoxin for cardiac issues and metformin for diabetes, and with normal renal and hepatic function and no pregnancy, what is the most suitable drug therapy to boost her mature neutrophil and lymphocyte counts?", "options": {"A": "XOLREMDI, daily oral administration with frequent monitoring of digoxin and glycemic control", "B": "Mavorixafor, daily oral administration without monitoring", "C": "XOLREMDI, daily oral administration with a drug holiday every month", "D": "No drug therapy recommended due to drug interactions"}}
{"id": "xujG4Mci8xup", "question_type": "open_ended_multi_choice", "question": "A 34-year-old woman with paroxysmal nocturnal hemoglobinuria (PNH) presents with persistent extravascular hemolysis (EVH) despite ongoing treatment with ravulizumab. She has a history of hyperlipidemia, which is well-controlled with rosuvastatin 10 mg daily. She has no hepatic impairment and is not pregnant. Which of the following is the most appropriate next step in her drug therapy to address her EVH?", "options": {"A": "Add Voydeya to her current ravulizumab regimen, monitoring for statin-related adverse effects.", "B": "Switch to sirolimus monotherapy.", "C": "Increase the dose of rosuvastatin above 10 mg daily while continuing ravulizumab.", "D": "Discontinue ravulizumab and start Voydeya monotherapy."}}
{"id": "mK9nJQ5fI5ig", "question_type": "open_ended_multi_choice", "question": "What is the appropriate course of action for clinicians when Imaavy is administered to a pregnant individual, or if pregnancy is discovered during ongoing Imaavy therapy?", "options": {"A": "Discontinue Imaavy immediately", "B": "Report Imaavy exposure to Janssen", "C": "Increase the dose of Imaavy", "D": "No action is required"}}
{"id": "Qg0k6ZHeQpA0", "question_type": "multi_choice", "question": "When reviewing the prescribing information for Modeyso, what should be considered regarding contraindications?", "options": {"A": "Modeyso is contraindicated in patients with active infection.", "B": "Modeyso is contraindicated in patients with a history of drug allergy.", "C": "Modeyso has no contraindications listed in its prescribing information.", "D": "Modeyso is contraindicated in patients with uncontrolled hypertension."}}
{"id": "a9mhl8dFULPC", "question_type": "multi_choice", "question": "A 45-year-old woman with disseminated pulmonary tuberculosis presents with persistent cough, fever, and significant weight loss. She is currently unable to swallow due to severe nausea and vomiting. She is not pregnant and has no history of hepatitis B or fungal infections. Which adjunctive corticosteroid therapy is most appropriate to administer alongside antituberculous chemotherapy for her current condition?", "options": {"A": "Prednisone oral tablets", "B": "DMT SUIK intravenous or intramuscular injection", "C": "GUNA-IL 2 oral solution", "D": "Dexamethasone sodium phosphate epidural injection"}}
{"id": "wa9DfVInkUxQ", "question_type": "open_ended_multi_choice", "question": "A 42-year-old woman in her second trimester of pregnancy has been diagnosed with non-alcoholic steatohepatitis (NASH) with moderate fibrosis. She is considering pharmacological therapy for her condition. According to current safety data, which medication should be avoided due to potential fetal risks?", "options": {"A": "Pentoxifylline extended-release tablets", "B": "Resmetirom administered once daily", "C": "Dapagliflozin once daily", "D": "Pentoxifylline immediate-release tablets"}}
{"id": "sQkMnVmuLkCB", "question_type": "open_ended_multi_choice", "question": "A 7-year-old child is diagnosed with relapsed acute erythroleukemia and genetic testing reveals a KMT2A translocation. The patient presents with anemia, thrombocytopenia, and hepatomegaly. The treatment plan requires a drug with established efficacy for this genetic subtype in pediatric patients. The child is not currently taking any medications known to prolong QTc interval, and baseline ECG is normal. Which drug is the most appropriate for initial therapy in this patient, considering age, genetic findings, and safety profile?", "options": {"A": "Revuforj administered twice daily, with BSA-based dosing for pediatric patients", "B": "Aldesleukin administered intravenously in a hospital setting", "C": "Dexamethasone administered as adjunctive palliative therapy", "D": "TaperDex 6-day oral regimen at standard adult dosing"}}
{"id": "5svztzgZGrn1", "question_type": "multi_choice", "question": "A 76-year-old man is diagnosed with wild-type transthyretin-mediated amyloid cardiomyopathy (ATTR-CM). He has a history of hyperlipidemia managed with rosuvastatin and is not taking any UGT inducers, CYP3A inducers, or CYP2C9 substrates. He is not planning to become pregnant and is not breastfeeding. Which of the following is the most appropriate drug to reduce his risk of cardiovascular death and hospitalization?", "options": {"A": "Dexrazoxane", "B": "Attruby", "C": "Vyndaqel", "D": "No pharmacologic therapy is indicated"}}
{"id": "QYzSxDRgPzYF", "question_type": "open_ended_multi_choice", "question": "A 28-year-old woman, currently 10 weeks pregnant, presents with a new diagnosis of molluscum contagiosum. She is worried about the risks associated with topical medications during pregnancy. There is no history of skin hypersensitivity or injury. What would be the best advice to offer her?", "options": {"A": "Adapalene applied nightly to lesions", "B": "Zelsuvmi applied topically as directed, with counseling about limited pregnancy safety data", "C": "Zelsuvmi applied twice daily to lesions", "D": "Adapalene applied twice daily to lesions"}}
{"id": "jPJHKsb8iK1X", "question_type": "open_ended_multi_choice", "question": "A 62-year-old man with chronic kidney disease-related anemia has been receiving dialysis for the past 6 months. His medical history includes cirrhosis and well-managed hypertension. He is not on statins or iron supplementation. What is the most suitable treatment option for his anemia?", "options": {"A": "Vafseo, as it is indicated for anemia in CKD patients on dialysis.", "B": "DMT SUIK (corticosteroid), considering his comorbidities.", "C": "Vafseo, but only if liver function tests are normal.", "D": "Cortisone aceticum, as it is safe in liver disease."}}
{"id": "s4VV8iGnfbP2", "question_type": "multi_choice", "question": "What is the recommended procedure regarding contact lens use when administering Vizz?", "options": {"A": "Keep contact lenses in during instillation.", "B": "Remove contact lenses before instillation and reinsert 10 minutes after.", "C": "Remove contact lenses and wait 1 hour before reinserting.", "D": "Do not use contact lenses at all during Vizz therapy."}}
{"id": "BULq9wkryHVf", "question_type": "open_ended_multi_choice", "question": "A pregnant woman, aged 32 and in her second trimester, is found to have a Staphylococcus aureus bacteremia. Her renal function is normal and she reports no drug allergies. Which antibiotic regimen is most appropriate for her condition?", "options": {"A": "Doxycycline Hyclate, 100 mg twice daily for 14 days", "B": "Zevtera, dosed appropriately for renal function and infection severity", "C": "Rituximab and Hyaluronidase, administered as per oncology protocols", "D": "Doxycycline Hyclate, with a reduced dose to minimize fetal exposure"}}
{"id": "XOOa6VkzNuK9", "question_type": "open_ended_multi_choice", "question": "A 30-year-old male patient with moderate chronic hand eczema has not responded to topical corticosteroids. He is undergoing therapy for active hepatitis C. What is the most appropriate medication regimen to manage his hand eczema at this time?", "options": {"A": "Delgocitinib topical therapy", "B": "Topical corticosteroids", "C": "Delgocitinib in combination with potent immunosuppressants", "D": "Delgocitinib after hepatitis C treatment is completed and infection resolved"}}
{"id": "ybeLOE28tnVM", "question_type": "open_ended_multi_choice", "question": "Given a 68-year-old patient diagnosed with ALK-positive locally advanced non-small cell lung cancer (NSCLC) who presents with moderate hepatic impairment (total bilirubin >1.5 to ≤3 times the upper limit of normal and any AST) and is not receiving any CYP3A4 inhibitors or inducers, which treatment regimen would be most appropriate in light of their liver function and drug safety considerations?", "options": {"A": "Erlotinib, standard dosing", "B": "Ensartinib, with increased monitoring and possible dose adjustment", "C": "Rozlytrek, standard dosing", "D": "Ensartinib, avoid use due to hepatic impairment"}}
{"id": "KnJ4YbaiUwPs", "question_type": "open_ended_multi_choice", "question": "Given a 72-year-old female patient with unresectable, metastatic, hormone receptor-positive, HER2-negative breast cancer who has previously received both endocrine therapy and chemotherapy, and who also has a history of arterial thromboembolic events and is currently taking anticoagulants, which medication would be most suitable for her cancer management considering her age and medical history?", "options": {"A": "MVASI", "B": "DATROWAY", "C": "Ketorolac Tromethamine", "D": "None of the above"}}
{"id": "rQmk4CsIYzqM", "question_type": "open_ended", "question": "A 45-year-old man with presbyopia is considering drug therapy. He wears contact lenses daily and often drives at night for work. Which of the following recommendations is most appropriate regarding the use of VIZZ (aceclidine) ophthalmic drops?", "options": {"A": "VIZZ can be used without any precautions related to contact lenses or night driving.", "B": "VIZZ should be avoided in patients who wear contact lenses due to risk of lens discoloration.", "C": "VIZZ may cause temporary blurred or dim vision; contact lenses should be removed before instillation and caution exercised during night driving.", "D": "VIZZ is contraindicated in all patients who drive for work."}}
{"id": "EJAs354vgb8V", "question_type": "open_ended_multi_choice", "question": "A 30-year-old man presents with moderate chronic hand eczema unresponsive to topical corticosteroids and is currently receiving treatment for active hepatitis C. Which is the best drug regimen to prescribe for his hand eczema under these circumstances?", "options": {"A": "Delgocitinib topical therapy", "B": "Topical corticosteroids", "C": "Delgocitinib in combination with potent immunosuppressants", "D": "Delgocitinib after hepatitis C treatment is completed and infection resolved"}}
{"id": "LrFaEfIXThbG", "question_type": "open_ended_multi_choice", "question": "A young boy, aged 7, with a history of hemophilia B, presents with repeated joint bleeding and increased bruising. He does not have factor IX inhibitors and needs ongoing prophylactic therapy to minimize bleeding frequency. Based on his clinical situation and age, which treatment plan should be recommended?", "options": {"A": "HYMPAVZI, administered weekly for routine prophylaxis", "B": "REBINYN, administered weekly for routine prophylaxis", "C": "SEVENFACT, administered for routine prophylaxis", "D": "HYMPAVZI, administered only during bleeding episodes"}}
{"id": "55xZJxJH52ye", "question_type": "open_ended_multi_choice", "question": "What is the best management strategy for a patient on Ibtrozi who requires gastric acid suppression?", "options": {"A": "Administer a proton pump inhibitor concurrently with Ibtrozi", "B": "Administer a locally acting antacid 2 hours before or after Ibtrozi", "C": "Administer an H2 receptor antagonist at the same time as Ibtrozi", "D": "Increase the dose of Ibtrozi when using acid-reducing agents"}}
{"id": "iHCfwrxKqUq6", "question_type": "open_ended_multi_choice", "question": "A pregnant woman, aged 35 and in her second trimester, presents with urinary symptoms including dysuria and frequency. She is diagnosed with an uncomplicated UTI, has normal kidney and liver function, and is not on any medications. Which drug would be the safest choice for symptomatic relief during her pregnancy?", "options": {"A": "Imipenem and Cilastatin", "B": "Gepotidacin", "C": "Flavoxate Hydrochloride", "D": "None; all are contraindicated in pregnancy"}}
{"id": "9mf8BTZwpuvF", "question_type": "open_ended_multi_choice", "question": "Would Blujepa be an appropriate choice for treating a 13-year-old female patient with a body weight of 45 kg diagnosed with uUTI?", "options": {"A": "Yes, Blujepa is indicated for this patient population.", "B": "No, Blujepa is not indicated for patients under 18 years of age.", "C": "No, Blujepa is only indicated for male pediatric patients.", "D": "No, Blujepa is not indicated for patients weighing less than 50 kg."}}
{"id": "hG8zC47pHGJ4", "question_type": "open_ended_multi_choice", "question": "In the combined results of Trials 1 and 2, what was the difference in the rate of JOURNAVX-treated patients experiencing a decrease in estimated glomerular filtration rate (eGFR) of at least 25% but less than 50%, compared to those receiving placebo?", "options": {"A": "Higher in JOURNAVX-treated patients", "B": "Lower in JOURNAVX-treated patients", "C": "Equal in both groups", "D": "Not reported for JOURNAVX"}}
{"id": "lghszxUnDTOp", "question_type": "open_ended", "question": "What precaution should females of reproductive potential take when prescribed Gomekli?", "options": {"A": "Use effective contraception during treatment and for 6 weeks after the last dose.", "B": "No contraception is needed as Gomekli does not affect fertility.", "C": "Use contraception only during the first month of treatment.", "D": "Discontinue all hormonal contraceptives."}}
{"id": "WdnTE2W7GDO9", "question_type": "multi_choice", "question": "Which of the following statements best describes the carcinogenicity assessment conducted for Modeyso?", "options": {"A": "Modeyso showed a dose-dependent increase in tumor formation.", "B": "Modeyso was found to be carcinogenic in rodent studies.", "C": "Carcinogenicity studies with Modeyso were not conducted.", "D": "Modeyso was tested for carcinogenicity only in vitro."}}
{"id": "gHyVfFpqXE85", "question_type": "open_ended_multi_choice", "question": "During which period is increased CYP substrate exposure most likely to occur when initiating Lynozyfic therapy?", "options": {"A": "From initiation of the step-up dosing schedule up to 14 days after the first 200 mg dose", "B": "Only after the second dose of Lynozyfic", "C": "During maintenance dosing only", "D": "After discontinuation of Lynozyfic"}}
{"id": "0cbNMIQjZAKN", "question_type": "open_ended_multi_choice", "question": "Which of the following statements best describes the recommended dosing schedule for Romvimza administration?", "options": {"A": "Romvimza should be taken once daily at the same time each day.", "B": "Romvimza should be administered twice weekly with at least 72 hours between doses.", "C": "Romvimza should be taken every other day.", "D": "Romvimza should be administered once weekly."}}
{"id": "0TseY6W1DA65", "question_type": "multi_choice", "question": "A 28-year-old woman with Niemann-Pick disease type C and progressive cognitive impairment is planning to become pregnant. She currently experiences frequent falls and dystonia. Which of the following is the most appropriate recommendation regarding drug therapy for her NPC-related neurological symptoms?", "options": {"A": "Start AQNEURSA (levacetylleucine) and advise contraception during treatment and for 60 days after discontinuation", "B": "Start Miglustat (Yargesa) and advise contraception during treatment and for 60 days after discontinuation", "C": "Start AQNEURSA (levacetylleucine) and advise contraception during treatment and for 7 days after discontinuation", "D": "Start Miglustat (Opfolda) in combination with Pombiliti and advise contraception during treatment and for 7 days after discontinuation"}}
{"id": "YK5XVhz9beLJ", "question_type": "open_ended_multi_choice", "question": "A 68-year-old individual with extensive-stage small cell lung cancer (ES-SCLC) has shown disease progression following platinum-based chemotherapy. The patient also has chronic kidney disease with a creatinine clearance of 45 mL/min and is currently receiving a P-glycoprotein inhibitor for an unrelated condition. Taking into account both efficacy and safety, which drug regimen would be most suitable for this patient?", "options": {"A": "Topotecan capsules, standard dose, administered orally once daily for 5 consecutive days every 21 days", "B": "Imdelltra, step-up dosing schedule, administered intravenously as per protocol", "C": "Ipilimumab, administered as a single agent every 3 weeks", "D": "Topotecan capsules, standard dose, administered with a drug holiday after each cycle"}}
{"id": "vkPaXzaAIBfQ", "question_type": "multi_choice", "question": "Which of the following is NOT a recommended supply for preparing and administering Gomekli tablets for oral suspension?", "options": {"A": "Milk", "B": "Dosing cup", "C": "10 mL oral syringe", "D": "Prescribed number of Gomekli tablets for oral suspension"}}
{"id": "Hf5Zyp6lz8rI", "question_type": "multi_choice", "question": "A patient is prescribed Wayrilz and is also taking an antacid. How should the administration of Wayrilz be managed in relation to the antacid?", "options": {"A": "Administer Wayrilz at least 2 hours before the antacid", "B": "Take Wayrilz and the antacid together", "C": "Administer Wayrilz at least 2 hours after the antacid", "D": "Crush Wayrilz and mix with the antacid"}}
{"id": "nWnafOBkz6Zo", "question_type": "multi_choice", "question": "Which of the following best describes the rationale for avoiding Blujepa in patients with severe hepatic impairment?", "options": {"A": "Risk of hepatotoxicity due to drug accumulation", "B": "Lack of efficacy in this population", "C": "Increased exposure to gepotidacin and risk of QTc prolongation", "D": "Blujepa is not metabolized by the liver"}}
{"id": "0ruORMSKmJPb", "question_type": "multi_choice", "question": "A 15-year-old female with WHIM syndrome presents with recurrent upper respiratory tract infections, severe periodontitis, and decreased circulating IgG concentration. She is currently pregnant and seeks treatment to increase her mature neutrophil and lymphocyte counts. Which drug regimen is most appropriate for her condition?", "options": {"A": "XOLREMDI, daily oral administration", "B": "Mavorixafor, daily oral administration", "C": "No drug therapy recommended due to pregnancy", "D": "XOLREMDI, weekly administration"}}
{"id": "ypqndJAyOgCf", "question_type": "multi_choice", "question": "A 2-year-old male is admitted with infectious diarrheal disease due to beta-lactamase producing Klebsiella pneumoniae. He is currently receiving probenecid for gout management. Which treatment regimen is most suitable for his infection?", "options": {"A": "Ampicillin with Sulbactam, standard dosing", "B": "Ampicillin with Sulbactam, with dose adjustment due to probenecid", "C": "Ofloxacin Otic Solution", "D": "Ciprofloxacin Ophthalmic Solution"}}
{"id": "Wdecrkrl2Fad", "question_type": "open_ended_multi_choice", "question": "A 52-year-old woman is experiencing difficulty reading small print and finds herself needing to hold items farther away to see them clearly. She is diagnosed with presbyopia and has no history of retinal disease, iritis, medication hypersensitivity, is not pregnant, and does not use contact lenses. Based on these details, which medication is most suitable for her treatment among the available options?", "options": {"A": "Aceclidine", "B": "Brimonidine tartrate", "C": "Phentolamine mesylate", "D": "No drug is appropriate"}}
{"id": "G1XHqsbIMjhk", "question_type": "open_ended_multi_choice", "question": "When a child is having heart surgery during their first RSV season, what is the recommended protocol for giving Enflonsia?", "options": {"A": "Delay Enflonsia until after the RSV season", "B": "Administer an additional Enflonsia injection soon after surgery", "C": "Discontinue Enflonsia permanently", "D": "Switch to oral Enflonsia therapy"}}
{"id": "XljktAXudz9i", "question_type": "open_ended_multi_choice", "question": "Which of the following statements best describes the effect of Journavx on hormonal contraceptives containing progestins other than levonorgestrel and norethindrone?", "options": {"A": "No additional contraceptive method is required.", "B": "Journavx increases the efficacy of all hormonal contraceptives.", "C": "Patients should use an additional nonhormonal contraceptive method or an alternative hormonal contraceptive during and for 28 days after Journavx treatment.", "D": "Journavx is contraindicated with all hormonal contraceptives."}}
{"id": "JmMBYyL50STw", "question_type": "open_ended_multi_choice", "question": "A 75-year-old patient with mild cognitive impairment from Alzheimer’s disease is being assessed for drug intervention. He has previously experienced a serious allergic reaction to monoclonal antibodies. He is not pregnant, is not breastfeeding, and does not require antithrombotic therapy. Which drug treatment approach is most appropriate for this individual?", "options": {"A": "Kisunla (donanemab-azbt), with pre-treatment using antihistamines", "B": "Kisunla (donanemab-azbt), contraindicated due to history of serious hypersensitivity", "C": "Kisunla (donanemab-azbt), recommended with regular MRI monitoring", "D": "Kisunla (donanemab-azbt), recommended only if patient is not ApoE ε4 homozygote"}}
{"id": "Cy43Ct4o2l3E", "question_type": "multi_choice", "question": "A 45-year-old woman is newly diagnosed with acute erythroleukemia and presents with anemia, thrombocytopenia, and splenomegaly. She has no history of cardiac disease, is not pregnant, and has normal hepatic and renal function. She is scheduled to begin induction therapy. Which drug regimen is most appropriate for remission induction in her case?", "options": {"A": "Daunorubicin Hydrochloride administered intravenously in combination with other approved anticancer drugs", "B": "TaperDex 12-day administered orally for 12 days as supportive therapy", "C": "REVUMENIB administered orally twice daily for 28-day cycles", "D": "TaperDex 12-day combined with REVUMENIB for induction therapy"}}
{"id": "7vljTfKv8U3U", "question_type": "open_ended_multi_choice", "question": "A 68-year-old individual with COPD and documented hepatic impairment comes in for routine management. He is stable and does not have any psychiatric conditions. Which of the following medications should be selected for his COPD maintenance therapy, given his age and liver disease?", "options": {"A": "Budesonide Inhalation", "B": "Fentanyl Citrate", "C": "Ensifentrine", "D": "Budesonide (oral)"}}
{"id": "ne1VmnhPSoWg", "question_type": "open_ended_multi_choice", "question": "For a patient taking Romvimza, what should be done if a dose is missed by more than 48 hours?", "options": {"A": "Take the missed dose immediately and resume the regular schedule.", "B": "Double the next scheduled dose.", "C": "Skip the missed dose and take the next dose on its regularly scheduled day.", "D": "Contact the physician before resuming therapy."}}
{"id": "GmTWQ1dXeG8F", "question_type": "open_ended_multi_choice", "question": "What is the appropriate clinical action to take for a patient with severe renal impairment (eGFR <30 mL/min) who requires Blujepa?", "options": {"A": "Monitor and correct serum electrolyte abnormalities and obtain ECG prior to and during treatment", "B": "Increase the dose of Blujepa", "C": "Administer Blujepa with a non-depolarizing neuromuscular blocker", "D": "Discontinue all other medications"}}
{"id": "HQM0gt9WMbjW", "question_type": "open_ended", "question": "A 58-year-old patient with metastatic carcinoid tumor presents with severe, persistent diarrhea and flushing. She has a history of mild hepatic impairment and is currently taking beta-blockers for hypertension. Which of the following is the most appropriate drug and route for acute management of her symptoms, considering her comorbidities and current medications?", "options": {"A": "MYCAPSSA (oral octreotide)", "B": "Octreotide injection (dose adjustment may be needed)", "C": "Hormone Harmony (homeopathic oral remedy)", "D": "Octreotide injection (standard dose, no adjustment)"}}
{"id": "4g6HTZG2T3pi", "question_type": "multi_choice", "question": "Which population should be advised not to breastfeed while undergoing treatment with Vanrafia?", "options": {"A": "Patients with severe hepatic impairment", "B": "Patients with diabetic kidney disease", "C": "Patients receiving Vanrafia", "D": "Patients with IgA nephropathy"}}
{"id": "B5ZK5wlZD1TD", "question_type": "open_ended", "question": "A clinical trial is being designed to test Tryptyr in a population with diverse comorbidities. Which exclusion criteria based on contraindications would be necessary for this study?", "options": {"A": "Exclude patients with known Tryptyr contraindications.", "B": "Exclude patients with severe cardiac disease.", "C": "Exclude patients with Tryptyr hypersensitivity.", "D": "No exclusion criteria based on contraindications are required."}}
{"id": "wUEaJF53qakf", "question_type": "open_ended_multi_choice", "question": "Considering a 67-year-old man with primary IgA nephropathy, a UPCR of 1.8 g/g, mild hepatic impairment, and no concurrent use of CYP3A inducers or OATP1B1/1B3 inhibitors, what is the most accurate assessment regarding the use of atrasentan (VANRAFIA) for this patient?", "options": {"A": "Atrasentan is contraindicated due to his age.", "B": "Atrasentan is contraindicated due to mild hepatic impairment.", "C": "Atrasentan is appropriate; no dose adjustment is needed for mild hepatic impairment or geriatric patients.", "D": "Atrasentan should be avoided because safety in older adults is not established."}}
{"id": "O3zE94d3GG0l", "question_type": "open_ended_multi_choice", "question": "A 34-year-old female presents with newly identified hypertension and increased mean arterial pressure. She intends to become pregnant within the next few months and is taking oral hormonal contraceptives. With normal kidney and liver function and no other health issues, what is the most appropriate antihypertensive therapy for her now?", "options": {"A": "Aprocitentan (TRYVIO), once daily", "B": "Bosentan (TRACLEER), twice daily", "C": "Chlorthalidone (THALITONE), once daily", "D": "Aprocitentan (TRYVIO), twice daily"}}
{"id": "ihRmtqU1NVVy", "question_type": "open_ended_multi_choice", "question": "What observations have been made about the use of Vizz in geriatric patients versus younger adults in terms of safety and effectiveness?", "options": {"A": "Geriatric patients experience significantly more adverse effects than younger adults.", "B": "Vizz is less effective in geriatric patients compared to younger adults.", "C": "No overall differences in safety or effectiveness have been observed between geriatric and younger adult patients.", "D": "Vizz is contraindicated in patients over 65 years of age."}}
{"id": "Y4MlZFq9YARM", "question_type": "multi_choice", "question": "A 28-year-old woman with newly diagnosed PNH is currently pregnant and requires complement inhibition therapy. She is eligible for all available therapies and has no history of complement inhibitor use. Which drug is the most appropriate choice, considering pregnancy safety data and recommendations?", "options": {"A": "Sirolimus", "B": "Ultomiris", "C": "Piasky", "D": "Cyclosporine"}}
{"id": "uIO4lBy00FyR", "question_type": "multi_choice", "question": "Which color additives in Romvimza capsules may cause allergic reactions, particularly in patients with aspirin sensitivity?", "options": {"A": "FD&C Green No. 3 and FD&C Red No. 3", "B": "FD&C Blue No. 1 and FD&C Red No. 40", "C": "FD&C Yellow No. 5 (tartrazine) and FD&C Yellow No. 6 (Sunset Yellow FCF)", "D": "FD&C Yellow No. 10 and FD&C Orange No. 2"}}
{"id": "E4id5xzmOjYL", "question_type": "multi_choice", "question": "For patients in the AK105-202 trial of penpulimab-kcqx, what proportion had tumors with PD-L1 tumor proportion score (TPS) ≥50%?", "options": {"A": "2.4%", "B": "10%", "C": "50%", "D": "37%"}}
{"id": "ytVVjhJLpzrn", "question_type": "open_ended_multi_choice", "question": "A 68-year-old man with hypertension, chronic kidney disease (eGFR 20 mL/min), and a history of elevated mean arterial pressure is not adequately controlled on standard antihypertensive therapy. He is being considered for add-on therapy. Which drug is least appropriate for this patient?", "options": {"A": "TRYVIO", "B": "Candesartan cilexetil", "C": "Latanoprost", "D": "Thiazide diuretic"}}
{"id": "SONXqhdc1rrO", "question_type": "open_ended_multi_choice", "question": "Which management strategy is recommended for patients receiving Hernexeos together with BCRP substrates that are not linked to serious adverse events from minimal changes in substrate levels?", "options": {"A": "Discontinue Hernexeos", "B": "Monitor for increased adverse reactions and adjust substrate dosage as clinically appropriate", "C": "Increase Hernexeos dose", "D": "No monitoring or adjustment needed"}}
{"id": "dC1SU8kzNTe5", "question_type": "open_ended_multi_choice", "question": "When considering a patient who has several comorbid conditions, which statement accurately describes the contraindications associated with Ekterly?", "options": {"A": "Ekterly is contraindicated in patients with diabetes.", "B": "Ekterly is contraindicated in patients with chronic kidney disease.", "C": "Ekterly is contraindicated in patients with a history of stroke.", "D": "Ekterly does not have any contraindications regardless of comorbidities."}}
{"id": "C5oCDxSgmiAp", "question_type": "multi_choice", "question": "How did Vanrafia perform compared to placebo in terms of percent reduction in UPCR at Week 36 in the main cohort of the ALIGN study?", "options": {"A": "Vanrafia achieved a 26% reduction versus 45% for placebo", "B": "Vanrafia achieved a 3% reduction versus 38% for placebo", "C": "Vanrafia achieved a 15% reduction versus 10% for placebo", "D": "Vanrafia achieved a 38% reduction versus 3% for placebo"}}
{"id": "uj2ySY9ZzDvi", "question_type": "open_ended_multi_choice", "question": "A 7-year-old boy (weight 28 kg) with chronic graft-versus-host disease (cGVHD) presents with airway obstruction, cough, and pulmonary infiltrates. He has a history of food intolerance and abnormal esophagus physiology. He is currently being treated for asthma with ritonavir, a strong CYP3A4 inhibitor. Which drug should be avoided due to his current medication and weight?", "options": {"A": "AXATILIMAB-CSFR", "B": "PredniSONE Tablets, USP, 5 mg", "C": "Budesonide Inhalation", "D": "PredniSONE combined with Budesonide Inhalation"}}
{"id": "oEzaKeBuNHTm", "question_type": "multi_choice", "question": "A 67-year-old female with a history of chronic renal impairment and congestive heart failure is diagnosed with acute nonlymphocytic leukemia. She previously received doxorubicin for breast cancer. Which drug regimen should be avoided due to increased risk of cardiotoxicity and organ toxicity?", "options": {"A": "PANRETIN gel, applied topically", "B": "Daunorubicin Hydrochloride, standard intravenous dosing", "C": "Daunorubicin Hydrochloride, with dosage reduction for renal impairment", "D": "Daunorubicin Hydrochloride, administered with cyclophosphamide"}}
{"id": "3nLsC5hOXbTx", "question_type": "open_ended_multi_choice", "question": "Which advice should be given to patients using Anzupgo regarding sun exposure?", "options": {"A": "Minimize exposure to sunlight and avoid sunlamps.", "B": "Increase exposure to sunlight for better efficacy.", "C": "No precautions regarding sunlight are necessary.", "D": "Use tanning beds regularly."}}
{"id": "0gWKAfWUwxc1", "question_type": "multi_choice", "question": "A 35-year-old woman with chronic hypoparathyroidism is currently pregnant and requires ongoing management of her condition. She is not on dialysis and has no history of skeletal malignancies, radiation therapy, or metabolic bone disease other than hypoparathyroidism. Which drug is the most appropriate for her treatment, considering fetal safety and established data for use in pregnancy?", "options": {"A": "Yorvipath", "B": "Palopegteriparatide", "C": "Calcitriol", "D": "Ergocalciferol"}}
{"id": "VSjIpKHQXzAt", "question_type": "open_ended_multi_choice", "question": "Regarding Ekterly 300 mg in the KONFIDENT trial, which description is correct?", "options": {"A": "Ekterly 300 mg was evaluated but is not a recommended dose for acute HAE attacks", "B": "Ekterly 300 mg was the preferred dose for all patients", "C": "Ekterly 300 mg was only used in patients under 18 years", "D": "Ekterly 300 mg was not evaluated in the trial"}}
{"id": "vwH9ISLTQNZj", "question_type": "open_ended_multi_choice", "question": "A 34-year-old female patient with primary IgA nephropathy and a urine protein-to-creatinine ratio of 2.1 g/g is being considered for atrasentan (VANRAFIA) to lower her proteinuria. She is of reproductive potential, not pregnant at present, but does not reliably use contraception. What is the best next step regarding atrasentan treatment for her?", "options": {"A": "Initiate atrasentan immediately, as she is not pregnant.", "B": "Delay atrasentan initiation until effective contraception is established and pregnancy is excluded.", "C": "Initiate atrasentan and advise her to start contraception after the first dose.", "D": "Atrasentan is safe to use regardless of contraception status."}}
{"id": "ufpTk90TVkCv", "question_type": "open_ended_multi_choice", "question": "A 54-year-old woman with unresectable, metastatic, hormone receptor-positive, HER2-negative breast cancer has previously received both endocrine-based therapy and chemotherapy. She has a history of mild renal impairment (creatinine clearance 60 mL/min) but no history of interstitial lung disease or pneumonitis. She is not pregnant or breastfeeding. Which drug is most appropriate for her cancer treatment, considering her renal status and prior therapies?", "options": {"A": "MVASI", "B": "Ketorolac Tromethamine", "C": "DATROWAY", "D": "None of the above"}}
{"id": "DVtu161a5zZu", "question_type": "open_ended_multi_choice", "question": "In the AK105-304 trial, what percentage of patients received cisplatin as the platinum agent in combination with penpulimab-kcqx and gemcitabine?", "options": {"A": "98%", "B": "2.4%", "C": "50%", "D": "36%"}}
{"id": "JID7k60FURzX", "question_type": "open_ended", "question": "A patient who wears contact lenses is prescribed Tryptyr. What is the recommended protocol regarding contact lens use during administration?", "options": {"A": "Remove contact lenses before administering Tryptyr and reinsert them 15 minutes after.", "B": "Keep contact lenses in during administration for optimal drug absorption.", "C": "Remove contact lenses and wait 1 hour before reinserting them.", "D": "Do not use Tryptyr if contact lenses are worn."}}
{"id": "i5rgSkN8bsuT", "question_type": "multi_choice", "question": "A 32-year-old woman with acute erythroleukemia and splenomegaly is currently 10 weeks pregnant. She is not taking any other medications and has no significant comorbidities. Which of the following drugs should be avoided due to the highest risk of embryo-fetal toxicity and teratogenicity, based on available evidence?", "options": {"A": "TaperDex 6-day oral regimen at the lowest effective dose", "B": "Aldesleukin administered intravenously in a hospital setting", "C": "Revuforj administered twice daily at standard dosing", "D": "Dexamethasone as adjunctive therapy for anemia"}}
{"id": "DMGkiyqAsYe6", "question_type": "multi_choice", "question": "A 68-year-old woman with low-risk myelodysplastic syndrome presents with transfusion-dependent anemia, requiring 5 units of red blood cells over the past 8 weeks. She has not responded to erythropoiesis-stimulating agents and is currently taking digoxin for atrial fibrillation. Her cytogenetic analysis does not show a deletion 5q abnormality. Which drug is the most appropriate for her treatment, considering her current medications and disease profile?", "options": {"A": "Imetelstat sodium, 7.5 mg/kg intravenously every 4 weeks", "B": "Inqovi, 35 mg orally once daily for 5 consecutive days every 28 days", "C": "Lenalidomide, 10 mg orally once daily", "D": "Lenalidomide, 25 mg orally once daily"}}
{"id": "rQglZkWjW964", "question_type": "open_ended_multi_choice", "question": "A 38-year-old woman with metastatic breast cancer (HR-positive, HER2-negative) is currently pregnant and seeking treatment options. She has no history of renal or hepatic impairment, and has previously received endocrine-based therapy and chemotherapy. Which of the following drugs should be avoided due to risk of embryo-fetal harm?", "options": {"A": "Ketorolac Tromethamine", "B": "DATROWAY", "C": "MVASI", "D": "All of the above"}}
{"id": "CiyIMRzZqUHV", "question_type": "multi_choice", "question": "A 58-year-old woman is newly diagnosed with metastatic non-small cell lung cancer (NSCLC). Genetic testing reveals a ROS1 gene rearrangement. She has a history of mild renal impairment (CLcr 55 mL/min), is currently taking a moderate CYP3A inhibitor for another condition, and has no history of cardiac disease or CNS symptoms. She is not pregnant and does not plan to breastfeed. Which drug regimen is most appropriate for her initial treatment?", "options": {"A": "LAZCLUZE (lazertinib plus amivantamab)", "B": "CYRAMZA in combination with erlotinib", "C": "Rozlytrek, with dose reduction due to CYP3A inhibitor", "D": "CYRAMZA in combination with docetaxel"}}
{"id": "5OP4IQoKGvwu", "question_type": "open_ended_multi_choice", "question": "A 28-year-old woman with sepiapterin-responsive phenylketonuria, scleroderma, and recent heavy menstrual bleeding is planning pregnancy. She is currently taking sulfasalazine for her autoimmune condition. Which management approach for her PKU should be avoided?", "options": {"A": "Sapropterin dihydrochloride administered daily with a phenylalanine-restricted diet", "B": "JAVYGTOR administered daily with a phenylalanine-restricted diet", "C": "Sephience administered daily with a phenylalanine-restricted diet", "D": "Sapropterin dihydrochloride administered every other day with a phenylalanine-restricted diet"}}
{"id": "OAbaHZKlTBZW", "question_type": "open_ended_multi_choice", "question": "A woman aged 38 presents with symptomatic TGCT and is being evaluated for systemic treatment. Her medical history includes chronic hepatitis B with increased liver enzymes, and she is currently taking a P-gp substrate medication. Surgical intervention is contraindicated because of potential severe morbidity. What is the most suitable drug regimen for her condition?", "options": {"A": "Turalio (pexidartinib hydrochloride) with standard dosing and no dietary restrictions", "B": "Romvimza (vimseltinib), ensuring it is administered at least 4 hours prior to her P-gp substrate", "C": "Romvimza (vimseltinib) with no adjustment for P-gp substrate timing", "D": "Turalio (pexidartinib hydrochloride) with a high-fat meal"}}
{"id": "6p6Cj6Z8hPWp", "question_type": "multi_choice", "question": "A 10-year-old girl with progressive diffuse midline glioma harboring an H3 K27M mutation has completed prior therapy. She is currently taking a medication known to prolong the QTc interval for a cardiac arrhythmia. Her oncologist is considering starting a new treatment for her glioma. Which of the following is the most appropriate approach regarding the use of MODEYSO (dordaviprone) in this patient?", "options": {"A": "Initiate MODEYSO at the standard dose without any changes to her current medications.", "B": "Start MODEYSO, but separate its administration from the QTc-prolonging drug and increase ECG monitoring.", "C": "Avoid using MODEYSO due to her age; it is not approved for pediatric patients.", "D": "Discontinue the QTc-prolonging drug and start MODEYSO at a reduced dose."}}
{"id": "DDpyzUnHvTph", "question_type": "open_ended_multi_choice", "question": "A pregnant 65-year-old woman presents with locally advanced cutaneous squamous cell carcinoma and is considering systemic therapy. She wishes to minimize any potential harm to her unborn child. What is the optimal recommendation for systemic drug treatment in this scenario?", "options": {"A": "Start ERBITUX, as it is safe in pregnancy", "B": "Begin TECENTRIQ, as immune checkpoint inhibitors are preferred in pregnancy", "C": "Initiate UNLOXCYT, as it is the only drug indicated for CSCC", "D": "Defer systemic therapy due to contraindication of all options in pregnancy"}}
{"id": "ZKLhePSK8Tzv", "question_type": "open_ended_multi_choice", "question": "A 9-year-old child presents with a metastatic solid tumor and is found to have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion by FDA-approved testing. The patient has mild renal impairment (eGFR 55 mL/min) and no history of cardiac disease. Which drug is most suitable for this patient, considering age, genetic findings, and renal function?", "options": {"A": "Erlotinib, 85 mg/m²/day orally", "B": "Lazcluze (lazertinib + amivantamab), standard pediatric dosing", "C": "Rozlytrek, weight-based dosing once daily", "D": "Erlotinib in combination with gemcitabine"}}
{"id": "4bB4ECMlzne7", "question_type": "open_ended_multi_choice", "question": "Regarding the results of mutagenicity assays conducted on Ibtrozi, which of the following is most accurate?", "options": {"A": "Ibtrozi was mutagenic in the in vitro bacterial reverse mutation (Ames) assay.", "B": "Ibtrozi was not mutagenic in the in vitro bacterial reverse mutation (Ames) assay and additional mutagenicity tests.", "C": "Ibtrozi was clastogenic in the in vivo micronucleus study in rats.", "D": "Ibtrozi induced aneugenicity in rat bone marrow and liver."}}
{"id": "eFD7WMMB8roa", "question_type": "open_ended_multi_choice", "question": "A 60-year-old woman with chronic diarrheal disease and primary biliary cholangitis (PBC) is being considered for Ocaliva therapy. She has compensated cirrhosis without portal hypertension and is also taking theophylline for asthma. What is the most important consideration when starting Ocaliva in this patient?", "options": {"A": "Ocaliva is contraindicated due to compensated cirrhosis.", "B": "Ocaliva can be started, but theophylline levels should be monitored closely.", "C": "Ocaliva should be started only if the patient is not taking any CYP1A2 substrates.", "D": "Ocaliva should be avoided due to risk of severe pruritus."}}
{"id": "cEwuCpsRwrlw", "question_type": "open_ended_multi_choice", "question": "A 10-year-old male with congenital hemophilia A, without any liver or gallbladder disorders, comes for routine prophylactic treatment to prevent bleeding. Based on his age and diagnosis, which medication is best suited for him?", "options": {"A": "Hemlibra administered subcutaneously once weekly", "B": "Qfitlia administered subcutaneously once monthly", "C": "Qfitlia administered subcutaneously once weekly", "D": "Fitusiran administered intravenously every two weeks"}}
{"id": "09eVxO8nWO95", "question_type": "multi_choice", "question": "Which of the following is TRUE regarding the administration of Modeyso via feeding tube?", "options": {"A": "Modeyso cannot be administered via feeding tube", "B": "Modeyso should be administered only by intravenous route", "C": "Modeyso capsules must be swallowed whole for tube administration", "D": "Modeyso should be mixed with food before tube administration"}}
{"id": "JDBqzaI1XdvP", "question_type": "open_ended_multi_choice", "question": "Which medication would be considered the safest and most appropriate for a 28-year-old woman with severe alopecia areata who plans to become pregnant, has normal renal and hepatic function, and is currently not taking any drugs?", "options": {"A": "LEQSELVI administered orally once daily", "B": "Hydroxychloroquine sulfate administered orally once daily", "C": "Triamcinolone acetonide nasal spray once daily", "D": "LEQSELVI administered orally every other day with a drug scheduler"}}
{"id": "wRiEqlosCZJL", "question_type": "open_ended_multi_choice", "question": "For a 10-year-old boy with Duchenne muscular dystrophy and a DMD gene mutation that allows for exon 51 skipping, and who has previously experienced hypersensitivity to intravenous therapies, which drug regimen should be selected for his management?", "options": {"A": "Eteplirsen administered once weekly", "B": "Deflazacort administered daily", "C": "Givinostat administered twice daily", "D": "Eteplirsen with a drug scheduler to minimize hypersensitivity risk"}}
{"id": "ShnRM3Bowd9m", "question_type": "open_ended_multi_choice", "question": "If a child is scheduled for heart surgery during their first RSV season, what is the recommended clinical action regarding Enflonsia administration?", "options": {"A": "Delay Enflonsia until after the RSV season", "B": "Administer an additional Enflonsia injection soon after surgery", "C": "Discontinue Enflonsia permanently", "D": "Switch to oral Enflonsia therapy"}}
{"id": "avULoWFO8JrR", "question_type": "open_ended", "question": "A 62-year-old patient with unresectable, metastatic non-squamous non-small cell lung cancer (NSCLC) is found to have a HER2 (ERBB2) tyrosine kinase domain activating mutation by FDA-approved testing. The patient has a history of mild chronic kidney disease (creatinine clearance 55 mL/min), but no significant cardiac disease and normal baseline liver function. She is currently taking a strong CYP3A inducer for epilepsy. Which drug regimen is most appropriate for her treatment, considering the need for dose adjustment and drug interactions?", "options": {"A": "HERNEXEOS with increased dose due to CYP3A inducer", "B": "TOPOTECAN at standard dose", "C": "TECENTRIQ monotherapy", "D": "HERNEXEOS at standard dose without adjustment"}}
{"id": "4QHrxF8SsA3N", "question_type": "open_ended_multi_choice", "question": "A 7-year-old with newly identified paroxysmal nocturnal hemoglobinuria (PNH) has no major coexisting illnesses and demonstrates normal liver and kidney function. Which drug should be initiated as the first treatment in this case?", "options": {"A": "Sirolimus", "B": "Voydeya as monotherapy", "C": "Ravulizumab", "D": "Voydeya added to eculizumab"}}
{"id": "3n7MeK5RwARx", "question_type": "open_ended_multi_choice", "question": "What dosage adjustment is advised for a pediatric patient weighing between 42.5 kg and less than 52.5 kg who develops a Grade 3 adverse reaction while receiving Modeyso?", "options": {"A": "Interrupt Modeyso until ≤Grade 1 or baseline, then resume at 375 mg once weekly", "B": "Permanently discontinue Modeyso", "C": "Increase dose to 500 mg once weekly", "D": "Continue at the same dose"}}
{"id": "IWcyz3fCUO1s", "question_type": "multi_choice", "question": "A 58-year-old woman is admitted to the hospital with acute supraventricular tachycardia. She has a history of hypertension and is currently taking an ACE inhibitor. Her liver function tests reveal moderate hepatic impairment (Child-Pugh B). Which of the following is the most appropriate drug for short-term reduction of her ventricular rate?", "options": {"A": "Pacerone (amiodarone)", "B": "RAPIBLYK (landiolol)", "C": "Propranolol", "D": "Diltiazem"}}
{"id": "fyEfK2Ig3i70", "question_type": "multi_choice", "question": "For patients receiving Imaavy concomitantly with monoclonal antibodies, what clinical action should be taken?", "options": {"A": "Closely monitor for reduced effectiveness of the monoclonal antibodies", "B": "Administer both drugs at the same time without monitoring", "C": "Increase the dose of Imaavy", "D": "Switch to oral monoclonal antibodies"}}
{"id": "0KGI9RNocGKv", "question_type": "multi_choice", "question": "What is known about the reversibility of Gomekli-induced infertility in females based on animal studies?", "options": {"A": "Reversibility is well established", "B": "Gomekli does not impair fertility", "C": "Reversibility is unknown", "D": "Infertility is permanent"}}
{"id": "R68YCes2CKk8", "question_type": "open_ended_multi_choice", "question": "In the case of a 38-year-old woman with metastatic HR-positive, HER2-negative breast cancer who is pregnant and has previously received both endocrine therapy and chemotherapy, and who does not have renal or hepatic impairment, which drug should be avoided because of its potential to cause embryo-fetal harm?", "options": {"A": "Ketorolac Tromethamine", "B": "DATROWAY", "C": "MVASI", "D": "All of the above"}}
{"id": "EqhH7G4s0QeI", "question_type": "open_ended_multi_choice", "question": "Select the statement that best summarizes Modeyso's effects on fertility.", "options": {"A": "Modeyso has no known effect on fertility.", "B": "Modeyso may adversely impact fertility in both males and females.", "C": "Modeyso improves fertility in females.", "D": "Modeyso only affects fertility in males."}}
{"id": "h7YCJlgPZl6n", "question_type": "open_ended_multi_choice", "question": "What is known about the safety and effectiveness of Datroway in pediatric patients?", "options": {"A": "Safety and effectiveness have been established", "B": "Safety is established, but effectiveness is unknown", "C": "Effectiveness is established, but safety is unknown", "D": "Safety and effectiveness have not been established"}}
{"id": "LXytZePe7d3e", "question_type": "multi_choice", "question": "A 28-year-old woman with classic congenital adrenal hyperplasia is pregnant and currently receiving glucocorticoid replacement therapy. She is seeking advice on adjunctive therapy to control androgen levels. Which statement best reflects the appropriateness of Crenessity for her condition?", "options": {"A": "Crenessity may be considered if benefits outweigh risks, but data in pregnancy are limited", "B": "Crenessity is contraindicated in pregnancy due to high risk of fetal malformations", "C": "Crenessity is recommended as first-line therapy in all pregnant women with CAH", "D": "Crenessity is only approved for use in pediatric patients"}}
{"id": "c57DEOSAY9HR", "question_type": "open_ended_multi_choice", "question": "Which of the following statements best describes the contraindication profile of Andembry?", "options": {"A": "Andembry is contraindicated in patients with hepatic impairment.", "B": "Andembry has no listed contraindications.", "C": "Andembry should not be used in patients with renal failure.", "D": "Andembry is contraindicated in pregnancy."}}
{"id": "1Mtj6wTGyNXv", "question_type": "multi_choice", "question": "A 32-year-old woman with Niemann-Pick disease type C and neurological symptoms is planning to become pregnant. She is currently taking N-acetyl-DL-leucine for symptomatic relief. Her physician is considering starting disease-modifying therapy. Which of the following is the most appropriate recommendation regarding drug therapy for her current situation?", "options": {"A": "Discontinue N-acetyl-DL-leucine and start Aqneursa after confirming non-pregnant status and counseling on contraception", "B": "Continue N-acetyl-DL-leucine and initiate Aqneursa immediately", "C": "Start Yargesa (miglustat) without contraception precautions", "D": "Initiate Opfolda (miglustat) in combination with Pombiliti regardless of pregnancy status"}}
{"id": "yxDtDvIyGqqj", "question_type": "open_ended_multi_choice", "question": "For a 68-year-old individual with ALK-positive locally advanced NSCLC and moderate hepatic impairment (total bilirubin greater than 1.5 but less than or equal to 3 times ULN, any AST), and no concurrent use of CYP3A4 inhibitors or inducers, which drug regimen should be selected to best account for hepatic function and safety?", "options": {"A": "Erlotinib, standard dosing", "B": "Ensartinib, with increased monitoring and possible dose adjustment", "C": "Rozlytrek, standard dosing", "D": "Ensartinib, avoid use due to hepatic impairment"}}
{"id": "dKodITOIvMov", "question_type": "open_ended_multi_choice", "question": "When prescribing Journavx, what assessment should be made regarding hepatic function?", "options": {"A": "Inquire and/or assess whether patients have hepatic impairment.", "B": "No assessment of hepatic function is necessary.", "C": "Only assess renal function.", "D": "Recommend liver biopsy before starting Journavx."}}
{"id": "IuDSzwsNvkhT", "question_type": "open_ended_multi_choice", "question": "In evaluating Emrelis for patients with concurrent health issues, what aspects of its safety profile are most relevant?", "options": {"A": "Emrelis is contraindicated in patients with diabetes.", "B": "Emrelis is contraindicated in patients with liver dysfunction.", "C": "Emrelis has no contraindications regardless of comorbidities.", "D": "Emrelis is contraindicated in patients with autoimmune diseases."}}
{"id": "Do99Udx0O4KD", "question_type": "open_ended_multi_choice", "question": "What is the recommended monitoring protocol for patients starting penpulimab-kcqx therapy?", "options": {"A": "Evaluate liver enzymes, creatinine, and thyroid function at baseline and periodically during treatment", "B": "Monitor only complete blood count at baseline", "C": "No laboratory monitoring is required", "D": "Monitor only during the first week of therapy"}}
{"id": "6k5MSlvwfseC", "question_type": "open_ended_multi_choice", "question": "A 38-year-old woman with primary biliary cholangitis and compensated cirrhosis (Child-Pugh class A) presents without signs of portal hypertension or hepatic decompensation. She is a CYP2C9 poor metabolizer and is currently on a moderate CYP3A4 inhibitor for another medical issue. Due to severe pruritus, she is unable to tolerate UDCA. What is the most suitable medication for managing her PBC?", "options": {"A": "Ocaliva 5 mg once daily as monotherapy", "B": "Livdelzi 10 mg once daily as monotherapy with close monitoring for adverse effects", "C": "Tricor 145 mg once daily as monotherapy", "D": "Livdelzi 10 mg once daily as monotherapy without monitoring"}}
{"id": "meNe8VET1dPu", "question_type": "multi_choice", "question": "For patients in the AK105-202 trial of penpulimab-kcqx, what proportion had tumors with PD-L1 tumor proportion score (TPS) ≥50%?", "options": {"A": "50%", "B": "10%", "C": "37%", "D": "2.4%"}}
{"id": "ffa325K8WRxA", "question_type": "open_ended_multi_choice", "question": "A 72-year-old with Alzheimer’s-related mild cognitive impairment is discovered to be an ApoE ε4 homozygote on genetic testing. The patient’s MRI indicates cerebral microhemorrhages, and they are on aspirin for cardiovascular indications. Which treatment plan is recommended for this patient?", "options": {"A": "Initiate KISUNLA (donanemab-azbt) with enhanced clinical vigilance and regular MRI monitoring.", "B": "Initiate KISUNLA without genetic testing or MRI monitoring.", "C": "Initiate KISUNLA and discontinue aspirin immediately.", "D": "Avoid KISUNLA due to increased risk of ARIA and intracerebral hemorrhage; consider alternative therapy if available."}}
{"id": "LXzDDTSi3sHN", "question_type": "open_ended_multi_choice", "question": "If a patient on Wayrilz begins treatment with a strong CYP3A inducer, what is the most significant risk associated with this drug combination?", "options": {"A": "Increased risk of hypertension", "B": "Reduced efficacy of Wayrilz", "C": "Increased risk of renal toxicity", "D": "Prolonged QT interval"}}
{"id": "sRuSkBtay4Wr", "question_type": "open_ended_multi_choice", "question": "Should the dosage of Datroway be altered for patients who have mild hepatic impairment?", "options": {"A": "Yes, reduce the dosage", "B": "Yes, increase the dosage", "C": "No dosage adjustment is recommended", "D": "Discontinue Datroway"}}
{"id": "Z2vOyM21znbh", "question_type": "open_ended_multi_choice", "question": "A 6-month-old infant with autosomal dominant adrenocortical carcinoma is being considered for chemotherapy. The infant was born prematurely and has a history of liver and renal dysfunction. Which of the following treatment options poses a specific risk due to its excipient and should be avoided in this patient?", "options": {"A": "Etoposide injection containing polysorbate 80", "B": "Lumisight (pegulicianine) administered at 1 mg/kg for imaging", "C": "Etoposide administered orally at a low dose", "D": "Lumisight (pegulicianine) administered at a reduced dose"}}
{"id": "810BoakyZ30C", "question_type": "open_ended_multi_choice", "question": "Before initiating Lynozyfic therapy for a patient with several existing health issues, what contraindications must the clinician consider?", "options": {"A": "Lynozyfic is contraindicated in patients with a history of anaphylaxis.", "B": "Lynozyfic should not be used in patients with severe renal impairment.", "C": "There are no contraindications listed for Lynozyfic.", "D": "Lynozyfic is contraindicated in pediatric populations."}}
{"id": "fkWarN2ueGda", "question_type": "open_ended", "question": "Which of the following should be discussed with patients or caregivers prior to starting Qfitlia prophylaxis regarding breakthrough bleed management?", "options": {"A": "The appropriate dosing and frequency of BPAs or CFCs.", "B": "The need to avoid all BPAs or CFCs permanently.", "C": "Switching to intravenous Qfitlia administration.", "D": "Discontinuing all medications except Qfitlia."}}
{"id": "n2beN9oUSgFc", "question_type": "multi_choice", "question": "A 7-year-old boy with Duchenne muscular dystrophy presents with progressive muscle weakness, calf muscle pseudohypertrophy, and elevated creatine kinase. Genetic testing confirms a DMD gene mutation amenable to exon 53 skipping. He has no history of renal impairment or arrhythmia. Which drug is the most appropriate for his treatment, considering his age and genetic profile?", "options": {"A": "Duvyzat administered orally twice daily", "B": "Exondys 51 administered intravenously once weekly", "C": "Viltepso administered intravenously once weekly", "D": "No drug therapy is appropriate due to age"}}
{"id": "x6gnOMYOmy9b", "question_type": "open_ended_multi_choice", "question": "A 72-year-old woman with chronic pulmonary heart disease and pulmonary hypertension associated with connective tissue disease is being considered for treprostinil therapy. She has mild hepatic insufficiency and is currently taking gemfibrozil for hyperlipidemia. Which of the following is the most appropriate approach to treprostinil therapy for this patient?", "options": {"A": "Initiate Tyvaso DPI at standard dose, no adjustment needed", "B": "Initiate Tyvaso DPI with slow uptitration and monitor for increased adverse effects", "C": "Switch gemfibrozil to another lipid-lowering agent and start Tyvaso DPI at standard dose", "D": "Avoid Tyvaso DPI and use subcutaneous treprostinil at standard dose"}}
{"id": "xxAtDCpOWz6H", "question_type": "open_ended_multi_choice", "question": "A 45-year-old female with chronic graft-versus-host disease, recurrent infections, raised liver transaminases, and thickened skin has failed two previous systemic therapies. She is neither pregnant nor planning to breastfeed, and her weight is 65 kg. Taking into account her disease progression and present condition, which drug is most appropriate for her subsequent treatment?", "options": {"A": "PredniSONE Tablets, USP, 5 mg", "B": "Budesonide Inhalation", "C": "AXATILIMAB-CSFR", "D": "Budesonide Inhalation combined with PredniSONE"}}
{"id": "TAe0P7cLiBhR", "question_type": "multi_choice", "question": "If Journavx is co-administered with a moderate CYP3A inhibitor, what adjustment should be made?", "options": {"A": "Increase the dose of Journavx.", "B": "Reduce the dose of Journavx.", "C": "Discontinue the CYP3A inhibitor.", "D": "No adjustment is necessary."}}
{"id": "KbOgHupTutRh", "question_type": "multi_choice", "question": "Which of the following recommendations is most appropriate for a woman who is breastfeeding and requires treatment with Modeyso?", "options": {"A": "Continue breastfeeding during Modeyso therapy.", "B": "Discontinue breastfeeding only if adverse effects are observed in the infant.", "C": "Pump and discard breast milk only on the day of Modeyso administration.", "D": "Breastfeeding is safe if Modeyso is administered at a low dose."}}
{"id": "COEl5LMjmbHF", "question_type": "open_ended_multi_choice", "question": "When administering Blujepa to a patient whose eGFR is less than 30 mL/min, which clinical intervention is recommended?", "options": {"A": "Monitor and correct serum electrolyte abnormalities and obtain ECG prior to and during treatment", "B": "Increase the dose of Blujepa", "C": "Administer Blujepa with a non-depolarizing neuromuscular blocker", "D": "Discontinue all other medications"}}
{"id": "4sNZMqY0fJKm", "question_type": "open_ended_multi_choice", "question": "A 35-year-old breastfeeding woman with primary axillary hyperhidrosis and a history of urinary retention is preparing for an extended stay in a hot climate. Based on her medical background and upcoming environmental exposure, which treatment option should she avoid?", "options": {"A": "Qbrexza (glycopyrronium), topical wipes once daily", "B": "Sofdra (sofpironium bromide), topical gel once daily", "C": "Oxytrol for Women (oxybutynin), transdermal patch twice weekly", "D": "Both Qbrexza and Sofdra should be avoided"}}
{"id": "pk89bdhG6iQZ", "question_type": "multi_choice", "question": "For patients in the AK105-202 trial of penpulimab-kcqx, what proportion had tumors with PD-L1 tumor proportion score (TPS) ≥50%?", "options": {"A": "10%", "B": "37%", "C": "50%", "D": "2.4%"}}
{"id": "msUzVdCWeCzc", "question_type": "open_ended_multi_choice", "question": "A 20-year-old male with a diagnosis of hemophilia B and documented factor IX inhibitors reports repeated episodes of spontaneous nosebleeds and slow wound healing. With an upcoming dental surgery, he needs a medication to manage bleeding as it occurs during the perioperative phase. Which agent is best suited for this purpose?", "options": {"A": "REBINYN, administered perioperatively", "B": "HYMPAVZI, administered perioperatively", "C": "SEVENFACT, administered perioperatively", "D": "REBINYN, administered as routine prophylaxis only"}}
{"id": "cZMrnFucMrMj", "question_type": "open_ended_multi_choice", "question": "Following subtotal resection, a 15-year-old with Grade 2 oligodendroglioma and a susceptible IDH1 mutation presents with no other medical concerns, is not pregnant, and does not use medications that induce or inhibit CYP1A2. Taking into account both efficacy and safety in this age group, which pharmacological intervention is most appropriate for this patient?", "options": {"A": "Avastin administered intravenously every 2 weeks", "B": "Zortress administered orally twice daily", "C": "Voranigo administered orally once daily", "D": "Avastin in combination with carboplatin and paclitaxel"}}
{"id": "1Bt5bY4lD5R3", "question_type": "open_ended_multi_choice", "question": "A researcher is interested in the potential mutagenic effects of Enflonsia. What is the status of mutagenesis studies for this drug?", "options": {"A": "No mutagenesis studies have been performed with Enflonsia.", "B": "Mutagenesis studies have shown positive results.", "C": "Mutagenesis studies have shown negative results.", "D": "Mutagenesis studies are ongoing."}}
{"id": "IADGkSGm2FDz", "question_type": "open_ended_multi_choice", "question": "A 45-year-old pregnant woman with a history of treated, unresectable intrahepatic cholangiocarcinoma and an FGFR2 rearrangement is not on any other medications. What is the most appropriate guidance concerning targeted therapy for her malignancy at this time?", "options": {"A": "Initiate PEMAZYRE at standard dosing", "B": "Start LYTGOBI with close fetal monitoring", "C": "Defer targeted therapy due to risk of fetal harm", "D": "Begin ZIIHERA with dose reduction"}}
{"id": "cY1K1IFttGr4", "question_type": "open_ended_multi_choice", "question": "A 34-year-old woman with adrenocortical carcinoma is scheduled for surgery and has a history of severe anaphylaxis to polyethylene glycol (PEG) following a prior imaging procedure. The surgical team is planning to use intraoperative fluorescence imaging to identify any remaining cancer tissue. Based on her medical history, which agent should be avoided?", "options": {"A": "Etoposide administered intravenously at a low starting dose", "B": "Lumisight (pegulicianine) administered at 1 mg/kg for intraoperative imaging", "C": "Etoposide administered orally at standard dosing", "D": "No imaging agent used during surgery"}}
{"id": "sOkU6bbOzRHH", "question_type": "open_ended_multi_choice", "question": "What is the appropriate management strategy for Gomekli if a patient experiences an asymptomatic absolute drop in left ventricular ejection fraction (LVEF) of 10% or more from baseline, resulting in a value below the lower limit of normal?", "options": {"A": "Continue Gomekli at current dose", "B": "Withhold Gomekli until ≤Grade 1, then resume at reduced dose", "C": "Permanently discontinue Gomekli", "D": "Increase Gomekli dose"}}
{"id": "lLqkXTvS9cz9", "question_type": "open_ended_multi_choice", "question": "For a 14-year-old male patient with hemophilia B, normal hepatic function, and no gallbladder or liver disease, what is the most suitable drug for routine prophylaxis to decrease bleeding events, and what justifies this selection?", "options": {"A": "Hemlibra, administered subcutaneously once weekly", "B": "Qfitlia, administered according to antithrombin-based dosing regimen", "C": "Hemlibra, administered subcutaneously every four weeks", "D": "Qfitlia, administered at a fixed dose of 80 mg once monthly"}}
{"id": "Bok4YQKq6Y1d", "question_type": "open_ended_multi_choice", "question": "A 54-year-old woman with primary biliary cholangitis continues to experience pruritus, fatigue, and elevated alkaline phosphatase after 12 months of ursodeoxycholic acid treatment. Her medical history includes osteoporosis and she is on atorvastatin for hyperlipidemia. There is no evidence of ascites, variceal bleeding, or hepatic encephalopathy. Based on her current medications and comorbidities, which medication should be added to her regimen for optimal management of PBC?", "options": {"A": "Elafibranor, once daily, in combination with UDCA", "B": "Seladelpar lysine, once daily, in combination with UDCA", "C": "Abatacept, once monthly", "D": "Elafibranor, once daily, as monotherapy"}}
{"id": "8wb8eqBbvySX", "question_type": "multi_choice", "question": "What is the recommendation regarding the use of live vaccines in patients receiving Anzupgo?", "options": {"A": "Live vaccines should be given only after discontinuing Anzupgo for 6 months", "B": "Live vaccines are recommended during Anzupgo therapy", "C": "Avoid live vaccines immediately prior to, during, and immediately after Anzupgo treatment", "D": "Live vaccines are contraindicated only in pediatric patients"}}
{"id": "jfSa9nywEVUe", "question_type": "open_ended_multi_choice", "question": "What is known about the safety and efficacy of Wayrilz when used in pediatric populations?", "options": {"A": "Safety and effectiveness have been established in pediatric patients.", "B": "Safety has been established, but effectiveness has not.", "C": "Effectiveness has been established, but safety has not.", "D": "Safety and effectiveness have not been established in pediatric patients."}}
{"id": "Xiy99fsxifcz", "question_type": "open_ended_multi_choice", "question": "A 62-year-old man with unresectable esophageal squamous cell carcinoma is experiencing chest pain, cough, and lymphadenopathy. His tumor demonstrates PD-L1 expression (CPS = 2), and he has mild hepatic impairment (AST 1.7 × ULN, ALT 1.6 × ULN, alkaline phosphatase 2.7 × ULN). As he prepares to start first-line systemic therapy, which initial drug regimen is most appropriate for his case?", "options": {"A": "Tevimbra in combination with platinum-containing chemotherapy, administered every 3 weeks", "B": "Docetaxel anhydrous monotherapy, administered every 3 weeks", "C": "Keytruda QLEX in combination with platinum- and fluoropyrimidine-based chemotherapy, administered every 3 weeks", "D": "Docetaxel anhydrous in combination with cisplatin and fluorouracil, administered every 3 weeks"}}
{"id": "6aioznVZe7hc", "question_type": "open_ended_multi_choice", "question": "A 68-year-old woman with myelodysplastic syndrome presents with transfusion-dependent anemia. Cytogenetic analysis reveals a deletion 5q abnormality. She has a history of chronic kidney disease (eGFR 35 mL/min/1.73m²) and is currently taking digoxin for atrial fibrillation. She is not pregnant and is not planning pregnancy. Which drug regimen is most appropriate for her anemia, considering her cytogenetic findings and comorbidities?", "options": {"A": "Lenalidomide, with dose adjustment for renal impairment and regular monitoring of digoxin levels", "B": "Reblozyl, administered every 3 weeks", "C": "Treosulfan (GRAFAPEX) as part of a preparative regimen for stem cell transplantation", "D": "Lenalidomide, standard dose without renal adjustment"}}
{"id": "SlqPZxJn8pFg", "question_type": "open_ended_multi_choice", "question": "A 15-year-old adolescent with a weight of 45 kg presents with moderate-to-severe atopic dermatitis that has failed to improve with topical prescription medications. The patient also has a history of frequent conjunctivitis and keratoconus. Considering the patient's age and associated conditions, what is the most appropriate systemic treatment option?", "options": {"A": "Dexamethasone sodium phosphate administered intramuscularly every 2 weeks", "B": "Adbry administered subcutaneously every other week", "C": "Ebglyss administered subcutaneously every 4 weeks", "D": "Dexamethasone sodium phosphate administered orally daily"}}
{"id": "BEjKCNeUfkcH", "question_type": "open_ended_multi_choice", "question": "What is the current understanding of Datroway's safety and effectiveness in the pediatric population?", "options": {"A": "Safety and effectiveness have been established", "B": "Safety is established, but effectiveness is unknown", "C": "Effectiveness is established, but safety is unknown", "D": "Safety and effectiveness have not been established"}}
{"id": "w361iB8is5wh", "question_type": "open_ended_multi_choice", "question": "A 67-year-old man with primary IgA nephropathy and UPCR of 1.8 g/g is being considered for proteinuria reduction therapy. He has mild hepatic impairment and is not taking any CYP3A inducers or OATP1B1/1B3 inhibitors. Which statement best reflects the appropriateness of atrasentan (VANRAFIA) for this patient?", "options": {"A": "Atrasentan is contraindicated due to his age.", "B": "Atrasentan is contraindicated due to mild hepatic impairment.", "C": "Atrasentan is appropriate; no dose adjustment is needed for mild hepatic impairment or geriatric patients.", "D": "Atrasentan should be avoided because safety in older adults is not established."}}
{"id": "nLS3t86S8Z2m", "question_type": "multi_choice", "question": "A 59-year-old man with metastatic undifferentiated pancreatic carcinoma previously progressed on gemcitabine-based therapy. He is currently taking phenytoin for seizure disorder, a strong CYP3A4 inducer. Which of the following is the best next step regarding his chemotherapy regimen?", "options": {"A": "Start Onivyde in combination with fluorouracil and leucovorin immediately", "B": "Start Irinotecan Hydrochloride 100 mg/5 mL as a single agent", "C": "Substitute phenytoin with a non-enzyme inducing therapy at least 2 weeks prior to starting Onivyde combination therapy", "D": "Start Onivyde as a single agent"}}
{"id": "YMDqUxZYcEzR", "question_type": "multi_choice", "question": "Which of the following statements best describes the contraindication profile of the drug Ekterly?", "options": {"A": "Ekterly is contraindicated in patients with severe hepatic impairment.", "B": "Ekterly should not be used in individuals with a history of hypersensitivity to its active ingredient.", "C": "Ekterly is contraindicated in patients with renal failure.", "D": "Ekterly is contraindicated in pregnant women."}}
{"id": "o1vWSTSRAlWN", "question_type": "open_ended_multi_choice", "question": "A 68-year-old woman with hereditary transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) is currently taking methotrexate for rheumatoid arthritis. She is not pregnant or breastfeeding. Which drug should be avoided due to the risk of increasing methotrexate toxicity, and which is the preferred option for her cardiomyopathy?", "options": {"A": "Dexrazoxane should be avoided; Attruby is preferred.", "B": "Vyndaqel should be avoided; Attruby is preferred.", "C": "Attruby should be avoided; Vyndaqel is preferred.", "D": "Dexrazoxane should be avoided; Vyndaqel is preferred."}}
{"id": "YosTeQOMIGMV", "question_type": "open_ended_multi_choice", "question": "A 65-year-old woman diagnosed with metastatic HER2-mutant non-squamous NSCLC requires systemic treatment. She is currently prescribed rifampin for latent tuberculosis, which is a strong CYP3A inducer. Her cardiac and hepatic function are normal, and she is not pregnant. What is the best way to proceed with drug selection and management for her lung cancer?", "options": {"A": "Initiate HERNEXEOS, but increase the dose due to the interaction with rifampin.", "B": "Start TECENTRIQ as a single agent, as it has no major CYP3A interactions.", "C": "Use etoposide in combination with other agents, as it is not affected by CYP3A inducers.", "D": "Avoid HERNEXEOS entirely and select an alternative therapy due to the drug interaction."}}
{"id": "AwYMl8B4EC2I", "question_type": "open_ended_multi_choice", "question": "A 10-year-old child is newly diagnosed with idiopathic hypoparathyroidism. The child has no history of malignancy, radiation exposure, or metabolic bone disease other than hypoparathyroidism. Which drug is most suitable for initial management of this pediatric patient?", "options": {"A": "Yorvipath", "B": "Ergocalciferol", "C": "Calcitriol", "D": "Palopegteriparatide"}}
{"id": "ILmCOZFo3QhP", "question_type": "multi_choice", "question": "Which color additives in Romvimza capsules may cause allergic reactions, particularly in patients with aspirin sensitivity?", "options": {"A": "FD&C Yellow No. 10 and FD&C Orange No. 2", "B": "FD&C Blue No. 1 and FD&C Red No. 40", "C": "FD&C Green No. 3 and FD&C Red No. 3", "D": "FD&C Yellow No. 5 (tartrazine) and FD&C Yellow No. 6 (Sunset Yellow FCF)"}}
{"id": "YmLbByB6imTx", "question_type": "open_ended_multi_choice", "question": "What should patients using contraceptives be advised regarding pregnancy likelihood while on Journavx?", "options": {"A": "Journavx may reversibly impact the likelihood to become pregnant; continue using contraceptives.", "B": "Journavx permanently prevents pregnancy.", "C": "Contraceptives are not needed while on Journavx.", "D": "Journavx increases fertility."}}
{"id": "5nYxpSoaed7y", "question_type": "open_ended_multi_choice", "question": "A 68-year-old with extensive-stage small cell lung cancer (ES-SCLC) and a creatinine clearance of 45 mL/min due to chronic kidney disease has progressed after platinum-based chemotherapy. The patient is also on a P-glycoprotein inhibitor for another medical issue. Which treatment regimen should be selected for optimal efficacy and safety in this scenario?", "options": {"A": "Topotecan capsules, standard dose, administered orally once daily for 5 consecutive days every 21 days", "B": "Imdelltra, step-up dosing schedule, administered intravenously as per protocol", "C": "Ipilimumab, administered as a single agent every 3 weeks", "D": "Topotecan capsules, standard dose, administered with a drug holiday after each cycle"}}
{"id": "zjY6SYKlH27M", "question_type": "open_ended_multi_choice", "question": "For patients with hemophilia A or B without inhibitory antibodies, how did Qfitlia prophylaxis using the AT-DR regimen compare to on-demand clotting factor concentrate (CFC) treatment in terms of annualized bleed rate for all treated bleeds?", "options": {"A": "Qfitlia AT-DR resulted in a 71% reduction in annualized bleed rate compared to on-demand CFC", "B": "Qfitlia AT-DR showed no significant difference compared to on-demand CFC", "C": "Qfitlia AT-DR resulted in a higher annualized bleed rate than on-demand CFC", "D": "Qfitlia AT-DR resulted in a 50% reduction in annualized bleed rate compared to on-demand CFC"}}
{"id": "IiRhzWrQmwvZ", "question_type": "open_ended", "question": "In the ATLAS-INH clinical study evaluating Qfitlia in males aged 12 years and older with hemophilia A or B and inhibitory antibodies, what was the primary reason the 80 mg monthly dose of Qfitlia was not approved for clinical use?", "options": {"A": "Insufficient efficacy in reducing annualized bleed rate", "B": "Increased risk of serious thrombotic events, gallbladder events, and hepatotoxicity", "C": "High incidence of allergic reactions", "D": "Poor patient adherence to subcutaneous administration"}}
{"id": "9ceCuUBBzyFg", "question_type": "open_ended_multi_choice", "question": "What considerations should be made regarding lactation when prescribing Brinsupri to a breastfeeding mother?", "options": {"A": "Brinsupri is contraindicated during lactation", "B": "There are no data on brensocatib in human milk or effects on the breastfed infant", "C": "Brinsupri is proven safe for breastfeeding infants", "D": "Brinsupri increases milk production"}}
{"id": "7zjsj0OrhfoO", "question_type": "open_ended_multi_choice", "question": "A 38-year-old woman with metastatic non-squamous NSCLC and a documented HER2 (ERBB2) tyrosine kinase domain activating mutation is planning pregnancy. She has already undergone systemic therapy and is otherwise healthy. What is the best treatment approach for her current circumstances?", "options": {"A": "Initiate Zongertinib immediately", "B": "Start Atezolizumab as monotherapy", "C": "Delay Zongertinib therapy until pregnancy status is clarified and effective contraception is in place", "D": "Begin Imfinzi in combination with platinum-based chemotherapy"}}
{"id": "KXq5hNmBq6Cl", "question_type": "open_ended_multi_choice", "question": "When a patient is receiving Romvimza and must also use an OCT2 substrate, what management strategy should be followed?", "options": {"A": "Refer to the prescribing information of the OCT2 substrate for dose modifications.", "B": "Increase the dose of Romvimza.", "C": "Administer Romvimza and the OCT2 substrate at the same time.", "D": "Discontinue the OCT2 substrate."}}
{"id": "dYFWqgwryw8d", "question_type": "open_ended_multi_choice", "question": "A pregnant 35-year-old woman with metastatic ROS1-positive non-small cell lung cancer, otherwise healthy and medication-free, seeks guidance on targeted treatment. What is the most suitable recommendation concerning taletrectinib use during her pregnancy?", "options": {"A": "Start taletrectinib 600 mg orally once daily as it is safe in pregnancy.", "B": "Delay taletrectinib until after delivery due to risk of fetal harm.", "C": "Start taletrectinib with close fetal monitoring.", "D": "Taletrectinib is only contraindicated in pediatric patients, not pregnant women."}}
{"id": "VXcNz5akgdAJ", "question_type": "open_ended", "question": "What precaution should be taken regarding sun exposure for patients using Anzupgo?", "options": {"A": "Advise patients to avoid sunlamps and minimize sunlight exposure by using sun-protective clothing or broad-spectrum sunscreen", "B": "Encourage daily sun exposure to improve vitamin D levels", "C": "No precautions are necessary regarding sun exposure", "D": "Recommend tanning beds for skin conditioning"}}
{"id": "HiE3EhU7IvaB", "question_type": "open_ended_multi_choice", "question": "A 35-year-old pregnant woman in her second trimester presents with dysuria, frequency, and suprapubic pain. Urine culture confirms Escherichia coli sensitive to multiple antibiotics. She has no history of drug allergies, renal impairment, or other comorbidities. She is seeking both symptom relief and definitive treatment. Which of the following is the most appropriate regimen?", "options": {"A": "Imipenem and cilastatin intravenously", "B": "Flavoxate hydrochloride orally for symptom relief plus an appropriate oral antibiotic", "C": "Sulopenem etzadroxil and probenecid (Orlynvah) orally", "D": "Flavoxate hydrochloride as monotherapy"}}
{"id": "YOGUqLbBsRTe", "question_type": "open_ended_multi_choice", "question": "A male patient aged 65, diagnosed with neurofibromatosis type 1, chronic myelogenous leukemia, hypertension, and mild renal impairment, presents complaining of joint pain and stiffness. He is taking an ACE inhibitor to control his blood pressure. Which option below is the least appropriate for treating his pain?", "options": {"A": "Celecoxib", "B": "Gomekli", "C": "PNV-DHA", "D": "Physical therapy only"}}
{"id": "fgamtVLFbEiS", "question_type": "multi_choice", "question": "What risk is increased when Lynozyfic is administered with CYP substrates?", "options": {"A": "Risk of adverse reactions related to CYP substrates", "B": "Risk of decreased efficacy of Lynozyfic", "C": "Risk of enhanced metabolism of CYP substrates", "D": "Risk of reduced cytokine release"}}
{"id": "ebWOhlW8rM2S", "question_type": "multi_choice", "question": "For which of the following drugs does the official labeling state that there are no contraindications?", "options": {"A": "Warfarin", "B": "Anzupgo", "C": "Metformin", "D": "Amiodarone"}}
{"id": "kkgTjt7A6Zv6", "question_type": "open_ended_multi_choice", "question": "A 72-year-old patient with mild cognitive impairment due to Alzheimer’s disease is being considered for drug therapy. Genetic testing reveals the patient is an ApoE ε4 homozygote. The patient has no history of hypersensitivity reactions, is not on antithrombotic therapy, and has no evidence of microhemorrhages or superficial siderosis on MRI. Which is the most appropriate drug treatment option for this patient?", "options": {"A": "Kisunla (donanemab-azbt), with enhanced clinical vigilance for ARIA and regular MRI monitoring", "B": "Kisunla (donanemab-azbt), without genetic testing or MRI monitoring", "C": "Kisunla (donanemab-azbt), contraindicated due to age", "D": "No drug therapy recommended due to ApoE ε4 homozygosity"}}
{"id": "fgYIYLjZxngW", "question_type": "open_ended_multi_choice", "question": "A 34-year-old woman with moderate-to-severe atopic dermatitis and a history of food intolerance and increased circulating IgE concentration is planning to become pregnant. She is considering systemic therapy after failing topical treatments. Which of the following is the most appropriate option for her at this time?", "options": {"A": "Adbry administered subcutaneously every other week", "B": "Dexamethasone sodium phosphate administered intravenously every 2 weeks", "C": "Ebglyss administered subcutaneously every 4 weeks", "D": "Dexamethasone sodium phosphate administered orally daily"}}
{"id": "NZLuAnN1Smis", "question_type": "open_ended", "question": "Which of the following is true regarding the contraindications for the drug Ibtrozi?", "options": {"A": "Ibtrozi has no listed contraindications.", "B": "Ibtrozi is contraindicated in patients with renal impairment.", "C": "Ibtrozi should not be used in patients with hepatic failure.", "D": "Ibtrozi is contraindicated in pregnancy."}}
{"id": "FVH6w4xbJr3S", "question_type": "open_ended_multi_choice", "question": "How is the warnings and precautions section characterized for Andembry?", "options": {"A": "There are no warnings and precautions listed for Andembry.", "B": "Andembry has multiple warnings and precautions related to hepatic impairment.", "C": "Andembry requires monitoring for cardiovascular side effects.", "D": "Andembry is contraindicated in pregnancy due to specific warnings."}}
{"id": "cgJ0K3tf1ilo", "question_type": "open_ended_multi_choice", "question": "A 42-year-old female patient with low-risk myelodysplastic syndrome, transfusion-dependent anemia, and a deletion 5q cytogenetic finding is planning pregnancy and is not on any form of contraception. Which drug must be strictly avoided in her management given her desire to conceive?", "options": {"A": "Imetelstat sodium, 7.5 mg/kg intravenously every 4 weeks", "B": "Lenalidomide, 10 mg orally once daily", "C": "Inqovi, 35 mg orally once daily for 5 consecutive days every 28 days", "D": "Inqovi, 20 mg orally once daily for 5 consecutive days every 28 days"}}
{"id": "V5RzKoDA6wJy", "question_type": "open_ended_multi_choice", "question": "Which statement most accurately summarizes the findings from carcinogenicity studies conducted for Emrelis?", "options": {"A": "Carcinogenicity studies in animals have been performed with Emrelis and showed no evidence of carcinogenicity.", "B": "Carcinogenicity studies in animals have not been performed with Emrelis or its small molecule MMAE.", "C": "Carcinogenicity studies in humans have demonstrated a high risk of cancer with Emrelis.", "D": "Carcinogenicity studies in animals have been performed only with the small molecule MMAE, not with Emrelis."}}
{"id": "fqp3jIYjqgSr", "question_type": "open_ended_multi_choice", "question": "A 70-year-old male with a history of osteoarthritis and hemophilia A (without factor VIII inhibitors) presents with persistent bleeding after minor trauma. He also has moderate renal impairment (creatinine clearance 45 ml/min). Which drug should be avoided due to his renal condition and risk of water intoxication?", "options": {"A": "MARSTACIMAB-HNCQ", "B": "Desmopressin Acetate", "C": "Factor VIII concentrate", "D": "DARATUMUMAB AND HYALURONIDASE-FIHJ"}}
{"id": "dwT9xec0b910", "question_type": "open_ended_multi_choice", "question": "A 14-year-old girl with relapsed low-grade glioma and confirmed BRAF fusion is currently taking fluconazole for a fungal infection. She is also using hormonal contraceptives. Her oncologist is considering targeted therapy. Which treatment option should be avoided due to drug interactions and contraceptive concerns?", "options": {"A": "VinCRIStine Sulfate administered intravenously, with careful monitoring for neurotoxicity.", "B": "OJEMDA administered orally once daily, despite concurrent fluconazole and hormonal contraceptive use.", "C": "Gliadel Wafer implantation as adjunct to surgery, regardless of glioma grade.", "D": "OJEMDA administered with a planned drug holiday every 3 months to minimize adverse effects."}}
{"id": "NUToxxj93N5x", "question_type": "open_ended_multi_choice", "question": "A 68-year-old female patient with myelodysplastic syndrome presents with anemia requiring regular transfusions. Cytogenetic testing identifies a 5q deletion. She has chronic kidney disease (eGFR 35 mL/min/1.73m²) and is on digoxin for atrial fibrillation. She is not pregnant and has no plans for pregnancy. What is the most appropriate drug therapy for her anemia, given her cytogenetic findings and medical history?", "options": {"A": "Lenalidomide, with dose adjustment for renal impairment and regular monitoring of digoxin levels", "B": "Reblozyl, administered every 3 weeks", "C": "Treosulfan (GRAFAPEX) as part of a preparative regimen for stem cell transplantation", "D": "Lenalidomide, standard dose without renal adjustment"}}
{"id": "pdUcy6VMHR8T", "question_type": "open_ended_multi_choice", "question": "A 68-year-old woman diagnosed with myelodysplastic syndrome and transfusion-dependent anemia is found to have a deletion 5q abnormality on cytogenetic analysis. Her past medical history includes chronic kidney disease (eGFR 35 mL/min/1.73m²) and she is currently taking digoxin for atrial fibrillation. She is not pregnant nor intending to become pregnant. Considering her cytogenetic results and comorbidities, which medication regimen should be selected to treat her anemia?", "options": {"A": "Lenalidomide, with dose adjustment for renal impairment and regular monitoring of digoxin levels", "B": "Reblozyl, administered every 3 weeks", "C": "Treosulfan (GRAFAPEX) as part of a preparative regimen for stem cell transplantation", "D": "Lenalidomide, standard dose without renal adjustment"}}
{"id": "1iKRH030qaum", "question_type": "open_ended_multi_choice", "question": "Which mechanism underlies the recommendation to avoid concomitant use of Romvimza with P-gp, BCRP, and OCT2 substrates?", "options": {"A": "Romvimza acts as an inhibitor of these transporters in vitro.", "B": "Romvimza induces hepatic enzymes.", "C": "Romvimza increases renal clearance of substrates.", "D": "Romvimza is a substrate for these transporters."}}
{"id": "RorQJLUay0Bx", "question_type": "open_ended_multi_choice", "question": "For a 16-year-old adolescent suffering from Niemann-Pick disease type C, who shows progressive neurological impairment, hepatomegaly, and moderate renal insufficiency (eGFR 35 mL/min/1.73 m²), which drug regimen and dosing approach is most appropriate for managing the neurological symptoms?", "options": {"A": "Standard-dose arimoclomol in combination with standard-dose miglustat", "B": "Standard-dose miglustat monotherapy", "C": "Dose-adjusted arimoclomol in combination with dose-adjusted miglustat", "D": "Standard-dose lithium carbonate"}}
{"id": "kGuo4jXJjD0u", "question_type": "multi_choice", "question": "A 7-year-old boy with severe hemophilia A and a history of factor VIII inhibitors requires routine prophylaxis to prevent bleeding episodes. He has normal hepatic and gallbladder function. Which of the following is the most appropriate prophylactic therapy for this patient?", "options": {"A": "Qfitlia, administered according to antithrombin-based dosing regimen", "B": "Qfitlia, administered at a fixed dose of 80 mg once monthly", "C": "Hemlibra, administered subcutaneously once weekly", "D": "Qfitlia, administered according to antithrombin-based dosing regimen with a planned drug holiday every 3 months"}}
{"id": "00Ns8mxxYAFd", "question_type": "open_ended_multi_choice", "question": "A 35-year-old woman with moderate-to-severe atopic dermatitis presents with recurrent pruritus, facial erythema, and flexural lichenification. She has a history of food intolerance and increased circulating IgE concentration. Previous topical corticosteroid therapy has failed to control her symptoms. She is not pregnant, does not have any active infections, and is not taking any immunosuppressive medications. Which drug regimen is most appropriate for her ongoing management?", "options": {"A": "DMT SUIK administered intravenously every 2 weeks for systemic control", "B": "Doxepin hydrochloride cream applied topically for up to 8 days for pruritus relief", "C": "Lebrikizumab-lbkz administered subcutaneously every 2 weeks as a targeted therapy", "D": "Doxepin hydrochloride cream applied daily for 3 months for long-term control"}}
{"id": "H6r1ycTXU3aP", "question_type": "open_ended_multi_choice", "question": "A 59-year-old woman with newly diagnosed multiple myeloma is being assessed for autologous stem cell transplantation. Her renal function is intact, she is not pregnant, and she has no history of thromboembolic events or neuropathy. She is not on any CNS depressant or cardiac medication. Which regimen is most appropriate to mobilize hematopoietic stem cells before transplantation in this patient?", "options": {"A": "Thalomid in combination with dexamethasone", "B": "LYNOZYFIC", "C": "Mozobil in combination with filgrastim", "D": "Thalomid monotherapy"}}
{"id": "RFwAamBujXSb", "question_type": "multi_choice", "question": "A 34-year-old woman with primary immunoglobulin A nephropathy (IgAN) and a urine protein-to-creatinine ratio (UPCR) of 2.0 g/g is at risk of rapid disease progression. She is planning to become pregnant and is currently not using any contraception. Which of the following is the most appropriate approach regarding drug therapy to reduce her proteinuria?", "options": {"A": "Advise against VANRAFIA therapy and recommend alternative management due to pregnancy plans.", "B": "Initiate VANRAFIA (atrasentan) 0.75 mg once daily and monitor for pregnancy during treatment.", "C": "Start VANRAFIA (atrasentan) at a reduced dose and discontinue if pregnancy occurs.", "D": "Begin VANRAFIA (atrasentan) and recommend breastfeeding during treatment."}}
{"id": "UtGY0Qa4cAd1", "question_type": "open_ended", "question": "A patient is receiving Emrelis and is prescribed a strong CYP3A inhibitor. What should the healthcare provider monitor for?", "options": {"A": "Signs of reduced MMAE exposure", "B": "Symptoms of Emrelis toxicity", "C": "Improved therapeutic response", "D": "No changes in patient status"}}
{"id": "vPLye6vXDR9c", "question_type": "open_ended_multi_choice", "question": "How does the safety profile and effectiveness of Vizz in geriatric patients (65+) compare to that in younger adult populations?", "options": {"A": "Geriatric patients experience significantly more adverse effects than younger adults.", "B": "Vizz is less effective in geriatric patients compared to younger adults.", "C": "No overall differences in safety or effectiveness have been observed between geriatric and younger adult patients.", "D": "Vizz is contraindicated in patients over 65 years of age."}}
{"id": "MAfOT2TXX7qV", "question_type": "open_ended_multi_choice", "question": "A 58-year-old man with previously treated, unresectable metastatic biliary tract cancer is found to have HER2-positive (IHC 3+) disease by an FDA-approved test. He has a history of chronic heart failure with a baseline left ventricular ejection fraction (LVEF) of 45%. He is not taking any strong CYP3A inhibitors or inducers. Which therapy is most appropriate for his cancer, considering his cardiac history?", "options": {"A": "ZIIHERA", "B": "LYTGOBI", "C": "PEMAZYRE", "D": "Trastuzumab"}}
{"id": "iVbnAokgwY5N", "question_type": "open_ended_multi_choice", "question": "For adult and pediatric patients weighing at least 52.5 kg who require concomitant use of strong CYP3A4 inhibitors with Modeyso, what management strategy is recommended?", "options": {"A": "Increase the dose of Modeyso", "B": "Reduce the dose of Modeyso", "C": "Discontinue Modeyso", "D": "Administer Modeyso with food"}}
{"id": "zyMXNgyx82hi", "question_type": "multi_choice", "question": "A 74-year-old man with intermediate-2 risk myelodysplastic syndrome (MDS) is being considered for drug therapy. He has moderate renal impairment (creatinine clearance 40 mL/min), is not eligible for stem cell transplantation, and is not taking any drugs metabolized by cytidine deaminase. Which of the following is the most suitable drug for his condition, considering his age, renal function, and MDS risk group?", "options": {"A": "Lenalidomide, with dose adjustment for renal impairment.", "B": "TREOSULFAN (GRAFAPEX) in combination with fludarabine as a transplant preparative regimen.", "C": "Lenalidomide, standard dose without adjustment.", "D": "INQOVI (cedazuridine and decitabine), administered orally once daily in 28-day cycles."}}
{"id": "GrQ2Y11TNbYt", "question_type": "multi_choice", "question": "A 28-year-old woman with cystic fibrosis and a history of cirrhosis and hepatosplenomegaly is planning to become pregnant. She has a confirmed F508del mutation and is currently taking oral contraceptives. Her liver function tests are mildly elevated (Child-Pugh Class A). Which of the following is the most suitable drug regimen for her cystic fibrosis management?", "options": {"A": "ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor) at reduced dosage due to oral contraceptive use", "B": "Insulin Aspart Protamine and Insulin Aspart Mix 70/30, administered before meals", "C": "ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor) at standard dosage, with regular liver function and ophthalmologic monitoring", "D": "ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor) is contraindicated due to pregnancy risk"}}
{"id": "1A2aTWIYOwK7", "question_type": "multi_choice", "question": "A 32-year-old woman with neurofibromatosis type 1 and symptomatic plexiform neurofibromas is currently pregnant. She is seeking treatment options for her neurofibromas. Which of the following drugs should be avoided due to the risk of fetal harm?", "options": {"A": "Celecoxib", "B": "Both Celecoxib and Gomekli", "C": "PNV-DHA", "D": "Gomekli"}}
{"id": "SLwVrvK5Km0L", "question_type": "multi_choice", "question": "A 60-year-old male with recurrent glioblastoma multiforme is being evaluated for systemic therapy. He has a history of hypertension that is well-controlled with medication and no evidence of recent surgery or wound healing complications. Genetic testing does not reveal an IDH1 or IDH2 mutation. Which of the following is the most appropriate treatment option for this patient?", "options": {"A": "Voranigo administered orally once daily", "B": "Zortress administered in combination with tacrolimus and corticosteroids", "C": "Avastin administered intravenously every 2 weeks", "D": "Voranigo in combination with a CYP1A2 inhibitor"}}
{"id": "YYzwUDYrG3us", "question_type": "open_ended_multi_choice", "question": "A 54-year-old woman with a history of osteoporosis and hyperlipidemia managed with atorvastatin presents with persistent symptoms and elevated alkaline phosphatase after 12 months of ursodeoxycholic acid for primary biliary cholangitis. She has no signs of ascites, variceal bleeding, or hepatic encephalopathy. Taking into account her current therapy and comorbid conditions, which additional drug is most appropriate for managing her PBC?", "options": {"A": "Elafibranor, once daily, in combination with UDCA", "B": "Seladelpar lysine, once daily, in combination with UDCA", "C": "Abatacept, once monthly", "D": "Elafibranor, once daily, as monotherapy"}}
{"id": "2qMtUgX2BlDq", "question_type": "open_ended_multi_choice", "question": "What is the reason for not initiating the preparative regimen with Grafapex when the stem cell donor cannot be secured?", "options": {"A": "Because profound myelosuppression with pancytopenia will occur in all patients", "B": "Because Grafapex requires donor stem cells for activation", "C": "Because the drug is ineffective without donor cells", "D": "Because of increased risk of renal toxicity"}}
{"id": "KmMEZrM9GKzi", "question_type": "open_ended_multi_choice", "question": "Has research in animals investigated the impact of Tryptyr on fertility in either sex?", "options": {"A": "Yes, and Tryptyr was found to impair fertility in both sexes.", "B": "Yes, and Tryptyr was found to have no effect on fertility.", "C": "No, studies to evaluate the potential effects of Tryptyr on fertility in animals have not been performed.", "D": "Yes, but only in female animals."}}
{"id": "8N7KAu9d31eS", "question_type": "open_ended_multi_choice", "question": "How should treatment be adjusted if a patient experiences intolerance to Datroway administered intravenously at 3 mg/kg every three weeks?", "options": {"A": "Increase the dose to 4 mg/kg", "B": "Continue at 3 mg/kg", "C": "Permanently discontinue Datroway", "D": "Reduce to 2 mg/kg"}}
{"id": "SLLWbTuLIdHm", "question_type": "open_ended_multi_choice", "question": "A 58-year-old male with a past medical history of glaucoma and recurrent herpes simplex keratitis presents with dry eye disease and requests a daily medication to manage his symptoms. Given his underlying conditions, which medication should be avoided and which would be the best choice for him?", "options": {"A": "Loteprednol etabonate ophthalmic gel, administered twice daily", "B": "Acoltremon ophthalmic solution, administered twice daily", "C": "Lifitegrast ophthalmic solution, administered twice daily", "D": "Loteprednol etabonate ophthalmic gel, administered once daily"}}
{"id": "nMttGcP31c1v", "question_type": "open_ended_multi_choice", "question": "A 45-year-old man with metastatic epithelioid sarcoma has a history of congestive heart failure and has previously received mediastinal radiation. His tumor is confirmed to be MSI-H by FDA-approved testing. He is not pregnant and has normal hepatic function. Which drug regimen is most suitable for his sarcoma?", "options": {"A": "Doxorubicin Hydrochloride every 3 weeks", "B": "KEYTRUDA QLEX every 3 weeks", "C": "Doxorubicin Hydrochloride in combination with trastuzumab every 3 weeks", "D": "Doxorubicin Hydrochloride with dose reduction every 3 weeks"}}
{"id": "a7hqBReNh4Ml", "question_type": "multi_choice", "question": "A 10-year-old boy with primary axillary hyperhidrosis and chronic renal failure is being considered for topical anticholinergic therapy. He is not taking any other medications. Which treatment option is most appropriate for his condition?", "options": {"A": "Qbrexza (glycopyrronium), topical wipes once daily", "B": "Sofdra (sofpironium bromide), topical gel once daily", "C": "Oxytrol for Women (oxybutynin), transdermal patch twice weekly", "D": "None of the above are appropriate due to his age and renal impairment"}}
{"id": "zkwUnWOLzW4I", "question_type": "multi_choice", "question": "A clinical trial protocol is being designed for a new medication. If the drug brand name is Ekterly, which exclusion criteria based on contraindications should be considered?", "options": {"A": "Exclude patients with a history of anaphylaxis to Ekterly.", "B": "Exclude patients with cardiac arrhythmias.", "C": "Exclude patients with severe renal impairment.", "D": "No exclusion criteria based on contraindications are necessary."}}
{"id": "KAiOJkxgTueg", "question_type": "open_ended_multi_choice", "question": "A 45-year-old woman with a syndrome of combined immunodeficiency and a history of B-cell chronic lymphocytic leukemia (CLL) has failed to respond to standard alkylating-agent therapy. She also has moderate renal impairment (creatinine clearance 45 mL/min/1.73 m²) and is not pregnant. Which drug regimen is most appropriate for her condition, considering dosage adjustments and safety profile?", "options": {"A": "Fludarabine Phosphate at standard adult dose (25 mg/m²/day for 5 days)", "B": "Fludarabine Phosphate with dose reduction and close monitoring", "C": "DMT SUIK at standard adult dose for neoplastic disease", "D": "Fludarabine Phosphate in combination with pentostatin"}}
{"id": "2oE9ZuB4yP6J", "question_type": "open_ended_multi_choice", "question": "A 34-year-old woman with moderate-to-severe atopic dermatitis, a history of food intolerance, and elevated IgE levels is planning pregnancy. After unsuccessful topical treatment, she is considering systemic therapy. What is the most suitable systemic treatment option for her at this time?", "options": {"A": "Adbry administered subcutaneously every other week", "B": "Dexamethasone sodium phosphate administered intravenously every 2 weeks", "C": "Ebglyss administered subcutaneously every 4 weeks", "D": "Dexamethasone sodium phosphate administered orally daily"}}
{"id": "lPd8GnDldbfm", "question_type": "multi_choice", "question": "Which of the following statements best describes the carcinogenicity assessment conducted for Modeyso?", "options": {"A": "Carcinogenicity studies with Modeyso were not conducted.", "B": "Modeyso was found to be carcinogenic in rodent studies.", "C": "Modeyso showed a dose-dependent increase in tumor formation.", "D": "Modeyso was tested for carcinogenicity only in vitro."}}
{"id": "5O1j7FgBYuyt", "question_type": "multi_choice", "question": "A clinician is considering Imaavy for a patient with a prior serious hypersensitivity reaction to one of its excipients. What is the appropriate clinical decision?", "options": {"A": "Do not prescribe Imaavy due to contraindication.", "B": "Prescribe Imaavy with dose adjustment.", "C": "Prescribe Imaavy with corticosteroid premedication.", "D": "Prescribe Imaavy only in a hospital setting."}}
{"id": "aFSC6h2KfntG", "question_type": "open_ended_multi_choice", "question": "A patient treated with Lynozyfic develops confusion and lethargy. What is the most appropriate immediate action?", "options": {"A": "Continue treatment and monitor at home", "B": "Contact their healthcare provider immediately", "C": "Increase the dose of Lynozyfic", "D": "Discontinue all medications"}}
{"id": "WhAfSaoyWKrd", "question_type": "multi_choice", "question": "A 22-year-old patient with cystic fibrosis, cirrhosis, and hepatosplenomegaly is homozygous for the F508del mutation. The patient is currently taking cyclosporine following a recent organ transplant. Which drug regimen should be avoided due to potential drug interactions and organ-specific risks?", "options": {"A": "SYMDEKO, with standard dosing and no consideration for hepatic impairment", "B": "SYMDEKO, with dose adjustment for hepatic impairment", "C": "Brinsupri, with monitoring for dental and skin adverse reactions", "D": "ORKAMBI, due to risk of liver failure and drug interaction with cyclosporine"}}
{"id": "RAFm6xClcppp", "question_type": "multi_choice", "question": "A 45-year-old male with a history of chronic rhinosinusitis and nasal polyps presents for ongoing symptoms despite prior ethmoid sinus surgery. He has no history of glaucoma, cataracts, or recent nasal trauma. He is seeking a long-term, locally acting therapy with minimal systemic absorption. Which of the following is the most appropriate treatment option for this patient, considering his age and surgical history?", "options": {"A": "Mometasone furoate cream applied topically to the nasal mucosa once daily", "B": "Sinuva sinus implant placed in the ethmoid sinus", "C": "Fluticasone propionate nasal spray twice daily", "D": "Mometasone furoate cream applied to the skin twice daily"}}
{"id": "MIOIXmjXRchN", "question_type": "multi_choice", "question": "A 42-year-old woman with recurrent low-grade serous ovarian carcinoma and confirmed KRAS mutation presents for treatment. She has previously received systemic therapy and is currently taking warfarin for atrial fibrillation. Which drug regimen is most appropriate for her cancer management?", "options": {"A": "AVMAPKI FAKZYNJA CO-PACK (avutometinib and defactinib)", "B": "AVMAPKI FAKZYNJA CO-PACK with warfarin co-administration", "C": "AVMAPKI FAKZYNJA CO-PACK after switching to a non-warfarin anticoagulant", "D": "AVMAPKI FAKZYNJA CO-PACK with dose reduction due to warfarin"}}
{"id": "Mx3dwqk1aYdq", "question_type": "multi_choice", "question": "A 6-month-old infant with severe RSV infection is hospitalized and requires mechanical ventilation. The infant's mother is currently pregnant. Which of the following is the most appropriate management regarding antiviral therapy for this patient?", "options": {"A": "Administer Restasis MultiDose ophthalmic emulsion.", "B": "Administer ENFLONSIA as a preventive measure.", "C": "Administer Virazole via inhalation, ensuring staff are experienced with ventilator use and monitoring.", "D": "Avoid Virazole due to teratogenic risk and select an alternative antiviral agent."}}
{"id": "ScRHt9UHq1sw", "question_type": "open_ended_multi_choice", "question": "A 45-year-old woman with adult-onset multiple myeloma and amyloidosis is currently pregnant. She has not received any prior therapy for multiple myeloma. Her physician is considering starting treatment and is evaluating the safety of available options. Which drug should be strictly avoided in this patient due to its risk profile?", "options": {"A": "Linvoseltamab-gcpt", "B": "Talquetamab-tgvs", "C": "Thalidomide", "D": "Dexamethasone monotherapy"}}
{"id": "kWgjsrdWlWcC", "question_type": "open_ended_multi_choice", "question": "A 45-year-old woman who is breastfeeding and has presbyopia seeks advice about safe medication use. She denies any history of ocular inflammation or retinal pathology. What is the best pharmacological treatment for her presbyopia in this context?", "options": {"A": "Oraverse administered as an intraoral injection", "B": "VIZZ topical ocular drops, considering low systemic absorption", "C": "Mirvaso topical gel applied to the face", "D": "VIZZ topical ocular drops, contraindicated due to lactation"}}
{"id": "56vFwGq7AVxR", "question_type": "open_ended_multi_choice", "question": "A 29-year-old pregnant woman with moderate to severe chronic hand eczema has not improved with topical corticosteroids. What is the most suitable advice concerning Anzupgo use in her case?", "options": {"A": "Consider Anzupgo only if the potential benefit justifies the potential risk to the fetus.", "B": "Initiate Anzupgo without any consideration of pregnancy status.", "C": "Anzupgo is contraindicated in all pregnant women regardless of severity.", "D": "Anzupgo is recommended as first-line therapy for all pregnant women with hand eczema."}}
{"id": "65fhGo3NUkyG", "question_type": "open_ended", "question": "Which of the following statements about co-administration of Enflonsia and routine childhood vaccines is correct?", "options": {"A": "Enflonsia must be administered at least two weeks apart from vaccines", "B": "Enflonsia cannot be given with any vaccines", "C": "Enflonsia can be given at the same time as routine childhood vaccines", "D": "Enflonsia should only be given after all vaccines are completed"}}
{"id": "4BWdSthcWFvI", "question_type": "multi_choice", "question": "A patient receiving penpulimab-kcqx develops Grade 3 immune-mediated pneumonitis. What is the recommended initial management strategy?", "options": {"A": "Continue penpulimab-kcqx and monitor closely", "B": "Withhold or permanently discontinue penpulimab-kcqx and initiate systemic corticosteroids", "C": "Switch to another PD-1/PD-L1 inhibitor", "D": "Treat with antibiotics and continue penpulimab-kcqx"}}
{"id": "V2rUyYcGe7vd", "question_type": "multi_choice", "question": "Which of the following statements best describes the contraindication profile of the drug Ekterly?", "options": {"A": "Ekterly is contraindicated in patients with severe hepatic impairment.", "B": "Ekterly should not be used in individuals with a history of hypersensitivity to its active ingredient.", "C": "Ekterly is contraindicated in pregnant women.", "D": "Ekterly has no listed contraindications."}}
{"id": "rtmaiTRgx6Ra", "question_type": "open_ended_multi_choice", "question": "If a patient becomes pregnant while receiving Vanrafia, what is the recommended clinical action?", "options": {"A": "Continue Vanrafia at a reduced dose", "B": "Switch to an alternative therapy", "C": "Discontinue Vanrafia as soon as possible", "D": "Monitor pregnancy closely without changing therapy"}}
{"id": "jWJPiodXXrfD", "question_type": "open_ended", "question": "In the ASPEN clinical trial evaluating Brinsupri for non-cystic fibrosis bronchiectasis (NCFB), which dosage group demonstrated the greatest improvement in post-bronchodilator FEV1 (mL) at Week 52 compared to placebo?", "options": {"A": "Brinsupri 10 mg", "B": "Brinsupri 25 mg", "C": "Placebo", "D": "Both Brinsupri 10 mg and 25 mg equally"}}
{"id": "qh40BNaaqdQS", "question_type": "open_ended_multi_choice", "question": "A 67-year-old man diagnosed with metastatic ROS1-positive NSCLC is taking IBTROZI (taletrectinib) at a dose of 600 mg orally once daily. His medical history includes osteoporosis and a recent rib fracture following a minor fall. He does not use any drugs that affect QTc or CYP3A metabolism. What should be the primary concern regarding his continued IBTROZI therapy?", "options": {"A": "Continue IBTROZI at the same dose without additional monitoring", "B": "Discontinue IBTROZI permanently due to fracture risk", "C": "Continue IBTROZI with prompt evaluation and monitoring for further skeletal fractures", "D": "Reduce IBTROZI dose to minimize risk of future fractures"}}
{"id": "Ljw6ZmaDocWj", "question_type": "open_ended_multi_choice", "question": "A 10-year-old boy weighing 35 kg with chronic graft-versus-host disease (cGVHD) is experiencing bronchiectasis, recurrent infections, and abnormal esophageal morphology. After failing two previous systemic therapies, he has normal liver function and is not currently on any other immunosuppressive medications. What is the most appropriate treatment option for him?", "options": {"A": "Niktimvo, intravenous infusion every 2 weeks", "B": "PredniSONE, 5 mg orally once daily", "C": "PONVORY, 20 mg orally once daily", "D": "Niktimvo, intravenous infusion every 4 weeks"}}
{"id": "iAfSFHvB2ZAZ", "question_type": "open_ended_multi_choice", "question": "A 35-year-old breastfeeding woman with primary axillary hyperhidrosis seeks topical treatment for her condition. She is healthy and not on any other medications. Which therapy should not be used because of the risk of drug passage into breast milk?", "options": {"A": "Qbrexza", "B": "Sofdra", "C": "Oxybutynin", "D": "Both Qbrexza and Sofdra"}}
{"id": "3dsBjIXWJsNA", "question_type": "multi_choice", "question": "A 58-year-old woman is newly diagnosed with metastatic non-small cell lung cancer (NSCLC). Genetic testing reveals a ROS1 gene rearrangement. She has a history of mild renal impairment (CLcr 55 mL/min), is currently taking a moderate CYP3A inhibitor for another condition, and has no history of cardiac disease or CNS symptoms. She is not pregnant and does not plan to breastfeed. Which drug regimen is most appropriate for her initial treatment?", "options": {"A": "CYRAMZA in combination with docetaxel", "B": "CYRAMZA in combination with erlotinib", "C": "LAZCLUZE (lazertinib plus amivantamab)", "D": "Rozlytrek, with dose reduction due to CYP3A inhibitor"}}
{"id": "34cWs8cQPiKw", "question_type": "open_ended_multi_choice", "question": "Why should Blujepa not be coadministered with drugs that are extensively metabolized by CYP3A4 and have a narrow therapeutic index?", "options": {"A": "Risk of decreased efficacy of Blujepa", "B": "Potential for increased toxicity of the coadministered drug", "C": "Increased risk of renal impairment", "D": "Potential for antagonistic pharmacodynamic effects"}}
{"id": "ZW9gEFxMia8e", "question_type": "multi_choice", "question": "A 16-year-old male with Niemann-Pick disease type C and progressive neurological decline is being considered for drug therapy. He has moderate renal impairment (eGFR 35 mL/min) and is currently taking metformin, an OCT2 substrate. Which of the following is the most appropriate approach to drug selection and management for this patient?", "options": {"A": "Start MIPLYFFA in combination with miglustat at standard dosing without adjustments", "B": "Start MIPLYFFA in combination with miglustat at reduced dosing and monitor for metformin toxicity", "C": "Start OPFOLDA in combination with Pombiliti", "D": "Start lithium carbonate therapy"}}
{"id": "0DjmTtY50egn", "question_type": "open_ended_multi_choice", "question": "Considering a 10-year-old male patient with Duchenne muscular dystrophy and a DMD gene mutation suitable for exon 51 skipping therapy, who has a documented history of hypersensitivity to IV medications, which treatment approach best aligns with his clinical needs?", "options": {"A": "Eteplirsen administered once weekly", "B": "Deflazacort administered daily", "C": "Givinostat administered twice daily", "D": "Eteplirsen with a drug scheduler to minimize hypersensitivity risk"}}
{"id": "j2D0ynjGLAkp", "question_type": "open_ended_multi_choice", "question": "When co-administering Blujepa with succinylcholine-type neuromuscular blocking agents, what is the primary clinical concern?", "options": {"A": "Exaggerated neuromuscular blockade", "B": "Reduced efficacy of Blujepa", "C": "Increased risk of hepatic toxicity", "D": "Development of hemolytic anemia"}}
{"id": "NGA4AR2Fykyb", "question_type": "multi_choice", "question": "A 10-year-old girl with progressive diffuse midline glioma harboring an H3 K27M mutation has completed prior therapy. She is currently taking a medication known to prolong the QTc interval for a cardiac arrhythmia. Her oncologist is considering starting a new treatment for her glioma. Which of the following is the most appropriate approach regarding the use of MODEYSO (dordaviprone) in this patient?", "options": {"A": "Initiate MODEYSO at the standard dose without any changes to her current medications.", "B": "Avoid using MODEYSO due to her age; it is not approved for pediatric patients.", "C": "Discontinue the QTc-prolonging drug and start MODEYSO at a reduced dose.", "D": "Start MODEYSO, but separate its administration from the QTc-prolonging drug and increase ECG monitoring."}}
{"id": "HDDQ9RW2Q67l", "question_type": "multi_choice", "question": "Has Tryptyr been shown to impair fertility in animal studies?", "options": {"A": "Yes, Tryptyr significantly impairs fertility in both male and female animals.", "B": "No, Tryptyr has been shown to have no effect on fertility in animal studies.", "C": "Tryptyr impairs fertility only in female animals.", "D": "Tryptyr increases fertility in animal models."}}
{"id": "QJ8jTGLLU5hB", "question_type": "open_ended_multi_choice", "question": "A 62-year-old female with unresectable, locally advanced intrahepatic cholangiocarcinoma and confirmed FGFR2 rearrangement is planning to become pregnant in the next few months. She is otherwise healthy and not currently on any CYP3A-modulating medications. Which treatment approach is most appropriate for her current situation?", "options": {"A": "Pemigatinib (PEMAZYRE) once daily, standard dose", "B": "Futibatinib (LYTGOBI) once daily, standard dose", "C": "Zanidatamab-hrii (ZIIHERA) every three weeks, standard dose", "D": "Delay initiation of FGFR-targeted therapy until pregnancy status is clarified and effective contraception is in place"}}
{"id": "X9F6g20krHo8", "question_type": "multi_choice", "question": "A 72-year-old patient with a history of chronic kidney disease and hypertension presents with acute pain following an appendectomy for a disorder of the appendix. The surgical team is considering options for postoperative pain management. Which drug is most appropriate for regional anesthesia in this elderly patient, taking into account the need for cautious dosing and monitoring due to decreased renal and hepatic function?", "options": {"A": "Adrenalin", "B": "DEXAMETHASONE", "C": "ROPIVACAINE HYDROCHLORIDE", "D": "TaperDex 12-day"}}
{"id": "Bj3FOlbtpFYI", "question_type": "open_ended", "question": "A 14-year-old patient presents with non-cystic fibrosis bronchiectasis, recurrent bronchopulmonary infections, and decreased forced expiratory flow 25-75%. The patient is scheduled to receive a live attenuated vaccine in two weeks and is currently experiencing mild gingival inflammation. Which drug regimen is most appropriate for managing their bronchiectasis at this time?", "options": {"A": "Brinsupri, initiated immediately at the recommended dose for pediatric patients 12 years and older", "B": "SYMDEKO, administered twice daily as per cystic fibrosis protocol", "C": "GENOTROPIN, administered daily for growth hormone deficiency", "D": "Brinsupri, initiated after completion of the live attenuated vaccine schedule and with regular dental checkups"}}
{"id": "bUnPuzpGXfBo", "question_type": "multi_choice", "question": "A 52-year-old woman presents with progressive difficulty focusing on near objects and is diagnosed with presbyopia. She has a history of iritis and is seeking pharmacological treatment to improve her near vision. Which of the following drugs is most appropriate for her condition?", "options": {"A": "VIZZ administered as topical ocular drops twice daily", "B": "Mirvaso topical gel applied once daily", "C": "Oraverse intraoral injection after dental procedures", "D": "VIZZ administered as topical ocular drops once daily"}}
{"id": "yL12zuGOjTmz", "question_type": "open_ended_multi_choice", "question": "A 54-year-old woman diagnosed with primary biliary cholangitis presents with persistent itching, increased alkaline phosphatase levels, and a background of cirrhosis with newly developed ascites. She cannot tolerate ursodeoxycholic acid and is looking for other therapeutic options. Her medications include a statin for hyperlipidemia. Which treatment plan would be most appropriate for her?", "options": {"A": "Elafibranor once daily as monotherapy", "B": "Colcrys daily for long-term management", "C": "Budesonide inhalation twice daily", "D": "Supportive care only; avoid Elafibranor due to decompensated cirrhosis"}}
{"id": "CVMjXBS74mt5", "question_type": "open_ended_multi_choice", "question": "A 68-year-old woman with intermediate-2 risk myelodysplastic syndromes (MDS) and chronic kidney disease (creatinine clearance of 35 mL/min) is not pregnant or breastfeeding. She is currently on a medication that is metabolized by cytidine deaminase for another health issue. Taking into account her comorbidities and ongoing medications, which treatment regimen would be most suitable for her MDS?", "options": {"A": "INQOVI (oral decitabine + cedazuridine) once daily for 5 days every 28-day cycle", "B": "Decitabine intravenous infusion daily for 5 days every 4 weeks", "C": "RYTELO intravenous infusion every 4 weeks with premedication for infusion reactions", "D": "INQOVI (oral decitabine + cedazuridine) with a drug holiday every other cycle"}}
{"id": "RXS5rnVOqK3p", "question_type": "open_ended_multi_choice", "question": "A 45-year-old woman with a history of mild hypertension, but without bronchospastic lung disease, liver impairment, pregnancy, or concurrent medications, presents to the emergency department with palpitations and is diagnosed with acute supraventricular tachycardia. The cardiology team is evaluating pharmacologic rate control strategies. Which agent is most appropriate for short-term control of her ventricular rate, and what is the recommended administration frequency?", "options": {"A": "Pacerone, administered as a single intravenous bolus, followed by oral maintenance dosing.", "B": "RAPIBLYK, administered as a continuous intravenous infusion titrated to effect.", "C": "Propranolol, administered orally twice daily.", "D": "Pacerone, administered orally once daily."}}
{"id": "s2eQSyGl2Dre", "question_type": "open_ended_multi_choice", "question": "A 58-year-old female with non-alcoholic steatohepatitis (NASH) and advanced (F3) liver fibrosis is being evaluated for medical treatment. Her medical history includes intermittent claudication and atrial fibrillation, for which she is prescribed warfarin. Her liver function tests are normal, and she has not developed decompensated cirrhosis. Taking into account her comorbid conditions and current medications, which pharmacological agent is most suitable for managing her NASH?", "options": {"A": "Resmetirom administered once daily in conjunction with diet and exercise", "B": "Pentoxifylline extended-release tablets twice daily", "C": "Dapagliflozin once daily", "D": "Pentoxifylline extended-release tablets once daily"}}
{"id": "HRl6PFiKpWnA", "question_type": "multi_choice", "question": "A 48-year-old woman with locally advanced breast cancer is experiencing severe postoperative pain following tumor resection. She has a history of peptic ulcer disease and mild renal impairment (eGFR 55 mL/min). She is not pregnant and weighs 65 kg. Which analgesic regimen is safest and most effective for her acute pain management over the next several days?", "options": {"A": "Ketorolac tromethamine for up to 5 days, with dose adjustment for renal impairment", "B": "Morphine sulfate titrated to pain, with careful monitoring for respiratory depression", "C": "Itovebi (inavolisib) in combination with palbociclib and fulvestrant for pain control", "D": "Ketorolac tromethamine for chronic pain management beyond 5 days"}}
{"id": "FcvkOcXKvLgX", "question_type": "open_ended", "question": "A 14-year-old patient with diffuse midline glioma (H3 K27M mutation) is being considered for dordaviprone (MODEYSO) therapy. The patient has a history of congenital long QT syndrome and is currently taking a medication known to prolong the QTc interval. What is the most appropriate course of action regarding dordaviprone (MODEYSO) administration?", "options": {"A": "Proceed with dordaviprone (MODEYSO) therapy with standard monitoring.", "B": "Avoid dordaviprone (MODEYSO) due to increased risk of life-threatening arrhythmias.", "C": "Start dordaviprone (MODEYSO) only if the QTc-prolonging medication is continued.", "D": "Initiate dordaviprone (MODEYSO) but reduce the dose due to age."}}
{"id": "NtZjEwcgRbYo", "question_type": "open_ended_multi_choice", "question": "A 14-year-old male with WHIM syndrome, presenting with recurrent bacterial infections, neutropenia, and bone marrow hypercellularity, is found to have moderate hepatic impairment. He is not taking any other medications and has no history of cardiac arrhythmias. Which of the following is the most appropriate course of action regarding XOLREMDI therapy?", "options": {"A": "XOLREMDI is not recommended due to moderate hepatic impairment.", "B": "XOLREMDI can be used at standard dosage without concern.", "C": "XOLREMDI should be used only with dose reduction.", "D": "XOLREMDI is recommended only if the patient is also taking a CYP2D6 substrate."}}
{"id": "Z4I8SDU2SyPX", "question_type": "multi_choice", "question": "A 7-year-old boy with Duchenne muscular dystrophy presents with progressive muscle weakness, elevated creatine kinase, and a history of arrhythmia. He is currently taking a medication known to prolong the QTc interval for his cardiac condition. Which drug regimen is most appropriate for treating his DMD, considering his cardiac profile and current medications?", "options": {"A": "Givinostat administered twice daily", "B": "Givinostat with a planned drug holiday every month", "C": "Deflazacort administered daily", "D": "Eteplirsen administered once weekly"}}
{"id": "xZwYyO9Re7uB", "question_type": "open_ended", "question": "A 35-year-old male presents with progressive proximal muscle weakness, scapular winging, and elevated creatine kinase levels. He is diagnosed with myofibrillar myopathy and is currently experiencing an acute exacerbation. His medical history is significant for hypertension, for which he takes amlodipine. He is not taking any immunosuppressive or antifungal medications. Which drug regimen is most appropriate for managing his acute myopathy symptoms, considering his comorbidities and current medications?", "options": {"A": "Sildenafil citrate 50 mg once daily", "B": "TaperDex 6-day corticosteroid regimen, starting at a low dose with blood pressure monitoring", "C": "Cortisone aceticum for appetite and water retention", "D": "TaperDex 6-day corticosteroid regimen at a high dose without monitoring"}}
{"id": "19KutX7drLjE", "question_type": "open_ended_multi_choice", "question": "What is the rationale for assessing a patient's vaccination status prior to starting Imaavy therapy?", "options": {"A": "Imaavy causes transient reduction in IgG levels, making live vaccines not recommended during treatment", "B": "Imaavy increases the risk of vaccine-induced fever", "C": "Imaavy enhances the efficacy of live vaccines", "D": "Imaavy interacts with inactivated vaccines to cause hypersensitivity"}}
{"id": "7rCjoznIoD2r", "question_type": "open_ended_multi_choice", "question": "A 45-year-old woman with dry eye disease who wears contact lenses every day is looking for symptom relief. She specifically wants a medication that she can use without having to remove her contact lenses first. Based on her preference and the safety of available therapies, which medication would be most suitable?", "options": {"A": "Acoltremon ophthalmic solution, administered twice daily", "B": "Loteprednol etabonate ophthalmic gel, administered twice daily", "C": "Lifitegrast ophthalmic solution, administered twice daily", "D": "Loteprednol etabonate ophthalmic gel, administered once daily"}}
{"id": "eJ4X4C7iB9Qh", "question_type": "open_ended", "question": "A 55-year-old man with metastatic non-squamous non-small cell lung cancer and confirmed HER2 (ERBB2) tyrosine kinase domain activating mutation is being considered for targeted therapy. He has a history of chronic heart failure with a left ventricular ejection fraction (LVEF) of 45%. He is not pregnant, not breastfeeding, and is taking no CYP3A inducers or BCRP substrates. Which of the following treatment options should be avoided due to his cardiac condition?", "options": {"A": "Zongertinib (HERNEXEOS) orally once daily", "B": "Durvalumab (IMFINZI) as a single agent every 2 weeks", "C": "Etoposide administered intravenously every 3 weeks", "D": "Durvalumab (IMFINZI) in combination with platinum-based chemotherapy"}}
{"id": "t9U7d5pY9fLl", "question_type": "multi_choice", "question": "A 42-year-old woman with a history of inoperable, functional adrenocortical carcinoma is being considered for systemic therapy. She is not pregnant, has normal hepatic and renal function, and is not taking any hormonal contraceptives or warfarin. Which drug is most appropriate for her treatment, considering her diagnosis and current medications?", "options": {"A": "Lumisight", "B": "Blue dye for sentinel lymph node mapping", "C": "Spironolactone", "D": "Lysodren"}}
{"id": "EAzR9RoPPGHn", "question_type": "open_ended_multi_choice", "question": "A pregnant 34-year-old in her second trimester presents with symptomatic supraventricular tachycardia and requires immediate pharmacologic rate control. She reports no prior health issues and is medication-free. Which medication would be the best choice for her?", "options": {"A": "Pacerone (amiodarone)", "B": "RAPIBLYK (landiolol)", "C": "Propranolol", "D": "Digoxin"}}
{"id": "izHHAKL6Ak5S", "question_type": "open_ended_multi_choice", "question": "A 28-year-old woman who is 10 weeks pregnant presents with newly diagnosed molluscum contagiosum. She is concerned about the safety of topical treatments during pregnancy. She has no history of skin allergies or damaged skin. Which of the following is the most appropriate recommendation for her?", "options": {"A": "Adapalene applied nightly to lesions", "B": "Zelsuvmi applied topically as directed, with counseling about limited pregnancy safety data", "C": "Zelsuvmi applied twice daily to lesions", "D": "Adapalene applied twice daily to lesions"}}
{"id": "xmJUq0LVL0fk", "question_type": "open_ended_multi_choice", "question": "For a 60-year-old man diagnosed with hypoparathyroidism and advanced renal impairment (eGFR 20 mL/min/1.73 m²), who is also receiving digoxin for atrial fibrillation and has no prior bone malignancy or radiation therapy, which drug would be the optimal and safest choice to manage his hypoparathyroidism in light of his renal function and digoxin use?", "options": {"A": "Ergocalciferol", "B": "Calcitriol", "C": "Yorvipath", "D": "Palopegteriparatide"}}
{"id": "TSjQhqLpEPIZ", "question_type": "multi_choice", "question": "A 58-year-old woman with chronic kidney disease has been receiving dialysis for the past four months. She presents with symptomatic anemia (hemoglobin 9.2 g/dL). Her medical history includes well-controlled hypertension and mild hyperlipidemia, for which she takes simvastatin 10 mg daily. She is not pregnant and has no history of liver disease or malignancy. Which of the following is the most appropriate pharmacologic treatment for her anemia, considering her current medications and comorbidities?", "options": {"A": "Vadadustat administered once daily, with careful monitoring of statin-related adverse effects and hemoglobin levels.", "B": "Fedratinib administered daily, with thiamine supplementation.", "C": "Homeopathic combination (Adrenalinum, etc.) for appetite and water retention symptoms.", "D": "Vadadustat administered once daily, with no adjustment for statin therapy."}}
{"id": "1kuNEWAdo1cL", "question_type": "open_ended", "question": "How did the mean change in MG-ADL total score from baseline over weeks 22, 23, and 24 compare between Imaavy and placebo groups in the clinical study?", "options": {"A": "Imaavy: -4.7; Placebo: -3.3; Difference: -1.5", "B": "Imaavy: -2.1; Placebo: -4.9; Difference: +2.8", "C": "Imaavy: -3.3; Placebo: -4.7; Difference: +1.4", "D": "Imaavy: -1.5; Placebo: -2.4; Difference: -0.9"}}
{"id": "lBqCVnFCxfNV", "question_type": "open_ended_multi_choice", "question": "A 65-year-old male with neurofibromatosis type 1 and a history of chronic myelogenous leukemia, hypertension, and mild renal impairment presents with joint stiffness and pain. He is currently taking an ACE inhibitor for blood pressure control. Which of the following drugs is least appropriate for managing his pain?", "options": {"A": "Celecoxib", "B": "Gomekli", "C": "PNV-DHA", "D": "Physical therapy only"}}
{"id": "2QBzuizWbUzy", "question_type": "multi_choice", "question": "What is the observed difference in safety or effectiveness of Emrelis between older (≥65 years) and younger patients with previously treated EGFR wild-type non-squamous NSCLC with c-Met protein overexpression?", "options": {"A": "Older patients have significantly higher adverse events", "B": "Younger patients have better effectiveness", "C": "Older patients require dose adjustment", "D": "No overall differences in safety or effectiveness were observed"}}
{"id": "jtwlO7BssZSX", "question_type": "open_ended_multi_choice", "question": "A 42-year-old male presents with moderate to severe acute pain following a sports-related injury. His liver and kidney function are normal, but he is currently prescribed a moderate CYP3A inhibitor for another health issue. He also takes a combined oral contraceptive containing ethinyl estradiol and norethindrone. What is the most suitable drug and dosing regimen for managing his pain?", "options": {"A": "Suzetrigine at standard adult dosage", "B": "Suzetrigine with reduced dosage", "C": "Ropivacaine Hydrochloride at standard dosage", "D": "Acetaminophen at maximum daily dosage"}}
{"id": "tzIB9MIJCpG7", "question_type": "open_ended_multi_choice", "question": "A man aged 45 with a history of diffuse midline glioma (H3 K27M mutated) that has progressed after prior therapy is now a candidate for MODEYSO. He is concurrently taking a strong CYP3A4 inhibitor for a separate condition. How should his glioma therapy be managed?", "options": {"A": "Start MODEYSO at the standard dose without adjusting for drug interactions.", "B": "Avoid using MODEYSO entirely due to his age.", "C": "Reduce the dose of MODEYSO if concomitant use with the CYP3A4 inhibitor cannot be avoided.", "D": "Discontinue the CYP3A4 inhibitor and start MODEYSO at a higher dose."}}
{"id": "hTFfz3pilpR9", "question_type": "open_ended_multi_choice", "question": "A 7-year-old patient has just been diagnosed with paroxysmal nocturnal hemoglobinuria (PNH) and has no notable comorbid conditions, with normal liver and kidney function. What is the most suitable first-line pharmacologic treatment for this child?", "options": {"A": "Sirolimus", "B": "Voydeya as monotherapy", "C": "Ravulizumab", "D": "Voydeya added to eculizumab"}}
{"id": "GlUKtQJk3xQ8", "question_type": "multi_choice", "question": "A 50-year-old woman with chronic hypoparathyroidism is currently being treated with digoxin for atrial fibrillation. Her serum calcium is well controlled on calcium and active vitamin D. She is being considered for additional therapy to better manage her hypoparathyroidism. Which of the following is the most important consideration if Yorvipath is initiated?", "options": {"A": "Yorvipath may increase the risk of digitalis toxicity due to elevated serum calcium", "B": "Yorvipath is contraindicated in patients with a history of atrial fibrillation", "C": "Yorvipath is not effective in patients taking active vitamin D", "D": "Yorvipath should be administered twice daily to minimize calcium fluctuations"}}
{"id": "VaKVuUSZotjS", "question_type": "open_ended_multi_choice", "question": "A 6-year-old child is diagnosed with community-acquired bacterial pneumonia and has no known drug allergies or renal issues. The parents express concerns about antibiotics that could cause long-term effects on teeth and bone development. Taking both effectiveness and safety into account, which antibiotic regimen would be most suitable for this patient?", "options": {"A": "Doxycycline Hyclate administered twice daily for 7 days", "B": "Rituximab and Hyaluronidase administered as a single agent", "C": "Zevtera administered according to pediatric dosing guidelines for 7 days", "D": "Doxycycline Hyclate with a planned drug holiday after 3 days"}}
{"id": "DANOiXZoUrcg", "question_type": "multi_choice", "question": "A patient with metastatic non-keratinizing nasopharyngeal carcinoma has progressed after platinum-based chemotherapy and one additional prior therapy. Which treatment option involving Penpulimab-kcqx is appropriate?", "options": {"A": "Penpulimab-kcqx in combination with cisplatin and gemcitabine", "B": "Penpulimab-kcqx as a single agent", "C": "Penpulimab-kcqx with carboplatin and paclitaxel", "D": "Penpulimab-kcqx as maintenance therapy after chemotherapy"}}
{"id": "9kgWCuGiqDpa", "question_type": "open_ended_multi_choice", "question": "A child aged 10 years and weighing 32 kg presents with a new diagnosis of paroxysmal nocturnal hemoglobinuria (PNH). There is no prior use of complement inhibitors, and the child is fully vaccinated against meningococcus. Based on age and weight criteria, what is the most suitable first-line treatment for this patient?", "options": {"A": "Ultomiris", "B": "Piasky", "C": "Sirolimus", "D": "Eculizumab"}}
{"id": "TUotC3iysJ56", "question_type": "open_ended_multi_choice", "question": "Which statement below reflects proper patient guidance for administering Andembry?", "options": {"A": "Inject Andembry intravenously without training.", "B": "Use Andembry for any condition with similar symptoms.", "C": "Do not give Andembry to other people, even if they have the same symptoms.", "D": "Mix Andembry with herbal supplements before injection."}}
{"id": "FvUJVJUZTnqF", "question_type": "open_ended_multi_choice", "question": "A 35-year-old pregnant woman has been diagnosed with inoperable adrenocortical carcinoma. Her liver and kidney function are normal, and she is not currently on any other medications. What is the best recommendation for systemic treatment of her cancer?", "options": {"A": "Initiate Lysodren therapy immediately", "B": "Use Lumisight for systemic treatment", "C": "Avoid Lysodren due to risk of fetal harm", "D": "Start hormonal contraceptives before Lysodren"}}
{"id": "Vs2gnCKKA98a", "question_type": "multi_choice", "question": "A patient with metastatic non-keratinizing nasopharyngeal carcinoma has progressed after platinum-based chemotherapy and one additional prior therapy. Which treatment option involving Penpulimab-kcqx is appropriate?", "options": {"A": "Penpulimab-kcqx in combination with cisplatin and gemcitabine", "B": "Penpulimab-kcqx as maintenance therapy after chemotherapy", "C": "Penpulimab-kcqx with carboplatin and paclitaxel", "D": "Penpulimab-kcqx as a single agent"}}
{"id": "VUi240JOmqZs", "question_type": "multi_choice", "question": "For patients with confirmed Grade 2 or higher ILD/pneumonitis while on Datroway, what is the recommended action regarding drug administration?", "options": {"A": "Permanently discontinue Datroway", "B": "Reduce Datroway dose", "C": "Continue Datroway with corticosteroids", "D": "Withhold Datroway temporarily"}}
{"id": "BcdbHEAwYgWY", "question_type": "multi_choice", "question": "A 62-year-old man is newly diagnosed with locally advanced unresectable gastroesophageal junction adenocarcinoma. His tumor is confirmed to be HER2-negative and CLDN18.2-positive by FDA-approved testing. He has normal hepatic and renal function, no history of hypersensitivity reactions, and is not taking any anticoagulants or CYP3A4 inhibitors. Which initial drug regimen is most appropriate for his first-line treatment?", "options": {"A": "Capecitabine monotherapy", "B": "Docetaxel in combination with cisplatin and fluorouracil", "C": "Zolbetuximab (Vyloy) in combination with fluoropyrimidine- and platinum-containing chemotherapy", "D": "Docetaxel monotherapy"}}
{"id": "MzFMIYVwT4gN", "question_type": "open_ended", "question": "Which of the following is a contraindication for receiving Enflonsia?", "options": {"A": "History of mild rash after vaccination", "B": "Concurrent use of herbal supplements", "C": "History of serious allergic reactions to any ingredient in Enflonsia", "D": "Receiving routine childhood vaccines"}}
{"id": "LguvayLTjEu7", "question_type": "open_ended_multi_choice", "question": "If a patient with liver problems misses a dose of Journavx and the next scheduled dose is within 6 hours, what is the recommended action?", "options": {"A": "Take the missed dose and the next scheduled dose together.", "B": "Skip the missed dose and take the next scheduled dose at the recommended time.", "C": "Double the next scheduled dose.", "D": "Take the missed dose immediately, regardless of timing."}}
{"id": "bMTHYlSGllQP", "question_type": "open_ended", "question": "A 32-year-old woman with a history of familial hypophosphatemia and recent diagnosis of infertility disorder is currently pregnant. Her physician is considering vitamin D supplementation to address her metabolic bone disorder. Which of the following is the most appropriate approach regarding ergocalciferol therapy for this patient?", "options": {"A": "Initiate ergocalciferol at standard doses, as pregnancy does not affect its safety profile.", "B": "Avoid ergocalciferol unless the potential benefits outweigh the significant fetal risks, and do not exceed 400 USP units daily.", "C": "Use clopidogrel bisulfate instead of ergocalciferol for metabolic bone disorder in pregnancy.", "D": "Administer ergocalciferol at high doses to ensure adequate vitamin D levels during pregnancy."}}
{"id": "LQH70C3rAsWK", "question_type": "multi_choice", "question": "A 10-day-old neonate, born at term and entering their first RSV season, is being evaluated for RSV prophylaxis. The infant has no history of hypersensitivity reactions and is otherwise healthy. The mother is of reproductive potential but is not currently pregnant or breastfeeding. Which drug is most appropriate for RSV prevention in this patient?", "options": {"A": "Restasis MultiDose, administered twice daily.", "B": "ENFLONSIA, administered as a single dose.", "C": "Virazole, administered as an inhalation solution.", "D": "Virazole, administered orally."}}
{"id": "YvotFJJ3a2VE", "question_type": "open_ended_multi_choice", "question": "How did the incidence of skin cancers in the ASPEN trial compare between Brinsupri 25 mg and placebo groups?", "options": {"A": "Higher in Brinsupri 25 mg group", "B": "Lower in Brinsupri 25 mg group", "C": "Equal in both groups", "D": "Not reported"}}
{"id": "ajUUEYC1lPLE", "question_type": "open_ended_multi_choice", "question": "A 65-year-old man with a history of hyperlipidemia and recent diagnosis of skin hemangioma is being considered for drug therapy. He is currently taking a strong CYP3A4 inhibitor for another condition. Which drug option poses the greatest risk of adverse reactions due to drug interactions in this patient?", "options": {"A": "HYFTOR topical (sirolimus) administered daily", "B": "Vincristine Sulfate intravenous administered weekly", "C": "HYFTOR topical (sirolimus) with reduced frequency", "D": "Vincristine Sulfate intravenous with drug scheduler"}}
{"id": "DIixhUv08Wvr", "question_type": "open_ended_multi_choice", "question": "A 60-year-old patient with presbyopia, taking a monoamine oxidase inhibitor for depression and beta-blockers for high blood pressure, asks for a medication to help with near vision. Which treatment option should be considered safest and most effective in his case?", "options": {"A": "Mirvaso topical gel applied to the face daily", "B": "Oraverse intraoral injection following dental anesthesia", "C": "VIZZ topical ocular drops once daily", "D": "Mirvaso topical gel applied twice daily"}}
{"id": "zPSndZu6tq9K", "question_type": "open_ended", "question": "A 32-year-old woman with diffuse midline glioma (H3 K27M mutation, progressive after prior therapy) is currently 10 weeks pregnant. She is otherwise healthy and not taking any other medications. Which of the following is the most appropriate recommendation regarding the use of MODEYSO?", "options": {"A": "Initiate MODEYSO at the standard dose, as it is safe in pregnancy.", "B": "Delay MODEYSO therapy until after delivery.", "C": "Advise against MODEYSO due to embryo-fetal toxicity and consider alternative therapies if available.", "D": "Start MODEYSO with close fetal monitoring throughout pregnancy."}}
{"id": "cxKPFlTi0NIv", "question_type": "open_ended_multi_choice", "question": "Which of the following is a contraindication for the administration of Imaavy?", "options": {"A": "History of severe allergic reaction to nipocalimab or any ingredient in Imaavy", "B": "Recent respiratory tract infection", "C": "Pregnancy", "D": "Peripheral edema"}}
{"id": "YbfRKObCSLjP", "question_type": "open_ended_multi_choice", "question": "A 65-year-old woman with mild dementia due to Alzheimer’s disease is planning to become pregnant. She asks about the safety of KISUNLA (donanemab-azbt) for her condition. What is the most appropriate recommendation regarding drug therapy?", "options": {"A": "Recommend KISUNLA, as it is safe for use during pregnancy.", "B": "Advise against KISUNLA due to lack of safety data in pregnancy; consider alternative therapy if available.", "C": "Initiate KISUNLA and monitor closely for ARIA.", "D": "Recommend KISUNLA only after the first trimester."}}
{"id": "cInJZ91ByG2J", "question_type": "open_ended_multi_choice", "question": "A 72-year-old male with a new diagnosis of recurrent, metastatic non-keratinizing nasopharyngeal carcinoma also has moderate renal impairment (creatinine clearance 35 mL/min) and a history of gastrointestinal bleeding. Which of the following drugs should be avoided due to his comorbidities and which is most suitable for his cancer treatment?", "options": {"A": "Capecitabine 500 mg twice daily, with dose reduction for renal impairment", "B": "Celecoxib 200 mg twice daily for pain management", "C": "Penpulimab-kcqx in combination with carboplatin and gemcitabine, administered every 3 weeks", "D": "Capecitabine 500 mg twice daily, standard dosing"}}
{"id": "lhv3eAhNoZxo", "question_type": "open_ended_multi_choice", "question": "A 55-year-old woman with metastatic squamous cell lung adenocarcinoma and abnormal liver function tests (AST and ALT >1.5 × ULN, alkaline phosphatase >2.5 × ULN) is being evaluated for second-line therapy after platinum-based chemotherapy failure. Which drug should be avoided due to her current condition?", "options": {"A": "KEYTRUDA QLEX (Pembrolizumab and Berahyaluronidase Alfa)", "B": "Docetaxel", "C": "Pemetrexed disodium", "D": "Docetaxel in combination with cisplatin"}}
{"id": "BDinUevObW5d", "question_type": "open_ended_multi_choice", "question": "A 17-year-old girl diagnosed with WHIM syndrome, experiencing recurrent bacterial infections and low circulating antibody levels, is being treated with digoxin for a heart condition and metformin for diabetes. She is neither pregnant nor has any renal or hepatic impairment. Which drug therapy strategy would best help raise her mature neutrophil and lymphocyte counts?", "options": {"A": "XOLREMDI, daily oral administration with frequent monitoring of digoxin and glycemic control", "B": "Mavorixafor, daily oral administration without monitoring", "C": "XOLREMDI, daily oral administration with a drug holiday every month", "D": "No drug therapy recommended due to drug interactions"}}
{"id": "gpZmW93W7Et1", "question_type": "multi_choice", "question": "For which patient populations is the use of Vizz contraindicated based on its official labeling?", "options": {"A": "None; there are no contraindications listed for Vizz", "B": "Patients with known hypersensitivity to Vizz", "C": "Patients with renal failure", "D": "Patients with severe hepatic impairment"}}
{"id": "Ni4zrfoItvWD", "question_type": "open_ended_multi_choice", "question": "A 7-year-old child presents with relapsed low-grade glioma. Genetic testing confirms a BRAF V600 mutation. The patient has no history of neurofibromatosis type 1 (NF1) and is not currently taking any CYP2C8 inhibitors or hormonal contraceptives. The family is concerned about the impact of therapy on growth and fertility. Which drug regimen is most appropriate for this patient, considering efficacy, safety, and approved indications?", "options": {"A": "OJEMDA administered once daily, with routine monitoring of growth and liver function.", "B": "VinCRIStine Sulfate administered intravenously weekly, despite lack of LGG-specific indication.", "C": "Gliadel Wafer implantation during surgery, although pediatric safety and efficacy are not established.", "D": "OJEMDA combined with hormonal contraceptives to prevent breakthrough bleeding."}}
{"id": "Tw3B8rA6G16t", "question_type": "open_ended_multi_choice", "question": "A 58-year-old man with a history of glaucoma and recurrent herpes simplex eye infections is diagnosed with dry eye disease. He is seeking a medication for daily use to relieve his symptoms. Which drug should be avoided due to his medical history, and which is the most suitable for his condition?", "options": {"A": "Loteprednol etabonate ophthalmic gel, administered twice daily", "B": "Acoltremon ophthalmic solution, administered twice daily", "C": "Lifitegrast ophthalmic solution, administered twice daily", "D": "Loteprednol etabonate ophthalmic gel, administered once daily"}}
{"id": "XkWSc7hmas5p", "question_type": "open_ended_multi_choice", "question": "How should the Hernexeos dose be altered for an 85 kg individual who needs concomitant treatment with a strong CYP3A inducer?", "options": {"A": "Increase to 240 mg once daily", "B": "Decrease to 60 mg once daily", "C": "Maintain at 120 mg once daily", "D": "Increase to 180 mg once daily"}}
{"id": "ZjjjHRhYWHCh", "question_type": "open_ended_multi_choice", "question": "A 48-year-old woman presents with recurrent, metastatic non-keratinizing nasopharyngeal carcinoma. She has a history of well-controlled hypertension and is currently receiving warfarin for atrial fibrillation. She is not pregnant or breastfeeding. Her renal and hepatic function are normal. Which of the following is the most appropriate first-line drug regimen for her cancer treatment?", "options": {"A": "Celecoxib 200 mg twice daily", "B": "Capecitabine 500 mg twice daily", "C": "Penpulimab-kcqx in combination with cisplatin and gemcitabine", "D": "Penpulimab-kcqx monotherapy"}}
{"id": "Tjwi95WjxwKD", "question_type": "open_ended_multi_choice", "question": "Is a change in Datroway dosage advised for those diagnosed with mild hepatic impairment?", "options": {"A": "Yes, reduce the dosage", "B": "Yes, increase the dosage", "C": "No dosage adjustment is recommended", "D": "Discontinue Datroway"}}
{"id": "CwX8mHTaynqZ", "question_type": "open_ended_multi_choice", "question": "For patients prescribed Vizz, what is the advised precaution regarding nighttime driving or operating equipment?", "options": {"A": "Ensure vision is clear before engaging in these activities.", "B": "Take Vizz immediately before driving.", "C": "Wear sunglasses at night.", "D": "Increase the dose if vision is blurred."}}
{"id": "RtvyyOzlDHZj", "question_type": "open_ended_multi_choice", "question": "A 15-year-old adolescent weighing 45 kg is newly diagnosed with paroxysmal nocturnal hemoglobinuria (PNH). She has no history of hepatic impairment or prior complement inhibitor therapy. Her parents are concerned about the safety and efficacy of available treatments for her age group. Which drug is most appropriate for initial therapy in this patient?", "options": {"A": "Danicopan as monotherapy", "B": "Pegcetacoplan as monotherapy", "C": "Crovalimab as monotherapy", "D": "Danicopan as add-on to ravulizumab"}}
{"id": "O5DVBrwrlZKD", "question_type": "open_ended", "question": "A 42-year-old adult with hereditary angioedema and a history of hypertension managed with an ACE inhibitor presents to the emergency department with an acute HAE attack. Which acute treatment option should be avoided due to potential drug interaction?", "options": {"A": "SEBETRALSTAT (EKTERLY) 300 mg orally at onset of attack", "B": "SAJAZIR (icatibant) injection 30 mg subcutaneously", "C": "Orladeyo 150 mg orally once daily", "D": "SAJAZIR (icatibant) injection 60 mg subcutaneously"}}
{"id": "lPw9JTmfjllY", "question_type": "open_ended_multi_choice", "question": "A 32-year-old woman with tuberculoma is currently breastfeeding her infant. She requires adjunctive corticosteroid therapy alongside antituberculous chemotherapy. Which corticosteroid option should be avoided due to its specific recommendation against use in nursing mothers?", "options": {"A": "PredniSONE oral tablets", "B": "TaperDex 12-day oral pack", "C": "Dexamethasone Sodium Phosphate IV/IM injection", "D": "TaperDex 6-day oral pack"}}
{"id": "rvMled35v7zY", "question_type": "multi_choice", "question": "A 52-year-old man with primary IgAN and UPCR of 1.8 g/g is being considered for VANRAFIA therapy to reduce proteinuria. He has a history of severe hepatic impairment. Which of the following is the most appropriate recommendation regarding VANRAFIA use in this patient?", "options": {"A": "Do not initiate VANRAFIA due to severe hepatic impairment.", "B": "Initiate VANRAFIA without dose adjustment and monitor liver enzymes regularly.", "C": "Start VANRAFIA at half the recommended dose and monitor for hepatotoxicity.", "D": "Begin VANRAFIA therapy and add a CYP3A inducer to reduce adverse effects."}}
{"id": "6KhVeLKjO2Cz", "question_type": "open_ended_multi_choice", "question": "A 45-year-old woman with dry eye disease wears contact lenses daily and seeks a medication for symptom relief. She prefers a treatment that does not require her to remove her lenses before administration. Which drug is most appropriate for her, considering her preference and the safety profile of available options?", "options": {"A": "Acoltremon ophthalmic solution, administered twice daily", "B": "Loteprednol etabonate ophthalmic gel, administered twice daily", "C": "Lifitegrast ophthalmic solution, administered twice daily", "D": "Loteprednol etabonate ophthalmic gel, administered once daily"}}
{"id": "6VjhH90hz0T7", "question_type": "open_ended_multi_choice", "question": "A 10-year-old child with congenital hemophilia A, and no prior hepatic or gallbladder disease, is seeking routine prophylaxis to prevent bleeding. Which medication is most appropriate for his age and condition?", "options": {"A": "Hemlibra administered subcutaneously once weekly", "B": "Qfitlia administered subcutaneously once monthly", "C": "Qfitlia administered subcutaneously once weekly", "D": "Fitusiran administered intravenously every two weeks"}}
{"id": "zNBZSMFQXAzt", "question_type": "open_ended_multi_choice", "question": "A 59-year-old woman with a diagnosis of BCG-unresponsive nonmuscle invasive bladder cancer with carcinoma in situ is currently pregnant. She is seeking advice on the safest drug therapy option for her condition. Which of the following statements best reflects the appropriate drug selection for this patient?", "options": {"A": "Gemcitabine is preferred due to its established safety in pregnancy.", "B": "Anktiva can be used safely during pregnancy because systemic exposure is low.", "C": "Both Anktiva and Gemcitabine are contraindicated in pregnancy due to potential fetal harm.", "D": "Gemcitabine is recommended because it is not absorbed systemically."}}
{"id": "NdLk0YqrTbaP", "question_type": "multi_choice", "question": "For patients taking Journavx who are also using hormonal contraceptives containing progestins other than levonorgestrel or norethindrone, what additional recommendation should be made?", "options": {"A": "Switch to a contraceptive containing ethinyl estradiol and levonorgestrel or norethindrone.", "B": "No additional contraceptive measures are needed.", "C": "Increase the dose of the current contraceptive.", "D": "Discontinue Journavx immediately."}}
{"id": "BJOZqyCnxMQY", "question_type": "open_ended_multi_choice", "question": "A patient receiving Blujepa develops diarrhea two weeks after completing therapy. What is the most important consideration in this case?", "options": {"A": "Evaluate for Clostridioides difficile infection (CDI)", "B": "Increase the dose of Blujepa", "C": "Start empiric antiviral therapy", "D": "Discontinue all medications immediately"}}
{"id": "XypnncAnvZOo", "question_type": "open_ended_multi_choice", "question": "A 65-year-old man with a history of chronic obstructive pulmonary disease (COPD) and type 2 diabetes is admitted for acute supraventricular tachycardia. He is currently on metformin and inhaled corticosteroids. Which of the following drugs should be avoided due to his comorbidities?", "options": {"A": "RAPIBLYK (landiolol)", "B": "Pacerone (amiodarone)", "C": "Propranolol", "D": "Adenosine"}}
{"id": "kLM3V6Vts3hS", "question_type": "open_ended", "question": "A 38-year-old woman with newly diagnosed locally advanced ROS1-positive non-small cell lung carcinoma is currently 10 weeks pregnant. She is otherwise healthy and not taking any other medications. Which of the following is the most appropriate recommendation regarding the use of IBTROZI for her cancer treatment?", "options": {"A": "Initiate IBTROZI at the standard adult dose, as pregnancy does not affect its safety.", "B": "Defer IBTROZI therapy until after delivery due to risk of fetal harm.", "C": "Start IBTROZI with close fetal monitoring, as animal studies show no risk.", "D": "Use IBTROZI only if no other ROS1 inhibitor is available, as it is safe in pregnancy."}}
{"id": "PaMM88cC5AKE", "question_type": "multi_choice", "question": "Following cholecystectomy due to gallbladder disease in patients treated with Qfitlia, what was the typical management regarding Qfitlia therapy?", "options": {"A": "Qfitlia dose was doubled", "B": "Qfitlia was permanently discontinued in all cases", "C": "Most patients resumed Qfitlia after surgery", "D": "Qfitlia was switched to fixed dose regimen"}}
{"id": "IcCdOQd9L00O", "question_type": "open_ended_multi_choice", "question": "A 58-year-old man with familial chylomicronemia syndrome, presenting with lipemia retinalis and episodic abdominal pain, also has mild renal impairment (eGFR 55 mL/min). He is not taking any other medications and has no history of hypersensitivity reactions. Which drug regimen is most suitable for reducing his triglyceride levels?", "options": {"A": "MYCOPHENOLATE MOFETIL, with dose adjustment for renal impairment.", "B": "TRYNGOLZA, administered at standard dosage and frequency.", "C": "TRYNGOLZA, with a reduced dose due to renal impairment.", "D": "MYCOPHENOLATE MOFETIL, with a structured drug scheduler to minimize side effects."}}
{"id": "M22qh4wgFUZZ", "question_type": "open_ended", "question": "A 68-year-old woman with a history of renal oncocytoma and mitochondrial inheritance presents with advanced renal cell carcinoma. She is currently taking simvastatin for hyperlipidemia and has mild hepatic impairment (total bilirubin ≤ ULN and ALT > ULN). Her blood pressure is well controlled. Which drug regimen is most appropriate for her treatment, considering her current medications and hepatic status?", "options": {"A": "VOTRIENT, with weekly liver function monitoring and dose adjustment if ALT elevations occur", "B": "Pazopanib tablets, without liver function monitoring", "C": "VOTRIENT, with no adjustment for simvastatin use", "D": "Pazopanib tablets, with dose reduction and weekly liver function monitoring if simvastatin is continued"}}
{"id": "bNFb2giKTE5t", "question_type": "open_ended_multi_choice", "question": "A 52-year-old man with severe symptomatic TGCT not amenable to surgery presents for treatment. He has moderate hepatic impairment (total bilirubin >1.5 to 3 × ULN, not due to Gilbert's syndrome, with any AST), but no history of allergic reactions or renal impairment. He is not pregnant, and his partner is not of reproductive potential. Which drug regimen is most suitable for his condition?", "options": {"A": "ROMVIMZA at standard dose", "B": "Turalio at standard dose", "C": "Turalio with dose reduction", "D": "ROMVIMZA with dose reduction"}}
{"id": "Lolv54lcm4vv", "question_type": "multi_choice", "question": "A 32-year-old woman with chronic graft-versus-host disease (cGVHD) and symptoms of myalgia, nail dystrophy, and recurrent infections is currently pregnant. She has failed two prior lines of systemic therapy. Her weight is 58 kg. Which drug should be avoided due to her pregnancy status?", "options": {"A": "PredniSONE Tablets, USP, 5 mg", "B": "AXATILIMAB-CSFR", "C": "Budesonide Inhalation", "D": "Low-dose Budesonide Inhalation"}}
{"id": "0CSBCzRkkTYK", "question_type": "open_ended", "question": "Which population should be advised not to breastfeed during and for 1 month after treatment with Romvimza?", "options": {"A": "Women receiving Romvimza", "B": "Men receiving Romvimza", "C": "Women receiving any chemotherapy", "D": "Women with hepatic impairment"}}
{"id": "SyQqWWLCknSq", "question_type": "multi_choice", "question": "During Vanrafia therapy, which of the following is a recommended action for patients who experience unprotected sex or contraceptive failure?", "options": {"A": "Wait until the next scheduled dose", "B": "Discontinue Vanrafia immediately", "C": "Seek advice on emergency contraception", "D": "Increase the dose of Vanrafia"}}
{"id": "h9mYwXrOTWCF", "question_type": "open_ended_multi_choice", "question": "A 34-year-old female patient with moderate-to-severe atopic dermatitis, elevated IgE, and food intolerance is preparing for pregnancy. Topical therapies have not been effective, and she is seeking systemic therapy. Which is the most appropriate systemic treatment for her at this point?", "options": {"A": "Adbry administered subcutaneously every other week", "B": "Dexamethasone sodium phosphate administered intravenously every 2 weeks", "C": "Ebglyss administered subcutaneously every 4 weeks", "D": "Dexamethasone sodium phosphate administered orally daily"}}
{"id": "4mmbZWd9N3Uv", "question_type": "multi_choice", "question": "Which population should be advised not to breastfeed during and for 2 weeks after treatment with Hernexeos?", "options": {"A": "Women receiving Hernexeos", "B": "Men receiving Hernexeos", "C": "Pediatric patients", "D": "Geriatric patients"}}
{"id": "QEuZpSInOzB0", "question_type": "open_ended_multi_choice", "question": "Which of the following is a recommended action if a patient develops new or worsening blurred vision while on Gomekli?", "options": {"A": "Continue Gomekli without changes", "B": "Withhold, reduce the dose, or permanently discontinue Gomekli based on severity", "C": "Increase the dose of Gomekli", "D": "Switch to a different MEK inhibitor"}}
{"id": "c4TclpGvBdYu", "question_type": "open_ended_multi_choice", "question": "For females with reproductive potential, what is the guidance on pregnancy testing before initiating Wayrilz treatment?", "options": {"A": "Pregnancy testing is not necessary.", "B": "Verify pregnancy status prior to initiating Wayrilz treatment.", "C": "Pregnancy testing should be done only after starting Wayrilz.", "D": "Pregnancy testing is required only if symptoms of pregnancy appear."}}
{"id": "8neX01vKXImP", "question_type": "multi_choice", "question": "For the drug Lynozyfic, what is known about its effects on fertility based on animal studies?", "options": {"A": "No animal studies have been performed to evaluate the effects of Lynozyfic on fertility.", "B": "Animal studies have shown Lynozyfic improves fertility.", "C": "Animal studies have shown Lynozyfic impairs fertility.", "D": "Animal studies are currently underway to assess fertility effects."}}
{"id": "n1udUYkCBBTr", "question_type": "open_ended_multi_choice", "question": "According to the ASPEN trial findings, how did the frequency of skin cancers vary between the Brinsupri 25 mg cohort and the placebo cohort?", "options": {"A": "Higher in Brinsupri 25 mg group", "B": "Lower in Brinsupri 25 mg group", "C": "Equal in both groups", "D": "Not reported"}}
{"id": "RIcnkVTZlW8r", "question_type": "open_ended_multi_choice", "question": "A 55-year-old man presents with metastatic non-squamous non-small cell lung carcinoma and a confirmed HER2 (ERBB2) tyrosine kinase domain activating mutation. He has chronic heart failure, with a left ventricular ejection fraction measured at 45%. He is not pregnant and is not on any CYP3A inducers or BCRP substrates. Which initial therapy is most suitable for managing his lung cancer?", "options": {"A": "Zongertinib, with close cardiac monitoring", "B": "Atezolizumab as first-line therapy", "C": "Imfinzi as a single agent", "D": "None of the above; alternative therapy should be considered due to cardiac contraindication"}}
{"id": "GGZkAqDvhfc1", "question_type": "multi_choice", "question": "For which of the following drugs does the official labeling state that there are no contraindications?", "options": {"A": "Clozapine", "B": "Warfarin", "C": "Metformin", "D": "Amiodarone"}}
{"id": "oCOjaI4aBspn", "question_type": "open_ended_multi_choice", "question": "A 28-year-old patient with classic congenital adrenal hyperplasia, treated with glucocorticoids, is preparing for pregnancy and seeks information on using crinecerfont (CRENESSITY) to regulate her androgen levels. What is the most appropriate recommendation for crinecerfont use in this context?", "options": {"A": "Crinecerfont is contraindicated in all pregnant women.", "B": "Crinecerfont may be considered if the benefits outweigh the risks, but exposure should be reported and monitored.", "C": "Crinecerfont is safe and recommended for all women planning pregnancy.", "D": "Crinecerfont should be discontinued immediately upon conception."}}
{"id": "KFmVb17ScHuv", "question_type": "multi_choice", "question": "A 34-year-old woman with primary immunoglobulin A nephropathy (IgAN) and a urine protein-to-creatinine ratio (UPCR) of 2.0 g/g is at risk of rapid disease progression. She is planning to become pregnant and is currently not using any contraception. Which of the following is the most appropriate approach regarding drug therapy to reduce her proteinuria?", "options": {"A": "Initiate VANRAFIA (atrasentan) 0.75 mg once daily and monitor for pregnancy during treatment.", "B": "Begin VANRAFIA (atrasentan) and recommend breastfeeding during treatment.", "C": "Start VANRAFIA (atrasentan) at a reduced dose and discontinue if pregnancy occurs.", "D": "Advise against VANRAFIA therapy and recommend alternative management due to pregnancy plans."}}
{"id": "M0sRuq2DDNLg", "question_type": "open_ended_multi_choice", "question": "A 42-year-old pregnant woman in her second trimester is diagnosed with non-alcoholic steatohepatitis (NASH) with moderate fibrosis. She is seeking pharmacological treatment to manage her condition. Which of the following drugs should be avoided due to potential risks to the fetus, based on available safety data?", "options": {"A": "Pentoxifylline extended-release tablets", "B": "Resmetirom administered once daily", "C": "Dapagliflozin once daily", "D": "Pentoxifylline immediate-release tablets"}}
{"id": "DVGeJHNwUTLc", "question_type": "open_ended_multi_choice", "question": "A 45-year-old male diagnosed with schizophrenia and hyperactivity, who also has moderate renal impairment (eGFR 45 mL/min), is being assessed for antipsychotic medication. His medical history is negative for hepatic impairment, BPH, or dementia-related psychosis. Which therapy is best suited for his case?", "options": {"A": "Cobenfy (xanomeline and trospium chloride), standard adult dose", "B": "Abilify Maintena (aripiprazole), standard adult dose", "C": "Cobenfy (xanomeline and trospium chloride), reduced dose", "D": "Abilify Maintena (aripiprazole), reduced dose for CYP2D6 poor metabolizers"}}
{"id": "A7SEjebhIdyY", "question_type": "open_ended_multi_choice", "question": "A 12-year-old male with genetically confirmed Duchenne muscular dystrophy (mutation amenable to exon 51 skipping) presents with mild kidney dysfunction and a history of allergic reactions to intravenous medications. He has no evidence of arrhythmias or hepatic disease. Which treatment would be most appropriate for him?", "options": {"A": "Viltepso administered intravenously once weekly", "B": "Exondys 51 administered intravenously once weekly", "C": "Duvyzat administered orally twice daily", "D": "Duvyzat administered with a drug holiday every 2 weeks"}}
{"id": "mF3kMr8TDPbd", "question_type": "multi_choice", "question": "A 32-year-old woman with a benign peripheral nerve sheath tumor and a history of hypertension presents for management. She recently discovered she is 8 weeks pregnant. Her current medications include a potassium supplement and an NSAID for pain. Which of the following antihypertensive agents is most appropriate for her at this time?", "options": {"A": "Losartan Potassium, 50 mg once daily", "B": "Continue current NSAID and potassium supplement", "C": "Switch to an antihypertensive agent considered safe in pregnancy, such as labetalol", "D": "Increase potassium supplementation and monitor blood pressure"}}
{"id": "YHGPK1hFVJFD", "question_type": "open_ended", "question": "A 62-year-old woman with metastatic non-squamous non-small cell lung carcinoma (NSCLC) has high c-Met protein overexpression (≥50% strong staining by FDA-approved test) and a history of mild hepatic impairment (total bilirubin ≤ULN and AST >ULN). She previously received systemic therapy and now presents with new-onset peripheral sensory neuropathy. Which drug regimen is most appropriate for her current condition, considering her hepatic status and risk of adverse effects?", "options": {"A": "EMRELIS (telisotuzumab vedotin) with close monitoring for neuropathy", "B": "Portrazza (necitumumab) in combination with gemcitabine and cisplatin", "C": "Rozlytrek (entrectinib) for ROS1-positive NSCLC", "D": "EMRELIS (telisotuzumab vedotin), but only if hepatic impairment is moderate or severe"}}
{"id": "TmNmKMaumbxn", "question_type": "multi_choice", "question": "A 32-year-old man with a history of hypoparathyroidism and prior external beam radiation therapy involving the skeleton presents for ongoing management. His albumin-corrected serum calcium is stable at 8.0 mg/dL on calcium and active vitamin D. He is not taking digoxin. Which of the following is the most appropriate next step in pharmacologic management?", "options": {"A": "Initiate Yorvipath once daily", "B": "Start GENOTROPIN at a reduced dose", "C": "Begin Tri-Vite Drops with Fluoride supplementation", "D": "Continue calcium and active vitamin D supplementation only"}}
{"id": "6QTJfhVUXdle", "question_type": "open_ended_multi_choice", "question": "When initiating prophylactic therapy with Qfitlia, what is the recommended action regarding the use of BPAs or CFCs to minimize the risk of thrombotic events?", "options": {"A": "Continue BPAs or CFCs indefinitely alongside Qfitlia.", "B": "Discontinue BPAs or CFCs no later than 7 days after starting Qfitlia.", "C": "Increase the dose of BPAs or CFCs after starting Qfitlia.", "D": "Switch BPAs or CFCs to oral administration after starting Qfitlia."}}
{"id": "vST6ZpPh6Miq", "question_type": "multi_choice", "question": "A 34-year-old woman with newly diagnosed prurigo nodularis is 20 weeks pregnant. She is seeking treatment for her severe itching and is concerned about fetal safety. Which of the following is the most appropriate therapeutic approach for her condition?", "options": {"A": "Nalbuphine Hydrochloride injection during labor and delivery only", "B": "Nalbuphine Hydrochloride injection for symptomatic relief, used routinely throughout pregnancy", "C": "NEMLUVIO combined with topical corticosteroids and live vaccines", "D": "NEMLUVIO administered every 4 weeks, with careful consideration of potential fetal exposure"}}
{"id": "3tg84jz2KD8i", "question_type": "open_ended_multi_choice", "question": "In the evaluation of Modeyso, which assays were used to assess genotoxicity, and what were the findings?", "options": {"A": "Ames and micronucleus assays; Modeyso was not genotoxic.", "B": "Comet assay and chromosomal aberration test; Modeyso was genotoxic.", "C": "Sister chromatid exchange and in vivo rat assay; Modeyso was genotoxic.", "D": "Ames and comet assays; Modeyso was genotoxic."}}
{"id": "kbXOMsrwZZrx", "question_type": "multi_choice", "question": "A 45-year-old man with chronic immune thrombocytopenia and autosomal dominant inheritance is being considered for second-line therapy after failing corticosteroids. He has severe renal impairment and is currently taking a strong CYP3A inhibitor for a fungal infection. Which drug is most appropriate for his condition?", "options": {"A": "Nplate (romiplostim) weekly subcutaneous injection", "B": "WAYRILZ (rilzabrutinib) 400 mg twice daily", "C": "DMT SUIK (corticosteroid) intravenous therapy", "D": "WAYRILZ (rilzabrutinib) with a drug scheduler to avoid CYP3A inhibitor overlap"}}
{"id": "lRgpy5yWawao", "question_type": "multi_choice", "question": "A 32-year-old man with a history of hypoparathyroidism and prior external beam radiation therapy involving the skeleton presents for ongoing management. His albumin-corrected serum calcium is stable at 8.0 mg/dL on calcium and active vitamin D. He is not taking digoxin. Which of the following is the most appropriate next step in pharmacologic management?", "options": {"A": "Initiate Yorvipath once daily", "B": "Continue calcium and active vitamin D supplementation only", "C": "Start GENOTROPIN at a reduced dose", "D": "Begin Tri-Vite Drops with Fluoride supplementation"}}
{"id": "OxThxQAwHWHZ", "question_type": "open_ended_multi_choice", "question": "A 38-year-old woman with metastatic non-squamous non-small cell lung cancer, harboring a confirmed HER2 (ERBB2) tyrosine kinase domain activating mutation, wishes to become pregnant. She has finished previous systemic treatments and is otherwise in good health. What is the most suitable management strategy for her at this time?", "options": {"A": "Initiate Zongertinib immediately", "B": "Start Atezolizumab as monotherapy", "C": "Delay Zongertinib therapy until pregnancy status is clarified and effective contraception is in place", "D": "Begin Imfinzi in combination with platinum-based chemotherapy"}}
{"id": "vi3AraZIjHg5", "question_type": "open_ended_multi_choice", "question": "A 68-year-old woman with a history of gout and chronic kidney disease (creatinine clearance 18 mL/min) presents with symptoms of an uncomplicated urinary tract infection. She has a documented allergy to cephalosporins but no known allergies to other antibiotics. She is not currently taking any medications with significant drug interactions. Which of the following is the most appropriate antibiotic therapy for her UTI?", "options": {"A": "Sulopenem etzadroxil and probenecid (Orlynvah) orally", "B": "Imipenem and cilastatin intravenously with renal dose adjustment", "C": "Flavoxate hydrochloride orally", "D": "Sulopenem etzadroxil and probenecid (Orlynvah) with a drug holiday"}}
{"id": "0HmgnRRL9uJP", "question_type": "open_ended_multi_choice", "question": "For a 68-year-old man diagnosed with familial chylomicronemia syndrome, who also has hepatic steatosis, intermittent abdominal pain, mild renal dysfunction (eGFR 55 mL/min), and mild hepatic impairment, which drug regimen should be selected to manage his triglyceride levels?", "options": {"A": "MYHIBBIN (mycophenolate mofetil) with dose adjustment for renal impairment", "B": "TRYNGOLZA (olezarsen sodium) at standard dosage and frequency", "C": "MYHIBBIN (mycophenolate mofetil) with dose adjustment for hepatic impairment", "D": "TRYNGOLZA (olezarsen sodium) with reduced frequency due to age"}}
{"id": "skKPsl29oxyq", "question_type": "multi_choice", "question": "A 67-year-old patient with metastatic non-small cell lung cancer (NSCLC) is found to have an EGFR exon 19 deletion mutation by FDA-approved testing. The patient has a history of deep vein thrombosis (DVT) and is currently receiving warfarin for anticoagulation. Which drug regimen is most appropriate for first-line treatment of this patient's NSCLC, considering their genetic profile and current medications?", "options": {"A": "Erlotinib monotherapy, 150 mg orally once daily", "B": "Rozlytrek monotherapy, 600 mg orally once daily", "C": "Lazcluze (lazertinib + amivantamab) combination therapy, standard dosing", "D": "Erlotinib in combination with platinum-based chemotherapy"}}
{"id": "XOAn0NffEBEx", "question_type": "open_ended_multi_choice", "question": "For what reason is it important to review age-appropriate immunizations before beginning treatment with Imaavy?", "options": {"A": "Imaavy causes transient reduction in IgG levels, making live vaccines not recommended during treatment", "B": "Imaavy increases the risk of vaccine-induced fever", "C": "Imaavy enhances the efficacy of live vaccines", "D": "Imaavy interacts with inactivated vaccines to cause hypersensitivity"}}
{"id": "yuBRPlo23E3m", "question_type": "open_ended_multi_choice", "question": "What is the appropriate course of action for the next Modeyso dose if a patient experiences vomiting shortly after taking it?", "options": {"A": "Retake the dose immediately", "B": "Skip the next scheduled dose", "C": "Do not take another dose; resume Modeyso on the next regularly scheduled weekly day", "D": "Double the dose at the next administration"}}
{"id": "o7rHE8tiLtY6", "question_type": "open_ended_multi_choice", "question": "If a patient develops clinically significant fluid retention while on Vanrafia, which management strategy is recommended?", "options": {"A": "Initiate or increase diuretic treatment and interrupt Vanrafia", "B": "Continue Vanrafia and monitor fluid status", "C": "Reduce the dose of Vanrafia", "D": "Switch to another endothelin receptor antagonist"}}
{"id": "EXivLAr0Rdqs", "question_type": "multi_choice", "question": "A 7-year-old boy with a diagnosis of immune thrombocytopenia, confirmed by thrombocytopenia and abnormal bleeding, has failed to respond to corticosteroids and IVIG. He has no significant hepatic or renal impairment. Which drug regimen is most suitable for his ongoing management?", "options": {"A": "WAYRILZ (rilzabrutinib) 400 mg twice daily", "B": "DMT SUIK (corticosteroid) intravenous therapy", "C": "Nplate (romiplostim) weekly subcutaneous injection", "D": "WAYRILZ (rilzabrutinib) with dose reduction"}}
{"id": "Qv9njR4z8zqK", "question_type": "multi_choice", "question": "A 40-year-old woman with a newly diagnosed trophoblastic neoplasm is being considered for chemotherapy. She has a history of severe hypersensitivity reaction to methotrexate. Her liver and kidney function are normal, and she is not pregnant. Which of the following is the most appropriate next step in her drug therapy?", "options": {"A": "Initiate methotrexate with close monitoring", "B": "Start paclitaxel protein-bound particles for injectable suspension (albumin-bound)", "C": "Administer Trexall at a reduced dose", "D": "Avoid methotrexate and consider alternative chemotherapy regimens"}}
{"id": "iXnpeKcW7u1L", "question_type": "open_ended_multi_choice", "question": "In the event that life-threatening arrhythmias occur in a patient receiving Modeyso, what is the recommended management approach?", "options": {"A": "Reduce the dose of Modeyso.", "B": "Interrupt Modeyso and resume after arrhythmia resolves.", "C": "Permanently discontinue Modeyso.", "D": "Continue Modeyso with increased monitoring."}}
{"id": "6TnANPkiYW06", "question_type": "open_ended_multi_choice", "question": "A 45-year-old woman presents to the emergency department with palpitations and is diagnosed with acute supraventricular tachycardia. She has a history of mild hypertension, but no evidence of bronchospastic lung disease or hepatic impairment. She is not pregnant and is not taking any other medications. The cardiology team is considering pharmacologic rate control. Which drug is the most appropriate for short-term ventricular rate reduction in this patient, and what is the recommended frequency of administration?", "options": {"A": "Pacerone, administered as a single intravenous bolus, followed by oral maintenance dosing.", "B": "RAPIBLYK, administered as a continuous intravenous infusion titrated to effect.", "C": "Propranolol, administered orally twice daily.", "D": "Pacerone, administered orally once daily."}}
{"id": "z4fZwovBozOW", "question_type": "open_ended_multi_choice", "question": "What is an accurate characterization of Blujepa's relationship with other antibacterial medications?", "options": {"A": "Blujepa antagonizes the activity of fluoroquinolones against Enterobacterales.", "B": "Blujepa shows no antagonism with multiple antibacterial drugs, including fluoroquinolones, sulfonamides, and cephalosporins.", "C": "Blujepa is only effective when used as monotherapy.", "D": "Blujepa synergizes with aminoglycosides against all gram-negative bacteria."}}
{"id": "VvmWBFsq6Bvu", "question_type": "open_ended_multi_choice", "question": "Prior to receiving a live attenuated vaccine, what should patients inform their healthcare provider about if they are taking Brinsupri?", "options": {"A": "That they are currently taking Brinsupri", "B": "Their history of allergies", "C": "Their family medical history", "D": "Their travel history"}}
{"id": "EFGzyZ0Ov3lY", "question_type": "multi_choice", "question": "A 68-year-old woman with low-risk myelodysplastic syndrome presents with transfusion-dependent anemia, requiring 5 units of red blood cells over the past 8 weeks. She has not responded to erythropoiesis-stimulating agents and is currently taking digoxin for atrial fibrillation. Her cytogenetic analysis does not show a deletion 5q abnormality. Which drug is the most appropriate for her treatment, considering her current medications and disease profile?", "options": {"A": "Lenalidomide, 10 mg orally once daily", "B": "Imetelstat sodium, 7.5 mg/kg intravenously every 4 weeks", "C": "Inqovi, 35 mg orally once daily for 5 consecutive days every 28 days", "D": "Lenalidomide, 25 mg orally once daily"}}
{"id": "tRdxUuqsP7K7", "question_type": "open_ended_multi_choice", "question": "A teenager aged 15 is diagnosed with generalized myasthenia gravis, as evidenced by anti-acetylcholine receptor antibody positivity and clinical signs such as ptosis and fatigable muscle weakness. The patient has no prior organophosphate poisoning, is not pregnant, and has no significant comorbidities. What is the most suitable drug regimen to manage this patient's condition, taking into account pediatric safety and efficacy?", "options": {"A": "Azathioprine, 50 mg daily, as an immunosuppressive adjunct", "B": "DuoDote, single dose for acute symptom management", "C": "IMAAVY, 15 mg/kg intravenous infusion every 2 weeks", "D": "Azathioprine, 100 mg daily, with a drug holiday every 2 months"}}
{"id": "05vaY9AvjEgy", "question_type": "open_ended_multi_choice", "question": "What is the recommendation regarding pregnancy testing for females of reproductive potential prior to initiating Vanrafia?", "options": {"A": "Pregnancy testing is not required", "B": "Pregnancy testing should be performed only if symptoms arise", "C": "Exclude pregnancy before initiating Vanrafia", "D": "Pregnancy testing should be performed monthly during treatment"}}
{"id": "nO1O79bHhbwH", "question_type": "open_ended_multi_choice", "question": "A woman aged 34, who has moderate-to-severe atopic dermatitis, increased circulating IgE, and a history of food intolerance, wishes to become pregnant. Having failed topical therapies, she is now evaluating systemic options. Which treatment would be most appropriate for her in this situation?", "options": {"A": "Adbry administered subcutaneously every other week", "B": "Dexamethasone sodium phosphate administered intravenously every 2 weeks", "C": "Ebglyss administered subcutaneously every 4 weeks", "D": "Dexamethasone sodium phosphate administered orally daily"}}
{"id": "XuoY1vBXBGE5", "question_type": "multi_choice", "question": "A 15-year-old female weighing 45 kg presents with symptoms of dysuria, urgency, and suprapubic pain. She is diagnosed with an uncomplicated urinary tract infection. Her medical history is notable for mild renal impairment (eGFR 55 mL/min), and she is currently taking digoxin for a cardiac condition. Which drug is the most appropriate for definitive treatment of her infection, considering her age, weight, renal function, and current medications?", "options": {"A": "Flavoxate Hydrochloride", "B": "Imipenem and Cilastatin", "C": "Gepotidacin", "D": "No drug is appropriate; recommend only symptomatic management"}}
{"id": "UlmzEZiWME5m", "question_type": "multi_choice", "question": "A 58-year-old woman with non-alcoholic steatohepatitis (NASH) and moderate liver fibrosis (stage F2) is being considered for pharmacologic therapy. She has a history of well-controlled hypertension and is currently taking atorvastatin 40 mg daily for hyperlipidemia. Her liver function tests are within normal limits, and she does not have decompensated cirrhosis. Which drug regimen is most appropriate for her NASH management, considering her comorbidities and current medications?", "options": {"A": "Rezdiffra, with atorvastatin dose limited to 40 mg daily", "B": "Pentoxifylline extended-release tablets, 400 mg three times daily", "C": "Farxiga, 10 mg once daily", "D": "Rezdiffra, with atorvastatin dose increased to 80 mg daily"}}
{"id": "IHJHWM0ETwnf", "question_type": "open_ended_multi_choice", "question": "A 62-year-old man with metastatic, unresectable esophageal squamous cell carcinoma (ESCC) presents with chest pain, cough, and lymphadenopathy. The tumor is PD-L1 positive (≥1). He has a history of well-controlled hypertension and is currently taking amiodarone for arrhythmia. Which first-line systemic therapy regimen is most appropriate for this patient?", "options": {"A": "Lenvatinib monotherapy", "B": "Tislelizumab-jsgr in combination with platinum-containing chemotherapy", "C": "Nivolumab and hyaluronidase in combination with fluoropyrimidine- and platinum-containing chemotherapy", "D": "Lenvatinib in combination with pembrolizumab"}}
{"id": "wqgS5B2NdI0C", "question_type": "multi_choice", "question": "A 28-year-old woman with classic congenital adrenal hyperplasia is pregnant and currently receiving glucocorticoid replacement therapy. She is seeking advice on adjunctive therapy to control androgen levels. Which statement best reflects the appropriateness of Crenessity for her condition?", "options": {"A": "Crenessity is contraindicated in pregnancy due to high risk of fetal malformations", "B": "Crenessity may be considered if benefits outweigh risks, but data in pregnancy are limited", "C": "Crenessity is recommended as first-line therapy in all pregnant women with CAH", "D": "Crenessity is only approved for use in pediatric patients"}}
{"id": "a9v9Ysd1QDAb", "question_type": "open_ended_multi_choice", "question": "A 38-year-old woman with metastatic non-squamous non-small cell lung carcinoma and a confirmed HER2 (ERBB2) tyrosine kinase domain activating mutation is planning to become pregnant. She has completed prior systemic therapy and is otherwise healthy. Which treatment approach is most appropriate for her current situation?", "options": {"A": "Initiate Zongertinib immediately", "B": "Start Atezolizumab as monotherapy", "C": "Delay Zongertinib therapy until pregnancy status is clarified and effective contraception is in place", "D": "Begin Imfinzi in combination with platinum-based chemotherapy"}}
{"id": "u53DFhMh58HA", "question_type": "open_ended_multi_choice", "question": "Which brand name drug should be prescribed to a 15-year-old patient diagnosed with generalized myasthenia gravis who is positive for anti-MuSK antibodies?", "options": {"A": "Imaavy", "B": "Pyridostigmine", "C": "Azathioprine", "D": "Eculizumab"}}
{"id": "xlJO7QvbBdGZ", "question_type": "open_ended", "question": "A researcher is evaluating the safety profile of Modeyso. Which statement best describes its contraindication status?", "options": {"A": "Modeyso is contraindicated in patients with a history of hypersensitivity reactions.", "B": "Modeyso should not be used in patients with severe hepatic impairment.", "C": "Modeyso has no listed contraindications.", "D": "Modeyso is contraindicated during lactation."}}
{"id": "f2jjwI9ltok6", "question_type": "open_ended_multi_choice", "question": "A 20-year-old male with hemophilia B and a history of developing factor IX inhibitors presents with spontaneous, recurrent epistaxis and poor wound healing. He is scheduled for dental surgery and requires on-demand control of bleeding episodes. Which drug is most suitable for his perioperative management?", "options": {"A": "REBINYN, administered perioperatively", "B": "HYMPAVZI, administered perioperatively", "C": "SEVENFACT, administered perioperatively", "D": "REBINYN, administered as routine prophylaxis only"}}
{"id": "jN4cXBnfONNL", "question_type": "open_ended_multi_choice", "question": "A 35-year-old woman, currently 10 weeks pregnant, presents with newly diagnosed primary biliary cholangitis, mild jaundice, and fatigue, but no hepatic decompensation. What is the safest and most appropriate first-line pharmacologic treatment for her?", "options": {"A": "IQIRVO (elafibranor) monotherapy", "B": "Tricor (fenofibrate) monotherapy", "C": "Urso 250 (ursodiol) monotherapy", "D": "IQIRVO (elafibranor) in combination with Tricor (fenofibrate)"}}
{"id": "bGkjI0tVohLk", "question_type": "open_ended_multi_choice", "question": "A 32-year-old pregnant woman in her second trimester is diagnosed with acquired thrombocytopenia. She is not taking any other medications and has no hepatic or renal impairment. Which drug is contraindicated for her condition due to pregnancy-related risks?", "options": {"A": "Dyural 40 Kit (methylprednisolone acetate) administered for obstetrical paracervical block anesthesia.", "B": "Betamethasone Dipropionate cream (augmented), 0.05%, applied to the smallest area for the shortest duration.", "C": "Dyural 40 Kit (methylprednisolone acetate) administered intramuscularly for hematologic indication, with fetal monitoring.", "D": "Hormone Harmony oral drops, after consulting a healthcare professional."}}
{"id": "qvMiYY0bYs7I", "question_type": "multi_choice", "question": "In the event of an overdose involving Ekterly, which resource is specifically recommended for obtaining management recommendations?", "options": {"A": "Contact the poison control help line (1-800-222-1222) or a medical toxicologist", "B": "Increase the dosage of Ekterly", "C": "Administer activated charcoal immediately", "D": "Monitor the patient without intervention"}}
{"id": "lDbV8At9bgV9", "question_type": "open_ended_multi_choice", "question": "A 16-year-old adolescent with hemophilia A and established hepatic impairment (Child-Pugh Class B) requires routine prophylaxis. He has no history of gallbladder disease and is not taking any hormonal contraceptives. Which drug regimen should be selected for this patient?", "options": {"A": "Qfitlia administered subcutaneously once monthly", "B": "Hemlibra administered subcutaneously once weekly", "C": "Qfitlia administered subcutaneously using antithrombin-based dosing every four weeks", "D": "Fitusiran administered intravenously every two weeks"}}
{"id": "0jI92A1zMKb0", "question_type": "multi_choice", "question": "A 35-year-old pregnant woman with a newly diagnosed renal oncocytoma and a family history of mitochondrial inheritance seeks treatment for her advanced renal cell carcinoma. She is not taking any other medications and has normal hepatic and renal function. Which of the following is the most appropriate recommendation regarding drug therapy for her condition?", "options": {"A": "Initiate VOTRIENT at standard dosing", "B": "Initiate pazopanib tablets at standard dosing", "C": "Advise against use of VOTRIENT or pazopanib tablets due to risk of fetal harm", "D": "Initiate pazopanib tablets with dose reduction"}}
{"id": "EyO1Dbhf0WCh", "question_type": "multi_choice", "question": "A 68-year-old woman with transfusion-dependent anemia is diagnosed with low-risk myelodysplastic syndrome (MDS) associated with a deletion 5q cytogenetic abnormality. She has normal renal function and is not pregnant. Her physician is considering starting drug therapy to reduce her transfusion needs. Which of the following drugs is most appropriate for her condition, considering both efficacy and safety for her specific MDS subtype?", "options": {"A": "TREOSULFAN (GRAFAPEX), in combination with fludarabine as a preparative regimen for allogeneic stem cell transplantation.", "B": "INQOVI (cedazuridine and decitabine), administered orally once daily in 28-day cycles.", "C": "Lenalidomide, administered orally once daily, with strict adherence to pregnancy prevention protocols.", "D": "Azacitidine, administered subcutaneously for 7 days every 28 days."}}
{"id": "MsGB3k6F8Rq0", "question_type": "open_ended_multi_choice", "question": "What is the advised clinical action for a hemophilia patient with a history of symptomatic gallbladder disease who is being assessed for Qfitlia treatment?", "options": {"A": "Consider alternative treatment for hemophilia", "B": "Increase Qfitlia dose", "C": "Monitor only for thrombotic events", "D": "Continue Qfitlia without modification"}}
{"id": "0ywmm08GNCEz", "question_type": "open_ended_multi_choice", "question": "A 32-year-old woman with schizophrenia and mild renal impairment (eGFR 65 mL/min) is being treated with a strong CYP2D6 inhibitor for another health issue. She does not have hepatic impairment or other significant comorbidities. She prefers oral therapy and is concerned about possible drug interactions. What is the most suitable antipsychotic regimen for her?", "options": {"A": "Cobenfy, administered orally at the standard adult dose", "B": "Abilify Maintena, administered as a monthly intramuscular injection with dose reduction", "C": "Cobenfy, administered orally with close monitoring for adverse reactions", "D": "Abilify Maintena, administered orally at the standard dose"}}
{"id": "pxm5bCWDIrXV", "question_type": "multi_choice", "question": "Which reproductive safety advice should be given to females of reproductive potential who are prescribed Hernexeos?", "options": {"A": "No contraception is needed during treatment", "B": "Use contraception only during the first week of treatment", "C": "Contraception is only needed if pregnancy is suspected", "D": "Discontinue contraception immediately after starting Hernexeos"}}
{"id": "P0C8GW4d4nbW", "question_type": "open_ended_multi_choice", "question": "A 34-year-old woman with a newly diagnosed adrenocortical carcinoma is scheduled for surgical resection. She has a documented history of severe anaphylactic reaction to polyethylene glycol (PEG) during a previous imaging procedure. The surgical team is considering intraoperative fluorescence imaging to detect residual cancerous tissue. Which agent should be avoided in this patient due to her medical history?", "options": {"A": "Etoposide administered intravenously at a low starting dose", "B": "Lumisight (pegulicianine) administered at 1 mg/kg for intraoperative imaging", "C": "Etoposide administered orally at standard dosing", "D": "No imaging agent used during surgery"}}
{"id": "X9cMNkpLtJn6", "question_type": "open_ended_multi_choice", "question": "In terms of safety, what differences, if any, have been reported between elderly and younger patients when using Tryptyr?", "options": {"A": "Clinically relevant differences in safety have been observed between elderly and younger patients.", "B": "Tryptyr is associated with increased adverse effects in elderly patients.", "C": "No clinically relevant differences in safety have been observed between elderly and younger patients.", "D": "Tryptyr is contraindicated in elderly patients."}}
{"id": "z7AgWhYdB57e", "question_type": "open_ended", "question": "A patient reports a previous episode of severe hypersensitivity after administration of Blujepa. What is the recommended clinical action?", "options": {"A": "Avoid prescribing Blujepa", "B": "Monitor closely during administration", "C": "Reduce the dose of Blujepa", "D": "Switch to a generic alternative"}}
{"id": "Ax8nAQgpo3BL", "question_type": "multi_choice", "question": "A 2-month-old infant, born prematurely and currently hospitalized with severe lower respiratory tract infection due to confirmed respiratory syncytial virus (RSV), is being considered for antiviral therapy. The infant is not on mechanical ventilation and has no known hypersensitivity to monoclonal antibodies. The mother is not pregnant or breastfeeding. Which of the following is the most appropriate drug for this patient's treatment, including recommended administration duration?", "options": {"A": "ENFLONSIA, administered as a single dose for prevention.", "B": "Virazole, administered as an inhalation solution for 3 to 7 days.", "C": "Restasis MultiDose, administered twice daily as ophthalmic drops.", "D": "Virazole, administered orally for 14 days."}}
{"id": "SryYsQTIgxpu", "question_type": "open_ended_multi_choice", "question": "A 42-year-old man with paroxysmal nocturnal hemoglobinuria (PNH) and a history of severe hepatic impairment (Child-Pugh C) is being considered for therapy. He is not currently on any complement inhibitors. Which of the following is the most appropriate drug therapy for his PNH?", "options": {"A": "Voydeya as add-on to ravulizumab", "B": "Ravulizumab monotherapy", "C": "Sirolimus", "D": "Voydeya monotherapy"}}
{"id": "IzeZmgmjbJ4y", "question_type": "multi_choice", "question": "A patient on Ibtrozi develops hyperuricemia without a history of gout. What is the recommended management approach?", "options": {"A": "Discontinue Ibtrozi permanently", "B": "Initiate urate-lowering medication as clinically indicated and adjust Ibtrozi dose based on severity", "C": "No intervention is necessary", "D": "Increase Ibtrozi dose"}}
{"id": "2ZFJY2SYbgaw", "question_type": "open_ended_multi_choice", "question": "A patient with a history of anaphylaxis to multiple medications is being considered for treatment with Gomekli. Based on the contraindications listed for Gomekli, what is the recommended course of action?", "options": {"A": "Gomekli should be avoided due to potential hypersensitivity.", "B": "Gomekli is contraindicated in patients with anaphylaxis history.", "C": "Gomekli can be used as there are no contraindications.", "D": "Gomekli should only be used after allergy testing."}}
{"id": "Wfvazo5vfMFY", "question_type": "open_ended_multi_choice", "question": "A 12-year-old patient with Duchenne muscular dystrophy and a mutation responsive to exon 51 skipping shows mild renal impairment and has previously experienced hypersensitivity to intravenous treatments. There are no signs of arrhythmias or liver dysfunction. What is the best therapeutic option for this patient?", "options": {"A": "Viltepso administered intravenously once weekly", "B": "Exondys 51 administered intravenously once weekly", "C": "Duvyzat administered orally twice daily", "D": "Duvyzat administered with a drug holiday every 2 weeks"}}
{"id": "uKrVFzAMOx8O", "question_type": "open_ended", "question": "A 72-year-old man with relapsed/refractory multiple myeloma has received five prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. He has no history of severe cardiac disease or hepatic impairment. He is not currently taking any medications with a narrow therapeutic index metabolized by CYP enzymes. Which of the following is the most appropriate next-line therapy for this patient, considering his treatment history and drug safety profile?", "options": {"A": "Darzalex Faspro in combination with lenalidomide and dexamethasone", "B": "Mozobil (plerixafor) with filgrastim", "C": "Lynozyfic (linvoseltamab-gcpt)", "D": "Darzalex Faspro monotherapy"}}
{"id": "d0V3ZCjPNVjk", "question_type": "open_ended", "question": "Which of the following statements best describes the carcinogenicity assessment of Tryptyr in animal studies?", "options": {"A": "Long-term animal studies have demonstrated a high carcinogenic potential for Tryptyr.", "B": "Long-term studies in animals have not been performed to evaluate the carcinogenic potential of Tryptyr.", "C": "Tryptyr was shown to be non-carcinogenic in all animal studies conducted.", "D": "Tryptyr has been proven to cause tumors in rodent models."}}
{"id": "9m5hZluWEjTi", "question_type": "multi_choice", "question": "A 42-year-old male with AIDS presents with multiple cutaneous lesions diagnosed as Kaposi’s sarcoma. He reports no symptoms of lymphedema, pulmonary involvement, or visceral disease, and has had fewer than 10 new lesions in the past month. He is currently using an insect repellent containing DEET for outdoor activities. Which treatment option is most appropriate for his cutaneous lesions?", "options": {"A": "PANRETIN gel, applied topically to lesions while continuing DEET use", "B": "PANRETIN gel, applied topically to lesions with discontinuation of DEET use", "C": "Daunorubicin Hydrochloride, administered intravenously", "D": "No drug therapy; monitor lesions without intervention"}}
{"id": "YJDCtvwuBA18", "question_type": "multi_choice", "question": "A 7-year-old girl with relapsed low-grade glioma is found to have a BRAF V600 mutation. She is currently taking a moderate CYP2C8 inhibitor for another condition. Her parents are concerned about the risk of growth reduction and want to know which drug would be most appropriate for her tumor treatment. Which option is the most suitable for this patient?", "options": {"A": "Tovorafenib administered once daily at the recommended pediatric dose", "B": "Etoposide administered intravenously every 3 weeks", "C": "NEUPOGEN administered daily as supportive care", "D": "Tovorafenib administered once daily, but with concurrent moderate CYP2C8 inhibitor"}}
{"id": "9kwxqkz2hBou", "question_type": "multi_choice", "question": "A 58-year-old man with a history of glaucoma and previous herpes simplex eye infection is experiencing severe symptoms of dry eye disease. He is considering prescription therapy and currently wears contact lenses daily. Which medication should be avoided due to his medical history and which is the most suitable for his condition?", "options": {"A": "Lotemax SM", "B": "Xiidra", "C": "TRYPTYR", "D": "Cyclosporine ophthalmic emulsion"}}
{"id": "Dyc6oQ5JggsW", "question_type": "open_ended_multi_choice", "question": "A male patient, age 55, has chronic kidney disease (eGFR 40 mL/min/1.73 m2) and epilepsy treated with phenytoin. He is hospitalized for an acute MRSA skin and soft tissue infection. Which antibiotic therapy should be selected for this case?", "options": {"A": "Doxycycline Hyclate, standard dosing without adjustment", "B": "Zevtera, with renal dose adjustment and monitoring for CNS effects", "C": "Rituximab and Hyaluronidase, as a single agent", "D": "Doxycycline Hyclate, with a drug holiday to reduce interaction risk"}}
{"id": "l4rBn5O5aqCQ", "question_type": "open_ended_multi_choice", "question": "A 45-year-old woman with non-alcoholic steatohepatitis (NASH) and moderate fibrosis (F2) is seeking treatment. She is currently breastfeeding her 3-month-old infant and has no history of liver or kidney impairment. Which drug is most appropriate for her NASH management, considering her lactation status?", "options": {"A": "Pentoxifylline extended-release tablets, 400 mg three times daily", "B": "Rezdiffra, standard dose", "C": "Farxiga, 10 mg once daily", "D": "None of the above drugs are recommended during breastfeeding"}}
{"id": "2VwXkFrDWQEE", "question_type": "open_ended_multi_choice", "question": "A 42-year-old man comes to the clinic with moderate to severe acute pain after injuring himself during sports. He has normal liver and kidney function, is on a moderate CYP3A inhibitor for a separate condition, and uses a combined oral contraceptive with ethinyl estradiol and norethindrone. Which pain management medication and dosing approach is recommended for him?", "options": {"A": "Suzetrigine at standard adult dosage", "B": "Suzetrigine with reduced dosage", "C": "Ropivacaine Hydrochloride at standard dosage", "D": "Acetaminophen at maximum daily dosage"}}
{"id": "ybzobRyqPoSI", "question_type": "open_ended_multi_choice", "question": "A 32-year-old woman with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (CML) presents for treatment. She is currently 10 weeks pregnant and expresses concern about the safety of medications for her fetus. Which of the following is the most appropriate recommendation regarding SPRYCEL therapy for this patient?", "options": {"A": "Initiate SPRYCEL at the standard adult dose and monitor fetal development closely.", "B": "Delay SPRYCEL therapy until after delivery due to risk of fetal harm.", "C": "Start SPRYCEL with a reduced dose to minimize fetal exposure.", "D": "Administer SPRYCEL only during the second trimester to avoid organogenesis."}}
{"id": "pbiKy9Hfyl0z", "question_type": "multi_choice", "question": "What should patients be instructed to do if they miss a dose of Journavx?", "options": {"A": "Refer to the specific instructions provided in the Dosage and Administration section.", "B": "Double the next dose.", "C": "Skip the missed dose and continue as normal.", "D": "Take the missed dose with the next meal."}}
{"id": "kGI5SJiEmSeK", "question_type": "multi_choice", "question": "A 12-year-old patient weighing 32 kg presents with progressive neurological deterioration, gait ataxia, and hepatomegaly. Genetic testing confirms Niemann-Pick disease type C. The patient has a history of feeding difficulties and generalized hypotonia. She is currently taking N-acetyl-DL-leucine for another condition. Which drug regimen is most appropriate for treating her neurological manifestations of NPC?", "options": {"A": "Miglustat (Yargesa) 100 mg twice daily", "B": "AQNEURSA (levacetylleucine) 4 g/day, continue N-acetyl-DL-leucine", "C": "AQNEURSA (levacetylleucine) 4 g/day, discontinue N-acetyl-DL-leucine prior to initiation", "D": "Miglustat (Opfolda) in combination with Pombiliti"}}
{"id": "V9HrJhRkMMUe", "question_type": "multi_choice", "question": "Which of the following statements best describes the carcinogenicity assessment for Imaavy (nipocalimab-aahu)?", "options": {"A": "Carcinogenicity studies have been conducted and showed no risk.", "B": "Carcinogenicity studies were inconclusive.", "C": "Carcinogenicity studies showed a high risk of cancer.", "D": "Carcinogenicity studies have not been conducted for Imaavy."}}
{"id": "P2RZsyqzyPpI", "question_type": "open_ended_multi_choice", "question": "A 67-year-old man with primary IgA nephropathy and a urine protein-to-creatinine ratio of 1.8 g/g is being evaluated for therapy to reduce proteinuria. He has mild hepatic impairment and is not on any CYP3A inducers or OATP1B1/1B3 inhibitors. Which statement most accurately describes the suitability of atrasentan (VANRAFIA) for him?", "options": {"A": "Atrasentan is contraindicated due to his age.", "B": "Atrasentan is contraindicated due to mild hepatic impairment.", "C": "Atrasentan is appropriate; no dose adjustment is needed for mild hepatic impairment or geriatric patients.", "D": "Atrasentan should be avoided because safety in older adults is not established."}}
{"id": "DelQEhKBY9FP", "question_type": "multi_choice", "question": "A patient receiving Grafapex presents with prolonged pancytopenia. Which scenario is most consistent with this finding?", "options": {"A": "The patient is experiencing a typical therapeutic response.", "B": "The patient has experienced an overdose of Grafapex.", "C": "The patient has developed an allergic reaction.", "D": "The patient has a viral infection."}}
{"id": "9K0maj7TJIpD", "question_type": "open_ended", "question": "Which premedication regimen is recommended prior to the administration of the first step-up dose of Lynozyfic to reduce the risk of cytokine release syndrome (CRS) and infusion-related reactions (IRR)?", "options": {"A": "Acetaminophen 650-1,000 mg orally, diphenhydramine 25 mg orally or IV, and dexamethasone 40 mg IV", "B": "Ibuprofen 400 mg orally, loratadine 10 mg orally, and methylprednisolone 20 mg IV", "C": "Acetaminophen 325 mg orally, diphenhydramine 50 mg orally, and dexamethasone 10 mg IV", "D": "Paracetamol 1,000 mg orally, cetirizine 10 mg orally, and hydrocortisone 100 mg IV"}}
{"id": "KgHwA7RAHblU", "question_type": "multi_choice", "question": "Which of the following statements is correct regarding the use of food when taking Gomekli tablets for oral suspension?", "options": {"A": "Gomekli must be taken with food", "B": "Gomekli must be taken on an empty stomach", "C": "Gomekli should be mixed with food before administration", "D": "Gomekli can be taken with or without food"}}
{"id": "aKZS6rNBZzeS", "question_type": "open_ended_multi_choice", "question": "Which of the following is a potential complication when penpulimab-kcqx is administered before or after allogeneic hematopoietic stem cell transplantation (HSCT)?", "options": {"A": "Hyperacute graft-versus-host-disease (GVHD)", "B": "Solid organ rejection only", "C": "Stevens-Johnson Syndrome", "D": "Diabetic ketoacidosis"}}
{"id": "fBY4yGLlsHRS", "question_type": "multi_choice", "question": "A 35-year-old woman with hypotrichosis simplex presents with sparse eyelashes and eyebrows. She is currently breastfeeding her infant and is considering treatment to enhance eyelash growth. She has no history of ocular inflammation or contact lens use. Which drug formulation is most appropriate for her, considering safety during lactation and minimizing potential systemic exposure?", "options": {"A": "LUMIGAN (bimatoprost ophthalmic solution 0.01%) once daily", "B": "Bimatoprost ophthalmic solution 0.03% once daily", "C": "LUMIGAN (bimatoprost ophthalmic solution 0.01%) twice daily", "D": "Bimatoprost ophthalmic solution 0.03% twice daily"}}
{"id": "Do4aoNi0mF8a", "question_type": "open_ended", "question": "A 35-year-old woman with KRAS-mutated recurrent low-grade serous ovarian carcinoma has completed prior systemic therapy. She is planning to become pregnant in the next few months and is currently breastfeeding her infant. Which of the following is the most appropriate recommendation regarding AVMAPKI FAKZYNJA CO-PACK?", "options": {"A": "Start AVMAPKI FAKZYNJA CO-PACK immediately and continue breastfeeding.", "B": "Delay AVMAPKI FAKZYNJA CO-PACK until breastfeeding is stopped and pregnancy is no longer planned.", "C": "Start AVMAPKI FAKZYNJA CO-PACK with close monitoring of liver function.", "D": "Start AVMAPKI FAKZYNJA CO-PACK with prophylactic topical corticosteroids for skin toxicity."}}
{"id": "sHUCj2qpNPgm", "question_type": "open_ended", "question": "In the MC‑FludT.14/L Trial II, which preparative regimen was Grafapex compared to for allogeneic transplantation in adults with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)?", "options": {"A": "Busulfan in combination with fludarabine", "B": "Cyclophosphamide in combination with fludarabine", "C": "Melphalan in combination with antithymocyte globulin", "D": "Treosulfan in combination with methotrexate"}}
{"id": "myFktRIdHHXH", "question_type": "multi_choice", "question": "Which of the following immune-mediated endocrinopathies has the highest reported incidence in patients treated with penpulimab-kcqx as a single agent?", "options": {"A": "Type 1 diabetes mellitus", "B": "Hyperthyroidism", "C": "Thyroiditis", "D": "Adrenal insufficiency"}}
{"id": "RFCRFCuzSN3Z", "question_type": "multi_choice", "question": "For the drug Lynozyfic, what is known about its effects on fertility based on animal studies?", "options": {"A": "Animal studies have shown Lynozyfic impairs fertility.", "B": "Animal studies have shown Lynozyfic improves fertility.", "C": "Animal studies have shown Lynozyfic has no effect on fertility.", "D": "Animal studies are currently underway to assess fertility effects."}}
{"id": "z4WXzgj8NAJy", "question_type": "multi_choice", "question": "A 28-year-old woman with newly diagnosed PNH is currently pregnant and requires complement inhibition therapy. She is eligible for all available therapies and has no history of complement inhibitor use. Which drug is the most appropriate choice, considering pregnancy safety data and recommendations?", "options": {"A": "Sirolimus", "B": "Cyclosporine", "C": "Piasky", "D": "Ultomiris"}}
{"id": "aRULiIZmhknO", "question_type": "open_ended_multi_choice", "question": "A 38-year-old woman with symptomatic tenosynovial giant cell tumor (TGCT) is being considered for systemic therapy. She has a history of chronic hepatitis B with elevated liver enzymes and is currently taking a P-glycoprotein (P-gp) substrate medication for another condition. Surgical resection is not recommended due to risk of severe morbidity. Which drug regimen is most appropriate for her TGCT management?", "options": {"A": "Turalio (pexidartinib hydrochloride) with standard dosing and no dietary restrictions", "B": "Romvimza (vimseltinib), ensuring it is administered at least 4 hours prior to her P-gp substrate", "C": "Romvimza (vimseltinib) with no adjustment for P-gp substrate timing", "D": "Turalio (pexidartinib hydrochloride) with a high-fat meal"}}
{"id": "FmdWa1DCHun0", "question_type": "open_ended", "question": "A 58-year-old woman with metastatic non-squamous NSCLC and confirmed HER2 (ERBB2) activating mutation is being considered for systemic therapy. She has a history of heart failure with a baseline left ventricular ejection fraction (LVEF) of 45%. Her liver and renal function are normal, and she is not pregnant or breastfeeding. Which of the following drugs should be avoided due to her cardiac condition?", "options": {"A": "TECENTRIQ", "B": "TOPOTECAN", "C": "HERNEXEOS", "D": "None of the above"}}
{"id": "LNMbmjXCg05e", "question_type": "open_ended_multi_choice", "question": "Which recommendation is appropriate for men undergoing Modeyso therapy who have female partners capable of becoming pregnant?", "options": {"A": "No contraception is necessary.", "B": "Use effective contraception during treatment and for 1 month after the last dose.", "C": "Discontinue Modeyso if pregnancy is suspected.", "D": "Monitor sperm count monthly."}}
{"id": "S5x3bgMKmEZF", "question_type": "open_ended_multi_choice", "question": "A 15-year-old boy diagnosed with hemophilia A (inherited factor VIII deficiency) experiences recurrent joint bleeds and has a consistently prolonged partial thromboplastin time. He has never developed inhibitors to factor VIII and is not on any other medications. As his doctor considers initiating regular prophylactic treatment to reduce bleeding episodes, which medication would be most suitable for him, taking into account his age, clinical indication, and safety considerations?", "options": {"A": "MARSTACIMAB-HNCQ", "B": "Desmopressin Acetate", "C": "DARATUMUMAB AND HYALURONIDASE-FIHJ", "D": "Factor IX concentrate"}}
{"id": "6eXQUitp4kYC", "question_type": "open_ended_multi_choice", "question": "In the context of a patient presenting with multiple comorbidities, which assertion about Ekterly's contraindications is correct?", "options": {"A": "Ekterly is contraindicated in patients with diabetes.", "B": "Ekterly is contraindicated in patients with chronic kidney disease.", "C": "Ekterly is contraindicated in patients with a history of stroke.", "D": "Ekterly does not have any contraindications regardless of comorbidities."}}
{"id": "WiPSzIvoRAY3", "question_type": "open_ended_multi_choice", "question": "A 55-year-old patient with metastatic non-squamous non-small cell lung cancer has an activating mutation in the HER2 (ERBB2) tyrosine kinase domain. His past medical history is notable for chronic heart failure and a left ventricular ejection fraction of 45%. He is not pregnant and does not use CYP3A inducers or BCRP substrates. What is the best initial therapeutic approach for his lung cancer?", "options": {"A": "Zongertinib, with close cardiac monitoring", "B": "Atezolizumab as first-line therapy", "C": "Imfinzi as a single agent", "D": "None of the above; alternative therapy should be considered due to cardiac contraindication"}}
{"id": "phoYC7XX2Kdo", "question_type": "open_ended_multi_choice", "question": "Which of the following is NOT listed as a potential immune-mediated adverse reaction associated with penpulimab-kcqx?", "options": {"A": "Myocarditis", "B": "Guillain-Barré syndrome", "C": "Hemolytic anemia", "D": "Pulmonary fibrosis"}}
{"id": "wZEFFSZZKlpq", "question_type": "multi_choice", "question": "A 77-year-old male with a diagnosis of wild-type transthyretin-mediated amyloidosis cardiomyopathy (ATTR-CM) presents for management. He has a history of hypertension controlled with amlodipine and is not taking any CYP2C9 substrate medications. He is otherwise healthy, with no hepatic impairment or respiratory disease. Which drug is most appropriate for reducing cardiovascular death and hospitalization in this patient, considering his age and disease subtype?", "options": {"A": "Mavacamten", "B": "Acoramidis Hydrochloride", "C": "Metoprolol Tartrate", "D": "Verapamil"}}
{"id": "KIlm4mkvkhgG", "question_type": "multi_choice", "question": "A 65-year-old man with chronic kidney disease and anemia is being evaluated for pharmacologic therapy. He has not yet started dialysis but is expected to begin within the next two months. His past medical history is significant for cirrhosis secondary to hepatitis C. Which of the following is the most appropriate recommendation regarding anemia management for this patient?", "options": {"A": "Avoid vadadustat due to underlying cirrhosis; consider alternative anemia management.", "B": "Start fedratinib with thiamine supplementation.", "C": "Initiate vadadustat immediately to treat anemia due to CKD.", "D": "Use the homeopathic combination for anemia symptoms."}}
{"id": "DgC0t30PBBSx", "question_type": "open_ended_multi_choice", "question": "A 34-year-old woman diagnosed with paroxysmal nocturnal hemoglobinuria (PNH) continues to experience extravascular hemolysis (EVH) despite receiving ravulizumab. Her hyperlipidemia is well managed with rosuvastatin 10 mg daily. She has no liver dysfunction and is not pregnant. What is the most appropriate adjustment to her medication regimen to address her ongoing EVH?", "options": {"A": "Add Voydeya to her current ravulizumab regimen, monitoring for statin-related adverse effects.", "B": "Switch to sirolimus monotherapy.", "C": "Increase the dose of rosuvastatin above 10 mg daily while continuing ravulizumab.", "D": "Discontinue ravulizumab and start Voydeya monotherapy."}}
{"id": "AkxI0fBJECW2", "question_type": "multi_choice", "question": "A 67-year-old man with persistent immune thrombocytopenia and autosomal dominant inheritance has failed previous corticosteroid therapy. He has a history of severe renal impairment and is currently taking a proton pump inhibitor for gastroesophageal reflux disease. Which drug should be avoided due to his comorbidities and medication regimen?", "options": {"A": "Prednisone", "B": "Rilzabrutinib", "C": "DMT SUIK (IV)", "D": "Dexamethasone sodium phosphate"}}
{"id": "x0u0iyGnSkbc", "question_type": "open_ended_multi_choice", "question": "A 38-year-old woman presents with moderate to severe chronic hand eczema that has not responded to topical corticosteroids. She is currently breastfeeding her 2-month-old infant and is concerned about drug safety for her child. Which treatment approach is most appropriate for her condition?", "options": {"A": "Initiate topical Anzupgo, advising her to avoid direct contact with the nipple and areola after application.", "B": "Initiate topical Anzupgo without any precautions regarding breastfeeding.", "C": "Initiate topical corticosteroids, despite her previous inadequate response.", "D": "Initiate topical Anzupgo in combination with another JAK inhibitor for enhanced efficacy."}}
{"id": "2vMP9juDJcLk", "question_type": "open_ended_multi_choice", "question": "A 12-year-old boy with familial chylomicronemia syndrome presents with increased circulating chylomicron concentration, failure to thrive, and recurrent nausea and vomiting. His parents inquire about drug therapy options to reduce his triglyceride levels. Which of the following is the most appropriate recommendation for this pediatric patient?", "options": {"A": "TRYNGOLZA (olezarsen sodium) at standard adult dosage", "B": "MYHIBBIN (mycophenolate mofetil) at pediatric dosage for transplant prophylaxis", "C": "TRYNGOLZA (olezarsen sodium) with a drug scheduler for pediatric use", "D": "Dietary management without pharmacologic therapy"}}
{"id": "bTOG9qTiaV3n", "question_type": "multi_choice", "question": "For patients with confirmed Grade 2 or higher ILD/pneumonitis while on Datroway, what is the recommended action regarding drug administration?", "options": {"A": "Continue Datroway with corticosteroids", "B": "Permanently discontinue Datroway", "C": "Reduce Datroway dose", "D": "Withhold Datroway temporarily"}}
{"id": "faaMR6J8Kyzm", "question_type": "open_ended_multi_choice", "question": "A 52-year-old woman reports problems with near vision, such as difficulty reading small text and needing to position objects farther away to see them well. She is diagnosed with presbyopia and has no history of retinal disorders, iritis, medication allergies, pregnancy, or contact lens use. Considering her clinical profile, which drug should be recommended for her treatment from the available choices?", "options": {"A": "Aceclidine", "B": "Brimonidine tartrate", "C": "Phentolamine mesylate", "D": "No drug is appropriate"}}
{"id": "JTv2TU8oPBqU", "question_type": "multi_choice", "question": "Which of the following is NOT a recommended supply for preparing and administering Gomekli tablets for oral suspension?", "options": {"A": "Prescribed number of Gomekli tablets for oral suspension", "B": "Dosing cup", "C": "10 mL oral syringe", "D": "Milk"}}
{"id": "Kq2aNLJAWsw5", "question_type": "open_ended_multi_choice", "question": "A 14-year-old patient diagnosed with non-cystic fibrosis bronchiectasis is being considered for therapy. Which branded medication is indicated for this condition in this age group?", "options": {"A": "Brinsupri", "B": "Albuterol", "C": "Azithromycin", "D": "Prednisone"}}
{"id": "qfXQ6P1yzwNg", "question_type": "multi_choice", "question": "A 10-year-old boy with a history of epilepsy controlled on valproic acid presents with fever, flank pain, and a diagnosis of complicated urinary tract infection. He has normal renal function and no known drug allergies. Which of the following is the most appropriate treatment option?", "options": {"A": "Imipenem and cilastatin intravenously", "B": "Sulopenem etzadroxil and probenecid (Orlynvah) orally", "C": "Flavoxate hydrochloride orally", "D": "Imipenem and cilastatin intravenously, with valproic acid continued"}}
{"id": "ktAyscfZwhEw", "question_type": "open_ended_multi_choice", "question": "A 68-year-old patient with ALK-positive locally advanced NSCLC has moderate liver impairment (total bilirubin above 1.5 up to 3 times the upper limit of normal, with any AST level) and is not currently on CYP3A4 inhibitors or inducers. Considering their hepatic status and drug safety, which regimen is most appropriate for this patient?", "options": {"A": "Erlotinib, standard dosing", "B": "Ensartinib, with increased monitoring and possible dose adjustment", "C": "Rozlytrek, standard dosing", "D": "Ensartinib, avoid use due to hepatic impairment"}}
{"id": "Cu7bSC7Daw5u", "question_type": "open_ended_multi_choice", "question": "In the ASPEN study, how did the annualized rate of severe pulmonary exacerbations compare between Brinsupri 25 mg and placebo?", "options": {"A": "Higher in Brinsupri 25 mg", "B": "Lower in Brinsupri 25 mg", "C": "Equal in both groups", "D": "Not reported"}}
{"id": "xEjBo8RpN0Yc", "question_type": "open_ended_multi_choice", "question": "Which of the following best describes the contraindication profile for the drug Datroway?", "options": {"A": "Datroway is contraindicated in patients with severe hepatic impairment.", "B": "Datroway is contraindicated in patients with known hypersensitivity to its components.", "C": "Datroway has no listed contraindications.", "D": "Datroway is contraindicated in pediatric populations."}}
{"id": "9xqO9NL4xDMf", "question_type": "multi_choice", "question": "A 16-year-old male with Niemann-Pick disease type C and progressive neurological decline is being considered for drug therapy. He has moderate renal impairment (eGFR 35 mL/min) and is currently taking metformin, an OCT2 substrate. Which of the following is the most appropriate approach to drug selection and management for this patient?", "options": {"A": "Start MIPLYFFA in combination with miglustat at standard dosing without adjustments", "B": "Start OPFOLDA in combination with Pombiliti", "C": "Start MIPLYFFA in combination with miglustat at reduced dosing and monitor for metformin toxicity", "D": "Start lithium carbonate therapy"}}
{"id": "BQzCUivS0qQr", "question_type": "multi_choice", "question": "A 28-year-old woman is admitted for labor and requests pain relief. She is otherwise healthy and is not taking any medications. She wishes to breastfeed her newborn after delivery. Which drug regimen is most appropriate for acute pain management during labor, considering safety for both mother and infant?", "options": {"A": "Ropivacaine Hydrochloride via epidural infusion", "B": "Suzetrigine administered every 6 hours", "C": "Acetaminophen every 4 hours", "D": "Childrens Pain Relief every 6 hours"}}
{"id": "JQaOwPZ6IOjv", "question_type": "multi_choice", "question": "A 45-year-old woman is newly diagnosed with acute erythroleukemia and presents with anemia, thrombocytopenia, and splenomegaly. She has no history of cardiac disease, is not pregnant, and has normal hepatic and renal function. She is scheduled to begin induction therapy. Which drug regimen is most appropriate for remission induction in her case?", "options": {"A": "TaperDex 12-day administered orally for 12 days as supportive therapy", "B": "Daunorubicin Hydrochloride administered intravenously in combination with other approved anticancer drugs", "C": "REVUMENIB administered orally twice daily for 28-day cycles", "D": "TaperDex 12-day combined with REVUMENIB for induction therapy"}}
{"id": "9iKp5pRNlxwM", "question_type": "open_ended_multi_choice", "question": "A 54-year-old woman with primary biliary cholangitis presents with persistent pruritus, elevated alkaline phosphatase, and a history of cirrhosis with recent development of ascites. She is intolerant to ursodeoxycholic acid and is seeking alternative therapy. Her current medications include a statin for hyperlipidemia. Which drug regimen is most appropriate for her condition?", "options": {"A": "Elafibranor once daily as monotherapy", "B": "Colcrys daily for long-term management", "C": "Budesonide inhalation twice daily", "D": "Supportive care only; avoid Elafibranor due to decompensated cirrhosis"}}
{"id": "P8971YIeOnkv", "question_type": "open_ended_multi_choice", "question": "When considering the use of Hernexeos in a diverse patient population, which of the following statements is accurate?", "options": {"A": "There are no contraindications for Hernexeos, regardless of patient characteristics.", "B": "Hernexeos is contraindicated in patients with autoimmune disorders.", "C": "Hernexeos should not be used in patients with a history of drug abuse.", "D": "Hernexeos is contraindicated in patients under 18 years old."}}
{"id": "l3oDJRbilVql", "question_type": "open_ended_multi_choice", "question": "What is the advised approach regarding pregnancy testing before starting Wayrilz therapy in women who are capable of becoming pregnant?", "options": {"A": "Pregnancy testing is not necessary.", "B": "Verify pregnancy status prior to initiating Wayrilz treatment.", "C": "Pregnancy testing should be done only after starting Wayrilz.", "D": "Pregnancy testing is required only if symptoms of pregnancy appear."}}
{"id": "4cGrg0nfDPAO", "question_type": "open_ended", "question": "A 34-year-old woman presents with moderate dry eye disease. She is 10 weeks pregnant and is concerned about the safety of medications for her developing fetus. She has no history of glaucoma, ocular infections, or recent ocular surgery. She wears contact lenses daily. Which of the following is the most appropriate pharmacologic treatment for her dry eye disease, considering her pregnancy and contact lens use?", "options": {"A": "TRYPTYR, administered after removing contact lenses, with lenses reinserted 15 minutes post-instillation", "B": "Lotemax SM, administered twice daily while continuing contact lens use", "C": "Xiidra, administered without removing contact lenses", "D": "Lotemax SM, administered after removing contact lenses, with lenses reinserted immediately"}}
{"id": "MOPOtsoUEfKm", "question_type": "open_ended_multi_choice", "question": "A 68-year-old female patient with chronic kidney disease (creatinine clearance 18 mL/min) and a history of gout presents with an uncomplicated urinary tract infection. She has a documented allergy to cephalosporins but reports no other antibiotic allergies and is not on medications with significant drug interactions. What is the most suitable antibiotic treatment for her UTI?", "options": {"A": "Sulopenem etzadroxil and probenecid (Orlynvah) orally", "B": "Imipenem and cilastatin intravenously with renal dose adjustment", "C": "Flavoxate hydrochloride orally", "D": "Sulopenem etzadroxil and probenecid (Orlynvah) with a drug holiday"}}
{"id": "A8hcoIx1g2Xn", "question_type": "open_ended_multi_choice", "question": "A 72-year-old woman with relapsed small cell lung cancer (SCLC) is seeking second-line therapy. She previously responded to first-line chemotherapy and is now 60 days since her last treatment. Given her history of frequent diarrhea and elevated risk for dehydration, which treatment option should be avoided in her case?", "options": {"A": "Imdelltra, administered intravenously with step-up dosing", "B": "Topotecan capsules, standard oral dosing for 5 days every 21 days", "C": "Ipilimumab, administered in combination with nivolumab", "D": "Topotecan capsules, dose reduced for age and diarrhea risk"}}
{"id": "X2fGgs0uM3TO", "question_type": "open_ended_multi_choice", "question": "A 3-year-old child presents with multiple umbilicated papules on the trunk and extremities. The diagnosis of molluscum contagiosum is confirmed. The parents are seeking a topical treatment. The child has no known allergies and no history of eczema or damaged skin. Which of the following is the most appropriate topical therapy for this patient, considering both efficacy and safety?", "options": {"A": "Adapalene applied once daily to affected areas", "B": "Zelsuvmi applied topically as directed for molluscum contagiosum", "C": "Adapalene applied twice daily to affected areas", "D": "No topical therapy recommended due to age"}}
{"id": "V8pRHXpKmbhI", "question_type": "open_ended_multi_choice", "question": "A 62-year-old male with metastatic non-small cell lung cancer (NSCLC) presents with a tumor that expresses PD-L1 at 1% or higher and tests negative for both EGFR and ALK mutations. His medical history includes autoimmune thyroiditis, for which he is euthyroid on levothyroxine. He is not pregnant and his liver function is normal. What is the most suitable first-line therapy for this patient?", "options": {"A": "CYRAMZA (ramucirumab) in combination with docetaxel every 3 weeks", "B": "ENSACOVE (ensartinib) 225 mg orally once daily", "C": "YERVOY (ipilimumab) in combination with nivolumab every 6 weeks", "D": "CYRAMZA (ramucirumab) in combination with erlotinib every 2 weeks"}}
{"id": "2UEqfypXK1El", "question_type": "multi_choice", "question": "How did the requirement for rescue medication compare between the Wayrilz and placebo groups during the double-blind period of the LUNA-3 study?", "options": {"A": "No patients required rescue medication in either group", "B": "58% of Wayrilz patients and 33% of placebo patients required rescue medication", "C": "Both groups had 33% requiring rescue medication", "D": "Both groups had 58% requiring rescue medication"}}
{"id": "DFb0IHE9KJIP", "question_type": "open_ended_multi_choice", "question": "What is the proper interval for giving Tryptyr and an additional topical ophthalmic eye drop to a patient who requires both treatments?", "options": {"A": "Administer both drops simultaneously", "B": "Administer Tryptyr first and the other drop immediately after", "C": "Administer the drugs at least five minutes apart", "D": "Wait one hour between drugs"}}
{"id": "Dvlx7fOFfRaL", "question_type": "multi_choice", "question": "A patient with a documented hypersensitivity reaction to atrasentan is being considered for Vanrafia therapy. What is the appropriate clinical action based on the drug's contraindications?", "options": {"A": "Do not administer Vanrafia", "B": "Administer Vanrafia with premedication", "C": "Reduce the dose of Vanrafia", "D": "Monitor closely during first administration"}}
{"id": "08TK3zngNHB0", "question_type": "multi_choice", "question": "A pregnant woman in her second trimester presents with severe erythema multiforme. She requires systemic corticosteroid therapy. Which drug should be used with the greatest caution due to its established teratogenicity in animal studies and potential risk to the fetus?", "options": {"A": "Prednisone", "B": "Dexamethasone", "C": "PRED FORTE", "D": "Topical corticosteroid"}}
{"id": "l6s0o9G0CLVQ", "question_type": "open_ended", "question": "Which of the following statements best describes the boxed warning for Grafapex?", "options": {"A": "Grafapex may cause mild gastrointestinal upset.", "B": "Grafapex is associated with severe and prolonged myelosuppression requiring stem cell transplantation.", "C": "Grafapex should be avoided in patients with renal impairment.", "D": "Grafapex is contraindicated in pregnancy due to teratogenicity."}}
{"id": "y4aYPETqpSfG", "question_type": "multi_choice", "question": "What risk is increased when Lynozyfic is administered with CYP substrates?", "options": {"A": "Risk of increased renal clearance of CYP substrates", "B": "Risk of decreased efficacy of Lynozyfic", "C": "Risk of enhanced metabolism of CYP substrates", "D": "Risk of reduced cytokine release"}}
{"id": "e3uJ44vz50wG", "question_type": "open_ended_multi_choice", "question": "In terms of comparing adverse reaction rates for Tryptyr across multiple clinical trials, which statement most appropriately reflects their comparability?", "options": {"A": "Adverse reaction rates from Tryptyr clinical trials cannot be directly compared to those from other drug trials due to varying conditions.", "B": "Adverse reaction rates for Tryptyr are always higher than those for other drugs.", "C": "Adverse reaction rates for Tryptyr are standardized across all clinical trials.", "D": "Adverse reaction rates for Tryptyr are only valid for European populations."}}
{"id": "vsyDkTMgYvb0", "question_type": "open_ended_multi_choice", "question": "In the context of treating recurrent or metastatic non-keratinizing nasopharyngeal carcinoma as a first-line option, which combination includes Penpulimab-kcqx?", "options": {"A": "Penpulimab-kcqx with cisplatin and gemcitabine", "B": "Penpulimab-kcqx with paclitaxel and carboplatin", "C": "Penpulimab-kcqx with gemcitabine alone", "D": "Penpulimab-kcqx with carboplatin and gemcitabine"}}
{"id": "aLpAdy9Siyk6", "question_type": "open_ended_multi_choice", "question": "A 15-year-old, 45-kg patient is seen for moderate-to-severe atopic dermatitis that has not responded to topical prescription therapies. The patient’s medical history includes recurrent conjunctivitis and keratoconus. Which systemic therapy should be selected as the safest and most effective option given the patient’s age and comorbidities?", "options": {"A": "Dexamethasone sodium phosphate administered intramuscularly every 2 weeks", "B": "Adbry administered subcutaneously every other week", "C": "Ebglyss administered subcutaneously every 4 weeks", "D": "Dexamethasone sodium phosphate administered orally daily"}}
{"id": "sWjnDLNLptHF", "question_type": "multi_choice", "question": "A patient receiving Emrelis develops new-onset blurred vision and keratitis. What is the recommended clinical action for Grade ≥2 ocular toxicity?", "options": {"A": "Continue Emrelis at the same dose", "B": "Withhold Emrelis and refer to an eye care professional", "C": "Permanently discontinue Emrelis immediately", "D": "Reduce the dose of Emrelis without referral"}}
{"id": "WC8rRm2XvdyD", "question_type": "multi_choice", "question": "A 6-month-old infant with severe RSV infection is hospitalized and requires mechanical ventilation. The infant's mother is currently pregnant. Which of the following is the most appropriate management regarding antiviral therapy for this patient?", "options": {"A": "Administer ENFLONSIA as a preventive measure.", "B": "Administer Virazole via inhalation, ensuring staff are experienced with ventilator use and monitoring.", "C": "Administer Restasis MultiDose ophthalmic emulsion.", "D": "Avoid Virazole due to teratogenic risk and select an alternative antiviral agent."}}
{"id": "1cuatVCilZs8", "question_type": "multi_choice", "question": "A patient using Vizz reports sudden onset of flashing lights, floaters, or vision loss. What is the recommended action?", "options": {"A": "Seek immediate medical care.", "B": "Continue using Vizz and monitor symptoms.", "C": "Increase the dosage of Vizz.", "D": "Switch to another ophthalmic medication."}}
{"id": "q6llgdmu75mu", "question_type": "open_ended_multi_choice", "question": "When administering Wayrilz, which of the following recommendations is correct regarding concomitant use with antacids or H2 blockers?", "options": {"A": "Take Wayrilz immediately after antacids or H2 blockers", "B": "Take Wayrilz at least 2 hours before antacids or H2 blockers", "C": "Take Wayrilz and antacids together with food", "D": "Take Wayrilz only at night if using H2 blockers"}}
{"id": "XLPNnE8ytIkP", "question_type": "open_ended_multi_choice", "question": "When Hernexeos is coadministered with BCRP substrates not associated with serious adverse reactions from minimal concentration changes, what is the recommended management strategy?", "options": {"A": "Discontinue Hernexeos", "B": "Monitor for increased adverse reactions and adjust substrate dosage as clinically appropriate", "C": "Increase Hernexeos dose", "D": "No monitoring or adjustment needed"}}
{"id": "aZKfQeHj4Qhe", "question_type": "open_ended_multi_choice", "question": "A 35-year-old woman with a history of recurrent low-grade serous ovarian carcinoma with a KRAS mutation is planning to start AVMAPKI FAKZYNJA CO-PACK. As she is breastfeeding her 3-month-old child, she is concerned about whether she can continue nursing while on this regimen. What is the most appropriate recommendation for her cancer treatment in relation to breastfeeding?", "options": {"A": "Start AVMAPKI FAKZYNJA CO-PACK and continue breastfeeding", "B": "Delay AVMAPKI FAKZYNJA CO-PACK until breastfeeding is discontinued", "C": "Start AVMAPKI FAKZYNJA CO-PACK and stop breastfeeding during treatment and for 2 weeks after the last dose", "D": "Start AVMAPKI FAKZYNJA CO-PACK with reduced dosage to minimize risk to the infant"}}
{"id": "qHVhAUzShr8K", "question_type": "multi_choice", "question": "A 36-year-old woman with KRAS-mutated recurrent low-grade serous ovarian carcinoma is being considered for AVMAPKI FAKZYNJA CO-PACK (avutometinib and defactinib) therapy. She is currently pregnant and not taking any other medications. What is the most appropriate recommendation regarding her cancer treatment?", "options": {"A": "Start AVMAPKI FAKZYNJA CO-PACK immediately, as it is the only approved therapy for her condition.", "B": "Delay AVMAPKI FAKZYNJA CO-PACK until after delivery due to risk of fetal harm.", "C": "Start AVMAPKI FAKZYNJA CO-PACK but reduce the dose to minimize fetal exposure.", "D": "Switch to an alternative systemic therapy with a better safety profile in pregnancy."}}
{"id": "gA9HeJ0rWSMj", "question_type": "multi_choice", "question": "How did the incidence rate of RSV-associated hospitalization through 150 days after dosing compare between Enflonsia and placebo in infants born at ≥29 weeks gestational age in Trial 004?", "options": {"A": "Enflonsia had a lower incidence rate than placebo", "B": "Enflonsia had a higher incidence rate than placebo", "C": "Both had identical incidence rates", "D": "Placebo had a lower incidence rate than Enflonsia"}}
{"id": "1LFZaOWxvMcT", "question_type": "multi_choice", "question": "A patient is prescribed Sephience and is also taking sulfasalazine. What is the recommended clinical action based on their concomitant use?", "options": {"A": "Continue both drugs without monitoring", "B": "Monitor for signs of hepatotoxicity", "C": "Increase the dose of Sephience", "D": "Add a PDE-5 inhibitor"}}
{"id": "daXLp2qyOQru", "question_type": "open_ended_multi_choice", "question": "A 14-year-old girl with a relapsed low-grade glioma harboring a BRAF fusion is being treated with fluconazole for a fungal infection and is currently on hormonal contraception. Her oncologist is evaluating targeted therapy options. Which therapy should be avoided because of potential drug interactions and concerns related to contraceptive effectiveness?", "options": {"A": "VinCRIStine Sulfate administered intravenously, with careful monitoring for neurotoxicity.", "B": "OJEMDA administered orally once daily, despite concurrent fluconazole and hormonal contraceptive use.", "C": "Gliadel Wafer implantation as adjunct to surgery, regardless of glioma grade.", "D": "OJEMDA administered with a planned drug holiday every 3 months to minimize adverse effects."}}
{"id": "4JgXwSKLMNDD", "question_type": "open_ended_multi_choice", "question": "Which statement most accurately characterizes the potential for fetal harm when Gomekli is administered during pregnancy?", "options": {"A": "Gomekli is safe for use during pregnancy", "B": "Gomekli may cause fetal harm or loss of pregnancy", "C": "Gomekli increases the risk of gestational diabetes", "D": "Gomekli prevents miscarriage"}}
{"id": "tYL9FmU3v5Tj", "question_type": "open_ended_multi_choice", "question": "Prior to initiating Anzupgo therapy, which immunization strategy is recommended?", "options": {"A": "Complete all age-appropriate vaccinations, including herpes zoster vaccination", "B": "Administer only live vaccines immediately before starting therapy", "C": "Delay all vaccinations until after Anzupgo therapy", "D": "Vaccinate only against influenza"}}
{"id": "J26eazejAE2Y", "question_type": "open_ended_multi_choice", "question": "A 28-year-old woman with ciliary dyskinesia-bronchiectasis is currently pregnant and requires management for recurrent bronchospasm. She has no history of cardiovascular disease, diabetes, or CFTR mutations. Which drug regimen is most appropriate for her, considering pregnancy safety and disease indication?", "options": {"A": "Albuterol Sulfate HFA inhalation aerosol, 90 mcg per actuation, as needed for bronchospasm", "B": "Kalydeco oral tablets, 150 mg twice daily", "C": "Albuterol Sulfate HFA inhalation aerosol, 180 mcg per actuation, three times daily", "D": "Kalydeco oral tablets, 75 mg twice daily"}}
{"id": "1aphHDjOiMrQ", "question_type": "multi_choice", "question": "Which of the following statements is correct regarding the freezing of Vizz?", "options": {"A": "Vizz should not be frozen under any circumstances.", "B": "Vizz can be frozen for up to 8 days during shipment.", "C": "Vizz should be frozen for long-term storage.", "D": "Vizz can be frozen after opening the vial."}}
{"id": "3Y9FqXXBTUrV", "question_type": "open_ended_multi_choice", "question": "A 45-year-old male diagnosed with COPD is receiving ritonavir, a powerful CYP3A4 inhibitor, for an unrelated medical issue. When selecting a maintenance therapy for his COPD, which drug would be the safest choice in terms of minimizing clinically significant drug interactions and adverse effects?", "options": {"A": "Budesonide Inhalation", "B": "Fentanyl Citrate", "C": "Ensifentrine", "D": "Budesonide (oral)"}}
{"id": "NHvZUsNHqxQd", "question_type": "open_ended", "question": "A 30-year-old woman with non-cystic fibrosis bronchiectasis, chronic sinusitis, and a history of recurrent bronchopulmonary infections is currently breastfeeding her infant. She is concerned about the safety of drug therapy for her condition and requests a drug holiday to minimize potential risks to her child. Which of the following is the most appropriate recommendation?", "options": {"A": "Initiate Brinsupri at the recommended adult dose, with regular dental and dermatologic monitoring, and continue breastfeeding without interruption", "B": "Recommend a drug holiday from Brinsupri during breastfeeding due to lack of data on excretion in human milk and potential adverse effects on the infant", "C": "Start SYMDEKO, as it is excreted in rat milk but has no reported adverse effects in humans", "D": "Begin GENOTROPIN therapy, as published data indicate no adverse effects in breastfed infants"}}
{"id": "UROlN8CbSthy", "question_type": "open_ended_multi_choice", "question": "A 15-year-old presents with generalized myasthenia gravis, confirmed by both anti-acetylcholine receptor antibody testing and symptoms including ptosis and muscle weakness that worsens with activity. The patient denies any history of organophosphate poisoning, is not pregnant, and is otherwise healthy. Which treatment regimen is most appropriate for this patient, given considerations for safety and effectiveness in children?", "options": {"A": "Azathioprine, 50 mg daily, as an immunosuppressive adjunct", "B": "DuoDote, single dose for acute symptom management", "C": "IMAAVY, 15 mg/kg intravenous infusion every 2 weeks", "D": "Azathioprine, 100 mg daily, with a drug holiday every 2 months"}}
{"id": "09cgdexS55X9", "question_type": "open_ended_multi_choice", "question": "A 45-year-old male with prurigo nodularis is planning to receive a live vaccine for travel purposes. He has no prior hypersensitivity reactions and is otherwise in good health. What is the most appropriate management strategy for his prurigo nodularis?", "options": {"A": "Initiate NEMLUVIO therapy immediately and administer the live vaccine during treatment", "B": "Delay NEMLUVIO therapy until after completion of all age-appropriate live vaccinations", "C": "Start Nalbuphine Hydrochloride injection for prurigo nodularis management", "D": "Begin NEMLUVIO therapy and combine with Nalbuphine Hydrochloride for enhanced efficacy"}}
{"id": "DSBvT8vcpY7R", "question_type": "open_ended_multi_choice", "question": "A 62-year-old male with unresectable, metastatic esophageal squamous cell carcinoma (ESCC) presents with chest pain, cough, and lymphadenopathy. His tumor expresses PD-L1 (≥1). He has a history of hypertension, which is well-controlled, and is currently taking amiodarone for arrhythmia. The oncology team is considering first-line systemic therapy. Which drug regimen is most appropriate for this patient?", "options": {"A": "Lenvatinib monotherapy", "B": "Tislelizumab-jsgr in combination with platinum-containing chemotherapy", "C": "Nivolumab and hyaluronidase in combination with fluoropyrimidine- and platinum-containing chemotherapy", "D": "Lenvatinib in combination with pembrolizumab"}}
{"id": "jngczjmW057R", "question_type": "open_ended", "question": "A patient with a history of anaphylaxis to multiple medications is being considered for Romvimza therapy. What does the contraindication profile of Romvimza indicate regarding its use in this patient?", "options": {"A": "Romvimza is contraindicated in patients with a history of anaphylaxis.", "B": "Romvimza should be avoided in patients with severe allergies.", "C": "Romvimza has no listed contraindications.", "D": "Romvimza is contraindicated in pediatric patients."}}
{"id": "b108JYgNxYlU", "question_type": "open_ended_multi_choice", "question": "Who should be instructed to avoid breastfeeding while undergoing treatment with Gomekli and for an additional week after completion?", "options": {"A": "Women receiving Gomekli", "B": "Men receiving Gomekli", "C": "Pediatric patients under 2 years old", "D": "Patients with mild renal impairment"}}
{"id": "zdz58G3OLHsn", "question_type": "open_ended_multi_choice", "question": "A 7-year-old boy diagnosed with myelodysplastic syndrome is scheduled for allogeneic hematopoietic stem cell transplantation. He has no history of seizures and is not taking any CYP2C19 or CYP3A4 substrate medications. Which drug regimen is most appropriate as part of his preparative regimen prior to transplantation?", "options": {"A": "Lenalidomide, oral daily dosing", "B": "Reblozyl, subcutaneous injection every 3 weeks", "C": "Treosulfan (GRAFAPEX) in combination with fludarabine, with supportive care for myelosuppression", "D": "Lenalidomide, with a planned drug scheduler to minimize cytopenias"}}
{"id": "ImLu8AvNbcxq", "question_type": "multi_choice", "question": "Which of the following instructions should be given to patients regarding the timing of Modeyso administration?", "options": {"A": "Take Modeyso orally once weekly on an empty stomach, at least 1 hour before or 3 hours after food, at the same time on the same day each week.", "B": "Take Modeyso twice daily with meals.", "C": "Take Modeyso once daily at bedtime, regardless of food intake.", "D": "Take Modeyso every other day with a glass of milk."}}
{"id": "AwhQH83GFtPs", "question_type": "multi_choice", "question": "A 7-year-old boy with Duchenne muscular dystrophy presents with progressive muscle weakness, calf muscle pseudohypertrophy, and elevated creatine kinase. Genetic testing confirms a DMD gene mutation amenable to exon 53 skipping. He has no history of renal impairment or arrhythmia. Which drug is the most appropriate for his treatment, considering his age and genetic profile?", "options": {"A": "No drug therapy is appropriate due to age", "B": "Exondys 51 administered intravenously once weekly", "C": "Duvyzat administered orally twice daily", "D": "Viltepso administered intravenously once weekly"}}
{"id": "PufpfpdvFmD9", "question_type": "open_ended", "question": "A 55-year-old woman with metastatic ROS1-positive non-small cell lung carcinoma is being evaluated for IBTROZI therapy. She has a history of gastroesophageal reflux disease and is currently taking omeprazole (a proton pump inhibitor) daily. What is the best strategy to optimize IBTROZI efficacy in this patient?", "options": {"A": "Continue omeprazole and administer IBTROZI at the usual time.", "B": "Discontinue omeprazole and avoid all acid-reducing agents during IBTROZI therapy.", "C": "Switch to a locally acting antacid and administer IBTROZI at least 2 hours before or after the antacid.", "D": "Continue omeprazole but increase the IBTROZI dose to compensate for reduced absorption."}}
{"id": "tezwe5qBH5wB", "question_type": "multi_choice", "question": "A patient receiving Emrelis develops new-onset blurred vision and keratitis. What is the recommended clinical action for Grade ≥2 ocular toxicity?", "options": {"A": "Continue Emrelis at the same dose", "B": "Permanently discontinue Emrelis immediately", "C": "Withhold Emrelis and refer to an eye care professional", "D": "Reduce the dose of Emrelis without referral"}}
{"id": "Tci33DHYZqCd", "question_type": "multi_choice", "question": "A 58-year-old man with metastatic cutaneous squamous cell carcinoma is not a candidate for curative surgery or radiation. He has a history of severe infusion-related reactions to monoclonal antibodies in the past. Which of the following systemic therapies is most appropriate for his condition, considering both indication and safety profile?", "options": {"A": "UNLOXCYT, as it is specifically indicated for CSCC despite higher infusion reaction risk", "B": "TECENTRIQ, as it is approved for CSCC and has a low rate of infusion reactions", "C": "ERBITUX, due to its lower risk of infusion reactions", "D": "No systemic therapy is appropriate due to infusion reaction history"}}
{"id": "Qp72wFO5fbXQ", "question_type": "open_ended_multi_choice", "question": "For individuals with mild liver dysfunction, is it necessary to adjust the dosage of Datroway?", "options": {"A": "Yes, reduce the dosage", "B": "Yes, increase the dosage", "C": "No dosage adjustment is recommended", "D": "Discontinue Datroway"}}
{"id": "8nd70ZzbVqPW", "question_type": "multi_choice", "question": "A 35-year-old woman with newly diagnosed non-keratinizing nasopharyngeal carcinoma is 10 weeks pregnant. She has no significant comorbidities and normal renal and hepatic function. Which of the following drugs is contraindicated for her cancer treatment due to risk of fetal harm?", "options": {"A": "Celecoxib 200 mg twice daily", "B": "Penpulimab-kcqx in combination with carboplatin and gemcitabine", "C": "Capecitabine 500 mg twice daily", "D": "Penpulimab-kcqx monotherapy"}}
{"id": "DZMAxa7Os1pt", "question_type": "open_ended_multi_choice", "question": "In a 5-year-old child diagnosed with classic congenital adrenal hyperplasia who is on glucocorticoid replacement and has severe renal impairment, what is the best next step regarding the administration of crinecerfont (CRENESSITY) to help control androgen excess?", "options": {"A": "Initiate crinecerfont at standard dosage as adjunctive therapy.", "B": "Initiate crinecerfont with dose adjustment due to renal impairment.", "C": "Crinecerfont is not recommended due to severe renal impairment.", "D": "Crinecerfont can be used only if the patient is monitored for hypersensitivity."}}
{"id": "kSpsCSJq5Rms", "question_type": "open_ended_multi_choice", "question": "A 32-year-old woman with schizophrenia and mild renal impairment (eGFR 65 mL/min) is currently taking a strong CYP2D6 inhibitor for another condition. She has no hepatic impairment or other comorbidities. She prefers an oral medication and is concerned about potential drug interactions. Which antipsychotic regimen is most appropriate for her?", "options": {"A": "Cobenfy, administered orally at the standard adult dose", "B": "Abilify Maintena, administered as a monthly intramuscular injection with dose reduction", "C": "Cobenfy, administered orally with close monitoring for adverse reactions", "D": "Abilify Maintena, administered orally at the standard dose"}}
{"id": "iLsKTP5Eh0WD", "question_type": "open_ended_multi_choice", "question": "Blujepa should not be administered in patients with which of the following medical histories?", "options": {"A": "History of severe hypersensitivity to Blujepa", "B": "History of mild rash after Blujepa", "C": "History of severe hypersensitivity to penicillin", "D": "History of mild hypersensitivity to Blujepa"}}
{"id": "JGouUgiRUXeU", "question_type": "open_ended_multi_choice", "question": "A woman, age 34, recently diagnosed with adrenocortical carcinoma, is set to undergo surgical removal of the tumor. She previously experienced a severe anaphylactic reaction to polyethylene glycol (PEG) during an imaging study. The team is considering fluorescence imaging during the operation to detect residual malignancy. Given her history, which agent is contraindicated?", "options": {"A": "Etoposide administered intravenously at a low starting dose", "B": "Lumisight (pegulicianine) administered at 1 mg/kg for intraoperative imaging", "C": "Etoposide administered orally at standard dosing", "D": "No imaging agent used during surgery"}}
{"id": "YjgWUsxrHjeP", "question_type": "open_ended_multi_choice", "question": "Which precaution should patients be advised to take when using the brand drug Vizz if they experience temporary dim or dark vision?", "options": {"A": "Avoid night driving and hazardous activities in poor illumination.", "B": "Increase screen time to improve vision adaptation.", "C": "Take Vizz only in the morning.", "D": "Wear sunglasses indoors."}}
{"id": "e1t4WBHjdreR", "question_type": "multi_choice", "question": "Which of the following recommendations is most appropriate for a woman who is breastfeeding and requires treatment with Modeyso?", "options": {"A": "Continue breastfeeding during Modeyso therapy.", "B": "Discontinue breastfeeding only if adverse effects are observed in the infant.", "C": "Breastfeeding is safe if Modeyso is administered at a low dose.", "D": "Advise not to breastfeed during Modeyso treatment and for 1 week after the last dose."}}
{"id": "kFze41TgyDyA", "question_type": "open_ended", "question": "Has Modeyso undergone dedicated fertility studies to assess its impact on reproductive function?", "options": {"A": "No, dedicated fertility studies were not conducted with Modeyso.", "B": "Yes, Modeyso was shown to impair fertility in animal models.", "C": "Yes, Modeyso improved fertility outcomes in clinical trials.", "D": "Modeyso was only tested for fertility effects in vitro."}}
{"id": "OeB7vu95rlS2", "question_type": "open_ended_multi_choice", "question": "For a 45-year-old woman with chronic hypoparathyroidism who has achieved an albumin-corrected serum calcium of 8.2 mg/dL through calcium and active vitamin D supplementation, and who has no history of bone malignancy, radiation exposure, metabolic bone disease, or use of medications affecting calcium levels, what is the most suitable pharmacologic therapy to start for her long-term management, taking into account both safety and efficacy?", "options": {"A": "GENOTROPIN administered once daily", "B": "Yorvipath administered once daily", "C": "Tri-Vite Drops with Fluoride administered daily", "D": "Somatropin administered twice daily"}}
{"id": "fSNWkjWthR6e", "question_type": "multi_choice", "question": "For a clinical trial involving Modeyso, which exclusion criteria based on contraindications would be supported by the drug's official documentation?", "options": {"A": "Exclude patients with liver failure", "B": "Exclude patients with known hypersensitivity to Modeyso", "C": "Exclude patients with severe cardiac disease", "D": "Exclude pregnant women"}}
{"id": "wViXUYy5H7Rb", "question_type": "open_ended_multi_choice", "question": "For a 72-year-old woman diagnosed with unresectable, metastatic, HR-positive, HER2-negative breast cancer, who has already undergone endocrine-based therapy and chemotherapy and has a background of arterial thromboembolic events requiring anticoagulation, which drug should be selected for her treatment in light of her age and comorbid conditions?", "options": {"A": "MVASI", "B": "DATROWAY", "C": "Ketorolac Tromethamine", "D": "None of the above"}}
{"id": "edAATjxy3D3F", "question_type": "multi_choice", "question": "If a patient’s blood phenylalanine does not decrease after 2 weeks of Sephience at the maximum daily dose, what is the recommended clinical action?", "options": {"A": "Increase the dose beyond 60 mg/kg", "B": "Continue current dose and monitor monthly", "C": "Discontinue Sephience", "D": "Switch to a high-protein diet"}}
{"id": "v9weuYFvn5Nk", "question_type": "multi_choice", "question": "When reviewing the prescribing information for Modeyso, what should be considered regarding contraindications?", "options": {"A": "Modeyso is contraindicated in patients with active infection.", "B": "Modeyso is contraindicated in patients with a history of drug allergy.", "C": "Modeyso is contraindicated in patients with uncontrolled hypertension.", "D": "Modeyso has no contraindications listed in its prescribing information."}}
{"id": "DUo2UsYDyGS8", "question_type": "open_ended_multi_choice", "question": "A woman aged 34 with a history of chronic immune thrombocytopenia and moderate hepatic impairment is experiencing abnormal bleeding. She tests positive for platelet antibodies and is currently taking a proton pump inhibitor for gastroesophageal reflux. Which drug treatment is most appropriate for her ITP?", "options": {"A": "WAYRILZ (rilzabrutinib) 400 mg twice daily", "B": "Nplate (romiplostim) weekly subcutaneous injection", "C": "DMT SUIK (corticosteroid) intravenous therapy", "D": "WAYRILZ (rilzabrutinib) with a drug holiday during PPI use"}}
{"id": "nzNKFoOf3lvT", "question_type": "open_ended_multi_choice", "question": "A 32-year-old pregnant woman in her second trimester presents with new-onset supraventricular tachycardia. She has no history of hepatic impairment, bronchospastic disease, or other comorbidities. The team is considering pharmacologic therapy for acute rate control. Which of the following is the most appropriate drug for this patient?", "options": {"A": "Pacerone", "B": "Propranolol", "C": "RAPIBLYK", "D": "Pacerone with a drug holiday"}}
{"id": "ViQbxX9C1Ybk", "question_type": "open_ended_multi_choice", "question": "For a 60-year-old male diagnosed with recurrent glioblastoma who also suffers from congestive heart failure and uncontrolled hypertension, which therapeutic agent should not be used because of its association with increased serious cardiovascular adverse events?", "options": {"A": "Zortress in combination with cyclosporine", "B": "Avastin administered every 2 weeks", "C": "Vorasidenib 40 mg once daily", "D": "Zortress combined with tacrolimus"}}
{"id": "EgK1iRdwBVey", "question_type": "open_ended_multi_choice", "question": "How does the safety profile of Tryptyr in elderly patients compare to that in younger adults based on current observations?", "options": {"A": "Clinically relevant differences in safety have been observed between elderly and younger patients.", "B": "Tryptyr is associated with increased adverse effects in elderly patients.", "C": "No clinically relevant differences in safety have been observed between elderly and younger patients.", "D": "Tryptyr is contraindicated in elderly patients."}}
{"id": "v7ja6vkHGrkk", "question_type": "multi_choice", "question": "A 35-year-old woman with newly diagnosed non-keratinizing nasopharyngeal carcinoma is 10 weeks pregnant. She has no significant comorbidities and normal renal and hepatic function. Which of the following drugs is contraindicated for her cancer treatment due to risk of fetal harm?", "options": {"A": "Celecoxib 200 mg twice daily", "B": "Capecitabine 500 mg twice daily", "C": "Penpulimab-kcqx in combination with carboplatin and gemcitabine", "D": "Penpulimab-kcqx monotherapy"}}
{"id": "fGDwXq0H5Pub", "question_type": "multi_choice", "question": "A 14-year-old patient presents with non-cystic fibrosis bronchiectasis, recurrent bronchopulmonary infections, and chronic sinusitis. The patient has a history of gingival sensitivity and is scheduled to receive a live attenuated vaccine in the coming weeks. Which drug regimen is most appropriate for managing this patient's bronchiectasis?", "options": {"A": "Brinsupri, with regular dental checkups and avoidance of live attenuated vaccines", "B": "SYMDEKO, with dose adjustment for age and monitoring for cataracts", "C": "ORKAMBI, with close monitoring of liver function and avoidance of CYP3A substrates", "D": "Brinsupri, administered concurrently with live attenuated vaccines"}}
{"id": "tFhwE1yLrlcr", "question_type": "open_ended_multi_choice", "question": "How should Gomekli therapy be adjusted in the case of an asymptomatic absolute decrease in LVEF by 10% or greater from baseline that falls below the lower limit of normal?", "options": {"A": "Continue Gomekli at current dose", "B": "Withhold Gomekli until ≤Grade 1, then resume at reduced dose", "C": "Permanently discontinue Gomekli", "D": "Increase Gomekli dose"}}
{"id": "vthPGhowhN7O", "question_type": "open_ended_multi_choice", "question": "A 34-year-old woman with familial chylomicronemia syndrome presents with recurrent episodes of pancreatitis, hepatosplenomegaly, and eruptive xanthomas. She is currently 10 weeks pregnant and is seeking treatment to reduce her triglyceride levels. Which drug is most appropriate for her condition, considering both efficacy and safety during pregnancy?", "options": {"A": "TRYNGOLZA (olezarsen sodium) administered as an adjunct to diet", "B": "MYHIBBIN (mycophenolate mofetil) administered twice daily", "C": "MYHIBBIN (mycophenolate mofetil) with a drug holiday during pregnancy", "D": "TRYNGOLZA (olezarsen sodium) with a drug holiday during pregnancy"}}
{"id": "GF4TYBEnC2xr", "question_type": "open_ended_multi_choice", "question": "A 68-year-old woman with prurigo nodularis seeks treatment. Her medical history includes COPD and ongoing benzodiazepine use for anxiety. She complains of intense itching but no notable pain. Taking into account her comorbid conditions and current medications, which drug regimen would be most suitable for her?", "options": {"A": "NEMLUVIO administered subcutaneously every 4 weeks", "B": "Nalbuphine Hydrochloride injection for pain management, titrated slowly", "C": "Nalbuphine Hydrochloride injection combined with benzodiazepine, at standard dosing", "D": "NEMLUVIO combined with live vaccine administration during therapy"}}
{"id": "1B7NEG6FoCon", "question_type": "open_ended_multi_choice", "question": "A 10-year-old boy (weight 35 kg) with chronic graft-versus-host disease (cGVHD) presents with bronchiectasis, recurrent infections, and abnormal esophagus morphology. He has failed two prior lines of systemic therapy. His hepatic function is normal, and he is not taking any other immunosuppressive drugs. Which treatment is most suitable for his condition?", "options": {"A": "Niktimvo, intravenous infusion every 2 weeks", "B": "PredniSONE, 5 mg orally once daily", "C": "PONVORY, 20 mg orally once daily", "D": "Niktimvo, intravenous infusion every 4 weeks"}}
{"id": "jxsLFUHGEhdi", "question_type": "multi_choice", "question": "A 45-year-old man with schizophrenia and a history of benign prostatic hyperplasia (BPH) and incomplete bladder emptying is being considered for antipsychotic therapy. He has normal renal and hepatic function. Which antipsychotic is most suitable for this patient?", "options": {"A": "Cobenfy, administered orally twice daily", "B": "Abilify Maintena, administered as a monthly intramuscular injection", "C": "Cobenfy, administered orally once daily with close monitoring", "D": "Abilify Maintena, administered as a biweekly intramuscular injection"}}
{"id": "j6x2598NTkE3", "question_type": "open_ended_multi_choice", "question": "A 38-year-old female diagnosed with primary biliary cholangitis and compensated cirrhosis (Child-Pugh A) has no clinical or laboratory evidence of portal hypertension or decompensated liver disease. She has a CYP2C9 poor metabolizer genotype and is taking a moderate CYP3A4 inhibitor for an unrelated condition. Given that she cannot use UDCA because of intolerable pruritus, which treatment is most appropriate for her PBC?", "options": {"A": "Ocaliva 5 mg once daily as monotherapy", "B": "Livdelzi 10 mg once daily as monotherapy with close monitoring for adverse effects", "C": "Tricor 145 mg once daily as monotherapy", "D": "Livdelzi 10 mg once daily as monotherapy without monitoring"}}
{"id": "i5CZWNzTCOY8", "question_type": "multi_choice", "question": "If a patient on Vanrafia develops aminotransferase elevations accompanied by bilirubin >2x ULN or clinical symptoms of hepatotoxicity, what is the recommended action?", "options": {"A": "Switch to another ERA", "B": "Reduce the dose of Vanrafia", "C": "Continue Vanrafia with close monitoring", "D": "Discontinue Vanrafia"}}
{"id": "iXEQzrK5mfiu", "question_type": "open_ended", "question": "Which of the following is recommended for patients taking Brinsupri to minimize dental side effects?", "options": {"A": "Avoid dental checkups", "B": "Brush and clean teeth as recommended by their dentist", "C": "Use only mouthwash", "D": "Increase sugar intake"}}
{"id": "6DutqKTgxkE1", "question_type": "open_ended", "question": "A 35-year-old woman with hereditary angioedema presents with an acute attack. She is currently pregnant in her third trimester and is not taking any ACE inhibitors. Which treatment option is most appropriate for her acute attack?", "options": {"A": "Firazyr administered subcutaneously for acute attack", "B": "TAKHZYRO administered subcutaneously for acute attack", "C": "ANDEMBRY administered subcutaneously for acute attack", "D": "TAKHZYRO administered subcutaneously for prophylaxis"}}
{"id": "JuZx5o6bkwUx", "question_type": "multi_choice", "question": "When counseling patients on Romvimza, what is the most important advice regarding concomitant medications and supplements?", "options": {"A": "Patients should avoid all over-the-counter products.", "B": "Only prescription medications need to be reported.", "C": "Patients may take any supplements without restriction.", "D": "Patients should inform their healthcare providers of all concomitant products, including over-the-counter products and supplements."}}
{"id": "Iq7ttdjm1uNa", "question_type": "open_ended_multi_choice", "question": "Which of the following statements about the cardiac electrophysiology of Datroway is correct?", "options": {"A": "At doses up to 10 mg/kg, a mean increase in the QTc interval greater than 20 ms was not observed.", "B": "Datroway causes a significant prolongation of the QTc interval at all tested doses.", "C": "QTc interval prolongation is dose-independent for Datroway.", "D": "QTc interval decreases with increasing doses of Datroway."}}
{"id": "uaEDXHSf0ahB", "question_type": "open_ended_multi_choice", "question": "A pregnant 35-year-old woman in her second trimester presents with painful urination, frequent urination, and lower abdominal pain. Urine culture reveals Escherichia coli, sensitive to multiple antibiotics. She denies any allergies or underlying health conditions. What is the best therapeutic approach for both symptom management and infection eradication?", "options": {"A": "Imipenem and cilastatin intravenously", "B": "Flavoxate hydrochloride orally for symptom relief plus an appropriate oral antibiotic", "C": "Sulopenem etzadroxil and probenecid (Orlynvah) orally", "D": "Flavoxate hydrochloride as monotherapy"}}
{"id": "0q5SVnFduHfZ", "question_type": "open_ended_multi_choice", "question": "A patient taking Modeyso experiences vomiting shortly after administration. What is the recommended action regarding the next dose?", "options": {"A": "Retake the dose immediately", "B": "Skip the next scheduled dose", "C": "Do not take another dose; resume Modeyso on the next regularly scheduled weekly day", "D": "Double the dose at the next administration"}}
{"id": "PGY8mdl46dyu", "question_type": "open_ended_multi_choice", "question": "A 42-year-old woman with metastatic NSCLC and an EGFR exon 19 deletion is being considered for first-line therapy. She is currently pregnant and has no history of thromboembolic events, cardiac disease, or hepatic/renal impairment. Which of the following treatment options should be avoided due to her pregnancy?", "options": {"A": "CYRAMZA in combination with erlotinib", "B": "Rozlytrek", "C": "LAZCLUZE (lazertinib plus amivantamab)", "D": "All of the above"}}
{"id": "yVQe7nA2ozj4", "question_type": "open_ended_multi_choice", "question": "A patient treated with Anzupgo develops a new episode of herpes zoster. What is the recommended clinical action?", "options": {"A": "Continue Anzupgo without interruption", "B": "Increase the dose of Anzupgo", "C": "Interrupt Anzupgo treatment until the episode resolves", "D": "Administer a live herpes zoster vaccine immediately"}}
{"id": "gk9CsFPKs953", "question_type": "multi_choice", "question": "A 65-year-old man with metastatic NSCLC and an EGFR exon 21 L858R mutation is being considered for first-line therapy. He has a history of hypertension controlled with medication, and chronic proteinuria (urine protein 1.8 g/24h). He is at increased risk for venous thromboembolism (VTE) due to prior DVT. Which treatment option is most suitable for his condition?", "options": {"A": "CYRAMZA in combination with erlotinib", "B": "Rozlytrek", "C": "LAZCLUZE (lazertinib plus amivantamab) with prophylactic anticoagulation", "D": "CYRAMZA in combination with docetaxel"}}
{"id": "M9pCiZ7lWgQr", "question_type": "open_ended_multi_choice", "question": "In the case of an Ekterly overdose, which action is NOT among the recommended steps?", "options": {"A": "Contacting the poison control help line", "B": "Consulting a medical toxicologist", "C": "Increasing the dose of Ekterly", "D": "Calling 1-800-222-1222"}}
{"id": "tzrYh3pCwsBQ", "question_type": "open_ended_multi_choice", "question": "A 38-year-old woman with metastatic pancreatic adenocarcinoma and NRG1 gene fusion is currently pregnant (first trimester). She has normal hepatic and cardiac function, and her neutrophil count is 2,000 cells/mm³. She is seeking systemic therapy for her cancer. Which of the following is the safest approach for her at this time?", "options": {"A": "Initiate BIZENGRI (zenocutuzumab) every 2 weeks", "B": "Start paclitaxel protein-bound particles for injectable suspension (albumin-bound) with gemcitabine", "C": "Begin Imbruvica (ibrutinib) therapy", "D": "Defer systemic therapy until after pregnancy"}}
{"id": "m0vxHxE1rk8E", "question_type": "open_ended_multi_choice", "question": "Given a 60-year-old male patient with hypoparathyroidism, severe chronic kidney disease (eGFR 20 mL/min/1.73 m²), and ongoing digoxin therapy for atrial fibrillation, with no history of bone cancer or radiation exposure, which medication would be the most appropriate and safest option to treat his hypoparathyroidism considering his renal status and current medications?", "options": {"A": "Ergocalciferol", "B": "Calcitriol", "C": "Yorvipath", "D": "Palopegteriparatide"}}
{"id": "STjDREVurIo8", "question_type": "open_ended", "question": "A 42-year-old woman presents with moderate to severe chronic hand eczema. She has a history of basal cell carcinoma and is currently undergoing regular skin examinations. She is not pregnant, not breastfeeding, and has no active infections. She previously failed topical corticosteroids. Which treatment regimen is most appropriate for her condition?", "options": {"A": "Initiate Anzupgo topical therapy with periodic skin examinations and sun protection measures.", "B": "Start Anzupgo topical therapy without any additional precautions.", "C": "Use Anzupgo in combination with oral JAK inhibitors.", "D": "Recommend Anzupgo for pediatric use."}}
{"id": "A1H5bTGAE7a8", "question_type": "open_ended_multi_choice", "question": "A 14-year-old patient with cystic fibrosis presents with recurrent respiratory infections, reduced forced vital capacity, and a history of elevated hepatic transaminases (ALT and AST). Genetic testing confirms homozygosity for the F508del mutation. The patient has mild hepatic impairment (Child-Pugh Class A) and is currently taking ciprofloxacin for a recent pulmonary exacerbation. Which drug regimen is most appropriate for long-term management of cystic fibrosis in this patient?", "options": {"A": "ALYFTREK at standard dosage, with monthly liver function monitoring.", "B": "SYMDEKO at standard dosage, with regular liver function monitoring.", "C": "SYMDEKO at reduced dosage due to ciprofloxacin co-administration.", "D": "ALYFTREK at reduced dosage due to ciprofloxacin co-administration."}}
{"id": "IeZVWVUG8q4K", "question_type": "multi_choice", "question": "Which statement best describes the contraindication profile of Lynozyfic?", "options": {"A": "Lynozyfic has multiple contraindications, including renal and hepatic impairment.", "B": "Lynozyfic is contraindicated in patients with hypersensitivity to its active ingredient.", "C": "Lynozyfic should not be used in elderly patients.", "D": "Lynozyfic has no listed contraindications."}}
{"id": "YC2mdNsOoZ3G", "question_type": "multi_choice", "question": "Which of the following is a recommended action if a patient receiving Hernexeos develops transaminase elevations during therapy?", "options": {"A": "Continue therapy without changes", "B": "Increase monitoring of renal function", "C": "Switch to a non-HER2 targeted therapy", "D": "Administer prophylactic antibiotics"}}
{"id": "dQtQnRJREF2X", "question_type": "open_ended_multi_choice", "question": "Is dosage adjustment recommended for patients with mild hepatic impairment receiving Datroway?", "options": {"A": "Yes, reduce the dosage", "B": "Yes, increase the dosage", "C": "No dosage adjustment is recommended", "D": "Discontinue Datroway"}}
{"id": "HTCXkPTLMizf", "question_type": "open_ended_multi_choice", "question": "For what reason should administration of Grafapex as a preparative regimen be withheld in the absence of an accessible stem cell donor?", "options": {"A": "Because profound myelosuppression with pancytopenia will occur in all patients", "B": "Because Grafapex requires donor stem cells for activation", "C": "Because the drug is ineffective without donor cells", "D": "Because of increased risk of renal toxicity"}}
{"id": "JfsclWPsbXSh", "question_type": "open_ended_multi_choice", "question": "In the case of a 72-year-old woman with unresectable, metastatic, hormone receptor-positive, HER2-negative breast cancer, previously treated with endocrine therapy and chemotherapy, and with a history of arterial thromboembolism currently managed with anticoagulation, which agent would be most appropriate for her ongoing cancer therapy when factoring in her age and existing health issues?", "options": {"A": "MVASI", "B": "DATROWAY", "C": "Ketorolac Tromethamine", "D": "None of the above"}}
{"id": "F5654G02qbOk", "question_type": "open_ended_multi_choice", "question": "A 45-year-old man with diffuse midline glioma (H3 K27M mutation, progressive after prior therapy) is being considered for treatment with MODEYSO. He is currently taking a strong CYP3A4 inhibitor for another condition. What is the most appropriate management strategy for his glioma therapy?", "options": {"A": "Start MODEYSO at the standard dose without adjusting for drug interactions.", "B": "Avoid using MODEYSO entirely due to his age.", "C": "Reduce the dose of MODEYSO if concomitant use with the CYP3A4 inhibitor cannot be avoided.", "D": "Discontinue the CYP3A4 inhibitor and start MODEYSO at a higher dose."}}
{"id": "OI82HMmk0NH3", "question_type": "open_ended_multi_choice", "question": "A 65-year-old man with metastatic NSCLC is found to have a ROS1 gene rearrangement by FDA-approved testing. He has a history of congestive heart failure (CHF) with reduced ejection fraction and is currently taking a medication known to prolong the QT interval. His hepatic and renal function are normal. Which of the following is the most appropriate next step in his systemic therapy?", "options": {"A": "Entrectinib (Rozlytrek)", "B": "Ipilimumab in combination with nivolumab", "C": "Telisotuzumab vedotin (EMRELIS)", "D": "Ipilimumab monotherapy"}}
{"id": "pNciJimU51DQ", "question_type": "open_ended_multi_choice", "question": "For a 28-year-old woman with severe alopecia areata who intends to get pregnant and has no renal or liver issues nor any current medications, which drug should be recommended as both safe and effective for her condition?", "options": {"A": "LEQSELVI administered orally once daily", "B": "Hydroxychloroquine sulfate administered orally once daily", "C": "Triamcinolone acetonide nasal spray once daily", "D": "LEQSELVI administered orally every other day with a drug scheduler"}}
{"id": "QXN0g9WeKzm6", "question_type": "multi_choice", "question": "A 32-year-old woman with Niemann-Pick disease type C and neurological symptoms is planning to become pregnant. She is currently taking N-acetyl-DL-leucine for symptomatic relief. Her physician is considering starting disease-modifying therapy. Which of the following is the most appropriate recommendation regarding drug therapy for her current situation?", "options": {"A": "Continue N-acetyl-DL-leucine and initiate Aqneursa immediately", "B": "Start Yargesa (miglustat) without contraception precautions", "C": "Discontinue N-acetyl-DL-leucine and start Aqneursa after confirming non-pregnant status and counseling on contraception", "D": "Initiate Opfolda (miglustat) in combination with Pombiliti regardless of pregnancy status"}}
{"id": "lOPCHwBhxJRt", "question_type": "open_ended_multi_choice", "question": "A 45-year-old breastfeeding woman presents with presbyopia and expresses concerns regarding medication safety. She has no prior ocular inflammation or retinal disease. What is the most suitable pharmacological therapy for her presbyopia?", "options": {"A": "Oraverse administered as an intraoral injection", "B": "VIZZ topical ocular drops, considering low systemic absorption", "C": "Mirvaso topical gel applied to the face", "D": "VIZZ topical ocular drops, contraindicated due to lactation"}}
{"id": "YTBr3t5KGNYb", "question_type": "open_ended_multi_choice", "question": "In the case of a 60-year-old woman who is pregnant and presents with BCG-unresponsive nonmuscle invasive bladder cancer with CIS, and who is otherwise healthy without any history of bladder perforation or mucosal compromise, which treatment is contraindicated because of possible fetal toxicity?", "options": {"A": "Nogapendekin alfa inbakicept-pmln (ANKTIVA) with Bacillus Calmette-Guérin (BCG)", "B": "Valrubicin intravesical therapy", "C": "Observation with planned cystectomy after delivery", "D": "Valrubicin intravesical therapy with Bacillus Calmette-Guérin (BCG)"}}
{"id": "WgFrZ9TCbNrH", "question_type": "open_ended_multi_choice", "question": "A pediatric patient, age 7, presents with a relapsed low-grade glioma and is confirmed to have a BRAF V600 mutation. There is no history of NF1, and the patient is not currently on CYP2C8 inhibitors or hormonal contraceptives. The family is worried about treatment-related risks to growth and fertility. What is the most suitable drug regimen for this patient, considering current evidence, safety profile, and regulatory approval?", "options": {"A": "OJEMDA administered once daily, with routine monitoring of growth and liver function.", "B": "VinCRIStine Sulfate administered intravenously weekly, despite lack of LGG-specific indication.", "C": "Gliadel Wafer implantation during surgery, although pediatric safety and efficacy are not established.", "D": "OJEMDA combined with hormonal contraceptives to prevent breakthrough bleeding."}}
{"id": "xh1IvOY03bdF", "question_type": "open_ended_multi_choice", "question": "What is the rationale for advising pregnancy testing prior to initiating Penpulimab-kcqx in females of reproductive potential?", "options": {"A": "Penpulimab-kcqx increases fertility.", "B": "Penpulimab-kcqx can cause fetal harm if administered during pregnancy.", "C": "Penpulimab-kcqx is only effective in pregnant women.", "D": "Penpulimab-kcqx prevents miscarriage."}}
{"id": "D1JAySPABrZd", "question_type": "open_ended_multi_choice", "question": "For a patient with multiple comorbidities, which statement is accurate regarding the use of Tryptyr?", "options": {"A": "Tryptyr should be avoided in patients with renal impairment due to contraindications.", "B": "Tryptyr can be considered for use regardless of contraindications, as none are listed.", "C": "Tryptyr is contraindicated in patients with a history of drug allergies.", "D": "Tryptyr is contraindicated in patients with cardiovascular disease."}}
{"id": "1PLTW7WAMArW", "question_type": "multi_choice", "question": "A 7-year-old boy is newly diagnosed with myelodysplastic syndrome (MDS) and is scheduled for allogeneic hematopoietic stem cell transplantation. He has no history of seizures, is not taking any CYP2C19 or CYP3A4 substrate medications, and is otherwise healthy. Which drug regimen is most appropriate as a preparative regimen for his transplant, considering age-specific safety and efficacy?", "options": {"A": "Lenalidomide, administered orally once daily.", "B": "INQOVI (cedazuridine and decitabine), administered orally in 28-day cycles.", "C": "TREOSULFAN (GRAFAPEX) in combination with fludarabine, administered intravenously for three consecutive days.", "D": "Busulfan, administered intravenously for two days."}}
{"id": "ETrQ7dbUwS1p", "question_type": "open_ended", "question": "A 65-year-old male with a history of chronic lung disease, bronchiectasis, and clubbing of fingers is being considered for pharmacologic therapy. He is currently taking oral estrogen for prostate cancer management and insulin for type 2 diabetes. Which drug is most suitable for treating his bronchiectasis, considering his comorbidities and age?", "options": {"A": "GENOTROPIN, with dose adjustment due to age and concurrent estrogen therapy", "B": "Brinsupri, at the standard adult dose with regular monitoring for dermatologic and dental adverse effects", "C": "SYMDEKO, with dose reduction due to possible hepatic impairment", "D": "GENOTROPIN, with increased monitoring for glucose intolerance and neoplasm risk"}}
{"id": "2j0lNsa4KPxB", "question_type": "multi_choice", "question": "For a clinical trial involving Modeyso, which exclusion criteria based on contraindications would be supported by the drug's official documentation?", "options": {"A": "Exclude patients with liver failure", "B": "Exclude patients with known hypersensitivity to Modeyso", "C": "No exclusion criteria based on contraindications are required", "D": "Exclude pregnant women"}}
{"id": "m37Yr57EK0j1", "question_type": "open_ended_multi_choice", "question": "Based on mutagenicity testing, which statement most accurately reflects the findings for the drug Ibtrozi?", "options": {"A": "Ibtrozi was mutagenic in the in vitro bacterial reverse mutation (Ames) assay.", "B": "Ibtrozi was not mutagenic in the in vitro bacterial reverse mutation (Ames) assay and additional mutagenicity tests.", "C": "Ibtrozi was clastogenic in the in vivo micronucleus study in rats.", "D": "Ibtrozi induced aneugenicity in rat bone marrow and liver."}}
{"id": "DdKMYm5Z3tnA", "question_type": "open_ended_multi_choice", "question": "A 35-year-old woman in her second trimester of pregnancy reports dysuria, increased urinary frequency, and suprapubic discomfort. Her urine culture grows Escherichia coli, which is sensitive to several antibiotics. She has no drug allergies, renal issues, or other medical problems. What is the most suitable treatment plan to address both her symptoms and the infection?", "options": {"A": "Imipenem and cilastatin intravenously", "B": "Flavoxate hydrochloride orally for symptom relief plus an appropriate oral antibiotic", "C": "Sulopenem etzadroxil and probenecid (Orlynvah) orally", "D": "Flavoxate hydrochloride as monotherapy"}}
{"id": "SMf8cubL4ecc", "question_type": "open_ended_multi_choice", "question": "A 72-year-old with mild cognitive impairment from Alzheimer’s disease is a candidate for medication. Genetic testing shows ApoE ε4 homozygosity. The patient has no hypersensitivity history, is not on antithrombotics, and MRI reveals no microhemorrhages or superficial siderosis. Which treatment approach is most appropriate?", "options": {"A": "Kisunla (donanemab-azbt), with enhanced clinical vigilance for ARIA and regular MRI monitoring", "B": "Kisunla (donanemab-azbt), without genetic testing or MRI monitoring", "C": "Kisunla (donanemab-azbt), contraindicated due to age", "D": "No drug therapy recommended due to ApoE ε4 homozygosity"}}
{"id": "umtcsviqYHXP", "question_type": "open_ended_multi_choice", "question": "A 54-year-old patient with primary biliary cholangitis experiences ongoing pruritus, raised alkaline phosphatase, and has a history of cirrhosis now complicated by ascites. She is intolerant to ursodeoxycholic acid and currently takes a statin for hyperlipidemia. What is the best alternative drug regimen to manage her condition?", "options": {"A": "Elafibranor once daily as monotherapy", "B": "Colcrys daily for long-term management", "C": "Budesonide inhalation twice daily", "D": "Supportive care only; avoid Elafibranor due to decompensated cirrhosis"}}
{"id": "ZmQEPev9S1PN", "question_type": "open_ended_multi_choice", "question": "A 59-year-old woman, currently pregnant, presents with BCG-unresponsive nonmuscle invasive bladder cancer with carcinoma in situ. She is asking for guidance on the safest medication to use. Which statement most appropriately addresses the correct drug selection for this patient?", "options": {"A": "Gemcitabine is preferred due to its established safety in pregnancy.", "B": "Anktiva can be used safely during pregnancy because systemic exposure is low.", "C": "Both Anktiva and Gemcitabine are contraindicated in pregnancy due to potential fetal harm.", "D": "Gemcitabine is recommended because it is not absorbed systemically."}}
{"id": "SyKNeBkDwD9y", "question_type": "open_ended", "question": "A 62-year-old man with metastatic ROS1-positive non-small cell lung carcinoma is being considered for IBTROZI therapy. He has a history of paroxysmal atrial fibrillation and is currently taking amiodarone, a known QTc-prolonging antiarrhythmic. What is the most appropriate course of action regarding IBTROZI initiation?", "options": {"A": "Start IBTROZI and continue amiodarone, monitoring ECG closely.", "B": "Avoid IBTROZI due to increased risk of QTc prolongation with concomitant amiodarone.", "C": "Start IBTROZI at a reduced dose with amiodarone.", "D": "Start IBTROZI only if the patient discontinues amiodarone and is stable off QTc-prolonging drugs."}}
{"id": "LLXEgKdW8mP7", "question_type": "multi_choice", "question": "A 42-year-old woman with end-stage renal disease on hemodialysis for six months presents with anemia. She has a history of uncontrolled hypertension and is currently being evaluated for possible active malignancy. Which of the following is the most appropriate course of action regarding vadadustat therapy for her anemia?", "options": {"A": "Do not initiate vadadustat due to uncontrolled hypertension and possible active malignancy.", "B": "Start vadadustat at the lowest effective dose, monitoring for cardiovascular events.", "C": "Begin fedratinib with thiamine supplementation.", "D": "Recommend the homeopathic combination for anemia management."}}
{"id": "XFZt8lbtuScg", "question_type": "open_ended_multi_choice", "question": "What is the appropriate response when acute gallbladder disease arises in a patient receiving Qfitlia therapy?", "options": {"A": "Consider interruption or discontinuation of Qfitlia", "B": "Increase the Qfitlia dose", "C": "Add a statin", "D": "Continue Qfitlia without changes"}}
{"id": "y8UbLE8JId21", "question_type": "open_ended_multi_choice", "question": "A 68-year-old female patient, whose epilepsy is managed with valproic acid, is hospitalized for a complicated urinary tract infection. Her kidney function is intact and she is not pregnant. Which drug poses a significant interaction with her current medication that could predispose her to seizures and should therefore be avoided?", "options": {"A": "Flavoxate Hydrochloride", "B": "Imipenem and Cilastatin", "C": "Gepotidacin", "D": "Both Flavoxate Hydrochloride and Gepotidacin"}}
{"id": "XQci09i1mcWK", "question_type": "multi_choice", "question": "A 60-year-old male with recurrent glioblastoma multiforme is being evaluated for systemic therapy. He has a history of hypertension that is well-controlled with medication and no evidence of recent surgery or wound healing complications. Genetic testing does not reveal an IDH1 or IDH2 mutation. Which of the following is the most appropriate treatment option for this patient?", "options": {"A": "Avastin administered intravenously every 2 weeks", "B": "Zortress administered in combination with tacrolimus and corticosteroids", "C": "Voranigo administered orally once daily", "D": "Voranigo in combination with a CYP1A2 inhibitor"}}
{"id": "MqzywX4tb9Pp", "question_type": "open_ended_multi_choice", "question": "A 72-year-old female with relapsed small cell lung cancer (SCLC) presents for second-line therapy. She previously responded to first-line chemotherapy and is now 60 days post-treatment. She has a history of frequent diarrhea and is at increased risk for dehydration. Which treatment option should be avoided due to her specific risk factors?", "options": {"A": "Imdelltra, administered intravenously with step-up dosing", "B": "Topotecan capsules, standard oral dosing for 5 days every 21 days", "C": "Ipilimumab, administered in combination with nivolumab", "D": "Topotecan capsules, dose reduced for age and diarrhea risk"}}
{"id": "klgpSZiRxwSe", "question_type": "open_ended_multi_choice", "question": "A 52-year-old man diagnosed with schizophrenia and benign prostatic hyperplasia (BPH) requires ongoing antipsychotic treatment. He does not have renal or hepatic dysfunction, and his cognition is normal. Taking into account his BPH and the potential for urinary retention, which antipsychotic agent would be most suitable for him?", "options": {"A": "Cobenfy (xanomeline and trospium chloride), standard adult dose", "B": "Abilify Maintena (aripiprazole), standard adult dose", "C": "Cobenfy (xanomeline and trospium chloride), reduced dose for geriatric patients", "D": "Abilify Maintena (aripiprazole), reduced dose for CYP2D6 poor metabolizers"}}
{"id": "FaiAXmndjxhZ", "question_type": "open_ended", "question": "A 35-year-old woman with chronic rhinosinusitis and nasal polyps, who is currently pregnant, presents for management of her symptoms. She previously underwent ethmoid sinus surgery. She is concerned about fetal safety and wants to minimize systemic corticosteroid exposure. Which of the following is the most appropriate recommendation?", "options": {"A": "Initiate Sinuva sinus implant after discussing potential risks and benefits", "B": "Start fluticasone propionate nasal spray for long-term control", "C": "Apply mometasone furoate cream to the nasal mucosa", "D": "Recommend a drug holiday from all corticosteroids until after pregnancy"}}
{"id": "vh9BIhCWvOk4", "question_type": "open_ended_multi_choice", "question": "A 67-year-old man with non-alcoholic steatohepatitis (NASH) and moderate liver fibrosis (F2) is being considered for drug therapy. He has mild renal impairment (eGFR 55 mL/min/1.73 m²) and is currently taking atorvastatin 80 mg daily for hyperlipidemia. Which drug regimen is most appropriate for his NASH, considering drug interactions and dosage adjustments?", "options": {"A": "Resmetirom once daily with atorvastatin reduced to 40 mg daily", "B": "Pentoxifylline extended-release tablets twice daily with atorvastatin 80 mg daily", "C": "Resmetirom once daily with atorvastatin 80 mg daily", "D": "Dapagliflozin once daily with atorvastatin 80 mg daily"}}
{"id": "cUjSwPtipNv3", "question_type": "open_ended_multi_choice", "question": "A 68-year-old man with pulmonary arterial hypertension (WHO Group 1) and moderate hepatic impairment is being considered for drug therapy. He has no history of bleeding disorders or cyclosporine use. Which drug is the most suitable for his condition?", "options": {"A": "Ambrisentan once daily", "B": "Macitentan once daily", "C": "Sotatercept-csrk every three weeks", "D": "Ambrisentan in combination with tadalafil"}}
{"id": "M8Wx4qqgQwkL", "question_type": "open_ended_multi_choice", "question": "A 15-year-old patient with a Grade 2 oligodendroglioma and a confirmed IDH1 mutation has undergone subtotal resection. The patient is otherwise healthy, not pregnant, and not taking any drugs that affect CYP1A2 activity. Based on efficacy and safety for this age group, what is the most suitable pharmacological therapy for this patient?", "options": {"A": "Avastin administered intravenously every 2 weeks", "B": "Zortress administered orally twice daily", "C": "Voranigo administered orally once daily", "D": "Avastin in combination with carboplatin and paclitaxel"}}
{"id": "iwDHSswUy0gT", "question_type": "multi_choice", "question": "A 59-year-old woman with extensive-stage small cell lung cancer and autosomal dominant inheritance presents for therapy after progression on platinum-based chemotherapy. She is currently pregnant and seeks advice on the safest treatment option for her condition. Which drug should be strictly avoided due to its risk profile in pregnancy?", "options": {"A": "Imdelltra, administered intravenously with step-up dosing", "B": "Topotecan capsules, administered orally as per standard schedule", "C": "Ipilimumab, administered every 3 weeks", "D": "Supportive care only, with no cytotoxic or immunotherapy agents"}}
{"id": "xuEWZgRMD81U", "question_type": "open_ended", "question": "A 32-year-old woman with primary motor cortex epilepsy presents for seizure management. She is currently 10 weeks pregnant and has a family history of congenital heart defects. Which of the following is the most appropriate recommendation regarding the use of Phenytoin Sodium for her seizure control?", "options": {"A": "Phenytoin Sodium should be initiated at standard dosing, as pregnancy does not affect its safety profile.", "B": "Phenytoin Sodium is contraindicated due to increased risk of congenital malformations and fetal hydantoin syndrome; alternative antiepileptic therapy should be considered.", "C": "Phenytoin Sodium is preferred in pregnancy if administered intravenously at a slow rate.", "D": "Phenytoin Sodium can be used safely during pregnancy if vitamin K is administered before delivery."}}
{"id": "2jeQsU4eJX7P", "question_type": "open_ended_multi_choice", "question": "A woman with ALG12-CDG who is currently pregnant presents with recurrent seizures and mild edema. Her physician is considering pharmacologic management for her symptoms. Which statement best reflects the use of acetazolamide in this patient?", "options": {"A": "Acetazolamide is contraindicated in pregnancy due to teratogenicity and should not be used.", "B": "Acetazolamide is the first-line therapy for edema and seizures in pregnant women with ALG12-CDG.", "C": "Acetazolamide can be used safely in pregnancy without any fetal risk.", "D": "Acetazolamide should be used only if the potential benefit justifies the potential risk to the fetus."}}
{"id": "wtODxw1UqTwJ", "question_type": "open_ended_multi_choice", "question": "A 67-year-old male with a history of hypertension, hyperlipidemia, and gout presents for management of his blood pressure. His renal function is mildly impaired (eGFR 55 mL/min), and he has no liver dysfunction. He is not currently on lithium therapy. Given his history of gout flares and concern about medications that could exacerbate his condition, which antihypertensive medication would be most suitable for him?", "options": {"A": "Chlorthalidone (THALITONE), once daily", "B": "Aprocitentan (TRYVIO), once daily in combination with other antihypertensives", "C": "Bosentan (TRACLEER), twice daily", "D": "Chlorthalidone (THALITONE), twice daily"}}
{"id": "cdGhBOE3po3z", "question_type": "multi_choice", "question": "A 35-year-old woman with hereditary angioedema is planning to become pregnant and requires prophylactic therapy. She is concerned about fetal safety and prefers a medication with reassuring animal data and minimal warnings. Which prophylactic agent is most appropriate based on available safety information?", "options": {"A": "Kalbitor", "B": "TAKHZYRO", "C": "ANDEMBRY", "D": "None of the above"}}
{"id": "aRGWJGy8xErt", "question_type": "open_ended_multi_choice", "question": "A 58-year-old man with hypoparathyroidism and infertility disorder is being considered for ergocalciferol therapy. He is currently taking thiazide diuretics for hypertension. What is the most appropriate recommendation regarding ergocalciferol use in this patient?", "options": {"A": "Ergocalciferol can be safely administered at standard doses regardless of concurrent thiazide diuretic use.", "B": "Ergocalciferol should be avoided due to the risk of hypercalcemia when used with thiazide diuretics in hypoparathyroid patients.", "C": "Clopidogrel bisulfate should be used instead of ergocalciferol for hypoparathyroidism.", "D": "Ergocalciferol should be administered only during a drug holiday from thiazide diuretics."}}
{"id": "SPCz5l3w3BBp", "question_type": "open_ended_multi_choice", "question": "If a patient develops abnormal liver tests during Wayrilz therapy, what is the recommended management if drug-induced liver injury (DILI) is suspected?", "options": {"A": "Withhold Wayrilz and discontinue upon confirmation of DILI", "B": "Continue Wayrilz at a reduced dose", "C": "Switch to another BTK inhibitor", "D": "Administer corticosteroids"}}
{"id": "LqpJapzEFhof", "question_type": "open_ended_multi_choice", "question": "Which of the following best describes a recommended instruction for patients using Andembry?", "options": {"A": "Inject Andembry intravenously without training.", "B": "Use Andembry for any condition with similar symptoms.", "C": "Do not give Andembry to other people, even if they have the same symptoms.", "D": "Mix Andembry with herbal supplements before injection."}}
{"id": "u23yaASLIgjb", "question_type": "open_ended_multi_choice", "question": "A 55-year-old woman with metastatic esophageal squamous cell carcinoma and PD-L1 CPS of 12 has already received platinum-based chemotherapy. She is currently on ritonavir for HIV and has normal liver function. Which agent should be selected for her second-line treatment?", "options": {"A": "Docetaxel anhydrous monotherapy, administered every 3 weeks", "B": "Tevimbra as a single agent, administered every 3 weeks", "C": "Keytruda QLEX as a single agent, administered every 3 weeks", "D": "Docetaxel anhydrous in combination with cisplatin and fluorouracil, administered every 3 weeks"}}
{"id": "3QPH16wpL6Be", "question_type": "multi_choice", "question": "A 62-year-old man with non-alcoholic steatohepatitis (NASH) and advanced liver fibrosis (stage F3) presents for treatment. He has a history of decompensated cirrhosis (Child-Pugh Class B), chronic kidney disease (eGFR 50 mL/min/1.73 m²), and is currently taking clopidogrel for coronary artery disease. Which of the following drugs is most appropriate for his NASH management?", "options": {"A": "Rezdiffra, with dose reduction due to clopidogrel", "B": "Pentoxifylline extended-release tablets, 400 mg three times daily", "C": "Farxiga, 10 mg once daily", "D": "Rezdiffra, standard dose"}}
{"id": "tMEdURibL2NJ", "question_type": "multi_choice", "question": "When considering pharmacological therapy for presbyopia in adults, which brand drug acts as a cholinergic agonist?", "options": {"A": "Xalatan", "B": "Timoptic", "C": "Vizz", "D": "Alrex"}}
{"id": "uuaRwMBjrL4Q", "question_type": "open_ended_multi_choice", "question": "A 42-year-old woman with low-risk myelodysplastic syndrome and transfusion-dependent anemia is found to have a deletion 5q cytogenetic abnormality. She is planning to become pregnant and is currently not using contraception. Which drug should be strictly avoided in her treatment due to her reproductive plans?", "options": {"A": "Imetelstat sodium, 7.5 mg/kg intravenously every 4 weeks", "B": "Lenalidomide, 10 mg orally once daily", "C": "Inqovi, 35 mg orally once daily for 5 consecutive days every 28 days", "D": "Inqovi, 20 mg orally once daily for 5 consecutive days every 28 days"}}
{"id": "NfOPQJy8wl9A", "question_type": "open_ended_multi_choice", "question": "A 10-year-old child with congenital dyserythropoietic anemia type 1B presents with severe anemia, growth delay, and splenomegaly. The patient has a history of recurrent infections and is currently experiencing neutropenia. The care team is considering pharmacologic options to reduce the risk of infection and improve neutrophil counts. Which of the following is the most appropriate drug for this patient, considering age and disease profile?", "options": {"A": "Fludarabine phosphate administered at standard adult dosing for 5 days every 28 days", "B": "Sitagliptin and metformin hydrochloride combination therapy, twice daily", "C": "Filgrastim administered subcutaneously at 5 mcg/kg/day, adjusted for pediatric use", "D": "Fludarabine phosphate in combination with pentostatin"}}
{"id": "7WtSk8SBBM4Z", "question_type": "open_ended_multi_choice", "question": "When Wayrilz is co-administered with a drug that is a CYP3A substrate, what monitoring or adjustment should be considered?", "options": {"A": "No monitoring is necessary", "B": "Decrease the dose of the CYP3A substrate", "C": "Monitor for adverse reactions of the CYP3A substrate and consider dosage adjustment", "D": "Increase the dose of Wayrilz"}}
{"id": "V3fjLOymLTLr", "question_type": "open_ended_multi_choice", "question": "Which of the following statements best describes the use of Wayrilz in pediatric populations?", "options": {"A": "Wayrilz is approved for use in children with chronic immune thrombocytopenia.", "B": "Safety and efficacy of Wayrilz in children have not been established.", "C": "Wayrilz is contraindicated in children under 12 years old.", "D": "Wayrilz is recommended for children with liver problems."}}
{"id": "F0rxm86PECoJ", "question_type": "open_ended_multi_choice", "question": "If a clinician suspects RSV in a patient who was recently given Enflonsia, but the rapid antigen test does not confirm infection, what is the recommended subsequent action?", "options": {"A": "Repeat the rapid antigen test", "B": "Initiate empirical antiviral therapy", "C": "Confirm diagnosis using an RT-PCR assay", "D": "Perform a chest X-ray"}}
{"id": "iYVZMJstzHqz", "question_type": "multi_choice", "question": "During the first 7 days after initiating Qfitlia, how should breakthrough bleeding be managed?", "options": {"A": "Use reduced dose and frequency of clotting factor concentrates (CFC) or bypassing agents (BPA)", "B": "Discontinue Qfitlia and administer antifibrinolytics", "C": "Manage the bleed using the patient's prior dosing regimen of CFC or BPA", "D": "Double the standard dose of CFC/BPA"}}
{"id": "gx1cuW897yrM", "question_type": "open_ended_multi_choice", "question": "A 55-year-old woman, pregnant and with a background of feeding difficulties in infancy, presents with metastatic esophageal squamous cell carcinoma that has progressed despite platinum-based chemotherapy. Given her pregnancy and concerns about fetal safety, which of the following therapies should be avoided in her current management?", "options": {"A": "Tislelizumab-jsgr as a single agent", "B": "Nivolumab and hyaluronidase as monotherapy", "C": "Lenvatinib monotherapy", "D": "All of the above"}}
{"id": "x1FoRfOcC4Oq", "question_type": "open_ended_multi_choice", "question": "A 35-year-old woman with moderate-to-severe atopic dermatitis is experiencing repeated episodes of itching, facial erythema, and lichenified skin in the flexures. Her history includes food intolerance and increased IgE levels. Topical corticosteroids have not provided adequate symptom control. She is not pregnant, is free of active infections, and is not on any immunosuppressive drugs. Which medication regimen is most appropriate for her ongoing care?", "options": {"A": "DMT SUIK administered intravenously every 2 weeks for systemic control", "B": "Doxepin hydrochloride cream applied topically for up to 8 days for pruritus relief", "C": "Lebrikizumab-lbkz administered subcutaneously every 2 weeks as a targeted therapy", "D": "Doxepin hydrochloride cream applied daily for 3 months for long-term control"}}
{"id": "zFMNCc2YGXc4", "question_type": "open_ended", "question": "A 45-year-old woman with chronic dry eye disease is seeking a new treatment. She is not pregnant or breastfeeding, has no history of glaucoma or ocular infections, and does not wear contact lenses. She previously underwent cataract surgery and is concerned about delayed healing and secondary infections. Which of the following is the most suitable pharmacologic option for her ongoing dry eye management?", "options": {"A": "Lotemax SM, administered daily for long-term management", "B": "Xiidra, administered as an ophthalmic solution twice daily", "C": "Lotemax SM, administered only during drug holidays", "D": "TRYPTYR, administered while wearing contact lenses"}}
{"id": "x2yXl2Eq3arA", "question_type": "open_ended_multi_choice", "question": "A 28-year-old pregnant woman, currently in her second trimester, has congenital hemophilia A (factor VIII deficiency) and no previous history of inhibitors or hypersensitivity. As she presents for routine prophylaxis, which approach should be taken for her prophylactic therapy?", "options": {"A": "Alhemo, as the benefits always outweigh the risks in pregnancy", "B": "Hemlibra, used only if the potential benefit outweighs the risk to the fetus", "C": "Alhemo, with no need for contraception or risk assessment", "D": "Hemlibra, as it is completely safe in pregnancy"}}
{"id": "E4LfF5Buc20d", "question_type": "open_ended_multi_choice", "question": "Given a 54-year-old female patient with unresectable, metastatic, hormone receptor-positive, HER2-negative breast cancer who has received both endocrine-based therapy and chemotherapy, and who has mild renal impairment (creatinine clearance 60 mL/min) without any history of interstitial lung disease, pneumonitis, pregnancy, or breastfeeding, which drug should be selected for her cancer therapy considering these factors?", "options": {"A": "MVASI", "B": "Ketorolac Tromethamine", "C": "DATROWAY", "D": "None of the above"}}
{"id": "XSyVv1RPFBvq", "question_type": "multi_choice", "question": "A 10-year-old child weighing 25 kg is newly diagnosed with Niemann-Pick disease type C and presents with progressive gait ataxia, cognitive impairment, and hepatomegaly. The patient is not currently taking any other medications and has normal renal function. The family is concerned about long-term safety and wants a treatment specifically approved for pediatric use in NPC. Which drug is the most appropriate choice for this patient, considering the safety and efficacy profile?", "options": {"A": "Aqneursa administered at the recommended dosage for pediatric patients ≥15 kg", "B": "Yargesa (miglustat) administered at standard adult dosing", "C": "Opfolda (miglustat) in combination with Pombiliti", "D": "N-acetyl-DL-leucine monotherapy"}}
{"id": "YUGTJiUKCZue", "question_type": "open_ended_multi_choice", "question": "In which type of patients is the use of Blujepa considered contraindicated?", "options": {"A": "Patients with a history of severe hypersensitivity to Blujepa", "B": "Patients with mild renal impairment", "C": "Patients with controlled hypertension", "D": "Patients with a history of seasonal allergies"}}
{"id": "iO2oc9OFuzah", "question_type": "multi_choice", "question": "What risk is increased when Lynozyfic is administered with CYP substrates?", "options": {"A": "Risk of reduced cytokine release", "B": "Risk of decreased efficacy of Lynozyfic", "C": "Risk of enhanced metabolism of CYP substrates", "D": "Risk of adverse reactions related to CYP substrates"}}
{"id": "tqMUQmRfWXWa", "question_type": "open_ended_multi_choice", "question": "A woman aged 68, known to have gout and chronic kidney disease (creatinine clearance 18 mL/min), comes in with symptoms indicative of an uncomplicated urinary tract infection. She is allergic to cephalosporins but has no other antibiotic allergies and is not taking any drugs that would cause major interactions. Which antibiotic regimen should be chosen for her UTI?", "options": {"A": "Sulopenem etzadroxil and probenecid (Orlynvah) orally", "B": "Imipenem and cilastatin intravenously with renal dose adjustment", "C": "Flavoxate hydrochloride orally", "D": "Sulopenem etzadroxil and probenecid (Orlynvah) with a drug holiday"}}
{"id": "zDOITpcj11im", "question_type": "open_ended_multi_choice", "question": "Considering her history of urinary retention, current breastfeeding status, and plans to spend several weeks in a hot environment, which treatment for primary axillary hyperhidrosis should a 35-year-old woman not use?", "options": {"A": "Qbrexza (glycopyrronium), topical wipes once daily", "B": "Sofdra (sofpironium bromide), topical gel once daily", "C": "Oxytrol for Women (oxybutynin), transdermal patch twice weekly", "D": "Both Qbrexza and Sofdra should be avoided"}}
{"id": "n1ZnyHX7R7a3", "question_type": "multi_choice", "question": "A 7-year-old girl with relapsed low-grade glioma is found to have a BRAF V600 mutation. She is currently taking a moderate CYP2C8 inhibitor for another condition. Her parents are concerned about the risk of growth reduction and want to know which drug would be most appropriate for her tumor treatment. Which option is the most suitable for this patient?", "options": {"A": "Tovorafenib administered once daily at the recommended pediatric dose", "B": "NEUPOGEN administered daily as supportive care", "C": "Etoposide administered intravenously every 3 weeks", "D": "Tovorafenib administered once daily, but with concurrent moderate CYP2C8 inhibitor"}}
{"id": "VLYEoKrFXIUv", "question_type": "multi_choice", "question": "A 42-year-old woman with newly diagnosed pulmonary arterial hypertension (PAH, WHO Group 1) presents for initial therapy. She is not pregnant, has no history of bleeding disorders, and is not taking any prostacyclin or antithrombotic agents. Her platelet count and hemoglobin are within normal limits. Which of the following is the most appropriate drug to initiate for her condition, considering efficacy and safety?", "options": {"A": "Winrevair administered according to recommended dosing schedule", "B": "Vasopressin administered intravenously", "C": "Epinephrine administered as a continuous infusion", "D": "Vasopressin combined with indomethacin"}}
{"id": "foNHJdYPeese", "question_type": "multi_choice", "question": "A 34-year-old woman with familial chylomicronemia syndrome presents with recurrent pancreatitis, hepatosplenomegaly, and eruptive xanthomas. She is currently 10 weeks pregnant and is seeking a medication to reduce her triglyceride levels. She is concerned about the safety of drug therapy during pregnancy. Which of the following is the most appropriate pharmacological option for her condition?", "options": {"A": "MYCOPHENOLATE MOFETIL, combined with a drug holiday during the first trimester.", "B": "MYCOPHENOLATE MOFETIL, with strict contraception counseling and regular pregnancy testing.", "C": "TRYNGOLZA administered as an adjunct to diet, with careful monitoring for hypersensitivity reactions.", "D": "TRYNGOLZA, but only after delivery due to lack of safety data in pregnancy."}}
{"id": "NxWxraY9x9Em", "question_type": "open_ended_multi_choice", "question": "Which of the following statements best describes the risk of fetal harm associated with Gomekli administration during pregnancy?", "options": {"A": "Gomekli is safe for use during pregnancy", "B": "Gomekli may cause fetal harm or loss of pregnancy", "C": "Gomekli increases the risk of gestational diabetes", "D": "Gomekli prevents miscarriage"}}
{"id": "JOqWPlCJBl06", "question_type": "open_ended", "question": "Which statement best describes the handling of Tryptyr to prevent contamination?", "options": {"A": "Do not touch the vial tip to the eye or other surfaces.", "B": "Always wear gloves when administering Tryptyr.", "C": "Sterilize the vial tip before each use.", "D": "Store Tryptyr in a sterile environment."}}
{"id": "AaADpuj9lD8O", "question_type": "open_ended_multi_choice", "question": "Which option most appropriately summarizes the reversibility of fertility impairment in males resulting from Emrelis exposure?", "options": {"A": "The effect is reversible", "B": "The effect is irreversible", "C": "The reversibility of the effect is unknown", "D": "Emrelis does not impair male fertility"}}
{"id": "JA3i9wVn577I", "question_type": "open_ended_multi_choice", "question": "In the context of a regulatory submission for Qfitlia, which of the following is appropriate to list as a contraindication?", "options": {"A": "There are no contraindications for Qfitlia.", "B": "Qfitlia is contraindicated in patients with renal failure.", "C": "Qfitlia is contraindicated in patients with a history of drug allergy.", "D": "Qfitlia is contraindicated in elderly patients."}}
{"id": "LSgBu2DqAWe4", "question_type": "multi_choice", "question": "A 52-year-old man with primary IgAN and UPCR of 1.8 g/g is being considered for VANRAFIA therapy to reduce proteinuria. He has a history of severe hepatic impairment. Which of the following is the most appropriate recommendation regarding VANRAFIA use in this patient?", "options": {"A": "Initiate VANRAFIA without dose adjustment and monitor liver enzymes regularly.", "B": "Do not initiate VANRAFIA due to severe hepatic impairment.", "C": "Start VANRAFIA at half the recommended dose and monitor for hepatotoxicity.", "D": "Begin VANRAFIA therapy and add a CYP3A inducer to reduce adverse effects."}}
{"id": "VtgYND9B5Nk1", "question_type": "multi_choice", "question": "A 68-year-old woman with newly diagnosed locally advanced ROS1-positive non-small cell lung carcinoma is being considered for targeted therapy. She has a history of osteoporosis and is currently taking a proton pump inhibitor for chronic gastroesophageal reflux disease. Which of the following is the most appropriate approach regarding the use of taletrectinib for her treatment?", "options": {"A": "Initiate taletrectinib 600 mg orally once daily without modification.", "B": "Initiate taletrectinib 600 mg orally once daily, but discontinue the proton pump inhibitor or adjust antacid timing.", "C": "Taletrectinib is contraindicated due to her age.", "D": "Taletrectinib is contraindicated due to her osteoporosis."}}
{"id": "ZsYMJrrdKJ2O", "question_type": "multi_choice", "question": "A clinical trial protocol is being designed for a new medication. If the drug brand name is Ekterly, which exclusion criteria based on contraindications should be considered?", "options": {"A": "Exclude patients with a history of anaphylaxis to Ekterly.", "B": "Exclude patients with cardiac arrhythmias.", "C": "No exclusion criteria based on contraindications are necessary.", "D": "Exclude patients with severe renal impairment."}}
{"id": "DWSL4hlQ0iux", "question_type": "multi_choice", "question": "A 62-year-old woman is newly diagnosed with acute myeloid leukemia with inv3(p21;q26.2). Her leukemia is confirmed to be CD33-positive. She has a history of mild hepatic impairment (ALT and AST mildly elevated), but no history of cardiac disease or prior anthracycline exposure. She is not pregnant and does not plan to undergo hematopoietic stem cell transplantation. Which drug regimen is most appropriate for initial induction therapy in this patient, considering her disease subtype and comorbidities?", "options": {"A": "Mitoxantrone administered intravenously in combination with cytarabine, every 3 weeks.", "B": "Daunorubicin hydrochloride in combination with cytarabine, every 3 weeks.", "C": "Mylotarg (gemtuzumab ozogamicin) in combination with standard chemotherapy, administered every 2 weeks.", "D": "Mylotarg monotherapy, administered every 2 weeks."}}
{"id": "ZrEJJC5BGqgc", "question_type": "multi_choice", "question": "A 10-year-old boy with primary axillary hyperhidrosis and chronic renal failure is being considered for topical anticholinergic therapy. He is not taking any other medications. Which treatment option is most appropriate for his condition?", "options": {"A": "Qbrexza (glycopyrronium), topical wipes once daily", "B": "Oxytrol for Women (oxybutynin), transdermal patch twice weekly", "C": "Sofdra (sofpironium bromide), topical gel once daily", "D": "None of the above are appropriate due to his age and renal impairment"}}
{"id": "n9eBY0zqDjej", "question_type": "open_ended_multi_choice", "question": "A 34-year-old woman comes in with severe alopecia areata. She is breastfeeding her infant, has normal renal and hepatic function, and is not taking any other drugs. Which medication is the best treatment option for her condition?", "options": {"A": "LEQSELVI administered orally once daily", "B": "Hydroxychloroquine sulfate administered orally once daily", "C": "Triamcinolone acetonide nasal spray once daily", "D": "LEQSELVI administered orally every other day with a drug holiday every 2 weeks"}}
{"id": "w1KUCg6tURLA", "question_type": "multi_choice", "question": "Which of the following statements best describes the effect of Emrelis on fertility in females?", "options": {"A": "Emrelis permanently impairs female fertility", "B": "Emrelis has no effect on female fertility", "C": "Emrelis may impair female fertility, but the effect is reversible", "D": "Emrelis improves female fertility"}}
{"id": "4UkKzzqTt8SQ", "question_type": "open_ended_multi_choice", "question": "A pregnant 42-year-old woman in her second trimester presents with non-alcoholic steatohepatitis (NASH) and moderate fibrosis. She is interested in drug treatment options. Based on known safety profiles, which drug poses potential risks to the fetus and should not be used?", "options": {"A": "Pentoxifylline extended-release tablets", "B": "Resmetirom administered once daily", "C": "Dapagliflozin once daily", "D": "Pentoxifylline immediate-release tablets"}}
{"id": "aSEvNKreWOam", "question_type": "multi_choice", "question": "A 7-year-old boy with Duchenne muscular dystrophy presents with progressive muscle weakness, calf muscle pseudohypertrophy, and elevated creatine kinase. Genetic testing confirms a DMD gene mutation amenable to exon 53 skipping. He has no history of renal impairment or arrhythmia. Which drug is the most appropriate for his treatment, considering his age and genetic profile?", "options": {"A": "Viltepso administered intravenously once weekly", "B": "Exondys 51 administered intravenously once weekly", "C": "Duvyzat administered orally twice daily", "D": "No drug therapy is appropriate due to age"}}
{"id": "HBA8ctyyel3R", "question_type": "open_ended", "question": "A 55-year-old man with chronic pulmonary heart disease and pulmonary arterial hypertension (PAH) is being evaluated for treatment. He has a history of severe asthma with frequent exacerbations, currently well-controlled on inhaled corticosteroids. He has no hepatic or renal impairment. Which of the following is the most appropriate drug choice for this patient?", "options": {"A": "Tyvaso DPI (inhaled treprostinil), four times daily", "B": "Oral treprostinil, three times daily", "C": "Tyvaso DPI (inhaled treprostinil), once daily", "D": "Subcutaneous treprostinil infusion, continuous administration"}}
{"id": "klUxsbAmbxAr", "question_type": "open_ended_multi_choice", "question": "A 6-year-old with community-acquired bacterial pneumonia is brought in by parents who are particularly concerned about antibiotics that could negatively affect teeth and bone growth in the long term. The child has no renal impairment or drug allergies. Which antibiotic therapy should be selected to best balance efficacy and safety for this patient?", "options": {"A": "Doxycycline Hyclate administered twice daily for 7 days", "B": "Rituximab and Hyaluronidase administered as a single agent", "C": "Zevtera administered according to pediatric dosing guidelines for 7 days", "D": "Doxycycline Hyclate with a planned drug holiday after 3 days"}}
{"id": "oQP8scFpeIav", "question_type": "open_ended_multi_choice", "question": "A patient with severe hepatic impairment (Child-Pugh Class C) is being considered for treatment with Blujepa. Which of the following is the most appropriate clinical action?", "options": {"A": "Avoid administration of Blujepa due to increased drug exposure and risk of QTc prolongation.", "B": "Administer Blujepa at a reduced dose with close monitoring.", "C": "Administer Blujepa with a strong CYP3A4 inhibitor to reduce side effects.", "D": "Proceed with standard dosing of Blujepa without additional precautions."}}
{"id": "q8HvZ5NEj0qy", "question_type": "open_ended_multi_choice", "question": "In patients treated with moderate CYP3A inhibitors, what change should be made to Journavx dosing after the fourth dose?", "options": {"A": "Reduce to 50 mg orally every 24 hours", "B": "Increase to 100 mg orally every 12 hours", "C": "Continue 50 mg orally every 12 hours", "D": "Discontinue Journavx"}}
{"id": "3cnFqqyoMZBp", "question_type": "open_ended_multi_choice", "question": "A clinical laboratory is validating a new aPTT assay. Which drug, if present in patient samples, should be considered as a potential source of assay interference due to its effect on the contact system?", "options": {"A": "Andembry", "B": "Warfarin", "C": "Aspirin", "D": "Clopidogrel"}}
{"id": "bsIjWNvBxCYP", "question_type": "open_ended_multi_choice", "question": "A 62-year-old male patient undergoing dialysis for 6 months due to CKD presents with anemia. He also has cirrhosis and controlled hypertension, and is not currently prescribed statins or iron supplements. Which therapy should be considered most appropriate for managing his anemia?", "options": {"A": "Vafseo, as it is indicated for anemia in CKD patients on dialysis.", "B": "DMT SUIK (corticosteroid), considering his comorbidities.", "C": "Vafseo, but only if liver function tests are normal.", "D": "Cortisone aceticum, as it is safe in liver disease."}}
{"id": "SLe6U4kohANQ", "question_type": "open_ended_multi_choice", "question": "How does simultaneous administration of Journavx influence the pharmacokinetics of ethinyl estradiol and levonorgestrel in a patient taking an oral contraceptive containing these agents?", "options": {"A": "Clinically significant increase in ethinyl estradiol and levonorgestrel levels.", "B": "Clinically significant decrease in ethinyl estradiol and levonorgestrel levels.", "C": "No clinically significant change in the pharmacokinetics of ethinyl estradiol and levonorgestrel.", "D": "Complete loss of contraceptive efficacy."}}
{"id": "7uHlFHdTMRr0", "question_type": "open_ended_multi_choice", "question": "A 34-year-old woman with newly diagnosed metastatic breast cancer is currently 10 weeks pregnant and is seeking pain management for severe bone metastasis-related pain. She has no history of renal or hepatic impairment. Which of the following analgesic options is most appropriate for her condition?", "options": {"A": "Morphine sulfate, with counseling on fetal risks and neonatal opioid withdrawal syndrome", "B": "Ketorolac tromethamine for up to 5 days", "C": "Itovebi (inavolisib) in combination with palbociclib and fulvestrant", "D": "Ketorolac tromethamine for chronic pain management"}}
{"id": "V2MwP2Gj8U2C", "question_type": "open_ended_multi_choice", "question": "A 34-year-old pregnant woman, 8 weeks into gestation, is diagnosed with metastatic ROS1-positive non-small cell lung cancer and is otherwise healthy without any concurrent medications. What is the most appropriate guidance concerning the use of IBTROZI (taletrectinib) in her case?", "options": {"A": "Initiate IBTROZI (taletrectinib) 600 mg orally once daily immediately", "B": "Initiate IBTROZI (taletrectinib) 600 mg orally once daily with close fetal monitoring", "C": "Defer IBTROZI (taletrectinib) therapy due to risk of embryo-fetal toxicity", "D": "Initiate IBTROZI (taletrectinib) at a reduced dose to minimize fetal risk"}}
{"id": "YPXntZPZftkB", "question_type": "open_ended_multi_choice", "question": "Given a patient with previously treated, unresectable metastatic biliary tract cancer who is confirmed HER2-positive (IHC 3+) by FDA-approved testing, has a history of reduced left ventricular ejection fraction (LVEF 45%), and is currently on strong CYP3A inhibitors, which therapy would be most appropriate?", "options": {"A": "Zanidatamab-hrii (ZIIHERA) every three weeks, standard dose", "B": "Futibatinib (LYTGOBI) once daily, standard dose", "C": "Pemigatinib (PEMAZYRE) once daily, standard dose", "D": "Zanidatamab-hrii (ZIIHERA) every three weeks, with cardiac monitoring and dose reduction"}}
{"id": "TOHW1avGc3it", "question_type": "open_ended_multi_choice", "question": "A 9-year-old boy with autosomal dominant atopic dermatitis is experiencing recurrent skin infections, persistent itching, and dry skin. He weighs 32 kg and also has allergic rhinitis and asthma. His mother is seeking advice regarding a new medication for his moderate-to-severe symptoms, as topical treatments have failed. What is the most suitable drug to initiate in this case?", "options": {"A": "Lebrikizumab-lbkz administered subcutaneously every 2 weeks", "B": "DMT SUIK administered intravenously as needed for severe exacerbations", "C": "Doxepin hydrochloride cream applied topically for up to 8 days", "D": "Lebrikizumab-lbkz administered subcutaneously every 4 weeks"}}
{"id": "fsj0PITbL2Lm", "question_type": "multi_choice", "question": "For patients taking Journavx who are also using hormonal contraceptives containing progestins other than levonorgestrel or norethindrone, what additional recommendation should be made?", "options": {"A": "No additional contraceptive measures are needed.", "B": "Switch to a contraceptive containing ethinyl estradiol and levonorgestrel or norethindrone.", "C": "Increase the dose of the current contraceptive.", "D": "Discontinue Journavx immediately."}}
{"id": "q2Hs78BUTDbH", "question_type": "open_ended_multi_choice", "question": "What is the best initial action to take for a patient who develops sudden dyspnea and cough while being treated with Ibtrozi?", "options": {"A": "Continue Ibtrozi and monitor symptoms", "B": "Immediately withhold Ibtrozi and evaluate for interstitial lung disease/pneumonitis", "C": "Reduce the dose of Ibtrozi without withholding", "D": "Start corticosteroids and continue Ibtrozi"}}
{"id": "RlaAqCXYIhpo", "question_type": "open_ended_multi_choice", "question": "A 67-year-old male with hypertension, hyperlipidemia, and a history of gout presents for antihypertensive therapy. His kidney function is mildly reduced (eGFR 55 mL/min), and he has no evidence of liver disease. He is not taking lithium. Given his past gout flares and concerns about drugs that could worsen gout, which antihypertensive drug is most appropriate for him?", "options": {"A": "Chlorthalidone (THALITONE), once daily", "B": "Aprocitentan (TRYVIO), once daily in combination with other antihypertensives", "C": "Bosentan (TRACLEER), twice daily", "D": "Chlorthalidone (THALITONE), twice daily"}}
{"id": "CLo6mxqKYBhi", "question_type": "open_ended_multi_choice", "question": "Which patient population should not receive Grafapex due to a specific contraindication?", "options": {"A": "Patients with hypersensitivity to any component of Grafapex", "B": "Patients with mild renal impairment", "C": "Patients with a history of hypertension", "D": "Patients with controlled diabetes"}}
{"id": "bX7bsyZ0nha2", "question_type": "open_ended_multi_choice", "question": "A 62-year-old female patient with metastatic, unresectable non-squamous NSCLC is identified as having a HER2 (ERBB2) tyrosine kinase domain activating mutation via FDA-approved testing. She has previously undergone platinum-based chemotherapy and now requires further systemic therapy. Her cardiac function is intact, and she does not use CYP3A inducers or BCRP substrates. She is not pregnant or planning to breastfeed. Which drug therapy should be selected next, taking into account both its approved indication and safety profile?", "options": {"A": "HERNEXEOS administered orally once daily, with regular monitoring of liver and cardiac function.", "B": "TECENTRIQ administered intravenously every 3 weeks as a single agent.", "C": "Etoposide administered intravenously in combination with other chemotherapeutic agents.", "D": "TECENTRIQ in combination with bevacizumab, paclitaxel, and carboplatin."}}
{"id": "9MESxtcDM6ax", "question_type": "multi_choice", "question": "A 45-year-old woman with symptomatic tenosynovial giant cell tumor (TGCT) is not a candidate for surgery due to the risk of worsening functional limitation. She has a history of aspirin sensitivity and previously experienced bronchial asthma triggered by food dyes. Her liver and renal function tests are within normal limits, and she is not pregnant or breastfeeding. Which drug is the most appropriate for her treatment?", "options": {"A": "Turalio", "B": "ROMVIMZA", "C": "Turalio with dose reduction", "D": "ROMVIMZA with dose reduction"}}
{"id": "oGlFnjtCXDsW", "question_type": "open_ended", "question": "A 16-year-old patient with hereditary angioedema requires prophylactic therapy to prevent attacks. The patient has moderate hepatic impairment (Child-Pugh B) and is not taking any medications known to induce P-gp or affect CYP2D6/CYP3A4. Which drug regimen is most appropriate for this patient?", "options": {"A": "Orladeyo 150 mg once daily", "B": "DAWNZERA 80 mg subcutaneously every 4 weeks", "C": "Orladeyo 110 mg once daily with food", "D": "Kalbitor as needed for prophylaxis"}}
{"id": "dO2l2Cz7SsDm", "question_type": "multi_choice", "question": "A 7-year-old girl with relapsed low-grade glioma is found to have a BRAF V600 mutation. She is currently taking a moderate CYP2C8 inhibitor for another condition. Her parents are concerned about the risk of growth reduction and want to know which drug would be most appropriate for her tumor treatment. Which option is the most suitable for this patient?", "options": {"A": "Tovorafenib administered once daily at the recommended pediatric dose", "B": "Tovorafenib administered once daily, but with concurrent moderate CYP2C8 inhibitor", "C": "Etoposide administered intravenously every 3 weeks", "D": "NEUPOGEN administered daily as supportive care"}}
{"id": "rHkCXuxpfL2s", "question_type": "multi_choice", "question": "For a clinical trial involving Modeyso, which exclusion criteria based on contraindications would be supported by the drug's official documentation?", "options": {"A": "Exclude patients with liver failure", "B": "No exclusion criteria based on contraindications are required", "C": "Exclude patients with known hypersensitivity to Modeyso", "D": "Exclude pregnant women"}}
{"id": "JL6j6GMFelb0", "question_type": "open_ended_multi_choice", "question": "For a 3-year-old boy with relapsed acute erythroleukemia, a KMT2A translocation, persistent anemia with ringed sideroblasts, hepatomegaly, weight below 40 kg, and no cardiac disease, what is the most suitable targeted therapy?", "options": {"A": "Daunorubicin Hydrochloride administered intravenously at standard pediatric dosing", "B": "TaperDex 12-day administered at the lowest effective dose to minimize growth suppression", "C": "REVUMENIB administered orally with BSA-based dosing and regular monitoring of bone growth", "D": "TaperDex 12-day combined with Daunorubicin Hydrochloride for induction therapy"}}
{"id": "2RWyh7sOPzrg", "question_type": "open_ended_multi_choice", "question": "What should a patient do if they forget to administer a scheduled dose of Tryptyr?", "options": {"A": "Double the next dose", "B": "Skip the next dose", "C": "Continue with the next scheduled dose", "D": "Administer the missed dose immediately"}}
{"id": "sOgO1fUjRbOJ", "question_type": "multi_choice", "question": "A 29-year-old woman with symptomatic TGCT is planning to become pregnant in the next few months. She is currently using hormonal contraceptives and has normal renal and hepatic function. Surgical resection is not feasible. Which of the following is the most appropriate pharmacologic approach for her?", "options": {"A": "Turalio (pexidartinib hydrochloride) with continued use of hormonal contraceptives", "B": "Turalio (pexidartinib hydrochloride) with non-hormonal contraception", "C": "Romvimza (vimseltinib) with effective contraception and regular pregnancy testing", "D": "Romvimza (vimseltinib) without any contraception"}}
{"id": "vQspXnjbGt3U", "question_type": "open_ended_multi_choice", "question": "A 38-year-old woman with paroxysmal nocturnal hemoglobinuria (PNH) who is currently being treated with pegcetacoplan is planning to become pregnant. She seeks advice regarding the safety of continuing pegcetacoplan during pregnancy and while breastfeeding. What is the most appropriate guidance for her situation?", "options": {"A": "Continue pegcetacoplan throughout pregnancy and breastfeeding, as animal studies show no adverse effects.", "B": "Switch to crovalimab, as animal studies show no adverse developmental outcomes and breastfeeding is not recommended during and for 9 months after the last dose.", "C": "Continue pegcetacoplan, but discontinue breastfeeding for 40 days after the last dose due to potential risks.", "D": "Switch to danicopan, as animal studies show no adverse developmental effects and breastfeeding is not recommended during and for 3 days after the last dose."}}
{"id": "o0TLs1EryDMv", "question_type": "open_ended_multi_choice", "question": "For a 68-year-old male with pulmonary arterial hypertension (WHO Group 1) and moderate hepatic impairment, who has neither a history of bleeding disorders nor cyclosporine use, which therapeutic agent is most suitable?", "options": {"A": "Ambrisentan once daily", "B": "Macitentan once daily", "C": "Sotatercept-csrk every three weeks", "D": "Ambrisentan in combination with tadalafil"}}
{"id": "edNODmd7JIKm", "question_type": "open_ended_multi_choice", "question": "For a 68-year-old man who has hypertension, chronic kidney disease with an eGFR of 20 mL/min, and elevated mean arterial pressure that is not managed by standard therapy, which medication would be the least advisable as an add-on treatment?", "options": {"A": "TRYVIO", "B": "Candesartan cilexetil", "C": "Latanoprost", "D": "Thiazide diuretic"}}
{"id": "OCfy8HUvuyTp", "question_type": "multi_choice", "question": "A patient on Journavx is also taking a sensitive CYP3A substrate where small changes in concentration may lead to loss of efficacy. What is the recommended management strategy?", "options": {"A": "Refer to the prescribing information for the CYP3A substrate for dosing instructions and consider dosage modification.", "B": "Discontinue Journavx.", "C": "No action is needed.", "D": "Increase the dose of Journavx."}}
{"id": "Jwu8rkneRl39", "question_type": "open_ended_multi_choice", "question": "A 35-year-old woman who is pregnant comes in with a complicated urinary tract infection. She has no known beta-lactam allergy, no history of glaucoma or seizures, and her kidney and liver function are normal. Which medication is the best choice for treating her infection, considering both pregnancy safety and therapeutic effectiveness?", "options": {"A": "Blujepa, administered according to standard dosing for complicated UTI.", "B": "Imipenem and Cilastatin Sodium intravenous therapy, following recommended dosing for adults.", "C": "Flavoxate Hydrochloride tablets for symptomatic relief only.", "D": "Flavoxate Hydrochloride combined with Blujepa for definitive treatment."}}
{"id": "Klqd9uNHdGV8", "question_type": "open_ended_multi_choice", "question": "A 68-year-old man with moderate to severe chronic hand eczema and a history of basal cell carcinoma is being considered for drug therapy. He has had an inadequate response to topical corticosteroids and is not taking any other immunosuppressants. What is the most appropriate management strategy?", "options": {"A": "Delgocitinib topical therapy with periodic skin examinations", "B": "Delgocitinib without any skin cancer monitoring", "C": "Combination of Delgocitinib and another JAK inhibitor", "D": "Topical corticosteroids despite prior inadequate response"}}
{"id": "BOJfScMBK4Io", "question_type": "open_ended_multi_choice", "question": "Which mechanism explains why Modeyso exposure is altered by CYP3A4 inhibitors and inducers?", "options": {"A": "Modeyso is a CYP3A4 substrate", "B": "Modeyso inhibits CYP2D6", "C": "Modeyso is metabolized by renal excretion", "D": "Modeyso is a P-glycoprotein substrate"}}
{"id": "JMyVJ12hhEXF", "question_type": "open_ended_multi_choice", "question": "A 35-year-old male, suffering from moderate to severe acute pain due to a traumatic injury, has moderate hepatic impairment (Child-Pugh Class B) and is being treated with a moderate CYP3A inhibitor. What is the most appropriate choice of drug and dosing strategy for managing his pain?", "options": {"A": "JOURNAVX at standard adult dosage", "B": "JOURNAVX at reduced dosage due to hepatic impairment and CYP3A inhibitor use", "C": "Ropivacaine Hydrochloride at standard adult dosage", "D": "Pain Relief Childrens (acetaminophen-based OTC) at pediatric dosing"}}
{"id": "VleCMpIv5w3i", "question_type": "multi_choice", "question": "A 58-year-old woman is admitted to the hospital with acute supraventricular tachycardia. She has a history of hypertension and is currently taking an ACE inhibitor. Her liver function tests reveal moderate hepatic impairment (Child-Pugh B). Which of the following is the most appropriate drug for short-term reduction of her ventricular rate?", "options": {"A": "RAPIBLYK (landiolol)", "B": "Propranolol", "C": "Pacerone (amiodarone)", "D": "Diltiazem"}}
{"id": "eboclrgpPNk5", "question_type": "multi_choice", "question": "A 68-year-old man with chronic atopic dermatitis, flexural lichenification, and recurrent pruritus is seeking relief for his symptoms. He has a history of mild cognitive impairment and is currently taking cimetidine for gastric reflux. He is not on any immunosuppressive therapy and has no active infections. Which treatment option should be avoided due to his current medication and risk profile?", "options": {"A": "Doxepin hydrochloride cream applied once daily for 8 days", "B": "DMT SUIK administered intramuscularly for acute exacerbation", "C": "Lebrikizumab-lbkz administered subcutaneously every 2 weeks", "D": "Doxepin hydrochloride cream applied three times daily for 8 days"}}
{"id": "lmcx7l8HHl8z", "question_type": "open_ended_multi_choice", "question": "Has the safety and effectiveness of Wayrilz been determined for pediatric patients?", "options": {"A": "Safety and effectiveness have been established in pediatric patients.", "B": "Safety has been established, but effectiveness has not.", "C": "Effectiveness has been established, but safety has not.", "D": "Safety and effectiveness have not been established in pediatric patients."}}
{"id": "0wTdVok1It7l", "question_type": "open_ended_multi_choice", "question": "A patient aged 72 with mild cognitive impairment secondary to Alzheimer’s disease is found to be homozygous for the ApoE ε4 allele following genetic testing. MRI imaging shows cerebral microhemorrhages, and the patient is taking aspirin for cardiovascular disease. What is the most appropriate therapeutic approach in this scenario?", "options": {"A": "Initiate KISUNLA (donanemab-azbt) with enhanced clinical vigilance and regular MRI monitoring.", "B": "Initiate KISUNLA without genetic testing or MRI monitoring.", "C": "Initiate KISUNLA and discontinue aspirin immediately.", "D": "Avoid KISUNLA due to increased risk of ARIA and intracerebral hemorrhage; consider alternative therapy if available."}}
{"id": "cd9WFoeCupft", "question_type": "open_ended_multi_choice", "question": "For the drug Lynozyfic, what is known about its potential to cause genetic mutations based on available studies?", "options": {"A": "Genotoxicity studies have demonstrated mutagenic effects.", "B": "No genotoxicity studies have been conducted with Lynozyfic.", "C": "Genotoxicity studies have shown no mutagenic effects.", "D": "Genotoxicity studies are currently underway."}}
{"id": "tHHsfKkN4Ci1", "question_type": "multi_choice", "question": "A 35-year-old male with isolated growth hormone deficiency type IB, presenting with short stature and reduced circulating growth hormone, is being considered for testosterone replacement therapy. He has a history of uncontrolled hypertension and mild edema. Which of the following is the most appropriate management regarding testosterone (Testopel) therapy for this patient?", "options": {"A": "Proceed with testosterone (Testopel) pellets and monitor blood pressure periodically.", "B": "Initiate testosterone (Testopel) pellets only after hypertension is controlled.", "C": "Start testosterone (Testopel) pellets regardless of hypertension status.", "D": "Testosterone (Testopel) pellets are contraindicated due to uncontrolled hypertension and edema."}}
{"id": "GpR9glBVM6ll", "question_type": "multi_choice", "question": "When reviewing the prescribing information for Modeyso, what should be considered regarding contraindications?", "options": {"A": "Modeyso is contraindicated in patients with active infection.", "B": "Modeyso has no contraindications listed in its prescribing information.", "C": "Modeyso is contraindicated in patients with a history of drug allergy.", "D": "Modeyso is contraindicated in patients with uncontrolled hypertension."}}
{"id": "Jl4mO8BRBppW", "question_type": "open_ended_multi_choice", "question": "In a 68-year-old female patient with hereditary transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) who is taking methotrexate for rheumatoid arthritis and is neither pregnant nor lactating, which medication poses a risk of increasing methotrexate toxicity and should therefore be avoided, and which is considered the optimal treatment for her cardiomyopathy?", "options": {"A": "Dexrazoxane should be avoided; Attruby is preferred.", "B": "Vyndaqel should be avoided; Attruby is preferred.", "C": "Attruby should be avoided; Vyndaqel is preferred.", "D": "Dexrazoxane should be avoided; Vyndaqel is preferred."}}
{"id": "9DV6hXQdwavK", "question_type": "multi_choice", "question": "A researcher is designing a clinical trial for Ibtrozi. Which exclusion criterion based on contraindications would be inappropriate to include?", "options": {"A": "Excluding patients with known contraindications to Ibtrozi.", "B": "Excluding patients with no contraindications to Ibtrozi.", "C": "Excluding patients with a history of severe allergic reactions to Ibtrozi.", "D": "Excluding patients with contraindications listed in section 4 of the prescribing information."}}
{"id": "vAaSF8VQiFDg", "question_type": "open_ended", "question": "A 55-year-old man with carcinoma of the stomach, salivary gland type, is being considered for off-label chemotherapy. He is homozygous for the UGT1A1*28 allele and is currently taking ketoconazole for a fungal infection. Which drug would pose the highest risk of severe neutropenia and drug interaction in this patient?", "options": {"A": "Avastin", "B": "Onivyde", "C": "Irinotecan Hydrochloride", "D": "None of these drugs are affected by UGT1A1 status or ketoconazole"}}
{"id": "5urJs2swBq64", "question_type": "open_ended_multi_choice", "question": "A 32-year-old pregnant woman with a syndrome of combined immunodeficiency and newly diagnosed B-cell chronic lymphocytic leukemia is being considered for drug therapy. Which of the following drugs should be avoided due to its established risk of fetal harm?", "options": {"A": "DMT SUIK (corticosteroid) at palliative dose", "B": "Fludarabine Phosphate at recommended dose", "C": "DMT SUIK (corticosteroid) at low dose", "D": "DMT SUIK (corticosteroid) with drug holiday"}}
{"id": "aowtnWQP4trE", "question_type": "open_ended", "question": "Which of the following statements best describes the carcinogenicity assessment of the drug Vizz in animal studies?", "options": {"A": "Long-term animal studies have confirmed Vizz's carcinogenic potential.", "B": "No long-term animal studies have been performed to evaluate Vizz's carcinogenic potential.", "C": "Vizz was found to be carcinogenic in short-term animal studies.", "D": "Vizz has been proven to be non-carcinogenic in humans."}}
{"id": "o1U0m2TYS7qb", "question_type": "open_ended", "question": "A 55-year-old man with acute myeloid leukemia with inv3(p21;q26.2) is scheduled for induction therapy. He has a history of congestive heart failure and previously received doxorubicin for lymphoma, reaching the recommended maximum cumulative dose. His liver and renal function are normal, and he is not CD33-positive. Which drug should be avoided due to his cardiac history and prior anthracycline exposure, and which is the most appropriate choice for induction therapy?", "options": {"A": "Mitoxantrone in combination with cytarabine, administered every 3 weeks.", "B": "Daunorubicin hydrochloride in combination with cytarabine, administered every 3 weeks.", "C": "Mylotarg (gemtuzumab ozogamicin) monotherapy, administered every 2 weeks.", "D": "Mylotarg (gemtuzumab ozogamicin) in combination with standard chemotherapy, administered every 2 weeks."}}
{"id": "OV3AC90YYepq", "question_type": "open_ended_multi_choice", "question": "A pregnant 34-year-old patient presents with NSTEMI and requires secondary prevention with antiplatelet medication. She is worried about the safety of these drugs during pregnancy. Which antiplatelet therapy would be safest and most suitable for her?", "options": {"A": "Flyrcado", "B": "BRILINTA", "C": "Clopidogrel", "D": "BRILINTA with aspirin"}}
{"id": "WnABI1saEWII", "question_type": "open_ended_multi_choice", "question": "A 62-year-old man diagnosed with metastatic non-keratinizing nasopharyngeal carcinoma has previously undergone platinum-based chemotherapy and another systemic therapy. His creatinine clearance is 40 mL/min, indicating moderate renal dysfunction. He is not receiving anticoagulants, is not pregnant, and has no prior immune-mediated conditions. Which medication should be considered most appropriate for his ongoing cancer management?", "options": {"A": "Capecitabine 500 mg twice daily", "B": "Penpulimab-kcqx monotherapy", "C": "Celecoxib 200 mg twice daily", "D": "Penpulimab-kcqx in combination with cisplatin and gemcitabine"}}
{"id": "tO2EiWdrH9Ts", "question_type": "multi_choice", "question": "A 60-year-old male with recurrent glioblastoma multiforme is being evaluated for systemic therapy. He has a history of hypertension that is well-controlled with medication and no evidence of recent surgery or wound healing complications. Genetic testing does not reveal an IDH1 or IDH2 mutation. Which of the following is the most appropriate treatment option for this patient?", "options": {"A": "Voranigo administered orally once daily", "B": "Avastin administered intravenously every 2 weeks", "C": "Zortress administered in combination with tacrolimus and corticosteroids", "D": "Voranigo in combination with a CYP1A2 inhibitor"}}
{"id": "jXphgxb6nlW1", "question_type": "multi_choice", "question": "What is known about the reversibility of Gomekli-induced infertility in females based on animal studies?", "options": {"A": "Reversibility is well established", "B": "Infertility is permanent", "C": "Gomekli does not impair fertility", "D": "Reversibility is unknown"}}
{"id": "dexRtSlM2hW4", "question_type": "multi_choice", "question": "A 2-month-old infant, born prematurely and currently hospitalized with severe lower respiratory tract infection due to confirmed respiratory syncytial virus (RSV), is being considered for antiviral therapy. The infant is not on mechanical ventilation and has no known hypersensitivity to monoclonal antibodies. The mother is not pregnant or breastfeeding. Which of the following is the most appropriate drug for this patient's treatment, including recommended administration duration?", "options": {"A": "Restasis MultiDose, administered twice daily as ophthalmic drops.", "B": "ENFLONSIA, administered as a single dose for prevention.", "C": "Virazole, administered as an inhalation solution for 3 to 7 days.", "D": "Virazole, administered orally for 14 days."}}
{"id": "Fji6KfN0Bu7n", "question_type": "open_ended_multi_choice", "question": "A patient is prescribed Ekterly and is also taking a strong CYP3A4 inducer. What is the recommended clinical action regarding the use of Ekterly in this scenario?", "options": {"A": "Continue Ekterly at the standard dose.", "B": "Increase the dose of Ekterly to compensate for reduced exposure.", "C": "Avoid the use of Ekterly with strong CYP3A4 inducers.", "D": "Administer Ekterly only if symptoms worsen."}}
{"id": "3bb9wgkogbPE", "question_type": "open_ended_multi_choice", "question": "For which patient history would prescribing Blujepa be contraindicated?", "options": {"A": "Severe hypersensitivity to Blujepa", "B": "Mild gastrointestinal upset after Blujepa", "C": "Family history of hypertension", "D": "Previous use of Blujepa without adverse effects"}}
{"id": "kOv5gPFObSv8", "question_type": "open_ended_multi_choice", "question": "A 9-year-old male patient with a history of autosomal dominant atopic dermatitis, frequent skin infections, pruritus, and xerosis, as well as allergic rhinitis and asthma, weighs 32 kg. After unsuccessful topical therapy, his mother inquires about alternative pharmacological options for his moderate-to-severe symptoms. Which medication would be most appropriate for this patient?", "options": {"A": "Lebrikizumab-lbkz administered subcutaneously every 2 weeks", "B": "DMT SUIK administered intravenously as needed for severe exacerbations", "C": "Doxepin hydrochloride cream applied topically for up to 8 days", "D": "Lebrikizumab-lbkz administered subcutaneously every 4 weeks"}}
{"id": "Whi0cFVPCFHh", "question_type": "multi_choice", "question": "A 60-year-old man with moderate-to-severe atopic dermatitis, recurrent skin infections, and a recent diagnosis of hypertension is being considered for systemic therapy after failing topical agents. He is scheduled to receive a live vaccine in the next month. Which of the following is the most appropriate next step in his management?", "options": {"A": "Start dexamethasone sodium phosphate immediately and continue with planned vaccination", "B": "Initiate Ebglyss therapy and proceed with live vaccine administration", "C": "Delay initiation of Adbry until after completion of live vaccine administration", "D": "Start dexamethasone sodium phosphate and schedule a drug holiday during vaccination"}}
{"id": "ArDyGRhv885x", "question_type": "open_ended_multi_choice", "question": "Regarding Lynozyfic, which description best represents its genotoxicity profile?", "options": {"A": "Genotoxicity studies have demonstrated a significant risk.", "B": "Genotoxicity studies have demonstrated no risk.", "C": "No genotoxicity studies have been conducted with Lynozyfic.", "D": "Genotoxicity studies in animals have shown inconclusive results."}}
{"id": "V94Ao8NAIOWe", "question_type": "open_ended_multi_choice", "question": "When a patient is receiving Grafapex together with a medication that is a sensitive substrate of CYP3A4, what should be the recommended course of action?", "options": {"A": "Monitor for adverse reactions and consider reducing the substrate dosage if recommended.", "B": "Increase the substrate dosage to compensate for reduced metabolism.", "C": "Discontinue Grafapex immediately.", "D": "No action is necessary as there is no interaction."}}
{"id": "eEaWA4zNTxyo", "question_type": "open_ended_multi_choice", "question": "A 34-year-old woman has recently been diagnosed with hypertension and has an elevated mean arterial pressure. She is considering pregnancy in the near future and is currently on oral hormonal contraceptives. Her renal and hepatic functions are normal, and she has no additional medical conditions. Which antihypertensive medication would be most suitable for her at this point?", "options": {"A": "Aprocitentan (TRYVIO), once daily", "B": "Bosentan (TRACLEER), twice daily", "C": "Chlorthalidone (THALITONE), once daily", "D": "Aprocitentan (TRYVIO), twice daily"}}
{"id": "FMfJpe3k1YE9", "question_type": "open_ended_multi_choice", "question": "A woman, aged 68, who has mild dementia caused by Alzheimer’s disease, is breastfeeding her baby. She does not have any history of hypersensitivity and is not on antithrombotic therapy. What is the most suitable strategy for pharmacological treatment in her case?", "options": {"A": "Kisunla (donanemab-azbt), after weighing the benefits of treatment against potential unknown risks to the breastfed infant", "B": "Kisunla (donanemab-azbt), contraindicated due to breastfeeding", "C": "Kisunla (donanemab-azbt), recommended only if the patient is not breastfeeding", "D": "No drug therapy recommended for Alzheimer’s disease in breastfeeding women"}}
{"id": "xzHChaU7sJWD", "question_type": "open_ended_multi_choice", "question": "When a patient receiving Ibtrozi develops a QTc interval above 500 msec or an increment from baseline exceeding 60 msec, what is the recommended management step?", "options": {"A": "Continue Ibtrozi at the same dose", "B": "Reduce the dose of Ibtrozi", "C": "Withhold Ibtrozi", "D": "Switch to a CYP3A inducer"}}
{"id": "AXrqJTtkOS3t", "question_type": "multi_choice", "question": "A 6-year-old child presents with community-acquired bacterial pneumonia. The child has no history of severe allergies, is not taking any other medications, and has normal renal function. The physician is considering antibiotic therapy. Which drug is most appropriate for treating this infection in this patient, given the risks associated with tooth development and the approved indications for pediatric use?", "options": {"A": "No antibiotic therapy is indicated", "B": "Doxycycline hyclate", "C": "Acetaminophen", "D": "Ceftobiprole medocaril sodium"}}
{"id": "y5WO9Ir7negf", "question_type": "open_ended_multi_choice", "question": "How is the safety and efficacy profile of ANZUPGO characterized for pediatric patients?", "options": {"A": "ANZUPGO is approved and safe for use in pediatric patients.", "B": "The safety and efficacy of ANZUPGO have not been established in pediatric patients.", "C": "ANZUPGO is contraindicated in pediatric patients.", "D": "ANZUPGO is recommended only for pediatric patients with severe disease."}}
{"id": "8WJ333lT7WVR", "question_type": "open_ended_multi_choice", "question": "If a patient on Wayrilz experiences gastrointestinal discomfort, what adjustment could be made to improve their ability to continue therapy?", "options": {"A": "Take Wayrilz with food", "B": "Take Wayrilz on an empty stomach", "C": "Reduce the dose by half", "D": "Switch to intravenous administration"}}
{"id": "LeQFb9ZsOAmb", "question_type": "multi_choice", "question": "A 35-year-old woman with chronic hypoparathyroidism is currently pregnant and requires ongoing management of her condition. She is not on dialysis and has no history of skeletal malignancies, radiation therapy, or metabolic bone disease other than hypoparathyroidism. Which drug is the most appropriate for her treatment, considering fetal safety and established data for use in pregnancy?", "options": {"A": "Ergocalciferol", "B": "Yorvipath", "C": "Calcitriol", "D": "Palopegteriparatide"}}
{"id": "KnGGkR60ArQt", "question_type": "multi_choice", "question": "A 12-year-old patient weighing 32 kg presents with progressive neurological deterioration, gait ataxia, and hepatomegaly. Genetic testing confirms Niemann-Pick disease type C. The patient has a history of feeding difficulties and generalized hypotonia. She is currently taking N-acetyl-DL-leucine for another condition. Which drug regimen is most appropriate for treating her neurological manifestations of NPC?", "options": {"A": "AQNEURSA (levacetylleucine) 4 g/day, discontinue N-acetyl-DL-leucine prior to initiation", "B": "AQNEURSA (levacetylleucine) 4 g/day, continue N-acetyl-DL-leucine", "C": "Miglustat (Yargesa) 100 mg twice daily", "D": "Miglustat (Opfolda) in combination with Pombiliti"}}
{"id": "4lhtHu07AQgj", "question_type": "open_ended_multi_choice", "question": "A 45-year-old woman with intermediate-risk myelodysplastic syndrome and ring sideroblasts has failed erythropoiesis stimulating agent (ESA) therapy and now requires regular red blood cell transfusions. She is planning pregnancy and is not currently using contraception. Which of the following drugs is contraindicated for her anemia management due to her reproductive status?", "options": {"A": "Reblozyl, administered subcutaneously every 3 weeks", "B": "Lenalidomide, oral daily dosing", "C": "Treosulfan (GRAFAPEX) as part of a preparative regimen for stem cell transplantation", "D": "Reblozyl, with a planned drug holiday every 2 months"}}
{"id": "kQXXfKEZk2MP", "question_type": "open_ended_multi_choice", "question": "A 35-year-old woman with symptomatic NYHA class II obstructive hypertrophic cardiomyopathy is being evaluated for medication management. She intends to become pregnant within the next year and is currently using a combined hormonal contraceptive that does not contain norethindrone. Which medication should be avoided because of its safety concerns in women who may become pregnant?", "options": {"A": "Metoprolol Tartrate", "B": "Acoramidis Hydrochloride", "C": "Mavacamten", "D": "Diltiazem"}}
{"id": "tgv1zMuFEErj", "question_type": "open_ended_multi_choice", "question": "A 58-year-old woman diagnosed with NASH and stage F3 fibrosis is a candidate for drug therapy. She has intermittent claudication and is on warfarin due to atrial fibrillation. Her liver function tests are normal, and there is no evidence of decompensated cirrhosis. Given her clinical profile and ongoing medications, which treatment option is most appropriate for her NASH?", "options": {"A": "Resmetirom administered once daily in conjunction with diet and exercise", "B": "Pentoxifylline extended-release tablets twice daily", "C": "Dapagliflozin once daily", "D": "Pentoxifylline extended-release tablets once daily"}}
{"id": "OnnD6ojTXNsv", "question_type": "multi_choice", "question": "A 15-year-old adolescent girl with hemophilia B (congenital factor IX deficiency) presents with menometrorrhagia and prolonged bleeding after dental extraction. She is currently pregnant and requires routine prophylaxis to prevent bleeding episodes. Which treatment option is most appropriate for her condition?", "options": {"A": "HYMPAVZI, administered weekly for prophylaxis", "B": "HYMPAVZI, administered only during bleeding episodes", "C": "SEVENFACT, administered weekly for prophylaxis", "D": "REBINYN, administered weekly for prophylaxis"}}
{"id": "xIJjkL7iqc5J", "question_type": "open_ended_multi_choice", "question": "A 62-year-old male diagnosed with unresectable esophageal squamous cell carcinoma presents with symptoms including chest pain, cough, and lymphadenopathy. The tumor is PD-L1 positive (CPS = 2), and laboratory results indicate mild hepatic dysfunction (AST 1.7 × ULN, ALT 1.6 × ULN, alkaline phosphatase 2.7 × ULN). What is the best initial systemic therapy regimen for this patient?", "options": {"A": "Tevimbra in combination with platinum-containing chemotherapy, administered every 3 weeks", "B": "Docetaxel anhydrous monotherapy, administered every 3 weeks", "C": "Keytruda QLEX in combination with platinum- and fluoropyrimidine-based chemotherapy, administered every 3 weeks", "D": "Docetaxel anhydrous in combination with cisplatin and fluorouracil, administered every 3 weeks"}}
{"id": "E6w5cwiAH7HD", "question_type": "open_ended_multi_choice", "question": "A 58-year-old man with a history of chronic kidney disease (estimated creatinine clearance 28 mL/min/1.73 m²) is diagnosed with Niemann-Pick disease type C and presents with progressive neurological deterioration and gait disturbance. He is not on any enzyme replacement therapy. Which of the following is the most suitable drug for his condition, considering his renal function?", "options": {"A": "Yargesa (miglustat) at standard dosing", "B": "Aqneursa at the recommended adult dosage", "C": "Opfolda (miglustat) in combination with Pombiliti", "D": "Yargesa (miglustat) with dose reduction for renal impairment"}}
{"id": "HvJSdhtAYEki", "question_type": "multi_choice", "question": "A 38-year-old woman with a recent diagnosis of schizophrenia presents for initiation of antipsychotic therapy. Her medical history is significant for moderate hepatic impairment (Child-Pugh Class B). She has no history of renal impairment, cardiovascular disease, or metabolic syndrome. Which antipsychotic regimen is most appropriate for this patient?", "options": {"A": "Cobenfy, administered orally at the recommended adult dose", "B": "Cobenfy, administered at a reduced dose due to hepatic impairment", "C": "Abilify Maintena, administered as a monthly intramuscular injection", "D": "Abilify Maintena, administered as a weekly intramuscular injection"}}
{"id": "nm5Mx1bxOO6h", "question_type": "open_ended_multi_choice", "question": "For which group is breastfeeding contraindicated during and for one week following Gomekli therapy?", "options": {"A": "Women receiving Gomekli", "B": "Men receiving Gomekli", "C": "Pediatric patients under 2 years old", "D": "Patients with mild renal impairment"}}
{"id": "hjt5xXrRgbpY", "question_type": "open_ended_multi_choice", "question": "A 60-year-old man with presbyopia is seeking treatment to improve his near vision. He has a history of retinal detachment and underwent retinal surgery two years ago. He does not have iritis or known drug allergies. Which of the following drugs should be avoided due to his medical history, and why?", "options": {"A": "Aceclidine", "B": "Brimonidine tartrate", "C": "Phentolamine mesylate", "D": "All are safe options"}}
{"id": "Z9dh43zabymV", "question_type": "open_ended_multi_choice", "question": "A 35-year-old patient with classic congenital adrenal hyperplasia is on glucocorticoid replacement therapy and has just started a strong CYP3A4 inducer for another illness. How should his Crenessity regimen be adjusted?", "options": {"A": "Continue Crenessity at the standard dose without adjustment", "B": "Discontinue Crenessity due to CYP3A4 inducer interaction", "C": "Increase both morning and evening doses of Crenessity two-fold", "D": "Reduce the glucocorticoid dose to compensate for increased Crenessity metabolism"}}
{"id": "KgwZihtS9eFw", "question_type": "multi_choice", "question": "A 67-year-old patient with metastatic non-small cell lung cancer (NSCLC) is found to have an EGFR exon 19 deletion mutation by FDA-approved testing. The patient has a history of deep vein thrombosis (DVT) and is currently receiving warfarin for anticoagulation. Which drug regimen is most appropriate for first-line treatment of this patient's NSCLC, considering their genetic profile and current medications?", "options": {"A": "Lazcluze (lazertinib + amivantamab) combination therapy, standard dosing", "B": "Erlotinib monotherapy, 150 mg orally once daily", "C": "Rozlytrek monotherapy, 600 mg orally once daily", "D": "Erlotinib in combination with platinum-based chemotherapy"}}
{"id": "v2NJarW1eERi", "question_type": "open_ended", "question": "A 15-year-old male with diffuse midline glioma (H3 K27M mutation, progressive after prior therapy) is being considered for MODEYSO therapy. He has a history of congenital long QT syndrome and is currently taking a medication known to prolong the QTc interval. What is the best course of action regarding MODEYSO administration?", "options": {"A": "Start MODEYSO at the standard dose and monitor ECGs periodically.", "B": "Avoid MODEYSO due to the risk of QTc interval prolongation and seek an alternative therapy.", "C": "Start MODEYSO but discontinue the other QTc-prolonging medication.", "D": "Start MODEYSO at a reduced dose to minimize QTc prolongation risk."}}
{"id": "yzPSxQ3rUJ2D", "question_type": "open_ended_multi_choice", "question": "A 45-year-old woman arrives at the emergency department with palpitations and is diagnosed with acute supraventricular tachycardia. Her medical history includes mild hypertension, but she does not have bronchospastic lung disease, hepatic impairment, or pregnancy, and she is not taking any other medications. The cardiology team wants to initiate pharmacologic rate control. Which medication should be selected for short-term reduction of ventricular rate in this scenario, and how frequently should it be administered?", "options": {"A": "Pacerone, administered as a single intravenous bolus, followed by oral maintenance dosing.", "B": "RAPIBLYK, administered as a continuous intravenous infusion titrated to effect.", "C": "Propranolol, administered orally twice daily.", "D": "Pacerone, administered orally once daily."}}
{"id": "3rEv4EX4iX5A", "question_type": "open_ended_multi_choice", "question": "What is the recommended action if a dose of Qfitlia is missed?", "options": {"A": "Skip the dose and wait for the next scheduled dose", "B": "Administer the missed dose as soon as possible and resume the usual dosing schedule", "C": "Double the next dose", "D": "Discontinue Qfitlia"}}
{"id": "hAYuyFoV913T", "question_type": "open_ended_multi_choice", "question": "A 58-year-old patient with newly diagnosed metastatic non-small cell lung cancer (NSCLC) is found to have an ALK-positive tumor by molecular testing. The patient has no history of prior ALK-inhibitor therapy, but has moderate hepatic impairment (total bilirubin >1.5 to ≤3 times ULN and any AST). The patient is currently taking a strong CYP3A inhibitor for a fungal infection. Which of the following is the most appropriate initial drug therapy for this patient’s NSCLC?", "options": {"A": "ENSACOVE (ensartinib) 225 mg orally once daily", "B": "CYRAMZA (ramucirumab) in combination with docetaxel every 3 weeks", "C": "YERVOY (ipilimumab) in combination with nivolumab every 6 weeks", "D": "ENSACOVE (ensartinib) 225 mg orally once daily with a planned drug holiday every 4 weeks"}}
{"id": "V560vIPgksPp", "question_type": "multi_choice", "question": "A 35-year-old patient with myelodysplastic syndrome is scheduled for allogeneic hematopoietic stem cell transplantation. Which regimen including Grafapex is appropriate based on its approved indications?", "options": {"A": "Grafapex plus fludarabine as a preparative regimen", "B": "Grafapex monotherapy as a preparative regimen", "C": "Grafapex plus cytarabine as maintenance therapy", "D": "Grafapex plus methotrexate for induction therapy"}}
{"id": "ZxWy624osfBr", "question_type": "open_ended_multi_choice", "question": "Which of the following is NOT listed as a recommended action in the event of an Ekterly overdose?", "options": {"A": "Contacting the poison control help line", "B": "Consulting a medical toxicologist", "C": "Increasing the dose of Ekterly", "D": "Calling 1-800-222-1222"}}
{"id": "iWsBXH6ZmHVJ", "question_type": "open_ended_multi_choice", "question": "A 60-year-old patient with presbyopia is considering pharmacological options to improve his near vision. His medical history includes retinal detachment and retinal surgery performed two years ago, with no iritis or known drug allergies. Given these details, which drug is contraindicated, and for what reason?", "options": {"A": "Aceclidine", "B": "Brimonidine tartrate", "C": "Phentolamine mesylate", "D": "All are safe options"}}
{"id": "65JqeAFwEOOF", "question_type": "open_ended_multi_choice", "question": "A woman aged 42, diagnosed with familial chylomicronemia syndrome and experiencing hepatic steatosis, memory issues, and high chylomicron counts, is breastfeeding her 2-month-old baby. What is the best pharmacological treatment to reduce her triglycerides?", "options": {"A": "MYCOPHENOLATE MOFETIL, as it has limited data but some infants breastfed during maternal use had no reported adverse events.", "B": "TRYNGOLZA, since animal data suggest low levels in milk and poor oral bioavailability, making it unlikely to harm the infant.", "C": "MYCOPHENOLATE MOFETIL, with additional barrier contraception to minimize infant exposure.", "D": "TRYNGOLZA, but only after cessation of breastfeeding due to unknown human data."}}
{"id": "ug7fR3TikROs", "question_type": "open_ended_multi_choice", "question": "For a patient with a documented history of anaphylactic reactions to various drugs, what guidance do Gomekli's contraindications provide about its use?", "options": {"A": "Gomekli should be avoided due to potential hypersensitivity.", "B": "Gomekli is contraindicated in patients with anaphylaxis history.", "C": "Gomekli can be used as there are no contraindications.", "D": "Gomekli should only be used after allergy testing."}}
{"id": "YqOsUbqlWJxM", "question_type": "open_ended_multi_choice", "question": "A pregnant 38-year-old woman presents with newly diagnosed unresectable esophageal squamous cell carcinoma, and her tumor is positive for PD-L1 (CPS = 3). She reports trouble with feeding and ongoing nausea. Based on her pregnancy, which of the following drugs is contraindicated?", "options": {"A": "Tevimbra in combination with platinum-containing chemotherapy", "B": "Keytruda QLEX in combination with platinum- and fluoropyrimidine-based chemotherapy", "C": "Docetaxel anhydrous in combination with cisplatin and fluorouracil", "D": "All of the above"}}
{"id": "xFgVzOoUfd9b", "question_type": "open_ended_multi_choice", "question": "A 42-year-old woman with primary biliary cholangitis presents with persistent pruritus, fatigue, and elevated alkaline phosphatase despite 6 months of treatment with ursodiol (Urso 250) at the recommended dose. She has no history of ascites, variceal bleeding, or hepatic encephalopathy. Her liver function tests are stable, and she is not pregnant or breastfeeding. Which drug regimen is most appropriate to optimize her management at this time?", "options": {"A": "Initiate Tricor (fenofibrate) as monotherapy for PBC.", "B": "Switch to IQIRVO (elafibranor) in combination with ursodiol.", "C": "Continue ursodiol (Urso 250) monotherapy despite inadequate response.", "D": "Add Tricor (fenofibrate) to ursodiol for dual therapy."}}
{"id": "RkpOpF490qTq", "question_type": "multi_choice", "question": "Which of the following statements best describes the results of mutagenicity testing for Hernexeos?", "options": {"A": "Hernexeos was mutagenic in the in vitro bacterial reverse mutation (Ames) assay.", "B": "Hernexeos was genotoxic in the in vivo rat bone marrow micronucleus test.", "C": "Hernexeos induced DNA breaks in the comet assay in liver and duodenum.", "D": "Hernexeos was not mutagenic in the in vitro bacterial reverse mutation (Ames) assay."}}
{"id": "c2FvheZz27ae", "question_type": "open_ended_multi_choice", "question": "A patient on Ibtrozi develops Grade 3 elevation of ALT (>5 - 20 × ULN). What is the recommended management?", "options": {"A": "Continue Ibtrozi at the same dose", "B": "Withhold Ibtrozi until recovery to Grade ≤1 or baseline, then resume at a reduced dose if resolved within 6 weeks", "C": "Permanently discontinue Ibtrozi immediately", "D": "Increase the dose of Ibtrozi"}}
{"id": "dZnS0CoQ3y8X", "question_type": "open_ended_multi_choice", "question": "Which of the following statements best describes the carcinogenicity studies performed for Emrelis?", "options": {"A": "Carcinogenicity studies in animals have been performed with Emrelis and showed no evidence of carcinogenicity.", "B": "Carcinogenicity studies in animals have not been performed with Emrelis or its small molecule MMAE.", "C": "Carcinogenicity studies in humans have demonstrated a high risk of cancer with Emrelis.", "D": "Carcinogenicity studies in animals have been performed only with the small molecule MMAE, not with Emrelis."}}
{"id": "FRyRe9uwpOpS", "question_type": "open_ended_multi_choice", "question": "What was the median duration of response (DOR) for penpulimab-kcqx in the AK105-202 study, and how was it estimated?", "options": {"A": "Not reached (NR), estimated using the Kaplan-Meier method", "B": "12.5 months, estimated using the Cox proportional hazards model", "C": "7.0 months, estimated using the log-rank test", "D": "9.6 months, estimated using the Wilcoxon test"}}
{"id": "LOXMepVsfY3j", "question_type": "open_ended_multi_choice", "question": "Which statement correctly describes how Blujepa interacts with other antimicrobial agents?", "options": {"A": "Blujepa antagonizes the activity of fluoroquinolones against Enterobacterales.", "B": "Blujepa shows no antagonism with multiple antibacterial drugs, including fluoroquinolones, sulfonamides, and cephalosporins.", "C": "Blujepa is only effective when used as monotherapy.", "D": "Blujepa synergizes with aminoglycosides against all gram-negative bacteria."}}
{"id": "O8PNy8hktpaD", "question_type": "open_ended_multi_choice", "question": "A 32-year-old woman diagnosed with cystic fibrosis and at least one responsive CFTR mutation presents with chronic lung disease, hepatomegaly, and Child-Pugh Class C cirrhosis. She is planning for pregnancy and is on hormonal contraceptives. What is the most appropriate and safest drug treatment for managing her cystic fibrosis in this context?", "options": {"A": "ALYFTREK at standard dosage, with close liver function monitoring.", "B": "SYMDEKO at reduced dosage, with regular liver function monitoring.", "C": "ALYFTREK at reduced dosage, with interruption of hormonal contraceptives.", "D": "SYMDEKO at standard dosage, with interruption of hormonal contraceptives."}}
{"id": "tdHpJUfrppwZ", "question_type": "open_ended_multi_choice", "question": "A 62-year-old male with metastatic non-keratinizing nasopharyngeal carcinoma has completed platinum-based chemotherapy and one additional line of treatment. He presents with moderate renal impairment (creatinine clearance of 40 mL/min), is not on anticoagulant therapy, is not pregnant, and has no history of immune-mediated diseases. What is the most suitable drug for his current cancer therapy?", "options": {"A": "Capecitabine 500 mg twice daily", "B": "Penpulimab-kcqx monotherapy", "C": "Celecoxib 200 mg twice daily", "D": "Penpulimab-kcqx in combination with cisplatin and gemcitabine"}}
{"id": "3rois3vnQu2Z", "question_type": "multi_choice", "question": "A 10-day-old neonate, born at term and entering their first RSV season, is being evaluated for RSV prophylaxis. The infant has no history of hypersensitivity reactions and is otherwise healthy. The mother is of reproductive potential but is not currently pregnant or breastfeeding. Which drug is most appropriate for RSV prevention in this patient?", "options": {"A": "Restasis MultiDose, administered twice daily.", "B": "Virazole, administered as an inhalation solution.", "C": "ENFLONSIA, administered as a single dose.", "D": "Virazole, administered orally."}}
{"id": "f5wa39byB3dh", "question_type": "open_ended_multi_choice", "question": "A 12-year-old boy with X-linked dominant scapuloperoneal myopathy presents with lower limb muscle weakness, steppage gait, and elevated creatine kinase. He has no history of diabetes or infection. His parents are concerned about the impact of long-term therapy on his growth. Which treatment option is most appropriate for his condition, considering his age and the need to minimize adverse effects?", "options": {"A": "Sildenafil citrate 100 mg daily", "B": "TaperDex 6-day corticosteroid regimen, titrated to the lowest effective dose with growth monitoring", "C": "Cortisone aceticum for water retention", "D": "TaperDex 6-day corticosteroid regimen at maximum adult dose"}}
{"id": "LqHaOWniLEDT", "question_type": "open_ended", "question": "Which patient populations were excluded from enrollment in the ATLAS-OLE study evaluating Qfitlia?", "options": {"A": "Patients with hemophilia B and no inhibitors", "B": "Patients with known co-existing coagulation disorders other than hemophilia A or B, increased risk of thrombosis, significant valvular disease or atrial fibrillation, co-existing thrombophilic disorder, AT activity <60% at screening, platelet count ≤100,000/μL, eGFR ≤45 mL/min, or clinically significant liver disease", "C": "Patients aged under 12 years", "D": "Patients with a history of mild bleeding episodes"}}
{"id": "orPlA5pFKIKi", "question_type": "multi_choice", "question": "A 42-year-old woman with a history of inoperable, functional adrenocortical carcinoma is being considered for systemic therapy. She is not pregnant, has normal hepatic and renal function, and is not taking any hormonal contraceptives or warfarin. Which drug is most appropriate for her treatment, considering her diagnosis and current medications?", "options": {"A": "Lumisight", "B": "Spironolactone", "C": "Lysodren", "D": "Blue dye for sentinel lymph node mapping"}}
{"id": "DhGsNaXvkhBi", "question_type": "open_ended_multi_choice", "question": "A 14-year-old boy with hypotrichosis simplex and sparse eyelashes is seeking treatment to improve eyelash growth. He has no other medical conditions and is not taking any medications. Which of the following is the most suitable recommendation regarding the use of prostaglandin analogs for this patient?", "options": {"A": "Initiate LUMIGAN (bimatoprost ophthalmic solution 0.01%) once daily", "B": "Initiate Bimatoprost ophthalmic solution 0.03% once daily", "C": "Neither LUMIGAN nor Bimatoprost should be used due to age-related safety concerns", "D": "Initiate Bimatoprost ophthalmic solution 0.03% twice daily"}}
{"id": "PLdoVydtacky", "question_type": "open_ended_multi_choice", "question": "A 32-year-old female patient with cystic fibrosis (confirmed to have at least one responsive CFTR mutation) has chronic lung disease, hepatomegaly, and advanced cirrhosis (Child-Pugh Class C). She is considering pregnancy and currently uses hormonal contraception. Which drug therapy should be chosen for optimal and safe management of her cystic fibrosis?", "options": {"A": "ALYFTREK at standard dosage, with close liver function monitoring.", "B": "SYMDEKO at reduced dosage, with regular liver function monitoring.", "C": "ALYFTREK at reduced dosage, with interruption of hormonal contraceptives.", "D": "SYMDEKO at standard dosage, with interruption of hormonal contraceptives."}}
{"id": "sSmsxfE8z6Of", "question_type": "multi_choice", "question": "Which of the following statements best describes the carcinogenicity assessment for Imaavy (nipocalimab-aahu)?", "options": {"A": "Carcinogenicity studies have been conducted and showed no risk.", "B": "Carcinogenicity studies were conducted only in rodents.", "C": "Carcinogenicity studies showed a high risk of cancer.", "D": "Carcinogenicity studies were inconclusive."}}
{"id": "ZinHDiv6x8EJ", "question_type": "multi_choice", "question": "A 42-year-old woman with recurrent low-grade serous ovarian carcinoma and confirmed KRAS mutation presents for treatment. She has previously received systemic therapy and is currently taking warfarin for atrial fibrillation. Which drug regimen is most appropriate for her cancer management?", "options": {"A": "AVMAPKI FAKZYNJA CO-PACK (avutometinib and defactinib)", "B": "AVMAPKI FAKZYNJA CO-PACK after switching to a non-warfarin anticoagulant", "C": "AVMAPKI FAKZYNJA CO-PACK with warfarin co-administration", "D": "AVMAPKI FAKZYNJA CO-PACK with dose reduction due to warfarin"}}
{"id": "Xj1HJ2Kod4Bi", "question_type": "open_ended_multi_choice", "question": "Which of the following is a correct counseling point for patients prescribed Ekterly?", "options": {"A": "Read the FDA-approved patient labeling (Patient Information)", "B": "Take Ekterly with grapefruit juice to enhance absorption", "C": "Double the dose if symptoms persist after 1 hour", "D": "Discontinue Ekterly if experiencing mild hepatic impairment"}}
{"id": "S0m8eRkyKB73", "question_type": "open_ended_multi_choice", "question": "A patient receiving Ibtrozi develops new-onset dyspnea and cough. What is the most appropriate initial management step?", "options": {"A": "Continue Ibtrozi and monitor symptoms", "B": "Immediately withhold Ibtrozi and evaluate for interstitial lung disease/pneumonitis", "C": "Reduce the dose of Ibtrozi without withholding", "D": "Start corticosteroids and continue Ibtrozi"}}
{"id": "ZIfE6G4TIOZd", "question_type": "open_ended_multi_choice", "question": "A 68-year-old woman with carcinoma of the stomach, salivary gland type, is being considered for off-label systemic therapy. She has a history of hypertension that is well-controlled with medication, but recently developed significant proteinuria (urine protein >3.5 grams/24 hours). She is not pregnant and is not breastfeeding. Which drug would be least appropriate for her due to her current renal findings, even if it might otherwise be considered for off-label use?", "options": {"A": "Irinotecan Hydrochloride", "B": "Onivyde", "C": "Avastin", "D": "None of these drugs are contraindicated"}}
{"id": "tTBxzSrvWrfw", "question_type": "multi_choice", "question": "Which of the following best describes the contraindication profile for the drug Qfitlia?", "options": {"A": "Qfitlia is contraindicated in pregnancy.", "B": "Qfitlia is contraindicated in patients with hepatic impairment.", "C": "Qfitlia should not be used in patients with a history of hypersensitivity reactions.", "D": "Qfitlia has no known contraindications."}}
{"id": "xBcZP493C1QP", "question_type": "multi_choice", "question": "For a female patient of reproductive potential who is about to start Wayrilz therapy, which of the following is the most appropriate recommendation regarding contraception?", "options": {"A": "No contraception is required during Wayrilz treatment.", "B": "Use effective contraception only during Wayrilz treatment.", "C": "Use effective contraception during Wayrilz treatment and for 1 week after stopping treatment.", "D": "Use contraception for 1 month after stopping Wayrilz."}}
{"id": "BaHyKyB7xIpz", "question_type": "multi_choice", "question": "A 35-year-old pregnant woman is diagnosed with low-grade glioma. She is seeking treatment options that minimize risk to her fetus. Genetic testing reveals no BRAF fusion or V600 mutation. Which of the following therapies is contraindicated for her due to pregnancy risk and lack of efficacy for her tumor profile?", "options": {"A": "OJEMDA, as a kinase inhibitor targeting BRAF mutations, administered orally.", "B": "Gliadel Wafer, implanted during surgery, with known embryo-fetal toxicity.", "C": "VinCRIStine Sulfate, administered intravenously, with risk of fetal harm.", "D": "Supportive care only, deferring cytotoxic or targeted therapy until after pregnancy."}}
{"id": "tKIpusIjAbsa", "question_type": "multi_choice", "question": "A 35-year-old female patient with Grade 2 IDH1-mutant astrocytoma has recently undergone gross total resection. She is planning pregnancy and currently uses hormonal contraception. Her oncologist is considering post-surgical drug therapy. Which treatment option should be avoided due to its impact on contraception and potential risk to a future pregnancy?", "options": {"A": "Avastin administered every 2 weeks", "B": "Vorasidenib 40 mg once daily", "C": "Zortress combined with tacrolimus and corticosteroids", "D": "No drug therapy; observation only"}}
{"id": "SJP1XVxkqbyV", "question_type": "open_ended_multi_choice", "question": "A 58-year-old female patient with a history of myocardial infarction and type 2 diabetes is being considered for antiplatelet therapy to prevent further cardiovascular events. She has moderate liver dysfunction and is currently on simvastatin 40 mg daily for dyslipidemia. Which antiplatelet drug would be most suitable for her continued treatment?", "options": {"A": "BRILINTA", "B": "Clopidogrel", "C": "Flyrcado", "D": "BRILINTA with simvastatin 80 mg"}}
{"id": "6N6KuBr6lD30", "question_type": "open_ended_multi_choice", "question": "A 9-year-old boy with cystic fibrosis, recurrent bronchopulmonary infections, and decreased body mass index is found to have moderate hepatic impairment (Child-Pugh Class B) and is currently receiving fluconazole for a fungal infection. His genotype includes at least one F508del mutation. Which drug regimen is most appropriate for his cystic fibrosis management?", "options": {"A": "ALYFTREK at standard dosage, with baseline and follow-up ophthalmological exams.", "B": "SYMDEKO at reduced dosage, with baseline and follow-up ophthalmological exams.", "C": "ALYFTREK at reduced dosage due to fluconazole co-administration.", "D": "SYMDEKO at standard dosage, with interruption for fluconazole therapy."}}
{"id": "XKfdxcqBwWWc", "question_type": "open_ended_multi_choice", "question": "A 45-year-old female with metastatic non-keratinizing nasopharyngeal carcinoma has disease progression after platinum-based chemotherapy and at least one other prior line of therapy. She is currently breastfeeding and wishes to continue. Which of the following treatment options is most appropriate for her current situation?", "options": {"A": "Penpulimab-kcqx as a single agent, administered every 3 weeks", "B": "Capecitabine 500 mg twice daily as monotherapy", "C": "Celecoxib 200 mg twice daily for symptom relief", "D": "Delay systemic therapy and continue breastfeeding for 4 months before starting Penpulimab-kcqx"}}
{"id": "ESWywkz5Lj9W", "question_type": "open_ended_multi_choice", "question": "If Enflonsia is administered concomitantly with injectable vaccines, what is the correct protocol?", "options": {"A": "Administer both in the same syringe", "B": "Administer Enflonsia and vaccines at the same injection site", "C": "Use separate syringes and different injection sites", "D": "Mix Enflonsia with vaccines in the same vial"}}
{"id": "z6LwObJJsIWK", "question_type": "multi_choice", "question": "For patients with confirmed Grade 2 or higher ILD/pneumonitis while on Datroway, what is the recommended action regarding drug administration?", "options": {"A": "Continue Datroway with corticosteroids", "B": "Reduce Datroway dose", "C": "Permanently discontinue Datroway", "D": "Withhold Datroway temporarily"}}
{"id": "DOUQUQGbeB6e", "question_type": "multi_choice", "question": "Why might concomitant use of Grafapex and certain CYP2C19 substrates increase the risk of serious or life-threatening toxicities?", "options": {"A": "Grafapex has no effect on CYP2C19 metabolism.", "B": "Grafapex induces CYP2C19, decreasing substrate exposure.", "C": "Grafapex inhibits CYP2C19, increasing substrate exposure.", "D": "Grafapex increases renal clearance of CYP2C19 substrates."}}
{"id": "gG3kLAkbMaOK", "question_type": "open_ended", "question": "A 59-year-old woman with newly diagnosed multiple myeloma is scheduled for autologous stem cell transplantation. She has normal cardiac and renal function, and no history of leukemia. Her oncologist is planning to mobilize hematopoietic stem cells for collection. Which regimen is most appropriate for stem cell mobilization in this patient?", "options": {"A": "Darzalex Faspro in combination with bortezomib, lenalidomide, and dexamethasone", "B": "Mozobil (plerixafor) in combination with filgrastim", "C": "Lynozyfic (linvoseltamab-gcpt)", "D": "Darzalex Faspro monotherapy"}}
{"id": "VcSqQ2BGHVt6", "question_type": "open_ended_multi_choice", "question": "A 59-year-old woman with newly diagnosed multiple myeloma is being evaluated for autologous stem cell transplantation. She has normal renal function, is not pregnant, and has no history of thromboembolism or neuropathy. She is currently not taking any CNS depressants or cardiac medications. Which of the following drug regimens is most appropriate for mobilizing hematopoietic stem cells prior to transplantation?", "options": {"A": "Thalomid in combination with dexamethasone", "B": "LYNOZYFIC", "C": "Mozobil in combination with filgrastim", "D": "Thalomid monotherapy"}}
{"id": "xEZ16IQ9kvDg", "question_type": "open_ended_multi_choice", "question": "A 12-year-old boy with Duchenne muscular dystrophy, confirmed by genetic testing to have a mutation amenable to exon 51 skipping, presents with mild renal impairment and a history of hypersensitivity to intravenous medications. He has no arrhythmias or hepatic dysfunction. Which treatment option is most appropriate for his condition?", "options": {"A": "Viltepso administered intravenously once weekly", "B": "Exondys 51 administered intravenously once weekly", "C": "Duvyzat administered orally twice daily", "D": "Duvyzat administered with a drug holiday every 2 weeks"}}
{"id": "zd7js4AcT8qF", "question_type": "open_ended_multi_choice", "question": "A newly diagnosed case of paroxysmal nocturnal hemoglobinuria (PNH) is seen in a 15-year-old adolescent weighing 45 kg, with no history of hepatic dysfunction or previous complement inhibitor use. Her parents are concerned about choosing an appropriate initial therapy for her age group. Which drug is best suited for starting treatment in this scenario?", "options": {"A": "Danicopan as monotherapy", "B": "Pegcetacoplan as monotherapy", "C": "Crovalimab as monotherapy", "D": "Danicopan as add-on to ravulizumab"}}
{"id": "FMA1FUq3aivq", "question_type": "open_ended_multi_choice", "question": "A 48-year-old female patient has recurrent, metastatic non-keratinizing nasopharyngeal carcinoma. She has well-managed hypertension and is taking warfarin for atrial fibrillation. She is not pregnant or breastfeeding, and her kidney and liver function tests are within normal limits. Which first-line drug regimen should be chosen for her cancer therapy?", "options": {"A": "Celecoxib 200 mg twice daily", "B": "Capecitabine 500 mg twice daily", "C": "Penpulimab-kcqx in combination with cisplatin and gemcitabine", "D": "Penpulimab-kcqx monotherapy"}}
{"id": "cLijyJWkY0Xc", "question_type": "open_ended_multi_choice", "question": "If a biomedical researcher is reviewing the contraindication profile of Hernexeos, what should they note?", "options": {"A": "There are no contraindications for Hernexeos.", "B": "Hernexeos is contraindicated in patients with a history of hypersensitivity reactions.", "C": "Hernexeos should not be administered to patients with cardiovascular disease.", "D": "Hernexeos is contraindicated in patients taking anticoagulants."}}
{"id": "HguTcnpuVIpp", "question_type": "open_ended_multi_choice", "question": "When considering the use of Tryptyr in elderly patients, what has been observed regarding its safety profile compared to younger adults?", "options": {"A": "Clinically relevant differences in safety have been observed between elderly and younger patients.", "B": "Tryptyr is associated with increased adverse effects in elderly patients.", "C": "No clinically relevant differences in safety have been observed between elderly and younger patients.", "D": "Tryptyr is contraindicated in elderly patients."}}
{"id": "xMNDiFfbmNzw", "question_type": "multi_choice", "question": "What should patients do if they are prescribed new medications or begin taking herbal supplements during Blujepa therapy?", "options": {"A": "Alert their healthcare provider", "B": "Discontinue Blujepa immediately", "C": "Double the dose of Blujepa", "D": "Ignore potential interactions"}}
{"id": "XwVKgRk8aLwn", "question_type": "open_ended_multi_choice", "question": "A 35-year-old woman presents to the emergency department with moderate to severe acute pain following a minor surgical procedure. She has a history of severe hepatic impairment (Child-Pugh Class C) and is currently taking ketoconazole for a fungal infection. Which drug is the most appropriate choice for acute pain management in this patient?", "options": {"A": "Suzetrigine", "B": "Ropivacaine Hydrochloride", "C": "Acetaminophen", "D": "Childrens Pain Relief"}}
{"id": "pnATEtYjUua9", "question_type": "open_ended", "question": "A 62-year-old woman with a history of iritis and previous retinal detachment is diagnosed with presbyopia. She is seeking pharmacological treatment to improve her near vision. Which drug should be avoided due to her ocular history, and why?", "options": {"A": "Mirvaso topical gel, due to risk of systemic hypotension", "B": "VIZZ (aceclidine) ophthalmic drops, due to risk of retinal tear/detachment and exacerbation of iritis", "C": "Oraverse, due to risk of cardiovascular events", "D": "VIZZ (aceclidine) ophthalmic drops, due to risk of hypersensitivity"}}
{"id": "OLlYKPNZqyZn", "question_type": "open_ended_multi_choice", "question": "A 16-year-old adolescent with Niemann-Pick disease type C, presenting with progressive neurologic deterioration and hepatomegaly, also has moderate renal impairment (eGFR 35 mL/min/1.73 m²). The patient is eligible for therapy targeting neurological symptoms. Which of the following best describes the appropriate drug regimen and dosing consideration for this patient?", "options": {"A": "Standard-dose arimoclomol in combination with standard-dose miglustat", "B": "Standard-dose miglustat monotherapy", "C": "Dose-adjusted arimoclomol in combination with dose-adjusted miglustat", "D": "Standard-dose lithium carbonate"}}
{"id": "ab2b1VDmLV2a", "question_type": "open_ended_multi_choice", "question": "A 58-year-old woman, who previously suffered a myocardial infarction and has type 2 diabetes, requires antiplatelet therapy to lower her risk of additional cardiovascular incidents. She has moderate hepatic impairment and is taking simvastatin 40 mg daily for her lipid disorder. Which antiplatelet agent should be selected for her ongoing care?", "options": {"A": "BRILINTA", "B": "Clopidogrel", "C": "Flyrcado", "D": "BRILINTA with simvastatin 80 mg"}}
{"id": "cshIffuLDqRV", "question_type": "open_ended_multi_choice", "question": "A 68-year-old man presents with pulmonary arterial hypertension classified as WHO Group 1 and has moderate hepatic impairment. There is no history of bleeding disorders or prior cyclosporine therapy. Which drug should be selected as the best treatment option for him?", "options": {"A": "Ambrisentan once daily", "B": "Macitentan once daily", "C": "Sotatercept-csrk every three weeks", "D": "Ambrisentan in combination with tadalafil"}}
{"id": "09z8xh2YuIXR", "question_type": "open_ended_multi_choice", "question": "A 35-year-old man with classic congenital adrenal hyperplasia is receiving glucocorticoid replacement therapy. He has recently started a strong CYP3A4 inducer for another condition. What is the most appropriate adjustment to his Crenessity regimen?", "options": {"A": "Continue Crenessity at the standard dose without adjustment", "B": "Discontinue Crenessity due to CYP3A4 inducer interaction", "C": "Increase both morning and evening doses of Crenessity two-fold", "D": "Reduce the glucocorticoid dose to compensate for increased Crenessity metabolism"}}
{"id": "I4l7FFKklat2", "question_type": "open_ended_multi_choice", "question": "A 7-year-old patient diagnosed with hereditary angioedema needs ongoing prophylactic treatment to reduce the risk of future episodes. Given that the child has no prior hypersensitivity reactions and is not on anticoagulant therapy, which medication is best suited for this patient, taking into account their age and approved uses?", "options": {"A": "Kalbitor", "B": "ANDEMBRY", "C": "TAKHZYRO", "D": "No drug is appropriate for this patient"}}
{"id": "nWGjUXjlTETT", "question_type": "open_ended_multi_choice", "question": "A 75-year-old man diagnosed with mild cognitive impairment secondary to Alzheimer’s disease is under review for possible medication. His medical history includes a significant hypersensitivity response to monoclonal antibody treatments. He is not pregnant, does not breastfeed, and has no indication for antithrombotic drugs. What would be the best drug treatment advice in this scenario?", "options": {"A": "Kisunla (donanemab-azbt), with pre-treatment using antihistamines", "B": "Kisunla (donanemab-azbt), contraindicated due to history of serious hypersensitivity", "C": "Kisunla (donanemab-azbt), recommended with regular MRI monitoring", "D": "Kisunla (donanemab-azbt), recommended only if patient is not ApoE ε4 homozygote"}}
{"id": "UFGvr10XNfNF", "question_type": "multi_choice", "question": "A 68-year-old man with relapsed multiple myeloma has previously received four lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. He has well-controlled hypertension and normal renal and hepatic function. He is not currently experiencing any infections. Which of the following is the most appropriate next-line therapy for his condition?", "options": {"A": "Thalomid in combination with dexamethasone", "B": "Observation only, as no further therapy is indicated", "C": "Mozobil in combination with filgrastim", "D": "LYNOZYFIC"}}
{"id": "CpjC283PGEYs", "question_type": "open_ended_multi_choice", "question": "A 60-year-old man, previously diagnosed with supraventricular tachycardia and moderate liver impairment (Child-Pugh B), is hospitalized for urgent rate control. He does not have bronchospastic disease and is not pregnant. Considering his hepatic status, which drug is contraindicated, and which alternative is recommended?", "options": {"A": "RAPIBLYK should be avoided; Propranolol is the most appropriate alternative.", "B": "Pacerone should be avoided; RAPIBLYK is the most appropriate alternative.", "C": "Propranolol should be avoided; Pacerone is the most appropriate alternative.", "D": "RAPIBLYK should be avoided; Pacerone is the most appropriate alternative."}}
{"id": "7bOuWjqZydj0", "question_type": "open_ended_multi_choice", "question": "A 34-year-old woman with chronic graft-versus-host disease (cGVHD) presents with morphea, muscle weakness, and recurrent infections. She is currently 10 weeks pregnant and has failed two prior lines of systemic therapy. Her weight is 65 kg and hepatic function is normal. Which drug regimen is safest and most appropriate for her current condition?", "options": {"A": "Niktimvo, intravenous infusion every 2 weeks", "B": "PredniSONE, 5 mg orally once daily", "C": "PONVORY, 20 mg orally once daily", "D": "Niktimvo, intravenous infusion every 4 weeks"}}
{"id": "Mzs3UtbVlf4r", "question_type": "multi_choice", "question": "A 32-year-old man with a history of hypoparathyroidism and prior external beam radiation therapy involving the skeleton presents for ongoing management. His albumin-corrected serum calcium is stable at 8.0 mg/dL on calcium and active vitamin D. He is not taking digoxin. Which of the following is the most appropriate next step in pharmacologic management?", "options": {"A": "Continue calcium and active vitamin D supplementation only", "B": "Start GENOTROPIN at a reduced dose", "C": "Initiate Yorvipath once daily", "D": "Begin Tri-Vite Drops with Fluoride supplementation"}}
{"id": "4UqDsw4yxchP", "question_type": "open_ended_multi_choice", "question": "A 34-year-old pregnant woman at 10 weeks gestation has recently been diagnosed with metastatic breast cancer and is experiencing severe pain due to bone metastases. She has normal renal and hepatic function. What is the most suitable analgesic option for her situation?", "options": {"A": "Morphine sulfate, with counseling on fetal risks and neonatal opioid withdrawal syndrome", "B": "Ketorolac tromethamine for up to 5 days", "C": "Itovebi (inavolisib) in combination with palbociclib and fulvestrant", "D": "Ketorolac tromethamine for chronic pain management"}}
{"id": "G9QBq73vAsck", "question_type": "open_ended_multi_choice", "question": "A 55-year-old pregnant woman with metastatic esophageal squamous cell carcinoma and a history of feeding difficulties in infancy is being evaluated for second-line therapy after failing platinum-based chemotherapy. She is concerned about the safety of her fetus. Which drug should not be administered to her at this time?", "options": {"A": "Tislelizumab-jsgr as a single agent", "B": "Nivolumab and hyaluronidase as monotherapy", "C": "Lenvatinib monotherapy", "D": "All of the above"}}
{"id": "8YseK2O5BuUJ", "question_type": "open_ended_multi_choice", "question": "A 58-year-old patient with known glaucoma and repeated episodes of herpes simplex eye infections is found to have dry eye disease. He seeks a daily therapy to help with his symptoms. Considering his history, identify the medication that should not be used and select the most suitable treatment.", "options": {"A": "Loteprednol etabonate ophthalmic gel, administered twice daily", "B": "Acoltremon ophthalmic solution, administered twice daily", "C": "Lifitegrast ophthalmic solution, administered twice daily", "D": "Loteprednol etabonate ophthalmic gel, administered once daily"}}
{"id": "BJCVVVbKNifx", "question_type": "open_ended_multi_choice", "question": "A 68-year-old patient with prurigo nodularis presents for treatment. She has a history of chronic obstructive pulmonary disease (COPD) and is currently taking a benzodiazepine for anxiety. She reports severe itching but denies significant pain. Which drug regimen is most appropriate for her condition, considering her comorbidities and current medications?", "options": {"A": "NEMLUVIO administered subcutaneously every 4 weeks", "B": "Nalbuphine Hydrochloride injection for pain management, titrated slowly", "C": "Nalbuphine Hydrochloride injection combined with benzodiazepine, at standard dosing", "D": "NEMLUVIO combined with live vaccine administration during therapy"}}
{"id": "8oy2RKzF9Qi5", "question_type": "open_ended_multi_choice", "question": "If a patient taking Hernexeos presents with Grade 3 ALT and/or AST elevation without a concurrent rise in total bilirubin, what management strategy is recommended?", "options": {"A": "Continue Hernexeos at the same dose", "B": "Interrupt Hernexeos until recovery, then resume at reduced dose", "C": "Permanently discontinue Hernexeos", "D": "Increase Hernexeos dose"}}
{"id": "T1GzPHvhyqfW", "question_type": "open_ended_multi_choice", "question": "When a patient is prescribed an oral contraceptive with ethinyl estradiol and levonorgestrel, what pharmacokinetic changes, if any, occur to these compounds when Journavx is taken at the same time?", "options": {"A": "Clinically significant increase in ethinyl estradiol and levonorgestrel levels.", "B": "Clinically significant decrease in ethinyl estradiol and levonorgestrel levels.", "C": "No clinically significant change in the pharmacokinetics of ethinyl estradiol and levonorgestrel.", "D": "Complete loss of contraceptive efficacy."}}
{"id": "jrlCP8GGorpN", "question_type": "open_ended_multi_choice", "question": "For a 45-year-old woman diagnosed with chronic graft-versus-host disease, presenting with frequent infections, increased hepatic transaminases, and indurated skin, who has not responded to two prior systemic treatments, is not pregnant nor intending to breastfeed, and has a body weight of 65 kg, which medication should be considered as the next therapeutic option given her current disease status?", "options": {"A": "PredniSONE Tablets, USP, 5 mg", "B": "Budesonide Inhalation", "C": "AXATILIMAB-CSFR", "D": "Budesonide Inhalation combined with PredniSONE"}}
{"id": "NV8peVVe7N6R", "question_type": "open_ended_multi_choice", "question": "A 60-year-old man with well-controlled epilepsy on valproic acid presents with a severe urinary tract infection. His renal and liver function are normal, and he has no history of drug allergies. Which medication should be avoided in this case due to the potential for drug interactions leading to breakthrough seizures?", "options": {"A": "Imipenem and Cilastatin Sodium intravenous therapy, following standard dosing.", "B": "Blujepa, administered according to recommended dosing for severe UTI.", "C": "Flavoxate Hydrochloride tablets for symptomatic relief.", "D": "Imipenem and Cilastatin Sodium with dose adjustment for renal function."}}
{"id": "bs6zCs1lQEwU", "question_type": "multi_choice", "question": "A 45-year-old woman with primary IgA nephropathy and UPCR of 2.0 g/g is currently breastfeeding her 2-month-old infant. She is otherwise healthy and not pregnant. Which is the most appropriate recommendation regarding atrasentan (VANRAFIA) therapy for her?", "options": {"A": "Initiate atrasentan and continue breastfeeding.", "B": "Atrasentan is safe to use during lactation.", "C": "Atrasentan is contraindicated only if she is pregnant.", "D": "Initiate atrasentan but advise her to stop breastfeeding during treatment."}}
{"id": "Zs2eCaYIfVzt", "question_type": "multi_choice", "question": "Which of the following statements best describes the contraindication profile of the drug Ekterly?", "options": {"A": "Ekterly has no listed contraindications.", "B": "Ekterly should not be used in individuals with a history of hypersensitivity to its active ingredient.", "C": "Ekterly is contraindicated in patients with severe hepatic impairment.", "D": "Ekterly is contraindicated in pregnant women."}}
{"id": "58T1oc9zahMM", "question_type": "multi_choice", "question": "A 28-year-old woman with cystic fibrosis and a history of cirrhosis and hepatosplenomegaly is planning to become pregnant. She has a confirmed F508del mutation and is currently taking oral contraceptives. Her liver function tests are mildly elevated (Child-Pugh Class A). Which of the following is the most suitable drug regimen for her cystic fibrosis management?", "options": {"A": "Insulin Aspart Protamine and Insulin Aspart Mix 70/30, administered before meals", "B": "ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor) at standard dosage, with regular liver function and ophthalmologic monitoring", "C": "ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor) at reduced dosage due to oral contraceptive use", "D": "ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor) is contraindicated due to pregnancy risk"}}
{"id": "7oPyTbRyhD5g", "question_type": "open_ended_multi_choice", "question": "A 45-year-old male with chronic obstructive pulmonary disease (COPD) is currently taking a strong CYP3A4 inhibitor (ritonavir) for another condition. He requires maintenance therapy for COPD. Which drug is least likely to result in significant drug interactions or increased risk of adverse effects in this scenario?", "options": {"A": "Budesonide Inhalation", "B": "Fentanyl Citrate", "C": "Ensifentrine", "D": "Budesonide (oral)"}}
{"id": "NpzGo79BsAUN", "question_type": "open_ended_multi_choice", "question": "A 38-year-old pregnant patient has recently been diagnosed with unresectable esophageal squamous cell carcinoma, with her tumor showing PD-L1 expression (CPS = 3). She is experiencing difficulty eating and persistent nausea. Which medication should not be administered to her because she is pregnant?", "options": {"A": "Tevimbra in combination with platinum-containing chemotherapy", "B": "Keytruda QLEX in combination with platinum- and fluoropyrimidine-based chemotherapy", "C": "Docetaxel anhydrous in combination with cisplatin and fluorouracil", "D": "All of the above"}}
{"id": "v8oOqtOwoGud", "question_type": "open_ended_multi_choice", "question": "What important information should be taken into account about Emrelis's contraindications when used in patients with existing comorbidities?", "options": {"A": "Emrelis is contraindicated in patients with diabetes.", "B": "Emrelis is contraindicated in patients with liver dysfunction.", "C": "Emrelis has no contraindications regardless of comorbidities.", "D": "Emrelis is contraindicated in patients with autoimmune diseases."}}
{"id": "OLnZ8A1ZA2nX", "question_type": "multi_choice", "question": "A 55-year-old woman with chronic obstructive pulmonary disease (COPD) and a history of major depressive disorder is being considered for maintenance therapy. She has no hepatic or renal impairment. Which drug should be avoided due to her psychiatric history, and which is the most appropriate for her COPD maintenance?", "options": {"A": "Ensifentrine", "B": "Fentanyl Citrate", "C": "Budesonide Inhalation", "D": "Budesonide (oral)"}}
{"id": "MLg9qsgmD1wa", "question_type": "open_ended_multi_choice", "question": "A 45-year-old woman diagnosed with paroxysmal nocturnal hemoglobinuria (PNH) presents with ongoing extravascular hemolysis despite receiving ravulizumab. Her medical history includes mild hepatic impairment (Child-Pugh Class B), and she is currently prescribed rosuvastatin 20 mg daily for hyperlipidemia. Taking into account her comorbidities and current treatments, which drug regimen should be recommended to address her EVH?", "options": {"A": "Add danicopan to her current ravulizumab regimen, maintaining her rosuvastatin dose at 20 mg once daily.", "B": "Switch to pegcetacoplan monotherapy and discontinue ravulizumab.", "C": "Add danicopan to her current ravulizumab regimen, but reduce rosuvastatin dose to no more than 10 mg once daily.", "D": "Switch to crovalimab monotherapy and discontinue ravulizumab."}}
{"id": "m2AvysByBaqB", "question_type": "open_ended_multi_choice", "question": "A 54-year-old woman with primary biliary cholangitis presents with persistent pruritus, fatigue, and elevated alkaline phosphatase despite 12 months of ursodeoxycholic acid therapy. She has a history of osteoporosis and is currently taking atorvastatin for hyperlipidemia. She has no evidence of ascites, variceal bleeding, or hepatic encephalopathy. Which drug is the most appropriate to add to her regimen for PBC management, considering her current medications and comorbidities?", "options": {"A": "Elafibranor, once daily, in combination with UDCA", "B": "Seladelpar lysine, once daily, in combination with UDCA", "C": "Abatacept, once monthly", "D": "Elafibranor, once daily, as monotherapy"}}
{"id": "TYeUfwXPlrwC", "question_type": "multi_choice", "question": "A 45-year-old woman is newly diagnosed with acute erythroleukemia and presents with anemia, thrombocytopenia, and splenomegaly. She has no history of cardiac disease, is not pregnant, and has normal hepatic and renal function. She is scheduled to begin induction therapy. Which drug regimen is most appropriate for remission induction in her case?", "options": {"A": "TaperDex 12-day administered orally for 12 days as supportive therapy", "B": "TaperDex 12-day combined with REVUMENIB for induction therapy", "C": "REVUMENIB administered orally twice daily for 28-day cycles", "D": "Daunorubicin Hydrochloride administered intravenously in combination with other approved anticancer drugs"}}
{"id": "XXX5bNzEshpl", "question_type": "open_ended_multi_choice", "question": "A 38-year-old woman with primary biliary cholangitis and a history of recurrent fungal infections and abnormal thyroid function is planning pregnancy. She has not responded adequately to ursodeoxycholic acid and is considering additional therapy. Which drug should be avoided due to its risk profile in pregnancy, and what is the most suitable alternative for her?", "options": {"A": "Elafibranor, once daily, in combination with UDCA", "B": "Seladelpar lysine, once daily, in combination with UDCA", "C": "Abatacept, once monthly", "D": "Elafibranor, once daily, as monotherapy"}}
{"id": "5PM0edI4NlHj", "question_type": "open_ended", "question": "A 7-year-old child with ALG12-CDG, presenting with global developmental delay, hepatomegaly, and a history of recurrent seizures, is being considered for adjunctive therapy for seizure control. The child is currently experiencing failure to thrive and has evidence of chronic metabolic acidosis. Which of the following best describes the appropriateness of acetazolamide for this patient?", "options": {"A": "Acetazolamide is suitable for long-term seizure control in this pediatric patient.", "B": "Acetazolamide should be avoided due to risk of growth retardation and exacerbation of acidosis.", "C": "Acetazolamide is recommended only if the patient has no hepatic involvement.", "D": "Acetazolamide is indicated for pediatric patients with ALG12-CDG regardless of metabolic status."}}
{"id": "cEfzYwrDeEfb", "question_type": "open_ended_multi_choice", "question": "A 67-year-old man diagnosed with NASH and stage F2 liver fibrosis is a candidate for drug therapy. His medical history includes mild renal impairment (eGFR 55 mL/min/1.73 m²), and he is taking atorvastatin 80 mg daily for lipid control. Considering possible drug interactions and the need for dose adjustments, which treatment plan is most appropriate for his NASH?", "options": {"A": "Resmetirom once daily with atorvastatin reduced to 40 mg daily", "B": "Pentoxifylline extended-release tablets twice daily with atorvastatin 80 mg daily", "C": "Resmetirom once daily with atorvastatin 80 mg daily", "D": "Dapagliflozin once daily with atorvastatin 80 mg daily"}}
{"id": "w8msz87p2COZ", "question_type": "open_ended_multi_choice", "question": "What underlying mechanism explains the advice to avoid combining Romvimza with medications that are substrates of P-gp, BCRP, and OCT2?", "options": {"A": "Romvimza acts as an inhibitor of these transporters in vitro.", "B": "Romvimza induces hepatic enzymes.", "C": "Romvimza increases renal clearance of substrates.", "D": "Romvimza is a substrate for these transporters."}}
{"id": "rQWVqFpVryve", "question_type": "multi_choice", "question": "A patient receiving Emrelis develops new-onset blurred vision and keratitis. What is the recommended clinical action for Grade ≥2 ocular toxicity?", "options": {"A": "Withhold Emrelis and refer to an eye care professional", "B": "Continue Emrelis at the same dose", "C": "Permanently discontinue Emrelis immediately", "D": "Reduce the dose of Emrelis without referral"}}
{"id": "EGcnNLnAPZiQ", "question_type": "open_ended", "question": "Which statement best describes the carcinogenic potential of Wayrilz in Tg.rasH2 mice?", "options": {"A": "Wayrilz was carcinogenic at all tested doses.", "B": "Wayrilz was carcinogenic only at the highest dose.", "C": "Wayrilz was not carcinogenic at doses up to 300 mg/kg/day.", "D": "Wayrilz induced tumors at low doses only."}}
{"id": "re9WOzArfUY3", "question_type": "open_ended_multi_choice", "question": "A 68-year-old woman with a malignant non-epithelial tumor of the ovary and a history of mild hepatic impairment (total bilirubin 1.3 x ULN, AST 8 x ULN) is being considered for chemotherapy. She is not currently taking any CYP2C8 or CYP3A4 inhibitors or inducers. Her baseline neutrophil count is 2,000 cells/mm³. Which of the following is the most appropriate chemotherapeutic agent for her, considering her age and hepatic function?", "options": {"A": "Etoposide administered by slow intravenous infusion at a cautious, low starting dose", "B": "Paclitaxel protein-bound particles for injectable suspension (albumin-bound) at standard adult dosing", "C": "Paclitaxel protein-bound particles for injectable suspension (albumin-bound) at a reduced dose for hepatic impairment", "D": "Etoposide administered by rapid intravenous injection at standard dosing"}}
{"id": "AmoK2IOIWL58", "question_type": "open_ended", "question": "For geriatric patients aged 65 and older, what is the current understanding of their response to Imaavy?", "options": {"A": "They respond better than younger adults", "B": "They respond worse than younger adults", "C": "There is insufficient data to determine differences in response", "D": "They have higher rates of adverse reactions"}}
{"id": "LpPBID69jEOX", "question_type": "open_ended_multi_choice", "question": "What is the recommended action if a patient develops signs of life-threatening arrhythmias while on Modeyso?", "options": {"A": "Reduce the dose of Modeyso.", "B": "Interrupt Modeyso and resume after arrhythmia resolves.", "C": "Permanently discontinue Modeyso.", "D": "Continue Modeyso with increased monitoring."}}
{"id": "3z9BThE8RI25", "question_type": "multi_choice", "question": "A 50-year-old woman with chronic hypoparathyroidism is currently being treated with digoxin for atrial fibrillation. Her serum calcium is well controlled on calcium and active vitamin D. She is being considered for additional therapy to better manage her hypoparathyroidism. Which of the following is the most important consideration if Yorvipath is initiated?", "options": {"A": "Yorvipath is contraindicated in patients with a history of atrial fibrillation", "B": "Yorvipath should be administered twice daily to minimize calcium fluctuations", "C": "Yorvipath is not effective in patients taking active vitamin D", "D": "Yorvipath may increase the risk of digitalis toxicity due to elevated serum calcium"}}
{"id": "BOtXinPjIOHl", "question_type": "multi_choice", "question": "In the AK105-304 trial, what was the major efficacy outcome measure used to evaluate penpulimab-kcqx in combination with platinum and gemcitabine?", "options": {"A": "Reduction in adverse events", "B": "Objective response rate (ORR) by investigator assessment", "C": "Quality of life improvement", "D": "BICR-assessed progression-free survival (PFS) according to RECIST v1.1"}}
{"id": "ldF9gXC9Ja7S", "question_type": "multi_choice", "question": "A 52-year-old woman presents with progressive difficulty focusing on near objects and is diagnosed with presbyopia. She has a history of iritis and is seeking pharmacological treatment to improve her near vision. Which of the following drugs is most appropriate for her condition?", "options": {"A": "VIZZ administered as topical ocular drops twice daily", "B": "VIZZ administered as topical ocular drops once daily", "C": "Oraverse intraoral injection after dental procedures", "D": "Mirvaso topical gel applied once daily"}}
{"id": "lmLZjIJmw5eF", "question_type": "open_ended_multi_choice", "question": "A 54-year-old man with a history of epilepsy and chronic kidney disease (creatinine clearance < 50 mL/min) is admitted with Staphylococcus aureus bloodstream infection (bacteremia). He is currently on anticonvulsant therapy and has no known allergies. Which antibiotic regimen is most appropriate for his condition, considering drug safety, dosing adjustments, and risk of CNS adverse effects?", "options": {"A": "Ceftobiprole medocaril sodium with renal dose adjustment", "B": "Ceftobiprole medocaril sodium at standard adult dose", "C": "Doxycycline hyclate", "D": "Acetaminophen"}}
{"id": "zuIioKjCFIUz", "question_type": "open_ended", "question": "A 45-year-old man with hereditary angioedema is being considered for prophylactic therapy. He is currently taking an ACE inhibitor for hypertension and has a history of mild hepatic impairment. Which drug is most suitable for long-term prophylaxis in this patient?", "options": {"A": "Firazyr administered subcutaneously for prophylaxis", "B": "TAKHZYRO administered subcutaneously for prophylaxis", "C": "ANDEMBRY administered subcutaneously for prophylaxis", "D": "Firazyr administered subcutaneously for acute attacks only"}}
{"id": "1dN6lF0VmLpc", "question_type": "multi_choice", "question": "If a patient develops Grade 4 peripheral neuropathy while receiving Emrelis, what is the recommended course of action?", "options": {"A": "Withhold Emrelis until recovery to Grade ≤1, then resume at the next lower dose", "B": "Permanently discontinue Emrelis", "C": "Resume Emrelis at the same dose after recovery", "D": "Reduce the dose by 50% and continue"}}
{"id": "OkBJ86FoHUEv", "question_type": "multi_choice", "question": "For the drug Lynozyfic, what is known about its effects on fertility based on animal studies?", "options": {"A": "Animal studies have shown Lynozyfic impairs fertility.", "B": "Animal studies have shown Lynozyfic improves fertility.", "C": "Animal studies are currently underway to assess fertility effects.", "D": "No animal studies have been performed to evaluate the effects of Lynozyfic on fertility."}}
{"id": "CSCeuga4K1hG", "question_type": "open_ended_multi_choice", "question": "A 55-year-old woman with metastatic esophageal squamous cell carcinoma, whose tumor expresses PD-L1 (CPS = 12), has previously received platinum-based chemotherapy and is now seeking second-line therapy. She is currently taking ritonavir for HIV and has no history of hepatic impairment. Which drug is most suitable for her next line of treatment?", "options": {"A": "Docetaxel anhydrous monotherapy, administered every 3 weeks", "B": "Tevimbra as a single agent, administered every 3 weeks", "C": "Keytruda QLEX as a single agent, administered every 3 weeks", "D": "Docetaxel anhydrous in combination with cisplatin and fluorouracil, administered every 3 weeks"}}
{"id": "97xQRs5dJQ56", "question_type": "open_ended_multi_choice", "question": "If concomitant use of Hernexeos with strong CYP3A inducers cannot be avoided, what adjustment should be made to the Hernexeos dosing regimen?", "options": {"A": "Decrease the dose of Hernexeos", "B": "Increase the dose of Hernexeos", "C": "Discontinue Hernexeos", "D": "Switch to a CYP3A inhibitor"}}
{"id": "acl7e2Io1RHK", "question_type": "open_ended", "question": "A 35-year-old woman with hereditary angioedema is currently taking digoxin for cardiac arrhythmia and is seeking prophylactic therapy to prevent HAE attacks. She has normal renal and hepatic function. Which drug is the most suitable option for her prophylaxis?", "options": {"A": "Orladeyo 150 mg once daily", "B": "DAWNZERA 80 mg subcutaneously every 4 weeks", "C": "Kalbitor as needed for prophylaxis", "D": "Orladeyo 300 mg once daily"}}
{"id": "3ZRNVMSFE6Lt", "question_type": "multi_choice", "question": "For a female patient of reproductive potential who is about to start Wayrilz therapy, which of the following is the most appropriate recommendation regarding contraception?", "options": {"A": "No contraception is required during Wayrilz treatment.", "B": "Use effective contraception only during Wayrilz treatment.", "C": "Contraception is only needed if pregnancy is confirmed.", "D": "Use contraception for 1 month after stopping Wayrilz."}}
{"id": "264nVsE9DWnq", "question_type": "open_ended_multi_choice", "question": "A 42-year-old patient with paroxysmal nocturnal hemoglobinuria (PNH) and significant hepatic impairment (Child-Pugh C) presents for management. He is not receiving any complement inhibitor treatment. What is the recommended pharmacologic approach for his PNH in this scenario?", "options": {"A": "Voydeya as add-on to ravulizumab", "B": "Ravulizumab monotherapy", "C": "Sirolimus", "D": "Voydeya monotherapy"}}
{"id": "tfOPdeEVm5xy", "question_type": "open_ended_multi_choice", "question": "A 32-year-old woman presents with moderate dry eye disease. She is currently 10 weeks pregnant and is concerned about the safety of medications for her developing fetus. She does not wear contact lenses and has no history of ocular infections or glaucoma. Which drug is the most appropriate for treating her dry eye disease, considering her pregnancy status and safety profile?", "options": {"A": "Lotemax SM", "B": "TRYPTYR", "C": "Xiidra", "D": "Artificial tears (non-prescription)"}}
{"id": "gubnEw3FFlnQ", "question_type": "multi_choice", "question": "A 32-year-old woman with chronic graft-versus-host disease (cGVHD) and symptoms of myalgia, nail dystrophy, and recurrent infections is currently pregnant. She has failed two prior lines of systemic therapy. Her weight is 58 kg. Which drug should be avoided due to her pregnancy status?", "options": {"A": "PredniSONE Tablets, USP, 5 mg", "B": "Budesonide Inhalation", "C": "Low-dose Budesonide Inhalation", "D": "AXATILIMAB-CSFR"}}
{"id": "TUg34GaMccvq", "question_type": "multi_choice", "question": "What is known about the reversibility of Gomekli-induced infertility in females based on animal studies?", "options": {"A": "Reversibility is unknown", "B": "Reversibility is well established", "C": "Gomekli does not impair fertility", "D": "Infertility is permanent"}}
{"id": "QVMFP2qOKeNr", "question_type": "open_ended_multi_choice", "question": "A 15-year-old female with relapsed pediatric low-grade glioma harboring a BRAF fusion is currently using hormonal contraceptives. She is not pregnant and has normal hepatic and renal function. Which drug regimen is most appropriate for her tumor treatment?", "options": {"A": "Tovorafenib once daily, with continued use of hormonal contraceptives", "B": "Tovorafenib once daily, with switch to effective nonhormonal contraception", "C": "Etoposide intravenous infusion every 3 weeks", "D": "NEUPOGEN daily for neutropenia prevention"}}
{"id": "DcA0Rm70fEYp", "question_type": "open_ended_multi_choice", "question": "A 15-year-old male with X-linked intellectual disability with isolated growth hormone deficiency has mild intellectual disability, short stature, and panhypopituitarism. He also has hypothyroidism and is currently receiving thyroid hormone replacement. His endocrinologist considers drug therapy to address his delayed puberty. Which of the following drug regimens is most appropriate for this patient?", "options": {"A": "Testosterone pellets every 3-6 months for androgen replacement", "B": "Growth hormone replacement therapy with daily injections", "C": "Testosterone combined with growth hormone replacement", "D": "No drug therapy; monitor for spontaneous puberty"}}
{"id": "Jco54jQkwuNZ", "question_type": "open_ended_multi_choice", "question": "For a 68-year-old male with symptomatic obstructive hypertrophic cardiomyopathy (NYHA class III) who is currently on verapamil and metoprolol tartrate for arrhythmia, which medication should be avoided because it could increase the risk of negative inotropic effects and lead to heart failure?", "options": {"A": "Acoramidis Hydrochloride", "B": "Mavacamten", "C": "Metoprolol Tartrate", "D": "Diltiazem"}}
{"id": "8qSGU9JWb7AA", "question_type": "open_ended_multi_choice", "question": "Which population should be advised not to breastfeed during and for 1 week after treatment with Gomekli?", "options": {"A": "Women receiving Gomekli", "B": "Men receiving Gomekli", "C": "Pediatric patients under 2 years old", "D": "Patients with mild renal impairment"}}
{"id": "yOJMv0oH0d55", "question_type": "open_ended_multi_choice", "question": "When assessing the contraindications associated with Hernexeos, what key information should a biomedical researcher be aware of?", "options": {"A": "There are no contraindications for Hernexeos.", "B": "Hernexeos is contraindicated in patients with a history of hypersensitivity reactions.", "C": "Hernexeos should not be administered to patients with cardiovascular disease.", "D": "Hernexeos is contraindicated in patients taking anticoagulants."}}
{"id": "pJdWDx14C4Pj", "question_type": "open_ended", "question": "A patient prescribed Sephience reports noticing a yellow or orange discoloration in their feces. What is the most appropriate counseling point for this patient?", "options": {"A": "Advise the patient that this is a known effect of Sephience and is not typically harmful.", "B": "Instruct the patient to discontinue Sephience immediately.", "C": "Recommend increasing fluid intake to resolve the discoloration.", "D": "Suggest switching to a different medication."}}
{"id": "qZExJvOxHuJV", "question_type": "open_ended_multi_choice", "question": "If penpulimab-kcqx is used in the period surrounding allogeneic hematopoietic stem cell transplantation, what is one potential adverse outcome that can occur?", "options": {"A": "Hyperacute graft-versus-host-disease (GVHD)", "B": "Solid organ rejection only", "C": "Stevens-Johnson Syndrome", "D": "Diabetic ketoacidosis"}}
{"id": "RKmIw7ayTvKL", "question_type": "open_ended_multi_choice", "question": "For a 68-year-old woman diagnosed with BCG-unresponsive nonmuscle invasive bladder cancer (NMIBC) characterized by CIS and papillary tumors, and with no prior bladder perforation, severe irritable symptoms, recent TURBT, pregnancy, or intention to breastfeed, which intravesical treatment regimen should be recommended?", "options": {"A": "Valrubicin intravesical therapy alone", "B": "Nogapendekin alfa inbakicept-pmln (ANKTIVA) in combination with Bacillus Calmette-Guérin (BCG)", "C": "Valrubicin in combination with Bacillus Calmette-Guérin (BCG)", "D": "Nogapendekin alfa inbakicept-pmln (ANKTIVA) monotherapy"}}
{"id": "rLYNkZERX5De", "question_type": "open_ended_multi_choice", "question": "For a 16-year-old adolescent diagnosed with hemophilia A and moderate liver dysfunction (Child-Pugh Class B), without a history of gallbladder disease or use of hormonal contraceptives, what is the recommended prophylactic drug regimen?", "options": {"A": "Qfitlia administered subcutaneously once monthly", "B": "Hemlibra administered subcutaneously once weekly", "C": "Qfitlia administered subcutaneously using antithrombin-based dosing every four weeks", "D": "Fitusiran administered intravenously every two weeks"}}
{"id": "D98qx9LHO2yp", "question_type": "open_ended_multi_choice", "question": "A 28-year-old woman with hemophilia A (reduced factor VIII activity) is planning to become pregnant. She has a history of spontaneous hematomas and abnormal bleeding but currently has no factor VIII inhibitors. Her physician is considering prophylactic therapy to reduce bleeding episodes. Which drug should be avoided due to its potential risk to the fetus?", "options": {"A": "Desmopressin Acetate", "B": "MARSTACIMAB-HNCQ", "C": "Factor VIII concentrate", "D": "Tranexamic acid"}}
{"id": "8UtOidOxydkR", "question_type": "open_ended", "question": "A 5-year-old child with phenylketonuria, severe eczema, and hyperactivity is found to have sepiapterin-responsive PKU. The child is not taking any other medications and has no history of bleeding or hypersensitivity reactions. Which drug and dosing schedule is most appropriate for this patient?", "options": {"A": "Sapropterin dihydrochloride 20 mg/kg daily with a drug holiday every 2 weeks", "B": "Sephience 60 mg/kg daily with a Phe-restricted diet and frequent blood Phe monitoring", "C": "JAVYGTOR 20 mg/kg daily with a drug scheduler alternating weekly dosing", "D": "Sephience 30 mg/kg every other day with a Phe-restricted diet"}}
{"id": "E8SCQFfggljJ", "question_type": "open_ended_multi_choice", "question": "A 3-year-old child presents with multiple umbilicated papules on the trunk and extremities. The diagnosis of molluscum contagiosum is confirmed. The child has no known allergies, is otherwise healthy, and has no damaged skin or eczema. The parents are seeking a topical treatment that is both safe and effective for this age group. Which of the following is the most appropriate therapy for this patient, considering the approved indications and safety profile?", "options": {"A": "Zelsuvmi applied topically as directed for molluscum contagiosum", "B": "Curist Acne Relief applied once daily to the lesions", "C": "Oral berdazimer (systemic administration)", "D": "No treatment, as there are no approved topical therapies for this age group"}}
{"id": "DUlICOMqop48", "question_type": "open_ended", "question": "A 42-year-old woman with presbyopia is currently breastfeeding her 2-month-old infant. She wishes to start pharmacological treatment to improve her near vision. She has no significant medical history and is not taking any other medications. Which of the following is the most appropriate option for her?", "options": {"A": "Pilocarpine Hydrochloride tablets, 5 mg orally three times daily", "B": "Aceclidine (VIZZ), one drop in each eye daily", "C": "VUITY, one drop in each eye daily", "D": "Pilocarpine Hydrochloride tablets, 10 mg orally once daily"}}
{"id": "qwWPt6xmYOtx", "question_type": "multi_choice", "question": "Which reproductive safety advice should be given to females of reproductive potential who are prescribed Hernexeos?", "options": {"A": "No contraception is needed during treatment", "B": "Use effective contraception during treatment and for 2 weeks after the last dose", "C": "Contraception is only needed if pregnancy is suspected", "D": "Discontinue contraception immediately after starting Hernexeos"}}
{"id": "E675XFR1hZ33", "question_type": "open_ended_multi_choice", "question": "A 60-year-old male with a history of epilepsy controlled on valproic acid presents with a severe urinary tract infection. He has normal renal and hepatic function and no known drug allergies. Which drug should be avoided due to the risk of breakthrough seizures from drug interactions?", "options": {"A": "Imipenem and Cilastatin Sodium intravenous therapy, following standard dosing.", "B": "Blujepa, administered according to recommended dosing for severe UTI.", "C": "Flavoxate Hydrochloride tablets for symptomatic relief.", "D": "Imipenem and Cilastatin Sodium with dose adjustment for renal function."}}
{"id": "u1Q38gH5Tqal", "question_type": "open_ended_multi_choice", "question": "Which management strategy should be implemented for patients aged adult or pediatric, with a minimum weight of 52.5 kg, who need to use Modeyso alongside strong CYP3A4 inhibitors?", "options": {"A": "Increase the dose of Modeyso", "B": "Reduce the dose of Modeyso", "C": "Discontinue Modeyso", "D": "Administer Modeyso with food"}}
{"id": "6jAfi3k4JxJR", "question_type": "multi_choice", "question": "A 68-year-old male with a history of nonmuscle invasive bladder cancer presents with persistent carcinoma in situ (CIS) after failing two courses of Bacillus Calmette-Guérin (BCG) therapy. He has no significant comorbidities and is not currently taking any other medications. He is concerned about the risk of disease progression and wishes to avoid unnecessary systemic toxicity. Which of the following is the most appropriate next step in drug therapy for this patient, considering his disease subtype and treatment history?", "options": {"A": "Initiate Gemcitabine as a single agent administered intravenously weekly.", "B": "Begin Gemcitabine in combination with carboplatin.", "C": "Start Anktiva in combination with BCG administered intravesically.", "D": "Recommend systemic paclitaxel therapy."}}
{"id": "xkm7ecPDLXHI", "question_type": "open_ended_multi_choice", "question": "A 38-year-old female with PNH on pegcetacoplan wishes to know if she can safely maintain her current treatment regimen throughout pregnancy and breastfeeding. What is the best advice to provide in this scenario?", "options": {"A": "Continue pegcetacoplan throughout pregnancy and breastfeeding, as animal studies show no adverse effects.", "B": "Switch to crovalimab, as animal studies show no adverse developmental outcomes and breastfeeding is not recommended during and for 9 months after the last dose.", "C": "Continue pegcetacoplan, but discontinue breastfeeding for 40 days after the last dose due to potential risks.", "D": "Switch to danicopan, as animal studies show no adverse developmental effects and breastfeeding is not recommended during and for 3 days after the last dose."}}
{"id": "kj4sG1sR0hTG", "question_type": "open_ended_multi_choice", "question": "What is the appropriate recommendation concerning contraceptive use for patients at risk of pregnancy during Vanrafia therapy?", "options": {"A": "No contraception is needed", "B": "Use contraception only during treatment", "C": "Use effective contraception prior to, during, and for two weeks after discontinuation of Vanrafia", "D": "Use contraception for one month after discontinuation"}}
{"id": "hw2xvWtJM0N0", "question_type": "multi_choice", "question": "A 62-year-old man with non-alcoholic steatohepatitis (NASH) and advanced liver fibrosis (stage F3) presents for treatment. He has a history of decompensated cirrhosis (Child-Pugh Class B), chronic kidney disease (eGFR 50 mL/min/1.73 m²), and is currently taking clopidogrel for coronary artery disease. Which of the following drugs is most appropriate for his NASH management?", "options": {"A": "Rezdiffra, with dose reduction due to clopidogrel", "B": "Rezdiffra, standard dose", "C": "Farxiga, 10 mg once daily", "D": "Pentoxifylline extended-release tablets, 400 mg three times daily"}}
{"id": "tnob1ll16oI1", "question_type": "open_ended_multi_choice", "question": "A 62-year-old man with anemia secondary to chronic kidney disease has been on dialysis for 6 months. His past medical history includes cirrhosis and stable hypertension. He is not taking statins or iron supplements at this time. What is the recommended treatment for his anemia?", "options": {"A": "Vafseo, as it is indicated for anemia in CKD patients on dialysis.", "B": "DMT SUIK (corticosteroid), considering his comorbidities.", "C": "Vafseo, but only if liver function tests are normal.", "D": "Cortisone aceticum, as it is safe in liver disease."}}
{"id": "geCi1W9d6uSD", "question_type": "open_ended_multi_choice", "question": "A 68-year-old woman, stable on valproic acid for epilepsy, is admitted for a complicated UTI. She has normal renal function and is not pregnant. Which of the following drugs should be avoided in her treatment plan due to a major drug interaction that could heighten her risk of seizures?", "options": {"A": "Flavoxate Hydrochloride", "B": "Imipenem and Cilastatin", "C": "Gepotidacin", "D": "Both Flavoxate Hydrochloride and Gepotidacin"}}
{"id": "yXDZWRhop7oN", "question_type": "open_ended_multi_choice", "question": "A 38-year-old woman with primary biliary cholangitis and compensated cirrhosis (Child-Pugh A) has no evidence of portal hypertension or decompensation. She is a CYP2C9 poor metabolizer and is currently taking a moderate CYP3A4 inhibitor for another condition. She cannot tolerate UDCA due to severe pruritus. Which drug is most appropriate for her PBC management?", "options": {"A": "Ocaliva 5 mg once daily as monotherapy", "B": "Livdelzi 10 mg once daily as monotherapy with close monitoring for adverse effects", "C": "Tricor 145 mg once daily as monotherapy", "D": "Livdelzi 10 mg once daily as monotherapy without monitoring"}}
{"id": "fX0J3YRMphcy", "question_type": "open_ended_multi_choice", "question": "For a 70-year-old male with a history of acute coronary syndrome and recent stent insertion, genetic testing reveals poor CYP2C19 metabolic activity. There is no evidence of hepatic impairment or active bleeding. Which antiplatelet medication should be chosen to maximize efficacy?", "options": {"A": "Clopidogrel", "B": "Flyrcado", "C": "BRILINTA", "D": "Clopidogrel with omeprazole"}}
{"id": "UFGDCxAWnggZ", "question_type": "multi_choice", "question": "Which of the following is TRUE regarding the administration of Modeyso via feeding tube?", "options": {"A": "Modeyso cannot be administered via feeding tube", "B": "Modeyso capsules must be swallowed whole for tube administration", "C": "Modeyso may be given through a naso-gastric or gastrostomy tube after preparing the liquid mixture", "D": "Modeyso should be mixed with food before tube administration"}}
{"id": "w78ZN0KFkomC", "question_type": "open_ended_multi_choice", "question": "Which statement best describes the comparability of adverse reaction rates for Tryptyr between different clinical trials?", "options": {"A": "Adverse reaction rates from Tryptyr clinical trials cannot be directly compared to those from other drug trials due to varying conditions.", "B": "Adverse reaction rates for Tryptyr are always higher than those for other drugs.", "C": "Adverse reaction rates for Tryptyr are standardized across all clinical trials.", "D": "Adverse reaction rates for Tryptyr are only valid for European populations."}}
{"id": "La94wZMNjDk4", "question_type": "open_ended_multi_choice", "question": "A 62-year-old male with metastatic non-small cell lung cancer (NSCLC) is found to have a PD-L1 positive tumor (at least 1%) and no EGFR or ALK mutations. His history includes autoimmune thyroiditis, managed with levothyroxine, and he is euthyroid. He is not pregnant and has normal hepatic function. Which therapy is most appropriate to initiate as first-line treatment?", "options": {"A": "CYRAMZA (ramucirumab) in combination with docetaxel every 3 weeks", "B": "ENSACOVE (ensartinib) 225 mg orally once daily", "C": "YERVOY (ipilimumab) in combination with nivolumab every 6 weeks", "D": "CYRAMZA (ramucirumab) in combination with erlotinib every 2 weeks"}}
{"id": "Pc8iyG6x1Ztr", "question_type": "multi_choice", "question": "Which of the following immune-mediated endocrinopathies has the highest reported incidence in patients treated with penpulimab-kcqx as a single agent?", "options": {"A": "Adrenal insufficiency", "B": "Hyperthyroidism", "C": "Thyroiditis", "D": "Hypothyroidism"}}
{"id": "pSmAK2c32SJL", "question_type": "open_ended_multi_choice", "question": "A 58-year-old woman diagnosed with locally advanced, hormone receptor-positive, HER2-negative breast cancer is found to carry a PIK3CA mutation through FDA-approved testing. She has well-controlled type 2 diabetes treated with oral hypoglycemic drugs, normal renal function, and is not pregnant or breastfeeding. She is being considered for a targeted therapy regimen to be given with palbociclib and fulvestrant. Which treatment approach is most appropriate for her, given her comorbidities and the safety considerations of the available options?", "options": {"A": "Carboplatin in combination with cyclophosphamide", "B": "Inavolisib in combination with palbociclib and fulvestrant", "C": "Esketamine as monotherapy", "D": "Carboplatin as a single agent"}}
{"id": "oCNp0nrEB0tQ", "question_type": "open_ended_multi_choice", "question": "A woman aged 28 with Niemann-Pick disease type C and neurological manifestations is planning to conceive. She has normal kidney function and is not on any medications that are OCT2 substrates. What is the best recommendation for drug treatment of her NPC at this time?", "options": {"A": "Initiate MIPLYFFA in combination with miglustat immediately", "B": "Delay MIPLYFFA and miglustat therapy until after pregnancy due to risk of embryofetal harm", "C": "Start OPFOLDA in combination with Pombiliti", "D": "Begin lithium carbonate therapy"}}
{"id": "Q7GRA9uwOq7u", "question_type": "open_ended_multi_choice", "question": "A 28-year-old woman affected by Niemann-Pick disease type C, who displays neurological symptoms and intends to become pregnant, has normal renal function and is not taking OCT2 substrate medications. What is the most appropriate advice concerning drug therapy for her NPC?", "options": {"A": "Initiate MIPLYFFA in combination with miglustat immediately", "B": "Delay MIPLYFFA and miglustat therapy until after pregnancy due to risk of embryofetal harm", "C": "Start OPFOLDA in combination with Pombiliti", "D": "Begin lithium carbonate therapy"}}
{"id": "2o9FvsAOXwUm", "question_type": "multi_choice", "question": "A 28-year-old woman with classic congenital adrenal hyperplasia is pregnant and currently receiving glucocorticoid replacement therapy. She is seeking advice on adjunctive therapy to control androgen levels. Which statement best reflects the appropriateness of Crenessity for her condition?", "options": {"A": "Crenessity is contraindicated in pregnancy due to high risk of fetal malformations", "B": "Crenessity is recommended as first-line therapy in all pregnant women with CAH", "C": "Crenessity may be considered if benefits outweigh risks, but data in pregnancy are limited", "D": "Crenessity is only approved for use in pediatric patients"}}
{"id": "NkQICkx8FtgP", "question_type": "open_ended_multi_choice", "question": "If a patient cannot tolerate Datroway at 3 mg/kg intravenously every 3 weeks, what is the recommended course of action?", "options": {"A": "Increase the dose to 4 mg/kg", "B": "Continue at 3 mg/kg", "C": "Permanently discontinue Datroway", "D": "Reduce to 2 mg/kg"}}
{"id": "x45xx47YD1r7", "question_type": "open_ended_multi_choice", "question": "A pregnant woman is newly diagnosed with low-grade glioma. She is in her first trimester and is concerned about fetal safety. Which of the following drugs is safest to use in her case?", "options": {"A": "Tovorafenib administered once daily", "B": "Etoposide administered intravenously", "C": "NEUPOGEN administered as needed for neutropenia", "D": "Tovorafenib administered with hormonal contraceptives"}}
{"id": "06lT92LlmhY7", "question_type": "open_ended_multi_choice", "question": "Considering a 14-year-old patient who has undergone subtotal resection for Grade 2 astrocytoma, tested positive for a susceptible IDH1 mutation, is not pregnant, has normal renal and hepatic function, and is not taking any CYP1A2 or CYP3A4 inhibitors or inducers, which treatment regimen is recommended for continued management based on efficacy and safety for this age group?", "options": {"A": "Vorasidenib 40 mg once daily, with regular liver function monitoring", "B": "Avastin administered every 2 weeks", "C": "Zortress in combination with cyclosporine and corticosteroids", "D": "Avastin in combination with carboplatin and paclitaxel"}}
{"id": "Ju7Lt4ljFq26", "question_type": "open_ended_multi_choice", "question": "A 35-year-old woman with metastatic ROS1-positive non-small cell lung carcinoma is currently pregnant and seeking advice on targeted therapy options. She is otherwise healthy and not taking any other medications. What is the most appropriate recommendation regarding taletrectinib therapy for her?", "options": {"A": "Start taletrectinib 600 mg orally once daily as it is safe in pregnancy.", "B": "Delay taletrectinib until after delivery due to risk of fetal harm.", "C": "Start taletrectinib with close fetal monitoring.", "D": "Taletrectinib is only contraindicated in pediatric patients, not pregnant women."}}
{"id": "741z04PPO7qb", "question_type": "multi_choice", "question": "For a clinical trial involving Modeyso, which exclusion criteria based on contraindications would be supported by the drug's official documentation?", "options": {"A": "No exclusion criteria based on contraindications are required", "B": "Exclude patients with known hypersensitivity to Modeyso", "C": "Exclude patients with liver failure", "D": "Exclude pregnant women"}}
{"id": "HmwSQiBwPmD6", "question_type": "open_ended_multi_choice", "question": "Which of the following statements is correct regarding the use of Blujepa in pediatric patients?", "options": {"A": "Blujepa is approved for all pediatric patients regardless of age or weight.", "B": "Blujepa is only approved for pediatric patients under 12 years of age.", "C": "Blujepa is approved for female pediatric patients 12 years and older, weighing at least 40 kg.", "D": "Blujepa is only approved for male pediatric patients."}}
{"id": "4u7um38TmJKQ", "question_type": "open_ended_multi_choice", "question": "A 68-year-old woman with myelodysplastic syndromes (MDS) presents with intermediate-2 risk disease and a history of chronic kidney disease (estimated creatinine clearance 35 mL/min). She is not pregnant and is not breastfeeding. She is currently taking a medication metabolized by cytidine deaminase for another condition. Which drug regimen is most appropriate for her MDS treatment, considering her comorbidities and current medications?", "options": {"A": "INQOVI (oral decitabine + cedazuridine) once daily for 5 days every 28-day cycle", "B": "Decitabine intravenous infusion daily for 5 days every 4 weeks", "C": "RYTELO intravenous infusion every 4 weeks with premedication for infusion reactions", "D": "INQOVI (oral decitabine + cedazuridine) with a drug holiday every other cycle"}}
{"id": "Ssw3KvbJfhTP", "question_type": "multi_choice", "question": "A patient receiving Modeyso develops a rash, hives, and low blood pressure. What is the most appropriate immediate clinical action?", "options": {"A": "Immediately discontinue Modeyso and initiate appropriate medical treatment and supportive care.", "B": "Temporarily interrupt Modeyso and observe for improvement.", "C": "Continue Modeyso and monitor symptoms closely.", "D": "Reduce the dose of Modeyso and prescribe antihistamines."}}
{"id": "Yl6qjY1BPuTv", "question_type": "open_ended_multi_choice", "question": "A 3-year-old male diagnosed with relapsed acute erythroleukemia and a KMT2A gene translocation presents with refractory anemia, ringed sideroblasts, and hepatomegaly. He weighs less than 40 kg and has no cardiac disease history. Which targeted therapy is most appropriate for this child?", "options": {"A": "Daunorubicin Hydrochloride administered intravenously at standard pediatric dosing", "B": "TaperDex 12-day administered at the lowest effective dose to minimize growth suppression", "C": "REVUMENIB administered orally with BSA-based dosing and regular monitoring of bone growth", "D": "TaperDex 12-day combined with Daunorubicin Hydrochloride for induction therapy"}}
{"id": "VkQjWsUI9XnB", "question_type": "multi_choice", "question": "If Journavx is co-administered with a moderate CYP3A inhibitor, what adjustment should be made?", "options": {"A": "Increase the dose of Journavx.", "B": "Switch to a strong CYP3A inducer.", "C": "Discontinue the CYP3A inhibitor.", "D": "No adjustment is necessary."}}
{"id": "7iBr6CMt9KAI", "question_type": "open_ended_multi_choice", "question": "A patient with severe renal impairment is being considered for Wayrilz therapy. What is the appropriate clinical decision?", "options": {"A": "Administer Wayrilz at a reduced dose.", "B": "Avoid use of Wayrilz.", "C": "Administer Wayrilz at the standard dose.", "D": "Increase the dose of Wayrilz."}}
{"id": "z7EwzE4Wj6op", "question_type": "open_ended_multi_choice", "question": "A 62-year-old female patient with a history of treated, unresectable intrahepatic cholangiocarcinoma is discovered to have a tumor with an FGFR2 gene fusion, as determined by an FDA-approved test. She also has severe renal impairment (eGFR 20 mL/min/1.73 m²), is not pregnant, and is not on strong CYP3A inhibitors or inducers. Given her renal status, which targeted drug should be selected for her?", "options": {"A": "LYTGOBI", "B": "ZIIHERA", "C": "PEMAZYRE", "D": "Gemcitabine"}}
{"id": "KgxHkWHThfpu", "question_type": "open_ended_multi_choice", "question": "A 34-year-old woman with newly diagnosed hypertension and elevated mean arterial pressure is seeking pharmacologic therapy. She is planning to become pregnant in the next few months and is currently using oral hormonal contraceptives. She has normal renal and hepatic function and no other comorbidities. Which antihypertensive agent is most appropriate for her at this time?", "options": {"A": "Aprocitentan (TRYVIO), once daily", "B": "Bosentan (TRACLEER), twice daily", "C": "Chlorthalidone (THALITONE), once daily", "D": "Aprocitentan (TRYVIO), twice daily"}}
{"id": "EyzRcS05FEM1", "question_type": "open_ended_multi_choice", "question": "When counseling a patient who has been prescribed Ekterly, which statement accurately reflects appropriate guidance?", "options": {"A": "Read the FDA-approved patient labeling (Patient Information)", "B": "Take Ekterly with grapefruit juice to enhance absorption", "C": "Double the dose if symptoms persist after 1 hour", "D": "Discontinue Ekterly if experiencing mild hepatic impairment"}}
{"id": "oOYhIqDYHeb1", "question_type": "open_ended", "question": "A 29-year-old woman with HIV wasting syndrome is seeking pharmacologic therapy to address her muscle wasting. She is currently breastfeeding her 2-month-old infant. Which of the following is the most appropriate recommendation regarding drug therapy for her condition?", "options": {"A": "Initiate oxandrolone while continuing breastfeeding", "B": "Start XYOSTED, as it is safe in lactating women", "C": "Avoid thalidomide due to risk of severe birth defects and discontinue breastfeeding if drug therapy is necessary", "D": "Begin thalidomide, as it is not excreted in human milk"}}
{"id": "WLVf5ioWPq68", "question_type": "open_ended_multi_choice", "question": "A 68-year-old woman with a medical history of gout and chronic kidney disease (creatinine clearance 18 mL/min) presents with an uncomplicated urinary tract infection. She has a cephalosporin allergy but no other known antibiotic allergies and is not on any medications with significant interaction risk. Which antibiotic therapy is most appropriate for managing her UTI?", "options": {"A": "Sulopenem etzadroxil and probenecid (Orlynvah) orally", "B": "Imipenem and cilastatin intravenously with renal dose adjustment", "C": "Flavoxate hydrochloride orally", "D": "Sulopenem etzadroxil and probenecid (Orlynvah) with a drug holiday"}}
{"id": "Z646gGtEuagY", "question_type": "open_ended_multi_choice", "question": "How should the comparability of adverse reaction rates for Tryptyr across different clinical trials be characterized?", "options": {"A": "Adverse reaction rates from Tryptyr clinical trials cannot be directly compared to those from other drug trials due to varying conditions.", "B": "Adverse reaction rates for Tryptyr are always higher than those for other drugs.", "C": "Adverse reaction rates for Tryptyr are standardized across all clinical trials.", "D": "Adverse reaction rates for Tryptyr are only valid for European populations."}}
{"id": "YGQ4OVXIiHSz", "question_type": "open_ended_multi_choice", "question": "A 35-year-old patient who is pregnant in her second trimester complains of dysuria and frequent urination. After confirming an uncomplicated urinary tract infection and normal renal and hepatic function, and noting she takes no medications, which drug should be selected for safe symptomatic treatment during pregnancy?", "options": {"A": "Imipenem and Cilastatin", "B": "Gepotidacin", "C": "Flavoxate Hydrochloride", "D": "None; all are contraindicated in pregnancy"}}
{"id": "Nj2GgQKSRaiU", "question_type": "open_ended", "question": "A 32-year-old woman with newly diagnosed myasthenia gravis is planning to become pregnant. She has anti-acetylcholine receptor antibody positivity and experiences fatigable weakness and ptosis. Which drug should be avoided due to insufficient safety data in pregnancy, and what is the best alternative for her current condition?", "options": {"A": "IMAAVY", "B": "DuoDote", "C": "Pyridostigmine Bromide", "D": "Mivacurium"}}
{"id": "18x6Wsj1ih4O", "question_type": "open_ended_multi_choice", "question": "A 45-year-old female patient with dry eye disease, who regularly wears contact lenses, wants a medication that she can use without having to remove her lenses. She is not pregnant, has no prior ocular infections, and desires a treatment proven to be safe for adults. Which drug best suits her needs based on these criteria?", "options": {"A": "TRYPTYR", "B": "Lotemax SM", "C": "Xiidra", "D": "Topical corticosteroid drops (other than Lotemax SM)"}}
{"id": "f9LQlaaXgvTo", "question_type": "open_ended_multi_choice", "question": "A 32-year-old pregnant woman at 10 weeks gestation has been newly diagnosed with generalized myasthenia gravis and tests positive for anti-MuSK antibodies. She also has a history of Hashimoto thyroiditis and is worried about medication safety during pregnancy. Which therapy should be avoided because it is known to be teratogenic and contraindicated for use during pregnancy?", "options": {"A": "IMAAVY, 15 mg/kg intravenous infusion every 2 weeks", "B": "Azathioprine, 75 mg daily oral administration", "C": "DuoDote, single dose for acute management", "D": "IMAAVY, 10 mg/kg intravenous infusion every 4 weeks"}}
{"id": "MwFx3Q1XrqaI", "question_type": "open_ended_multi_choice", "question": "A 77-year-old female with a history of BCG-unresponsive nonmuscle invasive bladder cancer and carcinoma in situ is being considered for further therapy. She has mild chronic liver disease and is concerned about the risk of severe systemic side effects, particularly myelosuppression and hepatic toxicity. Which of the following treatment options is most appropriate for her condition?", "options": {"A": "Gemcitabine administered intravenously, with close monitoring of blood counts and liver function.", "B": "Anktiva in combination with BCG administered intravesically.", "C": "Gemcitabine in combination with paclitaxel.", "D": "Gemcitabine with concurrent radiation therapy."}}
{"id": "03hAerqXpRwt", "question_type": "open_ended", "question": "If Anzupgo accidentally comes into contact with mucous membranes, what is the recommended immediate action?", "options": {"A": "Rinse thoroughly with water", "B": "Apply more Anzupgo to the area", "C": "Leave the area untreated", "D": "Cover the area with a bandage"}}
{"id": "j8pn18Kn4tx9", "question_type": "open_ended_multi_choice", "question": "A 42-year-old woman presents with progressive bilateral exophthalmos and is diagnosed with endocrine exophthalmos (Thyroid Eye Disease). She has a history of poorly controlled type 2 diabetes (HbA1c 9.2%) and reports frequent episodes of hyperglycemia. Her hearing is normal, and she has no history of inflammatory bowel disease. Which of the following is the most appropriate next step regarding drug therapy for her condition?", "options": {"A": "Initiate TEPEZZA therapy after ensuring glycemic control and close monitoring of blood glucose during treatment.", "B": "Start TEPEZZA immediately without addressing her hyperglycemia.", "C": "TEPEZZA is contraindicated due to her age; consider alternative therapy.", "D": "TEPEZZA is contraindicated due to her normal hearing; avoid use."}}
{"id": "P8o6kIK56Y1U", "question_type": "multi_choice", "question": "A 68-year-old man with chronic atopic dermatitis, flexural lichenification, and recurrent pruritus is seeking relief for his symptoms. He has a history of mild cognitive impairment and is currently taking cimetidine for gastric reflux. He is not on any immunosuppressive therapy and has no active infections. Which treatment option should be avoided due to his current medication and risk profile?", "options": {"A": "DMT SUIK administered intramuscularly for acute exacerbation", "B": "Doxepin hydrochloride cream applied three times daily for 8 days", "C": "Lebrikizumab-lbkz administered subcutaneously every 2 weeks", "D": "Doxepin hydrochloride cream applied once daily for 8 days"}}
{"id": "xdEOCT94XKfW", "question_type": "multi_choice", "question": "What is the recommendation regarding the use of live vaccines in patients receiving Anzupgo?", "options": {"A": "Avoid live vaccines immediately prior to, during, and immediately after Anzupgo treatment", "B": "Live vaccines are recommended during Anzupgo therapy", "C": "Live vaccines should be given only after discontinuing Anzupgo for 6 months", "D": "Live vaccines are contraindicated only in pediatric patients"}}
{"id": "h4vKW7Fy7htt", "question_type": "open_ended_multi_choice", "question": "A 62-year-old man is newly diagnosed with metastatic undifferentiated pancreatic carcinoma. He has no significant renal or hepatic impairment and is not taking any CYP3A4 inducers or inhibitors. His oncologist is considering first-line systemic therapy. Which regimen is most appropriate for this patient?", "options": {"A": "Onivyde in combination with oxaliplatin, fluorouracil, and leucovorin", "B": "Irinotecan Hydrochloride 100 mg/5 mL as a single agent", "C": "Onivyde as a single agent", "D": "Irinotecan Hydrochloride 100 mg/5 mL in combination with oxaliplatin, fluorouracil, and leucovorin"}}
{"id": "qzunUq3z4E2q", "question_type": "open_ended_multi_choice", "question": "A 68-year-old man with a recent history of myocardial infarction and hypertension is diagnosed with pemphigus vulgaris, presenting with oral mucosal blisters and recurrent infections. He is currently taking digitalis glycosides for heart failure and warfarin for atrial fibrillation. Which treatment option is most appropriate for his condition, considering his comorbidities and drug interactions?", "options": {"A": "DEXAMETHASONE SODIUM PHOSPHATE intravenous injection, starting at a low dose", "B": "Proleukin administered in a hospital setting with intensive care monitoring", "C": "TaperDex 12-day oral regimen at standard adult dosing", "D": "Proleukin administered subcutaneously with concurrent glucocorticoid therapy"}}
{"id": "GEnj1AReS6MS", "question_type": "open_ended_multi_choice", "question": "In a pediatric patient aged 3 years with relapsed acute erythroleukemia, KMT2A translocation, refractory anemia with ringed sideroblasts, hepatomegaly, body weight under 40 kg, and no prior cardiac disease, which drug should be selected for targeted treatment?", "options": {"A": "Daunorubicin Hydrochloride administered intravenously at standard pediatric dosing", "B": "TaperDex 12-day administered at the lowest effective dose to minimize growth suppression", "C": "REVUMENIB administered orally with BSA-based dosing and regular monitoring of bone growth", "D": "TaperDex 12-day combined with Daunorubicin Hydrochloride for induction therapy"}}
{"id": "4wmTALXMGrRB", "question_type": "open_ended", "question": "A 58-year-old woman with relapsed small cell lung cancer is being considered for oral chemotherapy. She is currently taking a strong P-glycoprotein inhibitor for another condition and has a baseline neutrophil count of 1,600/mm³ and platelet count of 110,000/mm³. She is not pregnant, has normal renal function, and no history of interstitial lung disease. Which drug regimen should be avoided due to drug interaction risk?", "options": {"A": "TOPOTECAN (HYCAMTIN) capsules at standard dose for 5 consecutive days every 21-day cycle", "B": "KOSELUGO administered twice daily", "C": "TOPOTECAN (HYCAMTIN) capsules at standard dose with concurrent P-glycoprotein inhibitor", "D": "TOPOTECAN (HYCAMTIN) capsules at reduced dose due to renal impairment"}}
{"id": "rcaeyyrpV62r", "question_type": "multi_choice", "question": "A 10-year-old boy with primary axillary hyperhidrosis and chronic renal failure is being considered for topical anticholinergic therapy. He is not taking any other medications. Which treatment option is most appropriate for his condition?", "options": {"A": "Qbrexza (glycopyrronium), topical wipes once daily", "B": "None of the above are appropriate due to his age and renal impairment", "C": "Oxytrol for Women (oxybutynin), transdermal patch twice weekly", "D": "Sofdra (sofpironium bromide), topical gel once daily"}}
{"id": "5fsr6mszuaQS", "question_type": "open_ended_multi_choice", "question": "A man aged 42, diagnosed with paroxysmal nocturnal hemoglobinuria (PNH) and suffering from severe hepatic dysfunction (Child-Pugh C), is being evaluated for initial therapy. He has no prior exposure to complement inhibitors. Which drug therapy should be selected for his PNH?", "options": {"A": "Voydeya as add-on to ravulizumab", "B": "Ravulizumab monotherapy", "C": "Sirolimus", "D": "Voydeya monotherapy"}}
{"id": "Gxgzk6Ue11vx", "question_type": "open_ended_multi_choice", "question": "A 7-year-old girl diagnosed with cystic fibrosis (F508del/F508del) presents with childhood bronchiectasis, failure to thrive, and elevated sweat chloride. She is currently on oral hormonal contraceptives for another indication. What is the most suitable drug regimen for her management?", "options": {"A": "Brinsupri, with monitoring for dermatologic adverse reactions", "B": "ORKAMBI, with counseling to use non-hormonal contraception", "C": "SYMDEKO, with standard dosing and no change to contraceptive regimen", "D": "ORKAMBI, with no contraceptive counseling required"}}
{"id": "LbEhGy08RANw", "question_type": "open_ended_multi_choice", "question": "What safety measure is recommended for individuals taking Vizz prior to nighttime driving or machinery operation?", "options": {"A": "Ensure vision is clear before engaging in these activities.", "B": "Take Vizz immediately before driving.", "C": "Wear sunglasses at night.", "D": "Increase the dose if vision is blurred."}}
{"id": "FptUe1ZqAwVQ", "question_type": "multi_choice", "question": "A 59-year-old woman with extensive-stage small cell lung cancer and autosomal dominant inheritance presents for therapy after progression on platinum-based chemotherapy. She is currently pregnant and seeks advice on the safest treatment option for her condition. Which drug should be strictly avoided due to its risk profile in pregnancy?", "options": {"A": "Topotecan capsules, administered orally as per standard schedule", "B": "Imdelltra, administered intravenously with step-up dosing", "C": "Ipilimumab, administered every 3 weeks", "D": "Supportive care only, with no cytotoxic or immunotherapy agents"}}
{"id": "Oapok4USSMbJ", "question_type": "multi_choice", "question": "A 62-year-old man is newly diagnosed with locally advanced unresectable gastroesophageal junction adenocarcinoma. His tumor is confirmed to be HER2-negative and CLDN18.2-positive by FDA-approved testing. He has normal hepatic and renal function, no history of hypersensitivity reactions, and is not taking any anticoagulants or CYP3A4 inhibitors. Which initial drug regimen is most appropriate for his first-line treatment?", "options": {"A": "Capecitabine monotherapy", "B": "Zolbetuximab (Vyloy) in combination with fluoropyrimidine- and platinum-containing chemotherapy", "C": "Docetaxel in combination with cisplatin and fluorouracil", "D": "Docetaxel monotherapy"}}
{"id": "vjWIQ1Sjj2QE", "question_type": "multi_choice", "question": "Which color additives in Romvimza capsules may cause allergic reactions, particularly in patients with aspirin sensitivity?", "options": {"A": "FD&C Yellow No. 5 (tartrazine) and FD&C Yellow No. 6 (Sunset Yellow FCF)", "B": "FD&C Blue No. 1 and FD&C Red No. 40", "C": "FD&C Green No. 3 and FD&C Red No. 3", "D": "FD&C Yellow No. 10 and FD&C Orange No. 2"}}
{"id": "8xy3TvGyX6Uc", "question_type": "open_ended_multi_choice", "question": "In the official prescribing information, what is stated under section 4 (Contraindications) for Datroway?", "options": {"A": "Use is contraindicated in patients with severe renal impairment.", "B": "No contraindications are listed.", "C": "Contraindicated in patients with a history of anaphylaxis to Datroway.", "D": "Contraindicated in patients under 18 years of age."}}
{"id": "5C9EEFXuhNgb", "question_type": "open_ended_multi_choice", "question": "Which of the following statements best describes the warnings and precautions section for the drug Andembry?", "options": {"A": "There are no warnings and precautions listed for Andembry.", "B": "Andembry has multiple warnings and precautions related to hepatic impairment.", "C": "Andembry requires monitoring for cardiovascular side effects.", "D": "Andembry is contraindicated in pregnancy due to specific warnings."}}
{"id": "qlpQsA7iih5C", "question_type": "open_ended_multi_choice", "question": "A woman aged 32, who is 10 weeks pregnant and has recently been diagnosed with generalized myasthenia gravis (anti-MuSK antibody positive), also has a history of Hashimoto thyroiditis. She seeks advice regarding safe medications for her condition during pregnancy. Which of the following treatments is contraindicated in pregnancy due to its established teratogenic effects?", "options": {"A": "IMAAVY, 15 mg/kg intravenous infusion every 2 weeks", "B": "Azathioprine, 75 mg daily oral administration", "C": "DuoDote, single dose for acute management", "D": "IMAAVY, 10 mg/kg intravenous infusion every 4 weeks"}}
{"id": "lStDR5ChCixe", "question_type": "open_ended_multi_choice", "question": "A 4-year-old male with Duchenne muscular dystrophy, presenting with delayed gross motor development and calf muscle pseudohypertrophy, is being considered for pharmacologic therapy. He has no history of cardiac arrhythmia or hepatic impairment. Which treatment is most appropriate for his age and condition?", "options": {"A": "Givinostat administered twice daily", "B": "Deflazacort administered daily at 0.9 mg/kg", "C": "Eteplirsen administered once weekly", "D": "Givinostat with dose reduction due to age"}}
{"id": "BGgRYgjFof0E", "question_type": "open_ended", "question": "A 35-year-old woman with non-cystic fibrosis bronchiectasis, chronic lung disease, and a history of gingival disease is planning to become pregnant. She is considering starting a new medication for her bronchiectasis. Which of the following is the most suitable drug option, taking into account disease indication and reproductive safety?", "options": {"A": "SYMDEKO, as it has reassuring animal safety data in pregnancy", "B": "BRENSOCATIB, with careful monitoring and counseling regarding limited pregnancy safety data", "C": "Insulin Aspart Protamine and Insulin Aspart Mix 70/30, as it is safe in pregnancy", "D": "BRENSOCATIB, without any consideration for pregnancy risks"}}
{"id": "leNDLdwuZ9s7", "question_type": "open_ended", "question": "Which of the following best describes the risk associated with combining Emrelis and strong CYP3A inhibitors?", "options": {"A": "Reduced efficacy of Emrelis", "B": "Increased risk of Emrelis adverse reactions", "C": "No pharmacological interaction", "D": "Decreased plasma concentration of MMAE"}}
{"id": "52U7nsvHO1tm", "question_type": "multi_choice", "question": "When counseling patients on Romvimza, what is the most important advice regarding concomitant medications and supplements?", "options": {"A": "Patients should avoid all over-the-counter products.", "B": "Patients should inform their healthcare providers of all concomitant products, including over-the-counter products and supplements.", "C": "Patients may take any supplements without restriction.", "D": "Only prescription medications need to be reported."}}
{"id": "FXb4Kdh9x55c", "question_type": "open_ended_multi_choice", "question": "A 35-year-old female patient with unresectable adrenocortical carcinoma is pregnant. She has no significant liver or kidney issues and is not on any other medications. What is the most appropriate recommendation for systemic management of her cancer?", "options": {"A": "Initiate Lysodren therapy immediately", "B": "Use Lumisight for systemic treatment", "C": "Avoid Lysodren due to risk of fetal harm", "D": "Start hormonal contraceptives before Lysodren"}}
{"id": "mAt04ZdwiYSU", "question_type": "open_ended_multi_choice", "question": "What should be done when a patient on Modeyso develops symptoms indicative of a life-threatening arrhythmia?", "options": {"A": "Reduce the dose of Modeyso.", "B": "Interrupt Modeyso and resume after arrhythmia resolves.", "C": "Permanently discontinue Modeyso.", "D": "Continue Modeyso with increased monitoring."}}
{"id": "AXCHgrVQn41J", "question_type": "open_ended_multi_choice", "question": "A 55-year-old woman with idiopathic pulmonary fibrosis and a history of pulmonary arterial hypertension is planning to become pregnant. She is currently experiencing exertional dyspnea and ground-glass opacification on HRCT. Which of the following IPF therapies is contraindicated due to her reproductive plans?", "options": {"A": "Pirfenidone, 801 mg three times daily", "B": "Prednisolone sodium phosphate, 10 mg daily", "C": "Nintedanib, 150 mg twice daily", "D": "Prednisolone sodium phosphate, 40 mg daily"}}
{"id": "Gm3ICusjYyij", "question_type": "open_ended", "question": "A 55-year-old man with a history of chronic kidney disease (creatinine clearance 40 mL/min) is newly diagnosed with a trophoblastic neoplasm. He is not taking any nephrotoxic or hepatotoxic medications. Which of the following is the most appropriate initial drug therapy for his condition?", "options": {"A": "Paclitaxel protein-bound particles for injectable suspension (albumin-bound)", "B": "Methotrexate", "C": "Trexall", "D": "Folic acid supplementation alone"}}
{"id": "ySLwalCIfrPe", "question_type": "open_ended_multi_choice", "question": "A pregnant 29-year-old patient in her second trimester presents with a recent diagnosis of choroid plexus carcinoma and needs immediate intervention. Which medication is contraindicated because of its risk for teratogenicity and harm to the fetus?", "options": {"A": "Lumisight (pegulicianine) administered as a single intraoperative dose", "B": "Etoposide administered intravenously at 100 mg/m² daily for 5 days", "C": "Etoposide administered orally at a reduced dose", "D": "Lumisight (pegulicianine) administered at a reduced dose"}}
{"id": "Xhc9taEUE0TU", "question_type": "open_ended_multi_choice", "question": "A 35-year-old woman with inoperable adrenocortical carcinoma is currently pregnant. She has no significant hepatic or renal impairment and is not taking any other medications. Which of the following is the most appropriate recommendation regarding systemic therapy for her cancer?", "options": {"A": "Initiate Lysodren therapy immediately", "B": "Use Lumisight for systemic treatment", "C": "Avoid Lysodren due to risk of fetal harm", "D": "Start hormonal contraceptives before Lysodren"}}
{"id": "XMUgXO7Rrbe6", "question_type": "multi_choice", "question": "A 35-year-old female patient with Grade 2 IDH1-mutant astrocytoma has recently undergone gross total resection. She is planning pregnancy and currently uses hormonal contraception. Her oncologist is considering post-surgical drug therapy. Which treatment option should be avoided due to its impact on contraception and potential risk to a future pregnancy?", "options": {"A": "Avastin administered every 2 weeks", "B": "Zortress combined with tacrolimus and corticosteroids", "C": "Vorasidenib 40 mg once daily", "D": "No drug therapy; observation only"}}
{"id": "CahqicbNHVQG", "question_type": "multi_choice", "question": "If a patient experiences Grade 3 cytokine release syndrome (CRS) during Lynozyfic therapy, what is the recommended action regarding the next dose?", "options": {"A": "Resume Lynozyfic at the same dose after CRS resolves", "B": "Permanently discontinue Lynozyfic", "C": "Resume Lynozyfic at a reduced dose (2.5 mg if last dose was 5 mg; restart step-up dosing from 5 mg if last dose was 25 mg)", "D": "Increase the infusion rate for the next dose"}}
{"id": "mNLRHX1YXdak", "question_type": "open_ended", "question": "A 55-year-old man with presbyopia is currently taking a beta-blocker for hypertension and inhaled ipratropium for COPD. He requests a medication to improve his near vision. Which of the following is the most suitable pharmacological option for this patient?", "options": {"A": "Pilocarpine Hydrochloride tablets, 5 mg orally three times daily", "B": "VUITY, one drop in each eye daily", "C": "Aceclidine (VIZZ), one drop in each eye daily", "D": "Pilocarpine Hydrochloride tablets, 10 mg orally once daily"}}
{"id": "hYLHRva5lVQ1", "question_type": "open_ended_multi_choice", "question": "For a 6-year-old patient with classic congenital adrenal hyperplasia who is currently on glucocorticoid replacement, has normal renal function, and no prior hypersensitivity reactions, what is the most appropriate adjunctive drug regimen to optimize androgen control?", "options": {"A": "Crenessity as adjunctive therapy to glucocorticoid replacement", "B": "Crenessity monotherapy without glucocorticoid replacement", "C": "Crenessity in a child under 4 years old", "D": "Crenessity in a patient with severe renal impairment"}}
{"id": "Dn2xA245qMho", "question_type": "open_ended_multi_choice", "question": "A patient is scheduled for a surgical procedure requiring general anesthesia with intravenous muscle relaxants. What consideration should be made regarding Blujepa therapy?", "options": {"A": "No special consideration is needed", "B": "Blujepa should be discontinued prior to surgery", "C": "Monitor for increased cholinergic effects due to potential interaction", "D": "Increase the dose of Blujepa"}}
{"id": "gTovWWx2xZ9U", "question_type": "open_ended_multi_choice", "question": "Select the statement that correctly represents a counseling point for a patient taking Ekterly.", "options": {"A": "Read the FDA-approved patient labeling (Patient Information)", "B": "Take Ekterly with grapefruit juice to enhance absorption", "C": "Double the dose if symptoms persist after 1 hour", "D": "Discontinue Ekterly if experiencing mild hepatic impairment"}}
{"id": "JbP7yZSmndDM", "question_type": "open_ended_multi_choice", "question": "A 3-year-old child with ciliary dyskinesia-bronchiectasis presents with frequent episodes of bronchospasm. The child has no history of cystic fibrosis or CFTR mutations. The pediatrician is considering pharmacologic management for bronchospasm. Which of the following is the most appropriate drug for this patient, considering age and disease profile?", "options": {"A": "Albuterol Sulfate HFA inhalation aerosol, 90 mcg per actuation, administered as needed for bronchospasm", "B": "Kalydeco oral granules, 50 mg twice daily", "C": "Albuterol Sulfate HFA inhalation aerosol, 180 mcg per actuation, administered three times daily", "D": "Kalydeco oral granules, 75 mg twice daily"}}
{"id": "pFLF7MKvQ7B2", "question_type": "open_ended_multi_choice", "question": "A 10-year-old boy with a syndrome of combined immunodeficiency and acute leukemia is being considered for immunosuppressive therapy. He has no renal impairment and is not receiving pentostatin. Which drug is most appropriate for his age and condition?", "options": {"A": "Fludarabine Phosphate at pediatric loading dose followed by continuous infusion", "B": "DMT SUIK (corticosteroid) at pediatric dose for acute leukemia", "C": "Fludarabine Phosphate at standard adult dose", "D": "Fludarabine Phosphate in combination with pentostatin"}}
{"id": "OEKa3hwEC0bH", "question_type": "multi_choice", "question": "A 72-year-old man with idiopathic pulmonary fibrosis, presenting with crackles and decreased DLCO, is being considered for antifibrotic therapy. He has a history of myocardial infarction and is on full anticoagulation therapy for atrial fibrillation. Which of the following drugs should be avoided due to increased risk of bleeding and arterial thromboembolic events?", "options": {"A": "Pirfenidone, 801 mg three times daily", "B": "Prednisolone sodium phosphate, 20 mg daily", "C": "Nintedanib, 150 mg twice daily", "D": "Pirfenidone, 267 mg three times daily"}}
{"id": "IYDHWoK8UfB4", "question_type": "open_ended_multi_choice", "question": "What guidance should healthcare providers offer to breastfeeding women who need to take Modeyso?", "options": {"A": "Do not breastfeed during treatment and for 1 week after the last dose.", "B": "Continue breastfeeding as usual.", "C": "Breastfeed only immediately before taking Modeyso.", "D": "Stop breastfeeding permanently."}}
{"id": "AncGAOi5YGby", "question_type": "multi_choice", "question": "A 28-year-old woman is admitted for labor and requests pain relief. She is otherwise healthy and is not taking any medications. She wishes to breastfeed her newborn after delivery. Which drug regimen is most appropriate for acute pain management during labor, considering safety for both mother and infant?", "options": {"A": "Suzetrigine administered every 6 hours", "B": "Ropivacaine Hydrochloride via epidural infusion", "C": "Acetaminophen every 4 hours", "D": "Childrens Pain Relief every 6 hours"}}
{"id": "q6ePtzvnWPun", "question_type": "multi_choice", "question": "For a female patient of reproductive potential who is about to start Wayrilz therapy, which of the following is the most appropriate recommendation regarding contraception?", "options": {"A": "No contraception is required during Wayrilz treatment.", "B": "Use effective contraception only during Wayrilz treatment.", "C": "Use contraception for 1 month after stopping Wayrilz.", "D": "Use effective contraception during Wayrilz treatment and for 1 week after stopping treatment."}}
{"id": "UvIGrHLasXUk", "question_type": "open_ended_multi_choice", "question": "A woman aged 35, who is 10 weeks into her pregnancy, has recently been diagnosed with primary biliary cholangitis. She is experiencing mild jaundice and fatigue, without any indications of hepatic decompensation. Which initial drug therapy is considered safest and most suitable for her?", "options": {"A": "IQIRVO (elafibranor) monotherapy", "B": "Tricor (fenofibrate) monotherapy", "C": "Urso 250 (ursodiol) monotherapy", "D": "IQIRVO (elafibranor) in combination with Tricor (fenofibrate)"}}
{"id": "VmOCfwpRNNFI", "question_type": "open_ended", "question": "A 13-year-old patient with generalized myasthenia gravis, anti-acetylcholine receptor antibody positivity, and a history of hepatitis is being considered for therapy. The patient weighs 45 kg and has no active infection. Which drug is most suitable for scheduled administration in this scenario?", "options": {"A": "DuoDote", "B": "IMAAVY", "C": "Pyridostigmine Bromide", "D": "Atropine"}}
{"id": "4W44Agp33Vuu", "question_type": "open_ended_multi_choice", "question": "For which patient history is Blujepa specifically contraindicated?", "options": {"A": "History of severe hypersensitivity to Blujepa", "B": "History of mild rash after Blujepa", "C": "History of severe hypersensitivity to penicillin", "D": "History of mild hypersensitivity to Blujepa"}}
{"id": "6JZSVxk5PWxr", "question_type": "open_ended_multi_choice", "question": "In the single-arm AK105-202 trial of penpulimab-kcqx for unresectable or metastatic non-keratinizing nasopharyngeal carcinoma after prior platinum-based chemotherapy, what was the observed objective response rate (ORR)?", "options": {"A": "28% (95% CI: 20, 37)", "B": "46% (95% CI: 35, 57)", "C": "10% (95% CI: 5, 15)", "D": "0.8% (95% CI: 0, 2)"}}
{"id": "34UVNegjud6h", "question_type": "open_ended_multi_choice", "question": "A 45-year-old man with primary IgA nephropathy and a urine protein-to-creatinine ratio of 2.1 g/g is being evaluated for VANRAFIA treatment. He is already on a potent CYP3A inducer for another medical issue. What is the most appropriate management regarding VANRAFIA in this context?", "options": {"A": "Initiate VANRAFIA at the standard dose and continue the CYP3A inducer.", "B": "Avoid concomitant use of VANRAFIA and the CYP3A inducer due to reduced efficacy.", "C": "Start VANRAFIA and increase the dose to compensate for the CYP3A inducer.", "D": "Begin VANRAFIA therapy and add an OATP1B1/1B3 inhibitor to enhance drug exposure."}}
{"id": "bk37dCAtDh1R", "question_type": "open_ended_multi_choice", "question": "A 2-year-old child with confirmed molybdenum cofactor deficiency type A presents with seizures, growth delay, and increased urinary sulfite. The family is planning a two-week vacation to a tropical region with high sun exposure. The physician is considering starting Nulibry to reduce mortality risk. What is the most important counseling point regarding Nulibry administration for this patient?", "options": {"A": "Nulibry should be discontinued during periods of high sun exposure to avoid adverse effects.", "B": "Nulibry can be administered without any special precautions regarding sunlight.", "C": "Nulibry should be continued, but strict sun avoidance and protective measures are essential due to the risk of photosensitivity.", "D": "Nulibry is not indicated for children under 6 years of age."}}
{"id": "3SJnsGOqi3E0", "question_type": "open_ended_multi_choice", "question": "A 58-year-old woman with newly diagnosed metastatic NSCLC is found to have PD-L1 expression ≥1% and no EGFR or ALK genomic aberrations. She has no significant comorbidities and normal hepatic and renal function. She is not taking any medications that interact with CYP3A or prolong the QT interval. Which of the following is the most appropriate first-line treatment for her?", "options": {"A": "Entrectinib (Rozlytrek)", "B": "Telisotuzumab vedotin (EMRELIS)", "C": "Ipilimumab in combination with nivolumab", "D": "Ipilimumab monotherapy"}}
{"id": "2aOOPvHohjNO", "question_type": "open_ended_multi_choice", "question": "What should individuals taking Brinsupri communicate to their healthcare provider prior to receiving a live attenuated vaccine?", "options": {"A": "That they are currently taking Brinsupri", "B": "Their history of allergies", "C": "Their family medical history", "D": "Their travel history"}}
{"id": "rBaSOtz43EDU", "question_type": "open_ended_multi_choice", "question": "A 7-year-old boy suffering from hemophilia B has recurrent hemarthroses and is prone to bruising, without any history of factor IX inhibitor development. He requires a prophylactic drug regimen to prevent further bleeding episodes. Given his clinical profile and age, which therapeutic approach is most suitable?", "options": {"A": "HYMPAVZI, administered weekly for routine prophylaxis", "B": "REBINYN, administered weekly for routine prophylaxis", "C": "SEVENFACT, administered for routine prophylaxis", "D": "HYMPAVZI, administered only during bleeding episodes"}}
{"id": "yprdyQoUcnkh", "question_type": "open_ended", "question": "A 45-year-old male with hereditary angioedema and moderate hepatic impairment (Child-Pugh Class B) presents with an acute attack. He is not taking any CYP3A4 inhibitors or inducers. Which drug regimen is most appropriate for his acute treatment?", "options": {"A": "EKTERLY, one dose of 300 mg orally, with a possible second dose after 3 hours if needed", "B": "SAJAZIR, standard dosing", "C": "TAKHZYRO, 300 mg every 2 weeks", "D": "EKTERLY, standard dosing without adjustment"}}
{"id": "uYSSRuU6IjQD", "question_type": "multi_choice", "question": "A 28-year-old woman with cystic fibrosis and a history of cirrhosis and hepatosplenomegaly is planning to become pregnant. She has a confirmed F508del mutation and is currently taking oral contraceptives. Her liver function tests are mildly elevated (Child-Pugh Class A). Which of the following is the most suitable drug regimen for her cystic fibrosis management?", "options": {"A": "ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor) at standard dosage, with regular liver function and ophthalmologic monitoring", "B": "Insulin Aspart Protamine and Insulin Aspart Mix 70/30, administered before meals", "C": "ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor) at reduced dosage due to oral contraceptive use", "D": "ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor) is contraindicated due to pregnancy risk"}}
{"id": "itpWmRkZuUxe", "question_type": "open_ended_multi_choice", "question": "A teenager, aged 16, with Niemann-Pick disease type C, presents with progressive neurological decline, hepatomegaly, and moderate renal dysfunction (eGFR 35 mL/min/1.73 m²). The patient qualifies for treatment targeting neurological symptoms. What regimen and dosing adjustment should be considered in this scenario?", "options": {"A": "Standard-dose arimoclomol in combination with standard-dose miglustat", "B": "Standard-dose miglustat monotherapy", "C": "Dose-adjusted arimoclomol in combination with dose-adjusted miglustat", "D": "Standard-dose lithium carbonate"}}
{"id": "nnq9ZCk5wPOJ", "question_type": "open_ended_multi_choice", "question": "Is there evidence from animal studies regarding the influence of Tryptyr on male or female reproductive capability?", "options": {"A": "Yes, and Tryptyr was found to impair fertility in both sexes.", "B": "Yes, and Tryptyr was found to have no effect on fertility.", "C": "No, studies to evaluate the potential effects of Tryptyr on fertility in animals have not been performed.", "D": "Yes, but only in female animals."}}
{"id": "eFXnvigUhXTd", "question_type": "open_ended_multi_choice", "question": "What is the most accurate way to describe how adverse reaction rates for Tryptyr can be compared between various clinical studies?", "options": {"A": "Adverse reaction rates from Tryptyr clinical trials cannot be directly compared to those from other drug trials due to varying conditions.", "B": "Adverse reaction rates for Tryptyr are always higher than those for other drugs.", "C": "Adverse reaction rates for Tryptyr are standardized across all clinical trials.", "D": "Adverse reaction rates for Tryptyr are only valid for European populations."}}
{"id": "ku1xOxCtVwjc", "question_type": "open_ended", "question": "An 11-year-old boy with Stage 2 type 1 diabetes mellitus 13 is being evaluated for therapy to delay progression to Stage 3 disease. He has no history of chronic infection, is up to date on vaccinations, and has normal liver function. Which of the following is the most appropriate treatment option for this patient, considering age and indication?", "options": {"A": "AFREZZA, administered as a rapid-acting inhaled insulin before meals", "B": "ADMELOG, administered as a rapid-acting subcutaneous injection before meals", "C": "TZIELD, administered as a 14-day intravenous infusion to delay progression", "D": "AFREZZA, administered with a drug scheduler alternating with ADMELOG"}}
{"id": "YhGMPJnwi16F", "question_type": "multi_choice", "question": "For a patient being considered for therapy with Andembry, which of the following is true regarding contraindications?", "options": {"A": "There are no contraindications for Andembry.", "B": "Andembry is contraindicated in patients with a history of anaphylaxis.", "C": "Andembry should be avoided in patients with renal insufficiency.", "D": "Andembry is contraindicated in pediatric populations."}}
{"id": "moFk8xjqz86h", "question_type": "multi_choice", "question": "For which patient populations is the use of Vizz contraindicated based on its official labeling?", "options": {"A": "Patients with severe hepatic impairment", "B": "Patients with known hypersensitivity to Vizz", "C": "Patients with renal failure", "D": "Patients with a history of cardiovascular disease"}}
{"id": "NHUjziWwoZ3H", "question_type": "open_ended_multi_choice", "question": "A researcher is compiling a database of drugs with no contraindications. Should Vizz be included in this database?", "options": {"A": "Yes, because Vizz has no contraindications listed", "B": "No, because Vizz is contraindicated in certain populations", "C": "No, because Vizz is contraindicated in patients with renal impairment", "D": "No, because Vizz is contraindicated in patients with allergies"}}
{"id": "nJjPrRfLZEY4", "question_type": "multi_choice", "question": "A 58-year-old man with a history of glaucoma and previous herpes simplex eye infection is experiencing severe symptoms of dry eye disease. He is considering prescription therapy and currently wears contact lenses daily. Which medication should be avoided due to his medical history and which is the most suitable for his condition?", "options": {"A": "Xiidra", "B": "TRYPTYR", "C": "Lotemax SM", "D": "Cyclosporine ophthalmic emulsion"}}
{"id": "kk1ETuhHzAKn", "question_type": "open_ended_multi_choice", "question": "A 58-year-old patient with previously treated, unresectable, locally advanced intrahepatic cholangiocarcinoma is found to have a tumor harboring an FGFR2 gene fusion, confirmed by an FDA-approved test. The patient also has severe renal impairment (eGFR 18 mL/min/1.73 m²) and is not pregnant. Which drug regimen is most appropriate for this patient, considering the need for dosage adjustment and established safety in severe renal impairment?", "options": {"A": "Futibatinib (LYTGOBI) once daily, standard dose", "B": "Pemigatinib (PEMAZYRE) once daily, with dosage reduction for severe renal impairment", "C": "Zanidatamab-hrii (ZIIHERA) every three weeks, standard dose", "D": "Futibatinib (LYTGOBI) with a drug holiday every two weeks"}}
{"id": "BBKHXCP0101I", "question_type": "open_ended_multi_choice", "question": "A 58-year-old woman with locally advanced, hormone receptor-positive, HER2-negative breast cancer and a confirmed PIK3CA mutation (via FDA-approved testing) has well-controlled type 2 diabetes on oral medications, normal renal function, and is neither pregnant nor breastfeeding. She is being evaluated for targeted therapy to use alongside palbociclib and fulvestrant. Taking into account her comorbidities and the safety profiles of the available treatments, which drug regimen is most suitable for her?", "options": {"A": "Carboplatin in combination with cyclophosphamide", "B": "Inavolisib in combination with palbociclib and fulvestrant", "C": "Esketamine as monotherapy", "D": "Carboplatin as a single agent"}}
{"id": "r0fTEQnpXC6A", "question_type": "open_ended_multi_choice", "question": "In the case of a 45-year-old pregnant patient with unresectable intrahepatic cholangiocarcinoma previously treated and found to have an FGFR2 rearrangement, with no concurrent medications, what is the best recommendation about initiating targeted therapy?", "options": {"A": "Initiate PEMAZYRE at standard dosing", "B": "Start LYTGOBI with close fetal monitoring", "C": "Defer targeted therapy due to risk of fetal harm", "D": "Begin ZIIHERA with dose reduction"}}
{"id": "9ZwwK6agvNuN", "question_type": "open_ended_multi_choice", "question": "A 62-year-old man with metastatic non-keratinizing nasopharyngeal carcinoma has previously received platinum-based chemotherapy and one other line of therapy. He has moderate renal impairment (creatinine clearance 40 mL/min) and is not taking any anticoagulants. He is not pregnant and does not have a history of immune-mediated disorders. Which drug is most appropriate for his current cancer management?", "options": {"A": "Capecitabine 500 mg twice daily", "B": "Penpulimab-kcqx monotherapy", "C": "Celecoxib 200 mg twice daily", "D": "Penpulimab-kcqx in combination with cisplatin and gemcitabine"}}
{"id": "h8K94w29qKaO", "question_type": "open_ended", "question": "If a patient receiving Penpulimab-kcqx develops Grade 3 immune-mediated colitis, what is the recommended management?", "options": {"A": "Continue treatment without modification", "B": "Withhold Penpulimab-kcqx and resume after resolution", "C": "Permanently discontinue Penpulimab-kcqx", "D": "Reduce the dose of Penpulimab-kcqx"}}
{"id": "VsD49Z2ZB0B9", "question_type": "multi_choice", "question": "A 60-year-old woman with recurrent low-grade serous ovarian carcinoma and a confirmed KRAS mutation is scheduled to begin AVMAPKI FAKZYNJA CO-PACK. She has a history of chronic gastroesophageal reflux disease and takes omeprazole (a proton pump inhibitor) daily. What is the best strategy to ensure effective cancer treatment?", "options": {"A": "Continue omeprazole and start AVMAPKI FAKZYNJA CO-PACK as planned", "B": "Continue omeprazole but administer FAKZYNJA 2 hours before or after a locally acting antacid", "C": "Discontinue omeprazole and avoid all gastric acid reducing agents during AVMAPKI FAKZYNJA CO-PACK therapy", "D": "Switch omeprazole to an H2 receptor antagonist and start AVMAPKI FAKZYNJA CO-PACK"}}
{"id": "mWrvcJJnrFZH", "question_type": "open_ended_multi_choice", "question": "A 15-year-old patient with hereditary angioedema arrives at the emergency department experiencing an acute episode. The patient is known to have had severe anaphylactic reactions to ecallantide in the past. Which therapy should not be administered, and what is the best choice for treating this acute attack?", "options": {"A": "Kalbitor", "B": "TAKHZYRO", "C": "ANDEMBRY", "D": "Supportive care only"}}
{"id": "32XKfOVfoKwu", "question_type": "open_ended_multi_choice", "question": "A 42-year-old male with paroxysmal nocturnal hemoglobinuria (PNH) and advanced liver disease (Child-Pugh class C) requires treatment. He has not received any complement inhibitor therapy to date. What is the most suitable drug regimen for managing his PNH?", "options": {"A": "Voydeya as add-on to ravulizumab", "B": "Ravulizumab monotherapy", "C": "Sirolimus", "D": "Voydeya monotherapy"}}
{"id": "6Ewku5H76Heu", "question_type": "multi_choice", "question": "A 28-year-old woman with newly diagnosed PNH is currently pregnant and requires complement inhibition therapy. She is eligible for all available therapies and has no history of complement inhibitor use. Which drug is the most appropriate choice, considering pregnancy safety data and recommendations?", "options": {"A": "Sirolimus", "B": "Piasky", "C": "Ultomiris", "D": "Cyclosporine"}}
{"id": "5TghZPbNariD", "question_type": "open_ended_multi_choice", "question": "A 58-year-old man with young-onset Parkinson disease is experiencing symptom fluctuations and end-of-dose wearing-off phenomena despite optimized therapy with carbidopa and levodopa. He has no history of liver disease, and his liver function tests are normal. He also reports mild depression and occasional hallucinations. He is considering adjunctive therapy to improve his motor symptoms. Which drug is most suitable for him, given his current profile?", "options": {"A": "Selegiline Hydrochloride", "B": "Carbidopa and Levodopa", "C": "Tasmar", "D": "Selegiline Hydrochloride combined with tricyclic antidepressant"}}
{"id": "KiVX4qcxYX97", "question_type": "open_ended", "question": "What should patients do if they experience blurred vision after using Vizz?", "options": {"A": "Refrain from driving or using machinery until vision is clear.", "B": "Increase the frequency of Vizz administration.", "C": "Ignore the symptom and continue normal activities.", "D": "Take an oral analgesic for relief."}}
{"id": "NdcFaGkzZTMs", "question_type": "open_ended_multi_choice", "question": "A 60-year-old male with presbyopia, currently on a monoamine oxidase inhibitor for depression and beta-blockers for hypertension, seeks a medication to enhance his near vision. What is the safest and most effective treatment for him?", "options": {"A": "Mirvaso topical gel applied to the face daily", "B": "Oraverse intraoral injection following dental anesthesia", "C": "VIZZ topical ocular drops once daily", "D": "Mirvaso topical gel applied twice daily"}}
{"id": "2NFcmvgyoudE", "question_type": "multi_choice", "question": "A 38-year-old female with schizophrenia and mild hepatic impairment (Child-Pugh Class A) is being considered for long-term antipsychotic therapy. She has no history of metabolic syndrome, renal impairment, or pregnancy. Which drug regimen is most appropriate for her?", "options": {"A": "Abilify Maintena (aripiprazole), standard adult dose", "B": "Cobenfy (xanomeline and trospium chloride), standard adult dose", "C": "Cobenfy (xanomeline and trospium chloride), reduced dose", "D": "Abilify Maintena (aripiprazole), reduced dose for elderly patients"}}
{"id": "qedYqBV3w2R3", "question_type": "open_ended_multi_choice", "question": "For individuals with various coexisting health issues, which of the following best reflects the contraindication profile of Ekterly?", "options": {"A": "Ekterly is contraindicated in patients with diabetes.", "B": "Ekterly is contraindicated in patients with chronic kidney disease.", "C": "Ekterly is contraindicated in patients with a history of stroke.", "D": "Ekterly does not have any contraindications regardless of comorbidities."}}
{"id": "ErCZfAh15F9u", "question_type": "open_ended_multi_choice", "question": "A male patient, age 45, has COPD and is currently on ritonavir, a strong CYP3A4 inhibitor, for another illness. As he starts maintenance therapy for his COPD, which drug is least likely to cause major interactions or increase the likelihood of adverse effects given his current regimen?", "options": {"A": "Budesonide Inhalation", "B": "Fentanyl Citrate", "C": "Ensifentrine", "D": "Budesonide (oral)"}}
{"id": "mWvtN5noNKAh", "question_type": "open_ended", "question": "If a researcher is interested in the potential for Enflonsia to cause genetic mutations, what information is available from nonclinical studies?", "options": {"A": "No mutagenesis studies have been performed with Enflonsia", "B": "Mutagenesis studies show no risk", "C": "Mutagenesis studies show a high risk", "D": "Mutagenesis studies are inconclusive"}}
{"id": "n5n55mbwE8GT", "question_type": "open_ended_multi_choice", "question": "If a regulatory submission for Enflonsia requires data on impairment of fertility, what information is available?", "options": {"A": "No reproductive toxicity studies have been conducted with Enflonsia.", "B": "Reproductive toxicity studies indicate no impairment of fertility.", "C": "Reproductive toxicity studies indicate potential impairment of fertility.", "D": "Reproductive toxicity studies are currently under review."}}
{"id": "uS4Et3HB2vjL", "question_type": "multi_choice", "question": "Which color additives in Romvimza capsules may cause allergic reactions, particularly in patients with aspirin sensitivity?", "options": {"A": "FD&C Blue No. 1 and FD&C Red No. 40", "B": "FD&C Yellow No. 5 (tartrazine) and FD&C Yellow No. 6 (Sunset Yellow FCF)", "C": "FD&C Green No. 3 and FD&C Red No. 3", "D": "FD&C Yellow No. 10 and FD&C Orange No. 2"}}
{"id": "a9caByagtJhm", "question_type": "open_ended_multi_choice", "question": "A 58-year-old individual with metastatic NSCLC and ROS1 rearrangement, as identified by FDA-approved testing, also has congestive heart failure and is taking a medication that increases the QTc interval. Considering these factors, which treatment option poses the greatest risk and should be avoided, and which is the preferred therapy?", "options": {"A": "Rozlytrek monotherapy, 600 mg orally once daily", "B": "Erlotinib monotherapy, 150 mg orally once daily", "C": "Lazcluze (lazertinib + amivantamab) combination therapy, standard dosing", "D": "Rozlytrek with dose reduction due to QTc-prolonging medication"}}
{"id": "um11MWAdLBDA", "question_type": "open_ended_multi_choice", "question": "When assessing the safety of topical Anzupgo for hand eczema in a 52-year-old patient with cardiovascular risk factors, which statement best summarizes its risk profile?", "options": {"A": "Anzupgo is associated with increased risk of death in patients with cardiovascular risk factors, similar to oral JAK inhibitors for rheumatoid arthritis.", "B": "Anzupgo is contraindicated in all patients over 50 years old.", "C": "It is unknown whether Anzupgo carries the same risk of increased mortality as oral JAK inhibitors used for rheumatoid arthritis.", "D": "Anzupgo is recommended over TNF blockers in patients with cardiovascular risk factors."}}
{"id": "NnNTlDgsoIMu", "question_type": "multi_choice", "question": "Which of the following statements best describes the contraindication profile of the drug Ekterly?", "options": {"A": "Ekterly is contraindicated in patients with severe hepatic impairment.", "B": "Ekterly should not be used in individuals with a history of hypersensitivity to its active ingredient.", "C": "Ekterly has no listed contraindications.", "D": "Ekterly is contraindicated in pregnant women."}}
{"id": "pi63spNBYQO1", "question_type": "open_ended", "question": "A 15-year-old adolescent with hereditary angioedema presents with an acute attack. The patient is currently taking a strong CYP3A4 inhibitor for another condition. Which drug is most appropriate for treating this acute attack?", "options": {"A": "SAJAZIR", "B": "EKTERLY", "C": "TAKHZYRO", "D": "None of the above"}}
{"id": "X5Arg1SjyHTr", "question_type": "open_ended", "question": "Which of the following is NOT recommended when Ekterly is used concomitantly with strong CYP3A4 inhibitors?", "options": {"A": "Avoid use of Ekterly.", "B": "Reduce the dose to 300 mg.", "C": "Administer a second dose after 3 hours if needed.", "D": "No dose modification is necessary."}}
{"id": "1xvDHV4KKZIM", "question_type": "multi_choice", "question": "For a patient being considered for therapy with Andembry, which of the following is true regarding contraindications?", "options": {"A": "Andembry should be avoided in patients with renal insufficiency.", "B": "Andembry is contraindicated in patients with a history of anaphylaxis.", "C": "Andembry is contraindicated in pediatric populations.", "D": "There are no contraindications for Andembry."}}
{"id": "2fu0ejlvg9JG", "question_type": "open_ended_multi_choice", "question": "A 35-year-old pregnant patient is diagnosed with a complicated urinary tract infection. She reports no allergies to beta-lactams and has no history of glaucoma or seizure disorders. Her liver and kidney functions are within normal limits. Taking into account both the safety and effectiveness of medications during pregnancy, which treatment option is most appropriate for her infection?", "options": {"A": "Blujepa, administered according to standard dosing for complicated UTI.", "B": "Imipenem and Cilastatin Sodium intravenous therapy, following recommended dosing for adults.", "C": "Flavoxate Hydrochloride tablets for symptomatic relief only.", "D": "Flavoxate Hydrochloride combined with Blujepa for definitive treatment."}}
{"id": "QRmFKup266zk", "question_type": "open_ended_multi_choice", "question": "Which of the following statements best describes the management of Grade 2 neurologic adverse reactions (excluding ICANS) during Lynozyfic treatment?", "options": {"A": "Continue Lynozyfic at the same dose and monitor", "B": "Withhold Lynozyfic until symptoms resolve to Grade 1 or baseline, then follow restart recommendations", "C": "Permanently discontinue Lynozyfic", "D": "Increase the dose of Lynozyfic"}}
{"id": "tTkXB7Mr6d3G", "question_type": "open_ended_multi_choice", "question": "A 42-year-old male experiences moderate to severe acute pain due to a sports injury. His hepatic and renal function tests are within normal limits. He is taking a moderate CYP3A inhibitor for another illness and uses a combined oral contraceptive containing ethinyl estradiol and norethindrone. Which choice of drug and dosing strategy would be most appropriate for his pain control?", "options": {"A": "Suzetrigine at standard adult dosage", "B": "Suzetrigine with reduced dosage", "C": "Ropivacaine Hydrochloride at standard dosage", "D": "Acetaminophen at maximum daily dosage"}}
{"id": "nOA95jBc7jCM", "question_type": "multi_choice", "question": "A 67-year-old patient with metastatic non-small cell lung cancer (NSCLC) is found to have an EGFR exon 19 deletion mutation by FDA-approved testing. The patient has a history of deep vein thrombosis (DVT) and is currently receiving warfarin for anticoagulation. Which drug regimen is most appropriate for first-line treatment of this patient's NSCLC, considering their genetic profile and current medications?", "options": {"A": "Erlotinib monotherapy, 150 mg orally once daily", "B": "Lazcluze (lazertinib + amivantamab) combination therapy, standard dosing", "C": "Rozlytrek monotherapy, 600 mg orally once daily", "D": "Erlotinib in combination with platinum-based chemotherapy"}}
{"id": "fwLLMfJPIfNu", "question_type": "multi_choice", "question": "A 58-year-old man with metastatic cutaneous squamous cell carcinoma is not a candidate for curative surgery or radiation. He has a history of severe infusion-related reactions to monoclonal antibodies in the past. Which of the following systemic therapies is most appropriate for his condition, considering both indication and safety profile?", "options": {"A": "ERBITUX, due to its lower risk of infusion reactions", "B": "TECENTRIQ, as it is approved for CSCC and has a low rate of infusion reactions", "C": "UNLOXCYT, as it is specifically indicated for CSCC despite higher infusion reaction risk", "D": "No systemic therapy is appropriate due to infusion reaction history"}}
{"id": "VdJjPTlEx779", "question_type": "multi_choice", "question": "For patients with confirmed Grade 2 or higher ILD/pneumonitis while on Datroway, what is the recommended action regarding drug administration?", "options": {"A": "Continue Datroway with corticosteroids", "B": "Reduce Datroway dose", "C": "Switch to another topoisomerase inhibitor", "D": "Withhold Datroway temporarily"}}
{"id": "rhGMQaQ9xdsM", "question_type": "multi_choice", "question": "Which population should be advised not to breastfeed during and for 2 weeks after treatment with Hernexeos?", "options": {"A": "Pediatric patients", "B": "Men receiving Hernexeos", "C": "Women receiving Hernexeos", "D": "Geriatric patients"}}
{"id": "264phzXoreeQ", "question_type": "open_ended_multi_choice", "question": "A 60-year-old man with hypoparathyroidism and severe chronic renal impairment (eGFR 20 mL/min/1.73 m²) is currently taking digoxin for atrial fibrillation. He has no history of bone malignancy or prior radiation therapy. Which drug is the safest and most effective choice for managing his hypoparathyroidism, considering his renal function and concomitant digoxin therapy?", "options": {"A": "Ergocalciferol", "B": "Calcitriol", "C": "Yorvipath", "D": "Palopegteriparatide"}}
{"id": "QfsHWM2YKzJ8", "question_type": "multi_choice", "question": "A 58-year-old woman is newly diagnosed with metastatic non-small cell lung cancer (NSCLC). Genetic testing reveals a ROS1 gene rearrangement. She has a history of mild renal impairment (CLcr 55 mL/min), is currently taking a moderate CYP3A inhibitor for another condition, and has no history of cardiac disease or CNS symptoms. She is not pregnant and does not plan to breastfeed. Which drug regimen is most appropriate for her initial treatment?", "options": {"A": "Rozlytrek, with dose reduction due to CYP3A inhibitor", "B": "CYRAMZA in combination with erlotinib", "C": "LAZCLUZE (lazertinib plus amivantamab)", "D": "CYRAMZA in combination with docetaxel"}}
{"id": "ekDBrrBozLxT", "question_type": "open_ended_multi_choice", "question": "How should gastric acid suppression be handled in a patient receiving Ibtrozi?", "options": {"A": "Administer a proton pump inhibitor concurrently with Ibtrozi", "B": "Administer a locally acting antacid 2 hours before or after Ibtrozi", "C": "Administer an H2 receptor antagonist at the same time as Ibtrozi", "D": "Increase the dose of Ibtrozi when using acid-reducing agents"}}
{"id": "Sy0skU2kMWYa", "question_type": "multi_choice", "question": "A patient receiving Grafapex presents with prolonged pancytopenia. Which scenario is most consistent with this finding?", "options": {"A": "The patient is suffering from dehydration.", "B": "The patient is experiencing a typical therapeutic response.", "C": "The patient has developed an allergic reaction.", "D": "The patient has a viral infection."}}
{"id": "42tFjwE8qNGW", "question_type": "multi_choice", "question": "A male patient taking Romvimza has a female partner of reproductive potential. What is the recommended guidance regarding contraception?", "options": {"A": "No contraception is needed for male patients.", "B": "Contraception is only required if the partner is pregnant.", "C": "Contraception is required for 6 months after stopping Romvimza.", "D": "Effective contraception should be used during treatment and for 1 month after the last dose."}}
{"id": "nksC25pRlveb", "question_type": "open_ended_multi_choice", "question": "A 60-year-old male patient with supraventricular tachycardia and moderate hepatic impairment (Child-Pugh B) presents for acute rate management. He is not pregnant and has no history of bronchospastic conditions. Which medication should be avoided in light of his liver disease, and what is the most suitable alternative?", "options": {"A": "RAPIBLYK should be avoided; Propranolol is the most appropriate alternative.", "B": "Pacerone should be avoided; RAPIBLYK is the most appropriate alternative.", "C": "Propranolol should be avoided; Pacerone is the most appropriate alternative.", "D": "RAPIBLYK should be avoided; Pacerone is the most appropriate alternative."}}
{"id": "AFYFV3SL0YGM", "question_type": "open_ended_multi_choice", "question": "A 34-year-old woman with chronic immune thrombocytopenia presents with abnormal bleeding and is found to be platelet antibody positive. She has a history of moderate hepatic impairment and is currently taking a proton pump inhibitor for gastroesophageal reflux disease. Which of the following is the most appropriate drug treatment for her ITP?", "options": {"A": "WAYRILZ (rilzabrutinib) 400 mg twice daily", "B": "Nplate (romiplostim) weekly subcutaneous injection", "C": "DMT SUIK (corticosteroid) intravenous therapy", "D": "WAYRILZ (rilzabrutinib) with a drug holiday during PPI use"}}
{"id": "PBvWNdxMPRyF", "question_type": "open_ended_multi_choice", "question": "A 52-year-old male with schizophrenia and a history of benign prostatic hyperplasia (BPH) presents for maintenance antipsychotic therapy. He has no significant renal or hepatic impairment, and his cognitive function is intact. Which antipsychotic is most appropriate for this patient, considering his comorbid BPH and risk of urinary retention?", "options": {"A": "Cobenfy (xanomeline and trospium chloride), standard adult dose", "B": "Abilify Maintena (aripiprazole), standard adult dose", "C": "Cobenfy (xanomeline and trospium chloride), reduced dose for geriatric patients", "D": "Abilify Maintena (aripiprazole), reduced dose for CYP2D6 poor metabolizers"}}
{"id": "YJ2ZZJvigiEl", "question_type": "multi_choice", "question": "A 42-year-old woman with a history of Grade 2 astrocytoma and recent surgical resection is found to have a susceptible IDH2 mutation. She is currently using a hormonal contraceptive and is considering starting targeted therapy. Which of the following is the most important consideration when initiating Voranigo for this patient?", "options": {"A": "Delay Voranigo initiation until 6 months after surgery", "B": "Reduce the dose of Voranigo due to her age", "C": "Avoid Voranigo due to risk of nephrotoxicity", "D": "Switch to a nonhormonal contraceptive method before starting Voranigo"}}
{"id": "CgYJMfjMpElU", "question_type": "open_ended_multi_choice", "question": "A 42-year-old woman presents with moderate to severe acute pain following abdominal surgery. She has a history of severe hepatic impairment (Child-Pugh Class C) and is currently taking a strong CYP3A inhibitor for another condition. Which drug regimen is most appropriate for her acute pain management?", "options": {"A": "JOURNAVX administered at standard adult dosage", "B": "Ropivacaine Hydrochloride via epidural block, starting at the low end of the dosage range", "C": "Pain Relief Childrens (acetaminophen-based OTC) at pediatric dosing", "D": "JOURNAVX with reduced dosage and avoidance of grapefruit products"}}
{"id": "9YwHLiWGaEQM", "question_type": "open_ended_multi_choice", "question": "A 75-year-old male with mild cognitive impairment attributed to Alzheimer’s disease is being considered for pharmacological management. He has a documented history of severe hypersensitivity reactions to monoclonal antibodies. He is neither pregnant nor breastfeeding and does not need antithrombotic medication. What is the most suitable drug therapy recommendation for him?", "options": {"A": "Kisunla (donanemab-azbt), with pre-treatment using antihistamines", "B": "Kisunla (donanemab-azbt), contraindicated due to history of serious hypersensitivity", "C": "Kisunla (donanemab-azbt), recommended with regular MRI monitoring", "D": "Kisunla (donanemab-azbt), recommended only if patient is not ApoE ε4 homozygote"}}
{"id": "Mf3frT1GWImT", "question_type": "open_ended_multi_choice", "question": "For a 13-year-old female patient weighing 45 kg and diagnosed with uncomplicated urinary tract infection, is Blujepa recommended as a treatment option?", "options": {"A": "Yes, Blujepa is indicated for this patient population.", "B": "No, Blujepa is not indicated for patients under 18 years of age.", "C": "No, Blujepa is only indicated for male pediatric patients.", "D": "No, Blujepa is not indicated for patients weighing less than 50 kg."}}
{"id": "jRzsNBy0cuJe", "question_type": "open_ended_multi_choice", "question": "What is the recommended adjustment to Journavx dosing following the fourth dose in patients who are receiving moderate CYP3A inhibitors?", "options": {"A": "Reduce to 50 mg orally every 24 hours", "B": "Increase to 100 mg orally every 12 hours", "C": "Continue 50 mg orally every 12 hours", "D": "Discontinue Journavx"}}
{"id": "dzLQs8b1JCMT", "question_type": "multi_choice", "question": "Which of the following instructions should be given to patients regarding the timing of Modeyso administration?", "options": {"A": "Take Modeyso only when symptoms occur.", "B": "Take Modeyso twice daily with meals.", "C": "Take Modeyso once daily at bedtime, regardless of food intake.", "D": "Take Modeyso every other day with a glass of milk."}}
{"id": "AUeFIx2nfIDF", "question_type": "open_ended_multi_choice", "question": "A 65-year-old woman with metastatic HER2-mutant non-squamous NSCLC is being evaluated for systemic therapy. She is currently taking rifampin, a strong CYP3A inducer, for latent tuberculosis. Her cardiac and liver function are normal, and she is not pregnant. Which of the following is the best approach to drug selection and management for her lung cancer?", "options": {"A": "Initiate HERNEXEOS, but increase the dose due to the interaction with rifampin.", "B": "Start TECENTRIQ as a single agent, as it has no major CYP3A interactions.", "C": "Use etoposide in combination with other agents, as it is not affected by CYP3A inducers.", "D": "Avoid HERNEXEOS entirely and select an alternative therapy due to the drug interaction."}}
{"id": "2vk9eJxwxOgu", "question_type": "open_ended_multi_choice", "question": "Following a negative rapid antigen test for RSV in a patient with recent Enflonsia administration and ongoing clinical suspicion, what is the appropriate next diagnostic step?", "options": {"A": "Repeat the rapid antigen test", "B": "Initiate empirical antiviral therapy", "C": "Confirm diagnosis using an RT-PCR assay", "D": "Perform a chest X-ray"}}
{"id": "WlEhbavVb8dv", "question_type": "open_ended_multi_choice", "question": "A 55-year-old woman with pulmonary arterial hypertension (WHO Group 1) is currently receiving prostacyclin infusion and antithrombotic therapy. Her platelet count is 45,000/mm³. She is being considered for a new drug to improve exercise capacity and reduce clinical worsening. Which drug should be avoided in her case?", "options": {"A": "Ambrisentan once daily", "B": "Macitentan once daily", "C": "Sotatercept-csrk every three weeks", "D": "Ambrisentan in combination with tadalafil"}}
{"id": "bdMIpIlNXrGQ", "question_type": "open_ended_multi_choice", "question": "A 45-year-old woman with a history of autoimmune hemolytic anemia is currently pregnant. She presents with worsening fatigue and laboratory evidence of anemia. She does not have chronic kidney disease and is not on dialysis. Which of the following is the most appropriate treatment for her anemia?", "options": {"A": "Vafseo, as it is effective for anemia in adults regardless of dialysis status.", "B": "DMT SUIK (corticosteroid), with careful consideration of maternal and fetal risks.", "C": "Cortisone aceticum, primarily for appetite and weight management.", "D": "Vafseo, but only after delivery due to pregnancy risk."}}
{"id": "1qrutECbTY91", "question_type": "multi_choice", "question": "A male patient taking Romvimza has a female partner of reproductive potential. What is the recommended guidance regarding contraception?", "options": {"A": "No contraception is needed for male patients.", "B": "Contraception is only required if the partner is pregnant.", "C": "Contraception is only necessary during the first week of therapy.", "D": "Contraception is required for 6 months after stopping Romvimza."}}
{"id": "AAPKunN7G0fr", "question_type": "open_ended_multi_choice", "question": "In the ASPEN trial, how did the frequency of severe pulmonary exacerbations per year differ between the Brinsupri 25 mg group and the placebo group?", "options": {"A": "Higher in Brinsupri 25 mg", "B": "Lower in Brinsupri 25 mg", "C": "Equal in both groups", "D": "Not reported"}}
{"id": "d28DOf6CagVM", "question_type": "multi_choice", "question": "A patient is prescribed Wayrilz and is also taking an antacid. How should the administration of Wayrilz be managed in relation to the antacid?", "options": {"A": "Crush Wayrilz and mix with the antacid", "B": "Take Wayrilz and the antacid together", "C": "Administer Wayrilz at least 2 hours after the antacid", "D": "Administer Wayrilz at least 2 hours before the antacid"}}
{"id": "s9eWi8xKUen5", "question_type": "open_ended_multi_choice", "question": "A 38-year-old woman diagnosed with symptomatic tenosynovial giant cell tumor (TGCT) has chronic hepatitis B and elevated liver enzymes. She is also on a medication that acts as a P-glycoprotein (P-gp) substrate. Due to the high risk of morbidity, surgery is not advised. Which systemic therapy regimen should be selected for her TGCT?", "options": {"A": "Turalio (pexidartinib hydrochloride) with standard dosing and no dietary restrictions", "B": "Romvimza (vimseltinib), ensuring it is administered at least 4 hours prior to her P-gp substrate", "C": "Romvimza (vimseltinib) with no adjustment for P-gp substrate timing", "D": "Turalio (pexidartinib hydrochloride) with a high-fat meal"}}
{"id": "bVCgjMPmQ1sc", "question_type": "open_ended_multi_choice", "question": "If a patient is on Brinsupri, what should they notify their healthcare provider about before getting a live attenuated vaccine?", "options": {"A": "That they are currently taking Brinsupri", "B": "Their history of allergies", "C": "Their family medical history", "D": "Their travel history"}}
{"id": "O8bN6NiNc2qK", "question_type": "open_ended_multi_choice", "question": "Which statement most appropriately summarizes the warnings and precautions for Andembry?", "options": {"A": "There are no warnings and precautions listed for Andembry.", "B": "Andembry has multiple warnings and precautions related to hepatic impairment.", "C": "Andembry requires monitoring for cardiovascular side effects.", "D": "Andembry is contraindicated in pregnancy due to specific warnings."}}
{"id": "Dqi43PL5yv9C", "question_type": "multi_choice", "question": "Following cholecystectomy due to gallbladder disease in patients treated with Qfitlia, what was the typical management regarding Qfitlia therapy?", "options": {"A": "Qfitlia was permanently discontinued in all cases", "B": "Most patients resumed Qfitlia after surgery", "C": "Qfitlia dose was doubled", "D": "Qfitlia was switched to fixed dose regimen"}}
{"id": "Kk4u5209MQWQ", "question_type": "open_ended_multi_choice", "question": "How has the carcinogenic potential of Tryptyr been evaluated according to available evidence?", "options": {"A": "Long-term animal studies have demonstrated a high carcinogenic risk for Tryptyr.", "B": "Long-term studies in animals have not been performed to evaluate the carcinogenic potential of Tryptyr.", "C": "Tryptyr has been shown to be non-carcinogenic in human clinical trials.", "D": "Tryptyr is classified as a probable human carcinogen based on in vitro data."}}
{"id": "H7dJBJk7M40i", "question_type": "open_ended_multi_choice", "question": "A 35-year-old pregnant woman at 10 weeks gestation has been newly diagnosed with primary biliary cholangitis. She presents with mild jaundice and fatigue but does not show any evidence of hepatic decompensation. What is the most appropriate and safest initial medication to start for her condition?", "options": {"A": "IQIRVO (elafibranor) monotherapy", "B": "Tricor (fenofibrate) monotherapy", "C": "Urso 250 (ursodiol) monotherapy", "D": "IQIRVO (elafibranor) in combination with Tricor (fenofibrate)"}}
{"id": "3tAK3CYRzlGD", "question_type": "open_ended_multi_choice", "question": "If a patient is prescribed Tryptyr along with another topical ophthalmic eye drop, how should the administration be timed?", "options": {"A": "Administer both drops simultaneously", "B": "Administer Tryptyr first and the other drop immediately after", "C": "Administer the drugs at least five minutes apart", "D": "Wait one hour between drugs"}}
{"id": "2irQvcw5EeVY", "question_type": "open_ended_multi_choice", "question": "How did the efficacy of Tryptyr compare to vehicle in terms of statistical significance for tear production improvement in both COMET-2 and COMET-3 studies?", "options": {"A": "No statistically significant difference was observed.", "B": "Statistically significant improvement favoring Tryptyr (p<0.01) was observed in both studies.", "C": "Statistically significant improvement favoring vehicle (p<0.01) was observed.", "D": "Statistical significance was only achieved in COMET-2."}}
{"id": "kDcIuxMTL2KX", "question_type": "open_ended_multi_choice", "question": "Considering a 14-year-old male with hemophilia B, absence of hepatic or gallbladder pathology, and normal liver function, which agent is recommended for regular prophylaxis against bleeding, and what is the rationale for this recommendation?", "options": {"A": "Hemlibra, administered subcutaneously once weekly", "B": "Qfitlia, administered according to antithrombin-based dosing regimen", "C": "Hemlibra, administered subcutaneously every four weeks", "D": "Qfitlia, administered at a fixed dose of 80 mg once monthly"}}
{"id": "iGTIBmnUPAwF", "question_type": "open_ended_multi_choice", "question": "A 45-year-old woman with metastatic non-keratinizing nasopharyngeal carcinoma has experienced disease progression after receiving platinum-based chemotherapy and at least one additional prior therapy. She is currently breastfeeding and wishes to maintain breastfeeding. What is the most suitable treatment option for her at this time?", "options": {"A": "Penpulimab-kcqx as a single agent, administered every 3 weeks", "B": "Capecitabine 500 mg twice daily as monotherapy", "C": "Celecoxib 200 mg twice daily for symptom relief", "D": "Delay systemic therapy and continue breastfeeding for 4 months before starting Penpulimab-kcqx"}}
{"id": "1S12Hwztk0nZ", "question_type": "open_ended_multi_choice", "question": "In which scenario would the use of Blujepa be contraindicated?", "options": {"A": "History of severe hypersensitivity to Blujepa", "B": "History of mild rash after Blujepa", "C": "History of severe hypersensitivity to penicillin", "D": "History of mild hypersensitivity to Blujepa"}}
{"id": "4qKkk7NNKSVe", "question_type": "multi_choice", "question": "A 35-year-old woman with hereditary angioedema is planning to become pregnant and requires prophylactic therapy. She is concerned about fetal safety and prefers a medication with reassuring animal data and minimal warnings. Which prophylactic agent is most appropriate based on available safety information?", "options": {"A": "ANDEMBRY", "B": "TAKHZYRO", "C": "Kalbitor", "D": "None of the above"}}
{"id": "QqJQilPAETOE", "question_type": "open_ended_multi_choice", "question": "A 42-year-old individual with hereditary angioedema presents during an acute attack. The patient has severe hepatic dysfunction (Child-Pugh Class C) and no kidney problems. Which medication should be chosen, considering the patient's liver impairment and the safety profile of the drugs?", "options": {"A": "Ekterly", "B": "Icatibant acetate", "C": "Sajazir", "D": "Icatibant"}}
{"id": "NvHxJyJVraDM", "question_type": "multi_choice", "question": "A 55-year-old adult with hereditary angioedema is experiencing an acute attack. The patient is currently taking a strong CYP3A4 inhibitor for another condition. Which drug is the most suitable for treating the acute attack, considering drug-drug interactions?", "options": {"A": "Sajazir", "B": "Ekterly", "C": "Icatibant acetate", "D": "Icatibant"}}
{"id": "HFqtj5VJEYQ1", "question_type": "open_ended_multi_choice", "question": "A 54-year-old female with primary biliary cholangitis, ongoing pruritus, elevated alkaline phosphatase, and cirrhosis complicated by new-onset ascites is unable to tolerate ursodeoxycholic acid. She is currently taking a statin for hyperlipidemia and is seeking alternative treatment options. What is the most suitable drug regimen for her situation?", "options": {"A": "Elafibranor once daily as monotherapy", "B": "Colcrys daily for long-term management", "C": "Budesonide inhalation twice daily", "D": "Supportive care only; avoid Elafibranor due to decompensated cirrhosis"}}
{"id": "7dEzG6vnZCqK", "question_type": "open_ended_multi_choice", "question": "In the case of a 14-year-old patient with non-cystic fibrosis bronchiectasis, which branded therapy is recommended for this age group?", "options": {"A": "Brinsupri", "B": "Albuterol", "C": "Azithromycin", "D": "Prednisone"}}
{"id": "D5mos93g3iUP", "question_type": "open_ended_multi_choice", "question": "A female patient of reproductive potential is prescribed Journavx and is currently using a hormonal contraceptive containing drospirenone. What additional advice should be given regarding contraception?", "options": {"A": "Use an additional nonhormonal contraceptive during Journavx treatment and for 28 days after discontinuation.", "B": "Discontinue all contraceptives while on Journavx.", "C": "Switch to a contraceptive containing norethindrone only.", "D": "No changes to contraceptive regimen are needed."}}
{"id": "d32CFK9JXb2X", "question_type": "multi_choice", "question": "A 16-year-old male with Niemann-Pick disease type C and progressive neurological decline is being considered for drug therapy. He has moderate renal impairment (eGFR 35 mL/min) and is currently taking metformin, an OCT2 substrate. Which of the following is the most appropriate approach to drug selection and management for this patient?", "options": {"A": "Start MIPLYFFA in combination with miglustat at standard dosing without adjustments", "B": "Start lithium carbonate therapy", "C": "Start OPFOLDA in combination with Pombiliti", "D": "Start MIPLYFFA in combination with miglustat at reduced dosing and monitor for metformin toxicity"}}
{"id": "zsdXKGfumiDA", "question_type": "open_ended_multi_choice", "question": "A 6-year-old patient presents with bacterial pneumonia acquired in the community. There is no history of renal impairment or drug allergies. The child's parents are worried about antibiotics that might have lasting impacts on dental and bone health. What is the most appropriate antibiotic treatment for this child, considering both safety and efficacy?", "options": {"A": "Doxycycline Hyclate administered twice daily for 7 days", "B": "Rituximab and Hyaluronidase administered as a single agent", "C": "Zevtera administered according to pediatric dosing guidelines for 7 days", "D": "Doxycycline Hyclate with a planned drug holiday after 3 days"}}
{"id": "569qHQvGkUfj", "question_type": "open_ended_multi_choice", "question": "Following abdominal surgery, a 42-year-old woman experiences moderate to severe acute pain. She has severe hepatic dysfunction classified as Child-Pugh Class C and is taking a strong CYP3A inhibitor. Which pain management regimen should be chosen for her?", "options": {"A": "JOURNAVX administered at standard adult dosage", "B": "Ropivacaine Hydrochloride via epidural block, starting at the low end of the dosage range", "C": "Pain Relief Childrens (acetaminophen-based OTC) at pediatric dosing", "D": "JOURNAVX with reduced dosage and avoidance of grapefruit products"}}
{"id": "Se7oMDpdUprq", "question_type": "multi_choice", "question": "For patients receiving Imaavy concomitantly with monoclonal antibodies, what clinical action should be taken?", "options": {"A": "Discontinue monoclonal antibodies immediately", "B": "Administer both drugs at the same time without monitoring", "C": "Increase the dose of Imaavy", "D": "Switch to oral monoclonal antibodies"}}
{"id": "roGt1SKjSFe4", "question_type": "open_ended_multi_choice", "question": "Which protocol should be observed when Enflonsia and injectable vaccines are administered concurrently?", "options": {"A": "Administer both in the same syringe", "B": "Administer Enflonsia and vaccines at the same injection site", "C": "Use separate syringes and different injection sites", "D": "Mix Enflonsia with vaccines in the same vial"}}
{"id": "WhtjRxn03keD", "question_type": "multi_choice", "question": "A 58-year-old woman is admitted to the hospital with acute supraventricular tachycardia. She has a history of hypertension and is currently taking an ACE inhibitor. Her liver function tests reveal moderate hepatic impairment (Child-Pugh B). Which of the following is the most appropriate drug for short-term reduction of her ventricular rate?", "options": {"A": "Diltiazem", "B": "RAPIBLYK (landiolol)", "C": "Pacerone (amiodarone)", "D": "Propranolol"}}
{"id": "cgKm01Nb7jxS", "question_type": "open_ended", "question": "A 35-year-old man with chronic hand eczema is being considered for topical therapy. He has a history of active hepatitis B infection and is currently receiving antiviral treatment. Which of the following is the most appropriate recommendation regarding Anzupgo (delgocitinib) for this patient?", "options": {"A": "Anzupgo (delgocitinib) is recommended as first-line therapy.", "B": "Anzupgo (delgocitinib) can be used safely in patients with active hepatitis B.", "C": "Anzupgo (delgocitinib) should be avoided due to his active hepatitis B infection.", "D": "Anzupgo (delgocitinib) should be combined with potent immunosuppressants for better efficacy."}}
{"id": "ehobljKlzdFl", "question_type": "multi_choice", "question": "A 10-day-old neonate, born at term and entering their first RSV season, is being evaluated for RSV prophylaxis. The infant has no history of hypersensitivity reactions and is otherwise healthy. The mother is of reproductive potential but is not currently pregnant or breastfeeding. Which drug is most appropriate for RSV prevention in this patient?", "options": {"A": "Restasis MultiDose, administered twice daily.", "B": "Virazole, administered as an inhalation solution.", "C": "Virazole, administered orally.", "D": "ENFLONSIA, administered as a single dose."}}
{"id": "abxJ6zB3oeIC", "question_type": "open_ended_multi_choice", "question": "A 55-year-old woman with WHO Group 1 pulmonary arterial hypertension, currently treated with prostacyclin infusion and antithrombotics, has a platelet count of 45,000/mm³. She is being considered for a new therapy to enhance exercise tolerance and limit disease progression. Which drug should be avoided in her case?", "options": {"A": "Ambrisentan once daily", "B": "Macitentan once daily", "C": "Sotatercept-csrk every three weeks", "D": "Ambrisentan in combination with tadalafil"}}
{"id": "QgchlK86ybcU", "question_type": "open_ended_multi_choice", "question": "A 45-year-old patient with progressive diffuse midline glioma (H3 K27M mutation) after previous treatments is being considered for MODEYSO. He is currently on a strong CYP3A4 inhibitor for another illness. What is the most suitable management plan for his glioma treatment?", "options": {"A": "Start MODEYSO at the standard dose without adjusting for drug interactions.", "B": "Avoid using MODEYSO entirely due to his age.", "C": "Reduce the dose of MODEYSO if concomitant use with the CYP3A4 inhibitor cannot be avoided.", "D": "Discontinue the CYP3A4 inhibitor and start MODEYSO at a higher dose."}}
{"id": "WglXMA1w8nl5", "question_type": "multi_choice", "question": "Which of the following statements best describes the carcinogenic potential of Journavx (suzetrigine) based on available animal studies?", "options": {"A": "Long-term animal studies have confirmed carcinogenicity of Journavx.", "B": "Long-term animal studies have not been completed to evaluate carcinogenic potential of Journavx.", "C": "Journavx is proven to be non-carcinogenic in humans.", "D": "Journavx is carcinogenic in short-term animal studies."}}
{"id": "bhgOZ6GDucmo", "question_type": "multi_choice", "question": "How did the requirement for rescue medication compare between the Wayrilz and placebo groups during the double-blind period of the LUNA-3 study?", "options": {"A": "58% of Wayrilz patients and 33% of placebo patients required rescue medication", "B": "33% of Wayrilz patients and 58% of placebo patients required rescue medication", "C": "Both groups had 33% requiring rescue medication", "D": "Both groups had 58% requiring rescue medication"}}
{"id": "rAwbixT71jrf", "question_type": "multi_choice", "question": "A 50-year-old woman with chronic hypoparathyroidism is currently being treated with digoxin for atrial fibrillation. Her serum calcium is well controlled on calcium and active vitamin D. She is being considered for additional therapy to better manage her hypoparathyroidism. Which of the following is the most important consideration if Yorvipath is initiated?", "options": {"A": "Yorvipath is contraindicated in patients with a history of atrial fibrillation", "B": "Yorvipath is not effective in patients taking active vitamin D", "C": "Yorvipath may increase the risk of digitalis toxicity due to elevated serum calcium", "D": "Yorvipath should be administered twice daily to minimize calcium fluctuations"}}
{"id": "ztl2sXXKmglD", "question_type": "open_ended_multi_choice", "question": "A 38-year-old woman, currently pregnant, has been found to have unresectable esophageal squamous cell carcinoma with PD-L1 expression (CPS = 3). She is having feeding difficulties and nausea. Considering her pregnancy, which drug should be avoided in her treatment?", "options": {"A": "Tevimbra in combination with platinum-containing chemotherapy", "B": "Keytruda QLEX in combination with platinum- and fluoropyrimidine-based chemotherapy", "C": "Docetaxel anhydrous in combination with cisplatin and fluorouracil", "D": "All of the above"}}
{"id": "qogeYFi9j53f", "question_type": "open_ended_multi_choice", "question": "What is the advised period for women of childbearing age to practice effective contraception after receiving their last dose of penpulimab-kcqx?", "options": {"A": "1 month", "B": "2 months", "C": "3 months", "D": "4 months"}}
{"id": "dsXVeHX6aBGy", "question_type": "open_ended", "question": "A 28-year-old pregnant woman with sepiapterin-responsive phenylketonuria presents for management. She has a history of heavy menstrual bleeding and currently reports superficial hematomas. Her blood phenylalanine levels are above target. Which treatment option is most appropriate for her PKU during pregnancy?", "options": {"A": "Sephience 60 mg/kg daily with continued monitoring for bleeding", "B": "Sapropterin dihydrochloride 20 mg/kg daily with a Phe-restricted diet", "C": "Sephience 60 mg/kg daily with a drug holiday during periods of active bleeding", "D": "JAVYGTOR 20 mg/kg daily with a Phe-restricted diet"}}
{"id": "1Rl0r2ummxfK", "question_type": "multi_choice", "question": "For a patient being considered for therapy with Andembry, which of the following is true regarding contraindications?", "options": {"A": "Andembry should be avoided in patients with renal insufficiency.", "B": "Andembry is contraindicated in patients with a history of anaphylaxis.", "C": "Andembry should not be administered to patients with active infection.", "D": "Andembry is contraindicated in pediatric populations."}}
{"id": "sfj8zsmB6ejl", "question_type": "open_ended_multi_choice", "question": "A 62-year-old male with anemia due to CKD on dialysis for 6 months also has a history of cirrhosis and controlled hypertension. He is not currently taking any statins or iron supplements. Which of the following is the most appropriate therapy for his anemia?", "options": {"A": "Vafseo, as it is indicated for anemia in CKD patients on dialysis.", "B": "DMT SUIK (corticosteroid), considering his comorbidities.", "C": "Vafseo, but only if liver function tests are normal.", "D": "Cortisone aceticum, as it is safe in liver disease."}}
{"id": "cvXBx0VBSzF6", "question_type": "multi_choice", "question": "A 35-year-old patient with myelodysplastic syndrome is scheduled for allogeneic hematopoietic stem cell transplantation. Which regimen including Grafapex is appropriate based on its approved indications?", "options": {"A": "Grafapex plus methotrexate for induction therapy", "B": "Grafapex monotherapy as a preparative regimen", "C": "Grafapex plus cytarabine as maintenance therapy", "D": "Grafapex plus fludarabine as a preparative regimen"}}
{"id": "uZE3d1sFONe9", "question_type": "open_ended", "question": "If a patient reports an allergic reaction to an inactive ingredient in Grafapex, what is the recommended clinical action?", "options": {"A": "Do not administer Grafapex", "B": "Administer Grafapex with premedication", "C": "Reduce the dose of Grafapex", "D": "Monitor the patient closely during administration"}}
{"id": "oE0P4SCaRnhw", "question_type": "open_ended_multi_choice", "question": "A patient who is currently taking Ibtrozi needs treatment for gastric acid suppression. What is the most suitable approach to manage this situation?", "options": {"A": "Administer a proton pump inhibitor concurrently with Ibtrozi", "B": "Administer a locally acting antacid 2 hours before or after Ibtrozi", "C": "Administer an H2 receptor antagonist at the same time as Ibtrozi", "D": "Increase the dose of Ibtrozi when using acid-reducing agents"}}
{"id": "sP2zGI92MuUF", "question_type": "multi_choice", "question": "A 29-year-old woman with type 1 diabetes mellitus 13 is planning pregnancy. She is currently using AFREZZA for glycemic control. She asks about the safety of continuing her current therapy during pregnancy and lactation. Which of the following is the most appropriate recommendation for glycemic management in this scenario?", "options": {"A": "Continue AFREZZA throughout pregnancy and lactation, as its safety is well established in these populations", "B": "Switch to ADMELOG, as published studies support its safety in pregnancy and lactation", "C": "Switch to TZIELD, as it is recommended for glycemic control in pregnant women", "D": "Discontinue all insulin therapy and initiate a drug holiday during pregnancy"}}
{"id": "lB46ZRcuBXF0", "question_type": "multi_choice", "question": "Which of the following best describes the rationale for avoiding Blujepa in patients with severe hepatic impairment?", "options": {"A": "Risk of hepatotoxicity due to drug accumulation", "B": "Increased exposure to gepotidacin and risk of QTc prolongation", "C": "Lack of efficacy in this population", "D": "Blujepa is not metabolized by the liver"}}
{"id": "3ry0rzTVLd0T", "question_type": "open_ended_multi_choice", "question": "When initiating treatment with Sephience, what guidance should be given to patients?", "options": {"A": "Inform their healthcare provider about all prescription, over-the-counter medications, and supplements they are taking.", "B": "Avoid all dairy products while on therapy.", "C": "Increase their daily intake of vitamin K.", "D": "Monitor their blood pressure daily."}}
{"id": "qMBdsKtZhZxA", "question_type": "multi_choice", "question": "A 34-year-old woman is admitted with Japanese encephalitis and develops severe cerebral edema, increased intracranial pressure, and reduced consciousness. She is currently 28 weeks pregnant. The medical team considers pharmacologic management for cerebral edema. Which of the following is the most appropriate drug regimen for this patient?", "options": {"A": "Methylprednisolone acetate (from Dyural 40 Kit) administered intramuscularly at standard dose", "B": "Bupivacaine hydrochloride (from Dyural 40 Kit) for epidural anesthesia at 0.75% concentration", "C": "Rituxan Hycela administered as a single agent", "D": "Enspryng administered subcutaneously every four weeks"}}
{"id": "5348sR4i0cIX", "question_type": "open_ended_multi_choice", "question": "A 7-year-old with relapsed acute erythroleukemia and a confirmed KMT2A translocation presents with anemia, thrombocytopenia, and hepatomegaly. The patient has a normal baseline ECG and is not on any medications that prolong QTc. Which medication is best suited as initial therapy for this pediatric patient, given the genetic mutation and safety considerations?", "options": {"A": "Revuforj administered twice daily, with BSA-based dosing for pediatric patients", "B": "Aldesleukin administered intravenously in a hospital setting", "C": "Dexamethasone administered as adjunctive palliative therapy", "D": "TaperDex 6-day oral regimen at standard adult dosing"}}
{"id": "npQ3Yl0fWFIc", "question_type": "multi_choice", "question": "A patient is prescribed Sephience and is also taking sulfasalazine. What is the recommended clinical action based on their concomitant use?", "options": {"A": "Continue both drugs without monitoring", "B": "Avoid concomitant use or monitor blood phenylalanine (Phe) levels if unavoidable", "C": "Increase the dose of Sephience", "D": "Add a PDE-5 inhibitor"}}
{"id": "QHA602n9kzBV", "question_type": "open_ended", "question": "For a patient receiving Qfitlia at a dose of 50 mg every 2 months, what is the recommended action if their AT activity is measured at less than 15%?", "options": {"A": "Continue current dosage", "B": "Increase dose to 50 mg every month", "C": "Reduce dose to 20 mg every 2 months", "D": "Discontinue Qfitlia"}}
{"id": "5EC4E4oYPd4W", "question_type": "multi_choice", "question": "Which of the following statements best describes the results of mutagenicity testing for Hernexeos?", "options": {"A": "Hernexeos was mutagenic in the in vitro bacterial reverse mutation (Ames) assay.", "B": "Hernexeos was not tested for mutagenicity.", "C": "Hernexeos induced DNA breaks in the comet assay in liver and duodenum.", "D": "Hernexeos was genotoxic in the in vivo rat bone marrow micronucleus test."}}
{"id": "iOLaHQSw8vwG", "question_type": "open_ended_multi_choice", "question": "A 34-year-old woman diagnosed with primary IgA nephropathy and a urine protein-to-creatinine ratio of 2.1 g/g is a candidate for atrasentan (VANRAFIA) to manage her proteinuria. She is of reproductive age, currently not pregnant, but her contraceptive practices are inconsistent. What is the most appropriate action concerning initiation of atrasentan in this patient?", "options": {"A": "Initiate atrasentan immediately, as she is not pregnant.", "B": "Delay atrasentan initiation until effective contraception is established and pregnancy is excluded.", "C": "Initiate atrasentan and advise her to start contraception after the first dose.", "D": "Atrasentan is safe to use regardless of contraception status."}}
{"id": "fZdc3zKUbo3W", "question_type": "multi_choice", "question": "A 60-year-old man with advanced primary cutaneous T-cell lymphoma is scheduled for systemic chemotherapy. He is not pregnant, not breastfeeding, and has no history of hepatic dysfunction or concurrent use of CYP3A inhibitors. Which drug and administration schedule is most appropriate for treating his underlying malignancy?", "options": {"A": "Flurandrenolide topical lotion 0.05% applied twice daily for symptom relief", "B": "Vinblastine Sulfate administered intrathecally every 7 days", "C": "Vinblastine Sulfate administered intravenously every 7 days by an experienced clinician", "D": "Flurandrenolide topical lotion 0.05% applied extensively for prolonged periods"}}
{"id": "getO9RFEt5ua", "question_type": "open_ended_multi_choice", "question": "A 7-year-old male diagnosed with hemophilia B is experiencing frequent joint bleeds and has a tendency to bruise easily. He has not developed inhibitors to factor IX and is in need of a regular prophylactic regimen to decrease bleeding episodes. Taking into account his age and medical background, which medication schedule would be best suited for him?", "options": {"A": "HYMPAVZI, administered weekly for routine prophylaxis", "B": "REBINYN, administered weekly for routine prophylaxis", "C": "SEVENFACT, administered for routine prophylaxis", "D": "HYMPAVZI, administered only during bleeding episodes"}}
{"id": "whWswAbyfjCw", "question_type": "open_ended", "question": "A 32-year-old woman with infectious anterior uveitis is currently breastfeeding and has a documented sulfite allergy. She requires a corticosteroid eye drop for treatment. Which drug should be avoided due to her allergy, and which is the most appropriate option for her condition?", "options": {"A": "Hydrocortisone", "B": "Prednisolone", "C": "Loteprednol Etabonate", "D": "Prednisolone with a drug holiday"}}
{"id": "RP8018V9ARW0", "question_type": "multi_choice", "question": "A 68-year-old man with chronic atopic dermatitis, flexural lichenification, and recurrent pruritus is seeking relief for his symptoms. He has a history of mild cognitive impairment and is currently taking cimetidine for gastric reflux. He is not on any immunosuppressive therapy and has no active infections. Which treatment option should be avoided due to his current medication and risk profile?", "options": {"A": "Doxepin hydrochloride cream applied three times daily for 8 days", "B": "DMT SUIK administered intramuscularly for acute exacerbation", "C": "Lebrikizumab-lbkz administered subcutaneously every 2 weeks", "D": "Doxepin hydrochloride cream applied once daily for 8 days"}}
{"id": "nJrUG8dcyBQC", "question_type": "open_ended_multi_choice", "question": "A 60-year-old man with recurrent glioblastoma and a medical history of congestive heart failure and poorly controlled hypertension is being evaluated for anti-tumor treatment. Which medication should be avoided because it poses a higher risk of serious cardiovascular side effects in this patient group?", "options": {"A": "Zortress in combination with cyclosporine", "B": "Avastin administered every 2 weeks", "C": "Vorasidenib 40 mg once daily", "D": "Zortress combined with tacrolimus"}}
{"id": "zCOSnNTvReLS", "question_type": "multi_choice", "question": "A 68-year-old woman with metastatic gastroesophageal junction adenocarcinoma is being considered for chemotherapy. She has a history of chronic liver disease with laboratory findings of bilirubin 2.1x ULN, AST 2.0x ULN, and alkaline phosphatase 3.0x ULN. She has no known drug allergies and is not taking anticoagulants. Which of the following drugs is contraindicated for her due to her hepatic impairment?", "options": {"A": "Docetaxel in combination with cisplatin and fluorouracil", "B": "Zolbetuximab (Vyloy) in combination with fluoropyrimidine- and platinum-containing chemotherapy", "C": "Capecitabine (with dose adjustment for hepatic impairment)", "D": "Zolbetuximab (Vyloy) monotherapy"}}
{"id": "Nk7uBBZrJP7u", "question_type": "multi_choice", "question": "Which of the following instructions should be given to patients regarding the timing of Modeyso administration?", "options": {"A": "Take Modeyso every other day with a glass of milk.", "B": "Take Modeyso twice daily with meals.", "C": "Take Modeyso once daily at bedtime, regardless of food intake.", "D": "Take Modeyso orally once weekly on an empty stomach, at least 1 hour before or 3 hours after food, at the same time on the same day each week."}}
{"id": "PgZkUV5nd7my", "question_type": "open_ended_multi_choice", "question": "A 28-year-old woman with severe alopecia areata wishes to conceive and has no renal or hepatic dysfunction. She is not on any medications. What is the safest and most suitable treatment option for her condition?", "options": {"A": "LEQSELVI administered orally once daily", "B": "Hydroxychloroquine sulfate administered orally once daily", "C": "Triamcinolone acetonide nasal spray once daily", "D": "LEQSELVI administered orally every other day with a drug scheduler"}}
{"id": "FOJLhYIdrlO8", "question_type": "multi_choice", "question": "Which of the following statements best describes the recommended dietary management during treatment with Sephience for PKU?", "options": {"A": "Patients must continue a Phe-restricted diet as directed by their healthcare provider.", "B": "Patients should discontinue all dietary restrictions while on Sephience.", "C": "Patients should increase protein intake without restriction.", "D": "No dietary modifications are necessary during treatment."}}
{"id": "3GKaFjx4p7tm", "question_type": "open_ended", "question": "In the randomized, double-blind, multi-center trial AK105-304 evaluating penpulimab-kcqx for first-line treatment of recurrent or metastatic nasopharyngeal carcinoma (NPC), what was the observed hazard ratio (HR) for BICR-assessed progression-free survival (PFS) when comparing penpulimab-kcqx plus platinum/gemcitabine to placebo plus platinum/gemcitabine?", "options": {"A": "0.45 (95% CI: 0.33, 0.62)", "B": "1.25 (95% CI: 0.90, 1.70)", "C": "0.75 (95% CI: 0.60, 0.95)", "D": "0.33 (95% CI: 0.20, 0.50)"}}
{"id": "9Okue9OuCcJf", "question_type": "open_ended_multi_choice", "question": "A patient aged 35, diagnosed with KRAS-mutated recurrent low-grade serous ovarian carcinoma, is scheduled to initiate AVMAPKI FAKZYNJA CO-PACK. She is currently breastfeeding her infant who is 3 months old and seeks recommendations about lactation safety during her cancer treatment. What should be advised regarding her therapy?", "options": {"A": "Start AVMAPKI FAKZYNJA CO-PACK and continue breastfeeding", "B": "Delay AVMAPKI FAKZYNJA CO-PACK until breastfeeding is discontinued", "C": "Start AVMAPKI FAKZYNJA CO-PACK and stop breastfeeding during treatment and for 2 weeks after the last dose", "D": "Start AVMAPKI FAKZYNJA CO-PACK with reduced dosage to minimize risk to the infant"}}
{"id": "YEiw7WzxmSob", "question_type": "open_ended_multi_choice", "question": "A 58-year-old patient with chronic kidney disease (estimated creatinine clearance 28 mL/min/1.73 m²) is newly diagnosed with Niemann-Pick disease type C and exhibits worsening neurological deficits and gait instability. He is not currently on enzyme replacement therapy. Considering his renal status, which drug should be selected for his management?", "options": {"A": "Yargesa (miglustat) at standard dosing", "B": "Aqneursa at the recommended adult dosage", "C": "Opfolda (miglustat) in combination with Pombiliti", "D": "Yargesa (miglustat) with dose reduction for renal impairment"}}
{"id": "xlVjterVxjpv", "question_type": "open_ended_multi_choice", "question": "Considering a 68-year-old patient with familial chylomicronemia syndrome, hepatic steatosis, episodes of abdominal pain, mild renal impairment (eGFR 55 mL/min), and mild hepatic impairment, which pharmacological therapy is best suited to reduce his triglyceride levels?", "options": {"A": "MYHIBBIN (mycophenolate mofetil) with dose adjustment for renal impairment", "B": "TRYNGOLZA (olezarsen sodium) at standard dosage and frequency", "C": "MYHIBBIN (mycophenolate mofetil) with dose adjustment for hepatic impairment", "D": "TRYNGOLZA (olezarsen sodium) with reduced frequency due to age"}}
{"id": "9Jw7WwsYE2Eu", "question_type": "multi_choice", "question": "A 7-year-old boy with sepiapterin-responsive phenylketonuria presents with a history of recurrent nosebleeds and easy bruising. He is not taking any medications that affect folate synthesis or sepiapterin reductase. His parents are concerned about starting a new medication for PKU. Which of the following is the most appropriate drug to initiate for his hyperphenylalaninemia?", "options": {"A": "Javygtor", "B": "Sapropterin dihydrochloride", "C": "Sephience", "D": "Trimethoprim"}}
{"id": "G0dVgjuwvEmq", "question_type": "open_ended_multi_choice", "question": "What findings have been reported regarding the safety and efficacy of Vizz in patients aged 65 and older compared to those who are younger adults?", "options": {"A": "Geriatric patients experience significantly more adverse effects than younger adults.", "B": "Vizz is less effective in geriatric patients compared to younger adults.", "C": "No overall differences in safety or effectiveness have been observed between geriatric and younger adult patients.", "D": "Vizz is contraindicated in patients over 65 years of age."}}
{"id": "g1UkW2zOhfij", "question_type": "open_ended_multi_choice", "question": "When penpulimab-kcqx is given before or after an allogeneic HSCT, which condition may potentially arise as a complication?", "options": {"A": "Hyperacute graft-versus-host-disease (GVHD)", "B": "Solid organ rejection only", "C": "Stevens-Johnson Syndrome", "D": "Diabetic ketoacidosis"}}
{"id": "Y6SmDe9C1XBb", "question_type": "multi_choice", "question": "Which of the following statements best describes the results of mutagenicity testing for Hernexeos?", "options": {"A": "Hernexeos was mutagenic in the in vitro bacterial reverse mutation (Ames) assay.", "B": "Hernexeos was not mutagenic in the in vitro bacterial reverse mutation (Ames) assay.", "C": "Hernexeos induced DNA breaks in the comet assay in liver and duodenum.", "D": "Hernexeos was genotoxic in the in vivo rat bone marrow micronucleus test."}}
{"id": "08Ho70HNbPny", "question_type": "multi_choice", "question": "A 28-year-old woman with Niemann-Pick disease type C and progressive cognitive impairment is planning to become pregnant. She currently experiences frequent falls and dystonia. Which of the following is the most appropriate recommendation regarding drug therapy for her NPC-related neurological symptoms?", "options": {"A": "Start Miglustat (Opfolda) in combination with Pombiliti and advise contraception during treatment and for 7 days after discontinuation", "B": "Start Miglustat (Yargesa) and advise contraception during treatment and for 60 days after discontinuation", "C": "Start AQNEURSA (levacetylleucine) and advise contraception during treatment and for 60 days after discontinuation", "D": "Start AQNEURSA (levacetylleucine) and advise contraception during treatment and for 7 days after discontinuation"}}
{"id": "6zsNBzoZ3YtC", "question_type": "multi_choice", "question": "During Vanrafia therapy, which of the following is a recommended action for patients who experience unprotected sex or contraceptive failure?", "options": {"A": "Seek advice on emergency contraception", "B": "Wait until the next scheduled dose", "C": "Discontinue Vanrafia immediately", "D": "Increase the dose of Vanrafia"}}
{"id": "SoqIGvnM6IF9", "question_type": "open_ended_multi_choice", "question": "A man aged 30 with persistent moderate hand eczema has failed to improve with topical corticosteroids. He is currently being treated for active hepatitis C infection. Which drug regimen should be considered most suitable for his eczema?", "options": {"A": "Delgocitinib topical therapy", "B": "Topical corticosteroids", "C": "Delgocitinib in combination with potent immunosuppressants", "D": "Delgocitinib after hepatitis C treatment is completed and infection resolved"}}
{"id": "4OEPiNWkjwJH", "question_type": "multi_choice", "question": "Which statement best describes the safety profile of Andembry in pregnant or breastfeeding individuals?", "options": {"A": "Andembry is proven safe in pregnancy and breastfeeding.", "B": "Andembry is recommended for all pregnant women with HAE.", "C": "Andembry is contraindicated in pregnancy.", "D": "It is not known if Andembry can harm an unborn baby or passes into breastmilk."}}
{"id": "kULrivg8bx6c", "question_type": "open_ended_multi_choice", "question": "In a 42-year-old woman diagnosed with low-risk myelodysplastic syndrome, transfusion-dependent anemia, and a deletion 5q abnormality who is planning a pregnancy and not practicing contraception, which treatment option should be excluded due to her reproductive intentions?", "options": {"A": "Imetelstat sodium, 7.5 mg/kg intravenously every 4 weeks", "B": "Lenalidomide, 10 mg orally once daily", "C": "Inqovi, 35 mg orally once daily for 5 consecutive days every 28 days", "D": "Inqovi, 20 mg orally once daily for 5 consecutive days every 28 days"}}
{"id": "sDstjfE6Qhe9", "question_type": "multi_choice", "question": "For patients receiving Imaavy concomitantly with monoclonal antibodies, what clinical action should be taken?", "options": {"A": "Increase the dose of Imaavy", "B": "Administer both drugs at the same time without monitoring", "C": "Closely monitor for reduced effectiveness of the monoclonal antibodies", "D": "Switch to oral monoclonal antibodies"}}
{"id": "Q4TgtEyptaDD", "question_type": "open_ended_multi_choice", "question": "A 32-year-old breastfeeding woman with severe alopecia areata and mild renal impairment seeks treatment for her patchy hair loss. She is not using any CYP2C9 inhibitors and has tested negative for CYP2C9 poor metabolizer status. What is the most suitable drug therapy for her condition?", "options": {"A": "Minoxidil topical solution", "B": "Imiquimod cream", "C": "Leqselvi (deuruxolitinib phosphate)", "D": "No drug is appropriate from the options provided"}}
{"id": "kT14reCL6zGA", "question_type": "open_ended", "question": "A 7-year-old boy presents with a genetic skin disease manifesting as severe psoriasis. His parents inquire about systemic treatment options. Which of the following is the most appropriate recommendation regarding acitretin therapy for this patient?", "options": {"A": "Start acitretin at the standard adult dose, monitoring for liver function abnormalities.", "B": "Begin acitretin at a reduced dose due to his age, with regular skeletal assessments.", "C": "Avoid acitretin therapy due to lack of established safety and risk of skeletal abnormalities in pediatric patients.", "D": "Prescribe acitretin only if topical therapies fail, with no additional precautions."}}
{"id": "hy6qvjOTRx4l", "question_type": "open_ended_multi_choice", "question": "Why is it necessary to evaluate whether a patient has received recommended vaccines before commencing Imaavy therapy?", "options": {"A": "Imaavy causes transient reduction in IgG levels, making live vaccines not recommended during treatment", "B": "Imaavy increases the risk of vaccine-induced fever", "C": "Imaavy enhances the efficacy of live vaccines", "D": "Imaavy interacts with inactivated vaccines to cause hypersensitivity"}}
{"id": "sl7DA7FwKWOk", "question_type": "open_ended", "question": "A 45-year-old woman with type 1 interferonopathy is being treated with probenecid for gout. She has no hepatic or renal impairment and is not pregnant. Her physician is considering Olumiant therapy. What is the most appropriate dosing strategy for Olumiant in this patient?", "options": {"A": "Olumiant should be administered at the standard adult dose.", "B": "Olumiant should be avoided due to the risk of serious infections.", "C": "Olumiant dose should be reduced by half due to interaction with probenecid.", "D": "Olumiant is contraindicated in patients with gout."}}
{"id": "l3mexd4hpEy6", "question_type": "open_ended_multi_choice", "question": "A 68-year-old woman with well-controlled epilepsy on valproic acid is admitted for a complicated urinary tract infection. She has normal renal function and is not pregnant. Which medication should not be used because it could interact with her antiepileptic therapy and elevate her seizure risk?", "options": {"A": "Flavoxate Hydrochloride", "B": "Imipenem and Cilastatin", "C": "Gepotidacin", "D": "Both Flavoxate Hydrochloride and Gepotidacin"}}
{"id": "prXEPsK4SddD", "question_type": "open_ended_multi_choice", "question": "A 10-year-old, 32 kg child has just been diagnosed with paroxysmal nocturnal hemoglobinuria (PNH). The patient has not previously received any complement inhibitor therapy and is current with meningococcal immunizations. Taking into account the patient's age and weight, which medication should be selected for initial therapy?", "options": {"A": "Ultomiris", "B": "Piasky", "C": "Sirolimus", "D": "Eculizumab"}}
{"id": "AAE8qChFsQCQ", "question_type": "open_ended_multi_choice", "question": "Which of the following statements best describes the safety and efficacy of ANZUPGO in pediatric patients?", "options": {"A": "ANZUPGO is approved and safe for use in pediatric patients.", "B": "The safety and efficacy of ANZUPGO have not been established in pediatric patients.", "C": "ANZUPGO is contraindicated in pediatric patients.", "D": "ANZUPGO is recommended only for pediatric patients with severe disease."}}
{"id": "x7ajzchy9jVx", "question_type": "open_ended", "question": "Which of the following statements is correct regarding co-administration of Enflonsia with childhood vaccines?", "options": {"A": "Enflonsia can be mixed with vaccines in the same syringe", "B": "Enflonsia should be administered using a separate syringe and at a different injection site", "C": "Enflonsia must not be given concomitantly with any vaccines", "D": "Enflonsia should be administered intravenously when given with vaccines"}}
{"id": "6ypmwjD3JT6p", "question_type": "open_ended_multi_choice", "question": "A 7-year-old boy, weighing 28 kg, has chronic graft-versus-host disease and is currently experiencing airway obstruction, cough, and pulmonary infiltrates. His history includes food intolerance and abnormal esophageal function. He is on ritonavir, a strong CYP3A4 inhibitor, for asthma. Given his weight and current therapy, which medication should not be used?", "options": {"A": "AXATILIMAB-CSFR", "B": "PredniSONE Tablets, USP, 5 mg", "C": "Budesonide Inhalation", "D": "PredniSONE combined with Budesonide Inhalation"}}
{"id": "aL6DnF6KsyK3", "question_type": "multi_choice", "question": "A 62-year-old woman with unresectable, metastatic non-squamous non-small cell lung carcinoma is found to have a HER2 (ERBB2) tyrosine kinase domain activating mutation by FDA-approved testing. She has previously received platinum-based chemotherapy. Her cardiac function is normal, and she is not pregnant or breastfeeding. However, she is currently taking rifampin, a strong CYP3A inducer, for latent tuberculosis. Which drug regimen is most appropriate for her lung cancer treatment?", "options": {"A": "Imfinzi in combination with platinum-based chemotherapy", "B": "Atezolizumab as monotherapy", "C": "Zongertinib with dose adjustment to account for CYP3A induction", "D": "Zongertinib at standard dose without adjustment"}}
{"id": "sDxQJvwdYLsh", "question_type": "open_ended_multi_choice", "question": "Which of the following statements best describes the evidence supporting the use of Grafapex in pediatric patients with AML or MDS as part of a preparative regimen prior to allogeneic hematopoietic stem cell transplant?", "options": {"A": "Safety and efficacy have been established in pediatric patients younger than 1 year of age.", "B": "Safety and efficacy have been established in pediatric patients 1 year of age and older based on adult studies and additional pediatric data.", "C": "Grafapex is contraindicated in all pediatric patients.", "D": "Only pharmacokinetic data are available for pediatric patients."}}
{"id": "zJ1h0cAjX5W2", "question_type": "open_ended_multi_choice", "question": "A 58-year-old man with primary motor cortex epilepsy and a history of chronic liver disease is being considered for intravenous Phenytoin Sodium therapy. His serum albumin is low, and he is also taking warfarin for atrial fibrillation. What is the most important consideration for his Phenytoin Sodium dosing and monitoring?", "options": {"A": "Standard dosing of Phenytoin Sodium is appropriate, with no need for additional monitoring.", "B": "Phenytoin Sodium should be avoided due to risk of drug interactions with warfarin and increased toxicity in hepatic impairment; careful monitoring of unbound phenytoin levels is required if used.", "C": "Phenytoin Sodium can be used at higher doses to compensate for low albumin.", "D": "Phenytoin Sodium is contraindicated in patients with atrial fibrillation."}}
{"id": "8QOsMOnp8RRJ", "question_type": "multi_choice", "question": "A 10-year-old boy with primary axillary hyperhidrosis and chronic renal failure is being considered for topical anticholinergic therapy. He is not taking any other medications. Which treatment option is most appropriate for his condition?", "options": {"A": "Sofdra (sofpironium bromide), topical gel once daily", "B": "Qbrexza (glycopyrronium), topical wipes once daily", "C": "Oxytrol for Women (oxybutynin), transdermal patch twice weekly", "D": "None of the above are appropriate due to his age and renal impairment"}}
{"id": "of5QBVmM7hVv", "question_type": "open_ended_multi_choice", "question": "Which of the following best describes the eligibility criteria for patients enrolled in the AK105-304 trial investigating penpulimab-kcqx in nasopharyngeal carcinoma?", "options": {"A": "Patients with recurrent or metastatic NPC, with local-regional recurrence and/or distant metastasis occurring ≥ 6 months after curative intent treatment, or primary metastatic NPC not suitable for local therapy at diagnosis.", "B": "Patients with newly diagnosed localized NPC only.", "C": "Patients with any solid tumor regardless of prior treatment.", "D": "Patients with keratinizing squamous cell carcinoma only."}}
{"id": "fsI8nVwJOim1", "question_type": "open_ended_multi_choice", "question": "A 3-year-old boy with relapsed acute erythroleukemia is found to have a KMT2A gene translocation. He has refractory anemia with ringed sideroblasts and hepatomegaly. His weight is below 40 kg, and he has no history of cardiac disease. Which drug is most suitable for targeted therapy in this pediatric patient?", "options": {"A": "Daunorubicin Hydrochloride administered intravenously at standard pediatric dosing", "B": "TaperDex 12-day administered at the lowest effective dose to minimize growth suppression", "C": "REVUMENIB administered orally with BSA-based dosing and regular monitoring of bone growth", "D": "TaperDex 12-day combined with Daunorubicin Hydrochloride for induction therapy"}}
{"id": "afDvCr08eEln", "question_type": "open_ended_multi_choice", "question": "How does Modeyso influence fertility, according to the following statements?", "options": {"A": "Modeyso has no known effect on fertility.", "B": "Modeyso may adversely impact fertility in both males and females.", "C": "Modeyso improves fertility in females.", "D": "Modeyso only affects fertility in males."}}
{"id": "59UI7f47Lkj3", "question_type": "open_ended_multi_choice", "question": "A 39-year-old pregnant woman with advanced HR-positive, HER2-negative, PIK3CA-mutated breast cancer and normal organ function is considering targeted therapy. What is the most suitable recommendation regarding drug treatment for her condition at this point?", "options": {"A": "Initiate inavolisib in combination with palbociclib and fulvestrant immediately", "B": "Start carboplatin-based chemotherapy", "C": "Delay initiation of inavolisib until after pregnancy due to embryo-fetal toxicity risk", "D": "Begin esketamine therapy for breast cancer"}}
{"id": "fnHT5Xw1H2RB", "question_type": "open_ended_multi_choice", "question": "What is the best immediate management for a patient on Vanrafia who now exhibits yellowing of the skin and dark urine?", "options": {"A": "Continue Vanrafia and monitor symptoms", "B": "Increase the dose of Vanrafia", "C": "Temporarily or permanently discontinue Vanrafia and evaluate for liver dysfunction", "D": "Switch to another endothelin receptor antagonist"}}
{"id": "HEtcR3Vsfchu", "question_type": "multi_choice", "question": "A 62-year-old woman with metastatic pancreatic adenocarcinoma presents for first-line systemic therapy. Her laboratory results show a baseline absolute neutrophil count of 1,200 cells/mm³ and total bilirubin 1.2 x ULN. She has no history of hypersensitivity to taxanes, and her cardiac function is normal. Which drug regimen is most appropriate for her initial treatment?", "options": {"A": "BIZENGRI (zenocutuzumab)", "B": "Paclitaxel protein-bound particles for injectable suspension (albumin-bound) in combination with gemcitabine", "C": "Imbruvica (ibrutinib)", "D": "Paclitaxel protein-bound particles for injectable suspension (albumin-bound) monotherapy"}}
{"id": "vnwwHTjLYWCS", "question_type": "multi_choice", "question": "A 5-year-old boy with BH4-responsive phenylketonuria presents with fair hair, generalized hypopigmentation, and a history of seizures. He is currently receiving levodopa for a movement disorder. His parents are concerned about the risk of hypophenylalaninemia and neurological side effects. Which drug regimen requires the most careful monitoring for neurological status and blood phenylalanine levels in this patient?", "options": {"A": "JAVYGTOR at 20 mg/kg per day with a phenylalanine-restricted diet", "B": "Sephience at 60 mg/kg per day with a phenylalanine-restricted diet", "C": "Sapropterin dihydrochloride at 20 mg/kg per day with a phenylalanine-restricted diet", "D": "Sephience at 20 mg/kg per day with a phenylalanine-restricted diet"}}
{"id": "tdpsTtL1rqKj", "question_type": "multi_choice", "question": "A 6-year-old child presents with community-acquired bacterial pneumonia. The child has no history of severe allergies, is not taking any other medications, and has normal renal function. The physician is considering antibiotic therapy. Which drug is most appropriate for treating this infection in this patient, given the risks associated with tooth development and the approved indications for pediatric use?", "options": {"A": "Ceftobiprole medocaril sodium", "B": "Doxycycline hyclate", "C": "Acetaminophen", "D": "No antibiotic therapy is indicated"}}
{"id": "zs3Ub1aEf2L5", "question_type": "multi_choice", "question": "A 36-year-old woman with KRAS-mutated recurrent low-grade serous ovarian carcinoma is being considered for AVMAPKI FAKZYNJA CO-PACK (avutometinib and defactinib) therapy. She is currently pregnant and not taking any other medications. What is the most appropriate recommendation regarding her cancer treatment?", "options": {"A": "Start AVMAPKI FAKZYNJA CO-PACK immediately, as it is the only approved therapy for her condition.", "B": "Start AVMAPKI FAKZYNJA CO-PACK but reduce the dose to minimize fetal exposure.", "C": "Delay AVMAPKI FAKZYNJA CO-PACK until after delivery due to risk of fetal harm.", "D": "Switch to an alternative systemic therapy with a better safety profile in pregnancy."}}
{"id": "bcqkSiEk3bnt", "question_type": "multi_choice", "question": "A 10-year-old child weighing 25 kg is newly diagnosed with Niemann-Pick disease type C and presents with progressive gait ataxia, cognitive impairment, and hepatomegaly. The patient is not currently taking any other medications and has normal renal function. The family is concerned about long-term safety and wants a treatment specifically approved for pediatric use in NPC. Which drug is the most appropriate choice for this patient, considering the safety and efficacy profile?", "options": {"A": "Yargesa (miglustat) administered at standard adult dosing", "B": "Aqneursa administered at the recommended dosage for pediatric patients ≥15 kg", "C": "Opfolda (miglustat) in combination with Pombiliti", "D": "N-acetyl-DL-leucine monotherapy"}}
{"id": "NdifbSwZGStF", "question_type": "open_ended", "question": "A 7-year-old boy (weight 25 kg) presents with a 3-day history of sore throat, fever, and difficulty swallowing. He is diagnosed with bacterial pharyngitis. His medical history is significant for epilepsy, and he is currently taking carbamazepine. Which of the following is the best drug choice for treating his infection, considering potential drug interactions and efficacy?", "options": {"A": "Ibuprofen, 200 mg orally every 6 hours as needed for pain and fever", "B": "Cefixime, 8 mg/kg orally once daily for 10 days", "C": "Amphotericin B liposome, 3 mg/kg IV daily for 14 days", "D": "Cefixime, 8 mg/kg orally once daily for 10 days with close monitoring of carbamazepine levels"}}
{"id": "sXVklJLv49bS", "question_type": "open_ended_multi_choice", "question": "What is the suggested management for a patient who is unable to tolerate intravenous Datroway at a dosage of 3 mg/kg every three weeks?", "options": {"A": "Increase the dose to 4 mg/kg", "B": "Continue at 3 mg/kg", "C": "Permanently discontinue Datroway", "D": "Reduce to 2 mg/kg"}}
{"id": "PViAEBwkiXzu", "question_type": "open_ended_multi_choice", "question": "What is the accurate assessment of Lynozyfic based on available genotoxicity studies?", "options": {"A": "Genotoxicity studies have demonstrated a significant risk.", "B": "Genotoxicity studies have demonstrated no risk.", "C": "No genotoxicity studies have been conducted with Lynozyfic.", "D": "Genotoxicity studies in animals have shown inconclusive results."}}
{"id": "tg9kRT0TREkL", "question_type": "open_ended_multi_choice", "question": "A 55-year-old man with newly diagnosed intermediate-2 risk myelodysplastic syndrome and chronic kidney disease (creatinine clearance 40 mL/min) is not taking medications metabolized by cytidine deaminase. Cytogenetic testing shows no 5q deletion. Which drug regimen should be considered optimal for his treatment in light of his renal impairment?", "options": {"A": "Lenalidomide, 10 mg orally once daily (no dose adjustment)", "B": "Imetelstat sodium, 7.5 mg/kg intravenously every 4 weeks", "C": "Inqovi, 35 mg orally once daily for 5 consecutive days every 28 days", "D": "Lenalidomide, 25 mg orally once daily (no dose adjustment)"}}
{"id": "V7nQJHUHm5vX", "question_type": "open_ended_multi_choice", "question": "Given a 68-year-old male patient diagnosed with acute erythroleukemia, who also has congestive heart failure, anemia, thrombocytopenia, splenomegaly, and mild renal impairment, and is not eligible for stem cell transplantation, which chemotherapy agent should be avoided due to his comorbid conditions, and which would be considered the safest for palliative care?", "options": {"A": "Daunorubicin Hydrochloride administered intravenously at reduced dose", "B": "REVUMENIB administered orally with ECG monitoring", "C": "TaperDex 12-day administered at the lowest effective dose with careful monitoring for fluid retention and hypertension", "D": "Daunorubicin Hydrochloride combined with REVUMENIB for induction therapy"}}
{"id": "scn1l9ORnVzD", "question_type": "open_ended_multi_choice", "question": "Which statement provides the most accurate summary of Ibtrozi’s performance in mutagenicity tests?", "options": {"A": "Ibtrozi was mutagenic in the in vitro bacterial reverse mutation (Ames) assay.", "B": "Ibtrozi was not mutagenic in the in vitro bacterial reverse mutation (Ames) assay and additional mutagenicity tests.", "C": "Ibtrozi was clastogenic in the in vivo micronucleus study in rats.", "D": "Ibtrozi induced aneugenicity in rat bone marrow and liver."}}
{"id": "ASzsWTghZDlq", "question_type": "multi_choice", "question": "How frequently was single-agent penpulimab-kcqx administered in the AK105-202 study for patients with unresectable or metastatic non-keratinizing nasopharyngeal carcinoma?", "options": {"A": "200 mg intravenously every 2 weeks", "B": "200 mg orally every day", "C": "400 mg intravenously every 4 weeks", "D": "100 mg intravenously every week"}}
{"id": "nZqHflCCOWkq", "question_type": "open_ended_multi_choice", "question": "A 42-year-old adult experiencing an acute hereditary angioedema attack has a history of severe liver impairment (Child-Pugh Class C) but normal renal function. Which drug is the safest and most suitable option for this patient, given their hepatic condition?", "options": {"A": "Ekterly", "B": "Icatibant acetate", "C": "Sajazir", "D": "Icatibant"}}
{"id": "RdSJmOwQ3c9P", "question_type": "open_ended_multi_choice", "question": "When preparing a regulatory submission for Enflonsia, what information can be provided about possible impairment of fertility?", "options": {"A": "No reproductive toxicity studies have been conducted with Enflonsia.", "B": "Reproductive toxicity studies indicate no impairment of fertility.", "C": "Reproductive toxicity studies indicate potential impairment of fertility.", "D": "Reproductive toxicity studies are currently under review."}}
{"id": "ih0Y3x70vshh", "question_type": "open_ended_multi_choice", "question": "When analyzing both Trials 1 and 2 together, how does the occurrence of a ≥25% but <50% decrease in estimated glomerular filtration rate (eGFR) among JOURNAVX recipients compare to that among placebo recipients?", "options": {"A": "Higher in JOURNAVX-treated patients", "B": "Lower in JOURNAVX-treated patients", "C": "Equal in both groups", "D": "Not reported for JOURNAVX"}}
{"id": "x6Iad1zG6Jnq", "question_type": "open_ended_multi_choice", "question": "A 7-year-old with Niemann-Pick disease type C is experiencing worsening gait ataxia, cognitive decline, and hepatosplenomegaly. With normal kidney function and no concurrent medications, which drug regimen is best suited to address the neurological symptoms in light of the patient's age and the specific disease?", "options": {"A": "MIPLYFFA in combination with miglustat, administered according to pediatric dosing guidelines", "B": "OPFOLDA in combination with Pombiliti", "C": "Lithium carbonate", "D": "MIPLYFFA monotherapy"}}
{"id": "0zSUc7VjClZf", "question_type": "open_ended_multi_choice", "question": "What information is available regarding mutagenesis research conducted on Enflonsia?", "options": {"A": "No mutagenesis studies have been performed with Enflonsia.", "B": "Mutagenesis studies have shown positive results.", "C": "Mutagenesis studies have shown negative results.", "D": "Mutagenesis studies are ongoing."}}
{"id": "viyCntCUXrmd", "question_type": "open_ended_multi_choice", "question": "A 3-year-old child with several umbilicated papules on the trunk and extremities is diagnosed with molluscum contagiosum. The parents inquire about topical therapy. The patient has no allergies or prior skin conditions such as eczema. Which topical treatment should be recommended for this child, balancing both safety and effectiveness?", "options": {"A": "Adapalene applied once daily to affected areas", "B": "Zelsuvmi applied topically as directed for molluscum contagiosum", "C": "Adapalene applied twice daily to affected areas", "D": "No topical therapy recommended due to age"}}
{"id": "GRrn0L2EVPxT", "question_type": "multi_choice", "question": "Which reproductive safety advice should be given to females of reproductive potential who are prescribed Hernexeos?", "options": {"A": "No contraception is needed during treatment", "B": "Discontinue contraception immediately after starting Hernexeos", "C": "Contraception is only needed if pregnancy is suspected", "D": "Use effective contraception during treatment and for 2 weeks after the last dose"}}
{"id": "ZSuolOGP0Eiy", "question_type": "multi_choice", "question": "When reviewing the prescribing information for Modeyso, what should be considered regarding contraindications?", "options": {"A": "Modeyso is contraindicated in patients with active infection.", "B": "Modeyso is contraindicated in patients with a history of drug allergy.", "C": "Modeyso is contraindicated in patients with chronic kidney disease.", "D": "Modeyso is contraindicated in patients with uncontrolled hypertension."}}
{"id": "6vu6tlHA3FU8", "question_type": "open_ended_multi_choice", "question": "A 45-year-old man with a history of deep vein thrombosis and hyperlipidemia presents with severe alopecia areata. He is not a CYP2C9 poor metabolizer and is not taking any CYP2C9 inhibitors. He is otherwise healthy and not on immunosuppressants. Which drug regimen is most suitable for his condition?", "options": {"A": "Minoxidil topical solution, twice daily", "B": "Imiquimod cream, three times per week", "C": "Leqselvi (deuruxolitinib phosphate), once daily", "D": "Leqselvi (deuruxolitinib phosphate), drug holiday every 2 weeks"}}
{"id": "Vldu7mndTjCO", "question_type": "open_ended_multi_choice", "question": "What is the recommended action regarding contraception for patients who can become pregnant while using Vanrafia?", "options": {"A": "No contraception is needed", "B": "Use contraception only during treatment", "C": "Use effective contraception prior to, during, and for two weeks after discontinuation of Vanrafia", "D": "Use contraception for one month after discontinuation"}}
{"id": "sdw71v2mHWN9", "question_type": "open_ended_multi_choice", "question": "A 29-year-old woman with tuberculous meningitis and subarachnoid block is currently breastfeeding her newborn. She requires adjunctive corticosteroid therapy in addition to antituberculous chemotherapy. Which corticosteroid should be avoided due to its explicit warning regarding nursing mothers?", "options": {"A": "Prednisone oral tablets", "B": "DMT SUIK intramuscular injection", "C": "Dexamethasone sodium phosphate injection", "D": "GUNA-IL 2 oral solution"}}
{"id": "kKqloxBbAgiP", "question_type": "open_ended_multi_choice", "question": "A 40-year-old male with established Niemann-Pick disease type C presents with progressive difficulties in walking, vertical supranuclear gaze palsy, and mild renal dysfunction (creatinine clearance 65 mL/min). He is currently not receiving any other treatments. Which therapy is best suited for managing his neurological manifestations?", "options": {"A": "Miglustat (Yargesa) 100 mg twice daily, with dose adjustment for renal impairment", "B": "AQNEURSA (levacetylleucine), standard dosing without renal adjustment", "C": "Miglustat (Opfolda) in combination with Pombiliti, with dose reduction for renal impairment", "D": "AQNEURSA (levacetylleucine), with dose reduction for renal impairment"}}
{"id": "QNeyF4z93Y2X", "question_type": "open_ended_multi_choice", "question": "A 58-year-old male with chronic kidney disease (CKD) has been on hemodialysis for 4 months and presents with anemia (hemoglobin 9.2 g/dL). His medical history includes controlled hypertension and hyperlipidemia managed with simvastatin 20 mg daily. He is currently taking oral iron supplements. Which of the following is the most appropriate drug regimen for treating his anemia?", "options": {"A": "Initiate Vafseo, ensuring it is administered at least 1 hour before iron supplements and reduce simvastatin to 5 mg daily.", "B": "Start Vafseo, continue current simvastatin dose, and take iron supplements simultaneously.", "C": "Begin corticosteroid therapy (DMT SUIK) for anemia management.", "D": "Start Cortisone aceticum for anemia associated with CKD."}}
{"id": "Fo8CcMOstXix", "question_type": "multi_choice", "question": "A 15-year-old female with WHIM syndrome presents with recurrent upper respiratory tract infections, severe periodontitis, and decreased circulating IgG concentration. She is currently pregnant and seeks treatment to increase her mature neutrophil and lymphocyte counts. Which drug regimen is most appropriate for her condition?", "options": {"A": "No drug therapy recommended due to pregnancy", "B": "Mavorixafor, daily oral administration", "C": "XOLREMDI, daily oral administration", "D": "XOLREMDI, weekly administration"}}
{"id": "isBpuzqjUBqK", "question_type": "open_ended_multi_choice", "question": "A 68-year-old man with chronic phase Ph+ CML is being considered for SPRYCEL therapy. He has a history of congestive heart failure and is currently taking a strong CYP3A4 inhibitor for another condition. Which of the following is the most appropriate approach to SPRYCEL administration in this patient?", "options": {"A": "Start SPRYCEL at the standard dose without adjustments.", "B": "Avoid SPRYCEL due to his age alone.", "C": "Initiate SPRYCEL with dose reduction and close monitoring for cardiac and drug toxicity.", "D": "Administer SPRYCEL with a CYP3A4 inducer to counteract inhibitor effects."}}
{"id": "I3OzOQBnqBwT", "question_type": "open_ended_multi_choice", "question": "A 10-year-old patient with cystic fibrosis, recurrent respiratory infections, hepatomegaly, and raised hepatic transaminases is found to have at least one F508del mutation in the CFTR gene. With a background of abnormal liver function and current Child-Pugh Class B hepatic impairment, which drug regimen should be selected to manage this patient's cystic fibrosis?", "options": {"A": "ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor) once daily", "B": "Insulin Aspart Protamine and Insulin Aspart Mix 70/30, administered twice daily", "C": "ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor) with reduced dosage and close liver monitoring", "D": "No CFTR modulator therapy; supportive care only"}}
{"id": "ot4gM7HHQsnx", "question_type": "multi_choice", "question": "A 35-year-old woman with pulmonary arterial hypertension is currently pregnant and presents for management of her PAH. She is concerned about the safety of her fetus and asks about drug therapy options. Which of the following is the most appropriate recommendation regarding drug therapy for her PAH?", "options": {"A": "Initiate Winrevair, as it is the first-line therapy for PAH", "B": "Start epinephrine infusion to manage her PAH", "C": "Avoid Winrevair due to embryo-fetal toxicity and advise against its use during pregnancy", "D": "Use vasopressin as a safe alternative for PAH in pregnancy"}}
{"id": "VC7gzVUtwyNn", "question_type": "open_ended_multi_choice", "question": "If a biomedical researcher is reviewing the safety profile of Andembry, what should they note about its warnings and precautions?", "options": {"A": "No warnings and precautions are specified for Andembry.", "B": "Andembry has warnings related to QT prolongation.", "C": "Andembry includes precautions for use in pediatric populations.", "D": "Andembry requires dose adjustment in patients with renal impairment."}}
{"id": "wPLflnidg08t", "question_type": "open_ended_multi_choice", "question": "A 32-year-old pregnant woman is diagnosed with acute bacterial skin and skin structure infection (ABSSSI) caused by methicillin-resistant Staphylococcus aureus. She has no known drug allergies and normal renal function. Which drug is most suitable for treating her infection, considering safety in pregnancy and approved indications?", "options": {"A": "Doxycycline hyclate", "B": "Acetaminophen", "C": "Ceftobiprole medocaril sodium", "D": "No antibiotic therapy is indicated during pregnancy"}}
{"id": "ExrHrf7o3Fbv", "question_type": "open_ended_multi_choice", "question": "A 7-year-old child is newly diagnosed with paroxysmal nocturnal hemoglobinuria (PNH). The child has no significant comorbidities and normal hepatic and renal function. Which of the following is the most appropriate initial drug therapy for this patient?", "options": {"A": "Sirolimus", "B": "Voydeya as monotherapy", "C": "Ravulizumab", "D": "Voydeya added to eculizumab"}}
{"id": "E0ve3GsAxnab", "question_type": "open_ended_multi_choice", "question": "What is the recommended approach regarding contraceptive use for patients taking hormonal contraceptives that contain progestins other than levonorgestrel and norethindrone while undergoing treatment with Journavx?", "options": {"A": "No additional contraceptive method is required.", "B": "Journavx increases the efficacy of all hormonal contraceptives.", "C": "Patients should use an additional nonhormonal contraceptive method or an alternative hormonal contraceptive during and for 28 days after Journavx treatment.", "D": "Journavx is contraindicated with all hormonal contraceptives."}}
{"id": "440a3VcJBkUV", "question_type": "open_ended_multi_choice", "question": "A 34-year-old woman with a history of chronic graft-versus-host disease (cGVHD) presents at 10 weeks gestation with morphea, muscle weakness, and recurrent infections. She has previously failed two systemic therapies, weighs 65 kg, and has normal hepatic function. Which treatment regimen is the safest and most appropriate for her current clinical status?", "options": {"A": "Niktimvo, intravenous infusion every 2 weeks", "B": "PredniSONE, 5 mg orally once daily", "C": "PONVORY, 20 mg orally once daily", "D": "Niktimvo, intravenous infusion every 4 weeks"}}
{"id": "JaftyQM1V3DA", "question_type": "open_ended_multi_choice", "question": "What information is available regarding the safety and efficacy of Datroway when used in children?", "options": {"A": "Safety and effectiveness have been established", "B": "Safety is established, but effectiveness is unknown", "C": "Effectiveness is established, but safety is unknown", "D": "Safety and effectiveness have not been established"}}
{"id": "AvzEA5dohYnf", "question_type": "open_ended_multi_choice", "question": "A 54-year-old male diagnosed with metastatic ROS1-positive NSCLC is a candidate for taletrectinib. His medical history includes atrial fibrillation, and he is taking amiodarone, a medication associated with QTc prolongation. What should be the recommended approach to taletrectinib therapy for this patient?", "options": {"A": "Proceed with taletrectinib 600 mg orally once daily and monitor ECG regularly.", "B": "Withhold taletrectinib due to risk of QTc interval prolongation from drug interaction.", "C": "Start taletrectinib at a reduced dose to minimize cardiac risk.", "D": "Taletrectinib is safe to use with amiodarone if electrolytes are monitored."}}
{"id": "7fM9J1Hkthtf", "question_type": "open_ended_multi_choice", "question": "A 65-year-old man with neurofibromatosis type 1, chronic myelogenous leukemia, hypertension, and mild renal impairment reports joint stiffness and pain. He is currently on an ACE inhibitor for hypertension. Of the following options, which is the least suitable choice for pain management in this patient?", "options": {"A": "Celecoxib", "B": "Gomekli", "C": "PNV-DHA", "D": "Physical therapy only"}}
{"id": "7REHUapYohzD", "question_type": "open_ended_multi_choice", "question": "A 34-year-old female patient with newly diagnosed adrenocortical carcinoma is scheduled for tumor resection. She has a documented severe anaphylactic response to polyethylene glycol (PEG) from a prior imaging procedure. The surgical team wishes to use intraoperative fluorescence imaging to locate remaining cancer cells. Which agent should not be used in this patient because of her medical history?", "options": {"A": "Etoposide administered intravenously at a low starting dose", "B": "Lumisight (pegulicianine) administered at 1 mg/kg for intraoperative imaging", "C": "Etoposide administered orally at standard dosing", "D": "No imaging agent used during surgery"}}
{"id": "jLwJzty6tST0", "question_type": "open_ended_multi_choice", "question": "A 68-year-old woman with a history of epilepsy controlled on valproic acid presents with a complicated urinary tract infection requiring hospitalization. Her renal function is normal, and she is not pregnant. Which drug should be avoided due to a significant drug interaction that may increase her risk of seizures?", "options": {"A": "Flavoxate Hydrochloride", "B": "Imipenem and Cilastatin", "C": "Gepotidacin", "D": "Both Flavoxate Hydrochloride and Gepotidacin"}}
{"id": "1Se5du9KQL4R", "question_type": "open_ended", "question": "A 9-year-old child presents with infectious anterior uveitis. The patient has no history of glaucoma or sulfite allergy. The ophthalmologist is considering corticosteroid therapy and wants to ensure both efficacy and safety for pediatric use. Which drug is most appropriate for this patient, considering established safety and effectiveness in children?", "options": {"A": "Loteprednol Etabonate", "B": "Prednisolone", "C": "Hydrocortisone", "D": "Loteprednol Etabonate with a drug holiday"}}
{"id": "oLDsoKpdueeB", "question_type": "open_ended_multi_choice", "question": "A 62-year-old male diagnosed with unresectable, metastatic ESCC is experiencing chest pain, cough, and lymphadenopathy. His tumor tests positive for PD-L1 expression (≥1). His medical history includes controlled hypertension and ongoing amiodarone therapy for arrhythmia. What is the most suitable first-line systemic treatment regimen for him?", "options": {"A": "Lenvatinib monotherapy", "B": "Tislelizumab-jsgr in combination with platinum-containing chemotherapy", "C": "Nivolumab and hyaluronidase in combination with fluoropyrimidine- and platinum-containing chemotherapy", "D": "Lenvatinib in combination with pembrolizumab"}}
{"id": "cJocvr1r8GOW", "question_type": "open_ended_multi_choice", "question": "Which statement best describes the clinical experience with overdose of Enflonsia?", "options": {"A": "Extensive clinical data are available regarding overdose management.", "B": "There is limited experience of overdose with Enflonsia.", "C": "Overdose cases always require surgical intervention.", "D": "Overdose is well-characterized in adult populations."}}
{"id": "ankMcpMqAZ08", "question_type": "multi_choice", "question": "A 6-year-old child presents with community-acquired bacterial pneumonia. The child has no history of severe allergies, is not taking any other medications, and has normal renal function. The physician is considering antibiotic therapy. Which drug is most appropriate for treating this infection in this patient, given the risks associated with tooth development and the approved indications for pediatric use?", "options": {"A": "Acetaminophen", "B": "Doxycycline hyclate", "C": "Ceftobiprole medocaril sodium", "D": "No antibiotic therapy is indicated"}}
{"id": "Kgt822lLEBTH", "question_type": "open_ended_multi_choice", "question": "A 12-year-old girl with severe chronic kidney disease presents with primary axillary hyperhidrosis. Her parents are looking for a safe and effective topical therapy suitable for her age. She is not currently on any medications. Which treatment option is most appropriate for her?", "options": {"A": "Oxybutynin", "B": "Qbrexza", "C": "Sofdra", "D": "No pharmacologic treatment is appropriate"}}
{"id": "KgmgaYJ47WcV", "question_type": "open_ended_multi_choice", "question": "A 68-year-old male with acute erythroleukemia, existing congestive heart failure, anemia, thrombocytopenia, splenomegaly, and mild renal impairment is being evaluated for chemotherapy, but is not suitable for stem cell transplant. Based on these clinical factors, which medication should be avoided, and which is the safest choice for palliative treatment?", "options": {"A": "Daunorubicin Hydrochloride administered intravenously at reduced dose", "B": "REVUMENIB administered orally with ECG monitoring", "C": "TaperDex 12-day administered at the lowest effective dose with careful monitoring for fluid retention and hypertension", "D": "Daunorubicin Hydrochloride combined with REVUMENIB for induction therapy"}}
{"id": "asDLgwE4Rfxg", "question_type": "open_ended_multi_choice", "question": "For a 39-year-old woman who is pregnant and has advanced HR-positive, HER2-negative, PIK3CA-mutated breast cancer, with no renal or hepatic impairment, what is the most appropriate guidance on initiating drug therapy at this stage?", "options": {"A": "Initiate inavolisib in combination with palbociclib and fulvestrant immediately", "B": "Start carboplatin-based chemotherapy", "C": "Delay initiation of inavolisib until after pregnancy due to embryo-fetal toxicity risk", "D": "Begin esketamine therapy for breast cancer"}}
{"id": "4HeiDc57Nu4b", "question_type": "open_ended_multi_choice", "question": "A 6-year-old child diagnosed with classic congenital adrenal hyperplasia is being treated with glucocorticoid replacement. The child has normal kidney function and no history of allergic reactions. The family seeks an additional therapy to improve androgen suppression. Which drug regimen would be most suitable for this scenario?", "options": {"A": "Crenessity as adjunctive therapy to glucocorticoid replacement", "B": "Crenessity monotherapy without glucocorticoid replacement", "C": "Crenessity in a child under 4 years old", "D": "Crenessity in a patient with severe renal impairment"}}
{"id": "NGVeP9bxHe8b", "question_type": "open_ended_multi_choice", "question": "What did the ASPEN study reveal about the yearly rate of severe pulmonary exacerbations when comparing Brinsupri 25 mg to placebo?", "options": {"A": "Higher in Brinsupri 25 mg", "B": "Lower in Brinsupri 25 mg", "C": "Equal in both groups", "D": "Not reported"}}
{"id": "EarTt4QsAgrK", "question_type": "multi_choice", "question": "For a patient with recurrent or metastatic nasopharyngeal carcinoma receiving Penpulimab-kcqx in combination with gemcitabine and cisplatin, what is the recommended order of drug administration during each cycle?", "options": {"A": "Gemcitabine first, cisplatin second, Penpulimab-kcqx last", "B": "Penpulimab-kcqx first, gemcitabine second, cisplatin last", "C": "Cisplatin first, Penpulimab-kcqx second, gemcitabine last", "D": "Gemcitabine first, Penpulimab-kcqx second, cisplatin last"}}
{"id": "rSwqV1SEsCwB", "question_type": "open_ended_multi_choice", "question": "A 55-year-old male patient presents with intermediate-2 risk myelodysplastic syndrome and chronic kidney disease (creatinine clearance 40 mL/min). He is not receiving any drugs metabolized by cytidine deaminase, and cytogenetic studies do not show a 5q deletion. What is the most suitable drug regimen for this patient, given his renal dysfunction?", "options": {"A": "Lenalidomide, 10 mg orally once daily (no dose adjustment)", "B": "Imetelstat sodium, 7.5 mg/kg intravenously every 4 weeks", "C": "Inqovi, 35 mg orally once daily for 5 consecutive days every 28 days", "D": "Lenalidomide, 25 mg orally once daily (no dose adjustment)"}}
{"id": "RwPiNxIOHyCk", "question_type": "multi_choice", "question": "A 62-year-old woman with unresectable, metastatic non-squamous non-small cell lung carcinoma is found to have a HER2 (ERBB2) tyrosine kinase domain activating mutation by FDA-approved testing. She has previously received platinum-based chemotherapy. Her cardiac function is normal, and she is not pregnant or breastfeeding. However, she is currently taking rifampin, a strong CYP3A inducer, for latent tuberculosis. Which drug regimen is most appropriate for her lung cancer treatment?", "options": {"A": "Zongertinib at standard dose without adjustment", "B": "Atezolizumab as monotherapy", "C": "Imfinzi in combination with platinum-based chemotherapy", "D": "Zongertinib with dose adjustment to account for CYP3A induction"}}
{"id": "rXl3uRplH6UP", "question_type": "open_ended_multi_choice", "question": "A pregnant 42-year-old woman with metastatic NSCLC and an EGFR exon 19 deletion, without any prior thromboembolic, cardiac, hepatic, or renal issues, is being considered for first-line therapy. Which of the following treatments is contraindicated in pregnancy?", "options": {"A": "CYRAMZA in combination with erlotinib", "B": "Rozlytrek", "C": "LAZCLUZE (lazertinib plus amivantamab)", "D": "All of the above"}}
{"id": "kvtNtihu3Dmf", "question_type": "open_ended_multi_choice", "question": "A 28-year-old pregnant woman, currently at 10 weeks gestation, has Niemann-Pick disease type C and presents with compulsive behaviors and dystonia. She is requesting advice on pharmacological management of her neurological symptoms. What is the most suitable recommendation regarding medication use in her case?", "options": {"A": "Initiate arimoclomol in combination with miglustat", "B": "Start miglustat monotherapy", "C": "Avoid both arimoclomol and miglustat due to potential fetal harm", "D": "Begin lithium carbonate therapy"}}
{"id": "yeLpPApyteLG", "question_type": "multi_choice", "question": "A 42-year-old woman with a history of Grade 2 astrocytoma and recent surgical resection is found to have a susceptible IDH2 mutation. She is currently using a hormonal contraceptive and is considering starting targeted therapy. Which of the following is the most important consideration when initiating Voranigo for this patient?", "options": {"A": "Reduce the dose of Voranigo due to her age", "B": "Switch to a nonhormonal contraceptive method before starting Voranigo", "C": "Avoid Voranigo due to risk of nephrotoxicity", "D": "Delay Voranigo initiation until 6 months after surgery"}}
{"id": "q6FydNH1MlpG", "question_type": "open_ended_multi_choice", "question": "A pregnant woman, aged 35, presents with a complicated urinary tract infection. She does not have beta-lactam allergies, glaucoma, or a seizure disorder, and her renal and hepatic function tests are normal. Based on pregnancy safety and efficacy, which drug should be chosen to manage her infection?", "options": {"A": "Blujepa, administered according to standard dosing for complicated UTI.", "B": "Imipenem and Cilastatin Sodium intravenous therapy, following recommended dosing for adults.", "C": "Flavoxate Hydrochloride tablets for symptomatic relief only.", "D": "Flavoxate Hydrochloride combined with Blujepa for definitive treatment."}}
{"id": "G7tqJHcM7sFS", "question_type": "open_ended_multi_choice", "question": "A 72-year-old woman with unresectable, metastatic, HR-positive, HER2-negative breast cancer has received prior endocrine-based therapy and chemotherapy. She has a history of arterial thromboembolic events and is currently on anticoagulation therapy. Which drug is most appropriate for her cancer treatment, considering her age and comorbidities?", "options": {"A": "MVASI", "B": "DATROWAY", "C": "Ketorolac Tromethamine", "D": "None of the above"}}
{"id": "7hT51S0P3O7f", "question_type": "open_ended_multi_choice", "question": "A 45-year-old male with primary IgAN and UPCR of 2.1 g/g is being considered for VANRAFIA therapy. He is currently taking a strong CYP3A inducer for another condition. What is the best course of action regarding VANRAFIA administration?", "options": {"A": "Initiate VANRAFIA at the standard dose and continue the CYP3A inducer.", "B": "Avoid concomitant use of VANRAFIA and the CYP3A inducer due to reduced efficacy.", "C": "Start VANRAFIA and increase the dose to compensate for the CYP3A inducer.", "D": "Begin VANRAFIA therapy and add an OATP1B1/1B3 inhibitor to enhance drug exposure."}}
{"id": "6QBMSosjtxtJ", "question_type": "open_ended_multi_choice", "question": "A 68-year-old woman with mild dementia due to Alzheimer’s disease is currently breastfeeding her infant. She has no history of hypersensitivity reactions and is not taking any antithrombotic medications. What is the most appropriate approach to drug therapy for her condition?", "options": {"A": "Kisunla (donanemab-azbt), after weighing the benefits of treatment against potential unknown risks to the breastfed infant", "B": "Kisunla (donanemab-azbt), contraindicated due to breastfeeding", "C": "Kisunla (donanemab-azbt), recommended only if the patient is not breastfeeding", "D": "No drug therapy recommended for Alzheimer’s disease in breastfeeding women"}}
{"id": "0kPMQdxpViWF", "question_type": "open_ended_multi_choice", "question": "Should Vizz be part of a collection of medications that are free from any contraindications, according to the criteria set by the researcher?", "options": {"A": "Yes, because Vizz has no contraindications listed", "B": "No, because Vizz is contraindicated in certain populations", "C": "No, because Vizz is contraindicated in patients with renal impairment", "D": "No, because Vizz is contraindicated in patients with allergies"}}
{"id": "EX2B5d10WN3v", "question_type": "open_ended", "question": "In Part 2 of Trial 1, what was the mean percent change in blood Phe from baseline to Weeks 5 and 6 for patients treated with Sephience compared to placebo?", "options": {"A": "-62.8% for Sephience, 1.4% for placebo", "B": "-415.8% for Sephience, -19.9% for placebo", "C": "-19.9% for Sephience, -415.8% for placebo", "D": "-125% for Sephience, 66% for placebo"}}
{"id": "PPe20meAPvz2", "question_type": "open_ended_multi_choice", "question": "A 12-year-old female patient with confirmed BH4-responsive phenylketonuria exhibits elevated phenylalanine concentrations, a history of eczema, and microcephaly. She is on methylphenidate for ADHD and has recently begun methotrexate for juvenile idiopathic arthritis. Taking into account her medication regimen and disease profile, what is the most appropriate approach to decrease her blood phenylalanine?", "options": {"A": "Sephience administered daily with a phenylalanine-restricted diet", "B": "Sapropterin dihydrochloride administered daily with a phenylalanine-restricted diet", "C": "JAVYGTOR administered daily with a phenylalanine-restricted diet", "D": "Sephience administered every other day with a phenylalanine-restricted diet"}}
{"id": "2J01F2YvWR9Q", "question_type": "open_ended", "question": "A 28-year-old woman with metastatic epithelioid sarcoma is currently in her first trimester of pregnancy. She has no significant cardiac or hepatic comorbidities. Her tumor does not show MSI-H, dMMR, or TMB-H features. Which of the following treatment options is most appropriate for her condition?", "options": {"A": "Doxorubicin Hydrochloride every 3 weeks", "B": "KEYTRUDA QLEX every 3 weeks", "C": "Delay systemic therapy until after the first trimester", "D": "Doxorubicin Hydrochloride in combination with paclitaxel every 3 weeks"}}
{"id": "IDL6tDbBZJIt", "question_type": "open_ended", "question": "A 13-year-old patient with hereditary angioedema and moderate hepatic impairment (Child-Pugh Class B) experiences an acute attack. The patient is not taking any CYP3A4 inhibitors or inducers. Which acute therapy and dosing schedule is most appropriate for this scenario?", "options": {"A": "SAJAZIR (icatibant) injection 30 mg subcutaneously", "B": "SEBETRALSTAT (EKTERLY) 300 mg orally, with a second 300 mg dose at least 3 hours later if needed", "C": "Orladeyo 110 mg orally once daily with food", "D": "SEBETRALSTAT (EKTERLY) 600 mg orally at onset of attack"}}
{"id": "IVK9OUheMDQd", "question_type": "open_ended_multi_choice", "question": "For patients—both adults and children—who weigh at least 52.5 kg and are prescribed Modeyso in combination with potent CYP3A4 inhibitors, what is the recommended course of action?", "options": {"A": "Increase the dose of Modeyso", "B": "Reduce the dose of Modeyso", "C": "Discontinue Modeyso", "D": "Administer Modeyso with food"}}
{"id": "aLvmquD9DLmV", "question_type": "multi_choice", "question": "A 68-year-old woman with transfusion-dependent anemia is diagnosed with low-risk myelodysplastic syndrome (MDS) associated with a deletion 5q cytogenetic abnormality. She has normal renal function and is not pregnant. Her physician is considering starting drug therapy to reduce her transfusion needs. Which of the following drugs is most appropriate for her condition, considering both efficacy and safety for her specific MDS subtype?", "options": {"A": "Azacitidine, administered subcutaneously for 7 days every 28 days.", "B": "INQOVI (cedazuridine and decitabine), administered orally once daily in 28-day cycles.", "C": "TREOSULFAN (GRAFAPEX), in combination with fludarabine as a preparative regimen for allogeneic stem cell transplantation.", "D": "Lenalidomide, administered orally once daily, with strict adherence to pregnancy prevention protocols."}}
{"id": "USVPJhRH4riV", "question_type": "multi_choice", "question": "If a patient on Vanrafia develops aminotransferase elevations accompanied by bilirubin >2x ULN or clinical symptoms of hepatotoxicity, what is the recommended action?", "options": {"A": "Add hepatoprotective agents", "B": "Reduce the dose of Vanrafia", "C": "Continue Vanrafia with close monitoring", "D": "Switch to another ERA"}}
{"id": "yBTtFBRfofk2", "question_type": "multi_choice", "question": "A 45-year-old woman with newly diagnosed presbyopia is considering pharmacological treatment. She has a history of severe allergic reactions to cholinergic agonists. She does not have cardiovascular disease, is not pregnant, and does not use contact lenses. Which drug should be avoided due to her allergy, and which is the most suitable alternative among the listed options?", "options": {"A": "Aceclidine should be avoided; Brimonidine tartrate is suitable", "B": "Aceclidine should be avoided; Phentolamine mesylate is suitable", "C": "Aceclidine is safe; Brimonidine tartrate is suitable", "D": "Aceclidine should be avoided; no suitable alternative among listed drugs"}}
{"id": "avXjxlnZUNQQ", "question_type": "multi_choice", "question": "Which of the following statements best describes the embryo-fetal toxicity risk associated with Romvimza?", "options": {"A": "Romvimza can cause fetal harm based on animal studies and its mechanism of action.", "B": "Romvimza is safe for use during pregnancy.", "C": "Romvimza has no effect on fetal development.", "D": "Romvimza only causes fetal harm at doses ten times the recommended human dose."}}
{"id": "wyV6une4vzs4", "question_type": "open_ended_multi_choice", "question": "For which patient population is Blujepa contraindicated?", "options": {"A": "Patients with a history of severe hypersensitivity to Blujepa", "B": "Patients with mild renal impairment", "C": "Patients with controlled hypertension", "D": "Patients with a history of seasonal allergies"}}
{"id": "cG6m5pmJFbXe", "question_type": "open_ended_multi_choice", "question": "A woman aged 42 presents with moderate to severe acute pain post-abdominal surgery. She has advanced hepatic impairment (Child-Pugh Class C) and is currently prescribed a strong CYP3A inhibitor. What is the most appropriate pharmacological approach for her acute pain control?", "options": {"A": "JOURNAVX administered at standard adult dosage", "B": "Ropivacaine Hydrochloride via epidural block, starting at the low end of the dosage range", "C": "Pain Relief Childrens (acetaminophen-based OTC) at pediatric dosing", "D": "JOURNAVX with reduced dosage and avoidance of grapefruit products"}}
{"id": "XAxUZcS4Xsdj", "question_type": "multi_choice", "question": "A 42-year-old woman with end-stage renal disease on hemodialysis for six months presents with anemia. She has a history of uncontrolled hypertension and is currently being evaluated for possible active malignancy. Which of the following is the most appropriate course of action regarding vadadustat therapy for her anemia?", "options": {"A": "Start vadadustat at the lowest effective dose, monitoring for cardiovascular events.", "B": "Recommend the homeopathic combination for anemia management.", "C": "Begin fedratinib with thiamine supplementation.", "D": "Do not initiate vadadustat due to uncontrolled hypertension and possible active malignancy."}}
{"id": "U6QQmLsSRWrt", "question_type": "open_ended_multi_choice", "question": "A 62-year-old man with unresectable, metastatic esophageal squamous cell carcinoma (ESCC) presents with symptoms including chest pain, cough, and lymphadenopathy. His tumor demonstrates PD-L1 expression of at least 1%. He has a well-managed history of hypertension and is currently on amiodarone for arrhythmia. As the oncology team evaluates options for first-line systemic therapy, which drug regimen should be selected?", "options": {"A": "Lenvatinib monotherapy", "B": "Tislelizumab-jsgr in combination with platinum-containing chemotherapy", "C": "Nivolumab and hyaluronidase in combination with fluoropyrimidine- and platinum-containing chemotherapy", "D": "Lenvatinib in combination with pembrolizumab"}}
{"id": "B9wYCxYSYwuz", "question_type": "open_ended_multi_choice", "question": "In reviewing the safety profile of Emrelis, what should be noted regarding its use in populations with comorbidities?", "options": {"A": "Emrelis is contraindicated in patients with diabetes.", "B": "Emrelis is contraindicated in patients with liver dysfunction.", "C": "Emrelis has no contraindications regardless of comorbidities.", "D": "Emrelis is contraindicated in patients with autoimmune diseases."}}
{"id": "Q88pVFoXiDUH", "question_type": "open_ended_multi_choice", "question": "A 70-year-old man with acute coronary syndrome and a newly placed stent requires antiplatelet treatment. His genetic profile indicates poor CYP2C19 metabolism. He has no liver disease or current bleeding. What is the best choice of antiplatelet agent for this patient?", "options": {"A": "Clopidogrel", "B": "Flyrcado", "C": "BRILINTA", "D": "Clopidogrel with omeprazole"}}
{"id": "3yXjfO94OTmI", "question_type": "open_ended", "question": "A clinician is considering combination therapy for a patient with moderate to severe chronic hand eczema. Which of the following combinations with Anzupgo is NOT recommended?", "options": {"A": "Anzupgo with another JAK inhibitor", "B": "Anzupgo with a topical emollient", "C": "Anzupgo with a mild topical corticosteroid", "D": "Anzupgo with a topical antibiotic"}}
{"id": "9sdRZXAyS0PC", "question_type": "open_ended_multi_choice", "question": "A 55-year-old female with a history of feeding difficulties in infancy and current diagnosis of metastatic esophageal squamous cell carcinoma (ESCC) is being considered for second-line therapy after progression on prior platinum-based chemotherapy. She is currently pregnant and expresses concern about fetal safety. Which of the following drugs is contraindicated for her treatment at this time?", "options": {"A": "Tislelizumab-jsgr as a single agent", "B": "Nivolumab and hyaluronidase as monotherapy", "C": "Lenvatinib monotherapy", "D": "All of the above"}}
{"id": "JgG9cRJMSFOs", "question_type": "multi_choice", "question": "A 65-year-old man with metastatic NSCLC and an EGFR exon 21 L858R mutation is being considered for first-line therapy. He has a history of hypertension controlled with medication, and chronic proteinuria (urine protein 1.8 g/24h). He is at increased risk for venous thromboembolism (VTE) due to prior DVT. Which treatment option is most suitable for his condition?", "options": {"A": "Rozlytrek", "B": "CYRAMZA in combination with erlotinib", "C": "LAZCLUZE (lazertinib plus amivantamab) with prophylactic anticoagulation", "D": "CYRAMZA in combination with docetaxel"}}
{"id": "cIQbjn5mjQ8P", "question_type": "open_ended_multi_choice", "question": "Given a 45-year-old female patient with chronic graft-versus-host disease who has experienced recurrent infections, elevated liver enzymes, and skin thickening, and who has failed two previous systemic therapies, is not pregnant or planning to breastfeed, and weighs 65 kg, what is the most suitable drug for her next line of treatment based on her clinical presentation and medical history?", "options": {"A": "PredniSONE Tablets, USP, 5 mg", "B": "Budesonide Inhalation", "C": "AXATILIMAB-CSFR", "D": "Budesonide Inhalation combined with PredniSONE"}}
{"id": "UCGY8HeSTZBP", "question_type": "open_ended_multi_choice", "question": "Before initiating Modeyso therapy in females of childbearing potential, what is the recommended procedure?", "options": {"A": "No specific action is required.", "B": "Start Modeyso immediately regardless of pregnancy status.", "C": "Verify pregnancy status prior to initiation.", "D": "Advise permanent contraception."}}
{"id": "KYj83Q3rbmPH", "question_type": "multi_choice", "question": "If a patient on Hernexeos weighing 92 kg cannot tolerate 60 mg once daily after dose reductions for adverse reactions, what is the recommended course of action?", "options": {"A": "Resume Hernexeos at 120 mg once daily", "B": "Permanently discontinue Hernexeos", "C": "Increase dose to 180 mg once daily", "D": "Switch to another HER2 inhibitor"}}
{"id": "miowObng8fVH", "question_type": "open_ended_multi_choice", "question": "Which of the following best describes the reversibility of Emrelis-induced fertility impairment in males?", "options": {"A": "The effect is reversible", "B": "The effect is irreversible", "C": "The reversibility of the effect is unknown", "D": "Emrelis does not impair male fertility"}}
{"id": "huTGXXYRB2de", "question_type": "open_ended", "question": "A 42-year-old patient with hereditary angioedema presents to the emergency department with an acute attack. The patient has a documented history of severe hypersensitivity to ecallantide. Which treatment option should be avoided, and what is the most appropriate therapy for this acute episode?", "options": {"A": "Kalbitor administered by a healthcare professional", "B": "Orladeyo 150 mg once daily", "C": "DAWNZERA 80 mg subcutaneously every 4 weeks", "D": "Supportive care without HAE-specific therapy"}}
{"id": "5bEVrX0kz6kN", "question_type": "open_ended", "question": "When using Lynozyfic concomitantly with certain CYP substrates, what is the recommended clinical action?", "options": {"A": "Monitor for toxicity unless otherwise recommended in the Prescribing Information", "B": "Discontinue all CYP substrates", "C": "Increase the dose of CYP substrates", "D": "No monitoring is required"}}
{"id": "720H1eQ7FGJb", "question_type": "open_ended_multi_choice", "question": "If a patient is receiving a moderate CYP3A4 inducer and needs Ekterly for an acute attack of hereditary angioedema, how should Ekterly therapy be adjusted?", "options": {"A": "Administer standard Ekterly dosage", "B": "Reduce Ekterly dosage by half", "C": "Avoid concomitant use of Ekterly", "D": "Increase Ekterly dosage"}}
{"id": "tbSQD6s9Uw91", "question_type": "open_ended_multi_choice", "question": "Is it appropriate for the researcher to add Vizz to a database specifically for drugs that have no contraindications?", "options": {"A": "Yes, because Vizz has no contraindications listed", "B": "No, because Vizz is contraindicated in certain populations", "C": "No, because Vizz is contraindicated in patients with renal impairment", "D": "No, because Vizz is contraindicated in patients with allergies"}}
{"id": "OejYvRvtdEWk", "question_type": "open_ended_multi_choice", "question": "A 60-year-old male with presbyopia wishes to enhance his near vision. He previously experienced retinal detachment and had retinal surgery two years prior. He has no history of iritis or drug allergies. Based on his medical background, which medication should not be used, and what is the rationale?", "options": {"A": "Aceclidine", "B": "Brimonidine tartrate", "C": "Phentolamine mesylate", "D": "All are safe options"}}
{"id": "gNKNIfSsu7WP", "question_type": "open_ended_multi_choice", "question": "After administering the fourth dose of Journavx to a patient on moderate CYP3A inhibitors, how should the dosage regimen be altered?", "options": {"A": "Reduce to 50 mg orally every 24 hours", "B": "Increase to 100 mg orally every 12 hours", "C": "Continue 50 mg orally every 12 hours", "D": "Discontinue Journavx"}}
{"id": "0oVmJdsoP348", "question_type": "multi_choice", "question": "A 40-year-old woman with moderate to severe hidradenitis suppurativa is considering starting systemic therapy. She has a history of poorly controlled type 2 diabetes and hepatic impairment. Her current medications include metformin and she occasionally consumes alcohol. Which of the following drugs should be avoided due to her comorbidities?", "options": {"A": "Adalimumab", "B": "Sitagliptin/Metformin Hydrochloride", "C": "Spironolactone", "D": "All of the above are equally appropriate"}}
{"id": "q67ier1h2vAM", "question_type": "open_ended_multi_choice", "question": "What is the recommended action before initiating Modeyso in females of reproductive potential?", "options": {"A": "No specific action is required.", "B": "Start Modeyso immediately regardless of pregnancy status.", "C": "Verify pregnancy status prior to initiation.", "D": "Advise permanent contraception."}}
{"id": "Qr4oQKP0R8X6", "question_type": "open_ended_multi_choice", "question": "A patient aged 39, pregnant and diagnosed with advanced breast cancer that is HR-positive, HER2-negative, and PIK3CA-mutated, presents with normal renal and hepatic function. What is the best advice concerning targeted drug therapy for her disease during pregnancy?", "options": {"A": "Initiate inavolisib in combination with palbociclib and fulvestrant immediately", "B": "Start carboplatin-based chemotherapy", "C": "Delay initiation of inavolisib until after pregnancy due to embryo-fetal toxicity risk", "D": "Begin esketamine therapy for breast cancer"}}
{"id": "8w8A8zsg4xqq", "question_type": "multi_choice", "question": "A 32-year-old woman with acute erythroleukemia and splenomegaly is currently 10 weeks pregnant. She is not taking any other medications and has no significant comorbidities. Which of the following drugs should be avoided due to the highest risk of embryo-fetal toxicity and teratogenicity, based on available evidence?", "options": {"A": "TaperDex 6-day oral regimen at the lowest effective dose", "B": "Revuforj administered twice daily at standard dosing", "C": "Aldesleukin administered intravenously in a hospital setting", "D": "Dexamethasone as adjunctive therapy for anemia"}}
{"id": "bcolH0G3fXy1", "question_type": "multi_choice", "question": "A 55-year-old man with prurigo nodularis and a documented history of hypersensitivity to nemolizumab-ilto presents for therapy. He is otherwise healthy, not pregnant, and has no renal impairment. Which drug regimen is most suitable for his condition?", "options": {"A": "Dupixent administered subcutaneously every two weeks", "B": "Nemluvio administered subcutaneously every four weeks", "C": "Apremilast 30 mg orally twice daily", "D": "Apremilast 30 mg orally once daily"}}
{"id": "sgPhuXVxOIBQ", "question_type": "multi_choice", "question": "A 45-year-old woman with newly diagnosed presbyopia is considering pharmacological treatment. She has a history of severe allergic reactions to cholinergic agonists. She does not have cardiovascular disease, is not pregnant, and does not use contact lenses. Which drug should be avoided due to her allergy, and which is the most suitable alternative among the listed options?", "options": {"A": "Aceclidine should be avoided; Brimonidine tartrate is suitable", "B": "Aceclidine should be avoided; no suitable alternative among listed drugs", "C": "Aceclidine should be avoided; Phentolamine mesylate is suitable", "D": "Aceclidine is safe; Brimonidine tartrate is suitable"}}
{"id": "iIw5w2n9HTCz", "question_type": "open_ended_multi_choice", "question": "A 35-year-old woman with idiopathic nephrotic syndrome (nephrosis) is planning pregnancy. She is currently breastfeeding and has a strong family history of osteoporosis. Which treatment option should be avoided due to her reproductive status and bone health risk?", "options": {"A": "PredniSONE Tablets, 5 mg daily", "B": "Bumex administered orally", "C": "Depo-Provera injection every 3 months", "D": "Bumex administered intravenously"}}
{"id": "IoZ16Tj8BX2g", "question_type": "open_ended_multi_choice", "question": "A 72-year-old patient with mild cognitive impairment due to Alzheimer’s disease is found to be an ApoE ε4 homozygote after genetic testing. The patient also has a history of cerebral microhemorrhages detected on MRI and is currently taking aspirin for cardiovascular disease. Which treatment approach is most appropriate for this patient?", "options": {"A": "Initiate KISUNLA (donanemab-azbt) with enhanced clinical vigilance and regular MRI monitoring.", "B": "Initiate KISUNLA without genetic testing or MRI monitoring.", "C": "Initiate KISUNLA and discontinue aspirin immediately.", "D": "Avoid KISUNLA due to increased risk of ARIA and intracerebral hemorrhage; consider alternative therapy if available."}}
{"id": "PqSurdk6ytTE", "question_type": "open_ended_multi_choice", "question": "A teenage male, age 15, with a known history of congenital factor VIII deficiency (hemophilia A), presents with repeated joint bleeding and a prolonged PTT. He does not have any factor VIII inhibitors and is not currently on any other drugs. His healthcare provider wants to start him on routine prophylaxis to prevent further bleeding. Which agent is best suited for this patient, based on his age, the indication, and the drug’s safety profile?", "options": {"A": "MARSTACIMAB-HNCQ", "B": "Desmopressin Acetate", "C": "DARATUMUMAB AND HYALURONIDASE-FIHJ", "D": "Factor IX concentrate"}}
{"id": "rOdiezbnxWVL", "question_type": "multi_choice", "question": "When administering Vizz, what instruction should be given to patients who wear contact lenses?", "options": {"A": "Do not use Vizz if wearing contact lenses.", "B": "Keep contact lenses in during instillation.", "C": "Reinsert contact lenses immediately after instillation.", "D": "Wait 30 minutes before reinserting contact lenses."}}
{"id": "DIrRpvYq2dfx", "question_type": "open_ended_multi_choice", "question": "A 42-year-old pregnant patient, currently in her second trimester, is diagnosed with moderate fibrosis due to non-alcoholic steatohepatitis (NASH). She seeks pharmacologic management. Considering available evidence on fetal safety, which medication should be avoided in this scenario?", "options": {"A": "Pentoxifylline extended-release tablets", "B": "Resmetirom administered once daily", "C": "Dapagliflozin once daily", "D": "Pentoxifylline immediate-release tablets"}}
{"id": "5O5v29dltX7f", "question_type": "multi_choice", "question": "A patient is scheduled to receive a live vaccine. What is the appropriate recommendation regarding Anzupgo therapy?", "options": {"A": "Start Anzupgo immediately after vaccination", "B": "Live vaccines should not be given right before, during, or right after Anzupgo treatment", "C": "Live vaccines are safe during Anzupgo therapy", "D": "Increase the dose of Anzupgo before vaccination"}}
{"id": "jAqCRFPTTGJX", "question_type": "open_ended", "question": "A 6-month-old infant with severe RSV infection is hospitalized and requires mechanical ventilator support. The infant's mother is currently pregnant and frequently visits the hospital room. Which of the following is the most appropriate approach regarding antiviral therapy for this patient?", "options": {"A": "Administer ribavirin inhalation solution, ensuring strict ventilator protocols and limiting exposure to the pregnant mother", "B": "Administer Enflonsia as a single dose for RSV treatment", "C": "Start quinidine gluconate for antiviral coverage", "D": "Administer ribavirin inhalation solution without any special precautions for visitors"}}
{"id": "LM6a8j9P9AZc", "question_type": "open_ended_multi_choice", "question": "How should the Modeyso dose be modified for a pediatric patient weighing at least 42.5 kg but less than 52.5 kg if they encounter a Grade 3 adverse reaction?", "options": {"A": "Interrupt Modeyso until ≤Grade 1 or baseline, then resume at 375 mg once weekly", "B": "Permanently discontinue Modeyso", "C": "Increase dose to 500 mg once weekly", "D": "Continue at the same dose"}}
{"id": "QSLAhwg2imCI", "question_type": "open_ended_multi_choice", "question": "A 12-year-old girl presents with primary axillary hyperhidrosis. She has a history of chronic kidney disease with severely impaired renal function. Her parents are seeking a topical treatment that is safe and effective for her age group. She is not taking any other medications. Which of the following is the most appropriate treatment option for her condition?", "options": {"A": "Oxybutynin", "B": "Qbrexza", "C": "Sofdra", "D": "No pharmacologic treatment is appropriate"}}
{"id": "PBXPvYtOY1My", "question_type": "multi_choice", "question": "A female patient of reproductive potential is prescribed Romvimza. What is the most appropriate counseling regarding contraception?", "options": {"A": "No contraception is necessary during Romvimza therapy.", "B": "Contraception should be used only for the first week of therapy.", "C": "Contraception is only required if the patient is pregnant.", "D": "Effective contraception should be used during treatment and for 1 month after the last dose."}}
{"id": "uemJGwpU499c", "question_type": "open_ended", "question": "A 58-year-old man with a history of chronic kidney disease (eGFR 28 mL/min/1.73 m²) and hypertension presents with moderate to severe hidradenitis suppurativa. He is currently taking an ACE inhibitor for blood pressure control. Which drug regimen is most suitable for treating his hidradenitis suppurativa?", "options": {"A": "Spironolactone, 50 mg once daily", "B": "Adalimumab, 40 mg subcutaneously every other week", "C": "Sitagliptin/Metformin Hydrochloride, 50/1000 mg twice daily", "D": "Spironolactone combined with Sitagliptin/Metformin Hydrochloride"}}
{"id": "to9gZIY7p2fE", "question_type": "open_ended_multi_choice", "question": "What is the most correct description of the carcinogenicity research carried out with Emrelis?", "options": {"A": "Carcinogenicity studies in animals have been performed with Emrelis and showed no evidence of carcinogenicity.", "B": "Carcinogenicity studies in animals have not been performed with Emrelis or its small molecule MMAE.", "C": "Carcinogenicity studies in humans have demonstrated a high risk of cancer with Emrelis.", "D": "Carcinogenicity studies in animals have been performed only with the small molecule MMAE, not with Emrelis."}}
{"id": "A7xNEGp9qlzW", "question_type": "open_ended_multi_choice", "question": "A 28-year-old male with severe alopecia areata is being evaluated for pharmacologic treatment. He has been identified as a CYP2C9 poor metabolizer and is currently on a moderate CYP2C9 inhibitor for another medical issue. He does not have any renal or hepatic impairment and is neither pregnant nor breastfeeding. Which medication would be the most suitable for his case?", "options": {"A": "Leqselvi (deuruxolitinib phosphate), once daily", "B": "Minoxidil topical solution, twice daily", "C": "Imiquimod cream, three times per week", "D": "None of the above drugs are appropriate"}}
{"id": "KeisHvIVuDBj", "question_type": "open_ended_multi_choice", "question": "Why is it contraindicated to begin Grafapex therapy if there is no available stem cell donor?", "options": {"A": "Because profound myelosuppression with pancytopenia will occur in all patients", "B": "Because Grafapex requires donor stem cells for activation", "C": "Because the drug is ineffective without donor cells", "D": "Because of increased risk of renal toxicity"}}
{"id": "KnEgGMgCWdra", "question_type": "open_ended_multi_choice", "question": "What is the appropriate method for administering Enflonsia together with injectable vaccines?", "options": {"A": "Administer both in the same syringe", "B": "Administer Enflonsia and vaccines at the same injection site", "C": "Use separate syringes and different injection sites", "D": "Mix Enflonsia with vaccines in the same vial"}}
{"id": "F7WYxJjCJpnd", "question_type": "open_ended", "question": "A 68-year-old male with non-cystic fibrosis bronchiectasis, decreased forced expiratory flow 25-75%, and a history of diabetes mellitus is being evaluated for pharmacologic management. He is currently taking oral antidiabetic agents and beta-blockers. Which medication is most appropriate for his bronchiectasis, considering drug interactions and age-specific safety?", "options": {"A": "Insulin Aspart Protamine and Insulin Aspart Mix 70/30, with dose adjustment for age and drug interactions", "B": "SYMDEKO, with monitoring for CYP3A-mediated drug interactions", "C": "BRENSOCATIB, with routine dental and dermatologic monitoring", "D": "SYMDEKO, with no need for drug interaction monitoring"}}
{"id": "NYbAKdq1XJGN", "question_type": "multi_choice", "question": "Which of the following recommendations is most appropriate for a woman who is breastfeeding and requires treatment with Modeyso?", "options": {"A": "Advise not to breastfeed during Modeyso treatment and for 1 week after the last dose.", "B": "Discontinue breastfeeding only if adverse effects are observed in the infant.", "C": "Continue breastfeeding during Modeyso therapy.", "D": "Breastfeeding is safe if Modeyso is administered at a low dose."}}
{"id": "Uj17yGOXvV6u", "question_type": "open_ended", "question": "A 35-year-old woman with vernal conjunctivitis is currently breastfeeding her infant. She requires treatment for moderate ocular inflammation. Which of the following drugs should be avoided due to the risk of serious adverse reactions in nursing infants?", "options": {"A": "Prednisolone acetate ophthalmic suspension", "B": "Dexamethasone (systemic administration)", "C": "Loratadine oral tablets", "D": "Prednisolone acetate ophthalmic suspension (topical use)"}}
{"id": "ttYl9Ug3IlXW", "question_type": "multi_choice", "question": "Which statement best describes the contraindication profile of Lynozyfic?", "options": {"A": "Lynozyfic has multiple contraindications, including renal and hepatic impairment.", "B": "Lynozyfic is contraindicated in patients with hypersensitivity to its active ingredient.", "C": "Lynozyfic is contraindicated in combination with certain antibiotics.", "D": "Lynozyfic should not be used in elderly patients."}}
{"id": "8Vt922qnGEoi", "question_type": "open_ended_multi_choice", "question": "If a patient vomits soon after taking their dose of Modeyso, what should be done about the following scheduled dose?", "options": {"A": "Retake the dose immediately", "B": "Skip the next scheduled dose", "C": "Do not take another dose; resume Modeyso on the next regularly scheduled weekly day", "D": "Double the dose at the next administration"}}
{"id": "0Z6O3WPkhptn", "question_type": "open_ended_multi_choice", "question": "A 12-year-old boy with classic congenital adrenal hyperplasia is receiving glucocorticoid replacement therapy. He is also prescribed rifampin, a strong CYP3A4 inducer, for a concurrent infection. His endocrinologist is considering adjunctive therapy with crinecerfont (CRENESSITY). What adjustment should be made to crinecerfont dosing in this scenario?", "options": {"A": "No adjustment is needed; use standard crinecerfont dosing.", "B": "Double both morning and evening doses of crinecerfont.", "C": "Double only the evening dose of crinecerfont.", "D": "Crinecerfont is contraindicated with rifampin."}}
{"id": "e8Z2HPT3VoYW", "question_type": "multi_choice", "question": "A 65-year-old man with chronic kidney disease and anemia is being evaluated for pharmacologic therapy. He has not yet started dialysis but is expected to begin within the next two months. His past medical history is significant for cirrhosis secondary to hepatitis C. Which of the following is the most appropriate recommendation regarding anemia management for this patient?", "options": {"A": "Initiate vadadustat immediately to treat anemia due to CKD.", "B": "Start fedratinib with thiamine supplementation.", "C": "Use the homeopathic combination for anemia symptoms.", "D": "Avoid vadadustat due to underlying cirrhosis; consider alternative anemia management."}}
{"id": "c3aCYcxKfXrQ", "question_type": "open_ended_multi_choice", "question": "A 62-year-old patient with metastatic non-small cell lung cancer (NSCLC) is found to have an EGFR exon 21 (L858R) substitution mutation by FDA-approved testing. The patient has a history of peptic ulcer disease and is currently taking omeprazole for gastric reflux. Which drug regimen is most appropriate for first-line treatment of this patient, considering drug interactions and safety profile?", "options": {"A": "Erlotinib, with avoidance of omeprazole and careful monitoring for gastrointestinal perforation", "B": "Ensartinib, administered once daily", "C": "Rozlytrek, administered once daily", "D": "Erlotinib, co-administered with omeprazole and no adjustment"}}
{"id": "CUZPHCb42qYr", "question_type": "open_ended_multi_choice", "question": "A 35-year-old woman, currently in her second trimester, comes in with dysuria, urinary frequency, and suprapubic pain. Her urine culture identifies Escherichia coli sensitive to various antibiotics. She has no history of allergies, renal dysfunction, or other illnesses. Which regimen is most appropriate to relieve her symptoms and treat the infection?", "options": {"A": "Imipenem and cilastatin intravenously", "B": "Flavoxate hydrochloride orally for symptom relief plus an appropriate oral antibiotic", "C": "Sulopenem etzadroxil and probenecid (Orlynvah) orally", "D": "Flavoxate hydrochloride as monotherapy"}}
{"id": "3tZtApQg9OqZ", "question_type": "open_ended_multi_choice", "question": "Which of the following is NOT a listed contraindication for Vanrafia based on its prescribing information?", "options": {"A": "Pregnancy", "B": "Hypersensitivity to atrasentan", "C": "History of hypersensitivity to any component of Vanrafia", "D": "Chronic kidney disease"}}
{"id": "GZmDAGd2cyci", "question_type": "multi_choice", "question": "A 29-year-old woman with moderate acute pain after orthopedic surgery is currently breastfeeding her newborn. She is not taking any CYP3A inhibitors or inducers, and her hepatic and renal function are normal. She requests pain relief that will not adversely affect her infant. Which drug is most suitable for her?", "options": {"A": "JOURNAVX at standard adult dosage", "B": "JOURNAVX with additional nonhormonal contraception", "C": "Pain Relief Childrens (acetaminophen-based OTC) at adult dosing", "D": "Ropivacaine Hydrochloride administered as a local infiltration"}}
{"id": "Kv1MbB7Ahdaz", "question_type": "multi_choice", "question": "A 60-year-old man with moderate-to-severe atopic dermatitis, recurrent skin infections, and a recent diagnosis of hypertension is being considered for systemic therapy after failing topical agents. He is scheduled to receive a live vaccine in the next month. Which of the following is the most appropriate next step in his management?", "options": {"A": "Start dexamethasone sodium phosphate immediately and continue with planned vaccination", "B": "Delay initiation of Adbry until after completion of live vaccine administration", "C": "Initiate Ebglyss therapy and proceed with live vaccine administration", "D": "Start dexamethasone sodium phosphate and schedule a drug holiday during vaccination"}}
{"id": "q5lw85N5m4RE", "question_type": "open_ended_multi_choice", "question": "Which of the following statements about the interaction of Blujepa with other antimicrobials is accurate?", "options": {"A": "Blujepa antagonizes the activity of fluoroquinolones against Enterobacterales.", "B": "Blujepa shows no antagonism with multiple antibacterial drugs, including fluoroquinolones, sulfonamides, and cephalosporins.", "C": "Blujepa is only effective when used as monotherapy.", "D": "Blujepa synergizes with aminoglycosides against all gram-negative bacteria."}}
{"id": "PUarvwUxVQP2", "question_type": "open_ended_multi_choice", "question": "During Penpulimab-kcqx administration, which management step is recommended for a Grade 3 infusion-related reaction?", "options": {"A": "Interrupt or slow the rate of infusion", "B": "Withhold Penpulimab-kcqx and resume after resolution", "C": "Permanently discontinue Penpulimab-kcqx", "D": "Reduce the dose and continue infusion"}}
{"id": "2wAH0DByTX5f", "question_type": "open_ended_multi_choice", "question": "A 59-year-old pregnant woman has BCG-unresponsive nonmuscle invasive bladder cancer with carcinoma in situ. She wants to know which drug therapy would be safest for her condition. Which statement most accurately describes the appropriate drug choice in her case?", "options": {"A": "Gemcitabine is preferred due to its established safety in pregnancy.", "B": "Anktiva can be used safely during pregnancy because systemic exposure is low.", "C": "Both Anktiva and Gemcitabine are contraindicated in pregnancy due to potential fetal harm.", "D": "Gemcitabine is recommended because it is not absorbed systemically."}}
{"id": "orm6BRejQjcc", "question_type": "open_ended", "question": "A 7-year-old child with diffuse midline glioma harboring an H3 K27M mutation has progressive disease following prior therapy. The patient is currently taking a strong CYP3A4 inhibitor for another condition. Which of the following is the most appropriate approach to drug therapy for this patient?", "options": {"A": "Initiate MODEYSO at the standard recommended dose without adjustment.", "B": "Avoid using MODEYSO and seek an alternative therapy not metabolized by CYP3A4.", "C": "Initiate MODEYSO at a reduced dose as recommended for patients on strong CYP3A4 inhibitors.", "D": "Discontinue the CYP3A4 inhibitor and start MODEYSO at the standard dose immediately."}}
{"id": "ySyDFVp4uyNG", "question_type": "multi_choice", "question": "How frequently was single-agent penpulimab-kcqx administered in the AK105-202 study for patients with unresectable or metastatic non-keratinizing nasopharyngeal carcinoma?", "options": {"A": "100 mg intravenously every week", "B": "200 mg orally every day", "C": "400 mg intravenously every 4 weeks", "D": "200 mg intravenously every 2 weeks"}}
{"id": "v8Hh9WsvVC7x", "question_type": "open_ended_multi_choice", "question": "A 52-year-old woman with primary biliary cholangitis and compensated cirrhosis has recently developed ascites and gastroesophageal varices, indicative of portal hypertension. She has shown inadequate improvement with ursodeoxycholic acid (UDCA) and is currently prescribed warfarin for atrial fibrillation. Which drug therapy should be considered for her PBC now?", "options": {"A": "Ocaliva 10 mg once daily in combination with UDCA", "B": "Livdelzi 10 mg once daily in combination with UDCA", "C": "Tricor 145 mg once daily as adjunct to UDCA", "D": "No disease-specific drug therapy should be initiated; continue UDCA alone"}}
{"id": "po8uwgG1Ads1", "question_type": "open_ended_multi_choice", "question": "A 35-year-old woman presents with severe erythema multiforme involving extensive skin lesions and mucosal involvement. She has a history of hypertension, currently controlled with diuretics, and is scheduled to receive a live attenuated vaccine in two weeks. Which drug is the most appropriate for her acute management, considering her comorbidities and upcoming vaccination?", "options": {"A": "PRED FORTE", "B": "Dexamethasone", "C": "Prednisone", "D": "Topical antihistamine"}}
{"id": "TSiTKjEUbJDN", "question_type": "open_ended_multi_choice", "question": "A 28-year-old female with sepiapterin-responsive phenylketonuria, who has scleroderma and has recently experienced heavy menstrual bleeding, is planning to conceive. Her current therapy includes sulfasalazine. Which drug regimen should not be used to manage her PKU in this context?", "options": {"A": "Sapropterin dihydrochloride administered daily with a phenylalanine-restricted diet", "B": "JAVYGTOR administered daily with a phenylalanine-restricted diet", "C": "Sephience administered daily with a phenylalanine-restricted diet", "D": "Sapropterin dihydrochloride administered every other day with a phenylalanine-restricted diet"}}
{"id": "XEEnnETIgrDz", "question_type": "open_ended_multi_choice", "question": "According to the prescribing information for Romvimza, which patient populations are contraindicated for its use?", "options": {"A": "Romvimza is contraindicated in patients with renal impairment.", "B": "Romvimza is contraindicated in patients with hepatic dysfunction.", "C": "Romvimza has no contraindications listed.", "D": "Romvimza is contraindicated in patients with cardiovascular disease."}}
{"id": "k9FhjQwuG7PC", "question_type": "open_ended_multi_choice", "question": "A 28-year-old female patient diagnosed with Niemann-Pick disease type C, presenting with neurological symptoms, is considering pregnancy. Her renal function is normal, and she is not currently using any OCT2 substrate drugs. What is the most suitable guidance regarding pharmacological management of her NPC?", "options": {"A": "Initiate MIPLYFFA in combination with miglustat immediately", "B": "Delay MIPLYFFA and miglustat therapy until after pregnancy due to risk of embryofetal harm", "C": "Start OPFOLDA in combination with Pombiliti", "D": "Begin lithium carbonate therapy"}}
{"id": "XVfQeSHdUwLs", "question_type": "open_ended", "question": "Which of the following statements best describes the results of long-term carcinogenicity studies conducted with Blujepa?", "options": {"A": "Long-term carcinogenicity studies have demonstrated a significant risk of cancer with Blujepa.", "B": "Long-term carcinogenicity studies have not been conducted with Blujepa.", "C": "Long-term carcinogenicity studies have shown Blujepa to be completely safe.", "D": "Long-term carcinogenicity studies have shown Blujepa to be mutagenic in rats."}}
{"id": "I8D1be842t7d", "question_type": "open_ended_multi_choice", "question": "A 65-year-old woman with locally advanced cutaneous squamous cell carcinoma is being considered for systemic therapy. She is currently pregnant and wishes to avoid any risk to the fetus. Which of the following is the best recommendation regarding systemic drug therapy for her cancer?", "options": {"A": "Start ERBITUX, as it is safe in pregnancy", "B": "Begin TECENTRIQ, as immune checkpoint inhibitors are preferred in pregnancy", "C": "Initiate UNLOXCYT, as it is the only drug indicated for CSCC", "D": "Defer systemic therapy due to contraindication of all options in pregnancy"}}
{"id": "6gA2jeZSISgT", "question_type": "open_ended_multi_choice", "question": "A 58-year-old woman with non-alcoholic steatohepatitis (NASH) and stage F3 liver fibrosis is being considered for pharmacological therapy. She has a history of intermittent claudication and is currently taking warfarin for atrial fibrillation. Her liver function tests are within normal limits, and she does not have decompensated cirrhosis. Which drug is most appropriate for treating her NASH, considering her comorbidities and current medications?", "options": {"A": "Resmetirom administered once daily in conjunction with diet and exercise", "B": "Pentoxifylline extended-release tablets twice daily", "C": "Dapagliflozin once daily", "D": "Pentoxifylline extended-release tablets once daily"}}
{"id": "p4D3AHEIXLsi", "question_type": "multi_choice", "question": "A 2-month-old infant, born prematurely and currently hospitalized with severe lower respiratory tract infection due to confirmed respiratory syncytial virus (RSV), is being considered for antiviral therapy. The infant is not on mechanical ventilation and has no known hypersensitivity to monoclonal antibodies. The mother is not pregnant or breastfeeding. Which of the following is the most appropriate drug for this patient's treatment, including recommended administration duration?", "options": {"A": "Virazole, administered as an inhalation solution for 3 to 7 days.", "B": "ENFLONSIA, administered as a single dose for prevention.", "C": "Restasis MultiDose, administered twice daily as ophthalmic drops.", "D": "Virazole, administered orally for 14 days."}}
{"id": "FBTjbYywv3tl", "question_type": "open_ended_multi_choice", "question": "A 78-year-old female with moderate renal impairment (eGFR 40 mL/min) is prescribed Blujepa for uUTI. What is the recommended dosage adjustment for this patient?", "options": {"A": "Increase the dose by 50%", "B": "No dosage adjustment is required", "C": "Reduce the dose by half", "D": "Avoid use of Blujepa"}}
{"id": "c8MhQqNFSyPn", "question_type": "open_ended_multi_choice", "question": "How should Hernexeos treatment be managed when a patient develops Grade 3 increases in ALT and/or AST, but total bilirubin levels remain normal?", "options": {"A": "Continue Hernexeos at the same dose", "B": "Interrupt Hernexeos until recovery, then resume at reduced dose", "C": "Permanently discontinue Hernexeos", "D": "Increase Hernexeos dose"}}
{"id": "XNSQLGTRZPEg", "question_type": "open_ended_multi_choice", "question": "If a patient receiving Enflonsia develops signs of anaphylaxis, what is the recommended immediate clinical action?", "options": {"A": "Initiate appropriate medications and/or supportive therapy", "B": "Discontinue all medications", "C": "Administer additional Enflonsia", "D": "Perform a rapid antigen test for RSV"}}
{"id": "V9mE7Z50Ed1V", "question_type": "multi_choice", "question": "A 45-year-old woman with symptomatic tenosynovial giant cell tumor (TGCT) is not a candidate for surgery due to the risk of worsening functional limitation. She has a history of aspirin sensitivity and previously experienced bronchial asthma triggered by food dyes. Her liver and renal function tests are within normal limits, and she is not pregnant or breastfeeding. Which drug is the most appropriate for her treatment?", "options": {"A": "ROMVIMZA with dose reduction", "B": "ROMVIMZA", "C": "Turalio with dose reduction", "D": "Turalio"}}
{"id": "szPz5LnxG40R", "question_type": "open_ended_multi_choice", "question": "A pregnant 59-year-old woman is diagnosed with BCG-unresponsive nonmuscle invasive bladder cancer with carcinoma in situ and is considering treatment options. Which of the following statements best summarizes the safest pharmacologic approach for her situation?", "options": {"A": "Gemcitabine is preferred due to its established safety in pregnancy.", "B": "Anktiva can be used safely during pregnancy because systemic exposure is low.", "C": "Both Anktiva and Gemcitabine are contraindicated in pregnancy due to potential fetal harm.", "D": "Gemcitabine is recommended because it is not absorbed systemically."}}
{"id": "J3HevBNGvU8u", "question_type": "multi_choice", "question": "Which of the following statements is correct regarding the freezing of Vizz?", "options": {"A": "Vizz should be frozen for long-term storage.", "B": "Vizz should not be frozen under any circumstances.", "C": "Vizz can be frozen for up to 8 days during shipment.", "D": "Vizz can be frozen after opening the vial."}}
{"id": "oNbj3G5saQCw", "question_type": "open_ended_multi_choice", "question": "Considering the age and approved indications, what is the most suitable medication for a 7-year-old child with hereditary angioedema who requires preventive therapy, has no hypersensitivity history, and is not taking anticoagulants?", "options": {"A": "Kalbitor", "B": "ANDEMBRY", "C": "TAKHZYRO", "D": "No drug is appropriate for this patient"}}
{"id": "t6FmlN8p3WyA", "question_type": "multi_choice", "question": "A 52-year-old man with primary IgAN and UPCR of 1.8 g/g is being considered for VANRAFIA therapy to reduce proteinuria. He has a history of severe hepatic impairment. Which of the following is the most appropriate recommendation regarding VANRAFIA use in this patient?", "options": {"A": "Initiate VANRAFIA without dose adjustment and monitor liver enzymes regularly.", "B": "Start VANRAFIA at half the recommended dose and monitor for hepatotoxicity.", "C": "Do not initiate VANRAFIA due to severe hepatic impairment.", "D": "Begin VANRAFIA therapy and add a CYP3A inducer to reduce adverse effects."}}
{"id": "Qz3whSSTc3pN", "question_type": "open_ended", "question": "What is the recommendation regarding breastfeeding for women taking Wayrilz?", "options": {"A": "Breastfeeding is safe during Wayrilz therapy.", "B": "Breastfeeding should be avoided only during the first week of Wayrilz therapy.", "C": "Advise not to breastfeed while taking Wayrilz and for at least 1 week after the final dose.", "D": "Breastfeeding can resume immediately after stopping Wayrilz."}}
{"id": "Qybyr2PX5iEk", "question_type": "open_ended_multi_choice", "question": "Considering a 45-year-old woman with chronic hypoparathyroidism who maintains an albumin-corrected serum calcium of 8.2 mg/dL on calcium and active vitamin D supplementation, and who has no history of bone cancer, radiation therapy, metabolic bone disorders, or medications that alter calcium levels, which pharmacologic agent is recommended for long-term management of her condition with regard to safety and efficacy?", "options": {"A": "GENOTROPIN administered once daily", "B": "Yorvipath administered once daily", "C": "Tri-Vite Drops with Fluoride administered daily", "D": "Somatropin administered twice daily"}}
{"id": "NDq3JrovfHOT", "question_type": "open_ended_multi_choice", "question": "A teenager aged 15 with a diagnosis of hereditary angioedema presents to the ED during an acute episode. Given the patient's history of life-threatening anaphylaxis to ecallantide, which treatment should be avoided and which is most appropriate for this situation?", "options": {"A": "Kalbitor", "B": "TAKHZYRO", "C": "ANDEMBRY", "D": "Supportive care only"}}
{"id": "ceO8dgQjodjK", "question_type": "open_ended_multi_choice", "question": "A 34-year-old breastfeeding woman, with no renal or hepatic dysfunction and no other medications, presents with severe alopecia areata. What is the most suitable pharmacological treatment for her?", "options": {"A": "LEQSELVI administered orally once daily", "B": "Hydroxychloroquine sulfate administered orally once daily", "C": "Triamcinolone acetonide nasal spray once daily", "D": "LEQSELVI administered orally every other day with a drug holiday every 2 weeks"}}
{"id": "9n7nHyeaHu1n", "question_type": "multi_choice", "question": "What is the recommended approach for using Journavx in patients with renal impairment and eGFR < 15 mL/min?", "options": {"A": "Avoid use of Journavx", "B": "Use standard dosage", "C": "Increase dosage", "D": "Monitor renal function closely but use standard dosage"}}
{"id": "7RrWfumWZs4X", "question_type": "open_ended_multi_choice", "question": "Given a 14-year-old patient with a Grade 2 astrocytoma post-subtotal resection and a confirmed IDH1 mutation, who is not pregnant, has normal renal and hepatic function, and is not on any CYP1A2 or CYP3A4 modulators, which ongoing treatment regimen would be most suitable in terms of efficacy and safety for this demographic?", "options": {"A": "Vorasidenib 40 mg once daily, with regular liver function monitoring", "B": "Avastin administered every 2 weeks", "C": "Zortress in combination with cyclosporine and corticosteroids", "D": "Avastin in combination with carboplatin and paclitaxel"}}
{"id": "wEovSFFoueHX", "question_type": "multi_choice", "question": "Which risk management program restricts the availability of Lynozyfic due to its potential for severe adverse effects?", "options": {"A": "Lynozyfic REMS", "B": "iPLEDGE", "C": "RiskMAP", "D": "Tysabri TOUCH"}}
{"id": "jrNM0iEwZu9x", "question_type": "multi_choice", "question": "If Journavx is co-administered with a moderate CYP3A inhibitor, what adjustment should be made?", "options": {"A": "Increase the dose of Journavx.", "B": "Discontinue the CYP3A inhibitor.", "C": "Reduce the dose of Journavx.", "D": "No adjustment is necessary."}}
{"id": "KH6CJnaa6SJD", "question_type": "multi_choice", "question": "A 67-year-old man with persistent immune thrombocytopenia and autosomal dominant inheritance has failed previous corticosteroid therapy. He has a history of severe renal impairment and is currently taking a proton pump inhibitor for gastroesophageal reflux disease. Which drug should be avoided due to his comorbidities and medication regimen?", "options": {"A": "Prednisone", "B": "DMT SUIK (IV)", "C": "Dexamethasone sodium phosphate", "D": "Rilzabrutinib"}}
{"id": "oQB34CSNBAPj", "question_type": "open_ended_multi_choice", "question": "Upon observing new onset yellow skin and dark urine in a patient currently receiving Vanrafia, what is the most appropriate intervention?", "options": {"A": "Continue Vanrafia and monitor symptoms", "B": "Increase the dose of Vanrafia", "C": "Temporarily or permanently discontinue Vanrafia and evaluate for liver dysfunction", "D": "Switch to another endothelin receptor antagonist"}}
{"id": "ppFaJ7dbMbPt", "question_type": "multi_choice", "question": "A 7-year-old girl with relapsed low-grade glioma is found to have a BRAF V600 mutation. She is currently taking a moderate CYP2C8 inhibitor for another condition. Her parents are concerned about the risk of growth reduction and want to know which drug would be most appropriate for her tumor treatment. Which option is the most suitable for this patient?", "options": {"A": "NEUPOGEN administered daily as supportive care", "B": "Tovorafenib administered once daily at the recommended pediatric dose", "C": "Etoposide administered intravenously every 3 weeks", "D": "Tovorafenib administered once daily, but with concurrent moderate CYP2C8 inhibitor"}}
{"id": "CCyz2KC01OSe", "question_type": "open_ended_multi_choice", "question": "Which of the following is an appropriate instruction to provide to patients using Ekterly?", "options": {"A": "Read the FDA-approved patient labeling (Patient Information)", "B": "Take Ekterly with grapefruit juice to enhance absorption", "C": "Double the dose if symptoms persist after 1 hour", "D": "Discontinue Ekterly if experiencing mild hepatic impairment"}}
{"id": "HKAUCNZxCXtl", "question_type": "multi_choice", "question": "A 68-year-old woman with transfusion-dependent anemia is diagnosed with low-risk myelodysplastic syndrome (MDS) associated with a deletion 5q cytogenetic abnormality. She has normal renal function and is not pregnant. Her physician is considering starting drug therapy to reduce her transfusion needs. Which of the following drugs is most appropriate for her condition, considering both efficacy and safety for her specific MDS subtype?", "options": {"A": "INQOVI (cedazuridine and decitabine), administered orally once daily in 28-day cycles.", "B": "Lenalidomide, administered orally once daily, with strict adherence to pregnancy prevention protocols.", "C": "TREOSULFAN (GRAFAPEX), in combination with fludarabine as a preparative regimen for allogeneic stem cell transplantation.", "D": "Azacitidine, administered subcutaneously for 7 days every 28 days."}}
{"id": "esBG31TEWveE", "question_type": "open_ended_multi_choice", "question": "Which of the following statements is true regarding the effect of anti-drug antibodies on the pharmacokinetics, pharmacodynamics, safety, or effectiveness of Imaavy?", "options": {"A": "Anti-drug antibodies significantly reduce the effectiveness of Imaavy", "B": "Neutralizing antibodies cause severe adverse reactions", "C": "No clinically relevant effect of antibodies, including neutralizing antibodies, was identified", "D": "Anti-drug antibodies increase the clearance of Imaavy"}}
{"id": "VjTB4XxCgkez", "question_type": "open_ended_multi_choice", "question": "Which of the following should patients be instructed to do when starting therapy with Sephience?", "options": {"A": "Inform their healthcare provider about all prescription, over-the-counter medications, and supplements they are taking.", "B": "Avoid all dairy products while on therapy.", "C": "Increase their daily intake of vitamin K.", "D": "Monitor their blood pressure daily."}}
{"id": "zSC0wiNEBlZy", "question_type": "open_ended_multi_choice", "question": "A 68-year-old male with symptomatic obstructive hypertrophic cardiomyopathy (NYHA class III) is being considered for drug therapy. He is currently taking verapamil and metoprolol tartrate for arrhythmia control. Which drug should NOT be initiated due to the risk of additive negative inotropic effects and potential for heart failure?", "options": {"A": "Acoramidis Hydrochloride", "B": "Mavacamten", "C": "Metoprolol Tartrate", "D": "Diltiazem"}}
{"id": "DGzsJO0EDgEl", "question_type": "open_ended_multi_choice", "question": "A 42-year-old woman with familial chylomicronemia syndrome, manifesting as hepatic steatosis, memory impairment, and increased circulating chylomicron concentration, is breastfeeding her 2-month-old infant. She is seeking pharmacological therapy to reduce her triglyceride levels. Which of the following is the most appropriate choice?", "options": {"A": "MYCOPHENOLATE MOFETIL, as it has limited data but some infants breastfed during maternal use had no reported adverse events.", "B": "TRYNGOLZA, since animal data suggest low levels in milk and poor oral bioavailability, making it unlikely to harm the infant.", "C": "MYCOPHENOLATE MOFETIL, with additional barrier contraception to minimize infant exposure.", "D": "TRYNGOLZA, but only after cessation of breastfeeding due to unknown human data."}}
{"id": "Eny2j55HBzPz", "question_type": "multi_choice", "question": "When considering pharmacological therapy for presbyopia in adults, which brand drug acts as a cholinergic agonist?", "options": {"A": "Alrex", "B": "Timoptic", "C": "Xalatan", "D": "Vizz"}}
{"id": "Mh5f0QqoIz04", "question_type": "open_ended_multi_choice", "question": "A 13-year-old female patient weighing 45 kg is diagnosed with uncomplicated urinary tract infection (uUTI). Is Blujepa an appropriate treatment option for her?", "options": {"A": "Yes, Blujepa is indicated for this patient population.", "B": "No, Blujepa is not indicated for patients under 18 years of age.", "C": "No, Blujepa is only indicated for male pediatric patients.", "D": "No, Blujepa is not indicated for patients weighing less than 50 kg."}}
{"id": "kPmX1FtRrtHr", "question_type": "open_ended_multi_choice", "question": "Which of the following statements best describes a contraindication for the use of Journavx?", "options": {"A": "Journavx should not be used with strong CYP3A inhibitors.", "B": "Journavx is contraindicated in patients with renal impairment.", "C": "Journavx must not be administered with food.", "D": "Journavx is contraindicated in pediatric patients."}}
{"id": "BKuM5pIkA9kD", "question_type": "open_ended_multi_choice", "question": "What potential reproductive risk should be discussed with patients of reproductive potential prior to initiating Grafapex?", "options": {"A": "Grafapex may cause temporary or permanent infertility in both females and males.", "B": "Grafapex increases fertility in females only.", "C": "Grafapex has no effect on reproductive health.", "D": "Grafapex causes permanent sterility in males only."}}
{"id": "B0DXtWrbZAh5", "question_type": "open_ended_multi_choice", "question": "A 72-year-old man with BCG-refractory carcinoma in situ (CIS) of the urinary bladder is unable to undergo immediate cystectomy due to high surgical risk. He recently underwent transurethral resection of the bladder (TURB) 5 days ago and currently has severe irritable bladder symptoms. Which treatment option should be avoided in this patient?", "options": {"A": "Valrubicin intravesical therapy", "B": "Nogapendekin alfa inbakicept-pmln (ANKTIVA) with Bacillus Calmette-Guérin (BCG)", "C": "Immediate cystectomy", "D": "Valrubicin intravesical therapy delayed for two weeks after TURB"}}
{"id": "4yfO73OJ69YP", "question_type": "open_ended_multi_choice", "question": "A 68-year-old female with hereditary transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) is undergoing methotrexate therapy for rheumatoid arthritis. She is neither pregnant nor breastfeeding. Which medication should be avoided because it may increase methotrexate toxicity, and which treatment is recommended for her cardiomyopathy?", "options": {"A": "Dexrazoxane should be avoided; Attruby is preferred.", "B": "Vyndaqel should be avoided; Attruby is preferred.", "C": "Attruby should be avoided; Vyndaqel is preferred.", "D": "Dexrazoxane should be avoided; Vyndaqel is preferred."}}
{"id": "FVLCZwn71SJx", "question_type": "open_ended", "question": "Which of the following statements about sharing Ekterly with others is correct?", "options": {"A": "Ekterly should not be given to other people, even if they have the same symptoms.", "B": "Ekterly can be shared with family members with similar symptoms.", "C": "Ekterly is safe for use in all individuals with hereditary angioedema.", "D": "Ekterly can be used for any acute allergic reaction."}}
{"id": "qdPcJH9JegOk", "question_type": "open_ended_multi_choice", "question": "A 52-year-old woman has been newly diagnosed with locally advanced ROS1-positive non-small cell lung cancer. She is currently receiving a strong CYP3A inhibitor for a fungal infection. She is neither pregnant nor breastfeeding, and her medical history is negative for liver disease or arrhythmias. What is the most suitable drug therapy for her lung cancer at this time?", "options": {"A": "IBTROZI (taletrectinib) 600 mg orally once daily", "B": "IBTROZI (taletrectinib) 600 mg orally once daily, with a drug holiday during antifungal therapy", "C": "IBTROZI (taletrectinib) 600 mg orally once daily, co-administered with the CYP3A inhibitor", "D": "Delay initiation of IBTROZI (taletrectinib) until the CYP3A inhibitor is discontinued"}}
{"id": "uZDdMDjYEC7p", "question_type": "multi_choice", "question": "A 38-year-old woman with a recent diagnosis of schizophrenia presents for initiation of antipsychotic therapy. Her medical history is significant for moderate hepatic impairment (Child-Pugh Class B). She has no history of renal impairment, cardiovascular disease, or metabolic syndrome. Which antipsychotic regimen is most appropriate for this patient?", "options": {"A": "Cobenfy, administered orally at the recommended adult dose", "B": "Abilify Maintena, administered as a monthly intramuscular injection", "C": "Cobenfy, administered at a reduced dose due to hepatic impairment", "D": "Abilify Maintena, administered as a weekly intramuscular injection"}}
{"id": "cDlKha5yQvnj", "question_type": "multi_choice", "question": "A 35-year-old pregnant woman is diagnosed with low-grade glioma. She is seeking treatment options that minimize risk to her fetus. Genetic testing reveals no BRAF fusion or V600 mutation. Which of the following therapies is contraindicated for her due to pregnancy risk and lack of efficacy for her tumor profile?", "options": {"A": "Gliadel Wafer, implanted during surgery, with known embryo-fetal toxicity.", "B": "VinCRIStine Sulfate, administered intravenously, with risk of fetal harm.", "C": "OJEMDA, as a kinase inhibitor targeting BRAF mutations, administered orally.", "D": "Supportive care only, deferring cytotoxic or targeted therapy until after pregnancy."}}
{"id": "PzB3DjUUGu42", "question_type": "open_ended_multi_choice", "question": "A 58-year-old female patient has recently been diagnosed with multiple myeloma, confirmed by findings of paraproteinemia and amyloidosis. She has not received chemotherapy or immunotherapy previously, is not pregnant, and has no past thromboembolic events. She is using antihistamines for seasonal allergies. Which drug regimen should be chosen for her initial management of multiple myeloma?", "options": {"A": "Thalidomide in combination with dexamethasone", "B": "Linvoseltamab-gcpt monotherapy", "C": "Talquetamab-tgvs monotherapy", "D": "Thalidomide monotherapy"}}
{"id": "nchfKbzETYQO", "question_type": "multi_choice", "question": "A 68-year-old woman with metastatic gastroesophageal junction adenocarcinoma is being considered for chemotherapy. She has a history of chronic liver disease with laboratory findings of bilirubin 2.1x ULN, AST 2.0x ULN, and alkaline phosphatase 3.0x ULN. She has no known drug allergies and is not taking anticoagulants. Which of the following drugs is contraindicated for her due to her hepatic impairment?", "options": {"A": "Zolbetuximab (Vyloy) monotherapy", "B": "Zolbetuximab (Vyloy) in combination with fluoropyrimidine- and platinum-containing chemotherapy", "C": "Capecitabine (with dose adjustment for hepatic impairment)", "D": "Docetaxel in combination with cisplatin and fluorouracil"}}
{"id": "ss1ytUR4QM4n", "question_type": "multi_choice", "question": "A 58-year-old woman is newly diagnosed with metastatic non-small cell lung cancer (NSCLC). Genetic testing reveals a ROS1 gene rearrangement. She has a history of mild renal impairment (CLcr 55 mL/min), is currently taking a moderate CYP3A inhibitor for another condition, and has no history of cardiac disease or CNS symptoms. She is not pregnant and does not plan to breastfeed. Which drug regimen is most appropriate for her initial treatment?", "options": {"A": "CYRAMZA in combination with erlotinib", "B": "Rozlytrek, with dose reduction due to CYP3A inhibitor", "C": "LAZCLUZE (lazertinib plus amivantamab)", "D": "CYRAMZA in combination with docetaxel"}}
{"id": "KvvOYGPmpZ4K", "question_type": "multi_choice", "question": "A 68-year-old man with chronic atopic dermatitis, flexural lichenification, and recurrent pruritus is seeking relief for his symptoms. He has a history of mild cognitive impairment and is currently taking cimetidine for gastric reflux. He is not on any immunosuppressive therapy and has no active infections. Which treatment option should be avoided due to his current medication and risk profile?", "options": {"A": "Lebrikizumab-lbkz administered subcutaneously every 2 weeks", "B": "DMT SUIK administered intramuscularly for acute exacerbation", "C": "Doxepin hydrochloride cream applied three times daily for 8 days", "D": "Doxepin hydrochloride cream applied once daily for 8 days"}}
{"id": "2D5xthudmQHe", "question_type": "multi_choice", "question": "A 60-year-old man with myopathy with eye involvement and a history of congestive heart failure is admitted for documented, life-threatening ventricular arrhythmia. He has mildly elevated liver enzymes at baseline. Which of the following best describes the considerations for initiating mexiletine hydrochloride in this patient?", "options": {"A": "Mexiletine hydrochloride can be started without concern for liver function monitoring.", "B": "Mexiletine hydrochloride should be avoided due to its proarrhythmic effects in mild arrhythmias.", "C": "Mexiletine hydrochloride may be used, but liver function should be closely monitored due to risk of acute liver injury.", "D": "Mexiletine hydrochloride is contraindicated in patients with myopathy with eye involvement."}}
{"id": "pFtmYbbTS8MO", "question_type": "open_ended_multi_choice", "question": "Which patient history is a contraindication for prescribing Blujepa?", "options": {"A": "Severe hypersensitivity to Blujepa", "B": "Mild gastrointestinal upset after Blujepa", "C": "Family history of hypertension", "D": "Previous use of Blujepa without adverse effects"}}
{"id": "srdCt8aBHgJh", "question_type": "multi_choice", "question": "If a patient taking Avmapki Fakzynja Co-Pack requires gastric acid suppression, which of the following regimens is recommended?", "options": {"A": "Administer a proton pump inhibitor concurrently", "B": "Administer FAKZYNJA 2 hours before or after a locally acting antacid", "C": "Administer an H2 receptor antagonist at bedtime", "D": "Increase the dose of Avmapki Fakzynja Co-Pack"}}
{"id": "v5ZVrNNukdfW", "question_type": "open_ended_multi_choice", "question": "What information is currently available regarding the safety and effectiveness of Wayrilz in children?", "options": {"A": "Safety and effectiveness have been established in pediatric patients.", "B": "Safety has been established, but effectiveness has not.", "C": "Effectiveness has been established, but safety has not.", "D": "Safety and effectiveness have not been established in pediatric patients."}}
{"id": "dSHhTUjHGrVS", "question_type": "open_ended_multi_choice", "question": "After completing treatment with penpulimab-kcqx, what is the recommended duration for females of reproductive potential to continue using effective contraception?", "options": {"A": "1 month", "B": "2 months", "C": "3 months", "D": "4 months"}}
{"id": "g5iDwLKzlB0B", "question_type": "multi_choice", "question": "A 28-year-old male with a history of Crohn's disease, currently on azathioprine, presents with newly diagnosed hepatosplenic T-cell lymphoma. He is being considered for immunosuppressive therapy. Which of the following drugs should be strictly avoided due to a known association with fatal hepatosplenic T-cell lymphoma in this patient population?", "options": {"A": "Fludarabine phosphate", "B": "Simponi Aria", "C": "Inflectra", "D": "Methotrexate"}}
{"id": "mqrEqILZl8Vf", "question_type": "multi_choice", "question": "Which of the following statements best describes the effect of Emrelis on fertility in females?", "options": {"A": "Emrelis permanently impairs female fertility", "B": "Emrelis impairs fertility only in males", "C": "Emrelis has no effect on female fertility", "D": "Emrelis improves female fertility"}}
{"id": "d8R0kY2ohNXS", "question_type": "multi_choice", "question": "A 7-year-old boy with a diagnosis of immune thrombocytopenia, confirmed by thrombocytopenia and abnormal bleeding, has failed to respond to corticosteroids and IVIG. He has no significant hepatic or renal impairment. Which drug regimen is most suitable for his ongoing management?", "options": {"A": "WAYRILZ (rilzabrutinib) 400 mg twice daily", "B": "WAYRILZ (rilzabrutinib) with dose reduction", "C": "DMT SUIK (corticosteroid) intravenous therapy", "D": "Nplate (romiplostim) weekly subcutaneous injection"}}
{"id": "Uj4XrZsagjcc", "question_type": "multi_choice", "question": "Which of the following is TRUE regarding the administration of Modeyso via feeding tube?", "options": {"A": "Modeyso cannot be administered via feeding tube", "B": "Modeyso should be mixed with food before tube administration", "C": "Modeyso capsules must be swallowed whole for tube administration", "D": "Modeyso may be given through a naso-gastric or gastrostomy tube after preparing the liquid mixture"}}
{"id": "m1n11Eo4AP1p", "question_type": "open_ended", "question": "If a patient is being treated with Imaavy and is scheduled for vaccination, what should they do?", "options": {"A": "Inform their healthcare provider about Imaavy treatment", "B": "Skip the vaccination", "C": "Double the vaccine dose", "D": "Receive only live vaccines"}}
{"id": "sgscV0RutG7a", "question_type": "open_ended_multi_choice", "question": "When taking Vizz, which precaution is advised for patients who encounter brief periods of reduced or darkened vision?", "options": {"A": "Avoid night driving and hazardous activities in poor illumination.", "B": "Increase screen time to improve vision adaptation.", "C": "Take Vizz only in the morning.", "D": "Wear sunglasses indoors."}}
{"id": "y9TaKbN4MfpG", "question_type": "multi_choice", "question": "A 62-year-old woman with unresectable, metastatic non-squamous non-small cell lung carcinoma is found to have a HER2 (ERBB2) tyrosine kinase domain activating mutation by FDA-approved testing. She has previously received platinum-based chemotherapy. Her cardiac function is normal, and she is not pregnant or breastfeeding. However, she is currently taking rifampin, a strong CYP3A inducer, for latent tuberculosis. Which drug regimen is most appropriate for her lung cancer treatment?", "options": {"A": "Atezolizumab as monotherapy", "B": "Zongertinib with dose adjustment to account for CYP3A induction", "C": "Imfinzi in combination with platinum-based chemotherapy", "D": "Zongertinib at standard dose without adjustment"}}
{"id": "jXGVLGpWPwA0", "question_type": "multi_choice", "question": "A 36-year-old woman with KRAS-mutated recurrent low-grade serous ovarian carcinoma is being considered for AVMAPKI FAKZYNJA CO-PACK (avutometinib and defactinib) therapy. She is currently pregnant and not taking any other medications. What is the most appropriate recommendation regarding her cancer treatment?", "options": {"A": "Start AVMAPKI FAKZYNJA CO-PACK immediately, as it is the only approved therapy for her condition.", "B": "Switch to an alternative systemic therapy with a better safety profile in pregnancy.", "C": "Start AVMAPKI FAKZYNJA CO-PACK but reduce the dose to minimize fetal exposure.", "D": "Delay AVMAPKI FAKZYNJA CO-PACK until after delivery due to risk of fetal harm."}}
{"id": "9FAclf8usufn", "question_type": "open_ended_multi_choice", "question": "In the context of the KONFIDENT trial, which statement best reflects the role of Ekterly 300 mg?", "options": {"A": "Ekterly 300 mg was evaluated but is not a recommended dose for acute HAE attacks", "B": "Ekterly 300 mg was the preferred dose for all patients", "C": "Ekterly 300 mg was only used in patients under 18 years", "D": "Ekterly 300 mg was not evaluated in the trial"}}
{"id": "5eZkLO13vWYe", "question_type": "multi_choice", "question": "A patient using Vizz reports sudden onset of flashing lights, floaters, or vision loss. What is the recommended action?", "options": {"A": "Wait 24 hours before contacting a physician.", "B": "Continue using Vizz and monitor symptoms.", "C": "Increase the dosage of Vizz.", "D": "Switch to another ophthalmic medication."}}
{"id": "kCO2e6SByr0Q", "question_type": "open_ended_multi_choice", "question": "A 58-year-old woman with a history of hypertension presents for management of persistently elevated systolic and diastolic blood pressure despite lifestyle modifications and prior monotherapy. She has stage 3 chronic kidney disease (eGFR 35 mL/min), mild hepatic impairment (Child-Pugh class A), and is not pregnant or breastfeeding. She is not taking lithium or any CYP2C9/CYP3A inhibitors. Which antihypertensive agent is most appropriate to add to her regimen, considering her comorbidities and the safety profiles of the available drugs?", "options": {"A": "Aprocitentan (TRYVIO), once daily in combination with other antihypertensives", "B": "Bosentan (TRACLEER), twice daily", "C": "Chlorthalidone (THALITONE), once daily", "D": "Bosentan (TRACLEER), once daily"}}
{"id": "EFBpadlCeimH", "question_type": "multi_choice", "question": "A 7-year-old boy with Duchenne muscular dystrophy presents with progressive muscle weakness, elevated creatine kinase, and a history of arrhythmia. He is currently taking a medication known to prolong the QTc interval for his cardiac condition. Which drug regimen is most appropriate for treating his DMD, considering his cardiac profile and current medications?", "options": {"A": "Eteplirsen administered once weekly", "B": "Givinostat administered twice daily", "C": "Deflazacort administered daily", "D": "Givinostat with a planned drug holiday every month"}}
{"id": "atlRco34LzVK", "question_type": "open_ended_multi_choice", "question": "Prior to starting Modeyso in women who may become pregnant, what step is advised?", "options": {"A": "No specific action is required.", "B": "Start Modeyso immediately regardless of pregnancy status.", "C": "Verify pregnancy status prior to initiation.", "D": "Advise permanent contraception."}}
{"id": "vtYugp2Fr9Yu", "question_type": "multi_choice", "question": "A 45-year-old woman with symptomatic tenosynovial giant cell tumor (TGCT) is not a candidate for surgery due to the risk of worsening functional limitation. She has a history of aspirin sensitivity and previously experienced bronchial asthma triggered by food dyes. Her liver and renal function tests are within normal limits, and she is not pregnant or breastfeeding. Which drug is the most appropriate for her treatment?", "options": {"A": "Turalio with dose reduction", "B": "ROMVIMZA", "C": "Turalio", "D": "ROMVIMZA with dose reduction"}}
{"id": "mJzm5ru9BJpK", "question_type": "open_ended_multi_choice", "question": "A 34-year-old pregnant woman in her second trimester presents with symptomatic supraventricular tachycardia requiring acute rate control. She has no significant past medical history and is not taking any other medications. Which drug is the most suitable for her condition?", "options": {"A": "Pacerone (amiodarone)", "B": "RAPIBLYK (landiolol)", "C": "Propranolol", "D": "Digoxin"}}
{"id": "bKojLOht5Hmh", "question_type": "multi_choice", "question": "What is the recommended procedure regarding contact lens use when administering Vizz?", "options": {"A": "Remove contact lenses before instillation and reinsert 10 minutes after.", "B": "Keep contact lenses in during instillation.", "C": "Remove contact lenses and wait 1 hour before reinserting.", "D": "Do not use contact lenses at all during Vizz therapy."}}
{"id": "1Fi3x85ecgSn", "question_type": "open_ended_multi_choice", "question": "A 72-year-old patient presents with mild cognitive impairment secondary to Alzheimer’s disease and is being considered for drug therapy. Genetic testing identifies ApoE ε4 homozygosity. There is no history of hypersensitivity reactions, no use of antithrombotic agents, and MRI findings are negative for microhemorrhages or superficial siderosis. What is the best drug treatment option for this patient?", "options": {"A": "Kisunla (donanemab-azbt), with enhanced clinical vigilance for ARIA and regular MRI monitoring", "B": "Kisunla (donanemab-azbt), without genetic testing or MRI monitoring", "C": "Kisunla (donanemab-azbt), contraindicated due to age", "D": "No drug therapy recommended due to ApoE ε4 homozygosity"}}
{"id": "CiLq4zuqLR5x", "question_type": "open_ended_multi_choice", "question": "A 65-year-old male with a medical history including neurofibromatosis type 1, chronic myelogenous leukemia, hypertension, and mild renal impairment comes in with joint pain and stiffness. His current medications include an ACE inhibitor for hypertension. Which of the following would be the least advisable for managing his pain?", "options": {"A": "Celecoxib", "B": "Gomekli", "C": "PNV-DHA", "D": "Physical therapy only"}}
{"id": "m1WBekqMIAFm", "question_type": "open_ended_multi_choice", "question": "A 42-year-old female patient with a history of severe hepatic impairment (Child-Pugh Class C) and currently on a potent CYP3A inhibitor presents with moderate to severe acute pain after abdominal surgery. What is the most suitable drug regimen for managing her acute pain?", "options": {"A": "JOURNAVX administered at standard adult dosage", "B": "Ropivacaine Hydrochloride via epidural block, starting at the low end of the dosage range", "C": "Pain Relief Childrens (acetaminophen-based OTC) at pediatric dosing", "D": "JOURNAVX with reduced dosage and avoidance of grapefruit products"}}
{"id": "EIn6oVa6IifF", "question_type": "multi_choice", "question": "Which of the following statements is correct regarding the freezing of Vizz?", "options": {"A": "Vizz should be frozen for long-term storage.", "B": "Vizz can be frozen for up to 8 days during shipment.", "C": "Vizz can be frozen after opening the vial.", "D": "Vizz should not be frozen under any circumstances."}}
{"id": "yq0hHlEObQih", "question_type": "multi_choice", "question": "A 62-year-old man with metastatic non-small cell lung carcinoma (NSCLC) presents for second-line therapy. His tumor is non-squamous, shows high c-Met protein overexpression (≥50% of tumor cells with strong staining), and he has a history of mild hepatic impairment (total bilirubin ≤ULN and AST >ULN). He is not taking any CYP3A inhibitors. Which drug regimen is most appropriate for this patient, considering his tumor profile and hepatic function?", "options": {"A": "Ipilimumab in combination with nivolumab", "B": "Entrectinib (Rozlytrek)", "C": "Telisotuzumab vedotin (EMRELIS)", "D": "Ipilimumab monotherapy"}}
{"id": "PxearlfgVHTr", "question_type": "open_ended_multi_choice", "question": "A 10-year-old boy, weighing 35 kg, has chronic graft-versus-host disease (cGVHD) complicated by bronchiectasis, frequent infections, and esophageal structural changes. He has failed two systemic therapies, has normal liver function, and is not on other immunosuppressants. Which treatment should be considered the best option for him?", "options": {"A": "Niktimvo, intravenous infusion every 2 weeks", "B": "PredniSONE, 5 mg orally once daily", "C": "PONVORY, 20 mg orally once daily", "D": "Niktimvo, intravenous infusion every 4 weeks"}}
{"id": "m86Rd35QmSAG", "question_type": "multi_choice", "question": "A 34-year-old woman with familial chylomicronemia syndrome presents with recurrent pancreatitis, hepatosplenomegaly, and eruptive xanthomas. She is currently 10 weeks pregnant and is seeking a medication to reduce her triglyceride levels. She is concerned about the safety of drug therapy during pregnancy. Which of the following is the most appropriate pharmacological option for her condition?", "options": {"A": "TRYNGOLZA administered as an adjunct to diet, with careful monitoring for hypersensitivity reactions.", "B": "MYCOPHENOLATE MOFETIL, with strict contraception counseling and regular pregnancy testing.", "C": "MYCOPHENOLATE MOFETIL, combined with a drug holiday during the first trimester.", "D": "TRYNGOLZA, but only after delivery due to lack of safety data in pregnancy."}}
{"id": "MK5zULNjAPOc", "question_type": "multi_choice", "question": "Following cholecystectomy due to gallbladder disease in patients treated with Qfitlia, what was the typical management regarding Qfitlia therapy?", "options": {"A": "Qfitlia was switched to fixed dose regimen", "B": "Qfitlia was permanently discontinued in all cases", "C": "Qfitlia dose was doubled", "D": "Most patients resumed Qfitlia after surgery"}}
{"id": "95H6hHiBhLa7", "question_type": "multi_choice", "question": "Which statement accurately reflects the statistical significance of Imaavy's effect on the Quantitative Myasthenia Gravis (QMG) total score in the clinical study?", "options": {"A": "Imaavy showed no statistically significant difference compared to placebo (p=0.45)", "B": "Imaavy demonstrated a statistically significant improvement in QMG total score compared to placebo (p<0.001)", "C": "Imaavy was inferior to placebo in QMG total score change (p=0.05)", "D": "Imaavy and placebo had identical effects on QMG total score (p=1.0)"}}
{"id": "4oftWX0e9wdR", "question_type": "open_ended_multi_choice", "question": "How should the Modeyso dose be adjusted for an adult patient who is concurrently prescribed a strong CYP3A4 inhibitor?", "options": {"A": "Increase to 625 mg once weekly", "B": "Reduce to 375 mg once weekly", "C": "Reduce to 500 mg once weekly", "D": "Discontinue Modeyso"}}
{"id": "MMUKeFBE9qx4", "question_type": "open_ended_multi_choice", "question": "A 34-year-old woman with idiopathic pulmonary arterial hypertension (WHO Group 1, Functional Class II) is planning to become pregnant in the next few months. She is currently breastfeeding her infant and is being considered for long-term therapy to improve exercise capacity and delay clinical worsening. Which drug is most appropriate for her condition?", "options": {"A": "Ambrisentan administered once daily", "B": "Macitentan administered once daily", "C": "Sotatercept-csrk administered every three weeks", "D": "None of the above drugs are appropriate"}}
{"id": "GQjkblkg9lKd", "question_type": "open_ended", "question": "A 62-year-old woman with unresectable, metastatic non-squamous non-small cell lung carcinoma is found to have a HER2 (ERBB2) tyrosine kinase domain activating mutation by FDA-approved testing. She previously received platinum-based chemotherapy and has a history of mild hepatic steatosis but normal liver function tests. She is not pregnant and is not breastfeeding. Her current medications do not include any strong CYP3A inducers or BCRP substrates. Which drug regimen is most appropriate for her ongoing treatment, considering efficacy and safety for her specific tumor profile?", "options": {"A": "Etoposide administered intravenously every 3 weeks", "B": "Durvalumab (IMFINZI) as a single agent every 2 weeks", "C": "Zongertinib (HERNEXEOS) orally once daily with regular liver function monitoring", "D": "Durvalumab (IMFINZI) in combination with platinum-based chemotherapy"}}
{"id": "3RPuX6zhgpjz", "question_type": "open_ended_multi_choice", "question": "What should healthcare providers do if Imaavy is administered during pregnancy or if a patient becomes pregnant while receiving Imaavy?", "options": {"A": "Discontinue Imaavy immediately", "B": "Report Imaavy exposure to Janssen", "C": "Increase the dose of Imaavy", "D": "No action is required"}}
{"id": "KVAoV1Wd9Td7", "question_type": "open_ended_multi_choice", "question": "For a 45-year-old woman suffering from dry eye disease who wears contact lenses and prefers a treatment that does not require lens removal, is not pregnant, and has no history of ocular infections, which drug would be most appropriate given her preferences and adult safety data?", "options": {"A": "TRYPTYR", "B": "Lotemax SM", "C": "Xiidra", "D": "Topical corticosteroid drops (other than Lotemax SM)"}}
{"id": "jy7Ur9J2rL25", "question_type": "open_ended_multi_choice", "question": "If a patient undergoing treatment with Anzupgo presents with a new episode of herpes zoster, what should be the next clinical action?", "options": {"A": "Continue Anzupgo without interruption", "B": "Increase the dose of Anzupgo", "C": "Interrupt Anzupgo treatment until the episode resolves", "D": "Administer a live herpes zoster vaccine immediately"}}
{"id": "RcbkAzVmvGIT", "question_type": "multi_choice", "question": "A 34-year-old woman with newly diagnosed prurigo nodularis is 20 weeks pregnant. She is seeking treatment for her severe itching and is concerned about fetal safety. Which of the following is the most appropriate therapeutic approach for her condition?", "options": {"A": "Nalbuphine Hydrochloride injection for symptomatic relief, used routinely throughout pregnancy", "B": "NEMLUVIO administered every 4 weeks, with careful consideration of potential fetal exposure", "C": "NEMLUVIO combined with topical corticosteroids and live vaccines", "D": "Nalbuphine Hydrochloride injection during labor and delivery only"}}
{"id": "MhvjGTXSWKGz", "question_type": "open_ended_multi_choice", "question": "What is the recommended approach regarding Emrelis use in pediatric patients?", "options": {"A": "Emrelis is approved for pediatric use", "B": "Safety and effectiveness have not been established in pediatric patients", "C": "Emrelis should be used with dose adjustment in pediatric patients", "D": "Emrelis is contraindicated in pediatric patients"}}
{"id": "rXArag8jRK5o", "question_type": "open_ended_multi_choice", "question": "A 14-year-old boy diagnosed with hemophilia B, who has no prior history of liver or gallbladder disease and exhibits normal liver function tests, is being evaluated for routine prophylactic therapy to minimize bleeding episodes. With no contraindications present, which medication should be selected for this patient, and what is the reasoning behind this choice?", "options": {"A": "Hemlibra, administered subcutaneously once weekly", "B": "Qfitlia, administered according to antithrombin-based dosing regimen", "C": "Hemlibra, administered subcutaneously every four weeks", "D": "Qfitlia, administered at a fixed dose of 80 mg once monthly"}}
{"id": "Byfv5zkrKonZ", "question_type": "multi_choice", "question": "Which of the following is a recommended action when Romvimza is used concomitantly with a P-glycoprotein (P-gp) substrate and co-administration cannot be avoided?", "options": {"A": "Administer Romvimza at least 4 hours after the P-gp substrate.", "B": "Administer Romvimza at least 4 hours before the P-gp substrate.", "C": "Administer both drugs simultaneously.", "D": "Discontinue the P-gp substrate."}}
{"id": "PIANfpRfaBpL", "question_type": "open_ended", "question": "Which of the following is true regarding the contraindications for Hernexeos?", "options": {"A": "Hernexeos has no listed contraindications.", "B": "Hernexeos is contraindicated in patients with renal impairment.", "C": "Hernexeos should not be used in pregnancy.", "D": "Hernexeos is contraindicated in patients with hepatic failure."}}
{"id": "dr7gennveCg6", "question_type": "multi_choice", "question": "Which of the following statements best describes the embryo-fetal toxicity risk associated with Romvimza?", "options": {"A": "Romvimza only causes fetal harm at doses ten times the recommended human dose.", "B": "Romvimza is safe for use during pregnancy.", "C": "Romvimza has no effect on fetal development.", "D": "Romvimza can cause fetal harm based on animal studies and its mechanism of action."}}
{"id": "kl9yGGWr5VQZ", "question_type": "open_ended", "question": "A 6-year-old girl with polyneuropathy due to drug presents with progressive lower limb muscle weakness, bowel incontinence, and primary adrenal insufficiency. She is currently taking anticoagulant therapy for a separate condition. Her parents are seeking nutritional supplementation to support her overall health. Which of the following is the most appropriate recommendation regarding PNV-DHA supplementation?", "options": {"A": "Recommend PNV-DHA daily, as it is safe for all children needing nutritional support", "B": "Avoid PNV-DHA due to increased bleeding risk with concurrent anticoagulant therapy", "C": "Recommend Skysona gene therapy to address her nutritional needs", "D": "Recommend Actos for nutritional supplementation"}}
{"id": "3pQfmKRNEmxU", "question_type": "open_ended_multi_choice", "question": "When comparing the safety and effectiveness of Vizz in geriatric patients (65 years and older) to younger adults, what has been observed?", "options": {"A": "Geriatric patients experience significantly more adverse effects than younger adults.", "B": "Vizz is less effective in geriatric patients compared to younger adults.", "C": "No overall differences in safety or effectiveness have been observed between geriatric and younger adult patients.", "D": "Vizz is contraindicated in patients over 65 years of age."}}
{"id": "JEcF0sYIjInd", "question_type": "open_ended_multi_choice", "question": "A 72-year-old individual diagnosed with mild cognitive impairment attributed to Alzheimer’s disease is being evaluated for pharmacologic treatment. Genetic analysis indicates the patient is homozygous for the ApoE ε4 allele. The patient has no prior hypersensitivity, is not receiving antithrombotic medications, and brain MRI shows no microhemorrhages or superficial siderosis. What is the most suitable drug therapy for this patient?", "options": {"A": "Kisunla (donanemab-azbt), with enhanced clinical vigilance for ARIA and regular MRI monitoring", "B": "Kisunla (donanemab-azbt), without genetic testing or MRI monitoring", "C": "Kisunla (donanemab-azbt), contraindicated due to age", "D": "No drug therapy recommended due to ApoE ε4 homozygosity"}}
{"id": "fyWwcMdxi3gR", "question_type": "open_ended_multi_choice", "question": "A 15-year-old male with hemophilia A (congenital factor VIII deficiency) presents with frequent joint hemorrhages and prolonged partial thromboplastin time. He has no history of factor VIII inhibitors and is not taking any other medications. His physician is considering routine prophylaxis to prevent bleeding episodes. Which drug is most appropriate for this patient, considering age, indication, and safety profile?", "options": {"A": "MARSTACIMAB-HNCQ", "B": "Desmopressin Acetate", "C": "DARATUMUMAB AND HYALURONIDASE-FIHJ", "D": "Factor IX concentrate"}}
{"id": "bJGudMYDSbOZ", "question_type": "multi_choice", "question": "Why might concomitant use of Grafapex and certain CYP2C19 substrates increase the risk of serious or life-threatening toxicities?", "options": {"A": "Grafapex inhibits CYP2C19, increasing substrate exposure.", "B": "Grafapex induces CYP2C19, decreasing substrate exposure.", "C": "Grafapex has no effect on CYP2C19 metabolism.", "D": "Grafapex increases renal clearance of CYP2C19 substrates."}}
{"id": "JZnKTuwH8VWx", "question_type": "open_ended_multi_choice", "question": "A 60-year-old pregnant woman has BCG-unresponsive nonmuscle invasive bladder cancer with carcinoma in situ (CIS). She is otherwise healthy and has no prior bladder perforation or mucosal injury. Which treatment option should be avoided because of risk to the fetus?", "options": {"A": "Nogapendekin alfa inbakicept-pmln (ANKTIVA) with Bacillus Calmette-Guérin (BCG)", "B": "Valrubicin intravesical therapy", "C": "Observation with planned cystectomy after delivery", "D": "Valrubicin intravesical therapy with Bacillus Calmette-Guérin (BCG)"}}
{"id": "jyQUeiS1nzFg", "question_type": "multi_choice", "question": "Which of the following statements accurately reflects the stratification factors used for randomization in the AK105-304 trial of penpulimab-kcqx?", "options": {"A": "Stage of disease (primary metastatic vs. recurrent), ECOG Performance Status (0 vs. 1), and liver metastasis (present vs. absent)", "B": "Age, gender, and prior radiotherapy", "C": "PD-L1 expression, histological subtype, and prior chemotherapy lines", "D": "Tumor size, race, and ECOG Performance Status (2 vs. 3)"}}
{"id": "AnGA1djEaOlS", "question_type": "multi_choice", "question": "A 36-year-old woman with KRAS-mutated recurrent low-grade serous ovarian carcinoma is being considered for AVMAPKI FAKZYNJA CO-PACK (avutometinib and defactinib) therapy. She is currently pregnant and not taking any other medications. What is the most appropriate recommendation regarding her cancer treatment?", "options": {"A": "Delay AVMAPKI FAKZYNJA CO-PACK until after delivery due to risk of fetal harm.", "B": "Start AVMAPKI FAKZYNJA CO-PACK immediately, as it is the only approved therapy for her condition.", "C": "Start AVMAPKI FAKZYNJA CO-PACK but reduce the dose to minimize fetal exposure.", "D": "Switch to an alternative systemic therapy with a better safety profile in pregnancy."}}
{"id": "WDb5ssTdoTSG", "question_type": "open_ended_multi_choice", "question": "A patient who has recently been treated with Enflonsia is suspected by their clinician to have RSV infection, yet their rapid antigen test returns negative. What should be the clinician's next course of action?", "options": {"A": "Repeat the rapid antigen test", "B": "Initiate empirical antiviral therapy", "C": "Confirm diagnosis using an RT-PCR assay", "D": "Perform a chest X-ray"}}
{"id": "T3UGWyl08Fyk", "question_type": "open_ended_multi_choice", "question": "A 5-year-old child (weight 18 kg) presents with hypertension, tachycardia, and elevated urinary norepinephrine levels. Genetic testing confirms autosomal dominant inheritance of pheochromocytoma. Which of the following medications is NOT recommended for this patient due to lack of established safety and efficacy in pediatric populations?", "options": {"A": "Phenoxybenzamine Hydrochloride", "B": "Phentolamine Mesylate (OraVerse)", "C": "Metyrosine", "D": "None of the above"}}
{"id": "VDbU999aAnM2", "question_type": "multi_choice", "question": "Which of the following statements is correct regarding the use of food when taking Gomekli tablets for oral suspension?", "options": {"A": "Gomekli must be taken with food", "B": "Gomekli must be taken on an empty stomach", "C": "Gomekli can be taken with or without food", "D": "Gomekli should be mixed with food before administration"}}
{"id": "lQIq5U2fNnVW", "question_type": "open_ended_multi_choice", "question": "A 55-year-old male with a history of epilepsy and chronic kidney disease (eGFR 40 mL/min/1.73 m2) is admitted with acute bacterial skin and skin structure infection caused by methicillin-resistant Staphylococcus aureus (MRSA). He is currently taking phenytoin for seizure control. Which of the following is the most appropriate antibiotic therapy for this patient?", "options": {"A": "Doxycycline Hyclate, standard dosing without adjustment", "B": "Zevtera, with renal dose adjustment and monitoring for CNS effects", "C": "Rituximab and Hyaluronidase, as a single agent", "D": "Doxycycline Hyclate, with a drug holiday to reduce interaction risk"}}
{"id": "p9oKVDFZC8KK", "question_type": "open_ended", "question": "A 68-year-old man with a history of glaucoma and recurrent herpes simplex keratitis presents with symptoms of dry eye disease. He is not currently using contact lenses and has not had recent ocular surgery. Which of the following is the safest and most appropriate pharmacologic treatment for his dry eye disease?", "options": {"A": "Lotemax SM, administered as a corticosteroid ophthalmic gel twice daily", "B": "TRYPTYR, administered after ensuring no contact lens use", "C": "Lotemax SM, administered with close intraocular pressure monitoring", "D": "Lotemax SM, administered only during acute flare-ups"}}
{"id": "ntwLG2Zikhbd", "question_type": "open_ended_multi_choice", "question": "A 45-year-old woman with chronic immune thrombocytopenia and abnormal bleeding is currently breastfeeding her infant. She has previously responded inadequately to oral corticosteroids and now requires a new treatment. Which therapy is contraindicated for her due to her lactation status?", "options": {"A": "DMT SUIK (IV)", "B": "Prednisone", "C": "Rilzabrutinib", "D": "Dexamethasone sodium phosphate"}}
{"id": "VwwdsJIzBBSm", "question_type": "multi_choice", "question": "A 78-year-old man with mild Alzheimer’s disease and a history of severe hypersensitivity reaction to monoclonal antibodies is being considered for drug therapy. He is not taking any antithrombotic medications and has no evidence of cerebral amyloid angiopathy on MRI. Which drug option is most suitable for this patient?", "options": {"A": "KISUNLA (donanemab-azbt), as hypersensitivity reactions are rare and manageable.", "B": "KISUNLA, with pre-treatment using antihistamines and corticosteroids.", "C": "Avoid KISUNLA due to contraindication from hypersensitivity; consider alternative therapy if available.", "D": "KISUNLA, but only at a reduced dosage."}}
{"id": "47zBiVE6cL0j", "question_type": "open_ended_multi_choice", "question": "If a patient needs to take both Romvimza and an Organic Cation Transporter 2 (OCT2) substrate, what is the recommended management plan?", "options": {"A": "Refer to the prescribing information of the OCT2 substrate for dose modifications.", "B": "Increase the dose of Romvimza.", "C": "Administer Romvimza and the OCT2 substrate at the same time.", "D": "Discontinue the OCT2 substrate."}}
{"id": "8qlXOGz6MnWj", "question_type": "open_ended", "question": "Journavx is known to induce CYP3A. What is the clinical implication when Journavx is co-administered with sensitive CYP3A substrates?", "options": {"A": "No adjustment is necessary for the CYP3A substrate.", "B": "The CYP3A substrate may require dosage adjustment.", "C": "Journavx should be discontinued.", "D": "The CYP3A substrate should be replaced with a CYP2C9 substrate."}}
{"id": "ErFmdB0VrrAS", "question_type": "multi_choice", "question": "Which clinical action should be taken when Emrelis is prescribed together with a strong CYP3A inhibitor?", "options": {"A": "Discontinue Emrelis immediately", "B": "Monitor for increased risk of adverse reactions to Emrelis", "C": "Increase the dose of Emrelis", "D": "No action is required"}}
{"id": "3OQQMgVXMsAS", "question_type": "open_ended_multi_choice", "question": "A 58-year-old man presents with recurrent, metastatic non-keratinizing nasopharyngeal carcinoma. His medical history includes coronary artery disease and ongoing warfarin therapy for atrial fibrillation. When choosing a systemic therapy, which regimen is most appropriate considering both his oncologic and cardiovascular history?", "options": {"A": "Penpulimab-kcqx in combination with cisplatin and gemcitabine, administered every 3 weeks", "B": "Capecitabine 500 mg twice daily as monotherapy", "C": "Celecoxib 200 mg twice daily for pain management", "D": "Capecitabine 500 mg twice daily in combination with warfarin"}}
{"id": "Jo4s7UUMQwWB", "question_type": "multi_choice", "question": "Which of the following statements best describes the embryo-fetal toxicity risk associated with Romvimza?", "options": {"A": "Romvimza is contraindicated only in male patients.", "B": "Romvimza is safe for use during pregnancy.", "C": "Romvimza has no effect on fetal development.", "D": "Romvimza only causes fetal harm at doses ten times the recommended human dose."}}
{"id": "uYRGhb75C4wg", "question_type": "open_ended_multi_choice", "question": "If a Grade 3 infusion-related reaction occurs in a patient being treated with Penpulimab-kcqx, what is the appropriate course of action?", "options": {"A": "Interrupt or slow the rate of infusion", "B": "Withhold Penpulimab-kcqx and resume after resolution", "C": "Permanently discontinue Penpulimab-kcqx", "D": "Reduce the dose and continue infusion"}}
{"id": "OejwtWqhl2qj", "question_type": "open_ended", "question": "A pediatric patient, age 4, presents with complete scalp alopecia and is being considered for immunosuppressive therapy. The child has no history of autoimmune arthritis or transplantation. Which of the following best describes the appropriateness of ORENCIA for this patient’s condition?", "options": {"A": "ORENCIA is approved for alopecia totalis in children aged 2 years and older.", "B": "ORENCIA may be used off-label for alopecia totalis in pediatric patients.", "C": "ORENCIA is not indicated for alopecia totalis and should not be used for this patient.", "D": "ORENCIA is only approved for use in children with polyarticular juvenile idiopathic arthritis or psoriatic arthritis."}}
{"id": "w9FSSr9rTxfY", "question_type": "multi_choice", "question": "A 38-year-old female with schizophrenia and mild hepatic impairment (Child-Pugh Class A) is being considered for long-term antipsychotic therapy. She has no history of metabolic syndrome, renal impairment, or pregnancy. Which drug regimen is most appropriate for her?", "options": {"A": "Cobenfy (xanomeline and trospium chloride), standard adult dose", "B": "Abilify Maintena (aripiprazole), standard adult dose", "C": "Cobenfy (xanomeline and trospium chloride), reduced dose", "D": "Abilify Maintena (aripiprazole), reduced dose for elderly patients"}}
{"id": "2WZ0bRn8PeNK", "question_type": "open_ended_multi_choice", "question": "A 45-year-old man with primary biliary cholangitis and abnormal circulating lipid concentration is being considered for adjunctive therapy to address his dyslipidemia. He has mild renal impairment (eGFR 55 mL/min/1.73m²) and no evidence of cirrhosis or portal hypertension. He is currently taking statin therapy for hypercholesterolemia. Which drug regimen is most suitable for his lipid management?", "options": {"A": "Ocaliva 10 mg once daily", "B": "Livdelzi 10 mg once daily", "C": "Tricor 54 mg once daily with dose reduction for renal impairment", "D": "Tricor 145 mg once daily without dose adjustment"}}
{"id": "3ZBaDfy5jixF", "question_type": "multi_choice", "question": "A 35-year-old woman with pulmonary arterial hypertension is currently pregnant and presents for management of her PAH. She is concerned about the safety of her fetus and asks about drug therapy options. Which of the following is the most appropriate recommendation regarding drug therapy for her PAH?", "options": {"A": "Initiate Winrevair, as it is the first-line therapy for PAH", "B": "Avoid Winrevair due to embryo-fetal toxicity and advise against its use during pregnancy", "C": "Start epinephrine infusion to manage her PAH", "D": "Use vasopressin as a safe alternative for PAH in pregnancy"}}
{"id": "IFxIy9ynCws6", "question_type": "open_ended_multi_choice", "question": "A 52-year-old patient with cardiovascular risk factors is considering topical Anzupgo for hand eczema. Which statement best reflects the risk profile of Anzupgo in this context?", "options": {"A": "Anzupgo is associated with increased risk of death in patients with cardiovascular risk factors, similar to oral JAK inhibitors for rheumatoid arthritis.", "B": "Anzupgo is contraindicated in all patients over 50 years old.", "C": "It is unknown whether Anzupgo carries the same risk of increased mortality as oral JAK inhibitors used for rheumatoid arthritis.", "D": "Anzupgo is recommended over TNF blockers in patients with cardiovascular risk factors."}}
{"id": "Vq0K1H2efM1C", "question_type": "open_ended_multi_choice", "question": "What is currently known about the presence of Penpulimab-kcqx in human milk and its impact on infants who are breastfed?", "options": {"A": "Penpulimab-kcqx is known to be present in human milk and is safe for the breastfed child.", "B": "There is no information regarding the presence of Penpulimab-kcqx in human milk or its effects on the breastfed child.", "C": "Penpulimab-kcqx is contraindicated only if the child is under 6 months old.", "D": "Penpulimab-kcqx increases milk production."}}
{"id": "I9kHH9MWnfCC", "question_type": "open_ended_multi_choice", "question": "Which of the following best summarizes the safety and effectiveness of Blujepa in geriatric patients (≥65 years old) with uUTI?", "options": {"A": "Geriatric patients have a significantly higher risk of adverse reactions compared to younger adults.", "B": "No overall differences in safety or effectiveness were observed between geriatric and younger adult patients, but increased sensitivity in some older individuals cannot be ruled out.", "C": "Blujepa is not recommended for patients over 75 years old.", "D": "Blujepa is only approved for use in patients under 65 years old."}}
{"id": "TthBHoSQVyzD", "question_type": "multi_choice", "question": "A 7-year-old boy with Duchenne muscular dystrophy presents with progressive muscle weakness, elevated creatine kinase, and a history of arrhythmia. He is currently taking a medication known to prolong the QTc interval for his cardiac condition. Which drug regimen is most appropriate for treating his DMD, considering his cardiac profile and current medications?", "options": {"A": "Givinostat administered twice daily", "B": "Eteplirsen administered once weekly", "C": "Deflazacort administered daily", "D": "Givinostat with a planned drug holiday every month"}}
{"id": "MrqlJUckGrHF", "question_type": "multi_choice", "question": "A 29-year-old woman with moderate acute pain after orthopedic surgery is currently breastfeeding her newborn. She is not taking any CYP3A inhibitors or inducers, and her hepatic and renal function are normal. She requests pain relief that will not adversely affect her infant. Which drug is most suitable for her?", "options": {"A": "JOURNAVX at standard adult dosage", "B": "Pain Relief Childrens (acetaminophen-based OTC) at adult dosing", "C": "Ropivacaine Hydrochloride administered as a local infiltration", "D": "JOURNAVX with additional nonhormonal contraception"}}
{"id": "i8bOSLGevmVO", "question_type": "open_ended_multi_choice", "question": "A 35-year-old pregnant woman presents with a complicated urinary tract infection. She has no history of beta-lactam allergy, glaucoma, or seizure disorder. Her renal and hepatic function are normal. Which drug is the most suitable for treating her infection, considering pregnancy safety and efficacy?", "options": {"A": "Blujepa, administered according to standard dosing for complicated UTI.", "B": "Imipenem and Cilastatin Sodium intravenous therapy, following recommended dosing for adults.", "C": "Flavoxate Hydrochloride tablets for symptomatic relief only.", "D": "Flavoxate Hydrochloride combined with Blujepa for definitive treatment."}}
{"id": "i4kodePWhyh3", "question_type": "open_ended_multi_choice", "question": "A 45-year-old man with chronic obstructive pulmonary disease (COPD) is being treated with ritonavir, a potent CYP3A4 inhibitor, for a separate condition. He needs to begin maintenance treatment for his COPD. Which medication would pose the lowest risk of significant drug interactions or heightened adverse effects in this context?", "options": {"A": "Budesonide Inhalation", "B": "Fentanyl Citrate", "C": "Ensifentrine", "D": "Budesonide (oral)"}}
{"id": "SmXWr4khZSdx", "question_type": "open_ended_multi_choice", "question": "If anaphylaxis occurs in a patient who is currently receiving Enflonsia, what should be the clinician's initial response?", "options": {"A": "Initiate appropriate medications and/or supportive therapy", "B": "Discontinue all medications", "C": "Administer additional Enflonsia", "D": "Perform a rapid antigen test for RSV"}}
{"id": "sj5uIbutBT9Y", "question_type": "multi_choice", "question": "Which of the following is a recommended action when Romvimza is used concomitantly with a P-glycoprotein (P-gp) substrate and co-administration cannot be avoided?", "options": {"A": "Administer Romvimza at least 4 hours after the P-gp substrate.", "B": "Administer both drugs simultaneously.", "C": "Administer Romvimza at least 4 hours before the P-gp substrate.", "D": "Discontinue the P-gp substrate."}}
{"id": "NB2YKIwzGBGb", "question_type": "open_ended_multi_choice", "question": "A 12-year-old girl presents with primary axillary hyperhidrosis and a history of prostatic hypertrophy. She is currently taking a strong CYP2D6 inhibitor for another condition. Which topical treatment is most appropriate for her hyperhidrosis, considering her age, comorbidities, and current medications?", "options": {"A": "Qbrexza (glycopyrronium), applied once daily", "B": "Sofdra (sofpironium bromide), applied once daily", "C": "Oxytrol for Women (oxybutynin), transdermal patch twice weekly", "D": "No anticholinergic therapy is appropriate due to her age and comorbidities"}}
{"id": "Hb5slXf8RNc7", "question_type": "multi_choice", "question": "Which of the following statements is correct regarding the use of food when taking Gomekli tablets for oral suspension?", "options": {"A": "Gomekli must be taken with food", "B": "Gomekli can be taken with or without food", "C": "Gomekli must be taken on an empty stomach", "D": "Gomekli should be mixed with food before administration"}}
{"id": "3aYP6Gg4jgCB", "question_type": "open_ended_multi_choice", "question": "A 60-year-old man presents with presbyopia and seeks treatment for near vision improvement. He underwent retinal surgery for retinal detachment two years ago and has no iritis or drug allergies. Considering his history, which medication should be avoided and why?", "options": {"A": "Aceclidine", "B": "Brimonidine tartrate", "C": "Phentolamine mesylate", "D": "All are safe options"}}
{"id": "kTEpvX4AbDV0", "question_type": "open_ended_multi_choice", "question": "A 68-year-old patient diagnosed with prurigo nodularis presents for management. She has chronic obstructive pulmonary disease and is currently on a benzodiazepine for anxiety. She describes severe pruritus without significant pain. Given her health background and medication use, what is the most appropriate therapeutic approach?", "options": {"A": "NEMLUVIO administered subcutaneously every 4 weeks", "B": "Nalbuphine Hydrochloride injection for pain management, titrated slowly", "C": "Nalbuphine Hydrochloride injection combined with benzodiazepine, at standard dosing", "D": "NEMLUVIO combined with live vaccine administration during therapy"}}
{"id": "Fy5bOzns42uT", "question_type": "open_ended_multi_choice", "question": "A 67-year-old male with non-alcoholic steatohepatitis (NASH) and moderate (F2) liver fibrosis is being evaluated for pharmacologic treatment. He has mild renal dysfunction (eGFR 55 mL/min/1.73 m²) and is currently on atorvastatin 80 mg daily for hyperlipidemia. Taking into account potential drug interactions and necessary dose modifications, which medication regimen is most suitable for managing his NASH?", "options": {"A": "Resmetirom once daily with atorvastatin reduced to 40 mg daily", "B": "Pentoxifylline extended-release tablets twice daily with atorvastatin 80 mg daily", "C": "Resmetirom once daily with atorvastatin 80 mg daily", "D": "Dapagliflozin once daily with atorvastatin 80 mg daily"}}
{"id": "L7nu6e04OJeT", "question_type": "multi_choice", "question": "A 62-year-old man with hypotrichosis simplex, presenting with sparse eyelashes and eyebrows, is considering treatment to improve eyelash growth. He wears soft contact lenses daily and is concerned about potential lens discoloration. Which treatment regimen best addresses his concerns?", "options": {"A": "Bimatoprost ophthalmic solution 0.03% once daily, with contact lenses left in during administration", "B": "LUMIGAN (bimatoprost ophthalmic solution 0.01%) once daily, with contact lenses removed before administration and reinserted after 15 minutes", "C": "LUMIGAN (bimatoprost ophthalmic solution 0.01%) once daily, with contact lenses left in during administration", "D": "Bimatoprost ophthalmic solution 0.03% once daily, with contact lenses removed before administration and reinserted after 30 minutes"}}
{"id": "yVFTAR5nVkmL", "question_type": "multi_choice", "question": "A 62-year-old man with metastatic non-small cell lung carcinoma (NSCLC) presents for second-line therapy. His tumor is non-squamous, shows high c-Met protein overexpression (≥50% of tumor cells with strong staining), and he has a history of mild hepatic impairment (total bilirubin ≤ULN and AST >ULN). He is not taking any CYP3A inhibitors. Which drug regimen is most appropriate for this patient, considering his tumor profile and hepatic function?", "options": {"A": "Ipilimumab in combination with nivolumab", "B": "Ipilimumab monotherapy", "C": "Entrectinib (Rozlytrek)", "D": "Telisotuzumab vedotin (EMRELIS)"}}
{"id": "IwRT3osyHIBt", "question_type": "open_ended_multi_choice", "question": "A 38-year-old male with HIV wasting syndrome is currently being treated with warfarin for a history of deep vein thrombosis. He has no significant hepatic or renal dysfunction. His physician is considering adjunctive pharmacologic therapy to address his muscle wasting. Which of the following is the most appropriate drug to initiate, considering his current medications and the need for close monitoring?", "options": {"A": "Oxandrolone, with careful INR monitoring and warfarin dose adjustment", "B": "XYOSTED, with no need for anticoagulation monitoring", "C": "Thalomid, as it does not interact with warfarin and is safe in HIV", "D": "Oxandrolone, without any need for INR monitoring"}}
{"id": "0mF5Rt9B28Hk", "question_type": "open_ended_multi_choice", "question": "A 32-year-old woman with malignant mesenchymoma is currently pregnant and requires chemotherapy. She is not breastfeeding and has no significant comorbidities. Which of the following drugs is contraindicated due to the risk of fetal harm, and should be strictly avoided in this patient?", "options": {"A": "Leukine administered with benzyl alcohol-free formulation", "B": "HYCAMTIN administered as per standard dosing", "C": "Vincristine Sulfate administered intravenously", "D": "Leukine administered for hematopoietic support"}}
{"id": "QSg4c2rQCWhw", "question_type": "multi_choice", "question": "If Journavx is co-administered with a moderate CYP3A inhibitor, what adjustment should be made?", "options": {"A": "Increase the dose of Journavx.", "B": "No adjustment is necessary.", "C": "Discontinue the CYP3A inhibitor.", "D": "Reduce the dose of Journavx."}}
{"id": "O9TTljnjFSUP", "question_type": "multi_choice", "question": "A patient with moderate hepatic impairment (Child-Pugh Class B) is being considered for treatment with Journavx. What adjustment should be made to the dosing regimen?", "options": {"A": "Increase the dosage compared to patients with normal hepatic function.", "B": "Use the same dosage as patients with normal hepatic function.", "C": "Use a lower dosage than in patients with normal hepatic function.", "D": "Avoid use of Journavx entirely."}}
{"id": "xNCoRc7sxnmL", "question_type": "multi_choice", "question": "Which of the following statements best describes the status of carcinogenicity studies for the drug Lynozyfic?", "options": {"A": "Carcinogenicity studies have been completed and showed no risk.", "B": "Carcinogenicity studies are ongoing for Lynozyfic.", "C": "No carcinogenicity studies have been conducted with Lynozyfic.", "D": "Carcinogenicity studies have shown a significant risk for Lynozyfic."}}
{"id": "DbHINIhpJHgZ", "question_type": "open_ended_multi_choice", "question": "A 12-year-old girl with BH4-responsive PKU, elevated blood phenylalanine, eczema, and microcephaly is being treated with methylphenidate for ADHD and methotrexate for juvenile idiopathic arthritis. Considering her current treatments and health status, which drug regimen should be chosen to best reduce her blood phenylalanine levels?", "options": {"A": "Sephience administered daily with a phenylalanine-restricted diet", "B": "Sapropterin dihydrochloride administered daily with a phenylalanine-restricted diet", "C": "JAVYGTOR administered daily with a phenylalanine-restricted diet", "D": "Sephience administered every other day with a phenylalanine-restricted diet"}}
{"id": "OGHFJYHrcglf", "question_type": "open_ended_multi_choice", "question": "When considering Qfitlia therapy for a hemophilia patient with prior symptomatic gallbladder disease, which clinical recommendation is most appropriate?", "options": {"A": "Consider alternative treatment for hemophilia", "B": "Increase Qfitlia dose", "C": "Monitor only for thrombotic events", "D": "Continue Qfitlia without modification"}}
{"id": "WBvY04FsYbyf", "question_type": "open_ended_multi_choice", "question": "A 38-year-old female patient diagnosed with metastatic non-squamous non-small cell lung carcinoma and a confirmed HER2 (ERBB2) tyrosine kinase domain activating mutation is considering pregnancy. Having completed all prior systemic therapy and being otherwise healthy, what is the most appropriate course of treatment for her now?", "options": {"A": "Initiate Zongertinib immediately", "B": "Start Atezolizumab as monotherapy", "C": "Delay Zongertinib therapy until pregnancy status is clarified and effective contraception is in place", "D": "Begin Imfinzi in combination with platinum-based chemotherapy"}}
{"id": "y549UiwW0gX9", "question_type": "multi_choice", "question": "What is the observed difference in safety or effectiveness of Emrelis between older (≥65 years) and younger patients with previously treated EGFR wild-type non-squamous NSCLC with c-Met protein overexpression?", "options": {"A": "Older patients have significantly higher adverse events", "B": "Younger patients have better effectiveness", "C": "Emrelis is contraindicated in older patients", "D": "Older patients require dose adjustment"}}
{"id": "ShVcsKfinRRp", "question_type": "open_ended_multi_choice", "question": "A 60-year-old male with generalized myasthenia gravis, anti-acetylcholine receptor antibody positive, also has chronic hepatitis and is currently receiving ribavirin therapy. He is being considered for immunosuppressive therapy. Which drug should be avoided due to the risk of severe pancytopenia and myelotoxicity from drug interactions?", "options": {"A": "IMAAVY, 15 mg/kg intravenous infusion every 2 weeks", "B": "Azathioprine, 100 mg daily oral administration", "C": "DuoDote, single dose for acute management", "D": "IMAAVY, 10 mg/kg intravenous infusion every 4 weeks"}}
{"id": "p7CkBqTaiGlZ", "question_type": "open_ended_multi_choice", "question": "A 7-year-old patient diagnosed with relapsed acute erythroleukemia and a KMT2A translocation presents with anemia, thrombocytopenia, and hepatomegaly. The child has a normal ECG and is not taking any medications affecting QTc interval. Which therapy is most appropriate to initiate, factoring in the patient's age, genetic findings, and safety profile?", "options": {"A": "Revuforj administered twice daily, with BSA-based dosing for pediatric patients", "B": "Aldesleukin administered intravenously in a hospital setting", "C": "Dexamethasone administered as adjunctive palliative therapy", "D": "TaperDex 6-day oral regimen at standard adult dosing"}}
{"id": "GGAGeBA709SO", "question_type": "open_ended_multi_choice", "question": "Which medication should be selected for long-term prophylaxis in a 7-year-old with hereditary angioedema, who has no history of allergic reactions and is not receiving anticoagulants, based on age appropriateness and current indications?", "options": {"A": "Kalbitor", "B": "ANDEMBRY", "C": "TAKHZYRO", "D": "No drug is appropriate for this patient"}}
{"id": "zdh5WtMzjYtt", "question_type": "open_ended", "question": "When co-administering Ibtrozi with a drug known to prolong the QTc interval, what additional clinical management should be considered?", "options": {"A": "No additional monitoring is required", "B": "Increase the frequency of QTc interval monitoring", "C": "Administer a CYP3A inhibitor", "D": "Discontinue all acid-reducing agents"}}
{"id": "RlRsMayeq3AS", "question_type": "multi_choice", "question": "A 35-year-old pregnant woman is diagnosed with low-grade glioma. She is seeking treatment options that minimize risk to her fetus. Genetic testing reveals no BRAF fusion or V600 mutation. Which of the following therapies is contraindicated for her due to pregnancy risk and lack of efficacy for her tumor profile?", "options": {"A": "OJEMDA, as a kinase inhibitor targeting BRAF mutations, administered orally.", "B": "VinCRIStine Sulfate, administered intravenously, with risk of fetal harm.", "C": "Gliadel Wafer, implanted during surgery, with known embryo-fetal toxicity.", "D": "Supportive care only, deferring cytotoxic or targeted therapy until after pregnancy."}}
{"id": "ZeiBkQ3Xg61i", "question_type": "open_ended_multi_choice", "question": "For a 60-year-old woman who is pregnant and diagnosed with BCG-unresponsive NMIBC with CIS, and who has no history of bladder perforation or mucosal compromise, which therapy poses a contraindication due to potential harm to her unborn child?", "options": {"A": "Nogapendekin alfa inbakicept-pmln (ANKTIVA) with Bacillus Calmette-Guérin (BCG)", "B": "Valrubicin intravesical therapy", "C": "Observation with planned cystectomy after delivery", "D": "Valrubicin intravesical therapy with Bacillus Calmette-Guérin (BCG)"}}
{"id": "afC3xktK9Hmy", "question_type": "multi_choice", "question": "A 35-year-old woman with chronic hypoparathyroidism is currently pregnant and requires ongoing management of her condition. She is not on dialysis and has no history of skeletal malignancies, radiation therapy, or metabolic bone disease other than hypoparathyroidism. Which drug is the most appropriate for her treatment, considering fetal safety and established data for use in pregnancy?", "options": {"A": "Yorvipath", "B": "Ergocalciferol", "C": "Calcitriol", "D": "Palopegteriparatide"}}
{"id": "nNclQKCFLN8W", "question_type": "open_ended_multi_choice", "question": "In a 6-month carcinogenicity study using Tg.rasH2 mice, what was the observed effect of Sephience on tumor incidence at exposures approximately 12- and 16-fold higher than the human exposure at the MRHD?", "options": {"A": "Sephience increased the incidence of tumors in male mice only.", "B": "Sephience increased the incidence of tumors in female mice only.", "C": "Sephience increased the incidence of tumors in both male and female mice.", "D": "Sephience did not increase the incidence of tumors in either male or female mice."}}
{"id": "05HcmQQipD2C", "question_type": "multi_choice", "question": "A 32-year-old woman with chronic graft-versus-host disease (cGVHD) and symptoms of myalgia, nail dystrophy, and recurrent infections is currently pregnant. She has failed two prior lines of systemic therapy. Her weight is 58 kg. Which drug should be avoided due to her pregnancy status?", "options": {"A": "AXATILIMAB-CSFR", "B": "Budesonide Inhalation", "C": "PredniSONE Tablets, USP, 5 mg", "D": "Low-dose Budesonide Inhalation"}}
{"id": "1rlVqy3J1bYK", "question_type": "multi_choice", "question": "For the drug Lynozyfic, what is known about its effects on fertility based on animal studies?", "options": {"A": "Animal studies have shown Lynozyfic impairs fertility.", "B": "Animal studies have shown Lynozyfic improves fertility.", "C": "No animal studies have been performed to evaluate the effects of Lynozyfic on fertility.", "D": "Animal studies are currently underway to assess fertility effects."}}
{"id": "8XLiHbv8oZUu", "question_type": "open_ended_multi_choice", "question": "In the event that a patient on Ibtrozi presents with a QTc interval over 500 msec or a rise greater than 60 msec compared to baseline, what is the appropriate clinical response?", "options": {"A": "Continue Ibtrozi at the same dose", "B": "Reduce the dose of Ibtrozi", "C": "Withhold Ibtrozi", "D": "Switch to a CYP3A inducer"}}
{"id": "FNy3xWcLJPAN", "question_type": "open_ended_multi_choice", "question": "A 68-year-old female patient with mild Alzheimer’s dementia is breastfeeding her infant. She reports no hypersensitivity reactions and is not taking antithrombotic agents. What is the most appropriate drug therapy approach for her situation?", "options": {"A": "Kisunla (donanemab-azbt), after weighing the benefits of treatment against potential unknown risks to the breastfed infant", "B": "Kisunla (donanemab-azbt), contraindicated due to breastfeeding", "C": "Kisunla (donanemab-azbt), recommended only if the patient is not breastfeeding", "D": "No drug therapy recommended for Alzheimer’s disease in breastfeeding women"}}
{"id": "sYbo0qWf36Rw", "question_type": "open_ended_multi_choice", "question": "What did the ASPEN trial reveal about the rates of skin cancers among subjects treated with Brinsupri 25 mg compared to those in the placebo group?", "options": {"A": "Higher in Brinsupri 25 mg group", "B": "Lower in Brinsupri 25 mg group", "C": "Equal in both groups", "D": "Not reported"}}
{"id": "nKehQCwuLiFp", "question_type": "open_ended_multi_choice", "question": "A 55-year-old man with epilepsy managed on phenytoin and chronic kidney disease (eGFR 40 mL/min/1.73 m2) presents with an acute skin infection due to methicillin-resistant Staphylococcus aureus (MRSA). What is the most suitable antibiotic regimen for him?", "options": {"A": "Doxycycline Hyclate, standard dosing without adjustment", "B": "Zevtera, with renal dose adjustment and monitoring for CNS effects", "C": "Rituximab and Hyaluronidase, as a single agent", "D": "Doxycycline Hyclate, with a drug holiday to reduce interaction risk"}}
{"id": "gTvNruuWPqLS", "question_type": "open_ended_multi_choice", "question": "A 62-year-old man with metastatic non-small cell lung cancer (NSCLC) has a tumor that is PD-L1 positive (≥1%) and negative for EGFR and ALK mutations. He has a history of autoimmune thyroiditis and is currently euthyroid on levothyroxine. He is not pregnant and has normal hepatic function. Which of the following therapies is most appropriate for his first-line treatment?", "options": {"A": "CYRAMZA (ramucirumab) in combination with docetaxel every 3 weeks", "B": "ENSACOVE (ensartinib) 225 mg orally once daily", "C": "YERVOY (ipilimumab) in combination with nivolumab every 6 weeks", "D": "CYRAMZA (ramucirumab) in combination with erlotinib every 2 weeks"}}
{"id": "D3chkzalkZhl", "question_type": "open_ended_multi_choice", "question": "If a patient using Vizz experiences episodes of temporary dim or dark vision, what precaution is recommended?", "options": {"A": "Avoid night driving and hazardous activities in poor illumination.", "B": "Increase screen time to improve vision adaptation.", "C": "Take Vizz only in the morning.", "D": "Wear sunglasses indoors."}}
{"id": "WI0I3cFZdER2", "question_type": "open_ended_multi_choice", "question": "A 35-year-old female patient with obstructive hypertrophic cardiomyopathy (NYHA class II) is seeking pharmacologic treatment. She plans to conceive within the next year and is on a combined hormonal contraceptive with a progestin other than norethindrone. Which drug is contraindicated due to its risk profile in women of childbearing age?", "options": {"A": "Metoprolol Tartrate", "B": "Acoramidis Hydrochloride", "C": "Mavacamten", "D": "Diltiazem"}}
{"id": "r1se5TvGQMMP", "question_type": "open_ended_multi_choice", "question": "A woman aged 35 presents with moderate-to-severe atopic dermatitis characterized by persistent pruritus, erythema on the face, and lichenification in flexural regions. She reports food intolerance and has high circulating IgE levels. Previous use of topical corticosteroids failed to control her symptoms. She is not pregnant, has no active infections, and is not receiving immunosuppressive therapy. Which pharmacologic regimen should be recommended for her continued management?", "options": {"A": "DMT SUIK administered intravenously every 2 weeks for systemic control", "B": "Doxepin hydrochloride cream applied topically for up to 8 days for pruritus relief", "C": "Lebrikizumab-lbkz administered subcutaneously every 2 weeks as a targeted therapy", "D": "Doxepin hydrochloride cream applied daily for 3 months for long-term control"}}
{"id": "ENKN9YVFLgpZ", "question_type": "open_ended_multi_choice", "question": "A 38-year-old pregnant woman with metastatic HR-positive, HER2-negative breast cancer, who has previously undergone endocrine therapy and chemotherapy and has normal renal and hepatic function, is considering her treatment options. Which medication listed below carries a risk of embryo-fetal harm and should therefore be avoided?", "options": {"A": "Ketorolac Tromethamine", "B": "DATROWAY", "C": "MVASI", "D": "All of the above"}}
{"id": "5bmcYtLmt5vs", "question_type": "multi_choice", "question": "How did Vanrafia perform compared to placebo in terms of percent reduction in UPCR at Week 36 in the main cohort of the ALIGN study?", "options": {"A": "Vanrafia achieved a 15% reduction versus 10% for placebo", "B": "Vanrafia achieved a 3% reduction versus 38% for placebo", "C": "Vanrafia achieved a 38% reduction versus 3% for placebo", "D": "Vanrafia achieved a 26% reduction versus 45% for placebo"}}
{"id": "vwkh7Z0Xe7ed", "question_type": "multi_choice", "question": "A 78-year-old man with mild Alzheimer’s disease and a history of severe hypersensitivity reaction to monoclonal antibodies is being considered for drug therapy. He is not taking any antithrombotic medications and has no evidence of cerebral amyloid angiopathy on MRI. Which drug option is most suitable for this patient?", "options": {"A": "KISUNLA (donanemab-azbt), as hypersensitivity reactions are rare and manageable.", "B": "KISUNLA, with pre-treatment using antihistamines and corticosteroids.", "C": "KISUNLA, but only at a reduced dosage.", "D": "Avoid KISUNLA due to contraindication from hypersensitivity; consider alternative therapy if available."}}
{"id": "BrtqTpcZ2iOj", "question_type": "open_ended_multi_choice", "question": "A 9-year-old child with neurofibromatosis type 1 presents with symptomatic plexiform neurofibromas that are not amenable to complete resection. The patient also has a history of visual impairment and abnormal electroretinogram. The physician is considering drug therapy and wants to minimize the risk of further ocular toxicity. Which of the following is the most appropriate drug for this patient?", "options": {"A": "Celecoxib", "B": "Gomekli", "C": "PNV-DHA", "D": "No drug therapy is appropriate due to ocular risk"}}
{"id": "nLltGRbEa531", "question_type": "open_ended", "question": "Which of the following is a recommended action if a patient misses a scheduled dose of Qfitlia?", "options": {"A": "Skip the dose and wait until the next scheduled dose", "B": "Double the next dose", "C": "Give the missed dose as soon as possible, then resume the regular dosing schedule", "D": "Discontinue Qfitlia permanently"}}
{"id": "8JrgR9UMKLqC", "question_type": "multi_choice", "question": "When considering pharmacological therapy for presbyopia in adults, which brand drug acts as a cholinergic agonist?", "options": {"A": "Vizz", "B": "Timoptic", "C": "Xalatan", "D": "Alrex"}}
{"id": "gW9m7Rsv4Y73", "question_type": "open_ended", "question": "A patient receiving Lynozyfic develops an absolute neutrophil count less than 0.5 × 10^9/L. What is the recommended action?", "options": {"A": "Continue Lynozyfic without interruption", "B": "Withhold Lynozyfic until absolute neutrophil count is 0.5 × 10^9/L or higher", "C": "Increase the dose of Lynozyfic", "D": "Switch to oral Lynozyfic"}}
{"id": "qakR861UumGf", "question_type": "open_ended_multi_choice", "question": "Which contraceptive guidance should be followed by patients with pregnancy potential who are taking Vanrafia?", "options": {"A": "No contraception is needed", "B": "Use contraception only during treatment", "C": "Use effective contraception prior to, during, and for two weeks after discontinuation of Vanrafia", "D": "Use contraception for one month after discontinuation"}}
{"id": "LVj1rnhyf2Xi", "question_type": "open_ended_multi_choice", "question": "A 38-year-old woman diagnosed with symptomatic TGCT, unsuitable for surgical intervention, is currently breastfeeding and intends to maintain lactation after therapy. She has normal hepatic and renal parameters, is not pregnant, and reports no allergies. Which medication and breastfeeding plan should be recommended?", "options": {"A": "Turalio, with breastfeeding resumed 1 week after final dose", "B": "ROMVIMZA, with breastfeeding resumed 1 week after final dose", "C": "ROMVIMZA, with breastfeeding resumed 1 month after final dose", "D": "Turalio, with breastfeeding resumed 1 month after final dose"}}
{"id": "NeC9cDyNqg7K", "question_type": "multi_choice", "question": "A 35-year-old woman with hereditary angioedema is planning to become pregnant and requires prophylactic therapy. She is concerned about fetal safety and prefers a medication with reassuring animal data and minimal warnings. Which prophylactic agent is most appropriate based on available safety information?", "options": {"A": "Kalbitor", "B": "ANDEMBRY", "C": "TAKHZYRO", "D": "None of the above"}}
{"id": "v48IPoLgnWQO", "question_type": "multi_choice", "question": "Which of the following best describes the rationale for avoiding Blujepa in patients with severe hepatic impairment?", "options": {"A": "Risk of hepatotoxicity due to drug accumulation", "B": "Blujepa is not metabolized by the liver", "C": "Lack of efficacy in this population", "D": "Increased exposure to gepotidacin and risk of QTc prolongation"}}
{"id": "YLy67pD0COFQ", "question_type": "open_ended_multi_choice", "question": "A 58-year-old woman with a past myocardial infarction and type 2 diabetes is prescribed antiplatelet therapy to minimize the chance of recurrent cardiovascular events. She has moderate liver impairment and is receiving simvastatin 40 mg daily for dyslipidemia. Which antiplatelet medication is most appropriate for her current management?", "options": {"A": "BRILINTA", "B": "Clopidogrel", "C": "Flyrcado", "D": "BRILINTA with simvastatin 80 mg"}}
{"id": "rMe0tFPygIqg", "question_type": "open_ended_multi_choice", "question": "Prior to beginning Wayrilz treatment in females of reproductive age, what is the recommended protocol for pregnancy testing?", "options": {"A": "Pregnancy testing is not necessary.", "B": "Verify pregnancy status prior to initiating Wayrilz treatment.", "C": "Pregnancy testing should be done only after starting Wayrilz.", "D": "Pregnancy testing is required only if symptoms of pregnancy appear."}}
{"id": "3721g0MhXOhg", "question_type": "open_ended_multi_choice", "question": "What should patients be advised to do if they experience signs or symptoms of hypersensitivity while taking Modeyso?", "options": {"A": "Seek immediate medical attention.", "B": "Skip the next dose and monitor symptoms.", "C": "Take an antihistamine and continue Modeyso.", "D": "Reduce the dose by half."}}
{"id": "5cQtlj5hGw6C", "question_type": "multi_choice", "question": "A 78-year-old man with mild Alzheimer’s disease and a history of severe hypersensitivity reaction to monoclonal antibodies is being considered for drug therapy. He is not taking any antithrombotic medications and has no evidence of cerebral amyloid angiopathy on MRI. Which drug option is most suitable for this patient?", "options": {"A": "Avoid KISUNLA due to contraindication from hypersensitivity; consider alternative therapy if available.", "B": "KISUNLA, with pre-treatment using antihistamines and corticosteroids.", "C": "KISUNLA (donanemab-azbt), as hypersensitivity reactions are rare and manageable.", "D": "KISUNLA, but only at a reduced dosage."}}
{"id": "fe5c6lGWJ8Cl", "question_type": "multi_choice", "question": "A patient receiving penpulimab-kcqx in combination with cisplatin and gemcitabine develops new-onset hyperglycemia and is diagnosed with type 1 diabetes mellitus. What is the recommended management?", "options": {"A": "Initiate insulin therapy as clinically indicated and withhold penpulimab-kcqx depending on severity", "B": "Continue penpulimab-kcqx and monitor glucose only", "C": "Switch to oral hypoglycemic agents", "D": "Discontinue all cancer therapy"}}
{"id": "82ZYiE1NwyN6", "question_type": "open_ended", "question": "A 45-year-old man with chronic dry eye disease wears contact lenses daily and seeks treatment for his symptoms. He has no history of ocular surgery, glaucoma, or infections. Which medication is most suitable for his condition, considering his use of contact lenses?", "options": {"A": "TRYPTYR (acoltremon ophthalmic solution), one drop in affected eye(s) twice daily", "B": "Lotemax SM (loteprednol etabonate ophthalmic gel) 0.38%, one drop in affected eye(s) twice daily", "C": "Xiidra (lifitegrast ophthalmic solution) 5%, one drop in affected eye(s) twice daily", "D": "Lotemax SM (loteprednol etabonate ophthalmic gel) 0.38%, one drop in affected eye(s) once daily"}}
{"id": "G8AgdPRBrR3U", "question_type": "open_ended_multi_choice", "question": "A 28-year-old woman with Niemann-Pick disease type C and neurological symptoms is planning to become pregnant. She currently has normal renal function and is not taking any OCT2 substrate medications. Which of the following is the most appropriate recommendation regarding drug therapy for her NPC?", "options": {"A": "Initiate MIPLYFFA in combination with miglustat immediately", "B": "Delay MIPLYFFA and miglustat therapy until after pregnancy due to risk of embryofetal harm", "C": "Start OPFOLDA in combination with Pombiliti", "D": "Begin lithium carbonate therapy"}}
{"id": "Owyf29rHIYEt", "question_type": "open_ended_multi_choice", "question": "A woman aged 34 with paroxysmal nocturnal hemoglobinuria (PNH) is experiencing ongoing extravascular hemolysis (EVH) while on ravulizumab therapy. Her hyperlipidemia is controlled with daily rosuvastatin 10 mg. She has no hepatic impairment and is not pregnant. To address her EVH, what is the most appropriate modification to her current drug therapy?", "options": {"A": "Add Voydeya to her current ravulizumab regimen, monitoring for statin-related adverse effects.", "B": "Switch to sirolimus monotherapy.", "C": "Increase the dose of rosuvastatin above 10 mg daily while continuing ravulizumab.", "D": "Discontinue ravulizumab and start Voydeya monotherapy."}}
{"id": "gF7SsaHbjfDx", "question_type": "open_ended_multi_choice", "question": "A 62-year-old man with unresectable esophageal squamous cell carcinoma, PD-L1 CPS of 2, and mild elevations in liver enzymes (AST 1.7 × ULN, ALT 1.6 × ULN, alkaline phosphatase 2.7 × ULN) presents with chest pain, cough, and lymphadenopathy. He is about to begin first-line systemic treatment. Which initial drug regimen should be selected for him?", "options": {"A": "Tevimbra in combination with platinum-containing chemotherapy, administered every 3 weeks", "B": "Docetaxel anhydrous monotherapy, administered every 3 weeks", "C": "Keytruda QLEX in combination with platinum- and fluoropyrimidine-based chemotherapy, administered every 3 weeks", "D": "Docetaxel anhydrous in combination with cisplatin and fluorouracil, administered every 3 weeks"}}
{"id": "OhhggN7YRcCi", "question_type": "open_ended_multi_choice", "question": "Given a 46-year-old female patient with metastatic breast cancer who is hormone receptor-positive, HER2-negative, and harbors a PIK3CA mutation, and who also has moderate renal impairment (eGFR 45 mL/min), is not pregnant, and is not breastfeeding: Which targeted therapy regimen would be most appropriate, taking into account her renal function and the need for dose modification?", "options": {"A": "Inavolisib in combination with palbociclib and fulvestrant, with reduced dosage", "B": "Carboplatin at standard dosage", "C": "Esketamine in conjunction with an oral antidepressant", "D": "Carboplatin in combination with aminoglycosides"}}
{"id": "dWg9ghKSxeFW", "question_type": "multi_choice", "question": "A 45-year-old woman with newly diagnosed presbyopia is considering pharmacological treatment. She has a history of severe allergic reactions to cholinergic agonists. She does not have cardiovascular disease, is not pregnant, and does not use contact lenses. Which drug should be avoided due to her allergy, and which is the most suitable alternative among the listed options?", "options": {"A": "Aceclidine should be avoided; no suitable alternative among listed drugs", "B": "Aceclidine should be avoided; Phentolamine mesylate is suitable", "C": "Aceclidine should be avoided; Brimonidine tartrate is suitable", "D": "Aceclidine is safe; Brimonidine tartrate is suitable"}}
{"id": "jRIL8CEyZrxf", "question_type": "multi_choice", "question": "A 35-year-old woman presents with complete scalp hair loss and is diagnosed with alopecia totalis. She has a history of moderately active rheumatoid arthritis and is currently receiving ORENCIA (abatacept) infusions every 4 weeks. Her physician is considering additional immunosuppressive therapy to address her alopecia. Which of the following is the most appropriate recommendation regarding her drug regimen?", "options": {"A": "Add a TNF antagonist to her current ORENCIA therapy.", "B": "Continue ORENCIA alone and avoid adding other biologic immunosuppressants.", "C": "Add a JAK inhibitor concurrently with ORENCIA.", "D": "Switch from ORENCIA to a combination of methotrexate and a TNF antagonist."}}
{"id": "OQU3Bwbl03Ad", "question_type": "open_ended_multi_choice", "question": "In the event of a Grade 3 infusion-related reaction during Penpulimab-kcqx administration, what is the recommended action?", "options": {"A": "Interrupt or slow the rate of infusion", "B": "Withhold Penpulimab-kcqx and resume after resolution", "C": "Permanently discontinue Penpulimab-kcqx", "D": "Reduce the dose and continue infusion"}}
{"id": "CUgUTNLGLwsi", "question_type": "open_ended_multi_choice", "question": "A 7-year-old boy with hemophilia B presents with recurrent joint hemorrhage and bruising susceptibility. He has no history of factor IX inhibitors and requires routine prophylaxis to reduce the frequency of bleeding episodes. Which drug regimen is most appropriate for this patient, considering his age and clinical profile?", "options": {"A": "HYMPAVZI, administered weekly for routine prophylaxis", "B": "REBINYN, administered weekly for routine prophylaxis", "C": "SEVENFACT, administered for routine prophylaxis", "D": "HYMPAVZI, administered only during bleeding episodes"}}
{"id": "TezQq7TFNbdo", "question_type": "open_ended_multi_choice", "question": "For a 38-year-old woman with symptomatic TGCT who cannot undergo surgery, is breastfeeding and wants to continue after treatment, with normal liver and kidney function, no allergies, and not pregnant, what is the optimal drug choice and schedule for resuming breastfeeding?", "options": {"A": "Turalio, with breastfeeding resumed 1 week after final dose", "B": "ROMVIMZA, with breastfeeding resumed 1 week after final dose", "C": "ROMVIMZA, with breastfeeding resumed 1 month after final dose", "D": "Turalio, with breastfeeding resumed 1 month after final dose"}}
{"id": "e8q4wyKTkl7z", "question_type": "open_ended_multi_choice", "question": "A patient on Blujepa reports watery diarrhea, abdominal cramps, and fever one month after completing therapy. What is the most appropriate next step?", "options": {"A": "Advise the patient to take over-the-counter antidiarrheal medication", "B": "Reassure the patient that diarrhea is a common side effect and will resolve", "C": "Evaluate for Clostridioides difficile infection and avoid antidiarrheal agents until assessed", "D": "Discontinue Blujepa immediately"}}
{"id": "nXBenoJVJ8QJ", "question_type": "open_ended_multi_choice", "question": "A 68-year-old woman with acute erythroleukemia and refractory anemia with ringed sideroblasts is being considered for drug therapy. She has a history of congestive heart failure and is currently taking a medication known to prolong QTc interval. Genetic testing does not show a KMT2A translocation. Which drug regimen is most suitable for her, considering her age, cardiac history, and current medications?", "options": {"A": "Revuforj, twice daily at standard adult dosing", "B": "Aldesleukin administered intravenously in an intensive care setting", "C": "TaperDex 6-day oral regimen, starting at the low end of the dosing range", "D": "Revuforj, with dose reduction due to QTc-prolonging drug interaction"}}
{"id": "kGhAciI34XLa", "question_type": "multi_choice", "question": "What is the observed difference in safety or effectiveness of Emrelis between older (≥65 years) and younger patients with previously treated EGFR wild-type non-squamous NSCLC with c-Met protein overexpression?", "options": {"A": "Older patients have significantly higher adverse events", "B": "Younger patients have better effectiveness", "C": "No overall differences in safety or effectiveness were observed", "D": "Older patients require dose adjustment"}}
{"id": "eKqll7fJ0BFP", "question_type": "open_ended_multi_choice", "question": "How can women exposed to Imaavy during pregnancy participate in the pregnancy safety study?", "options": {"A": "By calling 1-800-526-7736 or visiting www.IMAAVY.com", "B": "By contacting their local pharmacy", "C": "By reporting to the CDC", "D": "By sending an email to their physician"}}
{"id": "RiuhadjV8kIk", "question_type": "multi_choice", "question": "A 78-year-old man with mild Alzheimer’s disease and a history of severe hypersensitivity reaction to monoclonal antibodies is being considered for drug therapy. He is not taking any antithrombotic medications and has no evidence of cerebral amyloid angiopathy on MRI. Which drug option is most suitable for this patient?", "options": {"A": "KISUNLA (donanemab-azbt), as hypersensitivity reactions are rare and manageable.", "B": "Avoid KISUNLA due to contraindication from hypersensitivity; consider alternative therapy if available.", "C": "KISUNLA, with pre-treatment using antihistamines and corticosteroids.", "D": "KISUNLA, but only at a reduced dosage."}}
{"id": "pjvjBhOHuVQ2", "question_type": "open_ended_multi_choice", "question": "A 28-year-old man presents with severe alopecia areata and is a candidate for drug therapy. Genetic testing reveals he is a poor metabolizer via CYP2C9, and he is also taking a moderate CYP2C9 inhibitor for an unrelated condition. His renal and hepatic function are normal, and he is not pregnant or breastfeeding. Which treatment option is most appropriate for him?", "options": {"A": "Leqselvi (deuruxolitinib phosphate), once daily", "B": "Minoxidil topical solution, twice daily", "C": "Imiquimod cream, three times per week", "D": "None of the above drugs are appropriate"}}
{"id": "aY5CFLv068nH", "question_type": "multi_choice", "question": "A 6-month-old infant with severe RSV infection is hospitalized and requires mechanical ventilation. The infant's mother is currently pregnant. Which of the following is the most appropriate management regarding antiviral therapy for this patient?", "options": {"A": "Avoid Virazole due to teratogenic risk and select an alternative antiviral agent.", "B": "Administer ENFLONSIA as a preventive measure.", "C": "Administer Restasis MultiDose ophthalmic emulsion.", "D": "Administer Virazole via inhalation, ensuring staff are experienced with ventilator use and monitoring."}}
{"id": "j0qn4EOMrY6G", "question_type": "multi_choice", "question": "A 32-year-old woman presents with moderate to severe hidradenitis suppurativa. She is currently 10 weeks pregnant and is seeking treatment for her skin condition. Her renal and hepatic function are normal, and she is not taking any other medications. Which of the following drugs is the most appropriate for her condition?", "options": {"A": "Adalimumab", "B": "Spironolactone", "C": "Sitagliptin/Metformin Hydrochloride", "D": "No drug is appropriate; only surgical management should be considered"}}
{"id": "i2TzWU1he0TP", "question_type": "open_ended_multi_choice", "question": "A clinical trial protocol is being designed for a new indication of Datroway. Which of the following statements is accurate regarding exclusion criteria based on contraindications?", "options": {"A": "Patients with a history of allergic reactions to Datroway must be excluded due to contraindications.", "B": "No patients need to be excluded based on contraindications, as Datroway has none.", "C": "Patients with renal impairment should be excluded due to contraindications.", "D": "Pregnant women must be excluded due to contraindications."}}
{"id": "6JX9eqhPSn2i", "question_type": "open_ended", "question": "A pediatric patient (age 8) with a disorder of the appendix is being considered for corticosteroid therapy to control severe inflammation after conventional treatments have failed. The physician is concerned about potential adverse effects on growth and the need for careful monitoring. Which drug regimen is most appropriate for this patient, considering established safety and efficacy in pediatric populations?", "options": {"A": "Adrenalin", "B": "ROPIVACAINE HYDROCHLORIDE", "C": "TaperDex 12-day", "D": "DEXAMETHASONE"}}
{"id": "WT1JhY7r4ciA", "question_type": "open_ended_multi_choice", "question": "A 65-year-old woman with mild Alzheimer’s disease dementia is considering pregnancy and inquires about the safety of KISUNLA (donanemab-azbt) for her treatment. What is the best recommendation regarding the use of this medication?", "options": {"A": "Recommend KISUNLA, as it is safe for use during pregnancy.", "B": "Advise against KISUNLA due to lack of safety data in pregnancy; consider alternative therapy if available.", "C": "Initiate KISUNLA and monitor closely for ARIA.", "D": "Recommend KISUNLA only after the first trimester."}}
{"id": "47Lq6iSJYtxL", "question_type": "multi_choice", "question": "Which of the following is NOT a recommended supply for preparing and administering Gomekli tablets for oral suspension?", "options": {"A": "Prescribed number of Gomekli tablets for oral suspension", "B": "Dosing cup", "C": "Milk", "D": "10 mL oral syringe"}}
{"id": "H7lGFSgUdkGf", "question_type": "open_ended_multi_choice", "question": "A 45-year-old female patient with paroxysmal nocturnal hemoglobinuria (PNH) continues to have extravascular hemolysis despite ongoing ravulizumab therapy. She has mild hepatic impairment (Child-Pugh Class B) and is on rosuvastatin 20 mg once daily for hyperlipidemia. Considering her liver function and current medication regimen, which drug strategy is most appropriate for treating her EVH?", "options": {"A": "Add danicopan to her current ravulizumab regimen, maintaining her rosuvastatin dose at 20 mg once daily.", "B": "Switch to pegcetacoplan monotherapy and discontinue ravulizumab.", "C": "Add danicopan to her current ravulizumab regimen, but reduce rosuvastatin dose to no more than 10 mg once daily.", "D": "Switch to crovalimab monotherapy and discontinue ravulizumab."}}
{"id": "DK2ScN58K5xv", "question_type": "multi_choice", "question": "A male patient taking Romvimza has a female partner of reproductive potential. What is the recommended guidance regarding contraception?", "options": {"A": "No contraception is needed for male patients.", "B": "Contraception is only required if the partner is pregnant.", "C": "Effective contraception should be used during treatment and for 1 month after the last dose.", "D": "Contraception is required for 6 months after stopping Romvimza."}}
{"id": "lqAFK7QcjqaW", "question_type": "multi_choice", "question": "A 10-year-old boy with a history of epilepsy controlled on valproic acid presents with fever, flank pain, and a diagnosis of complicated urinary tract infection. He has normal renal function and no known drug allergies. Which of the following is the most appropriate treatment option?", "options": {"A": "Imipenem and cilastatin intravenously", "B": "Flavoxate hydrochloride orally", "C": "Sulopenem etzadroxil and probenecid (Orlynvah) orally", "D": "Imipenem and cilastatin intravenously, with valproic acid continued"}}
{"id": "9NsX68HhdoVP", "question_type": "open_ended_multi_choice", "question": "A 65-year-old female patient with metastatic HER2-mutant non-squamous NSCLC is undergoing assessment for systemic therapy. She is receiving rifampin, a strong CYP3A inducer, for latent TB. Her heart and liver function tests are normal, and pregnancy has been ruled out. What is the most appropriate approach to choosing and managing her lung cancer medication?", "options": {"A": "Initiate HERNEXEOS, but increase the dose due to the interaction with rifampin.", "B": "Start TECENTRIQ as a single agent, as it has no major CYP3A interactions.", "C": "Use etoposide in combination with other agents, as it is not affected by CYP3A inducers.", "D": "Avoid HERNEXEOS entirely and select an alternative therapy due to the drug interaction."}}
{"id": "NTNHrUMOgVnn", "question_type": "open_ended_multi_choice", "question": "A 14-year-old patient has been diagnosed with Grade 2 astrocytoma following a subtotal resection. Genetic testing confirms the presence of a susceptible IDH1 mutation. The patient is not pregnant, has normal renal and hepatic function, and is not taking any CYP1A2 or CYP3A4 inhibitors or inducers. Which drug regimen is most appropriate for ongoing treatment, considering both efficacy and safety for this patient population?", "options": {"A": "Vorasidenib 40 mg once daily, with regular liver function monitoring", "B": "Avastin administered every 2 weeks", "C": "Zortress in combination with cyclosporine and corticosteroids", "D": "Avastin in combination with carboplatin and paclitaxel"}}
{"id": "HaHbbO0DUxWB", "question_type": "open_ended_multi_choice", "question": "Why is concomitant administration of Romvimza and drugs that are substrates for P-gp, BCRP, and OCT2 discouraged?", "options": {"A": "Romvimza acts as an inhibitor of these transporters in vitro.", "B": "Romvimza induces hepatic enzymes.", "C": "Romvimza increases renal clearance of substrates.", "D": "Romvimza is a substrate for these transporters."}}
{"id": "zrvKhQtNsg0K", "question_type": "open_ended_multi_choice", "question": "A 45-year-old woman with dry eye disease uses contact lenses and prefers a medication that does not require her to remove them before administration. She is not pregnant, has no history of ocular infections, and is seeking a treatment with established safety in adults. Which drug is most appropriate for her, considering her preference and safety profile?", "options": {"A": "TRYPTYR", "B": "Lotemax SM", "C": "Xiidra", "D": "Topical corticosteroid drops (other than Lotemax SM)"}}
{"id": "uMuiZ0ipP5a8", "question_type": "multi_choice", "question": "A 68-year-old patient with tuberculoma and a history of recent myocardial infarction requires corticosteroid therapy as adjunct to antituberculous chemotherapy. Which corticosteroid should be used with particular caution due to an increased risk of left ventricular free wall rupture in this population?", "options": {"A": "PredniSONE oral tablets", "B": "TaperDex 12-day oral pack", "C": "Dexamethasone Sodium Phosphate IV/IM injection", "D": "TaperDex 6-day oral pack"}}
{"id": "TyChEHUIrTBB", "question_type": "open_ended", "question": "A 7-year-old child with diffuse midline glioma harboring an H3 K27M mutation has progressive disease following prior therapy. The patient is otherwise healthy, not taking any medications, and has no history of cardiac arrhythmias or hypersensitivity reactions. Which of the following is the most appropriate next step in drug treatment for this patient?", "options": {"A": "Initiate dordaviprone (MODEYSO) at the recommended pediatric dose.", "B": "Initiate dordaviprone (MODEYSO) but only after the patient turns 12 years old.", "C": "Withhold dordaviprone (MODEYSO) due to lack of established safety in pediatric patients.", "D": "Initiate dordaviprone (MODEYSO) only if the patient is also taking a CYP3A4 inhibitor."}}
{"id": "4l7sbL6tzEkA", "question_type": "multi_choice", "question": "A 65-year-old man with metastatic NSCLC and an EGFR exon 21 L858R mutation is being considered for first-line therapy. He has a history of hypertension controlled with medication, and chronic proteinuria (urine protein 1.8 g/24h). He is at increased risk for venous thromboembolism (VTE) due to prior DVT. Which treatment option is most suitable for his condition?", "options": {"A": "Rozlytrek", "B": "LAZCLUZE (lazertinib plus amivantamab) with prophylactic anticoagulation", "C": "CYRAMZA in combination with erlotinib", "D": "CYRAMZA in combination with docetaxel"}}
{"id": "0MyBtxzDlGTU", "question_type": "multi_choice", "question": "Which of the following statements best describes the carcinogenicity assessment conducted for Modeyso?", "options": {"A": "Modeyso was tested for carcinogenicity only in vitro.", "B": "Modeyso was found to be carcinogenic in rodent studies.", "C": "Modeyso showed a dose-dependent increase in tumor formation.", "D": "Carcinogenicity studies with Modeyso were not conducted."}}
{"id": "jAwkNZ2jrEla", "question_type": "multi_choice", "question": "A 68-year-old woman with low-risk myelodysplastic syndrome presents with transfusion-dependent anemia, requiring 5 units of red blood cells over the past 8 weeks. She has not responded to erythropoiesis-stimulating agents and is currently taking digoxin for atrial fibrillation. Her cytogenetic analysis does not show a deletion 5q abnormality. Which drug is the most appropriate for her treatment, considering her current medications and disease profile?", "options": {"A": "Lenalidomide, 10 mg orally once daily", "B": "Inqovi, 35 mg orally once daily for 5 consecutive days every 28 days", "C": "Lenalidomide, 25 mg orally once daily", "D": "Imetelstat sodium, 7.5 mg/kg intravenously every 4 weeks"}}
{"id": "jAYlV56G9ybU", "question_type": "open_ended_multi_choice", "question": "Which of the following statements best describes the dosing adjustment for Ekterly in patients with severe hepatic impairment?", "options": {"A": "Increase the dose to two tablets of 300 mg each.", "B": "Avoid use of Ekterly.", "C": "Reduce the dose to one tablet of 150 mg.", "D": "Administer a single dose of 600 mg."}}
{"id": "RDvKQTzPiS7u", "question_type": "open_ended", "question": "A 68-year-old man with moderate to severe chronic hand eczema and a history of cardiovascular disease is being considered for topical therapy. He has completed all age-appropriate vaccinations and has no active infections. Which of the following statements best reflects the considerations for using Anzupgo (delgocitinib) in this patient?", "options": {"A": "Anzupgo (delgocitinib) is contraindicated in all elderly patients regardless of comorbidities.", "B": "Anzupgo (delgocitinib) may be used, but periodic skin examinations and monitoring for cardiovascular events are recommended.", "C": "Anzupgo (delgocitinib) should only be used in pediatric patients.", "D": "Anzupgo (delgocitinib) is recommended to be used in combination with live vaccines."}}
{"id": "7Ixg8Eu2DkIg", "question_type": "open_ended", "question": "A 67-year-old man with ROS1-positive non-small cell lung carcinoma and a history of chronic hepatitis B is being evaluated for targeted therapy. His liver function tests are mildly elevated at baseline. Which of the following best describes the necessary monitoring and management if taletrectinib (IBTROZI) is initiated?", "options": {"A": "No special monitoring is required beyond routine clinical follow-up.", "B": "Monitor liver function tests prior to starting, every 2 weeks for the first 2 months, then monthly, with dose adjustments as needed.", "C": "Taletrectinib is contraindicated in all patients with any liver enzyme elevation.", "D": "Start taletrectinib and monitor only if symptoms of liver dysfunction develop."}}
{"id": "NoYnn1DCj5pj", "question_type": "open_ended_multi_choice", "question": "A 67-year-old man with primary biliary cholangitis, osteoporosis, and elevated alkaline phosphatase is being considered for pharmacologic therapy. He has no history of cirrhosis or hepatic decompensation and is not taking statins or other lipid-lowering agents. Which drug is most appropriate for his condition, considering his comorbidities and age?", "options": {"A": "Colcrys daily for long-term management", "B": "Budesonide inhalation twice daily", "C": "Elafibranor once daily, with monitoring for bone health", "D": "Elafibranor once daily, without bone health monitoring"}}
{"id": "kd1EkqIsYtBb", "question_type": "open_ended", "question": "A 35-year-old woman with diffuse midline glioma (H3 K27M mutation, progressive after prior therapy) is currently 10 weeks pregnant. She is otherwise healthy and not taking any other medications. What is the most appropriate recommendation regarding dordaviprone (MODEYSO) therapy for her?", "options": {"A": "Start dordaviprone (MODEYSO) immediately at the standard adult dose.", "B": "Delay dordaviprone (MODEYSO) until after delivery due to embryo-fetal toxicity risk.", "C": "Start dordaviprone (MODEYSO) with close fetal monitoring.", "D": "Start dordaviprone (MODEYSO) only if the patient is also breastfeeding."}}
{"id": "oyMbP6sW4LeZ", "question_type": "open_ended", "question": "If a patient requires long-term therapy with an antibody derivative containing the human Fc domain of the IgG subclass, what is the recommended approach regarding Imaavy administration?", "options": {"A": "Discontinue Imaavy and consider alternative therapies", "B": "Increase the dose of Imaavy", "C": "Continue Imaavy without any changes", "D": "Switch to a different FcRn-binding medication"}}
{"id": "0U654sWculI9", "question_type": "open_ended_multi_choice", "question": "A 7-year-old with Niemann-Pick disease type C is experiencing worsening gait ataxia, cognitive decline, and vertical supranuclear gaze palsy. With normal kidney function and no concurrent medications, what is the most suitable pharmacological treatment for the neurological symptoms of this disorder?", "options": {"A": "Miglustat monotherapy", "B": "Arimoclomol in combination with miglustat", "C": "Lithium carbonate", "D": "Arimoclomol monotherapy"}}
{"id": "8w2NFBojJf2u", "question_type": "multi_choice", "question": "A patient with metastatic non-keratinizing nasopharyngeal carcinoma has progressed after platinum-based chemotherapy and one additional prior therapy. Which treatment option involving Penpulimab-kcqx is appropriate?", "options": {"A": "Penpulimab-kcqx in combination with cisplatin and gemcitabine", "B": "Penpulimab-kcqx with carboplatin and paclitaxel", "C": "Penpulimab-kcqx as a single agent", "D": "Penpulimab-kcqx as maintenance therapy after chemotherapy"}}
{"id": "h0PLYAVcGN0I", "question_type": "multi_choice", "question": "A 77-year-old male with a diagnosis of wild-type transthyretin-mediated amyloidosis cardiomyopathy (ATTR-CM) presents for management. He has a history of hypertension controlled with amlodipine and is not taking any CYP2C9 substrate medications. He is otherwise healthy, with no hepatic impairment or respiratory disease. Which drug is most appropriate for reducing cardiovascular death and hospitalization in this patient, considering his age and disease subtype?", "options": {"A": "Metoprolol Tartrate", "B": "Mavacamten", "C": "Acoramidis Hydrochloride", "D": "Verapamil"}}
{"id": "j0ILrs3hfKb8", "question_type": "open_ended_multi_choice", "question": "A 35-year-old woman presents with oral mucosal blisters, abnormal blistering of the skin, and recurrent cutaneous abscess formation. She has a history of autoimmune antibody positivity and recent weight loss. She is currently breastfeeding her 2-month-old infant and is concerned about the safety of medications for her child. Which drug regimen is most appropriate for treating her pemphigus vulgaris while minimizing risk to her nursing infant?", "options": {"A": "Proleukin administered intravenously every 8 hours for 5 days", "B": "TaperDex 12-day oral regimen, titrated to the lowest effective dose", "C": "DEXAMETHASONE SODIUM PHOSPHATE intravenous injection, high-dose daily", "D": "Proleukin administered subcutaneously every other day"}}
{"id": "jsk4pJF3oOxs", "question_type": "open_ended_multi_choice", "question": "Which of the following best describes the contraindication profile of the drug Emrelis?", "options": {"A": "Emrelis is contraindicated in patients with severe hepatic impairment.", "B": "Emrelis has no known contraindications.", "C": "Emrelis should not be used in patients with a history of hypersensitivity to its active ingredient.", "D": "Emrelis is contraindicated in pregnancy."}}
{"id": "on2fzMrd0HiJ", "question_type": "open_ended", "question": "A 40-year-old male with autosomal dominant reading seizures is being considered for Fintepla therapy. He is currently taking a monoamine oxidase inhibitor (MAOI) for depression and has a history of well-controlled hypertension. His echocardiogram is normal, and he is not taking any other serotonergic drugs. What is the most appropriate action regarding Fintepla initiation?", "options": {"A": "Initiate Fintepla immediately at standard dosage", "B": "Delay Fintepla initiation until at least 14 days after discontinuing MAOI therapy", "C": "Start Fintepla only if blood pressure is elevated", "D": "Fintepla can be started concurrently with MAOI if cardiac monitoring is performed"}}
{"id": "7qwkaSmx2Os1", "question_type": "multi_choice", "question": "A 52-year-old woman presents with progressive difficulty focusing on near objects and is diagnosed with presbyopia. She has a history of iritis and is seeking pharmacological treatment to improve her near vision. Which of the following drugs is most appropriate for her condition?", "options": {"A": "VIZZ administered as topical ocular drops twice daily", "B": "Mirvaso topical gel applied once daily", "C": "VIZZ administered as topical ocular drops once daily", "D": "Oraverse intraoral injection after dental procedures"}}
{"id": "ouDrSd0tkiNT", "question_type": "multi_choice", "question": "A 7-year-old boy with Duchenne muscular dystrophy presents with progressive muscle weakness, elevated creatine kinase, and a history of arrhythmia. He is currently taking a medication known to prolong the QTc interval for his cardiac condition. Which drug regimen is most appropriate for treating his DMD, considering his cardiac profile and current medications?", "options": {"A": "Givinostat administered twice daily", "B": "Deflazacort administered daily", "C": "Eteplirsen administered once weekly", "D": "Givinostat with a planned drug holiday every month"}}
{"id": "HJq2CGdCVaP0", "question_type": "open_ended", "question": "Which of the following is an important counseling point regarding drug interactions for patients taking Modeyso?", "options": {"A": "Inform your healthcare provider about all medications, including prescription, over-the-counter drugs, vitamins, and herbal products, and consult before starting or stopping any medication or supplement.", "B": "Only avoid grapefruit juice while taking Modeyso.", "C": "No drug interactions are known with Modeyso.", "D": "Drug interactions are only a concern with antibiotics."}}
{"id": "cBxwIUYeXqfC", "question_type": "open_ended_multi_choice", "question": "If a patient on Qfitlia experiences jaundice with total bilirubin ≥2.5 mg/dL thought to be from hepatotoxicity and other causes ruled out, what is the recommended action?", "options": {"A": "Permanently discontinue Qfitlia", "B": "Reduce Qfitlia dose by half", "C": "Continue Qfitlia with close monitoring", "D": "Switch to antithrombin-based regimen"}}
{"id": "woMDWDfeBOi8", "question_type": "open_ended", "question": "A 45-year-old patient with tuberculoma is unable to swallow oral medications due to severe nausea and vomiting. The patient requires adjunctive corticosteroid therapy in addition to antituberculous chemotherapy. Which corticosteroid formulation is most appropriate for this patient’s current condition?", "options": {"A": "PredniSONE oral tablets", "B": "TaperDex 12-day oral pack", "C": "Dexamethasone Sodium Phosphate IV/IM injection", "D": "TaperDex 6-day oral pack"}}
{"id": "WqloeAuLg2pq", "question_type": "multi_choice", "question": "Which of the following statements best describes the carcinogenicity assessment for Imaavy (nipocalimab-aahu)?", "options": {"A": "Carcinogenicity studies have been conducted and showed no risk.", "B": "Carcinogenicity studies showed a high risk of cancer.", "C": "Carcinogenicity studies have not been conducted for Imaavy.", "D": "Carcinogenicity studies were inconclusive."}}
{"id": "Uhe9TesHkCBS", "question_type": "multi_choice", "question": "When considering pharmacological therapy for presbyopia in adults, which brand drug acts as a cholinergic agonist?", "options": {"A": "Pataday", "B": "Timoptic", "C": "Xalatan", "D": "Alrex"}}
{"id": "6YOL4dWv15NA", "question_type": "open_ended_multi_choice", "question": "If a patient with mild hepatic impairment (Child-Pugh Class A) is prescribed Ekterly for an acute HAE attack, what is the recommended initial dose?", "options": {"A": "300 mg (one tablet)", "B": "600 mg (two tablets)", "C": "900 mg (three tablets)", "D": "1,200 mg (four tablets)"}}
{"id": "LvdVUCQ7zJ1s", "question_type": "open_ended_multi_choice", "question": "A 52-year-old woman presents with difficulty reading small print and reports needing to hold objects farther away to see them clearly. She is diagnosed with presbyopia. She has no history of retinal disease, iritis, or hypersensitivity to medications. She is not pregnant and does not wear contact lenses. Which drug is most appropriate for her treatment, considering the available options and their indications?", "options": {"A": "Aceclidine", "B": "Brimonidine tartrate", "C": "Phentolamine mesylate", "D": "No drug is appropriate"}}
{"id": "77Rt3oEsdz1a", "question_type": "open_ended_multi_choice", "question": "Which excipient is present at the highest concentration per mL in Penpulimab-kcqx injection?", "options": {"A": "Sorbitol", "B": "Polysorbate 80", "C": "Acetic acid", "D": "Sodium acetate"}}
{"id": "Q1LmGmb60NdJ", "question_type": "open_ended_multi_choice", "question": "For a patient weighing 85 kg who is prescribed Hernexeos and is also taking a strong CYP3A inducer, what is the recommended adjustment to their Hernexeos dosage?", "options": {"A": "Increase to 240 mg once daily", "B": "Decrease to 60 mg once daily", "C": "Maintain at 120 mg once daily", "D": "Increase to 180 mg once daily"}}
{"id": "9qb3FJD3Gw5q", "question_type": "multi_choice", "question": "For patients taking Journavx who are also using hormonal contraceptives containing progestins other than levonorgestrel or norethindrone, what additional recommendation should be made?", "options": {"A": "No additional contraceptive measures are needed.", "B": "Use only barrier methods for contraception.", "C": "Increase the dose of the current contraceptive.", "D": "Discontinue Journavx immediately."}}
{"id": "ato93626uhFM", "question_type": "open_ended_multi_choice", "question": "A 42-year-old woman presents with moderate to severe chronic hand eczema. She has a documented allergy to topical corticosteroids and a history of recurrent herpes zoster infections. She is currently not on any immunosuppressants or JAK inhibitors. Which treatment option is most appropriate for her condition?", "options": {"A": "Delgocitinib topical therapy, with close monitoring for viral reactivation", "B": "Delgocitinib in combination with oral JAK inhibitor", "C": "Topical corticosteroids despite allergy", "D": "Delgocitinib topical therapy during active herpes zoster episode"}}
{"id": "qmjRF1ESaEZS", "question_type": "multi_choice", "question": "A 68-year-old man with idiopathic pulmonary fibrosis presents for ongoing management. He has a history of cirrhosis and chronic kidney disease (eGFR 25 mL/min), and recently experienced exertional dyspnea and clubbing of fingers. His liver function tests are mildly elevated, and he is not currently taking any CYP1A2 inhibitors or inducers. Which of the following is the most appropriate pharmacologic therapy for his IPF?", "options": {"A": "Pirfenidone, 801 mg three times daily", "B": "Nintedanib, 150 mg twice daily", "C": "Prednisolone sodium phosphate, 10 mg daily", "D": "Pirfenidone, 267 mg three times daily"}}
{"id": "cVxvzI19Mvg7", "question_type": "open_ended_multi_choice", "question": "A 15-year-old adolescent with hereditary angioedema presents to the emergency department with an acute attack. The patient has a documented history of severe anaphylactic reactions to ecallantide. Which treatment option should be avoided, and which is most suitable for managing this acute episode?", "options": {"A": "Kalbitor", "B": "TAKHZYRO", "C": "ANDEMBRY", "D": "Supportive care only"}}
{"id": "HA73LgjZiozA", "question_type": "open_ended_multi_choice", "question": "If a patient experiences life-threatening arrhythmias during treatment with Modeyso, what is the advised course of action?", "options": {"A": "Reduce the dose of Modeyso.", "B": "Interrupt Modeyso and resume after arrhythmia resolves.", "C": "Permanently discontinue Modeyso.", "D": "Continue Modeyso with increased monitoring."}}
{"id": "9LHRZCUjR9Ty", "question_type": "multi_choice", "question": "A 7-year-old boy is newly diagnosed with myelodysplastic syndrome (MDS) and is scheduled for allogeneic hematopoietic stem cell transplantation. He has no history of seizures, is not taking any CYP2C19 or CYP3A4 substrate medications, and is otherwise healthy. Which drug regimen is most appropriate as a preparative regimen for his transplant, considering age-specific safety and efficacy?", "options": {"A": "Lenalidomide, administered orally once daily.", "B": "TREOSULFAN (GRAFAPEX) in combination with fludarabine, administered intravenously for three consecutive days.", "C": "INQOVI (cedazuridine and decitabine), administered orally in 28-day cycles.", "D": "Busulfan, administered intravenously for two days."}}
{"id": "T8AmMyV77U1k", "question_type": "open_ended_multi_choice", "question": "When assessing the safety of Emrelis, what considerations should be made about its administration to individuals who have additional medical conditions?", "options": {"A": "Emrelis is contraindicated in patients with diabetes.", "B": "Emrelis is contraindicated in patients with liver dysfunction.", "C": "Emrelis has no contraindications regardless of comorbidities.", "D": "Emrelis is contraindicated in patients with autoimmune diseases."}}
{"id": "Ih2XZNOJJTxB", "question_type": "multi_choice", "question": "A 28-year-old woman with classic congenital adrenal hyperplasia is pregnant and currently receiving glucocorticoid replacement therapy. She is seeking advice on adjunctive therapy to control androgen levels. Which statement best reflects the appropriateness of Crenessity for her condition?", "options": {"A": "Crenessity is contraindicated in pregnancy due to high risk of fetal malformations", "B": "Crenessity is only approved for use in pediatric patients", "C": "Crenessity is recommended as first-line therapy in all pregnant women with CAH", "D": "Crenessity may be considered if benefits outweigh risks, but data in pregnancy are limited"}}
{"id": "SLUjRIsTwnVh", "question_type": "open_ended_multi_choice", "question": "A 5-year-old patient with classic congenital adrenal hyperplasia is being treated with glucocorticoids and has a history of severe renal impairment. As adjunctive therapy to further manage androgen levels is considered, what is the most appropriate approach to using crinecerfont (CRENESSITY) in this case?", "options": {"A": "Initiate crinecerfont at standard dosage as adjunctive therapy.", "B": "Initiate crinecerfont with dose adjustment due to renal impairment.", "C": "Crinecerfont is not recommended due to severe renal impairment.", "D": "Crinecerfont can be used only if the patient is monitored for hypersensitivity."}}
{"id": "ni3oSpamQscH", "question_type": "multi_choice", "question": "A 58-year-old man with a history of glaucoma and previous herpes simplex eye infection is experiencing severe symptoms of dry eye disease. He is considering prescription therapy and currently wears contact lenses daily. Which medication should be avoided due to his medical history and which is the most suitable for his condition?", "options": {"A": "Lotemax SM", "B": "TRYPTYR", "C": "Cyclosporine ophthalmic emulsion", "D": "Xiidra"}}
{"id": "XrLIelRij8qH", "question_type": "open_ended_multi_choice", "question": "Across the COMET-2 and COMET-3 trials, did Tryptyr demonstrate statistically significant efficacy over vehicle in enhancing tear production?", "options": {"A": "No statistically significant difference was observed.", "B": "Statistically significant improvement favoring Tryptyr (p<0.01) was observed in both studies.", "C": "Statistically significant improvement favoring vehicle (p<0.01) was observed.", "D": "Statistical significance was only achieved in COMET-2."}}
{"id": "rpZceHbUi5fL", "question_type": "open_ended_multi_choice", "question": "Regarding Blujepa's interactions with other antibiotics, which of the following is true?", "options": {"A": "Blujepa antagonizes the activity of fluoroquinolones against Enterobacterales.", "B": "Blujepa shows no antagonism with multiple antibacterial drugs, including fluoroquinolones, sulfonamides, and cephalosporins.", "C": "Blujepa is only effective when used as monotherapy.", "D": "Blujepa synergizes with aminoglycosides against all gram-negative bacteria."}}
{"id": "K3gDXNRRbMdG", "question_type": "multi_choice", "question": "In the context of hereditary angioedema management, which branded drug acts as a plasma kallikrein inhibitor?", "options": {"A": "Ekterly", "B": "Epinephrine", "C": "Diphenhydramine", "D": "Tranexamic acid"}}
{"id": "NH6BhAmTR0FV", "question_type": "open_ended_multi_choice", "question": "A 55-year-old woman diagnosed with pulmonary arterial hypertension (WHO Group 1) is receiving prostacyclin infusion and antithrombotic treatment. Her current platelet count is 45,000/mm³. As she is considered for an additional drug to improve her physical endurance and decrease the risk of worsening symptoms, which drug would be contraindicated for her?", "options": {"A": "Ambrisentan once daily", "B": "Macitentan once daily", "C": "Sotatercept-csrk every three weeks", "D": "Ambrisentan in combination with tadalafil"}}
{"id": "RVvcTjIF0pY3", "question_type": "multi_choice", "question": "During Vanrafia therapy, which of the following is a recommended action for patients who experience unprotected sex or contraceptive failure?", "options": {"A": "Wait until the next scheduled dose", "B": "Switch to a different medication", "C": "Discontinue Vanrafia immediately", "D": "Increase the dose of Vanrafia"}}
{"id": "do2lcUQvicgL", "question_type": "open_ended_multi_choice", "question": "A 34-year-old female with chronic immune thrombocytopenia, who is platelet antibody positive and has experienced abnormal bleeding, did not respond to corticosteroid therapy. She is considering pregnancy and has mild hepatic impairment. What is the most suitable next treatment option for her?", "options": {"A": "Rilzabrutinib", "B": "Prednisone", "C": "DMT SUIK (IV)", "D": "Dexamethasone sodium phosphate"}}
{"id": "Yo8tjY1k1FEz", "question_type": "open_ended_multi_choice", "question": "A 7-year-old male patient (28 kg) with cGVHD presents with symptoms of airway obstruction, cough, and pulmonary infiltrates. He has documented food intolerance and esophageal dysfunction. He is taking ritonavir, a strong CYP3A4 inhibitor, for asthma management. Based on his medication regimen and body weight, which drug must be avoided?", "options": {"A": "AXATILIMAB-CSFR", "B": "PredniSONE Tablets, USP, 5 mg", "C": "Budesonide Inhalation", "D": "PredniSONE combined with Budesonide Inhalation"}}
{"id": "SaOmlP3og7gk", "question_type": "open_ended_multi_choice", "question": "When assessing a new aPTT assay, which drug present in patient specimens should be recognized as a possible interferent due to its impact on the contact system?", "options": {"A": "Andembry", "B": "Warfarin", "C": "Aspirin", "D": "Clopidogrel"}}
{"id": "jyfrhKzQWrKM", "question_type": "open_ended_multi_choice", "question": "A 9-year-old patient with a metastatic solid tumor has tested positive for a neurotrophic tyrosine receptor kinase (NTRK) gene fusion using an FDA-approved assay. The child also has mild renal impairment (eGFR 55 mL/min) and no cardiac history. Taking into account the patient's age, genetic mutation, and renal function, which medication is most appropriate?", "options": {"A": "Erlotinib, 85 mg/m²/day orally", "B": "Lazcluze (lazertinib + amivantamab), standard pediatric dosing", "C": "Rozlytrek, weight-based dosing once daily", "D": "Erlotinib in combination with gemcitabine"}}
{"id": "0qXL0KwixN8s", "question_type": "multi_choice", "question": "A 10-year-old girl with progressive diffuse midline glioma harboring an H3 K27M mutation has completed prior therapy. She is currently taking a medication known to prolong the QTc interval for a cardiac arrhythmia. Her oncologist is considering starting a new treatment for her glioma. Which of the following is the most appropriate approach regarding the use of MODEYSO (dordaviprone) in this patient?", "options": {"A": "Start MODEYSO, but separate its administration from the QTc-prolonging drug and increase ECG monitoring.", "B": "Avoid using MODEYSO due to her age; it is not approved for pediatric patients.", "C": "Initiate MODEYSO at the standard dose without any changes to her current medications.", "D": "Discontinue the QTc-prolonging drug and start MODEYSO at a reduced dose."}}
{"id": "xAafq9KpHdBA", "question_type": "open_ended_multi_choice", "question": "A woman aged 52 with a diagnosis of primary biliary cholangitis now presents with compensated cirrhosis, recent ascites, and gastroesophageal varices, suggesting portal hypertension. Despite treatment with ursodeoxycholic acid (UDCA), her response has been insufficient. She is also on warfarin for atrial fibrillation. What is the most appropriate medication regimen for managing her PBC at this point?", "options": {"A": "Ocaliva 10 mg once daily in combination with UDCA", "B": "Livdelzi 10 mg once daily in combination with UDCA", "C": "Tricor 145 mg once daily as adjunct to UDCA", "D": "No disease-specific drug therapy should be initiated; continue UDCA alone"}}
{"id": "TD9mABT4HxFC", "question_type": "open_ended_multi_choice", "question": "A 7-year-old boy with a history of congenital hemophilia A (factor VIII deficiency) and no factor VIII inhibitors, who is otherwise healthy and not on any other medications, is being considered for regular prophylactic treatment. Which medication should be selected as the best option for preventing bleeding episodes in this case?", "options": {"A": "Alhemo administered as routine prophylaxis", "B": "Hemlibra administered as routine prophylaxis", "C": "Alhemo administered only during breakthrough bleeds", "D": "No prophylactic treatment is indicated for this patient"}}
{"id": "Sf4iPV2lz7qG", "question_type": "open_ended_multi_choice", "question": "Which statement accurately reflects the available data on Penpulimab-kcqx in human milk and its influence on breastfed infants?", "options": {"A": "Penpulimab-kcqx is known to be present in human milk and is safe for the breastfed child.", "B": "There is no information regarding the presence of Penpulimab-kcqx in human milk or its effects on the breastfed child.", "C": "Penpulimab-kcqx is contraindicated only if the child is under 6 months old.", "D": "Penpulimab-kcqx increases milk production."}}
{"id": "p09X87lxgAFw", "question_type": "multi_choice", "question": "Which of the following is a recommended action when Romvimza is used concomitantly with a P-glycoprotein (P-gp) substrate and co-administration cannot be avoided?", "options": {"A": "Administer Romvimza at least 4 hours after the P-gp substrate.", "B": "Reduce the dose of Romvimza by half.", "C": "Administer both drugs simultaneously.", "D": "Discontinue the P-gp substrate."}}
{"id": "HRUlLQX9d79U", "question_type": "multi_choice", "question": "A 68-year-old male with a history of nonmuscle invasive bladder cancer presents with persistent carcinoma in situ (CIS) after failing two courses of Bacillus Calmette-Guérin (BCG) therapy. He has no significant comorbidities and is not currently taking any other medications. He is concerned about the risk of disease progression and wishes to avoid unnecessary systemic toxicity. Which of the following is the most appropriate next step in drug therapy for this patient, considering his disease subtype and treatment history?", "options": {"A": "Initiate Gemcitabine as a single agent administered intravenously weekly.", "B": "Recommend systemic paclitaxel therapy.", "C": "Begin Gemcitabine in combination with carboplatin.", "D": "Start Anktiva in combination with BCG administered intravesically."}}
{"id": "4gjnis4u0zbj", "question_type": "open_ended_multi_choice", "question": "A 7-year-old boy diagnosed with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) is scheduled to begin chemotherapy. He has difficulty swallowing tablets and his parents ask about dispersing SPRYCEL in juice for easier administration. Which of the following best describes the appropriateness and considerations for SPRYCEL use in this scenario?", "options": {"A": "SPRYCEL is contraindicated in children under 12 years of age.", "B": "SPRYCEL can be used in children ≥1 year, but dispersing tablets in juice may lower drug exposure and efficacy.", "C": "SPRYCEL is only approved for adults and should not be used in pediatric patients.", "D": "SPRYCEL can be safely administered in juice without any impact on efficacy."}}
{"id": "19PW08JrNbJt", "question_type": "multi_choice", "question": "Which of the following statements best describes the effect of Emrelis on fertility in females?", "options": {"A": "Emrelis permanently impairs female fertility", "B": "Emrelis may impair female fertility, but the effect is reversible", "C": "Emrelis has no effect on female fertility", "D": "Emrelis improves female fertility"}}
{"id": "fHRDz1BWeTev", "question_type": "open_ended_multi_choice", "question": "A 45-year-old male patient with schizophrenia, hyperactivity, and an eGFR of 45 mL/min (indicating moderate renal impairment) is being evaluated for antipsychotic treatment. He has no prior history of liver disease, benign prostatic hyperplasia, or psychosis related to dementia. Which antipsychotic regimen is most appropriate for this patient?", "options": {"A": "Cobenfy (xanomeline and trospium chloride), standard adult dose", "B": "Abilify Maintena (aripiprazole), standard adult dose", "C": "Cobenfy (xanomeline and trospium chloride), reduced dose", "D": "Abilify Maintena (aripiprazole), reduced dose for CYP2D6 poor metabolizers"}}
{"id": "boDmQPSGTUM2", "question_type": "multi_choice", "question": "A 58-year-old man with metastatic cutaneous squamous cell carcinoma is not a candidate for curative surgery or radiation. He has a history of severe infusion-related reactions to monoclonal antibodies in the past. Which of the following systemic therapies is most appropriate for his condition, considering both indication and safety profile?", "options": {"A": "ERBITUX, due to its lower risk of infusion reactions", "B": "TECENTRIQ, as it is approved for CSCC and has a low rate of infusion reactions", "C": "No systemic therapy is appropriate due to infusion reaction history", "D": "UNLOXCYT, as it is specifically indicated for CSCC despite higher infusion reaction risk"}}
{"id": "xZ2AgJ3rmAmW", "question_type": "multi_choice", "question": "A 45-year-old woman with primary IgA nephropathy and UPCR of 2.0 g/g is currently breastfeeding her 2-month-old infant. She is otherwise healthy and not pregnant. Which is the most appropriate recommendation regarding atrasentan (VANRAFIA) therapy for her?", "options": {"A": "Initiate atrasentan and continue breastfeeding.", "B": "Initiate atrasentan but advise her to stop breastfeeding during treatment.", "C": "Atrasentan is contraindicated only if she is pregnant.", "D": "Atrasentan is safe to use during lactation."}}
{"id": "Van9ceVVWax5", "question_type": "multi_choice", "question": "A patient is prescribed Wayrilz and is also taking a moderate CYP3A inhibitor for a short-term infection. What is the recommended management strategy for this drug interaction?", "options": {"A": "Continue both drugs without adjustment.", "B": "Interrupt Wayrilz treatment during the course of the CYP3A inhibitor.", "C": "Increase the dose of Wayrilz.", "D": "Administer Wayrilz at least 2 hours after the CYP3A inhibitor."}}
{"id": "cJbqF1y5DGl8", "question_type": "open_ended_multi_choice", "question": "Which of the following accurately describes how Ekterly 300 mg was utilized in the KONFIDENT study?", "options": {"A": "Ekterly 300 mg was evaluated but is not a recommended dose for acute HAE attacks", "B": "Ekterly 300 mg was the preferred dose for all patients", "C": "Ekterly 300 mg was only used in patients under 18 years", "D": "Ekterly 300 mg was not evaluated in the trial"}}
{"id": "BodHrNMHE45d", "question_type": "open_ended", "question": "A 32-year-old woman presents with moderate dry eye disease. She is currently 10 weeks pregnant and is concerned about the safety of medications for her developing fetus. She does not wear contact lenses and has no history of ocular surgery, glaucoma, or eye infections. Which drug is the most appropriate for her treatment, considering both efficacy and safety during pregnancy?", "options": {"A": "Lotemax SM (loteprednol etabonate ophthalmic gel) 0.38%, one drop in affected eye(s) twice daily", "B": "TRYPTYR (acoltremon ophthalmic solution), one drop in affected eye(s) twice daily", "C": "Xiidra (lifitegrast ophthalmic solution) 5%, one drop in affected eye(s) twice daily", "D": "Lotemax SM (loteprednol etabonate ophthalmic gel) 0.38%, one drop in affected eye(s) once daily"}}
{"id": "Rfj4AV4zsTXP", "question_type": "open_ended_multi_choice", "question": "A 55-year-old male with chronic kidney disease (eGFR 40 mL/min/1.73 m2) and a history of epilepsy controlled with phenytoin is admitted for an acute MRSA skin and skin structure infection. What is the best antibiotic treatment option for this patient?", "options": {"A": "Doxycycline Hyclate, standard dosing without adjustment", "B": "Zevtera, with renal dose adjustment and monitoring for CNS effects", "C": "Rituximab and Hyaluronidase, as a single agent", "D": "Doxycycline Hyclate, with a drug holiday to reduce interaction risk"}}
{"id": "L74hVfbODHa9", "question_type": "open_ended_multi_choice", "question": "For a 54-year-old woman diagnosed with unresectable, metastatic, hormone receptor-positive, HER2-negative breast cancer, who has previously been treated with endocrine therapy and chemotherapy and has mild renal impairment (creatinine clearance 60 mL/min) but no history of interstitial lung disease, pneumonitis, pregnancy, or breastfeeding, what is the most appropriate drug choice for her ongoing cancer treatment, taking into account her renal status and treatment history?", "options": {"A": "MVASI", "B": "Ketorolac Tromethamine", "C": "DATROWAY", "D": "None of the above"}}
{"id": "F3ybSwfF8GCe", "question_type": "open_ended_multi_choice", "question": "A 58-year-old man, who has both glaucoma and a history of recurrent herpes simplex infections of the eye, is newly diagnosed with dry eye disease. He is looking for a daily treatment to alleviate his symptoms. Based on his medical background, which drug is contraindicated and which option is most appropriate?", "options": {"A": "Loteprednol etabonate ophthalmic gel, administered twice daily", "B": "Acoltremon ophthalmic solution, administered twice daily", "C": "Lifitegrast ophthalmic solution, administered twice daily", "D": "Loteprednol etabonate ophthalmic gel, administered once daily"}}
{"id": "SqHTLDg2NAia", "question_type": "open_ended", "question": "A 60-year-old man with multiple myeloma is scheduled for autologous stem cell transplantation. He has no prior history of leukemia, normal renal function, and is not taking any medications that are CYP substrates. Which regimen is most appropriate to mobilize hematopoietic stem cells for collection in this patient?", "options": {"A": "LYNOZYFIC as a single agent for stem cell mobilization", "B": "TALVEY in combination with filgrastim for stem cell mobilization", "C": "Mozobil in combination with filgrastim for stem cell mobilization", "D": "LYNOZYFIC in combination with Mozobil for enhanced mobilization"}}
{"id": "JPYR2xHzohGM", "question_type": "open_ended_multi_choice", "question": "In a prematurely born 6-month-old infant with autosomal dominant adrenocortical carcinoma and documented liver and kidney dysfunction, which chemotherapy option is contraindicated due to the potential harm from its excipient?", "options": {"A": "Etoposide injection containing polysorbate 80", "B": "Lumisight (pegulicianine) administered at 1 mg/kg for imaging", "C": "Etoposide administered orally at a low dose", "D": "Lumisight (pegulicianine) administered at a reduced dose"}}
{"id": "XytaqRCKohyC", "question_type": "multi_choice", "question": "A 35-year-old woman with hereditary angioedema is planning to become pregnant and requires prophylactic therapy. She is concerned about fetal safety and prefers a medication with reassuring animal data and minimal warnings. Which prophylactic agent is most appropriate based on available safety information?", "options": {"A": "Kalbitor", "B": "TAKHZYRO", "C": "None of the above", "D": "ANDEMBRY"}}
{"id": "UEjp5ymem7Dl", "question_type": "open_ended_multi_choice", "question": "A 62-year-old patient with metastatic non-keratinizing nasopharyngeal carcinoma has already been treated with platinum-based chemotherapy and one other regimen. He has moderate renal impairment (creatinine clearance 40 mL/min), is not using anticoagulants, is not pregnant, and has no history of immune-mediated disorders. Which drug is best suited for managing his cancer at this stage?", "options": {"A": "Capecitabine 500 mg twice daily", "B": "Penpulimab-kcqx monotherapy", "C": "Celecoxib 200 mg twice daily", "D": "Penpulimab-kcqx in combination with cisplatin and gemcitabine"}}
{"id": "pTkR8GtXe6g2", "question_type": "open_ended_multi_choice", "question": "What is a possible complication associated with administering penpulimab-kcqx either prior to or following allogeneic hematopoietic stem cell transplantation (HSCT)?", "options": {"A": "Hyperacute graft-versus-host-disease (GVHD)", "B": "Solid organ rejection only", "C": "Stevens-Johnson Syndrome", "D": "Diabetic ketoacidosis"}}
{"id": "rvSXr8AwBX2d", "question_type": "open_ended_multi_choice", "question": "A 58-year-old woman presents with newly diagnosed multiple myeloma, confirmed by paraproteinemia and amyloidosis. She has no prior history of chemotherapy or immunotherapy. She is not pregnant and has no history of thromboembolic events, but she is currently taking antihistamines for seasonal allergies. Which drug regimen is most appropriate for initial treatment of her multiple myeloma?", "options": {"A": "Thalidomide in combination with dexamethasone", "B": "Linvoseltamab-gcpt monotherapy", "C": "Talquetamab-tgvs monotherapy", "D": "Thalidomide monotherapy"}}
{"id": "VbDBy9P5gI9i", "question_type": "open_ended_multi_choice", "question": "A 29-year-old woman with moderate to severe chronic hand eczema is currently pregnant. She has not responded to topical corticosteroids. Which of the following is the most appropriate recommendation regarding the use of Anzupgo?", "options": {"A": "Consider Anzupgo only if the potential benefit justifies the potential risk to the fetus.", "B": "Initiate Anzupgo without any consideration of pregnancy status.", "C": "Anzupgo is contraindicated in all pregnant women regardless of severity.", "D": "Anzupgo is recommended as first-line therapy for all pregnant women with hand eczema."}}
{"id": "oFa8IVOn3lue", "question_type": "open_ended_multi_choice", "question": "A 7-year-old boy with Chagas cardiomyopathy and symptomatic heart failure (reduced LVEF) is being considered for pharmacologic therapy. He has normal renal and hepatic function and no history of angioedema. Which drug regimen is most appropriate for his age and condition?", "options": {"A": "Amiodarone hydrochloride with monthly drug holidays", "B": "Entresto administered twice daily with dose adjusted for pediatric use", "C": "Diovan administered once daily, despite lack of pediatric safety data", "D": "Entresto administered once weekly to minimize side effects"}}
{"id": "c1j6sIlM9SHF", "question_type": "open_ended", "question": "Which of the following statements best describes the results of carcinogenicity studies conducted with Blujepa?", "options": {"A": "Long-term carcinogenicity studies have not been conducted with Blujepa.", "B": "Blujepa was found to be carcinogenic in mice.", "C": "Blujepa was found to be non-carcinogenic in rats.", "D": "Blujepa showed carcinogenic effects in human cell lines."}}
{"id": "9wi0SFwzgayj", "question_type": "open_ended_multi_choice", "question": "A 34-year-old woman in her first trimester (10 weeks pregnant) has just been diagnosed with metastatic breast cancer and is suffering from significant bone pain. Her renal and hepatic function are intact. Which pain management strategy is most appropriate for her condition?", "options": {"A": "Morphine sulfate, with counseling on fetal risks and neonatal opioid withdrawal syndrome", "B": "Ketorolac tromethamine for up to 5 days", "C": "Itovebi (inavolisib) in combination with palbociclib and fulvestrant", "D": "Ketorolac tromethamine for chronic pain management"}}
{"id": "Rvpb79X7EZ4A", "question_type": "open_ended_multi_choice", "question": "For a 5-year-old child with classic congenital adrenal hyperplasia receiving glucocorticoid therapy and suffering from severe renal impairment, what is the recommended course of action concerning crinecerfont (CRENESSITY) as an adjunct to improve androgen regulation?", "options": {"A": "Initiate crinecerfont at standard dosage as adjunctive therapy.", "B": "Initiate crinecerfont with dose adjustment due to renal impairment.", "C": "Crinecerfont is not recommended due to severe renal impairment.", "D": "Crinecerfont can be used only if the patient is monitored for hypersensitivity."}}
{"id": "rEVkzncgZjJO", "question_type": "open_ended_multi_choice", "question": "A teenager, age 15, is diagnosed with Grade 2 oligodendroglioma featuring a susceptible IDH1 mutation after subtotal surgical removal. The patient has no other health issues, is not pregnant, and is not on any CYP1A2-modifying medications. Which pharmacological treatment should be recommended, considering both effectiveness and safety for adolescents?", "options": {"A": "Avastin administered intravenously every 2 weeks", "B": "Zortress administered orally twice daily", "C": "Voranigo administered orally once daily", "D": "Avastin in combination with carboplatin and paclitaxel"}}
{"id": "PYuGdQQ4pVRs", "question_type": "open_ended_multi_choice", "question": "A clinician suspects RSV infection in a patient who recently received Enflonsia, but the rapid antigen test is negative. What is the recommended next step?", "options": {"A": "Repeat the rapid antigen test", "B": "Initiate empirical antiviral therapy", "C": "Confirm diagnosis using an RT-PCR assay", "D": "Perform a chest X-ray"}}
{"id": "fg6QfdeTlVJs", "question_type": "open_ended_multi_choice", "question": "For a regulatory filing concerning Enflonsia, what data are available about its effects on fertility?", "options": {"A": "No reproductive toxicity studies have been conducted with Enflonsia.", "B": "Reproductive toxicity studies indicate no impairment of fertility.", "C": "Reproductive toxicity studies indicate potential impairment of fertility.", "D": "Reproductive toxicity studies are currently under review."}}
{"id": "wtNge9jBeQeG", "question_type": "multi_choice", "question": "Which of the following statements best describes the carcinogenicity assessment conducted for Modeyso?", "options": {"A": "Modeyso was shown to reduce the risk of cancer in animal models.", "B": "Modeyso was found to be carcinogenic in rodent studies.", "C": "Modeyso showed a dose-dependent increase in tumor formation.", "D": "Modeyso was tested for carcinogenicity only in vitro."}}
{"id": "ogF0QKFKQBIl", "question_type": "open_ended", "question": "A 35-year-old woman with hypersensitivity reaction disease is currently breastfeeding her infant. She requires short-term management of moderate pruritus due to atopic dermatitis. Which drug should be avoided due to the risk of serious adverse reactions in nursing infants?", "options": {"A": "DEXAMETHASONE SODIUM PHOSPHATE injection", "B": "PHENERGAN (promethazine) injection", "C": "DOXEPIN HYDROCHLORIDE (PRUDOXIN) cream", "D": "Topical corticosteroid (hydrocortisone)"}}
{"id": "Hi43QAfSNog8", "question_type": "open_ended", "question": "A 2-month-old infant, born prematurely and currently hospitalized with severe lower respiratory tract infection due to confirmed respiratory syncytial virus (RSV), is being considered for antiviral therapy. The infant is not on mechanical ventilation and there is no concern for pregnancy or lactation. Which drug is most appropriate for treating this patient's current condition, considering the severity and setting?", "options": {"A": "Ribavirin administered as an inhalation solution for 3 to 7 days", "B": "Enflonsia administered as a single dose for RSV prevention", "C": "Quinidine gluconate administered orally for 5 days", "D": "No antiviral therapy, as all options are contraindicated in this patient"}}
{"id": "HhIMZ6wNKQzv", "question_type": "open_ended", "question": "A 15-year-old adolescent with a diagnosis of hereditary angioedema is seeking long-term prophylactic therapy to prevent future attacks. The patient has normal hepatic and renal function and no history of hypersensitivity reactions. Which of the following is the most appropriate treatment option for this patient, including recommended dosing frequency?", "options": {"A": "Firazyr, administered subcutaneously as needed for acute attacks", "B": "Donidalorsen, administered subcutaneously every 4 weeks for prophylaxis", "C": "Icatibant, administered subcutaneously as needed for acute attacks", "D": "Sajazir, administered subcutaneously as needed for acute attacks"}}
{"id": "9mpiAqpCKP1F", "question_type": "multi_choice", "question": "Which of the following is TRUE regarding the administration of Modeyso via feeding tube?", "options": {"A": "Modeyso cannot be administered via feeding tube", "B": "Modeyso may be given through a naso-gastric or gastrostomy tube after preparing the liquid mixture", "C": "Modeyso capsules must be swallowed whole for tube administration", "D": "Modeyso should be mixed with food before tube administration"}}
{"id": "gK4bh7F1qFWj", "question_type": "open_ended_multi_choice", "question": "In a 68-year-old man with poorly controlled hypertension, chronic kidney disease (eGFR 20 mL/min), and a history of high mean arterial pressure, which add-on antihypertensive drug would be least appropriate to prescribe?", "options": {"A": "TRYVIO", "B": "Candesartan cilexetil", "C": "Latanoprost", "D": "Thiazide diuretic"}}
{"id": "t667D9UUHH6g", "question_type": "open_ended_multi_choice", "question": "What should be done if a patient following the usual Journavx dosing regimen fails to take two or more doses?", "options": {"A": "Take 100 mg as soon as possible, then resume the next scheduled dose.", "B": "Skip all missed doses and wait until the next scheduled dose.", "C": "Take 50 mg as soon as possible, then double the next dose.", "D": "Take 200 mg immediately."}}
{"id": "Onm4A9f8Ae0z", "question_type": "multi_choice", "question": "A patient receiving Modeyso develops a rash, hives, and low blood pressure. What is the most appropriate immediate clinical action?", "options": {"A": "Continue Modeyso and monitor symptoms closely.", "B": "Immediately discontinue Modeyso and initiate appropriate medical treatment and supportive care.", "C": "Temporarily interrupt Modeyso and observe for improvement.", "D": "Reduce the dose of Modeyso and prescribe antihistamines."}}
{"id": "8CcbQWidXE7o", "question_type": "open_ended_multi_choice", "question": "A 6-month-old infant, born prematurely and diagnosed with autosomal dominant adrenocortical carcinoma, has a history of liver and renal dysfunction. When considering chemotherapy for this patient, which treatment option should be specifically avoided because of its excipient-related risk?", "options": {"A": "Etoposide injection containing polysorbate 80", "B": "Lumisight (pegulicianine) administered at 1 mg/kg for imaging", "C": "Etoposide administered orally at a low dose", "D": "Lumisight (pegulicianine) administered at a reduced dose"}}
{"id": "gveM2BWZBnje", "question_type": "multi_choice", "question": "Which of the following immune-mediated endocrinopathies has the highest reported incidence in patients treated with penpulimab-kcqx as a single agent?", "options": {"A": "Hypothyroidism", "B": "Hyperthyroidism", "C": "Thyroiditis", "D": "Adrenal insufficiency"}}
{"id": "pZW4Pb2hCMah", "question_type": "multi_choice", "question": "A 34-year-old woman with primary immunoglobulin A nephropathy (IgAN) and a urine protein-to-creatinine ratio (UPCR) of 2.0 g/g is at risk of rapid disease progression. She is planning to become pregnant and is currently not using any contraception. Which of the following is the most appropriate approach regarding drug therapy to reduce her proteinuria?", "options": {"A": "Initiate VANRAFIA (atrasentan) 0.75 mg once daily and monitor for pregnancy during treatment.", "B": "Advise against VANRAFIA therapy and recommend alternative management due to pregnancy plans.", "C": "Start VANRAFIA (atrasentan) at a reduced dose and discontinue if pregnancy occurs.", "D": "Begin VANRAFIA (atrasentan) and recommend breastfeeding during treatment."}}
{"id": "psHDLEnErK3O", "question_type": "open_ended_multi_choice", "question": "A 34-year-old female with chronic immune thrombocytopenia, who is platelet antibody positive, presents with abnormal bleeding. She has moderate hepatic impairment and is on a proton pump inhibitor for GERD. What is the most suitable pharmacological therapy for her ITP?", "options": {"A": "WAYRILZ (rilzabrutinib) 400 mg twice daily", "B": "Nplate (romiplostim) weekly subcutaneous injection", "C": "DMT SUIK (corticosteroid) intravenous therapy", "D": "WAYRILZ (rilzabrutinib) with a drug holiday during PPI use"}}
{"id": "58rX0EtWGWxj", "question_type": "multi_choice", "question": "A 42-year-old woman with a history of Grade 2 astrocytoma and recent surgical resection is found to have a susceptible IDH2 mutation. She is currently using a hormonal contraceptive and is considering starting targeted therapy. Which of the following is the most important consideration when initiating Voranigo for this patient?", "options": {"A": "Switch to a nonhormonal contraceptive method before starting Voranigo", "B": "Reduce the dose of Voranigo due to her age", "C": "Avoid Voranigo due to risk of nephrotoxicity", "D": "Delay Voranigo initiation until 6 months after surgery"}}
{"id": "EgjmnrcKs8ie", "question_type": "open_ended_multi_choice", "question": "If a patient on Ibtrozi develops Grade 2 QTc interval prolongation (QTc interval 481-500 msec), what is the recommended management?", "options": {"A": "Continue Ibtrozi at the same dose without interruption", "B": "Withhold Ibtrozi until recovery to Grade ≤1 or baseline, correct electrolytes and/or change concomitant medications, then resume at same dose", "C": "Permanently discontinue Ibtrozi", "D": "Reduce the dose immediately without withholding"}}
{"id": "yYBtcJkWpCUT", "question_type": "multi_choice", "question": "A 58-year-old woman with non-alcoholic steatohepatitis (NASH) and moderate liver fibrosis (stage F2) is being considered for pharmacologic therapy. She has a history of well-controlled hypertension and is currently taking atorvastatin 40 mg daily for hyperlipidemia. Her liver function tests are within normal limits, and she does not have decompensated cirrhosis. Which drug regimen is most appropriate for her NASH management, considering her comorbidities and current medications?", "options": {"A": "Pentoxifylline extended-release tablets, 400 mg three times daily", "B": "Rezdiffra, with atorvastatin dose limited to 40 mg daily", "C": "Farxiga, 10 mg once daily", "D": "Rezdiffra, with atorvastatin dose increased to 80 mg daily"}}
{"id": "1ViVxQrwyVDJ", "question_type": "multi_choice", "question": "A 38-year-old woman with a recent diagnosis of schizophrenia presents for initiation of antipsychotic therapy. Her medical history is significant for moderate hepatic impairment (Child-Pugh Class B). She has no history of renal impairment, cardiovascular disease, or metabolic syndrome. Which antipsychotic regimen is most appropriate for this patient?", "options": {"A": "Cobenfy, administered orally at the recommended adult dose", "B": "Abilify Maintena, administered as a weekly intramuscular injection", "C": "Cobenfy, administered at a reduced dose due to hepatic impairment", "D": "Abilify Maintena, administered as a monthly intramuscular injection"}}
{"id": "F5M9aoUeuNnz", "question_type": "open_ended_multi_choice", "question": "Which statement most accurately summarizes the current assessment of Tryptyr's carcinogenic risk?", "options": {"A": "Long-term animal studies have demonstrated a high carcinogenic risk for Tryptyr.", "B": "Long-term studies in animals have not been performed to evaluate the carcinogenic potential of Tryptyr.", "C": "Tryptyr has been shown to be non-carcinogenic in human clinical trials.", "D": "Tryptyr is classified as a probable human carcinogen based on in vitro data."}}
{"id": "fVo8brxyq3PE", "question_type": "open_ended_multi_choice", "question": "During a regulatory review, which statement about the contraindications of Wayrilz would be most accurate?", "options": {"A": "Wayrilz is contraindicated in patients with a history of hypersensitivity reactions.", "B": "Wayrilz is contraindicated in patients with severe renal impairment.", "C": "Wayrilz has no contraindications listed in its prescribing information.", "D": "Wayrilz is contraindicated in pregnant women."}}
{"id": "PLAjAvpdM9Ef", "question_type": "open_ended_multi_choice", "question": "How is the risk of fetal harm described in relation to the use of Gomekli during pregnancy?", "options": {"A": "Gomekli is safe for use during pregnancy", "B": "Gomekli may cause fetal harm or loss of pregnancy", "C": "Gomekli increases the risk of gestational diabetes", "D": "Gomekli prevents miscarriage"}}
{"id": "zNevHd3As2xJ", "question_type": "open_ended_multi_choice", "question": "A 67-year-old man with primary biliary cholangitis and cirrhosis presents with new onset ascites and mild hepatic encephalopathy. He is a CYP2C9 poor metabolizer and is currently taking a moderate CYP3A4 inhibitor for another condition. Which of the following drugs is contraindicated for his PBC management, and why?", "options": {"A": "Seladelpar lysine, once daily, in combination with UDCA", "B": "Elafibranor, once daily, in combination with UDCA", "C": "Abatacept, once monthly", "D": "Seladelpar lysine, once daily, as monotherapy"}}
{"id": "fp6kXaq17gaJ", "question_type": "multi_choice", "question": "A 55-year-old woman with chronic obstructive pulmonary disease (COPD) and a history of major depressive disorder is being considered for maintenance therapy. She has no hepatic or renal impairment. Which drug should be avoided due to her psychiatric history, and which is the most appropriate for her COPD maintenance?", "options": {"A": "Fentanyl Citrate", "B": "Ensifentrine", "C": "Budesonide Inhalation", "D": "Budesonide (oral)"}}
{"id": "ygNMZYVbB0P3", "question_type": "open_ended_multi_choice", "question": "Which statement correctly summarizes what is known about ANZUPGO's safety and efficacy in pediatric populations?", "options": {"A": "ANZUPGO is approved and safe for use in pediatric patients.", "B": "The safety and efficacy of ANZUPGO have not been established in pediatric patients.", "C": "ANZUPGO is contraindicated in pediatric patients.", "D": "ANZUPGO is recommended only for pediatric patients with severe disease."}}
{"id": "ct1WhCAVUrhl", "question_type": "multi_choice", "question": "A 68-year-old man with a history of glaucoma and hypertension presents with severe vernal conjunctivitis unresponsive to antihistamines. He is being considered for corticosteroid therapy. Which drug should be avoided due to the increased risk of intraocular pressure and potential optic nerve damage in this patient?", "options": {"A": "Prednisolone acetate ophthalmic suspension", "B": "Dexamethasone ophthalmic solution", "C": "Loratadine oral tablets", "D": "Prednisolone acetate ophthalmic suspension (prolonged use)"}}
{"id": "YYLnyqJwxkYm", "question_type": "open_ended_multi_choice", "question": "Considering a 68-year-old man who has moderate to severe chronic hand eczema, a history of basal cell carcinoma, and has failed to improve with topical corticosteroids (with no other immunosuppressant use), which management plan is most appropriate?", "options": {"A": "Delgocitinib topical therapy with periodic skin examinations", "B": "Delgocitinib without any skin cancer monitoring", "C": "Combination of Delgocitinib and another JAK inhibitor", "D": "Topical corticosteroids despite prior inadequate response"}}
{"id": "kBw5c9zJwb0t", "question_type": "open_ended_multi_choice", "question": "For a 34-year-old woman who is 8 weeks pregnant and has metastatic ROS1-positive NSCLC, and who takes no other medications, what is the best recommendation regarding starting IBTROZI (taletrectinib) therapy?", "options": {"A": "Initiate IBTROZI (taletrectinib) 600 mg orally once daily immediately", "B": "Initiate IBTROZI (taletrectinib) 600 mg orally once daily with close fetal monitoring", "C": "Defer IBTROZI (taletrectinib) therapy due to risk of embryo-fetal toxicity", "D": "Initiate IBTROZI (taletrectinib) at a reduced dose to minimize fetal risk"}}
{"id": "9cFFx5I57Zom", "question_type": "open_ended_multi_choice", "question": "A 62-year-old man diagnosed with metastatic NSCLC has a tumor that is PD-L1 positive (≥1%) and lacks EGFR and ALK mutations. He has a background of autoimmune thyroiditis but is currently euthyroid on levothyroxine, is not pregnant, and has normal liver function. Which treatment should be selected as his first-line therapy?", "options": {"A": "CYRAMZA (ramucirumab) in combination with docetaxel every 3 weeks", "B": "ENSACOVE (ensartinib) 225 mg orally once daily", "C": "YERVOY (ipilimumab) in combination with nivolumab every 6 weeks", "D": "CYRAMZA (ramucirumab) in combination with erlotinib every 2 weeks"}}
{"id": "mTK0lhfC49tt", "question_type": "open_ended_multi_choice", "question": "A 32-year-old woman with myopathy with eye involvement and a history of sustained ventricular tachycardia is 10 weeks pregnant. Her cardiologist is considering antiarrhythmic therapy. Which statement best reflects the use of mexiletine hydrochloride in her case?", "options": {"A": "Mexiletine hydrochloride is contraindicated in pregnancy due to proven teratogenicity.", "B": "Mexiletine hydrochloride may be considered if the potential benefit justifies the potential risk to the fetus.", "C": "Mexiletine hydrochloride is the first-line antiarrhythmic for all pregnant women with arrhythmias.", "D": "Mexiletine hydrochloride is safe to use during pregnancy without any special considerations."}}
{"id": "blG24hil6gW1", "question_type": "open_ended_multi_choice", "question": "A 32-year-old woman who is pregnant and has normal renal function, with no history of drug allergies, is found to have an acute bacterial skin and skin structure infection due to methicillin-resistant Staphylococcus aureus. Which drug should be selected for her treatment, with regard to safety during pregnancy and official approval for this indication?", "options": {"A": "Doxycycline hyclate", "B": "Acetaminophen", "C": "Ceftobiprole medocaril sodium", "D": "No antibiotic therapy is indicated during pregnancy"}}
{"id": "NE9vZl4bcaFY", "question_type": "multi_choice", "question": "A 48-year-old woman with a history of dermatomyositis (a form of myopathy) presents with proximal muscle weakness, skin rash, and elevated creatine kinase. She is currently pregnant (second trimester) and is concerned about the safety of medications for her and her fetus. Which of the following is the most appropriate management strategy for her myopathy symptoms?", "options": {"A": "Sildenafil citrate 50 mg daily", "B": "TaperDex 6-day corticosteroid regimen, used only if the potential benefit justifies the potential risk to the fetus", "C": "Cortisone aceticum for appetite control", "D": "TaperDex 6-day corticosteroid regimen at high dose without consideration of pregnancy"}}
{"id": "5ZQqDEfdMDtF", "question_type": "open_ended_multi_choice", "question": "A 46-year-old woman with metastatic breast cancer is found to have a PIK3CA mutation and is hormone receptor-positive, HER2-negative. She has moderate renal impairment (eGFR 45 mL/min), is not pregnant, and is not breastfeeding. She is eligible for targeted therapy. Which drug regimen should be considered, given her renal function and the need for dose adjustment?", "options": {"A": "Inavolisib in combination with palbociclib and fulvestrant, with reduced dosage", "B": "Carboplatin at standard dosage", "C": "Esketamine in conjunction with an oral antidepressant", "D": "Carboplatin in combination with aminoglycosides"}}
{"id": "aq1Vc8l1YrBt", "question_type": "open_ended_multi_choice", "question": "If a patient is taking Romvimza and a BCRP substrate, what should be consulted for appropriate dose modifications?", "options": {"A": "The prescribing information of the BCRP substrate.", "B": "The Romvimza prescribing information only.", "C": "General drug interaction guidelines.", "D": "No consultation is needed."}}
{"id": "Pme9dGAlgbwB", "question_type": "open_ended_multi_choice", "question": "What is the appropriate counseling for a patient taking Romvimza regarding breastfeeding?", "options": {"A": "Breastfeeding is permitted during Romvimza therapy.", "B": "Breastfeeding should be discontinued only during the first week of Romvimza therapy.", "C": "Females should not breastfeed during treatment and for 1 month after the final dose.", "D": "Breastfeeding is allowed if the infant is older than 6 months."}}
{"id": "PWifAvn2Wbc8", "question_type": "open_ended_multi_choice", "question": "A 42-year-old man with severe alopecia areata is found to be a CYP2C9 poor metabolizer after genetic testing. He has normal renal and hepatic function and is not pregnant or breastfeeding. Which drug regimen is most suitable for his condition?", "options": {"A": "LEQSELVI administered orally once daily", "B": "Hydroxychloroquine sulfate administered orally once daily", "C": "Triamcinolone acetonide nasal spray twice daily", "D": "LEQSELVI administered orally every other day"}}
{"id": "Yyqz8ZBBC7hb", "question_type": "multi_choice", "question": "Which of the following is NOT a recommended supply for preparing and administering Gomekli tablets for oral suspension?", "options": {"A": "Prescribed number of Gomekli tablets for oral suspension", "B": "Milk", "C": "10 mL oral syringe", "D": "Dosing cup"}}
{"id": "qA3mTjFQtkZT", "question_type": "open_ended", "question": "A 42-year-old woman presents with moderate to severe chronic hand eczema. She has a history of inadequate response to topical corticosteroids and is currently breastfeeding her infant. She is considering topical therapy and asks about safety precautions. Which treatment approach is most appropriate for her?", "options": {"A": "Start Anzupgo (delgocitinib) and advise her to avoid direct contact with the nipple and surrounding area immediately after application.", "B": "Start Anzupgo (delgocitinib) without any additional precautions regarding breastfeeding.", "C": "Start Anzupgo (delgocitinib) in combination with another JAK inhibitor.", "D": "Start Anzupgo (delgocitinib) and recommend discontinuing breastfeeding entirely."}}
{"id": "REOHR0pVoXVT", "question_type": "open_ended_multi_choice", "question": "A 65-year-old female patient with mild Alzheimer’s-related dementia is planning a pregnancy and asks about the safety of KISUNLA (donanemab-azbt). What is the most appropriate guidance concerning her medication options?", "options": {"A": "Recommend KISUNLA, as it is safe for use during pregnancy.", "B": "Advise against KISUNLA due to lack of safety data in pregnancy; consider alternative therapy if available.", "C": "Initiate KISUNLA and monitor closely for ARIA.", "D": "Recommend KISUNLA only after the first trimester."}}
{"id": "O8JKDByG2rD2", "question_type": "open_ended_multi_choice", "question": "In a 60-year-old male patient diagnosed with generalized myasthenia gravis (anti-acetylcholine receptor antibody positive) and chronic hepatitis, who is taking ribavirin, which immunosuppressive drug poses a significant risk of severe pancytopenia and myelotoxicity due to potential drug interactions and should therefore be avoided?", "options": {"A": "IMAAVY, 15 mg/kg intravenous infusion every 2 weeks", "B": "Azathioprine, 100 mg daily oral administration", "C": "DuoDote, single dose for acute management", "D": "IMAAVY, 10 mg/kg intravenous infusion every 4 weeks"}}
{"id": "Zrceh5t4I9CJ", "question_type": "open_ended", "question": "A pregnant woman in her third trimester is admitted for surgical management of a disorder of the appendix. She requires anesthesia for the procedure. Considering the safety profile of available drugs during pregnancy and the risk of fetal harm, which drug is most appropriate for epidural anesthesia in this patient?", "options": {"A": "DEXAMETHASONE", "B": "ROPIVACAINE HYDROCHLORIDE", "C": "Adrenalin", "D": "TaperDex 12-day"}}
{"id": "yMoPyQ00JL3L", "question_type": "open_ended_multi_choice", "question": "A 30-year-old woman with a history of tuberous sclerosis and facial angiofibroma is currently pregnant and seeking treatment for a newly diagnosed skin hemangioma. She is not breastfeeding and is not taking any CYP3A4 inhibitors. Which drug should be avoided due to her pregnancy status?", "options": {"A": "Vincristine Sulfate intravenous", "B": "HYFTOR topical (sirolimus)", "C": "HYFTOR topical (sirolimus) with drug holiday", "D": "Vincristine Sulfate oral"}}
{"id": "XLwDszqf2znM", "question_type": "open_ended_multi_choice", "question": "A 35-year-old woman with KRAS-mutated recurrent low-grade serous ovarian carcinoma is planning to start AVMAPKI FAKZYNJA CO-PACK. She is currently breastfeeding her 3-month-old infant and is concerned about the safety of continuing lactation during treatment. What is the most appropriate recommendation regarding her cancer therapy?", "options": {"A": "Start AVMAPKI FAKZYNJA CO-PACK and continue breastfeeding", "B": "Delay AVMAPKI FAKZYNJA CO-PACK until breastfeeding is discontinued", "C": "Start AVMAPKI FAKZYNJA CO-PACK and stop breastfeeding during treatment and for 2 weeks after the last dose", "D": "Start AVMAPKI FAKZYNJA CO-PACK with reduced dosage to minimize risk to the infant"}}
{"id": "Qd9htX9y34ed", "question_type": "open_ended", "question": "A patient receiving Romvimza develops AST and/or ALT increases greater than 8 times the upper limit of normal (ULN). What is the recommended management?", "options": {"A": "Withhold Romvimza until AST and ALT resolve to baseline.", "B": "Resume Romvimza at the next lower dose level.", "C": "Permanently discontinue Romvimza.", "D": "Continue Romvimza at the same dose."}}
{"id": "7w8q2PynlmwS", "question_type": "multi_choice", "question": "A 2-month-old infant, born prematurely and currently hospitalized with severe lower respiratory tract infection due to confirmed respiratory syncytial virus (RSV), is being considered for antiviral therapy. The infant is not on mechanical ventilation and has no known hypersensitivity to monoclonal antibodies. The mother is not pregnant or breastfeeding. Which of the following is the most appropriate drug for this patient's treatment, including recommended administration duration?", "options": {"A": "Virazole, administered orally for 14 days.", "B": "ENFLONSIA, administered as a single dose for prevention.", "C": "Restasis MultiDose, administered twice daily as ophthalmic drops.", "D": "Virazole, administered as an inhalation solution for 3 to 7 days."}}
{"id": "L32RIC1Ubsi2", "question_type": "multi_choice", "question": "A 48-year-old woman is diagnosed with persistent, recurrent cervical adenocarcinoma. Her tumor expresses PD-L1 (CPS ≥1) as confirmed by an FDA-approved test. She has no history of autoimmune disease, is not pregnant, and has normal hepatic and renal function. She is currently not receiving any other immunosuppressive therapy. Which of the following is the most appropriate drug regimen for her condition, considering both efficacy and safety?", "options": {"A": "Docetaxel administered every 3 weeks as a single agent", "B": "Gemcitabine administered weekly as a single agent", "C": "Keytruda QLEX in combination with chemotherapy, with or without bevacizumab", "D": "Docetaxel in combination with cisplatin and fluorouracil"}}
{"id": "nd7by3WReEa9", "question_type": "multi_choice", "question": "A 65-year-old man with chronic kidney disease and anemia is being evaluated for pharmacologic therapy. He has not yet started dialysis but is expected to begin within the next two months. His past medical history is significant for cirrhosis secondary to hepatitis C. Which of the following is the most appropriate recommendation regarding anemia management for this patient?", "options": {"A": "Initiate vadadustat immediately to treat anemia due to CKD.", "B": "Start fedratinib with thiamine supplementation.", "C": "Avoid vadadustat due to underlying cirrhosis; consider alternative anemia management.", "D": "Use the homeopathic combination for anemia symptoms."}}
{"id": "MOVlVgrYfjqt", "question_type": "open_ended_multi_choice", "question": "When a patient on Imaavy requires ongoing treatment with FcRn-binding medications, which of the following approaches is NOT advised?", "options": {"A": "Discontinue Imaavy and use alternative therapies", "B": "Continue Imaavy and monitor for reduced effectiveness", "C": "Increase the dose of FcRn-binding medication", "D": "Switch to non-FcRn-binding alternatives"}}
{"id": "7L4ZrPnjAllZ", "question_type": "open_ended_multi_choice", "question": "A 68-year-old patient with chronic obstructive pulmonary disease (COPD) presents for ongoing maintenance therapy. He has a history of hepatic impairment and is currently stable with no psychiatric disorders. Which of the following drugs is most appropriate for maintenance treatment of his COPD, considering his age and comorbidities?", "options": {"A": "Budesonide Inhalation", "B": "Fentanyl Citrate", "C": "Ensifentrine", "D": "Budesonide (oral)"}}
{"id": "VF4hjScAFoDy", "question_type": "multi_choice", "question": "A 68-year-old woman with metastatic gastroesophageal junction adenocarcinoma is being considered for chemotherapy. She has a history of chronic liver disease with laboratory findings of bilirubin 2.1x ULN, AST 2.0x ULN, and alkaline phosphatase 3.0x ULN. She has no known drug allergies and is not taking anticoagulants. Which of the following drugs is contraindicated for her due to her hepatic impairment?", "options": {"A": "Zolbetuximab (Vyloy) in combination with fluoropyrimidine- and platinum-containing chemotherapy", "B": "Docetaxel in combination with cisplatin and fluorouracil", "C": "Capecitabine (with dose adjustment for hepatic impairment)", "D": "Zolbetuximab (Vyloy) monotherapy"}}
{"id": "2D9oJteE095I", "question_type": "multi_choice", "question": "A 68-year-old woman with transfusion-dependent anemia is diagnosed with low-risk myelodysplastic syndrome (MDS) associated with a deletion 5q cytogenetic abnormality. She has normal renal function and is not pregnant. Her physician is considering starting drug therapy to reduce her transfusion needs. Which of the following drugs is most appropriate for her condition, considering both efficacy and safety for her specific MDS subtype?", "options": {"A": "Lenalidomide, administered orally once daily, with strict adherence to pregnancy prevention protocols.", "B": "INQOVI (cedazuridine and decitabine), administered orally once daily in 28-day cycles.", "C": "TREOSULFAN (GRAFAPEX), in combination with fludarabine as a preparative regimen for allogeneic stem cell transplantation.", "D": "Azacitidine, administered subcutaneously for 7 days every 28 days."}}
{"id": "UyRJcBOSTjeD", "question_type": "multi_choice", "question": "If a patient’s blood phenylalanine does not decrease after 2 weeks of Sephience at the maximum daily dose, what is the recommended clinical action?", "options": {"A": "Increase the dose beyond 60 mg/kg", "B": "Discontinue Sephience", "C": "Continue current dose and monitor monthly", "D": "Switch to a high-protein diet"}}
{"id": "2k50hYhA5gB3", "question_type": "open_ended_multi_choice", "question": "A 67-year-old patient with chronic pulmonary heart disease and a history of idiopathic pulmonary fibrosis (IPF) is being considered for therapy to improve exercise ability. The patient has well-controlled hypertension, no history of asthma or COPD, and normal hepatic and renal function. She is currently taking bosentan for pulmonary arterial hypertension. Which of the following is the most appropriate drug and route of administration for this patient, considering her clinical profile and current medications?", "options": {"A": "Tyvaso DPI (inhaled treprostinil), administered four times daily", "B": "Oral treprostinil, administered three times daily", "C": "Subcutaneous treprostinil infusion, continuous administration", "D": "Tyvaso DPI (inhaled treprostinil), administered once daily"}}
{"id": "AauTHniZbhWX", "question_type": "open_ended_multi_choice", "question": "Which of the following patient histories would prevent you from prescribing Blujepa?", "options": {"A": "Severe hypersensitivity to Blujepa", "B": "Mild gastrointestinal upset after Blujepa", "C": "Family history of hypertension", "D": "Previous use of Blujepa without adverse effects"}}
{"id": "fCwzNAcWGkg3", "question_type": "open_ended_multi_choice", "question": "What is the potential effect of Wayrilz on drugs that are substrates of P-gp, BCRP, or OATP1B transporters?", "options": {"A": "Wayrilz induces these transporters, reducing substrate exposure", "B": "Wayrilz inhibits these transporters, potentially increasing substrate exposure and risk of adverse reactions", "C": "Wayrilz has no effect on these transporters", "D": "Wayrilz increases the metabolism of these substrates"}}
{"id": "HFckzbcBqImu", "question_type": "multi_choice", "question": "For patients in the AK105-202 trial of penpulimab-kcqx, what proportion had tumors with PD-L1 tumor proportion score (TPS) ≥50%?", "options": {"A": "37%", "B": "10%", "C": "50%", "D": "2.4%"}}
{"id": "877Gqgzo1hBU", "question_type": "open_ended_multi_choice", "question": "A 72-year-old patient with newly diagnosed recurrent, metastatic non-keratinizing nasopharyngeal carcinoma also has moderate renal impairment (creatinine clearance 35 mL/min) and a history of gastrointestinal bleeding. Given these health issues, identify the medication that should be avoided and the one most suitable for treating his cancer.", "options": {"A": "Capecitabine 500 mg twice daily, with dose reduction for renal impairment", "B": "Celecoxib 200 mg twice daily for pain management", "C": "Penpulimab-kcqx in combination with carboplatin and gemcitabine, administered every 3 weeks", "D": "Capecitabine 500 mg twice daily, standard dosing"}}
{"id": "TBRL6Dje1uCc", "question_type": "open_ended_multi_choice", "question": "A 32-year-old woman presents with moderate dry eye disease. She is currently 10 weeks pregnant and is concerned about the safety of medications for her developing fetus. She does not wear contact lenses. Which drug is the most appropriate choice for treating her dry eye disease, considering her pregnancy status and the safety profile of available treatments?", "options": {"A": "Loteprednol etabonate ophthalmic gel, administered twice daily", "B": "Lifitegrast ophthalmic solution, administered twice daily", "C": "Acoltremon ophthalmic solution, administered twice daily", "D": "Loteprednol etabonate ophthalmic gel, administered once daily"}}
{"id": "5Hkh9wtCXvMY", "question_type": "open_ended_multi_choice", "question": "A 62-year-old woman with previously treated, unresectable intrahepatic cholangiocarcinoma is found to have a tumor harboring an FGFR2 gene fusion by an FDA-approved test. She also has a history of severe renal impairment (eGFR 20 mL/min/1.73 m²). She is not pregnant and is not taking any strong CYP3A inhibitors or inducers. Which drug is the most appropriate targeted therapy for her condition, considering her renal function?", "options": {"A": "LYTGOBI", "B": "ZIIHERA", "C": "PEMAZYRE", "D": "Gemcitabine"}}
{"id": "YrbeiO6RNzDh", "question_type": "open_ended_multi_choice", "question": "A 28-year-old woman with a history of molybdenum cofactor deficiency type A, confirmed by genetic testing and elevated urinary sulfite, is currently breastfeeding her newborn. She has experienced progressive intellectual disability and spastic tetraparesis since childhood. She is considering starting drug therapy to reduce her risk of mortality. Which of the following statements best reflects the current evidence regarding the use of Nulibry in her situation?", "options": {"A": "Nulibry is contraindicated during lactation due to proven adverse effects on breastfed infants.", "B": "Nulibry can be used, but the benefits and risks to both mother and infant should be carefully weighed, as there are no data on its presence in human milk.", "C": "Nulibry is only approved for pediatric patients and should not be used in adults.", "D": "Nulibry is the only drug with established safety in breastfeeding women with MoCD Type A."}}
{"id": "QKko8yfNSVK5", "question_type": "open_ended_multi_choice", "question": "What should a biomedical researcher consider regarding the contraindication profile of Hernexeos during their review?", "options": {"A": "There are no contraindications for Hernexeos.", "B": "Hernexeos is contraindicated in patients with a history of hypersensitivity reactions.", "C": "Hernexeos should not be administered to patients with cardiovascular disease.", "D": "Hernexeos is contraindicated in patients taking anticoagulants."}}
{"id": "yMeVcjczTeIh", "question_type": "open_ended_multi_choice", "question": "Which medication regimen is most appropriate for a 16-year-old male with hemophilia A and Child-Pugh Class B hepatic impairment who needs routine prophylaxis, given that he has no history of gallbladder disease and is not on hormonal contraceptives?", "options": {"A": "Qfitlia administered subcutaneously once monthly", "B": "Hemlibra administered subcutaneously once weekly", "C": "Qfitlia administered subcutaneously using antithrombin-based dosing every four weeks", "D": "Fitusiran administered intravenously every two weeks"}}
{"id": "raYUMzwnwKrp", "question_type": "open_ended_multi_choice", "question": "Considering tear production outcomes, how did Tryptyr's effectiveness versus vehicle compare in terms of statistical significance in the COMET-2 and COMET-3 studies?", "options": {"A": "No statistically significant difference was observed.", "B": "Statistically significant improvement favoring Tryptyr (p<0.01) was observed in both studies.", "C": "Statistically significant improvement favoring vehicle (p<0.01) was observed.", "D": "Statistical significance was only achieved in COMET-2."}}
{"id": "coGtV2pdb0Ky", "question_type": "open_ended_multi_choice", "question": "A 45-year-old woman with paroxysmal nocturnal hemoglobinuria (PNH) is experiencing extravascular hemolysis while being treated with ravulizumab. She also has mild hepatic impairment (Child-Pugh Class B) and is taking rosuvastatin 20 mg daily for hyperlipidemia. Given her current medications and comorbid conditions, what is the most suitable pharmacologic approach to manage her EVH?", "options": {"A": "Add danicopan to her current ravulizumab regimen, maintaining her rosuvastatin dose at 20 mg once daily.", "B": "Switch to pegcetacoplan monotherapy and discontinue ravulizumab.", "C": "Add danicopan to her current ravulizumab regimen, but reduce rosuvastatin dose to no more than 10 mg once daily.", "D": "Switch to crovalimab monotherapy and discontinue ravulizumab."}}
{"id": "uO85A0TTzUac", "question_type": "open_ended_multi_choice", "question": "When reviewing the prescribing information for Romvimza, what should clinicians note regarding contraindications?", "options": {"A": "Romvimza is contraindicated in patients with renal impairment.", "B": "Romvimza is contraindicated in patients with hepatic dysfunction.", "C": "Romvimza has no contraindications listed.", "D": "Romvimza is contraindicated in patients with cardiovascular disease."}}
{"id": "XTnn1tl4CBCy", "question_type": "multi_choice", "question": "What is the effect of strong and moderate CYP3A4 inducers on the anti-tumor activity of Modeyso?", "options": {"A": "Increase anti-tumor activity", "B": "Decrease anti-tumor activity", "C": "No effect on anti-tumor activity", "D": "Cause unpredictable changes"}}
{"id": "kLu29N66V462", "question_type": "multi_choice", "question": "A 76-year-old man is diagnosed with wild-type transthyretin-mediated amyloid cardiomyopathy (ATTR-CM). He has a history of hyperlipidemia managed with rosuvastatin and is not taking any UGT inducers, CYP3A inducers, or CYP2C9 substrates. He is not planning to become pregnant and is not breastfeeding. Which of the following is the most appropriate drug to reduce his risk of cardiovascular death and hospitalization?", "options": {"A": "Attruby", "B": "Dexrazoxane", "C": "Vyndaqel", "D": "No pharmacologic therapy is indicated"}}
{"id": "Mi5nkIkT8J5A", "question_type": "open_ended", "question": "What is the recommended action if a patient develops Grade 3 Cytokine Release Syndrome (CRS) while receiving Lynozyfic?", "options": {"A": "Continue Lynozyfic at the same dose", "B": "Withhold Lynozyfic until CRS resolves and modify the next dose or discontinue permanently based on severity", "C": "Increase the dose of Lynozyfic", "D": "Switch to oral administration"}}
{"id": "77kwrry00LE8", "question_type": "open_ended_multi_choice", "question": "Which of the following statements best describes the risk associated with administering Penpulimab-kcqx to pregnant women?", "options": {"A": "Penpulimab-kcqx is safe to use during pregnancy as animal studies have shown no adverse effects.", "B": "Penpulimab-kcqx can cause fetal harm due to its mechanism of action, and animal studies suggest increased risk of immune-mediated fetal loss.", "C": "Penpulimab-kcqx is recommended for use in all trimesters of pregnancy.", "D": "Penpulimab-kcqx has been proven to prevent miscarriage in pregnant women."}}
{"id": "fiYu1nOAPfeb", "question_type": "open_ended_multi_choice", "question": "A 45-year-old male with a history of basal cell carcinoma and persistent moderate to severe hand eczema is being considered for topical therapy. He has no active infections and is not receiving immunosuppressive treatment. What is the optimal management strategy in this case?", "options": {"A": "Start topical Anzupgo with regular skin examinations to monitor for non-melanoma skin cancer.", "B": "Start topical Anzupgo without any need for skin cancer monitoring.", "C": "Start topical Anzupgo in combination with potent immunosuppressants.", "D": "Start topical Anzupgo and schedule live vaccinations during treatment."}}
{"id": "75Y40iQjKWwj", "question_type": "open_ended", "question": "When managing a patient who develops cytokine release syndrome (CRS) during Lynozyfic therapy, what is the recommended initial action?", "options": {"A": "Increase the dose of Lynozyfic", "B": "Continue Lynozyfic without modification", "C": "Withhold Lynozyfic until CRS resolves", "D": "Switch to a different immunotherapy"}}
{"id": "zXc7k2AEDmwK", "question_type": "open_ended", "question": "A 47-year-old woman with metastatic HER2-mutant non-squamous NSCLC is currently breastfeeding and wishes to begin systemic therapy. She has no significant comorbidities and is not taking any interacting medications. Which of the following drugs is contraindicated for her due to her lactation status?", "options": {"A": "TOPOTECAN", "B": "TECENTRIQ", "C": "HERNEXEOS", "D": "All of the above"}}
{"id": "l85QvULPnGhV", "question_type": "open_ended_multi_choice", "question": "A 28-year-old woman in her first trimester (10 weeks pregnant) has recently been diagnosed with molluscum contagiosum. She is anxious about using topical treatments while pregnant. Her medical history is negative for skin allergies or lesions. Which recommendation is most appropriate in her case?", "options": {"A": "Adapalene applied nightly to lesions", "B": "Zelsuvmi applied topically as directed, with counseling about limited pregnancy safety data", "C": "Zelsuvmi applied twice daily to lesions", "D": "Adapalene applied twice daily to lesions"}}
{"id": "vEbrkHWtXkgi", "question_type": "open_ended_multi_choice", "question": "For which category of patients is Blujepa not recommended due to contraindications?", "options": {"A": "Patients with a history of severe hypersensitivity to Blujepa", "B": "Patients with mild renal impairment", "C": "Patients with controlled hypertension", "D": "Patients with a history of seasonal allergies"}}
{"id": "CiAoS468DJec", "question_type": "multi_choice", "question": "Which reproductive safety advice should be given to females of reproductive potential who are prescribed Hernexeos?", "options": {"A": "No contraception is needed during treatment", "B": "Contraception is only needed if pregnancy is suspected", "C": "Use effective contraception during treatment and for 2 weeks after the last dose", "D": "Discontinue contraception immediately after starting Hernexeos"}}
{"id": "mNqJUYOiuXQR", "question_type": "open_ended_multi_choice", "question": "Which statement most accurately characterizes the impact of Modeyso on fertility?", "options": {"A": "Modeyso has no known effect on fertility.", "B": "Modeyso may adversely impact fertility in both males and females.", "C": "Modeyso improves fertility in females.", "D": "Modeyso only affects fertility in males."}}
{"id": "dS3fmEBJ9DbJ", "question_type": "open_ended_multi_choice", "question": "A 14-year-old male with hemophilia B and no history of hepatic or gallbladder disease is being considered for routine prophylaxis to reduce bleeding episodes. He has normal liver function tests and no contraindications to therapy. Which drug is the most appropriate for this patient, and what is the rationale for its selection?", "options": {"A": "Hemlibra, administered subcutaneously once weekly", "B": "Qfitlia, administered according to antithrombin-based dosing regimen", "C": "Hemlibra, administered subcutaneously every four weeks", "D": "Qfitlia, administered at a fixed dose of 80 mg once monthly"}}
{"id": "0wf5haZJ1qqM", "question_type": "open_ended", "question": "A 77-year-old woman with relapsed multiple myeloma, who has received four prior lines of therapy (including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody), is being considered for further treatment. She has mild chronic kidney disease (eGFR 55 mL/min), no hepatic dysfunction, and no history of severe infections. She is otherwise healthy but is concerned about the risk of fatal adverse reactions. Which therapy is most appropriate for her?", "options": {"A": "TALVEY, with close monitoring for neurologic toxicity and oral adverse effects", "B": "LYNOZYFIC, with step-up dosing and monitoring for neutropenia and hepatotoxicity", "C": "Mozobil, with dose adjustment for renal impairment", "D": "TALVEY, with a reduced dosing frequency to minimize adverse events"}}
{"id": "MD43gKPDAefr", "question_type": "open_ended_multi_choice", "question": "A woman aged 28, diagnosed with sepiapterin-responsive phenylketonuria and a history of scleroderma, is preparing for pregnancy and has recently had significant menstrual bleeding. She uses sulfasalazine to treat her autoimmune disease. Which treatment regimen for her PKU is contraindicated?", "options": {"A": "Sapropterin dihydrochloride administered daily with a phenylalanine-restricted diet", "B": "JAVYGTOR administered daily with a phenylalanine-restricted diet", "C": "Sephience administered daily with a phenylalanine-restricted diet", "D": "Sapropterin dihydrochloride administered every other day with a phenylalanine-restricted diet"}}
{"id": "q8kt81MtYQaL", "question_type": "multi_choice", "question": "A 68-year-old woman with newly diagnosed locally advanced ROS1-positive non-small cell lung carcinoma is being considered for targeted therapy. She has a history of osteoporosis and is currently taking a proton pump inhibitor for chronic gastroesophageal reflux disease. Which of the following is the most appropriate approach regarding the use of taletrectinib for her treatment?", "options": {"A": "Initiate taletrectinib 600 mg orally once daily without modification.", "B": "Taletrectinib is contraindicated due to her age.", "C": "Initiate taletrectinib 600 mg orally once daily, but discontinue the proton pump inhibitor or adjust antacid timing.", "D": "Taletrectinib is contraindicated due to her osteoporosis."}}
{"id": "lwVqBJvhe8kZ", "question_type": "multi_choice", "question": "A 38-year-old woman with a recent diagnosis of schizophrenia presents for initiation of antipsychotic therapy. Her medical history is significant for moderate hepatic impairment (Child-Pugh Class B). She has no history of renal impairment, cardiovascular disease, or metabolic syndrome. Which antipsychotic regimen is most appropriate for this patient?", "options": {"A": "Abilify Maintena, administered as a monthly intramuscular injection", "B": "Cobenfy, administered orally at the recommended adult dose", "C": "Cobenfy, administered at a reduced dose due to hepatic impairment", "D": "Abilify Maintena, administered as a weekly intramuscular injection"}}
{"id": "i69l8FGR3z2r", "question_type": "multi_choice", "question": "A 42-year-old woman with newly diagnosed pulmonary arterial hypertension (PAH, WHO Group 1) presents for initial therapy. She is not pregnant, has no history of bleeding disorders, and is not taking any prostacyclin or antithrombotic agents. Her platelet count and hemoglobin are within normal limits. Which of the following is the most appropriate drug to initiate for her condition, considering efficacy and safety?", "options": {"A": "Epinephrine administered as a continuous infusion", "B": "Vasopressin administered intravenously", "C": "Vasopressin combined with indomethacin", "D": "Winrevair administered according to recommended dosing schedule"}}
{"id": "hR3oIVm27iJU", "question_type": "open_ended", "question": "A 15-year-old adolescent with hereditary angioedema presents with frequent attacks and is seeking a long-term prophylactic therapy. The patient has mild renal impairment but is not on any medications known to induce P-gp. Which drug regimen is most appropriate for this patient to prevent future HAE attacks?", "options": {"A": "Orladeyo 150 mg orally once daily", "B": "SAJAZIR (icatibant) injection as needed for acute attacks", "C": "SEBETRALSTAT (EKTERLY) 300 mg orally at onset of attack", "D": "Orladeyo 300 mg orally once daily"}}
{"id": "tZKkezqr3l6e", "question_type": "open_ended_multi_choice", "question": "For women who are currently breastfeeding and require Modeyso, what is the advised course of action?", "options": {"A": "Do not breastfeed during treatment and for 1 week after the last dose.", "B": "Continue breastfeeding as usual.", "C": "Breastfeed only immediately before taking Modeyso.", "D": "Stop breastfeeding permanently."}}
{"id": "D1urB5ovXWOR", "question_type": "open_ended_multi_choice", "question": "A 28-year-old woman with a diagnosis of reading seizures and EEG abnormalities is currently pregnant. She has no history of cardiac disease, and her renal and hepatic function are normal. She is not taking any serotonergic drugs. Which of the following is the most appropriate recommendation regarding the use of Fintepla for her seizure management?", "options": {"A": "Fintepla can be used safely throughout pregnancy without any precautions", "B": "Fintepla should be avoided due to potential fetal harm observed in animal studies", "C": "Fintepla is only contraindicated in patients with renal impairment", "D": "Fintepla is recommended only if the patient is also breastfeeding"}}
{"id": "aIDwLut3wqKy", "question_type": "open_ended_multi_choice", "question": "A 35-year-old woman with young-onset Parkinson disease presents with agitation, anxiety, and short attention span. She is currently taking carbidopa and levodopa and has recently started fluoxetine for depression. She is seeking additional therapy to help with her motor symptoms. Which of the following adjunctive drugs should be avoided due to her current medication regimen?", "options": {"A": "Tasmar", "B": "Carbidopa and Levodopa", "C": "Selegiline Hydrochloride", "D": "Tasmar combined with Carbidopa and Levodopa"}}
{"id": "GEY9kqrKWmuB", "question_type": "open_ended_multi_choice", "question": "How would you best characterize the carcinogenicity studies that have been performed regarding Emrelis?", "options": {"A": "Carcinogenicity studies in animals have been performed with Emrelis and showed no evidence of carcinogenicity.", "B": "Carcinogenicity studies in animals have not been performed with Emrelis or its small molecule MMAE.", "C": "Carcinogenicity studies in humans have demonstrated a high risk of cancer with Emrelis.", "D": "Carcinogenicity studies in animals have been performed only with the small molecule MMAE, not with Emrelis."}}
{"id": "brD3UX2J6zHZ", "question_type": "open_ended_multi_choice", "question": "A clinical trial protocol excludes patients based on drug contraindications. For Avmapki Fakzynja Co-Pack, which exclusion criterion would be unsupported by the drug's contraindication section?", "options": {"A": "Excluding patients with known hypersensitivity to Avmapki Fakzynja Co-Pack", "B": "Excluding patients with severe hepatic impairment", "C": "Excluding all patients, as there are no contraindications", "D": "Excluding patients with a history of cardiovascular disease"}}
{"id": "Nbcpr9r02SFz", "question_type": "open_ended_multi_choice", "question": "For patients in the AK105-304 study receiving penpulimab-kcqx in combination with platinum and gemcitabine, what was the median progression-free survival (PFS) as assessed by blinded independent central review (BICR)?", "options": {"A": "9.6 months (95% CI: 7.1, 12.5)", "B": "7.0 months (95% CI: 6.9, 7.3)", "C": "12.5 months (95% CI: 10.0, 15.0)", "D": "6.0 months (95% CI: 5.0, 7.0)"}}
{"id": "pbqEOdGcSgi4", "question_type": "open_ended_multi_choice", "question": "A 32-year-old woman who is 10 weeks pregnant presents with moderate dry eye disease. She does not wear contact lenses and is worried about the safety of medications during pregnancy. Considering her gestational status and the safety profiles of available treatments, which is the best drug option for her dry eye disease?", "options": {"A": "Loteprednol etabonate ophthalmic gel, administered twice daily", "B": "Lifitegrast ophthalmic solution, administered twice daily", "C": "Acoltremon ophthalmic solution, administered twice daily", "D": "Loteprednol etabonate ophthalmic gel, administered once daily"}}
{"id": "FzHkWUVwTHCu", "question_type": "open_ended_multi_choice", "question": "Which of the following is true regarding the contraindications for the drug Sephience?", "options": {"A": "Sephience is contraindicated in patients with hepatic impairment.", "B": "Sephience is contraindicated in patients with renal failure.", "C": "Sephience has no listed contraindications.", "D": "Sephience is contraindicated in pediatric patients."}}
{"id": "EpC7cYTPKIfk", "question_type": "open_ended", "question": "A 58-year-old man is newly diagnosed with metastatic squamous non-small cell lung carcinoma. He has a history of coronary artery disease and controlled hypertension. Laboratory tests reveal normal magnesium, potassium, and calcium levels. He is scheduled to start first-line therapy. Which drug regimen should be avoided due to increased risk of cardiopulmonary arrest and is not suitable for patients with significant cardiac comorbidities?", "options": {"A": "Rozlytrek (entrectinib) for ROS1-positive NSCLC", "B": "Portrazza (necitumumab) in combination with gemcitabine and cisplatin", "C": "EMRELIS (telisotuzumab vedotin) for c-Met overexpressing NSCLC", "D": "Portrazza (necitumumab) as monotherapy"}}
{"id": "41AyJHfJ9V8G", "question_type": "open_ended", "question": "A 14-year-old boy with sepiapterin-responsive phenylketonuria, presenting with aggressive behavior, compulsive behaviors, and a history of superficial hematomas, is scheduled to start pharmacologic therapy. He is not taking any DHFR or SR inhibitors. Which drug regimen should be avoided due to his medical history?", "options": {"A": "Sapropterin dihydrochloride 20 mg/kg daily with a Phe-restricted diet", "B": "Sephience 60 mg/kg daily with a Phe-restricted diet", "C": "JAVYGTOR 20 mg/kg daily with a Phe-restricted diet", "D": "Sephience 60 mg/kg daily with a Phe-restricted diet and frequent blood Phe monitoring"}}
{"id": "tePydGpjC2oQ", "question_type": "open_ended_multi_choice", "question": "A 68-year-old male patient diagnosed with pulmonary arterial hypertension (WHO Group 1) and moderate liver dysfunction is being evaluated for pharmacologic treatment. He does not have any bleeding disorders and has never used cyclosporine. Which medication would be most appropriate for his case?", "options": {"A": "Ambrisentan once daily", "B": "Macitentan once daily", "C": "Sotatercept-csrk every three weeks", "D": "Ambrisentan in combination with tadalafil"}}
{"id": "BCwp3az6sQit", "question_type": "open_ended_multi_choice", "question": "A 10-year-old boy diagnosed with Duchenne muscular dystrophy, carrying a DMD gene mutation responsive to exon 51 skipping, is being evaluated for treatment. Given his prior hypersensitivity reactions to intravenous drugs, which therapeutic regimen would be most appropriate for him?", "options": {"A": "Eteplirsen administered once weekly", "B": "Deflazacort administered daily", "C": "Givinostat administered twice daily", "D": "Eteplirsen with a drug scheduler to minimize hypersensitivity risk"}}
{"id": "b3yUWy5KwPJz", "question_type": "multi_choice", "question": "A 5-year-old boy with BH4-responsive phenylketonuria presents with fair hair, generalized hypopigmentation, and a history of seizures. He is currently receiving levodopa for a movement disorder. His parents are concerned about the risk of hypophenylalaninemia and neurological side effects. Which drug regimen requires the most careful monitoring for neurological status and blood phenylalanine levels in this patient?", "options": {"A": "Sephience at 20 mg/kg per day with a phenylalanine-restricted diet", "B": "Sephience at 60 mg/kg per day with a phenylalanine-restricted diet", "C": "Sapropterin dihydrochloride at 20 mg/kg per day with a phenylalanine-restricted diet", "D": "JAVYGTOR at 20 mg/kg per day with a phenylalanine-restricted diet"}}
{"id": "7LYUiecO0u58", "question_type": "open_ended_multi_choice", "question": "A 7-year-old with cystic fibrosis, confirmed to be homozygous for the F508del mutation, presents with bronchiectasis, poor growth, and high sweat chloride. She is currently prescribed oral hormonal contraceptives for another condition. What is the most appropriate drug regimen for her?", "options": {"A": "Brinsupri, with monitoring for dermatologic adverse reactions", "B": "ORKAMBI, with counseling to use non-hormonal contraception", "C": "SYMDEKO, with standard dosing and no change to contraceptive regimen", "D": "ORKAMBI, with no contraceptive counseling required"}}
{"id": "3gdlfY80zGNK", "question_type": "multi_choice", "question": "A 5-year-old boy with BH4-responsive phenylketonuria presents with fair hair, generalized hypopigmentation, and a history of seizures. He is currently receiving levodopa for a movement disorder. His parents are concerned about the risk of hypophenylalaninemia and neurological side effects. Which drug regimen requires the most careful monitoring for neurological status and blood phenylalanine levels in this patient?", "options": {"A": "Sephience at 60 mg/kg per day with a phenylalanine-restricted diet", "B": "JAVYGTOR at 20 mg/kg per day with a phenylalanine-restricted diet", "C": "Sapropterin dihydrochloride at 20 mg/kg per day with a phenylalanine-restricted diet", "D": "Sephience at 20 mg/kg per day with a phenylalanine-restricted diet"}}
{"id": "mxDn42GxD0Px", "question_type": "open_ended_multi_choice", "question": "A woman aged 45 with dry eye disease, who uses contact lenses and wishes to avoid taking them out before applying her medication, is looking for a therapy with a well-established safety profile in adults. She is neither pregnant nor has a history of eye infections. Which medication is the most suitable choice for her?", "options": {"A": "TRYPTYR", "B": "Lotemax SM", "C": "Xiidra", "D": "Topical corticosteroid drops (other than Lotemax SM)"}}
{"id": "1YMW6DexoMj9", "question_type": "open_ended_multi_choice", "question": "Considering a 17-year-old female patient with WHIM syndrome, frequent bacterial infections, and reduced antibody levels, who is currently on digoxin and metformin, is not pregnant, and has normal kidney and liver function, what is the optimal pharmacological intervention to enhance her mature neutrophil and lymphocyte levels?", "options": {"A": "XOLREMDI, daily oral administration with frequent monitoring of digoxin and glycemic control", "B": "Mavorixafor, daily oral administration without monitoring", "C": "XOLREMDI, daily oral administration with a drug holiday every month", "D": "No drug therapy recommended due to drug interactions"}}
{"id": "NgccMxmzxtA5", "question_type": "multi_choice", "question": "A 58-year-old woman with non-alcoholic steatohepatitis (NASH) and moderate liver fibrosis (stage F2) is being considered for pharmacologic therapy. She has a history of well-controlled hypertension and is currently taking atorvastatin 40 mg daily for hyperlipidemia. Her liver function tests are within normal limits, and she does not have decompensated cirrhosis. Which drug regimen is most appropriate for her NASH management, considering her comorbidities and current medications?", "options": {"A": "Pentoxifylline extended-release tablets, 400 mg three times daily", "B": "Rezdiffra, with atorvastatin dose increased to 80 mg daily", "C": "Farxiga, 10 mg once daily", "D": "Rezdiffra, with atorvastatin dose limited to 40 mg daily"}}
{"id": "waR09I0m27xA", "question_type": "multi_choice", "question": "Which statement best describes the contraindication profile of Lynozyfic?", "options": {"A": "Lynozyfic has multiple contraindications, including renal and hepatic impairment.", "B": "Lynozyfic is contraindicated in patients with hypersensitivity to its active ingredient.", "C": "Lynozyfic has no listed contraindications.", "D": "Lynozyfic should not be used in elderly patients."}}
{"id": "vCjmpqzTxNth", "question_type": "open_ended_multi_choice", "question": "Which branded drug is approved for use in a 14-year-old with non-cystic fibrosis bronchiectasis?", "options": {"A": "Brinsupri", "B": "Albuterol", "C": "Azithromycin", "D": "Prednisone"}}
{"id": "cqofFbING5pm", "question_type": "open_ended_multi_choice", "question": "When preparing to drive at night or use machinery, what should patients who are on Vizz be mindful of?", "options": {"A": "Ensure vision is clear before engaging in these activities.", "B": "Take Vizz immediately before driving.", "C": "Wear sunglasses at night.", "D": "Increase the dose if vision is blurred."}}
{"id": "50K0jKf3k6Cw", "question_type": "open_ended_multi_choice", "question": "A 34-year-old woman with metastatic ROS1-positive NSCLC is 8 weeks pregnant and seeking treatment options. She is otherwise healthy and not taking any other medications. Which of the following is the most appropriate recommendation regarding IBTROZI (taletrectinib) therapy?", "options": {"A": "Initiate IBTROZI (taletrectinib) 600 mg orally once daily immediately", "B": "Initiate IBTROZI (taletrectinib) 600 mg orally once daily with close fetal monitoring", "C": "Defer IBTROZI (taletrectinib) therapy due to risk of embryo-fetal toxicity", "D": "Initiate IBTROZI (taletrectinib) at a reduced dose to minimize fetal risk"}}
{"id": "kTZkPFFeYZZp", "question_type": "multi_choice", "question": "What is the recommended procedure regarding contact lens use when administering Vizz?", "options": {"A": "Remove contact lenses and wait 1 hour before reinserting.", "B": "Keep contact lenses in during instillation.", "C": "Remove contact lenses before instillation and reinsert 10 minutes after.", "D": "Do not use contact lenses at all during Vizz therapy."}}
{"id": "n7R8DtLpr1IJ", "question_type": "open_ended_multi_choice", "question": "A 52-year-old woman with newly diagnosed locally advanced ROS1-positive non-small cell lung carcinoma is currently taking a strong CYP3A inhibitor for a fungal infection. She is not pregnant or breastfeeding and has no history of liver disease or arrhythmias. Which of the following is the most appropriate drug treatment for her lung cancer at this time?", "options": {"A": "IBTROZI (taletrectinib) 600 mg orally once daily", "B": "IBTROZI (taletrectinib) 600 mg orally once daily, with a drug holiday during antifungal therapy", "C": "IBTROZI (taletrectinib) 600 mg orally once daily, co-administered with the CYP3A inhibitor", "D": "Delay initiation of IBTROZI (taletrectinib) until the CYP3A inhibitor is discontinued"}}
{"id": "YtJ6xTJfn154", "question_type": "open_ended_multi_choice", "question": "A 68-year-old man with familial chylomicronemia syndrome and a history of hepatic steatosis and episodic abdominal pain is being considered for pharmacologic therapy to reduce his triglyceride levels. He has mild renal impairment (eGFR 55 mL/min) and mild hepatic impairment. Which drug regimen is most suitable for this patient?", "options": {"A": "MYHIBBIN (mycophenolate mofetil) with dose adjustment for renal impairment", "B": "TRYNGOLZA (olezarsen sodium) at standard dosage and frequency", "C": "MYHIBBIN (mycophenolate mofetil) with dose adjustment for hepatic impairment", "D": "TRYNGOLZA (olezarsen sodium) with reduced frequency due to age"}}
{"id": "kum5tObqK3Dq", "question_type": "open_ended_multi_choice", "question": "A 7-year-old boy with cystic fibrosis presents with recurrent lung infections, poor growth, exocrine pancreatic insufficiency, and significantly elevated liver enzymes (ALT and AST greater than three times the upper limit of normal, bilirubin more than twice the upper limit). He is currently on a potent CYP3A inducer for another medical issue. What is the most appropriate management strategy for his cystic fibrosis pharmacotherapy?", "options": {"A": "Initiate ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor) at standard pediatric dosage", "B": "Initiate ALYFTREK with dose reduction due to CYP3A inducer", "C": "Avoid ALYFTREK and consider alternative supportive management", "D": "Switch CYP3A inducer to a CYP3A inhibitor and start ALYFTREK"}}
{"id": "WZnNbi2CGe7T", "question_type": "open_ended_multi_choice", "question": "For patients with mild hepatic impairment (Child-Pugh class A), what is the recommended dose modification for Wayrilz?", "options": {"A": "Reduce the dose by half.", "B": "Increase the dose.", "C": "No dose modification is required.", "D": "Avoid use of Wayrilz."}}
{"id": "aPqT0ac6uFZ7", "question_type": "open_ended_multi_choice", "question": "If a patient receiving Ibtrozi experiences acute onset of cough and difficulty breathing, what is the most appropriate first management approach?", "options": {"A": "Continue Ibtrozi and monitor symptoms", "B": "Immediately withhold Ibtrozi and evaluate for interstitial lung disease/pneumonitis", "C": "Reduce the dose of Ibtrozi without withholding", "D": "Start corticosteroids and continue Ibtrozi"}}
{"id": "HrZBdY0E4fmK", "question_type": "open_ended_multi_choice", "question": "A 7-year-old child with cystic fibrosis exhibits recurrent pulmonary infections, growth failure, exocrine pancreatic insufficiency, and liver function tests showing ALT and AST greater than three times the upper limit of normal and bilirubin exceeding twice the upper limit. He is currently receiving a strong CYP3A inducer for another health issue. What is the best course of action regarding his cystic fibrosis drug treatment?", "options": {"A": "Initiate ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor) at standard pediatric dosage", "B": "Initiate ALYFTREK with dose reduction due to CYP3A inducer", "C": "Avoid ALYFTREK and consider alternative supportive management", "D": "Switch CYP3A inducer to a CYP3A inhibitor and start ALYFTREK"}}
{"id": "TpTw6uB8AUo8", "question_type": "open_ended_multi_choice", "question": "When a patient cannot handle Datroway given intravenously at 3 mg/kg every three weeks, what is the appropriate next step?", "options": {"A": "Increase the dose to 4 mg/kg", "B": "Continue at 3 mg/kg", "C": "Permanently discontinue Datroway", "D": "Reduce to 2 mg/kg"}}
{"id": "ZSJpkp9q4pUr", "question_type": "multi_choice", "question": "A 10-year-old child weighing 25 kg is newly diagnosed with Niemann-Pick disease type C and presents with progressive gait ataxia, cognitive impairment, and hepatomegaly. The patient is not currently taking any other medications and has normal renal function. The family is concerned about long-term safety and wants a treatment specifically approved for pediatric use in NPC. Which drug is the most appropriate choice for this patient, considering the safety and efficacy profile?", "options": {"A": "Opfolda (miglustat) in combination with Pombiliti", "B": "Yargesa (miglustat) administered at standard adult dosing", "C": "Aqneursa administered at the recommended dosage for pediatric patients ≥15 kg", "D": "N-acetyl-DL-leucine monotherapy"}}
{"id": "aExeOfnmnFNe", "question_type": "multi_choice", "question": "For patients taking Journavx who are also using hormonal contraceptives containing progestins other than levonorgestrel or norethindrone, what additional recommendation should be made?", "options": {"A": "No additional contraceptive measures are needed.", "B": "Increase the dose of the current contraceptive.", "C": "Switch to a contraceptive containing ethinyl estradiol and levonorgestrel or norethindrone.", "D": "Discontinue Journavx immediately."}}
{"id": "edYgAgzSszEn", "question_type": "open_ended_multi_choice", "question": "A young girl, aged 12, who has advanced chronic kidney disease, comes in with primary axillary hyperhidrosis. Her caregivers are interested in a topical treatment that is both effective and safe for children her age. She is not taking any other drugs. Which of the following should be recommended?", "options": {"A": "Oxybutynin", "B": "Qbrexza", "C": "Sofdra", "D": "No pharmacologic treatment is appropriate"}}
{"id": "uyOVOUD7Qxti", "question_type": "multi_choice", "question": "Which of the following statements best describes the carcinogenic potential of Vizz based on available animal studies?", "options": {"A": "Long-term animal studies have demonstrated a high carcinogenic risk for Vizz.", "B": "Long-term animal studies have not been performed to evaluate the carcinogenic potential of Vizz.", "C": "Short-term animal studies have shown Vizz to be non-carcinogenic.", "D": "Vizz has been shown to cause tumors in mice but not in rats."}}
{"id": "YTpXRo4eFBmm", "question_type": "multi_choice", "question": "Which of the following is a recommended action when Romvimza is used concomitantly with a P-glycoprotein (P-gp) substrate and co-administration cannot be avoided?", "options": {"A": "Administer Romvimza at least 4 hours before the P-gp substrate.", "B": "Administer Romvimza at least 4 hours after the P-gp substrate.", "C": "Administer both drugs simultaneously.", "D": "Discontinue the P-gp substrate."}}
{"id": "e75xxRgr39K1", "question_type": "open_ended_multi_choice", "question": "A 67-year-old man with metastatic ROS1-positive NSCLC is prescribed IBTROZI (taletrectinib) 600 mg orally once daily. He has a history of osteoporosis and recently suffered a rib fracture after a minor fall. He is not taking any drugs that prolong QTc or affect CYP3A metabolism. What is the most important consideration for his ongoing IBTROZI therapy?", "options": {"A": "Continue IBTROZI at the same dose without additional monitoring", "B": "Discontinue IBTROZI permanently due to fracture risk", "C": "Continue IBTROZI with prompt evaluation and monitoring for further skeletal fractures", "D": "Reduce IBTROZI dose to minimize risk of future fractures"}}
{"id": "iubRSM8Xdj55", "question_type": "open_ended_multi_choice", "question": "Which of the following best summarizes the mutagenesis findings for Modeyso?", "options": {"A": "Modeyso was not genotoxic in both in vitro and in vivo assays.", "B": "Modeyso was genotoxic in in vitro assays but not in vivo.", "C": "Modeyso was genotoxic in all assays performed.", "D": "Modeyso was not tested for genotoxicity."}}
{"id": "C4p3jIazQFEr", "question_type": "open_ended_multi_choice", "question": "For male patients prescribed Modeyso with female partners who may conceive, what precaution should be advised?", "options": {"A": "No contraception is necessary.", "B": "Use effective contraception during treatment and for 1 month after the last dose.", "C": "Discontinue Modeyso if pregnancy is suspected.", "D": "Monitor sperm count monthly."}}
{"id": "PeneASH2gN3x", "question_type": "open_ended_multi_choice", "question": "A 72-year-old female patient with relapsed SCLC, who had a positive response to initial chemotherapy and is 60 days post-treatment, presents for further management. She has a notable history of recurrent diarrhea, increasing her risk of dehydration. Based on these factors, which therapy should not be recommended for her?", "options": {"A": "Imdelltra, administered intravenously with step-up dosing", "B": "Topotecan capsules, standard oral dosing for 5 days every 21 days", "C": "Ipilimumab, administered in combination with nivolumab", "D": "Topotecan capsules, dose reduced for age and diarrhea risk"}}
{"id": "6Uu6seLgJoHV", "question_type": "open_ended_multi_choice", "question": "A 7-year-old boy weighing 28 kg with chronic graft-versus-host disease (cGVHD) is experiencing airway obstruction, cough, and pulmonary infiltrates. His medical history includes food intolerance and abnormal esophageal physiology. He is currently receiving ritonavir, a potent CYP3A4 inhibitor, as part of his asthma treatment. Considering his current medications and weight, which drug should not be administered?", "options": {"A": "AXATILIMAB-CSFR", "B": "PredniSONE Tablets, USP, 5 mg", "C": "Budesonide Inhalation", "D": "PredniSONE combined with Budesonide Inhalation"}}
{"id": "QphsqmF15oUr", "question_type": "open_ended_multi_choice", "question": "Which description most appropriately reflects what is known about Enflonsia overdose in clinical practice?", "options": {"A": "Extensive clinical data are available regarding overdose management.", "B": "There is limited experience of overdose with Enflonsia.", "C": "Overdose cases always require surgical intervention.", "D": "Overdose is well-characterized in adult populations."}}
{"id": "RuqO0pzpYs9L", "question_type": "open_ended_multi_choice", "question": "A 58-year-old female patient with locally advanced, hormone receptor-positive, HER2-negative breast cancer tests positive for a PIK3CA mutation using an FDA-approved assay. She has type 2 diabetes that is well managed with oral agents, normal kidney function, and is not pregnant or breastfeeding. She is a candidate for targeted therapy in combination with palbociclib and fulvestrant. Considering her medical history and the safety of the available drugs, which regimen should be selected?", "options": {"A": "Carboplatin in combination with cyclophosphamide", "B": "Inavolisib in combination with palbociclib and fulvestrant", "C": "Esketamine as monotherapy", "D": "Carboplatin as a single agent"}}
{"id": "PPocwGEvRtuI", "question_type": "multi_choice", "question": "A 60-year-old man with a history of inoperable adrenocortical carcinoma and mild hepatic impairment is being considered for Lysodren therapy. He is also taking warfarin for atrial fibrillation. What is the most appropriate next step regarding his cancer treatment?", "options": {"A": "Start Lysodren without any adjustments", "B": "Avoid Lysodren due to interaction with warfarin", "C": "Use Lumisight for systemic therapy", "D": "Start Lysodren, but monitor warfarin INR closely and adjust warfarin dose as needed"}}
{"id": "FBChfJGjNUCq", "question_type": "multi_choice", "question": "A 42-year-old woman with newly diagnosed pulmonary arterial hypertension (PAH, WHO Group 1) presents for initial therapy. She is not pregnant, has no history of bleeding disorders, and is not taking any prostacyclin or antithrombotic agents. Her platelet count and hemoglobin are within normal limits. Which of the following is the most appropriate drug to initiate for her condition, considering efficacy and safety?", "options": {"A": "Epinephrine administered as a continuous infusion", "B": "Vasopressin administered intravenously", "C": "Winrevair administered according to recommended dosing schedule", "D": "Vasopressin combined with indomethacin"}}
{"id": "0JZ5bpcMaxA5", "question_type": "open_ended_multi_choice", "question": "How should a patient proceed if they intend to change their contraceptive method during Vanrafia treatment?", "options": {"A": "Change birth control without consulting a healthcare provider", "B": "Contact their healthcare provider to select another acceptable form", "C": "Stop all contraception immediately", "D": "Switch to natural family planning methods"}}
{"id": "8Wh3BkRoFcDe", "question_type": "open_ended_multi_choice", "question": "A woman, age 35, who is breastfeeding her 2-month-old baby, presents with primary axillary hyperhidrosis and wishes to start a topical medication. She has no other health issues or medications. Which topical treatment is contraindicated due to possible transfer into breast milk?", "options": {"A": "Qbrexza", "B": "Sofdra", "C": "Oxybutynin", "D": "Both Qbrexza and Sofdra"}}
{"id": "mNHSOEYwdMc8", "question_type": "open_ended", "question": "Which of the following statements best describes the contraindication profile of the drug Tryptyr?", "options": {"A": "Tryptyr is contraindicated in patients with hepatic impairment.", "B": "Tryptyr should not be used in individuals with a history of hypersensitivity to its components.", "C": "Tryptyr has no listed contraindications.", "D": "Tryptyr is contraindicated in pregnancy."}}
{"id": "cbpgPV9Qhnyr", "question_type": "multi_choice", "question": "A 62-year-old woman with metastatic pancreatic adenocarcinoma presents for first-line systemic therapy. Her laboratory results show a baseline absolute neutrophil count of 1,200 cells/mm³ and total bilirubin 1.2 x ULN. She has no history of hypersensitivity to taxanes, and her cardiac function is normal. Which drug regimen is most appropriate for her initial treatment?", "options": {"A": "Paclitaxel protein-bound particles for injectable suspension (albumin-bound) in combination with gemcitabine", "B": "Paclitaxel protein-bound particles for injectable suspension (albumin-bound) monotherapy", "C": "Imbruvica (ibrutinib)", "D": "BIZENGRI (zenocutuzumab)"}}
{"id": "YbiRwMgEFKbq", "question_type": "multi_choice", "question": "A 15-year-old adolescent presents to the emergency department with an acute attack of hereditary angioedema. The patient has no history of hepatic or renal impairment and is not currently taking any medications. Which drug is the most appropriate for treating this acute attack, considering age-specific approval and safety?", "options": {"A": "Icatibant acetate", "B": "Ekterly", "C": "Sajazir", "D": "Icatibant"}}
{"id": "dY6mQoxbtEvL", "question_type": "open_ended", "question": "In the event that a patient on Romvimza develops AST and/or ALT increases >3–5 times ULN and total bilirubin increases up to 2 times ULN, what is the recommended initial management?", "options": {"A": "Continue Romvimza at the same dose.", "B": "Withhold Romvimza until liver enzymes and bilirubin resolve to baseline or ≤3 times ULN.", "C": "Reduce Romvimza dose immediately.", "D": "Switch to another medication."}}
{"id": "Oe3Q1ORKirqN", "question_type": "open_ended_multi_choice", "question": "A 10-year-old child presents with elevated systolic and diastolic blood pressure and is diagnosed with hypertension. The child has no history of liver or kidney disease and is otherwise healthy. Which antihypertensive agent is most suitable for this patient?", "options": {"A": "TRYVIO", "B": "Candesartan cilexetil", "C": "Latanoprost", "D": "Beta-blocker"}}
{"id": "Bufbefx17iWH", "question_type": "open_ended_multi_choice", "question": "In the case of a 52-year-old patient with cardiovascular risk factors contemplating topical Anzupgo for hand eczema, which statement most appropriately characterizes the potential risks of Anzupgo?", "options": {"A": "Anzupgo is associated with increased risk of death in patients with cardiovascular risk factors, similar to oral JAK inhibitors for rheumatoid arthritis.", "B": "Anzupgo is contraindicated in all patients over 50 years old.", "C": "It is unknown whether Anzupgo carries the same risk of increased mortality as oral JAK inhibitors used for rheumatoid arthritis.", "D": "Anzupgo is recommended over TNF blockers in patients with cardiovascular risk factors."}}
{"id": "ljkoN8Mz9uuz", "question_type": "open_ended_multi_choice", "question": "A 72-year-old individual with mild cognitive impairment attributed to Alzheimer’s disease is identified as an ApoE ε4 homozygote through genetic analysis. MRI reveals cerebral microhemorrhages, and the patient is currently prescribed aspirin for cardiovascular reasons. What is the most suitable management strategy for this patient?", "options": {"A": "Initiate KISUNLA (donanemab-azbt) with enhanced clinical vigilance and regular MRI monitoring.", "B": "Initiate KISUNLA without genetic testing or MRI monitoring.", "C": "Initiate KISUNLA and discontinue aspirin immediately.", "D": "Avoid KISUNLA due to increased risk of ARIA and intracerebral hemorrhage; consider alternative therapy if available."}}
{"id": "dXZoV3f2Hcio", "question_type": "open_ended_multi_choice", "question": "A 35-year-old woman in her second trimester of pregnancy reports dysuria and increased urinary frequency. She is found to have an uncomplicated urinary tract infection, with normal renal and hepatic function and no current medications. Which medication is considered safest for symptomatic management in this scenario?", "options": {"A": "Imipenem and Cilastatin", "B": "Gepotidacin", "C": "Flavoxate Hydrochloride", "D": "None; all are contraindicated in pregnancy"}}
{"id": "ZkLxp0DVu8qf", "question_type": "open_ended_multi_choice", "question": "Which population should be advised not to breastfeed during and for 3 months after treatment with Lynozyfic?", "options": {"A": "Women receiving Lynozyfic", "B": "Men receiving Lynozyfic", "C": "Pediatric patients", "D": "Geriatric patients"}}
{"id": "57c5BAIwx5jh", "question_type": "open_ended_multi_choice", "question": "A 55-year-old man with symptomatic TGCT and moderate renal impairment (CLcr 40 mL/min) is being evaluated for systemic therapy. He has no history of liver disease, is not taking any CYP3A substrates, and is able to comply with dietary recommendations. Which treatment regimen is most suitable for his condition?", "options": {"A": "Romvimza (vimseltinib) at standard dosing without renal adjustment", "B": "Turalio (pexidartinib hydrochloride) with dose reduction for renal impairment and administration with a low-fat meal", "C": "Turalio (pexidartinib hydrochloride) at standard dosing with a high-fat meal", "D": "Romvimza (vimseltinib) with dose reduction for renal impairment"}}
{"id": "gEJ2LaaTCXdy", "question_type": "open_ended_multi_choice", "question": "Which of the following best describes the immunogenicity data available for Datroway?", "options": {"A": "There is insufficient information to characterize the anti-drug antibody response and its effects on pharmacokinetics, pharmacodynamics, safety, or effectiveness.", "B": "High rates of anti-drug antibody formation have been observed.", "C": "Anti-drug antibodies significantly reduce drug efficacy.", "D": "Immunogenicity is not a concern for Datroway."}}
{"id": "sD9BDZnDvbs4", "question_type": "open_ended_multi_choice", "question": "For patients experiencing gastrointestinal symptoms while taking Wayrilz, what adjustment may improve tolerability?", "options": {"A": "Take Wayrilz with food", "B": "Take Wayrilz on an empty stomach", "C": "Reduce the dose by half", "D": "Switch to intravenous administration"}}
{"id": "LM8fryQhlLim", "question_type": "multi_choice", "question": "A 60-year-old man with a history of inoperable adrenocortical carcinoma and mild hepatic impairment is being considered for Lysodren therapy. He is also taking warfarin for atrial fibrillation. What is the most appropriate next step regarding his cancer treatment?", "options": {"A": "Start Lysodren without any adjustments", "B": "Avoid Lysodren due to interaction with warfarin", "C": "Start Lysodren, but monitor warfarin INR closely and adjust warfarin dose as needed", "D": "Use Lumisight for systemic therapy"}}
{"id": "shsNqhnS7DnN", "question_type": "multi_choice", "question": "Which statement best describes the safety profile of Andembry in pregnant or breastfeeding individuals?", "options": {"A": "It is not known if Andembry can harm an unborn baby or passes into breastmilk.", "B": "Andembry is proven safe in pregnancy and breastfeeding.", "C": "Andembry is contraindicated in pregnancy.", "D": "Andembry is recommended for all pregnant women with HAE."}}
{"id": "kt1FXFdVN3dq", "question_type": "open_ended_multi_choice", "question": "A 7-year-old child is newly diagnosed with acute myeloid leukemia related to topoisomerase type 2 inhibitor exposure. The patient has no history of cardiac disease, normal hepatic and renal function, and is not receiving any CYP3A4, CYP2D6, or P-gp inhibitors. Which drug regimen is most appropriate for induction therapy in this pediatric patient?", "options": {"A": "Idamycin PFS in combination with other antileukemic drugs", "B": "Doxorubicin Hydrochloride as part of a multi-agent chemotherapy regimen", "C": "GUNA-IL 2 administered 15 minutes before meals", "D": "Idamycin PFS monotherapy"}}
{"id": "VGMzNw64M51b", "question_type": "open_ended_multi_choice", "question": "A woman aged 65 with mild dementia attributed to Alzheimer’s disease is planning to become pregnant and seeks advice about using KISUNLA (donanemab-azbt). What should you recommend regarding drug therapy in this scenario?", "options": {"A": "Recommend KISUNLA, as it is safe for use during pregnancy.", "B": "Advise against KISUNLA due to lack of safety data in pregnancy; consider alternative therapy if available.", "C": "Initiate KISUNLA and monitor closely for ARIA.", "D": "Recommend KISUNLA only after the first trimester."}}
{"id": "FxzvQR3UWJlS", "question_type": "open_ended_multi_choice", "question": "A 35-year-old woman diagnosed with symptomatic NYHA class II obstructive hypertrophic cardiomyopathy is considering pharmacologic therapy. She is preparing for pregnancy in the upcoming year and currently uses a combined hormonal contraceptive that does not include norethindrone. Which medication should be avoided because of its potential risks to women who are of reproductive age?", "options": {"A": "Metoprolol Tartrate", "B": "Acoramidis Hydrochloride", "C": "Mavacamten", "D": "Diltiazem"}}
{"id": "Py5sRhSLakV2", "question_type": "open_ended_multi_choice", "question": "A 65-year-old woman who is pregnant is found to have locally advanced cutaneous squamous cell carcinoma and is being assessed for systemic therapy. She prefers to avoid any therapy that could endanger her fetus. What should be recommended regarding systemic drug therapy for her cancer?", "options": {"A": "Start ERBITUX, as it is safe in pregnancy", "B": "Begin TECENTRIQ, as immune checkpoint inhibitors are preferred in pregnancy", "C": "Initiate UNLOXCYT, as it is the only drug indicated for CSCC", "D": "Defer systemic therapy due to contraindication of all options in pregnancy"}}
{"id": "BKISu87WXEX4", "question_type": "open_ended_multi_choice", "question": "Given a patient who has experienced anaphylaxis from several medications, what is the advised management regarding Gomekli according to its contraindications?", "options": {"A": "Gomekli should be avoided due to potential hypersensitivity.", "B": "Gomekli is contraindicated in patients with anaphylaxis history.", "C": "Gomekli can be used as there are no contraindications.", "D": "Gomekli should only be used after allergy testing."}}
{"id": "WbotL1d0BfEq", "question_type": "open_ended_multi_choice", "question": "Which of the following statements best describes the management of immune-mediated rash or dermatitis in patients treated with penpulimab-kcqx?", "options": {"A": "All cases require permanent discontinuation of penpulimab-kcqx", "B": "Mild to moderate non-exfoliative rashes may be managed with topical therapies", "C": "Systemic corticosteroids are contraindicated", "D": "No intervention is necessary for any grade"}}
{"id": "J1k1XUHEYKWW", "question_type": "open_ended_multi_choice", "question": "For an adult taking Modeyso who requires a strong CYP3A4 inhibitor, what is the appropriate change to their Modeyso dosing regimen?", "options": {"A": "Increase to 625 mg once weekly", "B": "Reduce to 375 mg once weekly", "C": "Reduce to 500 mg once weekly", "D": "Discontinue Modeyso"}}
{"id": "ZG2CIHyZaox1", "question_type": "open_ended_multi_choice", "question": "A 54-year-old man with metastatic ROS1-positive non-small cell lung carcinoma is being considered for taletrectinib therapy. He has a history of atrial fibrillation and is currently taking amiodarone, a drug known to prolong the QTc interval. What is the best course of action regarding taletrectinib treatment?", "options": {"A": "Proceed with taletrectinib 600 mg orally once daily and monitor ECG regularly.", "B": "Withhold taletrectinib due to risk of QTc interval prolongation from drug interaction.", "C": "Start taletrectinib at a reduced dose to minimize cardiac risk.", "D": "Taletrectinib is safe to use with amiodarone if electrolytes are monitored."}}
{"id": "KuNeENKL6eCu", "question_type": "open_ended_multi_choice", "question": "A 15-year-old girl weighing 45 kg has just been diagnosed with paroxysmal nocturnal hemoglobinuria (PNH). She has no prior liver disease and has not received any complement inhibitor treatment. Her parents are seeking guidance on the safest and most effective initial therapy for her. Which medication should be recommended as the first-line treatment?", "options": {"A": "Danicopan as monotherapy", "B": "Pegcetacoplan as monotherapy", "C": "Crovalimab as monotherapy", "D": "Danicopan as add-on to ravulizumab"}}
{"id": "RpuT5BZzN08R", "question_type": "multi_choice", "question": "A 32-year-old woman with WHIM syndrome, characterized by myelokathexis, recurrent bacterial infections, and bronchiectasis, is planning to become pregnant. She currently has normal renal and hepatic function and is not taking any medications that interact with CYP3A4 or P-gp. Which of the following is the most appropriate recommendation regarding XOLREMDI therapy?", "options": {"A": "XOLREMDI is safe to use during breastfeeding.", "B": "XOLREMDI can be safely used during pregnancy with close fetal monitoring.", "C": "XOLREMDI is recommended only if the patient is also taking a strong CYP3A4 inhibitor.", "D": "XOLREMDI should not be initiated due to the risk of fetal harm; effective contraception is required during and for 3 weeks after treatment."}}
{"id": "gIHBOKq2izOk", "question_type": "open_ended_multi_choice", "question": "A 45-year-old patient diagnosed with prurigo nodularis is preparing to get a live vaccine for travel. He is otherwise healthy and has no history of allergic reactions. What is the best treatment plan for his prurigo nodularis in this context?", "options": {"A": "Initiate NEMLUVIO therapy immediately and administer the live vaccine during treatment", "B": "Delay NEMLUVIO therapy until after completion of all age-appropriate live vaccinations", "C": "Start Nalbuphine Hydrochloride injection for prurigo nodularis management", "D": "Begin NEMLUVIO therapy and combine with Nalbuphine Hydrochloride for enhanced efficacy"}}
{"id": "1dcu8gWezKLp", "question_type": "open_ended_multi_choice", "question": "A woman aged 32 with schizophrenia and mild renal impairment (eGFR 65 mL/min) is receiving a strong CYP2D6 inhibitor for another illness. She has no hepatic impairment or other medical issues. Preferring oral medication and worried about drug interactions, which antipsychotic regimen should be recommended for her?", "options": {"A": "Cobenfy, administered orally at the standard adult dose", "B": "Abilify Maintena, administered as a monthly intramuscular injection with dose reduction", "C": "Cobenfy, administered orally with close monitoring for adverse reactions", "D": "Abilify Maintena, administered orally at the standard dose"}}
{"id": "WZHXV4mUBqBi", "question_type": "open_ended_multi_choice", "question": "A 32-year-old female patient presents with severe alopecia areata and patchy hair loss. She is breastfeeding, has mild renal impairment, is negative for CYP2C9 poor metabolizer status, and is not taking CYP2C9 inhibitors. What is the best drug option for treating her condition?", "options": {"A": "Minoxidil topical solution", "B": "Imiquimod cream", "C": "Leqselvi (deuruxolitinib phosphate)", "D": "No drug is appropriate from the options provided"}}
{"id": "7JkKEoWHTHcH", "question_type": "open_ended_multi_choice", "question": "A young adult male diagnosed with hemophilia B and a known history of factor IX inhibitor development presents with recurrent spontaneous epistaxis and impaired wound healing. He is scheduled for a dental procedure and requires immediate perioperative bleeding control. Which drug should be selected for his management?", "options": {"A": "REBINYN, administered perioperatively", "B": "HYMPAVZI, administered perioperatively", "C": "SEVENFACT, administered perioperatively", "D": "REBINYN, administered as routine prophylaxis only"}}
{"id": "J8yeIrkd6tji", "question_type": "open_ended", "question": "A 32-year-old woman with type 1 interferonopathy presents for treatment. She is currently 10 weeks pregnant and has a history of mild renal impairment (eGFR 55 mL/min/1.73m²). Her physician is considering immunomodulatory therapy. Which of the following is the most appropriate recommendation regarding the use of Olumiant for this patient?", "options": {"A": "Olumiant is appropriate at the standard adult dose.", "B": "Olumiant is appropriate with a reduced dose due to renal impairment.", "C": "Olumiant should be avoided due to pregnancy.", "D": "Olumiant is appropriate only if combined with a biologic DMARD."}}
{"id": "IS8gEa1v8yXt", "question_type": "open_ended_multi_choice", "question": "A 68-year-old woman with myelodysplastic syndrome and transfusion-dependent anemia is found to have a deletion 5q on cytogenetic analysis. Her medical history includes chronic kidney disease (eGFR 35 mL/min/1.73m²) and atrial fibrillation managed with digoxin. She is neither pregnant nor planning pregnancy. Taking into account her cytogenetic profile and comorbid conditions, which treatment regimen is most suitable for her anemia?", "options": {"A": "Lenalidomide, with dose adjustment for renal impairment and regular monitoring of digoxin levels", "B": "Reblozyl, administered every 3 weeks", "C": "Treosulfan (GRAFAPEX) as part of a preparative regimen for stem cell transplantation", "D": "Lenalidomide, standard dose without renal adjustment"}}
{"id": "Zqu5pvSLoOYz", "question_type": "open_ended_multi_choice", "question": "Which precaution should be taken by patients using Vizz before driving at night or operating machinery?", "options": {"A": "Ensure vision is clear before engaging in these activities.", "B": "Take Vizz immediately before driving.", "C": "Wear sunglasses at night.", "D": "Increase the dose if vision is blurred."}}
{"id": "qdvDoTILsdS4", "question_type": "open_ended_multi_choice", "question": "A 68-year-old patient with metastatic non-squamous lung adenocarcinoma and a history of chronic kidney disease (creatinine clearance 38 mL/min) is being considered for systemic therapy. The patient has no EGFR or ALK genomic tumor aberrations and is not currently taking ibuprofen. Which drug regimen is most appropriate for initial treatment in this patient?", "options": {"A": "Pemetrexed disodium in combination with platinum chemotherapy", "B": "Docetaxel in combination with cisplatin", "C": "KEYTRUDA QLEX (Pembrolizumab and Berahyaluronidase Alfa) in combination with platinum chemotherapy", "D": "Pemetrexed disodium as a single agent"}}
{"id": "hJjo9sBJh2Jp", "question_type": "multi_choice", "question": "A 42-year-old woman with young-onset Parkinson disease presents with significant bradykinesia, rigidity, and postural instability. She has a history of mild hepatic steatosis, and her recent liver function tests show ALT and AST values slightly above the upper limit of normal. She is currently not taking any adjunctive therapies and is seeking a new medication to improve her motor symptoms. Which of the following is the most appropriate drug to initiate for her condition?", "options": {"A": "Tasmar", "B": "Carbidopa and Levodopa", "C": "Selegiline Hydrochloride", "D": "Tasmar combined with Selegiline Hydrochloride"}}
{"id": "8tBh3hg5sqCB", "question_type": "open_ended_multi_choice", "question": "A 60-year-old male with recurrent glioblastoma is being considered for anti-tumor therapy. He has a history of congestive heart failure and poorly controlled hypertension. Which drug should be avoided due to increased risk of serious cardiovascular adverse events in this patient population?", "options": {"A": "Zortress in combination with cyclosporine", "B": "Avastin administered every 2 weeks", "C": "Vorasidenib 40 mg once daily", "D": "Zortress combined with tacrolimus"}}
{"id": "INrGw1tuBtFH", "question_type": "open_ended_multi_choice", "question": "A 16-year-old adolescent with severe alopecia areata and no gastrointestinal symptoms is being considered for systemic therapy. She has normal liver function and no history of infections or immunosuppressant use. Which drug regimen is most appropriate for her condition?", "options": {"A": "Vedolizumab administered intravenously every 8 weeks", "B": "Ritlecitinib administered orally once daily", "C": "Vedolizumab administered with a TNF blocker", "D": "Ritlecitinib administered with cyclosporine"}}
{"id": "URo1nA6FagWN", "question_type": "open_ended", "question": "A 35-year-old woman with autosomal dominant immune thrombocytopenia presents with abnormal bleeding and is found to be platelet antibody positive. She has a history of moderate hepatic impairment (Child-Pugh class B) and severe renal impairment. She previously failed corticosteroid therapy. Which drug is the most appropriate for her persistent ITP, considering her comorbidities and drug safety profile?", "options": {"A": "WAYRILZ (Rilzabrutinib) 400 mg twice daily", "B": "PROMACTA (Eltrombopag) 50 mg once daily with dose adjustment", "C": "Prednisone 60 mg daily", "D": "WAYRILZ (Rilzabrutinib) 200 mg once daily"}}
{"id": "pVZQua2yJJNY", "question_type": "multi_choice", "question": "In the AK105-304 trial, what was the major efficacy outcome measure used to evaluate penpulimab-kcqx in combination with platinum and gemcitabine?", "options": {"A": "Objective response rate (ORR) by investigator assessment", "B": "BICR-assessed progression-free survival (PFS) according to RECIST v1.1", "C": "Quality of life improvement", "D": "Reduction in adverse events"}}
{"id": "352XsT7nCJOl", "question_type": "open_ended_multi_choice", "question": "A 27-year-old woman with newly diagnosed reactive arthritis presents with joint stiffness, fever, and recurrent urinary tract infections. She is 10 weeks pregnant and has a documented Chlamydia trachomatis infection. Which of the following is the most appropriate pharmacologic treatment for her infection, considering her pregnancy status?", "options": {"A": "Doxycycline hyclate 100 mg orally twice daily for 7 days", "B": "Renflexis intravenous infusion every 8 weeks", "C": "Azithromycin single oral dose", "D": "Doxycycline hyclate in combination with methotrexate"}}
{"id": "T7ixkZ0ngd8P", "question_type": "open_ended_multi_choice", "question": "A 55-year-old woman diagnosed with metastatic esophageal squamous cell carcinoma, whose tumor shows PD-L1 expression (CPS = 12), has previously undergone platinum-based chemotherapy. She is seeking a second-line treatment and is taking ritonavir for HIV, with no history of hepatic impairment. What is the most suitable drug for her subsequent therapy?", "options": {"A": "Docetaxel anhydrous monotherapy, administered every 3 weeks", "B": "Tevimbra as a single agent, administered every 3 weeks", "C": "Keytruda QLEX as a single agent, administered every 3 weeks", "D": "Docetaxel anhydrous in combination with cisplatin and fluorouracil, administered every 3 weeks"}}
{"id": "b0WG9Q2LRRrB", "question_type": "multi_choice", "question": "Has Tryptyr been shown to impair fertility in animal studies?", "options": {"A": "Studies to evaluate the potential effects of Tryptyr on fertility in animals have not been performed.", "B": "No, Tryptyr has been shown to have no effect on fertility in animal studies.", "C": "Yes, Tryptyr significantly impairs fertility in both male and female animals.", "D": "Tryptyr increases fertility in animal models."}}
{"id": "oOWSYOohgPo3", "question_type": "multi_choice", "question": "A 7-year-old boy is diagnosed with severe erythema multiforme (Stevens-Johnson syndrome). He has a history of asthma and is currently receiving macrolide antibiotics for a respiratory infection. Which drug should be avoided due to increased risk of adverse reactions and drug interactions in this pediatric patient?", "options": {"A": "Prednisone", "B": "Dexamethasone", "C": "PRED FORTE", "D": "Oral antihistamine"}}
{"id": "V3nHcwxx0kgn", "question_type": "open_ended_multi_choice", "question": "A 54-year-old female diagnosed with primary biliary cholangitis reports ongoing pruritus, fatigue, and high alkaline phosphatase levels, despite a year of ursodeoxycholic acid therapy. She has osteoporosis and is taking atorvastatin for elevated cholesterol. She does not have ascites, variceal bleeding, or hepatic encephalopathy. Considering her existing comorbidities and medications, what is the most suitable drug to introduce to her PBC treatment plan?", "options": {"A": "Elafibranor, once daily, in combination with UDCA", "B": "Seladelpar lysine, once daily, in combination with UDCA", "C": "Abatacept, once monthly", "D": "Elafibranor, once daily, as monotherapy"}}
{"id": "Dc0D4SMwEQml", "question_type": "open_ended", "question": "For which of the following excipient-related patient histories is Imaavy contraindicated?", "options": {"A": "History of serious hypersensitivity reaction to any excipient in Imaavy", "B": "History of mild gastrointestinal upset with lactose", "C": "History of urticaria with shellfish", "D": "History of headache with acetaminophen"}}
{"id": "YWUF8VltkJGx", "question_type": "open_ended_multi_choice", "question": "A 9-year-old boy with Duchenne muscular dystrophy, presenting with progressive muscle weakness, calf muscle hypertrophy, and a history of arrhythmia, is not amenable to exon 51 or exon 53 skipping therapies. He is currently taking a medication known to prolong the QTc interval. Which of the following is the most appropriate management regarding DMD drug therapy?", "options": {"A": "Initiate Duvyzat orally twice daily with close ECG monitoring", "B": "Start Viltepso intravenously once weekly", "C": "Begin Exondys 51 intravenously once weekly", "D": "Avoid Duvyzat due to arrhythmia risk and QTc-prolonging drug interaction"}}
{"id": "SceNBZ0X8K66", "question_type": "open_ended_multi_choice", "question": "A 7-year-old child diagnosed with Niemann-Pick disease type C presents with progressive gait ataxia, cognitive impairment, and vertical supranuclear gaze palsy. The patient has normal renal function and is not taking any other medications. Which of the following is the most appropriate drug regimen for treating the neurological manifestations of this patient's condition?", "options": {"A": "Miglustat monotherapy", "B": "Arimoclomol in combination with miglustat", "C": "Lithium carbonate", "D": "Arimoclomol monotherapy"}}
{"id": "0ocffLv7gLFV", "question_type": "multi_choice", "question": "For patients receiving Hernexeos, what is the recommended clinical action when coadministering with BCRP substrates where even minimal concentration increases may cause serious adverse reactions?", "options": {"A": "Avoid concomitant use and consider alternative therapies", "B": "Increase the dose of the BCRP substrate", "C": "Decrease the dose of Hernexeos", "D": "Monitor for decreased efficacy of Hernexeos"}}
{"id": "VZrBhC8LQotc", "question_type": "open_ended_multi_choice", "question": "A 60-year-old woman with high-risk myelodysplastic syndromes is currently pregnant. She has no history of renal impairment and is not taking any other medications. She is seeking advice on the safest drug therapy for her condition. Which of the following is the most appropriate recommendation?", "options": {"A": "Decitabine intravenous infusion daily for 5 days every 4 weeks", "B": "INQOVI (oral decitabine + cedazuridine) once daily for 5 days every 28-day cycle", "C": "RYTELO intravenous infusion every 4 weeks with premedication for infusion reactions", "D": "No drug therapy; all options are contraindicated during pregnancy due to embryo-fetal toxicity"}}
{"id": "rKMUSShUxNYf", "question_type": "open_ended_multi_choice", "question": "A male patient, age 52, has schizophrenia and a history of benign prostatic hyperplasia (BPH). He is cognitively intact and has no notable hepatic or renal issues. When selecting a maintenance antipsychotic, which option best addresses his comorbid BPH and the associated risk of urinary retention?", "options": {"A": "Cobenfy (xanomeline and trospium chloride), standard adult dose", "B": "Abilify Maintena (aripiprazole), standard adult dose", "C": "Cobenfy (xanomeline and trospium chloride), reduced dose for geriatric patients", "D": "Abilify Maintena (aripiprazole), reduced dose for CYP2D6 poor metabolizers"}}
{"id": "v1CctprwJrGR", "question_type": "open_ended_multi_choice", "question": "A 10-year-old male patient (35 kg) with a history of chronic graft-versus-host disease (cGVHD) presents with bronchiectasis, repeated infections, and esophageal abnormalities. He has not responded to two prior systemic treatments, has normal hepatic function, and is not receiving additional immunosuppressive drugs. Which therapy would be most appropriate for his situation?", "options": {"A": "Niktimvo, intravenous infusion every 2 weeks", "B": "PredniSONE, 5 mg orally once daily", "C": "PONVORY, 20 mg orally once daily", "D": "Niktimvo, intravenous infusion every 4 weeks"}}
{"id": "maeA7qfYlaoA", "question_type": "open_ended_multi_choice", "question": "A patient with metastatic NSCLC on Hernexeos develops symptomatic congestive heart failure. What is the recommended management?", "options": {"A": "Interrupt Hernexeos until symptoms resolve, then resume at reduced dose", "B": "Permanently discontinue Hernexeos", "C": "Continue Hernexeos with close monitoring", "D": "Reduce Hernexeos dose by one level"}}
{"id": "frfiUb5GkwVy", "question_type": "open_ended_multi_choice", "question": "A 68-year-old woman with BCG-unresponsive nonmuscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) and papillary tumors is being considered for intravesical therapy. She has no history of bladder perforation, severe irritable bladder symptoms, or recent transurethral resection. She is not pregnant and does not plan to breastfeed. Which drug regimen is most appropriate for her condition?", "options": {"A": "Valrubicin intravesical therapy alone", "B": "Nogapendekin alfa inbakicept-pmln (ANKTIVA) in combination with Bacillus Calmette-Guérin (BCG)", "C": "Valrubicin in combination with Bacillus Calmette-Guérin (BCG)", "D": "Nogapendekin alfa inbakicept-pmln (ANKTIVA) monotherapy"}}
{"id": "d4WJgPO0ceH7", "question_type": "multi_choice", "question": "What is the recommendation regarding the use of live vaccines in patients receiving Anzupgo?", "options": {"A": "No specific recommendations regarding live vaccines", "B": "Live vaccines are recommended during Anzupgo therapy", "C": "Live vaccines should be given only after discontinuing Anzupgo for 6 months", "D": "Live vaccines are contraindicated only in pediatric patients"}}
{"id": "PUfpC4suKTN5", "question_type": "open_ended_multi_choice", "question": "A 70-year-old man with a diagnosis of unresectable, metastatic esophageal squamous cell carcinoma (ESCC) and stage 3 chronic kidney disease (CKD) comes for a treatment plan. He has mild proteinuria, as well as symptoms of nausea and vomiting. The tumor shows PD-L1 expression of 1% or higher. Which drug should be selected as first-line therapy for this patient?", "options": {"A": "Lenvatinib monotherapy", "B": "Tislelizumab-jsgr in combination with platinum-containing chemotherapy", "C": "Nivolumab and hyaluronidase in combination with fluoropyrimidine- and platinum-containing chemotherapy", "D": "Lenvatinib in combination with everolimus"}}
{"id": "tD93HGRaCSlg", "question_type": "open_ended_multi_choice", "question": "A 32-year-old woman, 10 weeks into her pregnancy, reports moderate dry eye disease and expresses concern regarding the safety of potential medications for her unborn child. She does not wear contact lenses. Taking into account her pregnancy and the safety of current therapies, which drug should be recommended for her dry eye disease?", "options": {"A": "Loteprednol etabonate ophthalmic gel, administered twice daily", "B": "Lifitegrast ophthalmic solution, administered twice daily", "C": "Acoltremon ophthalmic solution, administered twice daily", "D": "Loteprednol etabonate ophthalmic gel, administered once daily"}}
{"id": "9flDOyhqw1Y0", "question_type": "multi_choice", "question": "A 32-year-old woman with Niemann-Pick disease type C and neurological symptoms is planning to become pregnant. She is currently taking N-acetyl-DL-leucine for symptomatic relief. Her physician is considering starting disease-modifying therapy. Which of the following is the most appropriate recommendation regarding drug therapy for her current situation?", "options": {"A": "Continue N-acetyl-DL-leucine and initiate Aqneursa immediately", "B": "Discontinue N-acetyl-DL-leucine and start Aqneursa after confirming non-pregnant status and counseling on contraception", "C": "Start Yargesa (miglustat) without contraception precautions", "D": "Initiate Opfolda (miglustat) in combination with Pombiliti regardless of pregnancy status"}}
{"id": "mlFcwCkBFchs", "question_type": "open_ended_multi_choice", "question": "A 58-year-old man with a history of type 2 diabetes mellitus and recent diagnosis of polyneuropathy due to drug presents for glycemic management. He has a history of congestive heart failure (NYHA Class III) and mild hepatic impairment. Which of the following is the most appropriate pharmacologic approach for his diabetes, considering his comorbidities and the safety profile of available agents?", "options": {"A": "Actos 45 mg orally once daily", "B": "Skysona gene therapy infusion", "C": "PNV-DHA multivitamin/mineral supplementation", "D": "Non-thiazolidinedione antidiabetic therapy (e.g., metformin or insulin, not listed here)"}}
{"id": "lf0jjEzfa640", "question_type": "multi_choice", "question": "Which of the following statements is correct regarding the use of food when taking Gomekli tablets for oral suspension?", "options": {"A": "Gomekli can be taken with or without food", "B": "Gomekli must be taken on an empty stomach", "C": "Gomekli must be taken with food", "D": "Gomekli should be mixed with food before administration"}}
{"id": "eFlCR4wDdWtK", "question_type": "open_ended", "question": "A 12-year-old boy presents with severe itching, redness, and swelling of both eyes during the spring season. He is diagnosed with vernal conjunctivitis. His medical history is significant for asthma. The ophthalmologist is considering topical corticosteroid therapy for ocular inflammation. Which drug is most appropriate for this patient, considering his age and comorbid asthma?", "options": {"A": "Prednisolone acetate ophthalmic suspension", "B": "Dexamethasone ophthalmic solution", "C": "Loratadine oral tablets", "D": "Prednisolone acetate ophthalmic suspension (contains sodium bisulfite)"}}
{"id": "18wlMLsQTfRc", "question_type": "open_ended_multi_choice", "question": "A 12-year-old female with significant renal impairment due to chronic kidney disease is experiencing primary axillary hyperhidrosis. Her parents request a topical therapy that is age-appropriate and safe. She has no other medications. What is the best treatment choice in this scenario?", "options": {"A": "Oxybutynin", "B": "Qbrexza", "C": "Sofdra", "D": "No pharmacologic treatment is appropriate"}}
{"id": "ZSYakXVBMwsT", "question_type": "open_ended", "question": "For a patient taking Brinsupri, is it necessary to coordinate dosing with meals?", "options": {"A": "Yes, Brinsupri must be taken only with food.", "B": "No, Brinsupri can be taken with or without food.", "C": "Yes, Brinsupri must be taken only on an empty stomach.", "D": "Yes, Brinsupri must be taken with a high-fat meal."}}
{"id": "9v5dktFIiltJ", "question_type": "multi_choice", "question": "A clinical trial protocol is being developed for Emrelis. Which statement about its contraindications should be included in the protocol documentation?", "options": {"A": "Emrelis is contraindicated in patients with cardiovascular disease.", "B": "Emrelis should not be administered to pediatric patients.", "C": "There are no contraindications listed for Emrelis.", "D": "Emrelis is contraindicated in patients with a history of drug allergy."}}
{"id": "AUf37EfORbA2", "question_type": "open_ended_multi_choice", "question": "For a patient with multiple comorbidities, which of the following is true regarding the contraindications for Ekterly?", "options": {"A": "Ekterly is contraindicated in patients with diabetes.", "B": "Ekterly is contraindicated in patients with chronic kidney disease.", "C": "Ekterly is contraindicated in patients with a history of stroke.", "D": "Ekterly does not have any contraindications regardless of comorbidities."}}
{"id": "m2Vw5FMYMsl2", "question_type": "open_ended_multi_choice", "question": "A man aged 35 arrives with moderate to severe acute pain after trauma. He has moderate liver dysfunction (Child-Pugh Class B) and is taking a moderate CYP3A inhibitor. Which medication and dosing approach should be selected for his pain management?", "options": {"A": "JOURNAVX at standard adult dosage", "B": "JOURNAVX at reduced dosage due to hepatic impairment and CYP3A inhibitor use", "C": "Ropivacaine Hydrochloride at standard adult dosage", "D": "Pain Relief Childrens (acetaminophen-based OTC) at pediatric dosing"}}
{"id": "8sCzcujsLGvP", "question_type": "open_ended_multi_choice", "question": "Considering a 55-year-old patient with symptomatic TGCT, moderate renal impairment (CLcr 40 mL/min), no history of hepatic disease, no use of CYP3A substrates, and ability to comply with dietary recommendations, which systemic treatment regimen is recommended?", "options": {"A": "Romvimza (vimseltinib) at standard dosing without renal adjustment", "B": "Turalio (pexidartinib hydrochloride) with dose reduction for renal impairment and administration with a low-fat meal", "C": "Turalio (pexidartinib hydrochloride) at standard dosing with a high-fat meal", "D": "Romvimza (vimseltinib) with dose reduction for renal impairment"}}
{"id": "Lo3nAxLuiemV", "question_type": "open_ended_multi_choice", "question": "How did the incidence of decreased estimated glomerular filtration rate (eGFR) of ≥25% but <50% in JOURNAVX-treated patients compare to placebo in the pooled Trials 1 and 2?", "options": {"A": "Higher in JOURNAVX-treated patients", "B": "Lower in JOURNAVX-treated patients", "C": "Equal in both groups", "D": "Not reported for JOURNAVX"}}
{"id": "CfZkyYukggsX", "question_type": "open_ended_multi_choice", "question": "A 29-year-old woman with newly diagnosed endocrine exophthalmos is planning to become pregnant within the next few months. She currently has no other significant medical history and is not taking any medications. What is the most appropriate recommendation regarding TEPEZZA therapy for her condition?", "options": {"A": "Initiate TEPEZZA therapy with no additional precautions.", "B": "Advise against TEPEZZA therapy due to risk of fetal harm; recommend effective contraception prior to, during, and for 6 months after treatment.", "C": "Start TEPEZZA and discontinue only if pregnancy occurs.", "D": "TEPEZZA is safe in pregnancy based on animal studies."}}
{"id": "8uYP2SfHEBRT", "question_type": "open_ended_multi_choice", "question": "A 58-year-old man, known to have chronic kidney disease (creatinine clearance 28 mL/min/1.73 m²), presents with progressive neurological decline and gait disturbances due to Niemann-Pick disease type C. He has not started enzyme replacement therapy. Which medication is best suited for his condition, given his level of renal function?", "options": {"A": "Yargesa (miglustat) at standard dosing", "B": "Aqneursa at the recommended adult dosage", "C": "Opfolda (miglustat) in combination with Pombiliti", "D": "Yargesa (miglustat) with dose reduction for renal impairment"}}
{"id": "tjWgnf3frJKa", "question_type": "multi_choice", "question": "For which of the following drugs does the official labeling state that there are no contraindications?", "options": {"A": "Amiodarone", "B": "Warfarin", "C": "Metformin", "D": "Anzupgo"}}
{"id": "0JqRL9ZtFrmP", "question_type": "open_ended_multi_choice", "question": "For a 45-year-old woman who is pregnant and has previously treated, unresectable intrahepatic cholangiocarcinoma with an FGFR2 rearrangement, and is not currently taking any medications, what should be recommended regarding targeted cancer therapy?", "options": {"A": "Initiate PEMAZYRE at standard dosing", "B": "Start LYTGOBI with close fetal monitoring", "C": "Defer targeted therapy due to risk of fetal harm", "D": "Begin ZIIHERA with dose reduction"}}
{"id": "qCwRrIQV4kCT", "question_type": "multi_choice", "question": "How did the requirement for rescue medication compare between the Wayrilz and placebo groups during the double-blind period of the LUNA-3 study?", "options": {"A": "33% of Wayrilz patients and 58% of placebo patients required rescue medication", "B": "58% of Wayrilz patients and 33% of placebo patients required rescue medication", "C": "Both groups had 33% requiring rescue medication", "D": "Both groups had 58% requiring rescue medication"}}
{"id": "IORHjgbkIMW3", "question_type": "open_ended_multi_choice", "question": "A 68-year-old man with a genetic skin disease and severe psoriasis is being considered for acitretin therapy. He has a history of mild hepatic impairment and is currently taking glyburide for diabetes. What is the most appropriate approach to acitretin dosing and monitoring in this patient?", "options": {"A": "Start acitretin at the standard adult dose and monitor only for skin improvement.", "B": "Initiate acitretin at a low dose, closely monitor liver function and blood glucose levels due to increased plasma concentrations and potential drug interactions.", "C": "Avoid acitretin entirely due to his age and diabetes.", "D": "Begin acitretin at a high dose to ensure rapid disease control, with no need for additional monitoring."}}
{"id": "FYemCoMPSlFY", "question_type": "open_ended_multi_choice", "question": "For a 67-year-old male patient diagnosed with primary IgA nephropathy, presenting with a UPCR of 1.8 g/g, mild hepatic impairment, and no use of CYP3A inducers or OATP1B1/1B3 inhibitors, which statement correctly summarizes the appropriateness of atrasentan (VANRAFIA) as a proteinuria-lowering therapy?", "options": {"A": "Atrasentan is contraindicated due to his age.", "B": "Atrasentan is contraindicated due to mild hepatic impairment.", "C": "Atrasentan is appropriate; no dose adjustment is needed for mild hepatic impairment or geriatric patients.", "D": "Atrasentan should be avoided because safety in older adults is not established."}}
{"id": "gegGKIdClaKl", "question_type": "multi_choice", "question": "A 22-year-old patient with cystic fibrosis, cirrhosis, and hepatosplenomegaly is homozygous for the F508del mutation. The patient is currently taking cyclosporine following a recent organ transplant. Which drug regimen should be avoided due to potential drug interactions and organ-specific risks?", "options": {"A": "ORKAMBI, due to risk of liver failure and drug interaction with cyclosporine", "B": "SYMDEKO, with dose adjustment for hepatic impairment", "C": "Brinsupri, with monitoring for dental and skin adverse reactions", "D": "SYMDEKO, with standard dosing and no consideration for hepatic impairment"}}
{"id": "SWEm4qQDulBu", "question_type": "open_ended_multi_choice", "question": "Which action is NOT included in the list of recommended responses to an Ekterly overdose?", "options": {"A": "Contacting the poison control help line", "B": "Consulting a medical toxicologist", "C": "Increasing the dose of Ekterly", "D": "Calling 1-800-222-1222"}}
{"id": "sRld5xcY5h2m", "question_type": "open_ended_multi_choice", "question": "What change might enhance the tolerability of Wayrilz for individuals who report gastrointestinal symptoms during treatment?", "options": {"A": "Take Wayrilz with food", "B": "Take Wayrilz on an empty stomach", "C": "Reduce the dose by half", "D": "Switch to intravenous administration"}}
{"id": "ltIeV1xncvIH", "question_type": "multi_choice", "question": "Which patient population is Vizz contraindicated for due to hypersensitivity concerns?", "options": {"A": "Patients with known hypersensitivity to aceclidine or any ingredient in Vizz", "B": "Patients with a history of glaucoma", "C": "Patients under 18 years old", "D": "Pregnant women"}}
{"id": "NEeLiVOfq4uk", "question_type": "open_ended_multi_choice", "question": "A 45-year-old female presents to the ED with palpitations and is found to have acute supraventricular tachycardia. She has a past medical history of mild hypertension, but no bronchospastic disease, liver dysfunction, or pregnancy, and takes no other drugs. The team is considering pharmacologic options for rate control. What is the most suitable drug for short-term ventricular rate reduction in this patient, and what is the appropriate dosing schedule?", "options": {"A": "Pacerone, administered as a single intravenous bolus, followed by oral maintenance dosing.", "B": "RAPIBLYK, administered as a continuous intravenous infusion titrated to effect.", "C": "Propranolol, administered orally twice daily.", "D": "Pacerone, administered orally once daily."}}
{"id": "1KxjqsJYQrXE", "question_type": "open_ended_multi_choice", "question": "For how long should females of reproductive potential use effective contraception after the last dose of penpulimab-kcqx?", "options": {"A": "1 month", "B": "2 months", "C": "3 months", "D": "4 months"}}
{"id": "2CBmNF2gvmpt", "question_type": "multi_choice", "question": "A 29-year-old woman with moderate acute pain after orthopedic surgery is currently breastfeeding her newborn. She is not taking any CYP3A inhibitors or inducers, and her hepatic and renal function are normal. She requests pain relief that will not adversely affect her infant. Which drug is most suitable for her?", "options": {"A": "JOURNAVX at standard adult dosage", "B": "Ropivacaine Hydrochloride administered as a local infiltration", "C": "Pain Relief Childrens (acetaminophen-based OTC) at adult dosing", "D": "JOURNAVX with additional nonhormonal contraception"}}
{"id": "odCir1qhEiSR", "question_type": "open_ended", "question": "A patient prescribed Brinsupri misses a scheduled dose. What is the recommended action regarding the next dose?", "options": {"A": "Take the missed dose immediately and then resume the regular schedule.", "B": "Double the next dose to compensate for the missed dose.", "C": "Skip the missed dose and take the next dose at the regular time.", "D": "Take half the next dose and resume the regular schedule."}}
{"id": "ROdI0YNpMwBO", "question_type": "open_ended_multi_choice", "question": "A 62-year-old with metastatic NSCLC tests positive for an EGFR exon 21 (L858R) mutation using an FDA-approved assay. The patient also has a background of peptic ulcer disease and is taking omeprazole for reflux symptoms. Considering both drug interactions and the safety profile, what is the most appropriate initial therapy for this patient?", "options": {"A": "Erlotinib, with avoidance of omeprazole and careful monitoring for gastrointestinal perforation", "B": "Ensartinib, administered once daily", "C": "Rozlytrek, administered once daily", "D": "Erlotinib, co-administered with omeprazole and no adjustment"}}
{"id": "yPJtnOjAOTKA", "question_type": "multi_choice", "question": "A 32-year-old woman with WHIM syndrome, characterized by myelokathexis, recurrent bacterial infections, and bronchiectasis, is planning to become pregnant. She currently has normal renal and hepatic function and is not taking any medications that interact with CYP3A4 or P-gp. Which of the following is the most appropriate recommendation regarding XOLREMDI therapy?", "options": {"A": "XOLREMDI is recommended only if the patient is also taking a strong CYP3A4 inhibitor.", "B": "XOLREMDI can be safely used during pregnancy with close fetal monitoring.", "C": "XOLREMDI should not be initiated due to the risk of fetal harm; effective contraception is required during and for 3 weeks after treatment.", "D": "XOLREMDI is safe to use during breastfeeding."}}
{"id": "8L7JgKK9uhst", "question_type": "multi_choice", "question": "A 7-year-old boy with sepiapterin-responsive phenylketonuria presents with a history of recurrent nosebleeds and easy bruising. He is not taking any medications that affect folate synthesis or sepiapterin reductase. His parents are concerned about starting a new medication for PKU. Which of the following is the most appropriate drug to initiate for his hyperphenylalaninemia?", "options": {"A": "Sephience", "B": "Javygtor", "C": "Sapropterin dihydrochloride", "D": "Trimethoprim"}}
{"id": "xkQIxzHDBU9g", "question_type": "open_ended_multi_choice", "question": "A clinical investigator is planning a study and must exclude participants who have contraindications to certain medications. Which drug listed below would not require any exclusion criteria related to contraindications?", "options": {"A": "Wayrilz", "B": "A drug with known contraindication in pregnancy", "C": "A drug contraindicated in patients with cardiac arrhythmia", "D": "A drug contraindicated in patients with hepatic insufficiency"}}
{"id": "W2GhsBJOaO6r", "question_type": "open_ended_multi_choice", "question": "A 42-year-old adult with hereditary angioedema presents with an acute attack. The patient has a history of severe hepatic impairment (Child-Pugh Class C) but no renal impairment. Which drug should be selected for this patient, considering hepatic function and drug safety?", "options": {"A": "Ekterly", "B": "Icatibant acetate", "C": "Sajazir", "D": "Icatibant"}}
{"id": "INamMev5OS3v", "question_type": "open_ended", "question": "A 9-year-old boy presents with Japanese encephalitis, exhibiting focal motor seizures, increased CSF protein concentration, and cerebral edema. He has a history of mild hepatic impairment. Which of the following drug options is most appropriate for symptomatic management in this patient?", "options": {"A": "Bupivacaine hydrochloride (from Dyural 40 Kit) for regional anesthesia", "B": "Methylprednisolone acetate (from Dyural 40 Kit) administered intramuscularly at reduced dose", "C": "Rituxan Hycela administered in combination with chemotherapy", "D": "Enspryng administered monthly"}}
{"id": "kNcB92bOJJ0n", "question_type": "open_ended_multi_choice", "question": "Before being administered a live attenuated vaccine, what information should patients disclose to their healthcare provider if they are using Brinsupri?", "options": {"A": "That they are currently taking Brinsupri", "B": "Their history of allergies", "C": "Their family medical history", "D": "Their travel history"}}
{"id": "4Y2zcEG2daLp", "question_type": "open_ended_multi_choice", "question": "A 30-year-old woman with diffuse midline glioma harboring an H3 K27M mutation is prescribed Modeyso. She is planning to become pregnant. What is the most appropriate counseling regarding Modeyso and pregnancy?", "options": {"A": "Modeyso is safe to use during pregnancy.", "B": "Modeyso should be avoided during pregnancy due to risk of fetal harm.", "C": "Modeyso can be used in pregnancy if the benefits outweigh the risks.", "D": "Modeyso is only contraindicated in the first trimester."}}
{"id": "s3XTNnRiolvv", "question_type": "multi_choice", "question": "When administering Vizz, what instruction should be given to patients who wear contact lenses?", "options": {"A": "Keep contact lenses in during instillation.", "B": "Remove contact lenses prior to instillation and wait 10 minutes before reinserting.", "C": "Reinsert contact lenses immediately after instillation.", "D": "Wait 30 minutes before reinserting contact lenses."}}
{"id": "It6rsT84LJFA", "question_type": "multi_choice", "question": "A 14-year-old female patient weighing 45 kg presents with symptoms of dysuria, urgency, and suprapubic pain. She is diagnosed with an uncomplicated urinary tract infection caused by Escherichia coli. Her medical history is notable for mild renal impairment (eGFR 50 mL/min), and she is currently taking digoxin for a cardiac condition. Which drug regimen is most appropriate for treating her infection, considering her age, renal function, and concomitant medication?", "options": {"A": "Flavoxate Hydrochloride tablets for symptomatic relief, administered three times daily.", "B": "Blujepa administered as per recommended dosing for uUTI, with monitoring of digoxin levels.", "C": "Imipenem and Cilastatin Sodium intravenous therapy, with dosage adjustment for renal impairment.", "D": "Blujepa administered as per recommended dosing for uUTI, without monitoring of digoxin levels."}}
{"id": "eZVooGFC4x0V", "question_type": "multi_choice", "question": "A 35-year-old female patient with Grade 2 IDH1-mutant astrocytoma has recently undergone gross total resection. She is planning pregnancy and currently uses hormonal contraception. Her oncologist is considering post-surgical drug therapy. Which treatment option should be avoided due to its impact on contraception and potential risk to a future pregnancy?", "options": {"A": "Vorasidenib 40 mg once daily", "B": "Avastin administered every 2 weeks", "C": "Zortress combined with tacrolimus and corticosteroids", "D": "No drug therapy; observation only"}}
{"id": "xk2s7JaQQPLa", "question_type": "open_ended_multi_choice", "question": "A 55-year-old man with intermediate-2 risk myelodysplastic syndrome is newly diagnosed and has a history of chronic kidney disease (creatinine clearance 40 mL/min). He is not taking any drugs metabolized by cytidine deaminase. Cytogenetic testing reveals no deletion 5q abnormality. Which drug regimen is most suitable for his condition, considering his renal impairment?", "options": {"A": "Lenalidomide, 10 mg orally once daily (no dose adjustment)", "B": "Imetelstat sodium, 7.5 mg/kg intravenously every 4 weeks", "C": "Inqovi, 35 mg orally once daily for 5 consecutive days every 28 days", "D": "Lenalidomide, 25 mg orally once daily (no dose adjustment)"}}
{"id": "Foavjsm0UfYt", "question_type": "open_ended_multi_choice", "question": "A 52-year-old female patient presents with symptoms of presbyopia, including trouble reading fine print and the need to hold objects at a greater distance for clear vision. She has no prior retinal disease, iritis, drug hypersensitivity, is not pregnant, and does not wear contact lenses. Given these factors, which of the listed drugs is most appropriate for her management?", "options": {"A": "Aceclidine", "B": "Brimonidine tartrate", "C": "Phentolamine mesylate", "D": "No drug is appropriate"}}
{"id": "7CmT5NEHCoBb", "question_type": "multi_choice", "question": "A 38-year-old female with schizophrenia and mild hepatic impairment (Child-Pugh Class A) is being considered for long-term antipsychotic therapy. She has no history of metabolic syndrome, renal impairment, or pregnancy. Which drug regimen is most appropriate for her?", "options": {"A": "Cobenfy (xanomeline and trospium chloride), standard adult dose", "B": "Cobenfy (xanomeline and trospium chloride), reduced dose", "C": "Abilify Maintena (aripiprazole), standard adult dose", "D": "Abilify Maintena (aripiprazole), reduced dose for elderly patients"}}
{"id": "P3qQKQxoGq3p", "question_type": "multi_choice", "question": "A 22-year-old patient with cystic fibrosis, cirrhosis, and hepatosplenomegaly is homozygous for the F508del mutation. The patient is currently taking cyclosporine following a recent organ transplant. Which drug regimen should be avoided due to potential drug interactions and organ-specific risks?", "options": {"A": "Brinsupri, with monitoring for dental and skin adverse reactions", "B": "SYMDEKO, with dose adjustment for hepatic impairment", "C": "ORKAMBI, due to risk of liver failure and drug interaction with cyclosporine", "D": "SYMDEKO, with standard dosing and no consideration for hepatic impairment"}}
{"id": "1W9uAmjEcY4u", "question_type": "multi_choice", "question": "A 34-year-old woman with familial chylomicronemia syndrome presents with recurrent pancreatitis, hepatosplenomegaly, and eruptive xanthomas. She is currently 10 weeks pregnant and is seeking a medication to reduce her triglyceride levels. She is concerned about the safety of drug therapy during pregnancy. Which of the following is the most appropriate pharmacological option for her condition?", "options": {"A": "TRYNGOLZA, but only after delivery due to lack of safety data in pregnancy.", "B": "MYCOPHENOLATE MOFETIL, with strict contraception counseling and regular pregnancy testing.", "C": "MYCOPHENOLATE MOFETIL, combined with a drug holiday during the first trimester.", "D": "TRYNGOLZA administered as an adjunct to diet, with careful monitoring for hypersensitivity reactions."}}
{"id": "WfAwrYR4gqUb", "question_type": "multi_choice", "question": "Which of the following best describes the incidence of nausea or vomiting in patients treated with JOURNAVX compared to those treated with hydrocodone bitartrate/acetaminophen (HB/APAP) in Trial 1 for moderate to severe acute pain?", "options": {"A": "Incidence only reported for HB/APAP-treated patients", "B": "Higher in JOURNAVX-treated patients than in HB/APAP-treated patients", "C": "Equal incidence in both groups", "D": "Incidence only reported for JOURNAVX-treated patients"}}
{"id": "lZirsY3sruVV", "question_type": "multi_choice", "question": "A patient receiving Modeyso develops a rash, hives, and low blood pressure. What is the most appropriate immediate clinical action?", "options": {"A": "Continue Modeyso and monitor symptoms closely.", "B": "Temporarily interrupt Modeyso and observe for improvement.", "C": "Immediately discontinue Modeyso and initiate appropriate medical treatment and supportive care.", "D": "Reduce the dose of Modeyso and prescribe antihistamines."}}
{"id": "n6TMMxuTm2ii", "question_type": "open_ended_multi_choice", "question": "A 55-year-old female patient with metastatic esophageal squamous cell carcinoma and a PD-L1 CPS of 12 has completed platinum-based chemotherapy and is now considering options for second-line treatment. She is currently on ritonavir for HIV and has no liver dysfunction. Which medication would be the most appropriate choice for her next therapy?", "options": {"A": "Docetaxel anhydrous monotherapy, administered every 3 weeks", "B": "Tevimbra as a single agent, administered every 3 weeks", "C": "Keytruda QLEX as a single agent, administered every 3 weeks", "D": "Docetaxel anhydrous in combination with cisplatin and fluorouracil, administered every 3 weeks"}}
{"id": "6R3c6Gspri32", "question_type": "open_ended_multi_choice", "question": "A 38-year-old breastfeeding woman has persistent moderate to severe chronic hand eczema that has not improved with topical corticosteroids. She is worried about medication safety for her nursing infant. What is the most suitable management option for her?", "options": {"A": "Initiate topical Anzupgo, advising her to avoid direct contact with the nipple and areola after application.", "B": "Initiate topical Anzupgo without any precautions regarding breastfeeding.", "C": "Initiate topical corticosteroids, despite her previous inadequate response.", "D": "Initiate topical Anzupgo in combination with another JAK inhibitor for enhanced efficacy."}}
{"id": "kHBr7O9Ybg2N", "question_type": "multi_choice", "question": "A 74-year-old man with intermediate-2 risk myelodysplastic syndrome (MDS) is being considered for drug therapy. He has moderate renal impairment (creatinine clearance 40 mL/min), is not eligible for stem cell transplantation, and is not taking any drugs metabolized by cytidine deaminase. Which of the following is the most suitable drug for his condition, considering his age, renal function, and MDS risk group?", "options": {"A": "Lenalidomide, with dose adjustment for renal impairment.", "B": "TREOSULFAN (GRAFAPEX) in combination with fludarabine as a transplant preparative regimen.", "C": "INQOVI (cedazuridine and decitabine), administered orally once daily in 28-day cycles.", "D": "Lenalidomide, standard dose without adjustment."}}
{"id": "GaRlyP4mkfAi", "question_type": "open_ended_multi_choice", "question": "A 28-year-old woman with a history of compulsive behaviors and dystonia due to Niemann-Pick disease type C is in her first trimester of pregnancy (10 weeks). She is looking for treatment options to manage her neurological symptoms. What would be the most appropriate recommendation regarding drug therapy for her situation?", "options": {"A": "Initiate arimoclomol in combination with miglustat", "B": "Start miglustat monotherapy", "C": "Avoid both arimoclomol and miglustat due to potential fetal harm", "D": "Begin lithium carbonate therapy"}}
{"id": "ynNNYhSttiXQ", "question_type": "multi_choice", "question": "Which of the following statements best describes the effect of Emrelis on fertility in females?", "options": {"A": "Emrelis may impair female fertility, but the effect is reversible", "B": "Emrelis permanently impairs female fertility", "C": "Emrelis has no effect on female fertility", "D": "Emrelis improves female fertility"}}
{"id": "Q7duwcvbSyjH", "question_type": "open_ended_multi_choice", "question": "A 58-year-old male with a diagnosis of recurrent, metastatic non-keratinizing nasopharyngeal carcinoma, who also has coronary artery disease and is receiving warfarin for atrial fibrillation, requires systemic therapy. Given his comorbidities, which treatment regimen would be most suitable?", "options": {"A": "Penpulimab-kcqx in combination with cisplatin and gemcitabine, administered every 3 weeks", "B": "Capecitabine 500 mg twice daily as monotherapy", "C": "Celecoxib 200 mg twice daily for pain management", "D": "Capecitabine 500 mg twice daily in combination with warfarin"}}
{"id": "zCeS79M1F27x", "question_type": "open_ended_multi_choice", "question": "A 10-year-old with cystic fibrosis and a confirmed F508del CFTR mutation presents with recurrent lung infections, hepatomegaly, and elevated liver enzymes. The patient has a history of abnormal liver tests and is currently classified as Child-Pugh Class B for hepatic impairment. What is the most suitable drug regimen for managing this patient's cystic fibrosis?", "options": {"A": "ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor) once daily", "B": "Insulin Aspart Protamine and Insulin Aspart Mix 70/30, administered twice daily", "C": "ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor) with reduced dosage and close liver monitoring", "D": "No CFTR modulator therapy; supportive care only"}}
{"id": "DJsYkE1xyk3F", "question_type": "open_ended_multi_choice", "question": "A 58-year-old patient diagnosed with metastatic non-small cell lung cancer (NSCLC) has a ROS1-positive tumor confirmed by FDA-approved testing. Given the patient's history of congestive heart failure and current use of a medication that prolongs the QTc interval, which therapy should be avoided due to these comorbidities and drug interactions, and which is the most suitable treatment?", "options": {"A": "Rozlytrek monotherapy, 600 mg orally once daily", "B": "Erlotinib monotherapy, 150 mg orally once daily", "C": "Lazcluze (lazertinib + amivantamab) combination therapy, standard dosing", "D": "Rozlytrek with dose reduction due to QTc-prolonging medication"}}
{"id": "cpFtCCM9FwC4", "question_type": "multi_choice", "question": "For patients receiving Imaavy concomitantly with monoclonal antibodies, what clinical action should be taken?", "options": {"A": "Administer both drugs at the same time without monitoring", "B": "Closely monitor for reduced effectiveness of the monoclonal antibodies", "C": "Increase the dose of Imaavy", "D": "Switch to oral monoclonal antibodies"}}
{"id": "Oo69ujFobWBs", "question_type": "open_ended_multi_choice", "question": "A 35-year-old woman with newly diagnosed type 1 diabetes mellitus 13 presents for initial management. She has a history of asthma and is currently using an inhaled corticosteroid. She does not smoke and is not pregnant. Which of the following drugs is the most appropriate for glycemic control in this patient, considering her comorbidities and the safety profile of available therapies?", "options": {"A": "AFREZZA, administered as a rapid-acting inhaled insulin before meals", "B": "ADMELOG, administered as a rapid-acting subcutaneous injection before meals", "C": "TZIELD, administered as a 14-day intravenous infusion to delay diabetes progression", "D": "AFREZZA, administered as a rapid-acting inhaled insulin with a drug holiday every 6 months"}}
{"id": "mbcZgHVq4v0M", "question_type": "multi_choice", "question": "Which of the following best describes the contraindication profile for the drug Qfitlia?", "options": {"A": "Qfitlia should not be used in patients with a history of hypersensitivity reactions.", "B": "Qfitlia is contraindicated in patients with hepatic impairment.", "C": "Qfitlia has no known contraindications.", "D": "Qfitlia is contraindicated in pregnancy."}}
{"id": "B0pXj00AJlt9", "question_type": "open_ended", "question": "A 29-year-old woman with severe chronic hand eczema is currently breastfeeding her newborn. She has no active infections and is not taking other JAK inhibitors or immunosuppressants. She asks about starting Anzupgo and is concerned about potential risks to her infant. What is the best recommendation?", "options": {"A": "Begin Anzupgo therapy and advise her to avoid direct contact between treated skin and the nipple area during breastfeeding.", "B": "Start Anzupgo therapy without any breastfeeding precautions.", "C": "Anzupgo is contraindicated in all breastfeeding women.", "D": "Recommend Anzupgo for use in her infant instead."}}
{"id": "kXrVmvtq3CGq", "question_type": "open_ended_multi_choice", "question": "A 28-year-old woman in her second trimester of pregnancy, diagnosed with congenital hemophilia A (factor VIII deficiency), is undergoing evaluation for routine prophylactic treatment. She has no prior history of inhibitor development or hypersensitivity reactions. What is the most suitable prophylactic therapy approach for her at this time?", "options": {"A": "Alhemo, as the benefits always outweigh the risks in pregnancy", "B": "Hemlibra, used only if the potential benefit outweighs the risk to the fetus", "C": "Alhemo, with no need for contraception or risk assessment", "D": "Hemlibra, as it is completely safe in pregnancy"}}
{"id": "usLkW010hhxo", "question_type": "multi_choice", "question": "A 29-year-old pregnant woman is diagnosed with cutaneous AIDS-related Kaposi’s sarcoma, presenting with fewer than 10 new lesions in the past month and no systemic symptoms. She is seeking treatment for her skin lesions. Which of the following is the safest approach regarding drug therapy?", "options": {"A": "PANRETIN gel, applied topically to lesions", "B": "Daunorubicin Hydrochloride, administered intravenously", "C": "Avoid both PANRETIN gel and Daunorubicin Hydrochloride due to teratogenicity and fetal harm", "D": "PANRETIN gel, applied topically with concurrent systemic anti-KS therapy"}}
{"id": "PBlU2ymPgJiP", "question_type": "open_ended_multi_choice", "question": "A 45-year-old man with celiac disease and a history of thrombocytosis and macrocytic anemia is being evaluated for new drug therapy. He is a current smoker and has a family history of cardiovascular disease. Which drug should be avoided due to increased risk of malignancy and major adverse cardiovascular events in this patient profile?", "options": {"A": "Vedolizumab administered intravenously every 8 weeks", "B": "Ritlecitinib administered orally once daily", "C": "Vedolizumab administered with natalizumab", "D": "Vedolizumab administered with live vaccines"}}
{"id": "rya1FPU4l0B4", "question_type": "multi_choice", "question": "A 58-year-old woman is admitted to the hospital with acute supraventricular tachycardia. She has a history of hypertension and is currently taking an ACE inhibitor. Her liver function tests reveal moderate hepatic impairment (Child-Pugh B). Which of the following is the most appropriate drug for short-term reduction of her ventricular rate?", "options": {"A": "Propranolol", "B": "RAPIBLYK (landiolol)", "C": "Pacerone (amiodarone)", "D": "Diltiazem"}}
{"id": "vjebwLETfZoI", "question_type": "multi_choice", "question": "A 68-year-old woman with low-risk myelodysplastic syndrome presents with transfusion-dependent anemia, requiring 5 units of red blood cells over the past 8 weeks. She has not responded to erythropoiesis-stimulating agents and is currently taking digoxin for atrial fibrillation. Her cytogenetic analysis does not show a deletion 5q abnormality. Which drug is the most appropriate for her treatment, considering her current medications and disease profile?", "options": {"A": "Lenalidomide, 10 mg orally once daily", "B": "Inqovi, 35 mg orally once daily for 5 consecutive days every 28 days", "C": "Imetelstat sodium, 7.5 mg/kg intravenously every 4 weeks", "D": "Lenalidomide, 25 mg orally once daily"}}
{"id": "Q4qRKEY6jgxN", "question_type": "open_ended_multi_choice", "question": "In the ASPEN trial, what was the difference in skin cancer occurrence between participants receiving Brinsupri 25 mg and those given placebo?", "options": {"A": "Higher in Brinsupri 25 mg group", "B": "Lower in Brinsupri 25 mg group", "C": "Equal in both groups", "D": "Not reported"}}
{"id": "erOvYSwMqNQm", "question_type": "open_ended_multi_choice", "question": "When considering Gomekli for someone with multiple medication-induced anaphylactic episodes, what does the list of contraindications suggest as the appropriate action?", "options": {"A": "Gomekli should be avoided due to potential hypersensitivity.", "B": "Gomekli is contraindicated in patients with anaphylaxis history.", "C": "Gomekli can be used as there are no contraindications.", "D": "Gomekli should only be used after allergy testing."}}
{"id": "qrKfbIEHNPwa", "question_type": "multi_choice", "question": "A patient using Vizz reports sudden onset of flashing lights, floaters, or vision loss. What is the recommended action?", "options": {"A": "Increase the dosage of Vizz.", "B": "Continue using Vizz and monitor symptoms.", "C": "Seek immediate medical care.", "D": "Switch to another ophthalmic medication."}}
{"id": "lyGEWznssmqY", "question_type": "open_ended_multi_choice", "question": "A 13-year-old patient presents with an acute attack of hereditary angioedema. Which branded medication is indicated for this scenario?", "options": {"A": "Ekterly", "B": "Lisinopril", "C": "Cetirizine", "D": "Prednisone"}}
{"id": "3xzVTlP4ncDR", "question_type": "multi_choice", "question": "Prior to administering Tryptyr, which of the following steps is necessary for patients who wear contact lenses?", "options": {"A": "Leave contact lenses in during administration", "B": "Remove contact lenses and reinsert immediately after dosing", "C": "Remove contact lenses and wait 15 minutes before reinserting", "D": "Do not use Tryptyr if wearing contact lenses"}}
{"id": "cwMniOzlAUvw", "question_type": "open_ended_multi_choice", "question": "A child aged 7 years presents with a new diagnosis of paroxysmal nocturnal hemoglobinuria (PNH), and is otherwise healthy with normal hepatic and renal parameters. What is the recommended initial medication for managing this patient?", "options": {"A": "Sirolimus", "B": "Voydeya as monotherapy", "C": "Ravulizumab", "D": "Voydeya added to eculizumab"}}
{"id": "nSP1KNYOLwYn", "question_type": "open_ended_multi_choice", "question": "A 40-year-old male with confirmed Niemann-Pick disease type C presents with progressive gait disturbance, vertical supranuclear gaze palsy, and mild renal impairment (estimated creatinine clearance 65 mL/min). He is not taking any other medications. Which treatment option is most suitable for his neurological symptoms?", "options": {"A": "Miglustat (Yargesa) 100 mg twice daily, with dose adjustment for renal impairment", "B": "AQNEURSA (levacetylleucine), standard dosing without renal adjustment", "C": "Miglustat (Opfolda) in combination with Pombiliti, with dose reduction for renal impairment", "D": "AQNEURSA (levacetylleucine), with dose reduction for renal impairment"}}
{"id": "hgPEjbkQpHzM", "question_type": "open_ended", "question": "A 60-year-old woman with malignant pheochromocytoma and a history of proteinuria and renal artery stenosis is not a candidate for surgical intervention. She is currently taking haloperidol for a psychiatric disorder. Which of the following medications should be avoided due to the risk of potentiating extrapyramidal side effects?", "options": {"A": "Phenoxybenzamine Hydrochloride", "B": "Phentolamine Mesylate", "C": "Metyrosine", "D": "Epinephrine"}}
{"id": "S8L8Ry5XnQoq", "question_type": "open_ended_multi_choice", "question": "A 45-year-old woman with metastatic non-keratinizing nasopharyngeal carcinoma has shown disease progression after platinum-based chemotherapy and at least one other prior regimen. She is currently breastfeeding and prefers not to stop. Which of the following is the best treatment option for her situation?", "options": {"A": "Penpulimab-kcqx as a single agent, administered every 3 weeks", "B": "Capecitabine 500 mg twice daily as monotherapy", "C": "Celecoxib 200 mg twice daily for symptom relief", "D": "Delay systemic therapy and continue breastfeeding for 4 months before starting Penpulimab-kcqx"}}
{"id": "IRG2x2SuSeis", "question_type": "open_ended", "question": "A 7-year-old boy presents with newly diagnosed acute myeloid leukemia with inv3(p21;q26.2). He is CD33-positive and has no significant comorbidities. His cardiac function is normal, and he has not received prior chemotherapy. His parents are concerned about long-term side effects, especially cardiac toxicity. Which induction therapy is most suitable for this patient, considering efficacy and safety in pediatric populations?", "options": {"A": "Mitoxantrone in combination with cytarabine, administered every 3 weeks.", "B": "Daunorubicin hydrochloride in combination with cytarabine, administered every 3 weeks.", "C": "Mylotarg (gemtuzumab ozogamicin) in combination with standard chemotherapy, administered every 2 weeks.", "D": "Mylotarg monotherapy, administered every 2 weeks."}}
{"id": "Wrw3VoM8C7Lr", "question_type": "open_ended_multi_choice", "question": "When a patient who is taking a moderate CYP3A4 inducer requires Ekterly for an acute HAE episode, what is the recommended management approach?", "options": {"A": "Administer standard Ekterly dosage", "B": "Reduce Ekterly dosage by half", "C": "Avoid concomitant use of Ekterly", "D": "Increase Ekterly dosage"}}
{"id": "DY9wXnPxf0Ke", "question_type": "open_ended_multi_choice", "question": "As a clinician prepares to prescribe Lynozyfic to a patient with various comorbidities, which contraindications should be reviewed?", "options": {"A": "Lynozyfic is contraindicated in patients with a history of anaphylaxis.", "B": "Lynozyfic should not be used in patients with severe renal impairment.", "C": "There are no contraindications listed for Lynozyfic.", "D": "Lynozyfic is contraindicated in pediatric populations."}}
{"id": "xhGkFeseJPkW", "question_type": "multi_choice", "question": "A patient is prescribed Sephience and is also taking sulfasalazine. What is the recommended clinical action based on their concomitant use?", "options": {"A": "Avoid concomitant use or monitor blood phenylalanine (Phe) levels if unavoidable", "B": "Continue both drugs without monitoring", "C": "Increase the dose of Sephience", "D": "Add a PDE-5 inhibitor"}}
{"id": "GVgCvzhSaUTU", "question_type": "open_ended_multi_choice", "question": "Which of the following statements best describes the effect of Modeyso on fertility?", "options": {"A": "Modeyso has no known effect on fertility.", "B": "Modeyso may adversely impact fertility in both males and females.", "C": "Modeyso improves fertility in females.", "D": "Modeyso only affects fertility in males."}}
{"id": "sxLOLFC5pzit", "question_type": "open_ended_multi_choice", "question": "Penpulimab-kcqx is used in combination with which drugs as a first-line therapy for recurrent or metastatic non-keratinizing nasopharyngeal carcinoma?", "options": {"A": "Penpulimab-kcqx with cisplatin and gemcitabine", "B": "Penpulimab-kcqx with paclitaxel and carboplatin", "C": "Penpulimab-kcqx with gemcitabine alone", "D": "Penpulimab-kcqx with carboplatin and gemcitabine"}}
{"id": "DdsfFVXoeXXo", "question_type": "open_ended_multi_choice", "question": "How would you characterize the clinical experience with cases of Enflonsia overdose?", "options": {"A": "Extensive clinical data are available regarding overdose management.", "B": "There is limited experience of overdose with Enflonsia.", "C": "Overdose cases always require surgical intervention.", "D": "Overdose is well-characterized in adult populations."}}
{"id": "EavxJpZo2H1P", "question_type": "open_ended_multi_choice", "question": "A 28-year-old pregnant woman at 10 weeks gestation has been newly diagnosed with molluscum contagiosum. She expresses concern regarding the safety of topical therapies during pregnancy. She reports no prior skin allergies or areas of damaged skin. What is the most suitable recommendation for her treatment?", "options": {"A": "Adapalene applied nightly to lesions", "B": "Zelsuvmi applied topically as directed, with counseling about limited pregnancy safety data", "C": "Zelsuvmi applied twice daily to lesions", "D": "Adapalene applied twice daily to lesions"}}
{"id": "Iwl8vSiELo2i", "question_type": "multi_choice", "question": "For which patient populations is the use of Vizz contraindicated based on its official labeling?", "options": {"A": "Patients with severe hepatic impairment", "B": "Patients with known hypersensitivity to Vizz", "C": "Patients with renal failure", "D": "None; there are no contraindications listed for Vizz"}}
{"id": "QItxEjh6YvvE", "question_type": "open_ended_multi_choice", "question": "A 52-year-old woman with primary biliary cholangitis presents with compensated cirrhosis and recent onset of ascites and gastroesophageal varices, indicating portal hypertension. She has an inadequate response to ursodeoxycholic acid (UDCA). Her current medications include warfarin for atrial fibrillation. Which of the following is the most appropriate drug therapy for her PBC at this time?", "options": {"A": "Ocaliva 10 mg once daily in combination with UDCA", "B": "Livdelzi 10 mg once daily in combination with UDCA", "C": "Tricor 145 mg once daily as adjunct to UDCA", "D": "No disease-specific drug therapy should be initiated; continue UDCA alone"}}
{"id": "9biijuMSPZ2k", "question_type": "open_ended_multi_choice", "question": "A 65-year-old woman with metastatic non-small cell lung cancer (NSCLC) has a tumor that is EGFR exon 21 (L858R) mutation positive. She has mild hepatic impairment and is not pregnant. She is not taking any CYP3A or P-gp modulators. Her oncologist is considering first-line therapy. Which regimen is most suitable for her?", "options": {"A": "ENSACOVE (ensartinib) 225 mg orally once daily", "B": "CYRAMZA (ramucirumab) in combination with erlotinib, administered every 2 weeks", "C": "YERVOY (ipilimumab) in combination with nivolumab and platinum-doublet chemotherapy every 3 weeks", "D": "CYRAMZA (ramucirumab) as monotherapy every 2 weeks"}}
{"id": "SkSmU6Lgv1mI", "question_type": "open_ended_multi_choice", "question": "A 35-year-old woman with hemophilia A, a prior cholecystectomy for symptomatic gallbladder disease, normal liver function, and who is not pregnant, comes for routine prophylactic treatment. What is the most suitable prophylactic therapy for her?", "options": {"A": "Qfitlia, administered according to antithrombin-based dosing regimen", "B": "Hemlibra, administered subcutaneously every two weeks", "C": "Qfitlia, administered at a fixed dose of 80 mg once monthly", "D": "Qfitlia, administered according to antithrombin-based dosing regimen with concurrent hormonal contraceptives"}}
{"id": "UFp1E3s3Zvcs", "question_type": "open_ended", "question": "A 35-year-old woman presents with acute infectious diarrheal disease caused by Escherichia coli. She has a documented history of severe penicillin allergy, including anaphylaxis. She is not pregnant and is otherwise healthy. Which of the following drugs is most appropriate for treating her condition?", "options": {"A": "Ampicillin with Sulbactam", "B": "Ofloxacin Otic Solution", "C": "Ciprofloxacin Ophthalmic Solution", "D": "Supportive care only, no antibacterial therapy"}}
{"id": "rLyngD9lEt8r", "question_type": "open_ended_multi_choice", "question": "For a patient using an oral contraceptive containing ethinyl estradiol and levonorgestrel, what is the effect of concomitant Journavx administration on the pharmacokinetics of these contraceptive components?", "options": {"A": "Clinically significant increase in ethinyl estradiol and levonorgestrel levels.", "B": "Clinically significant decrease in ethinyl estradiol and levonorgestrel levels.", "C": "No clinically significant change in the pharmacokinetics of ethinyl estradiol and levonorgestrel.", "D": "Complete loss of contraceptive efficacy."}}
{"id": "1gRhzS7ZTFXn", "question_type": "multi_choice", "question": "Which of the following best describes the incidence of nausea or vomiting in patients treated with JOURNAVX compared to those treated with hydrocodone bitartrate/acetaminophen (HB/APAP) in Trial 1 for moderate to severe acute pain?", "options": {"A": "Higher in JOURNAVX-treated patients than in HB/APAP-treated patients", "B": "Lower in JOURNAVX-treated patients than in HB/APAP-treated patients", "C": "Equal incidence in both groups", "D": "Incidence only reported for JOURNAVX-treated patients"}}
{"id": "KqSQt3ef94GN", "question_type": "open_ended_multi_choice", "question": "A 12-year-old girl diagnosed with tetrahydrobiopterin (BH4)-responsive phenylketonuria presents with high blood phenylalanine, eczema, and microcephaly. She is receiving methylphenidate for ADHD and methotrexate for juvenile idiopathic arthritis. Given her current medications and medical conditions, which treatment strategy would be most suitable to lower her blood phenylalanine levels?", "options": {"A": "Sephience administered daily with a phenylalanine-restricted diet", "B": "Sapropterin dihydrochloride administered daily with a phenylalanine-restricted diet", "C": "JAVYGTOR administered daily with a phenylalanine-restricted diet", "D": "Sephience administered every other day with a phenylalanine-restricted diet"}}
{"id": "D03rKOhQevQP", "question_type": "multi_choice", "question": "In the event of an overdose involving Ekterly, which resource is specifically recommended for obtaining management recommendations?", "options": {"A": "Monitor the patient without intervention", "B": "Increase the dosage of Ekterly", "C": "Administer activated charcoal immediately", "D": "Contact the poison control help line (1-800-222-1222) or a medical toxicologist"}}
{"id": "NJUOXz4nEtiG", "question_type": "open_ended_multi_choice", "question": "What is the most accurate statement regarding the established safety and effectiveness of ANZUPGO in children?", "options": {"A": "ANZUPGO is approved and safe for use in pediatric patients.", "B": "The safety and efficacy of ANZUPGO have not been established in pediatric patients.", "C": "ANZUPGO is contraindicated in pediatric patients.", "D": "ANZUPGO is recommended only for pediatric patients with severe disease."}}
{"id": "IaY4C1q1hY8s", "question_type": "open_ended_multi_choice", "question": "A 45-year-old woman with chronic hypoparathyroidism has achieved an albumin-corrected serum calcium of 8.2 mg/dL using calcium and active vitamin D supplementation. She has no history of bone malignancy, radiation therapy, or metabolic bone disease. She is not taking digoxin or any other medications affecting calcium levels. Which of the following is the most appropriate pharmacologic therapy to initiate for long-term management of her hypoparathyroidism, considering safety and efficacy?", "options": {"A": "GENOTROPIN administered once daily", "B": "Yorvipath administered once daily", "C": "Tri-Vite Drops with Fluoride administered daily", "D": "Somatropin administered twice daily"}}
{"id": "GpBproqG6ja3", "question_type": "multi_choice", "question": "A patient receiving penpulimab-kcqx develops Grade 3 immune-mediated pneumonitis. What is the recommended initial management strategy?", "options": {"A": "Continue penpulimab-kcqx and monitor closely", "B": "Treat with antibiotics and continue penpulimab-kcqx", "C": "Switch to another PD-1/PD-L1 inhibitor", "D": "Withhold or permanently discontinue penpulimab-kcqx and initiate systemic corticosteroids"}}
{"id": "ixeUyR8QmlMa", "question_type": "open_ended", "question": "A patient receiving Lynozyfic achieves and maintains a very good partial response (VGPR) at or after Week 24 and has received at least 17 doses of 200 mg. What is the recommended dosing frequency for subsequent Lynozyfic infusions?", "options": {"A": "Continue 200 mg weekly", "B": "Increase to 400 mg every 2 weeks", "C": "Decrease to 200 mg every 4 weeks", "D": "Discontinue Lynozyfic"}}
{"id": "NabGEN8guGB4", "question_type": "multi_choice", "question": "A patient receiving Grafapex presents with prolonged pancytopenia. Which scenario is most consistent with this finding?", "options": {"A": "The patient has developed an allergic reaction.", "B": "The patient is experiencing a typical therapeutic response.", "C": "The patient has experienced an overdose of Grafapex.", "D": "The patient has a viral infection."}}
{"id": "ppIuqBQzdPHi", "question_type": "open_ended_multi_choice", "question": "A 42-year-old patient with hereditary angioedema is experiencing an acute episode. The patient has advanced liver disease classified as Child-Pugh Class C, but renal function is normal. Taking into account the patient's hepatic status and medication safety, which treatment is most appropriate?", "options": {"A": "Ekterly", "B": "Icatibant acetate", "C": "Sajazir", "D": "Icatibant"}}
{"id": "uWT45qWcCPQO", "question_type": "open_ended_multi_choice", "question": "When Ekterly is administered with weak CYP3A4 inhibitors, what is the recommended dose modification?", "options": {"A": "Reduce the dose to 150 mg.", "B": "Increase the dose to 600 mg.", "C": "No dose modification is recommended.", "D": "Avoid use of Ekterly."}}
{"id": "Oa830WRCCgnr", "question_type": "open_ended_multi_choice", "question": "A 34-year-old pregnant woman with chronic graft-versus-host disease (cGVHD) is experiencing morphea, muscle weakness, and frequent infections. She is 10 weeks into her pregnancy, has not responded to two previous systemic treatments, weighs 65 kg, and has normal liver function. What is the safest and most suitable drug regimen for her situation?", "options": {"A": "Niktimvo, intravenous infusion every 2 weeks", "B": "PredniSONE, 5 mg orally once daily", "C": "PONVORY, 20 mg orally once daily", "D": "Niktimvo, intravenous infusion every 4 weeks"}}
{"id": "lKmqCFC2Coy4", "question_type": "open_ended", "question": "A patient with a history of severe allergic reaction to Blujepa presents for treatment of a urinary tract infection. Which of the following is the most appropriate course of action?", "options": {"A": "Prescribe Blujepa with close monitoring", "B": "Prescribe Blujepa at a reduced dose", "C": "Avoid Blujepa and select an alternative antibiotic", "D": "Premedicate with antihistamines before giving Blujepa"}}
{"id": "t8O8ifenXISC", "question_type": "multi_choice", "question": "A 7-year-old boy with a diagnosis of immune thrombocytopenia, confirmed by thrombocytopenia and abnormal bleeding, has failed to respond to corticosteroids and IVIG. He has no significant hepatic or renal impairment. Which drug regimen is most suitable for his ongoing management?", "options": {"A": "WAYRILZ (rilzabrutinib) 400 mg twice daily", "B": "Nplate (romiplostim) weekly subcutaneous injection", "C": "DMT SUIK (corticosteroid) intravenous therapy", "D": "WAYRILZ (rilzabrutinib) with dose reduction"}}
{"id": "iMGNBvdNWgKh", "question_type": "open_ended_multi_choice", "question": "A 42-year-old woman who is breastfeeding her 2-month-old infant has familial chylomicronemia syndrome, characterized by hepatic steatosis, impaired memory, and increased chylomicrons. She requests drug therapy to decrease her triglyceride levels. Which medication is most appropriate in this scenario?", "options": {"A": "MYCOPHENOLATE MOFETIL, as it has limited data but some infants breastfed during maternal use had no reported adverse events.", "B": "TRYNGOLZA, since animal data suggest low levels in milk and poor oral bioavailability, making it unlikely to harm the infant.", "C": "MYCOPHENOLATE MOFETIL, with additional barrier contraception to minimize infant exposure.", "D": "TRYNGOLZA, but only after cessation of breastfeeding due to unknown human data."}}
{"id": "IrlfwOwz4SzU", "question_type": "open_ended_multi_choice", "question": "A patient experienced anaphylaxis after receiving a medication containing nipocalimab. Which statement best describes the appropriateness of prescribing Imaavy to this patient?", "options": {"A": "Imaavy should not be prescribed due to the risk of serious hypersensitivity reactions.", "B": "Imaavy can be prescribed with close monitoring.", "C": "Imaavy is safe if premedication with antihistamines is used.", "D": "Imaavy is contraindicated only if the patient has asthma."}}
{"id": "Id7BVvmvYqS4", "question_type": "open_ended_multi_choice", "question": "A 68-year-old patient with a diagnosis of chronic obstructive pulmonary disease and known hepatic impairment is being evaluated for maintenance treatment. He remains stable and has no psychiatric disorders. Based on his age and comorbidities, which drug is best suited for his long-term COPD therapy?", "options": {"A": "Budesonide Inhalation", "B": "Fentanyl Citrate", "C": "Ensifentrine", "D": "Budesonide (oral)"}}
{"id": "myPw6E8wLSpu", "question_type": "open_ended", "question": "A 52-year-old woman with chronic diarrheal disease is diagnosed with primary biliary cholangitis (PBC). She has compensated cirrhosis but recent imaging reveals ascites and persistent thrombocytopenia, indicating portal hypertension. She is currently taking warfarin for atrial fibrillation. Which of the following is the most appropriate drug management for her PBC?", "options": {"A": "Initiate Ocaliva 5 mg once daily and monitor INR closely.", "B": "Initiate Ocaliva 10 mg once daily in combination with ursodeoxycholic acid.", "C": "Do not initiate Ocaliva due to contraindication; consider alternative management.", "D": "Initiate Ocaliva 5 mg once daily, but schedule a drug holiday every 2 weeks."}}
{"id": "Dkj3LGeGgnv3", "question_type": "multi_choice", "question": "A 29-year-old woman with moderate acute pain after orthopedic surgery is currently breastfeeding her newborn. She is not taking any CYP3A inhibitors or inducers, and her hepatic and renal function are normal. She requests pain relief that will not adversely affect her infant. Which drug is most suitable for her?", "options": {"A": "Ropivacaine Hydrochloride administered as a local infiltration", "B": "JOURNAVX at standard adult dosage", "C": "Pain Relief Childrens (acetaminophen-based OTC) at adult dosing", "D": "JOURNAVX with additional nonhormonal contraception"}}
{"id": "8rTObe7zJLRW", "question_type": "open_ended_multi_choice", "question": "Which of the following is NOT a recommended strategy when essential long-term use of FcRn-binding medications is required in a patient treated with Imaavy?", "options": {"A": "Discontinue Imaavy and use alternative therapies", "B": "Continue Imaavy and monitor for reduced effectiveness", "C": "Increase the dose of FcRn-binding medication", "D": "Switch to non-FcRn-binding alternatives"}}
{"id": "bhW9tkBXAyw0", "question_type": "open_ended_multi_choice", "question": "A 5-year-old child with classic congenital adrenal hyperplasia is currently receiving glucocorticoid replacement therapy. The patient has a history of severe renal impairment and is being considered for adjunctive therapy to better control androgen levels. Which of the following is the most appropriate next step regarding the use of crinecerfont (CRENESSITY) in this patient?", "options": {"A": "Initiate crinecerfont at standard dosage as adjunctive therapy.", "B": "Initiate crinecerfont with dose adjustment due to renal impairment.", "C": "Crinecerfont is not recommended due to severe renal impairment.", "D": "Crinecerfont can be used only if the patient is monitored for hypersensitivity."}}
{"id": "J5weplQX5qFW", "question_type": "open_ended_multi_choice", "question": "A 34-year-old woman with primary IgA nephropathy and a urine protein-to-creatinine ratio of 2.1 g/g is being considered for drug therapy to reduce proteinuria. She is of reproductive age, not currently pregnant, but reports inconsistent use of contraception. Which is the most appropriate course of action regarding atrasentan (VANRAFIA) therapy for this patient?", "options": {"A": "Initiate atrasentan immediately, as she is not pregnant.", "B": "Delay atrasentan initiation until effective contraception is established and pregnancy is excluded.", "C": "Initiate atrasentan and advise her to start contraception after the first dose.", "D": "Atrasentan is safe to use regardless of contraception status."}}
{"id": "q5QTmtO70PdA", "question_type": "multi_choice", "question": "A 29-year-old woman with symptomatic TGCT is planning to become pregnant in the next few months. She is currently using hormonal contraceptives and has normal renal and hepatic function. Surgical resection is not feasible. Which of the following is the most appropriate pharmacologic approach for her?", "options": {"A": "Turalio (pexidartinib hydrochloride) with continued use of hormonal contraceptives", "B": "Romvimza (vimseltinib) with effective contraception and regular pregnancy testing", "C": "Turalio (pexidartinib hydrochloride) with non-hormonal contraception", "D": "Romvimza (vimseltinib) without any contraception"}}
{"id": "2RGcyMtrAES2", "question_type": "open_ended_multi_choice", "question": "A 62-year-old woman with unresectable intrahepatic cholangiocarcinoma previously treated with standard therapies is found to have an FGFR2 gene fusion confirmed by an FDA-approved assay. She has severe renal impairment (eGFR 20 mL/min/1.73 m²), is not pregnant, and is not using any strong CYP3A modulators. Based on her renal function, which targeted therapy is most suitable for her?", "options": {"A": "LYTGOBI", "B": "ZIIHERA", "C": "PEMAZYRE", "D": "Gemcitabine"}}
{"id": "xFd3KlayDtA3", "question_type": "open_ended_multi_choice", "question": "Upon observing anaphylactic reactions in a patient being treated with Enflonsia, which immediate intervention is advised?", "options": {"A": "Initiate appropriate medications and/or supportive therapy", "B": "Discontinue all medications", "C": "Administer additional Enflonsia", "D": "Perform a rapid antigen test for RSV"}}
{"id": "sqfTz9N8rgSu", "question_type": "open_ended_multi_choice", "question": "Which of the following is the correct procedure for using Vizz if a patient is also using another topical ophthalmic product?", "options": {"A": "Administer both products simultaneously.", "B": "Administer Vizz and the other product at least 5 minutes apart.", "C": "Wait 2 minutes between the two products.", "D": "Administer the other product immediately after Vizz."}}
{"id": "gvxOvCuVtu64", "question_type": "multi_choice", "question": "When administering Vizz, what instruction should be given to patients who wear contact lenses?", "options": {"A": "Wait 30 minutes before reinserting contact lenses.", "B": "Keep contact lenses in during instillation.", "C": "Reinsert contact lenses immediately after instillation.", "D": "Remove contact lenses prior to instillation and wait 10 minutes before reinserting."}}
{"id": "UKJBYl4u5z6X", "question_type": "open_ended_multi_choice", "question": "A 16-year-old adolescent with a history of chronic rhinosinusitis and nasal polyps is being considered for corticosteroid therapy. He has not had ethmoid sinus surgery. Which of the following is the most appropriate next step in management?", "options": {"A": "Recommend Sinuva sinus implant for targeted local therapy", "B": "Prescribe fluticasone propionate nasal spray for symptomatic relief", "C": "Apply mometasone furoate cream to the nasal mucosa", "D": "Initiate mometasone furoate cream for skin symptoms only if present"}}
{"id": "9hQ15AI5uMpd", "question_type": "multi_choice", "question": "A 58-year-old man with type 1 interferonopathy and a history of deep vein thrombosis (DVT) and myocardial infarction is being considered for Olumiant therapy. He is not currently on any other immunosuppressants and has normal hepatic and renal function. What is the most appropriate action regarding Olumiant use in this patient?", "options": {"A": "Olumiant is suitable at the standard dose since he is not on other immunosuppressants.", "B": "Olumiant should be avoided due to his history of thrombosis and cardiovascular events.", "C": "Olumiant is appropriate only if his renal function is monitored closely.", "D": "Olumiant is recommended with a drug holiday every 2 weeks."}}
{"id": "dd9IIYlmLiKN", "question_type": "open_ended_multi_choice", "question": "For the first-line treatment of recurrent or metastatic non-keratinizing nasopharyngeal carcinoma, which regimen combines Penpulimab-kcqx with other agents?", "options": {"A": "Penpulimab-kcqx with cisplatin and gemcitabine", "B": "Penpulimab-kcqx with paclitaxel and carboplatin", "C": "Penpulimab-kcqx with gemcitabine alone", "D": "Penpulimab-kcqx with carboplatin and gemcitabine"}}
{"id": "MqqbgTpQObNo", "question_type": "open_ended_multi_choice", "question": "A 32-year-old woman in her second trimester of pregnancy presents with a bloodstream infection caused by Staphylococcus aureus. She has normal kidney function and no history of drug allergies. What is the most suitable antibiotic treatment for her?", "options": {"A": "Doxycycline Hyclate, 100 mg twice daily for 14 days", "B": "Zevtera, dosed appropriately for renal function and infection severity", "C": "Rituximab and Hyaluronidase, administered as per oncology protocols", "D": "Doxycycline Hyclate, with a reduced dose to minimize fetal exposure"}}
{"id": "2p29FShD2V7T", "question_type": "open_ended_multi_choice", "question": "A 45-year-old female patient with chronic hypoparathyroidism has stabilized her albumin-corrected serum calcium at 8.2 mg/dL with calcium and active vitamin D supplements. She has no prior bone malignancy, radiation therapy, metabolic bone disease, and is not on digoxin or other drugs that impact calcium. Which pharmacologic treatment should be initiated for optimal long-term management of her hypoparathyroidism, based on safety and effectiveness?", "options": {"A": "GENOTROPIN administered once daily", "B": "Yorvipath administered once daily", "C": "Tri-Vite Drops with Fluoride administered daily", "D": "Somatropin administered twice daily"}}
{"id": "R7pUMtAlIItR", "question_type": "open_ended_multi_choice", "question": "A 15-year-old male with a diagnosis of hemophilia A (factor VIII deficiency) has frequent joint hemorrhages and a prolonged partial thromboplastin time. There is no evidence of factor VIII inhibitor development, and he is not taking additional medications. When considering regular prophylactic therapy to minimize bleeding risk, which medication is most appropriate for this patient, given his age, clinical context, and safety profile?", "options": {"A": "MARSTACIMAB-HNCQ", "B": "Desmopressin Acetate", "C": "DARATUMUMAB AND HYALURONIDASE-FIHJ", "D": "Factor IX concentrate"}}
{"id": "YiMkhPBCvuOg", "question_type": "open_ended_multi_choice", "question": "A patient with non-keratinizing nasopharyngeal carcinoma who has previously received platinum-based chemotherapy and at least one other treatment, but whose disease has progressed, is being considered for further therapy. Which treatment option involving Penpulimab-kcqx is appropriate?", "options": {"A": "Penpulimab-kcqx monotherapy", "B": "Penpulimab-kcqx combined with cisplatin and gemcitabine", "C": "Penpulimab-kcqx combined with carboplatin and gemcitabine", "D": "Penpulimab-kcqx combined with radiation therapy"}}
{"id": "2KWSeVFPf5G4", "question_type": "open_ended_multi_choice", "question": "When giving Enflonsia at the same time as injectable vaccines, what procedure should be followed?", "options": {"A": "Administer both in the same syringe", "B": "Administer Enflonsia and vaccines at the same injection site", "C": "Use separate syringes and different injection sites", "D": "Mix Enflonsia with vaccines in the same vial"}}
{"id": "T8MQVfabZBAt", "question_type": "open_ended_multi_choice", "question": "Has the potential effect of Tryptyr on male or female fertility been evaluated in animal studies?", "options": {"A": "Yes, and Tryptyr was found to impair fertility in both sexes.", "B": "Yes, and Tryptyr was found to have no effect on fertility.", "C": "No, studies to evaluate the potential effects of Tryptyr on fertility in animals have not been performed.", "D": "Yes, but only in female animals."}}
{"id": "5x2MLoTDUWuC", "question_type": "open_ended", "question": "A 38-year-old man with hereditary angioedema and a history of moderate hepatic impairment (total bilirubin >1.5 x ULN) is seeking prophylactic therapy to prevent attacks. He is not taking any ACE inhibitors and has no known drug allergies. Which of the following is the most appropriate recommendation?", "options": {"A": "Donidalorsen, administered subcutaneously every 4 weeks", "B": "Firazyr, administered subcutaneously as needed for acute attacks", "C": "Icatibant, administered subcutaneously as needed for acute attacks", "D": "Sajazir, administered subcutaneously as needed for acute attacks"}}
{"id": "REJG5rxeVsvq", "question_type": "open_ended_multi_choice", "question": "Upon beginning Sephience therapy, what instructions are most important for patients to follow?", "options": {"A": "Inform their healthcare provider about all prescription, over-the-counter medications, and supplements they are taking.", "B": "Avoid all dairy products while on therapy.", "C": "Increase their daily intake of vitamin K.", "D": "Monitor their blood pressure daily."}}
{"id": "ctKRAwuPY9xL", "question_type": "open_ended_multi_choice", "question": "A woman aged 45 with a history of dry eye disease uses contact lenses daily and requests a treatment that does not necessitate lens removal prior to administration. Taking into account her preference and the safety profiles of the medications, which option is best for her?", "options": {"A": "Acoltremon ophthalmic solution, administered twice daily", "B": "Loteprednol etabonate ophthalmic gel, administered twice daily", "C": "Lifitegrast ophthalmic solution, administered twice daily", "D": "Loteprednol etabonate ophthalmic gel, administered once daily"}}
{"id": "mxurFUL9rjIl", "question_type": "open_ended_multi_choice", "question": "In a 68-year-old male patient diagnosed with symptomatic obstructive hypertrophic cardiomyopathy (NYHA class III) and already receiving verapamil and metoprolol tartrate for arrhythmia control, which drug should not be started due to the danger of additive negative inotropic effects and the potential for precipitating heart failure?", "options": {"A": "Acoramidis Hydrochloride", "B": "Mavacamten", "C": "Metoprolol Tartrate", "D": "Diltiazem"}}
{"id": "KsggwgMPVhdI", "question_type": "open_ended_multi_choice", "question": "A 34-year-old woman, currently in her second trimester of pregnancy, comes to the clinic with symptomatic supraventricular tachycardia that necessitates urgent rate control. She has no notable medical history and is not on any medications. What is the most appropriate drug to manage her condition?", "options": {"A": "Pacerone (amiodarone)", "B": "RAPIBLYK (landiolol)", "C": "Propranolol", "D": "Digoxin"}}
{"id": "IAJNkYmqQqMU", "question_type": "open_ended_multi_choice", "question": "A 72-year-old woman with relapsed small cell lung cancer, 60 days after responding to first-line chemotherapy, presents for second-line treatment. She has frequent diarrhea and is prone to dehydration. Considering her clinical background, which treatment option is contraindicated due to her specific risk profile?", "options": {"A": "Imdelltra, administered intravenously with step-up dosing", "B": "Topotecan capsules, standard oral dosing for 5 days every 21 days", "C": "Ipilimumab, administered in combination with nivolumab", "D": "Topotecan capsules, dose reduced for age and diarrhea risk"}}
{"id": "9YNNnUihPf73", "question_type": "open_ended_multi_choice", "question": "A 35-year-old pregnant woman in her second trimester presents with symptoms of dysuria and frequency. She is diagnosed with an uncomplicated urinary tract infection. Her renal and hepatic function are normal, and she is not taking any medications. Which drug is the safest option for symptomatic relief during pregnancy?", "options": {"A": "Imipenem and Cilastatin", "B": "Gepotidacin", "C": "Flavoxate Hydrochloride", "D": "None; all are contraindicated in pregnancy"}}
{"id": "uvx48tQJfMwS", "question_type": "open_ended_multi_choice", "question": "A child aged 7, recently diagnosed with Niemann-Pick disease type C, presents with progressive neurological symptoms, including gait ataxia, cognitive deficits, and vertical supranuclear gaze palsy. The patient’s renal function is normal and there are no other medications being taken. Which drug regimen should be selected to address the neurological features of this disease?", "options": {"A": "Miglustat monotherapy", "B": "Arimoclomol in combination with miglustat", "C": "Lithium carbonate", "D": "Arimoclomol monotherapy"}}
{"id": "EAIwpLzfViOC", "question_type": "multi_choice", "question": "A 67-year-old patient with metastatic non-small cell lung cancer (NSCLC) is found to have an EGFR exon 19 deletion mutation by FDA-approved testing. The patient has a history of deep vein thrombosis (DVT) and is currently receiving warfarin for anticoagulation. Which drug regimen is most appropriate for first-line treatment of this patient's NSCLC, considering their genetic profile and current medications?", "options": {"A": "Erlotinib monotherapy, 150 mg orally once daily", "B": "Erlotinib in combination with platinum-based chemotherapy", "C": "Rozlytrek monotherapy, 600 mg orally once daily", "D": "Lazcluze (lazertinib + amivantamab) combination therapy, standard dosing"}}
{"id": "NjvRoelUwvcn", "question_type": "multi_choice", "question": "In the event of an overdose involving Ekterly, which resource is specifically recommended for obtaining management recommendations?", "options": {"A": "Administer activated charcoal immediately", "B": "Increase the dosage of Ekterly", "C": "Contact the poison control help line (1-800-222-1222) or a medical toxicologist", "D": "Monitor the patient without intervention"}}
{"id": "eZYFhbefooGV", "question_type": "open_ended", "question": "A clinical trial protocol includes Hernexeos. Which statement best reflects its contraindication status?", "options": {"A": "Hernexeos can be administered without restriction based on contraindications.", "B": "Hernexeos requires screening for hepatic dysfunction before use.", "C": "Hernexeos should be avoided in patients with severe allergies.", "D": "Hernexeos is contraindicated in patients with active infection."}}
{"id": "OFBWCKqGdkqC", "question_type": "open_ended_multi_choice", "question": "A 29-year-old woman in her second trimester of pregnancy has been newly diagnosed with choroid plexus carcinoma and requires urgent treatment. Which drug should be avoided due to its potential to cause teratogenic effects and fetal harm?", "options": {"A": "Lumisight (pegulicianine) administered as a single intraoperative dose", "B": "Etoposide administered intravenously at 100 mg/m² daily for 5 days", "C": "Etoposide administered orally at a reduced dose", "D": "Lumisight (pegulicianine) administered at a reduced dose"}}
{"id": "kwnm38tnK4vp", "question_type": "open_ended", "question": "Which statement accurately reflects the efficacy of Wayrilz compared to placebo in achieving a durable platelet response in the LUNA-3 study?", "options": {"A": "Wayrilz achieved a 23.1% higher durable platelet response rate than placebo", "B": "Wayrilz and placebo had equivalent durable platelet response rates", "C": "Placebo achieved a higher durable platelet response rate than Wayrilz", "D": "Wayrilz achieved a 50% higher durable platelet response rate than placebo"}}
{"id": "21zOMUKpZOS5", "question_type": "multi_choice", "question": "A 65-year-old man with metastatic NSCLC and an EGFR exon 21 L858R mutation is being considered for first-line therapy. He has a history of hypertension controlled with medication, and chronic proteinuria (urine protein 1.8 g/24h). He is at increased risk for venous thromboembolism (VTE) due to prior DVT. Which treatment option is most suitable for his condition?", "options": {"A": "Rozlytrek", "B": "CYRAMZA in combination with docetaxel", "C": "LAZCLUZE (lazertinib plus amivantamab) with prophylactic anticoagulation", "D": "CYRAMZA in combination with erlotinib"}}
{"id": "0U3fbushinD8", "question_type": "open_ended_multi_choice", "question": "When considering Blujepa therapy for an individual with severe hepatic dysfunction (Child-Pugh Class C), what is the best clinical course of action?", "options": {"A": "Avoid administration of Blujepa due to increased drug exposure and risk of QTc prolongation.", "B": "Administer Blujepa at a reduced dose with close monitoring.", "C": "Administer Blujepa with a strong CYP3A4 inhibitor to reduce side effects.", "D": "Proceed with standard dosing of Blujepa without additional precautions."}}
{"id": "43j0Vcd25y1t", "question_type": "open_ended", "question": "A 67-year-old woman with KRAS-mutated recurrent low-grade serous ovarian carcinoma, previously treated with systemic therapy, is prescribed AVMAPKI FAKZYNJA CO-PACK. She is also taking omeprazole for chronic gastroesophageal reflux disease. What is the best approach to her cancer therapy?", "options": {"A": "Continue omeprazole and start AVMAPKI FAKZYNJA CO-PACK at the recommended dose.", "B": "Discontinue omeprazole and start AVMAPKI FAKZYNJA CO-PACK.", "C": "Switch omeprazole to a locally acting antacid and schedule AVMAPKI FAKZYNJA CO-PACK 2 hours apart.", "D": "Reduce the dose of AVMAPKI FAKZYNJA CO-PACK and continue omeprazole."}}
{"id": "nLUDuc7Yg9GR", "question_type": "open_ended_multi_choice", "question": "What is known about the response of geriatric patients (65 years and older) to Qfitlia based on clinical studies?", "options": {"A": "They respond significantly better than younger subjects", "B": "They respond significantly worse than younger subjects", "C": "There were insufficient numbers to determine if they respond differently", "D": "They should not receive Qfitlia under any circumstances"}}
{"id": "WfQTmlbafwD8", "question_type": "open_ended_multi_choice", "question": "A 38-year-old woman with compensated cirrhosis (Child-Pugh A) secondary to primary biliary cholangitis has no portal hypertension or decompensation. She is identified as a CYP2C9 poor metabolizer and is on a moderate CYP3A4 inhibitor for another illness. Since she experiences severe pruritus with UDCA, which medication should be selected for her PBC management?", "options": {"A": "Ocaliva 5 mg once daily as monotherapy", "B": "Livdelzi 10 mg once daily as monotherapy with close monitoring for adverse effects", "C": "Tricor 145 mg once daily as monotherapy", "D": "Livdelzi 10 mg once daily as monotherapy without monitoring"}}
{"id": "P4YkyBBXxnhn", "question_type": "open_ended_multi_choice", "question": "When managing an overdose of Ekterly, which of the following actions is NOT advised?", "options": {"A": "Contacting the poison control help line", "B": "Consulting a medical toxicologist", "C": "Increasing the dose of Ekterly", "D": "Calling 1-800-222-1222"}}
{"id": "GOwFgEPwx7s7", "question_type": "open_ended_multi_choice", "question": "A 28-year-old woman with Niemann-Pick disease type C and a history of compulsive behaviors and dystonia is currently 10 weeks pregnant. She is seeking treatment for her neurological symptoms. Which of the following is the most appropriate recommendation regarding drug therapy for her condition?", "options": {"A": "Initiate arimoclomol in combination with miglustat", "B": "Start miglustat monotherapy", "C": "Avoid both arimoclomol and miglustat due to potential fetal harm", "D": "Begin lithium carbonate therapy"}}
{"id": "WmOx1oDHr0YK", "question_type": "multi_choice", "question": "How frequently was single-agent penpulimab-kcqx administered in the AK105-202 study for patients with unresectable or metastatic non-keratinizing nasopharyngeal carcinoma?", "options": {"A": "200 mg orally every day", "B": "200 mg intravenously every 2 weeks", "C": "400 mg intravenously every 4 weeks", "D": "100 mg intravenously every week"}}
{"id": "9jac0xSt81s8", "question_type": "open_ended", "question": "A patient receiving Hernexeos develops a Grade 3 decrease in left ventricular ejection fraction (LVEF). What is the recommended management strategy?", "options": {"A": "Continue Hernexeos at the same dose", "B": "Interrupt, reduce the dose, or permanently discontinue Hernexeos based on severity", "C": "Switch to an alternative anti-HER2 therapy", "D": "Increase the dose of Hernexeos"}}
{"id": "hByxG7a6w42f", "question_type": "open_ended", "question": "A 45-year-old woman with metastatic non-squamous NSCLC tests positive for ROS1 gene fusion by FDA-approved assay. She is currently taking a strong CYP3A inhibitor for another condition and has mild renal impairment (CLcr 60 mL/min). She is not pregnant and is using effective contraception. Which drug is most suitable for her, considering drug interactions and molecular profile?", "options": {"A": "Portrazza (necitumumab) in combination with gemcitabine and cisplatin", "B": "EMRELIS (telisotuzumab vedotin)", "C": "Rozlytrek (entrectinib) with dose reduction due to CYP3A inhibitor", "D": "Rozlytrek (entrectinib) at standard dose, ignoring CYP3A interaction"}}
{"id": "TEWsCivnmc81", "question_type": "open_ended_multi_choice", "question": "In a 7-year-old patient with Niemann-Pick disease type C who exhibits progressive gait ataxia, cognitive impairment, and vertical supranuclear gaze palsy, and who has normal renal function without other medications, which treatment is most appropriate for managing the neurological manifestations?", "options": {"A": "Miglustat monotherapy", "B": "Arimoclomol in combination with miglustat", "C": "Lithium carbonate", "D": "Arimoclomol monotherapy"}}
{"id": "iXkaQ77aKNFf", "question_type": "multi_choice", "question": "A 15-year-old adolescent presents to the emergency department with an acute attack of hereditary angioedema. The patient has no history of hepatic or renal impairment and is not currently taking any medications. Which drug is the most appropriate for treating this acute attack, considering age-specific approval and safety?", "options": {"A": "Ekterly", "B": "Sajazir", "C": "Icatibant acetate", "D": "Icatibant"}}
{"id": "TlYxnRnMdv6y", "question_type": "open_ended_multi_choice", "question": "If a regulatory submission for Qfitlia requires a summary of contraindications, which of the following should be reported?", "options": {"A": "There are no contraindications for Qfitlia.", "B": "Qfitlia is contraindicated in patients with renal failure.", "C": "Qfitlia is contraindicated in patients with a history of drug allergy.", "D": "Qfitlia is contraindicated in elderly patients."}}
{"id": "Yd4lFymTrkUN", "question_type": "multi_choice", "question": "A 60-year-old man with moderate-to-severe atopic dermatitis, recurrent skin infections, and a recent diagnosis of hypertension is being considered for systemic therapy after failing topical agents. He is scheduled to receive a live vaccine in the next month. Which of the following is the most appropriate next step in his management?", "options": {"A": "Delay initiation of Adbry until after completion of live vaccine administration", "B": "Initiate Ebglyss therapy and proceed with live vaccine administration", "C": "Start dexamethasone sodium phosphate immediately and continue with planned vaccination", "D": "Start dexamethasone sodium phosphate and schedule a drug holiday during vaccination"}}
{"id": "moqGWUOsBSIC", "question_type": "open_ended", "question": "A 40-year-old woman with metastatic HER2-mutant non-small cell lung carcinoma is currently breastfeeding and wishes to continue. She has normal hepatic and cardiac function and is not taking any strong CYP3A inducers or BCRP substrates. Which of the following drugs is contraindicated for her due to her lactation status?", "options": {"A": "Etoposide administered intravenously every 3 weeks", "B": "Durvalumab (IMFINZI) as a single agent every 2 weeks", "C": "Zongertinib (HERNEXEOS) orally once daily", "D": "None of the above drugs are contraindicated in breastfeeding"}}
{"id": "iJr5s59Lyodt", "question_type": "open_ended_multi_choice", "question": "A 7-year-old with relapsed low-grade glioma is found to have a BRAF V600 mutation on genetic testing. The child does not have neurofibromatosis type 1 (NF1) and is not using CYP2C8 inhibitors or hormonal contraceptives. The family expresses concerns regarding potential effects of treatment on growth and fertility. Based on efficacy, safety, and approved indications, which therapeutic regimen should be recommended?", "options": {"A": "OJEMDA administered once daily, with routine monitoring of growth and liver function.", "B": "VinCRIStine Sulfate administered intravenously weekly, despite lack of LGG-specific indication.", "C": "Gliadel Wafer implantation during surgery, although pediatric safety and efficacy are not established.", "D": "OJEMDA combined with hormonal contraceptives to prevent breakthrough bleeding."}}
{"id": "yDCWwhLQDx5h", "question_type": "multi_choice", "question": "A 38-year-old female with schizophrenia and mild hepatic impairment (Child-Pugh Class A) is being considered for long-term antipsychotic therapy. She has no history of metabolic syndrome, renal impairment, or pregnancy. Which drug regimen is most appropriate for her?", "options": {"A": "Cobenfy (xanomeline and trospium chloride), standard adult dose", "B": "Abilify Maintena (aripiprazole), reduced dose for elderly patients", "C": "Cobenfy (xanomeline and trospium chloride), reduced dose", "D": "Abilify Maintena (aripiprazole), standard adult dose"}}
{"id": "XN538ieJtJsP", "question_type": "open_ended_multi_choice", "question": "What should patients be advised to do when they start taking Sephience?", "options": {"A": "Inform their healthcare provider about all prescription, over-the-counter medications, and supplements they are taking.", "B": "Avoid all dairy products while on therapy.", "C": "Increase their daily intake of vitamin K.", "D": "Monitor their blood pressure daily."}}
{"id": "akGa8LTmQEnx", "question_type": "open_ended_multi_choice", "question": "Which of the following statements best describes the results of mutagenicity testing for the drug Ibtrozi?", "options": {"A": "Ibtrozi was mutagenic in the in vitro bacterial reverse mutation (Ames) assay.", "B": "Ibtrozi was not mutagenic in the in vitro bacterial reverse mutation (Ames) assay and additional mutagenicity tests.", "C": "Ibtrozi was clastogenic in the in vivo micronucleus study in rats.", "D": "Ibtrozi induced aneugenicity in rat bone marrow and liver."}}
{"id": "bBV29FrYrawD", "question_type": "open_ended_multi_choice", "question": "For a 46-year-old woman diagnosed with metastatic breast cancer that is hormone receptor-positive, HER2-negative, and has a PIK3CA mutation, who also has moderate renal impairment (eGFR 45 mL/min), is not pregnant, and is not breastfeeding, what targeted therapy regimen should be considered, given the requirement for renal dose adjustment?", "options": {"A": "Inavolisib in combination with palbociclib and fulvestrant, with reduced dosage", "B": "Carboplatin at standard dosage", "C": "Esketamine in conjunction with an oral antidepressant", "D": "Carboplatin in combination with aminoglycosides"}}
{"id": "IvuynDwfcQnw", "question_type": "open_ended_multi_choice", "question": "A 35-year-old female with moderate-to-severe atopic dermatitis continues to experience recurrent itching, facial redness, and thickened skin in flexural areas. Her medical history includes food intolerance and elevated serum IgE. Topical corticosteroids have not been effective in managing her condition. She is neither pregnant nor currently infected, and she is not on immunosuppressants. What is the most suitable drug regimen for her ongoing treatment?", "options": {"A": "DMT SUIK administered intravenously every 2 weeks for systemic control", "B": "Doxepin hydrochloride cream applied topically for up to 8 days for pruritus relief", "C": "Lebrikizumab-lbkz administered subcutaneously every 2 weeks as a targeted therapy", "D": "Doxepin hydrochloride cream applied daily for 3 months for long-term control"}}
{"id": "aXe2awtywXWP", "question_type": "open_ended", "question": "Which of the following statements best describes the use of Ekterly in pregnant or breastfeeding women?", "options": {"A": "It is not known if Ekterly can harm an unborn baby or passes into breastmilk.", "B": "Ekterly is contraindicated in pregnancy and lactation.", "C": "Ekterly is proven safe for use during pregnancy and breastfeeding.", "D": "Ekterly should be used only in the third trimester."}}
{"id": "DFFyrUVyLgkF", "question_type": "multi_choice", "question": "A 58-year-old man with metastatic cutaneous squamous cell carcinoma is not a candidate for curative surgery or radiation. He has a history of severe infusion-related reactions to monoclonal antibodies in the past. Which of the following systemic therapies is most appropriate for his condition, considering both indication and safety profile?", "options": {"A": "ERBITUX, due to its lower risk of infusion reactions", "B": "UNLOXCYT, as it is specifically indicated for CSCC despite higher infusion reaction risk", "C": "TECENTRIQ, as it is approved for CSCC and has a low rate of infusion reactions", "D": "No systemic therapy is appropriate due to infusion reaction history"}}
{"id": "JoG0psdMc0u4", "question_type": "open_ended_multi_choice", "question": "A 68-year-old man with acute erythroleukemia and a history of congestive heart failure is being considered for chemotherapy. He has anemia, thrombocytopenia, and splenomegaly. His renal function is mildly impaired, and he is not a candidate for stem cell transplantation. Which drug should be avoided due to his comorbidities, and which is the safest option for palliative management?", "options": {"A": "Daunorubicin Hydrochloride administered intravenously at reduced dose", "B": "REVUMENIB administered orally with ECG monitoring", "C": "TaperDex 12-day administered at the lowest effective dose with careful monitoring for fluid retention and hypertension", "D": "Daunorubicin Hydrochloride combined with REVUMENIB for induction therapy"}}
{"id": "vrANAiKPbKw2", "question_type": "open_ended_multi_choice", "question": "A 42-year-old pregnant woman with metastatic non-small cell lung cancer (NSCLC) harboring an EGFR exon 19 deletion is being evaluated for initial therapy. She has no history of thromboembolic events, cardiac disease, or hepatic/renal dysfunction. Which of the following therapies should be avoided because of her pregnancy?", "options": {"A": "CYRAMZA in combination with erlotinib", "B": "Rozlytrek", "C": "LAZCLUZE (lazertinib plus amivantamab)", "D": "All of the above"}}
{"id": "vPUGreSj3DZi", "question_type": "open_ended_multi_choice", "question": "A 67-year-old man with hypertension, hyperlipidemia, and a history of gout presents for blood pressure management. He has mild renal impairment (eGFR 55 mL/min) and no hepatic dysfunction. He is not taking lithium. He reports previous episodes of gout flares and is concerned about medications that may worsen his condition. Which antihypertensive agent is most appropriate for this patient?", "options": {"A": "Chlorthalidone (THALITONE), once daily", "B": "Aprocitentan (TRYVIO), once daily in combination with other antihypertensives", "C": "Bosentan (TRACLEER), twice daily", "D": "Chlorthalidone (THALITONE), twice daily"}}
{"id": "zRLJHlSfe0lb", "question_type": "multi_choice", "question": "A patient using Vizz reports sudden onset of flashing lights, floaters, or vision loss. What is the recommended action?", "options": {"A": "Switch to another ophthalmic medication.", "B": "Continue using Vizz and monitor symptoms.", "C": "Increase the dosage of Vizz.", "D": "Seek immediate medical care."}}
